Substituted 1,2,3-triazoles as NR2B-selective NMDA modulators

ABSTRACT

Substituted 1,2,3-triazoles as NR2B receptor ligands. Such compounds may be used in NR2B receptor modulation and in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by NR2B receptor activity.

This application is a divisional application of U.S. application Ser.No. 15/428,710 filed Feb. 9, 2017 which claims the benefit of U.S.Provisional Application No. 62/293,680, filed on Feb. 10, 2016, each ofwhich is incorporated herein by reference in their entireties.

FIELD OF THE INVENTION

The present invention is related to compounds having NR2B modulatingproperties, pharmaceutical compositions comprising these compounds,chemical processes for preparing these compounds and their use in thetreatment of diseases associated with NR2B receptor activity in animals,in particular humans.

BACKGROUND OF THE INVENTION

Glutamate is one of the major excitatory neurotransmitters that iswidely spread in the brain. First indication of its role as anexcitatory messenger was in the 1950's when it was observed thatintravenous administration of glutamate induces convulsions. However,the detection of the whole glutamatergic neurotransmitter system withits various receptors did not take place before the 1970's and 1980'swhen numerous antagonists were developed or, as in the case of PCP andketamine, were identified as antagonists. Finally, in the 1990'smolecular biology provided the tools for the classification of theglutamatergic receptors.

N-methyl-D-aspartate (NMDA) receptors are a subtype of ionotropicglutamate receptors that mediate excitatory synaptic transmission in thebrain. NMDA receptors are ubiquitously distributed throughout the brainand play a key role in synaptic plasticity, synaptogenesis,excitotoxicity, memory acquisition and learning. NMDA receptors aredistinct from other major subtypes of ionotropic glutamate receptors(AMPA and kainate receptors) in that they are blocked by Mg²⁺ at restingmembrane potentials, are highly Ca²⁺ permeable, and requireco-activation by two distinct neurotransmitters: glutamate and glycine(or D-serine) (Traynelis S F et al., Pharmacol Rev. 2010; 62(3):405-96).The influx of Ca²⁺ through NMDA receptors triggers signaling cascadesand regulates gene expression that is critical for different forms ofsynaptic plasticity including both long-term potentiation of synapseefficacy (LTP) (Berberich S et al., Neuropharmacology 2007; 52(1):77-86)and long-term depression (LTD) (Massey, P V et al., J Neurosci. 2004Sep. 8; 24(36):7821-8).

The vast majority of the mammalian NMDA receptors form a heterotetramermade of two obligatory GluN1 units and two variable GluN2 receptorsubunits encoded by the GRIN1 gene and one of four GRIN2 genes,respectively. One or both GluN2 subunits can be potentially replaced bya GluN3A or a GluN3B subunit. The GRIN1 gene product has 8 splicevariants while there are 4 different GRIN2 genes (GRIN2A-D) encodingfour distinct GluN2 subunits. The glycine binding site is present on theGluN1 subunit and the glutamate binding site is present on the GluN2subunit.

The GluNR2 subunits play a dominant role in determining the functionaland pharmacological properties of the NMDA receptor assembly and exhibitdistinct distribution in different areas of the brain. For instance,GluN2B subunits are expressed primarily in the forebrain in the adultmammalian brain (Paoletti P et al., Nat Rev Neurosci. 2013;14(6):383-400; Watanabe M et al., J Comp Neurol. 1993; 338(3):377-90)and are implicated in learning, memory processing, mood, attention,emotion and pain perception (Cull-Candy S et al., Curr Opin Neurobiol.2001; 11(3):327-35).

Compounds that modulate GluN2B-containing NMDA receptor function can beuseful in treatment of many neurological and psychiatric disordersincluding but not limited to bipolar disorder (Martucci L et al.,Schizophrenia Res, 2006; 84(2-3):214-21), major depressive disorder(Miller O H et al., eLife. 2014; 3:e03581; Li N et al., Biol Psychiatry.2011; 69(8):754-61), treatment-resistant depression (Preskom S H et al.J Clin Psychopharmacol. 2008; 28(6):631-7) and ther mood disorders(including schizophrenia (Grimwood S et al., Neuroreport. 1999;10(3):461-5; Weickert C S et al. Molecular Psychiatry (2013) 18,1185-1192), ante- and postpartum depression, seasonal affective disorderand the like), Alzheimer's disease (Hanson J E et al., Neurobiol Dis.2015; 74:254-62; Li S et al., J Neurosci. 2011; 31(18):6627-38) andother dementias (Orgogozo J M et al. Stroke 2002, 33: 1834-1839),Parkinson's disease (Duty S, CNS Drugs. 2012; 26(12):1017-32;Steece-Collier K et al., Exp Neurol. 2000; 163(1):239-43; Leaver K R etal. Clin Exp Pharmacol Physiol. 2008; 35(11):1388-94), Huntington'schorea (Tang T S et al., Proc Natl Acad Sci USA. 2005; 102(7):2602-7; UiL et al., J Neurophysiol. 2004; 92(5):2738-46), multiple sclerosis(Grasselli G et al., Br J Pharmacol. 2013; 168(2):502-17; Farjam M etal., Iran J Pharm Res. 2014; 13(2):695-705), cognitive impairment (WangD et al. 2014, Expert Opin Ther Targets Expert Opin Ther Targets. 2014,18(10):1121-30), head injury (Bullock M R et al., Ann N Y Acad Sci.1999; 890:51-8), spinal cord injury, stroke (Yang Y et al., J Neurosurg.2003; 98(2):397-403), epilepsy (Naspolini A P et al., Epilepsy Res. 2012June; 100(1-2):12-9), movement disorders (e.g. dyskinesias) (MorissetteM et al., Mov Disord. 2006; 21(1):9-17), various neurodegenerativediseases (e.g. amyotrophic lateral sclerosis (Fuller P I et al.,Neurosci Lett. 2006; 399(1-2):157-61) or neurodegeneration associatedwith bacterial or chronic infections), glaucoma (Naskar R et al. SeminOphthalmol. 1999 September; 14(3):152-8), pain (e.g. chronic, cancer,post-operative and neuropathic pain (Wu L J and Zhuo M,Neurotherapeutics. 2009; 6(4):693-702), diabetic neuropathy, migraine(Peeters M et al., J Pharmacol Exp Ther. 2007; 321(2):564-72), cerebralischemia (Yuan H et al., Neuron. 2015; 85(6):1305-18), encephalitis(Dalmau J. et al., Lancet Neurol. 2008; 7(12):1091-8.), autism andautism spectrum disorders (Won H. et al., Nature. 2012;486(7402):261-5), memory and learning disorders (Tang, Y. P. et al.,Nature. 1999; 401(6748):63-9), obsessive compulsive disorder (Arnold P Det al., Psychiatry Res. 2009; 172(2):136-9.), attention deficithyperactivity disorder (ADHD) (Dorval K M et al., Genes Brain Behav.2007; 6(5):444-52), PTSD (Haller J et al. Behav Pharmacol. 2011;22(2):113-21; Leaderbrand K et al. Neurobiol Learn Mem. 2014;113:35-40), tinnitus (Guitton M J, and Dudai Y, Neural Plast. 2007;80904; Hu S S et al. 2016; 273(2): 325-332), sleep disorders (likenarcolepsy or excessive daytime sleepiness, patent WO 2009058261 A1),vertigo and nystagmus (Straube A. et al., Curr Opin Neurol. 2005;18(1):11-4; Starck M et al. J Neurol. 1997 January; 244(1):9-16),anxiety autoimmunological disorders like neuropsychiatric systemic lupuserythematosus (Kowal C et al. Proc. Nat. Acad. Sci. U.S.A. 2006; 103,19854-19859) and addictive illnesses (e.g. alcohol addiction, drugaddiction) (Nagy J, 2004, Curr Drug Targets CNS Neurol Disord. 2004;3(3):169-79; Shen H et al., Proc Nat Acad Sci USA. 2011;108(48):19407-12).

In view of the clinical importance of NR2B, the identification ofcompounds that modulate NR2B receptor function represents an attractiveavenue into the development of new therapeutic agents. Such compoundsare provided herein.

SUMMARY OF THE INVENTION

The invention is directed to the general and preferred embodimentsdefined, respectively, by the independent and dependent claims appendedhereto, which are incorporated by reference herein. One aspect of thisinvention concerns compounds of Formula (I):

wherein:

-   Ar¹ is selected from the group consisting of:    -   (a) phenyl substituted with one substituent selected from the        group consisting of: halo, C₁₋₆alkyl, C₁₋₆perhaloalkyl, and        OC₁₋₆perhaloalkyl; phenyl substituted with two or three        substituents each independently selected from the group        consisting of: halo, C₁₋₆alkyl, C₁₋₆perhaloalkyl, OC₁₋₆alkyl,        OC₁₋₆perhaloalkyl, C₃₋₆-cycloalkyl, and azetidinyl;    -   (b) pyridinyl; pyridinyl substituted with one or two members        each independently selected from the group consisting of: halo,        CH₃, CF₃, and CF₂H; and    -   (c) thienyl substituted with CF₃;        1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl; or        2,3-dihydro-1H-inden-5-yl;-   R¹ is H, halo, or CH₃;-   R² is H or CH₃; and-   Ar³ is selected from the group consisting of:    -   (a) pyridinyl; pyridinyl substituted with one or two        substituents each independently selected from the group        consisting of: Cl, F, CH₃, OCH₃, CF₃, C(CH₃)₂OH; azetidin-1-yl;        3-fluoroazetidin-1-yl; and 3,3-difluoroazetidin-1-yl;    -   (b) pyridazinyl; pyridazinyl substituted with one or two        substituents each independently selected from the group        consisting of: CH₃, OCH₃, and CF₃;    -   (c) pyrimidin-4-yl; pyrimidin-4-yl substituted with one or two        substituents each independently selected from the group        consisting of: Cl, CH₃, CF₃, and OCH₃; pyrimidin-2-yl;        pyrimidin-2-yl substituted one or two members each independently        selected from the group consisting of: halo, C₁₋₆alkyl,        C₁₋₆alkyl substituted with OH or OCH₃, C(OH)(CH₃)(CF₃),        CH₂OCHF₂, CH₂OCF₃, CH₂OCH₂CH₃, CH(NH₂)CH₃. CH₂NH(CH₃),        C₁₋₆perhaloalkyl, OC₁₋₆alkyl, OC₁₋₆perhaloalkyl, C(═N—OH)(CH₃),        NH₂, NH(CH₃), N(CH₃)₂; NH(CH₂CH₃), NH(CH₂CHF₂), NH(cyclopropyl),        NH(difluorocydobutyl), NH-oxetanyl, CN, C(═O)CH₃, C(═O)NH(CH₃),        C(═O)N(CH₃)₂, SO₂CH₃, CO₂CH₃, C(CH₃)(═N—OH), cyclopropyl,        azetidin-1-yl, 3-fluoroazetidin-1-yl, 3,3-difluoroazetidin-1-yl,        3-(difluoromethyl)azetidin-1-yl, 3-methoxyazetidin-1-yl,        3-fluoro-3-methyl-azetidin-1-yl, pyrrolidin-1-yl,        3-fluoropyrrolidin-1-yl, 3,3-difluoropyrrolidin-1-yl,        piperidin-1-yl, morpholinyl, 1H-pyrrol-2-yl, 2-furyl,        1H-pyrazol-4-yl, 1H-pyrazol-5-yl, 1H-pyrazol-1-yl,        2-methyl-1H-imidazol-1-yl, 1-methylpyrazol-3-yl, and phenyl;    -   (d) 5-fluoro-pyrazin-2-yl; 5-methylpyrazin-2-yl;        6-methylpyrazin-2-yl; pyrazin-4-yl; (2-thienyl)pyrazin-2-yl, and        2,3-dimethylpyrazin-5-yl; and    -   (e) 5-methyl-1H-imidazol-2-yl; 5-methylthiazol-2-yl;        and pharmaceutically acceptable salts Formula (I).

One aspect of this invention concerns compounds of Formula (II):

wherein:

-   Ar^(1′) is phenyl substituted with C₁₋₃perhaloalkyl; or phenyl    substituted with two substituents each independently selected from    the group consisting of: halo, C₁₋₃alkyl, C₁₋₃perhaloalkyl, and    OC₁₋₃perhaloalkyl;-   R^(2′) is H or CH₃; and-   Ar² is selected from the group consisting of:    -   (a) pyridin-2-yl; pyridazin-3-yl; pyrimidin-4-yl;        pyrimidin-2-yl; pyrimidin-2-yl substituted with one or two        substituents each independently selected from the group        consisting of halo, C₁₋₃alkyl, C(CH₃)₂OH, C₁₋₃perhaloalkyl,        OCH₃, and cyclopropyl; and    -   (b) 1-methyl-imidazol-2-yl; oxazol-2-yl; 1-methyl-pyrazol-4-yl;        1-methyl-pyrazol-3-yl; and 1-methyl-1H-pyrazol-5-yl;        and pharmaceutically acceptable salts Formula (II).

Further embodiments are provided by pharmaceutically acceptable salts ofcompounds of Formula (I) or Formula (II), pharmaceutically acceptableprodrugs of compounds of Formula (I) or Formula (II), andpharmaceutically active metabolites of compounds of Formula (I) orFormula (II).

In certain embodiments, the compounds of Formula (I) are compoundsselected from those species described or exemplified in the detaileddescription below.

In certain embodiments, the compounds of Formula (II) are compoundsselected from those species described or exemplified in the detaileddescription below.

In a further aspect, the invention relates to enantiomers anddiastereomers of the compounds of Formula (I) or Formula (II), as wellas the pharmaceutically acceptable salts.

In a further aspect, the invention relates to pharmaceuticalcompositions for treating a disease, disorder, or medical conditionmediated by NR2B receptor activity, comprising an effective amount of atleast one compound selected from compounds of Formula (I),pharmaceutically acceptable salts of compounds of Formula (I),pharmaceutically acceptable prodrugs of compounds of Formula (I), andpharmaceutically active metabolites of Formula (I).

In a further aspect, the invention relates to pharmaceuticalcompositions for treating a disease, disorder, or medical conditionmediated by NR2B receptor activity, comprising an effective amount of atleast one compound selected from compounds of Formula (II),pharmaceutically acceptable salts of compounds of Formula (II),pharmaceutically acceptable prodrugs of compounds of Formula (II), andpharmaceutically active metabolites of Formula (II).

Pharmaceutical compositions according to the invention may furthercomprise one or more pharmaceutically acceptable excipients.

In another aspect, the chemical embodiments of the present invention areuseful as NR2B receptor modulators. Thus, the invention is directed to amethod for modulating NR2B receptor activity, including when suchreceptor is in a subject, comprising exposing NR2B receptor to aneffective amount of at least one compound selected from compounds ofFormula (I) or Formula (II), pharmaceutically acceptable salts ofcompounds of Formula (I) or Formula (II), pharmaceutically acceptableprodrugs of compounds of Formula (I) or Formula (II), andpharmaceutically active metabolites of compounds of Formula (I) orFormula (II).

In another aspect, the invention is directed to a method of treating asubject suffering from, or diagnosed with a disease, disorder, ormedical condition mediated by NR2B receptor activity, comprisingadministering to the subject in need of such treatment an effectiveamount of at least one compound selected from compounds of Formula (I)or Formula (II), pharmaceutically acceptable salts of compounds ofFormula (I) or Formula (II), pharmaceutically acceptable prodrugs ofcompounds of Formula (I) or Formula (II), and pharmaceutically activemetabolites of compounds of Formula (I) or Formula (II). Additionalembodiments of methods of treatment are set forth in the detaileddescription.

In another aspect, the method of studying isotopically labeled compoundsin metabolic studies (preferably with ¹⁴C), reaction kinetic studies(with, for example ²H or ³H), detection or imaging techniques [such aspositron emission tomography (PET) or single-photon emission computedtomography (SPECT)] including drug or substrate tissue distributionassays, or in radioactive treatment of patients. For example, an ¹⁸F or¹¹C labeled compound may be particularly preferred for PET or SPECTstudies.

Additional embodiments of this invention include methods of makingcompounds of Formula (I) or Formula (II), pharmaceutically acceptablesalts of compounds of Formula (I) or Formula (II), pharmaceuticallyacceptable prodrugs of compounds of Formula (I) or Formula (II), andpharmaceutically active metabolites of Formula (I) or Formula (II).

An object of the present invention is to overcome or ameliorate at leastone of the disadvantages of the conventional methodologies and/or priorart, or to provide a useful alternative thereto.

Additional embodiments, features, and advantages of the invention willbe apparent from the following detailed description and through practiceof the invention.

DETAILED DESCRIPTION OF INVENTION

In one aspect, provided herein are compounds of Formula (I), andpharmaceutically acceptable salts thereof,

wherein:

-   Ar¹ is selected from the group consisting of:    -   (a) phenyl substituted with one substituent selected from the        group consisting of: halo, C₁₋₆alkyl, C₁₋₆perhaloalkyl, and        OC₁₋₆perhaloalkyl; phenyl substituted with two or three        substituents each independently selected from the group        consisting of: halo, C₁₋₆alkyl, C₁₋₆perhaloalkyl, OC₁₋₆alkyl,        OC₁₋₆perhaloalkyl, C₃₋₆cycloalkyl, and azetidinyl;    -   (b) pyridinyl; pyridinyl substituted with one or two members        each independently selected from the group consisting of: halo,        CH₃, CF₃, and CF₂H; and    -   (c) thienyl substituted with CF₃;        1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl; or        2,3-dihydro-1H-inden-5-yl;-   R¹ is H, halo, or CH₃;-   R² is H or CH₃; and-   Ar³ is selected from the group consisting of:    -   (a) pyridinyl; pyridinyl substituted with one or two        substituents each independently selected from the group        consisting of: Cl, F, CH₃, OCH₃, CF₃, C(CH₃)₂OH; azetidin-1-yl;        3-fluoroazetidin-1-yl; and 3,3-difluoroazetidin-1-yl;    -   (b) pyridazinyl; pyridazinyl substituted with one or two        substituents each independently selected from the group        consisting of: CH₃, OCH₃, and CF₃;    -   (c) pyrimidin-4-yl; pyrimidin-4-yl substituted with one or two        substituents each independently selected from the group        consisting of: Cl, CH₃, CF₃, and OCH₃; pyrimidin-2-yl;        pyrimidin-2-yl substituted one or two members each independently        selected from the group consisting of: halo, C₁₋₆alkyl,        C₁₋₆alkyl substituted with OH or OCH₃, C(OH)(CH₃)(CF₃),        CH₂OCHF₂, CH₂OCF₃, CH₂OCH₂CH₃, CH(NH₂)CH₃, CH₂NH(CH₃),        C₁₋₆perhaloalkyl, OC₁₋₆alkyl, OC₁₋₆perhaloalkyl, C(═N—OH)(CH₃),        NH₂, NH(CH₃), N(CH₃)₂; NH(CH₂CH₃), NH(CH₂CHF₂), NH(cyclopropyl),        NH(difluorocydobutyl), NH-oxetanyl, CN, C(═O)CH₃, C(═O)NH(CH₃),        C(═O)N(CH₃)₂, SO₂CH₃, CO₂CH₃, C(CH₃)(═N—OH), cyclopropyl,        azetidin-1-yl, 3-fluoroazetidin-1-yl, 3,3-difluoroazetidin-1-yl,        3-(difluoromethyl)azetidin-1-yl, 3-methoxyazetidin-1-yl,        3-fluoro-3-methyl-azetidin-1-yl, pyrrolidin-1-yl,        3-fluoropyrrolidin-1-yl, 3,3-difluoropyrrolidin-1-yl,        piperidin-1-yl, morpholinyl, 1H-pyrrol-2-yl, 2-furyl,        1H-pyrazol-4-yl, 1H-pyrazol-5-yl, 1H-pyrazol-1-yl,        2-methyl-1H-imidazol-1-yl, 1-methylpyrazol-3-yl, and phenyl;    -   (d) 5-fluoro-pyrazin-2-yl; 5-methylpyrazin-2-yl;        6-methylpyrazin-2-yl; pyrazin-4-yl; (2-thienyl)pyrazin-2-yl, and        2,3-dimethylpyrazin-5-yl; and    -   (e) 5-methyl-1H-imidazol-2-yl; 5-methylthiazol-2-yl.

An additional embodiment of the invention is a compound of Formula (I)wherein R¹ is H, F, I or CH₃.

An additional embodiment of the invention is a compound of Formula (I)wherein R¹ is H.

An additional embodiment of the invention is a compound of Formula (I)wherein R² is H.

An additional embodiment of the invention is a compound of Formula (I)wherein Ar¹ is phenyl substituted with one substituent selected from thegroup consisting of: Br, Cl, F, CH₃, CF₃, CHF₂, CF₂CH₃, CH(CH₃)₂, OCHF₂,and OCF₃.

An additional embodiment of the invention is a compound of Formula (I)wherein Ar¹ is 3-bromophenyl, 3-fluorophenyl, 4-fluorophenyl,4-chlorophenyl, 2-methylphenyl, 3-methylphenyl, 4-methylphenyl,3-isopropylphenyl, 3-(trifluoromethyl)phenyl, 3-(difluoromethyl)phenyl,3-(1,1-difluoroethyl)phenyl, 3-(trifluoromethoxy)phenyl,4-(trifluoromethoxy)phenyl, 3-(difluoromethoxy)phenyl, or4-(difluoromethoxy)phenyl.

An additional embodiment of the invention is a compound of Formula (I)wherein Ar¹ is phenyl substituted with two substituents eachindependently selected from the group consisting of: Br, Cl, F, CH₃,CH₂CH₃, CH(CH₃)₂, CF₃, CF₂H, CF₂CH₃, CH₂CH₂CH₂Cl, CH₂CH₂CH₂F, OCH₃,OCF₂H, OCH₂CH₂F, cyclopropyl, and azetidin-1-yl.

An additional embodiment of the invention is a compound of Formula (I)wherein Ar¹ is 2,4-difluoro-5-methyl-phenyl,3-(difluoromethyl)-2,4-difluoro-phenyl, or 2,4-difluoro-3-methyl-phenyl.

An additional embodiment of the invention is a compound of Formula (I)wherein Ar¹ is 6-methyl-pyridin-2-yl, 2-methyl-pyridin-4-yl,5-methyl-pyridin-3-yl, 4-methyl-pyridin-2-yl, 2-bromo-pyridin-4-yl,2-(trifluoromethyl)-pyridin-4-yl,5-chloro-6-(trifluoromethyl)pyridin-2-yl,2-(difluoromethyl)pyridin-4-yl, 5-(trifluoromethyl)pyridin-2-yl,5-bromo-6-fluoropyridin-3-yl, or pyridin-4-yl.

An additional embodiment of the invention is a compound of Formula (I)wherein Ar¹ is 6-methyl-pyridin-2-yl, 2-methyl-pyridin-4-yl,5-methyl-pyridin-3-yl, 4-methyl-pyridin-2-yl, 2-bromo-pyridin-4-yl,2-(trifluoromethyl)-pyridin-4-yl;1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl;5-(trifluoromethyl)thiophen-2-yl or 2,3-dihydro-1H-inden-5-yl.

An additional embodiment of the invention is a compound of Formula (I)wherein Ar¹ is 4-chloro-3-(difluoromethoxy)phenyl,3-(difluoromethyl)-4-fluoro-phenyl,4-chloro-3-(1,1-difluoroethyl)phenyl,3-(1,1-difluoroethyl)-4-fluoro-phenyl,3-(difluoromethoxy)-4-fluoro-phenyl, 4-chloro-3-(difluoromethyl)phenyl,4-chloro-3-(2-fluoroethoxy)phenyl, 3-(3-chloropropyl)-4-fluoro-phenyl,or 5-(trifluoromethyl)thiophen-2-yl.

An additional embodiment of the invention is a compound of Formula (I)wherein Ar³ is pyridin-2-yl, 3-fluoro-pyridin-2-yl,6-fluoro-pyridin-2-yl, 3-chloro-pyridin-2-yl, 5-chloro-pyridin-2-yl,4-methyl-pyridin-2-yl, 5-methyl-pyridin-2-yl, 6-methyl-pyridin-2-yl,5-(trifluoromethyl)pyridine-2-yl,6-(trifluoromethyl)pyridine-2-yl,pyridine-3-yl, 3-methoxy-pyridin-2-yl,2-methoxy-pyridin-3-yl, 2-methyl-pyridin-5-yl,2,3-dimethyl-pyridin-2-yl, 5-chloro-3-methoxy-pyridin-2-yl, or2-chloro-5-methyl-pyridin-4-yl.

An additional embodiment of the invention is a compound of Formula (I)wherein Ar³ is pyrimidin-2-yl; pyrimidin-2-yl substituted one or twomembers each independently selected from the group consisting of: halo,C₁₋₃alkyl, C₁₋₃alkyl substituted with OH or OCH₃, C(OH)(CH₃)(CF₃),CH(NH₂)CH₃, CH₂NH(CH₃), C₁₋₃perhaloalkyl, OC₁₋₃alkyl, OC₁₋₃perhaloalkyl,NH₂; NH(CH₃), N(CH₃)₂, NH(CH₂CH₃), NH(CH₂CHF₂), CN, C(═O)CH₃,C(═O)NH(CH₃), C(═O)N(CH₃)₂, SO₂CH₃, CO₂CH₃, cyclopropyl, azetidin-1-yl,3-fluoroazetidin-1-yl, 3,3-difluoroazetidin-1-yl,3-(difluoromethyl)azetidin-1-yl, 3-methoxyazetidin-1-yl,3-fluoro-3-methyl-azetidin-1-yl, pyrrolidin-1-yl,3-fluoropyrrolidin-1-yl, 3,3-difluoropyrrolidin-1-yl, piperidin-1-yl,morpholinyl, 2-furyl, 1H-pyrazol-4-yl, and 1-methylpyrazol-3-yl.

An additional embodiment of the invention is a compound of Formula (I)wherein Ar³ is pyrimidin-2-yl substituted one or two members eachindependently selected from the group consisting of: halo, C₁₋₆alkyl,C₁₋₆alkyl substituted with OH or CH₃, C₁₋₆perhaloalkyl, OC₁₋₆alkyl,OC₁₋₆perhaloalkyl, and azetidine-1-yl.

An additional embodiment of the invention is a compound of Formula (I)having the Formula (IA):

wherein

-   Ar¹ is phenyl substituted with two substituents each independently    selected from the group consisting of: halo, C₁₋₃perhaloalkyl, and    OC₁₋₃perhaloalkyl; and-   Ar³ is selected from the group consisting of pyridin-2-yl,    pyridin-3-yl, 3-chloro-pyridin-2-yl, 5-chloro-pyridin-2-yl,    3-fluoro-pyridin-2-yl, 6-fluoro-pyridin-2-yl, 4-methyl-pyridin-2-yl,    2-methyl-pyridin-5-yl, 5-methyl-pyridin-2-yl, 6-methyl-pyridin-2-yl,    2,3-dimethyl-pyridin-6-yl, 2-chloro-5-methylpyridin-4-yl,    3-methoxy-pyridin-2-yl, 2-methoxy-pyridin-3-yl,    2-(pyridin-3-yl)propan-2-ol, 5-chloro-3-methoxy-pyridin-2-yl,    5-(trifluoromethyl)pyridin-2-yl, 6-(trifluoromethyl)pyridin-2-yl,    pyridazin-3-yl, pyrazin-2-yl, 5-methylpyrazin-2-yl,    5-fluoro-pyrazin-2-yl, and (2-thienyl)pyrazin-2-yl;    and pharmaceutically acceptable salts of compounds of Formula (IA).

An additional embodiment of the invention is a compound of Formula (I)having the Formula (IB):

wherein

-   Ar¹ is phenyl substituted with two substituents each independently    selected from the group consisting of: halo, C₁₋₃alkyl,    C₁₋₃perhaloalkyl, OCH₃, and OC₁₋₃perhaloalkyl;-   R¹ is selected from the group consisting of: H, F, I, and CH₃;-   R² is H or CH₃;-   n is 0, 1, or 2; and-   each R⁴ is independently selected from the group consisting of:    halo, C₁₋₆alkyl, C₁₋₆alkyl substituted with OH or OCH₃,    C(OH)(CH₃)(CF₃), CH(NH₂)CH₃, CH₂NH(CH₃), C₁₋₆perhaloalkyl,    OC₁₋₆alkyl, OC₁₋₆perhaloalkyl, NH₂, NH(CH₃), N(CH₃)₂, NH(CH₂CH₃),    NH(CH₂CHF₂), CN, C(═O)CH₃, C(═O)NH(CH₃), C(═O)N(CH₃)₂, SO₂CH₃,    CO₂CH₃, cyclopropyl, azetidin-1-yl, 3-fluoroazetidin-1-yl,    3,3-difluoroazetidin-1-yl, 3-(difluoromethyl)azetidin-1-yl,    3-methoxyazetidin-1-yl, 3-fluoro-3-methyl-azetidin-1-yl,    pyrrolidin-1-yl, 3-fluoropyrrolidin-1-yl,    3,3-difluoropyrrolidin-1-yl, piperidin-1-yl, morpholine, 2-furyl,    1H-pyrazol-4-yl, and 1-methylpyrazol-3-yl;    and pharmaceutically acceptable salts of compounds of Formula (IB).

An additional embodiment of the invention is a compound of Formula (I)having the Formula (IB) wherein:

-   Ar¹ is selected from the group consisting of:    4-chloro-3-(difluoromethoxy)phenyl,    3-(difluoromethoxy)-4-fluoro-phenyl,    3-(difluoromethoxy)-4-methyl-phenyl,    4-chloro-3-(1,1-difluoroethyl)phenyl,    3-(1,1-difluoroethyl)-4-fluoro-phenyl,    4-chloro-3-(2-fluoroethoxy)phenyl,    3-(3-chloropropyl)-4-fluoro-phenyl,    4-fluoro-3-(3-fluoropropyl)phenyl, 3-bromo-4-fluoro-phenyl,    2-fluoro-3-(trifluoromethyl)phenyl,    3-(difluoromethyl)-4-fluoro-phenyl,    4-chloro-3-(difluoromethyl)phenyl, 4-chloro-3-methoxy-phenyl),    4-fluoro-3-isopropyl-phenyl, 3-chloro-4-fluoro-phenyl,    3-ethyl-4-fluoro-phenyl, 3,4-difluorophenyl,    4-fluoro-3-methyl-phenyl, and 3,5-dimethylphenyl;-   R¹ is H;-   R² is H;-   n is 1 or 2; and-   each R⁴ is independently selected from the group consisting of: Cl,    F, C₁₋₃alkyl, C₁₋₃perhaloalkyl, CH₂OH, CH₂OCH₃, C(CH₃)₂(OH), OCH₃,    OC₁₋₃perhaloalkyl, C(═O)CH₃, and azetidine-1-yl.

An additional embodiment of the invention is a compound of Formula (I)having the Formula (IC):

wherein

-   Ar¹ is selected from the group consisting of: 2-bromo-pyridin-4-yl,    6-methyl-pyridin-2-yl, 4-methyl-pyridin-2-yl, 2-methyl-pyridin-4-yl,    5-methyl-pyridin-3-yl, 2-(trifluoromethyl)-pyridin-4-yl,    5-(trifluoromethyl)pyridin-2-yl,    5-chloro-6-(trifluoromethyl)pyridin-2-yl,    5-bromo-6-methyl-pyridin-2-yl, 5-bromo-6-fluoropyridin-3-yl, and    5-(trifluoromethyl)-2-thienyl;-   R⁶ is selected from the group consisting of: Cl, F, CH₃, CH₂CH₃,    CF₃, and OCH₃; and-   R⁷ is H or CH₃;    and pharmaceutically acceptable salts of compounds of Formula (IC).

An additional embodiment of the invention is a compound of Formula (I)having the Formula (ID):

wherein

-   Ar¹ is phenyl substituted with one substituent selected from the    group consisting of: Br, Cl, F, C₁₋₃alkyl, C₁₋₃perhaloalkyl, and    OC₁₋₃perhaloalkyl;-   n is 0, 1, or 2; and    each R⁴ is independently selected from the group consisting of: Br,    Cl, F, C₁₋₃alkyl, C₁₋₃perhaloalkyl, OCH₃, OCHF₂, CH₂OH, CH₂OCH₃,    CH(CH₃)(OH), C(OH)(CH₃)₂, C(OCH₃)(CH₃)₂, C(OH)(CH₃)(CF₃), NH₂,    NH(CH₃), N(CH₃)₂, C(═O)CH₃, cyclopropyl, azetidine-1-yl,    3-fluoroazetidin-1-yl, pyrrolidin-1-yl, and piperidin-1-yl;    and pharmaceutically acceptable salts of compounds of Formula (ID).

An additional embodiment of the invention is a compound of Formula (II)wherein:

-   Ar^(1′) is phenyl substituted with C₁₋₆perhaloalkyl; or phenyl    substituted with two substituents each independently selected from    the group consisting of: halo, C₁₋₃alkyl, C₁₋₃perhaloalkyl, and    OC₁₋₃perhaloalkyl;-   R^(2′) is H or CH₃; and-   Ar² is selected from the group consisting of:    -   (a) pyridin-2-yl; pyridazin-3-yl; pyrimidin-4-yl;        pyrimidin-2-yl; pyrimidin-2-yl substituted with one or two        substituents each independently selected from the group        consisting of halo, C₁₋₃alkyl, C(CH₃)₂OH, C₁₋₃perhaloalkyl,        OCH₃, and cyclopropyl; and    -   (b) 1-methyl-imidazol-2-yl; oxazol-2-yl; 1-methyl-pyrazol-4-yl;        1-methyl-pyrazol-3-yl; and 1-methyl-1H-pyrazol-5-yl;        and pharmaceutically acceptable salts of compounds of Formula        (II).

An additional embodiment of the invention is a compound of Formula (II)having the Formula (IIA):

wherein:

-   Ar^(1′) is selected from the group consisting of:    4-chloro-3-(difluoromethoxy)phenyl,    3-(difluoromethoxy)-4-fluoro-phenyl,    4-fluoro-3-(trifluoromethyl)phenyl,    3-(difluoromethyl)-4-fluoro-phenyl, and    4-chloro-3-(difluoromethyl)phenyl; and-   Ar² is selected from the group consisting of: oxazol-2-yl,    pyrimidin-4-yl, 1-methyl-pyrazol-3-yl, 1-methyl-imidazol-2-yl, and    1-methyl-pyrazol-4-yl; and pharmaceutically acceptable salts of    compounds of Formula (IIA).

An additional embodiment of the invention is a compound of Formula (II)having the Formula (IIB):

wherein:

-   Ar^(1′) is selected from the group consisting of:    3-(difluoromethyl)phenyl, 4-fluoro-3-methyl-phenyl,    4-chloro-3-(difluoromethoxy)phenyl,    3-(difluoromethoxy)-4-fluoro-phenyl,    4-fluoro-3-(trifluoromethyl)phenyl,    3-(difluoromethyl)-4-fluoro-phenyl,    4-chloro-3-(difluoromethyl)phenyl, and    3-(1,1-difluoroethyl)-4-fluoro-phenyl;-   n is 1 or 2; and-   each R⁴ is independently selected from the group consisting of halo,    C₁₋₃alkyl, C(CH₃)₂OH, C₁₋₃perhaloalkyl, OCH₃, and cyclopropyl;    and pharmaceutically acceptable salts of compounds of Formula (IIB).

A further embodiment of the current invention is a compound as shownbelow in Table 1.

Ex #. Compound Name 12-((1-(4-Chloro-3-(difluoromethyl)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidine; 42-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyridine; 53-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]pyridine; 82-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]-6-methyl-pyridine; 92-[[1-(3-Bromo-4-fluoro-phenyl)triazol-4-yl]methoxy]pyrimidine; 102-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]pyrimidine; 112-[[1-[4-Chloro-3-(difluoromethyl)phenyl]triazol-4- yl]methoxy]pyridine;12 4-[[1-[4-Chloro-3-(difluoromethyl)phenyl]triazol-4-yl]methoxy]pyrimidine; 134-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]pyrimidine; 143-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]pyridazine; 152-[[1-(4-Chloro-3-methoxy-phenyl)triazol-4-yl]methoxy]- pyrimidine; 162-[[1-(3-Bromo-4-fluoro-phenyl)triazol-4-yl]methoxy]-5-methyl-pyrimidine; 172-[[1-(3-Bromo-4-fluoro-phenyl)triazol-4-yl]methoxy]-4-methyl-pyrimidine; 18 2-[[1-(3-Bromo-4-fluoro-phenyl)triazol-4-yl]methoxy]-4,6-dimethyl-pyrimidine; 192-[[1-(3-Bromo-4-fluoro-phenyl)triazol-4-yl]methoxy]-5-fluoro-pyrimidine; 20 2-[[1-(4-Fluoro-3-methoxy-phenyl)triazol-4-yl]methoxy]-pyrimidine; 21 2-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]-4-methyl-pyrimidine; 222-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]-5-methyl-pyrimidine; 232-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]pyrazine; 252-[[1-[3-(Difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyrimidine; 262-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]-5-methoxy-pyrimidine; 272-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]-5-ethyl-pyrimidine; 285-Chloro-2-[[1-[4-chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]pyrimidine; 292-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]-4-methoxy-pyrimidine; 302-[[1-[4-Chloro-3-(difluoromethyl)phenyl]triazol-4-yl]methoxy]-4-methyl-pyrimidine; 312-[[1-[4-Chloro-3-(difluoromethyl)phenyl]triazol-4-yl]methoxy]-5-methyl-pyrimidine; 322-[[1-[4-Chloro-3-(difluoromethyl)phenyl]triazol-4-yl]methoxy]-5-ethyl-pyrimidine; 332-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyrimidine; 342-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]-5-methyl-pyrazine; 352-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]-5-(difluoromethoxy)pyrimidine; 375-Chloro-2-[[1-(2,4-difluoro-3-methyl-phenyl)triazol-4-yl]methoxy]pyrimidine; 382-[[1-(2,4-Difluoro-3-methyl-phenyl)triazol-4-yl]methoxy]-5-methyl-pyrimidine; 392-[[1-(2,4-Difluoro-3-methyl-phenyl)triazol-4-yl]methoxy]-5-ethyl-pyrimidine; 402-[[1-(3-Bromo-4-fluoro-phenyl)triazol-4-yl]methoxy]-5-ethyl-pyrimidine; 412-[[1-(3-Bromo-4-fluoro-phenyl)triazol-4-yl]methoxy]-5-methoxy-pyrimidine; 422-[[1-(3-Bromo-4-fluoro-phenyl)triazol-4-yl]methoxy]-5-chloro-pyrimidine; 432-[[1-(3-Bromo-4-fluoro-phenyl)triazol-4-yl]methoxy]-5-isopropyl-pyrimidine; 442-[[1-(3-Bromo-4-fluoro-phenyl)triazol-4-yl]methoxy]-5-(trifluoromethyl)pyrimidine; 452-[[1-[4-Chloro-3-(difluoromethyl)phenyl]triazol-4-yl]methoxy]-5-(trifluoromethyl)pyrimidine; 462-[[1-[4-Chloro-3-(difluoromethyl)phenyl]triazol-4-yl]methoxy]-5-methoxy-pyrimidine; 475-Chloro-2-[[1-[4-chloro-3-(difluoromethyl)phenyl]triazol-4-yl]methoxy]pyrimidine; 482-[[1-[4-Chloro-3-(difluoromethyl)phenyl]triazol-4-yl]methoxy]-5-isopropyl-pyrimidine; 495-Chloro-2-[[1-[3-(difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyrimidine; 502-[[1-[3-(Difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-5-(trifluoromethyl)pyrimidine; 512-[[1-[3-(Difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-5-methyl-pyrimidine; 522-[[1-[3-(Difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-4-methyl-pyrimidine; 53(R/S)-2-[1-[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]ethoxy]pyrimidine; 54(R*)-2-[1-[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]ethoxy]pyrimidine; 55(S*)-2-[1-[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]ethoxy]pyrimidine; 56(R/S)-2-[1-[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]ethoxy]-5-methyl-pyrimidine; 57(R*)-2-[1-[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]ethoxy]-5-methyl-pyrimidine; 58(S*)-2-[1-[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]ethoxy]-5-methyl-pyrimidine; 59(R/S)-2-[1-[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]ethoxy]-4-methyl-pyrimidine; 60(R/S)-5-Chloro-2-[1-[1-[4-chloro-3-(difluoromethoxy)phenyl]-triazol-4-yl]ethoxy]pyrimidine; 615-Chloro-2-[[1-[3-(difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyrimidine; 622-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]-5-(trifluoromethyl)pyrimidine; 632-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]-5-methyl-pyrimidine; 642-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]-4-methyl-pyrimidine; 652-[[1-[3-(Difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-5-(trifluoromethyl)pyridine; 662-[[1-[4-Chloro-3-(difluoromethyl)phenyl]triazol-4-yl]methoxy]-5-fluoro-pyrimidine; 672-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-5-ethyl-pyrimidine; 682-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-5-methoxy-pyrimidine; 695-Chloro-2-[[1-[3-(1,1-difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyrimidine; 702-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-5-isopropyl-pyrimidine; 712-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-5-(trifluoromethyl)pyrimidine; 725-Ethyl-2-[[1-[4-fluoro-3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]pyrimidine; 732-[[1-[4-Fluoro-3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]-5-methoxy-pyrimidine; 745-Chloro-2-[[1-[4-fluoro-3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]pyrimidine; 752-[[1-[4-Fluoro-3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]-5-isopropyl-pyrimidine; 762-[[1-[4-Fluoro-3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]-5-(trifluoromethyl)pyrimidine; 772-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-5-methyl-pyrimidine; 782-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyrimidine; 792-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-4-methyl-pyrimidine; 802-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-5-fluoro-pyrimidine; 812-[[1-[4-Fluoro-3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]-5-methyl-pyrimidine; 822-[[1-[4-Fluoro-3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]pyrimidine; 832-[[1-[4-Fluoro-3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]-4-methyl-pyrimidine; 845-Fuoro-2-[[1-[4-fluoro-3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]pyrimidine; 852-[[1-(3-Bromo-4-fluoro-phenyl)triazol-4-yl]methoxy]-4,5-dimethyl-pyrimidine; 862-[[1-[4-Chloro-3-(difluoromethyl)phenyl]triazol-4-yl]methoxy]-4,5-dimethyl-pyrimidine; 872-[[1-(4-Chloro-3-methoxy-phenyl)triazol-4-yl]methoxy]-5-methoxy-pyrimidine; 882-[[1-(4-Chloro-3-methoxy-phenyl)triazol-4-yl]methoxy]-5-methyl-pyrimidine; 892-[[1-[3-(Difluoromethyl)phenyl]triazol-4-yl]methoxy]-5-methyl-pyrimidine; 902-[[1-[3-(Difluoromethyl)phenyl]triazol-4-yl]methoxy]-5-methoxy-pyrimidine; 912-[[1-[3-(Difluoromethyl)phenyl]triazol-4-yl]methoxy]-5-ethyl-pyrimidine; 925-Chloro-2-[[1-[3-(difluoromethyl)phenyl]triazol-4-yl]methoxy]pyrimidine; 932-[[1-[3-(Difluoromethyl)phenyl]triazol-4-yl]methoxy]pyrimidine; 942-[[1-(5-Bromo-6-methyl-2-pyridyl)triazol-4-yl]methoxy]-5-methyl-pyrimidine; 952-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]-5-fluoro-pyrimidine; 962-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]-5-(difluoromethyl)pyrimidine; 1033-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]-2-methoxy-pyridine; 1045-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]-2-methyl-pyridine; 1053-Chloro-2-[[1-[4-chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]pyridine; 1065-Chloro-2-[[1-[4-chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]-3-methoxy-pyridine; 1072-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]-3-fluoro-pyridine; 1082-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]-3-methoxy-pyridine; 1112-[[1-[3-(Difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyridine; 1125-Chloro-2[[1-[3-(difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyridine; 1132-[[1-[3-(Difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-6-methyl-pyridine; 1142-[[1-[3-(Difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-5-methyl-pyridine; 1152-[[1-[3-(Difluoromethy)-4-fluoro-phenyl]triazol-4-yl]methoxy]-4-methyl-pyridine; 1162-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]-4-methyl-pyridine; 1175-Chloro-2-[[1-[3-(difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyridine; 1182-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]-5-methyl-pyridine; 1192-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]-5-(trifluoromethyl)pyridine; 1205-Methyl-2-((1-(5-(trifluoromethyl)thiophen-2-yl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidine; 1215-Methyl-2-((1-(4-(trifluoromethyl)thiophen-2-yl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidine; 1222-((1-(3-(Difluoromethyl)-2-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-5-methylpyrimidine; 1232-((1-(4-Chlorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-5-methylpyrimidine; 1242-((1-(4-Chloro-3-(oxetan-3-yl)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)-5-methylpyrimidine; 1252-((1-(4-Chloro-3-(difluoromethyl)phenyl)-5-fluoro-1H-1,2,3-triazol-4-yl)methoxy)-5-methylpyrimidine; 1262-((1-(4-Chloro-3-(difluoromethyl)phenyl)-5-(trifluoromethyl)-1H-1,2,3-triazol-4-yl)methoxy)-5-methylpyrimidine; 1272-((1-(4-Chloro-3-(difluoromethyl)phenyl)-5-methyl-1H-1,2,3-triazol-4-yl)methoxy)-5-methylpyrimidine; 1282-((1-(4-Chloro-3-(difluoromethyl)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)-5-methylthiazole; 1291-(4-Chloro-3-(difluoromethyl)phenyl)-4-(((5-methyl-1H-imidazol-2-yl)oxy)methyl)-1H-1,2,3-triazole; 1302-((1-(4-Chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)-5-methylpyridine; 1312-((1-(4-Chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)-6-methylpyridine; 1326-((1-(4-Chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)-2,3-dimethylpyridine; 1332-((1-(4-Chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)-6-methylpyrazine; 1345-((1-(4-Chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)-2,3-dimethylpyrazine; 1355-((1-(4-Chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)-2-methylpyrimidine; 1366-((1-(4-Chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)-3,4-dimethylpyridazine; 1373-((1-(4-Chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)-6-(trifluoromethyl)pyridazine; 1383-((1-(4-Chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)-6-methoxypyridazine; 1394-((1-(4-Chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)-2-methylpyrimidine; 1404-((1-(4-Chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl]methoxy)-2-(trifluoromethyl)pyrimidine; 1414-((1-(4-Chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl]methoxy)-2-methoxypyrimidine; 1422-((1-(5-Chloro-6-(trifluoromethyl)pyridin-2-yl)-1H-1,2,3-triazol-4-yl)methoxy)-5-methylpyrimidine; 1432-((1-(2-(Difluoromethyl)pyridin-4-yl)-1H-1,2,3-triazol-4-yl)methoxy)-5-methylpyrimidine; 1463-((1-(4-Chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)-4-methoxypyridine; 1474-Chloro-3-((1-(4-chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyridine; 1484-((1-(3-(Difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)-5-methoxypyrimidine; 1492-((1-(3-(Difluoromethyl)phenyl)-5-methyl-1H-1,2,3-triazol-4-yl)methoxy)-5-methylpyrimidine; 1505-Methyl-2-((1-(5-(trifluoromethyl)pyridin-2-yl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidine; 1512-((1-(5-Bromo-6-fluoropyridin-3-yl)-1H-1,2,3-triazol-4-yl)methoxy)-5-methylpyrimidine; 1525-Methyl-2-((1-(pyridin-4-yl)-1H-1,2,3-triazol-4- yl)methoxy)pyrimidine;155 2-[[1-[3-(Difluoromethyl)phenyl]triazol-4-yl]methoxy]-4,5-dimethyl-pyrimidine; 1561-[2-[[1-[3-(Difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyrimidin-5-yl]ethanone; 157(R/S)-1-[2-[[1-[3-(Difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyrimidin-5-yl]ethanol; 1582-[[1-[4-Fluoro-3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]pyridine; 159 [2-[[1-[3-(Difluoromethyl)phenyl]triazol-4-yl]methoxy]pyrimidin-4-yl]methanol; 160[2-[[1-[3-(Difluoromethyl)phenyl]triazol-4-yl]methoxy]-pyrimidin-5-yl]methanol; 1612-[[1-[3-(Difluoromethyl)phenyl]triazol-4-yl]methoxy]-5-methyl-pyrimidin-4-amine; 1622-[[1-[3-(Difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-N-methyl-pyrimidine-4-carboxamide; 163 (R/S)1-[2-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyrimidin-4-yl]ethanamine; 1645-Chloro-2-[[1-(4-fluorophenyl)triazol-4-yl]methoxy]pyrimidine; 1655-(Azetidin-1-yl)-2-[[1-[3-(difluoromethoxy)-4-fluoro-phenyl]-triazol-4-yl]methoxy]pyrimidine; 1662-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]-4-(3,3-difluoropyrrolidin-1-yl)pyrimidine; 1672-((1-(3-(Difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-5-fluoropyrimidin-4-amine; 1682-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]-4-pyrrolidin-1-yl-pyrimidine; 1692-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]-4-(1-piperidyl)pyrimidine; 1704-[2-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyrimidin-4-yl]morpholine; 1712-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]-N-methyl-pyrimidin-4-amine; 1722-[[1-[3-(Difluoromethyl)phenyl]-5-methyl-triazol-4-yl]methoxy]-5-methoxy-pyrimidine; 1732-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]-5-methyl-triazol-4-yl]methoxy]-5-methyl-pyrimidine; 1745-Methyl-2-[[1-(6-methyl-2-pyridyl)triazol-4-yl]methoxy]- pyrimidine;175 5-Methyl-2-[[1-(2-methyl-4-pyridyl)triazol-4-yl]methoxy]-pyrimidine; 1765-Methyl-2-[[1-(5-methyl-3-pyridyl)triazol-4-yl]methoxy]- pyrimidine;177 2-[[1-(2-Bromo-4-pyridyl)triazol-4-yl]methoxy]-5-methyl- pyrimidine;178 2-[2-[[1-(3-Cyclobutyl-4-fluoro-phenyl)triazol-4-yl]methoxy]pyrimidin-5-yl]propan-2-ol; 1792-[2-[[1-(4-Fluoro-3-isopropyl-phenyl)triazol-4-yl]methoxy]pyrimidin-5-yl]propan-2-ol; 1802-[2-[[1-(3-Cyclopropyl-4-fluoro-phenyl)triazol-4-yl]methoxy]pyrimidin-5-yl]propan-2-ol; 1812-[2-[[1-(4-Fluoro-3-methyl-phenyl)triazol-4-yl]methoxy]-pyrimidin-5-yl]propan-2-ol; 1822-[2-[[1-(3-Ethyl-4-fluoro-phenyl)triazol-4-yl]methoxy]pyrimidin-5-yl]propan-2-ol; 1835-Bromo-2-[[1-[3-(1,1-difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyrimidine; 1842-[[1-[3-(1,1-Difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]-methoxy]-5-(1-methylpyrazol-3-yl)pyrimidine; 1852-[[1-[3-(1,1-Difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]-methoxy]-5-(1H-pyrazol-4-yl)pyrimidine; 1862-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-4-(1H-pyrazol-4-yl)pyrimidine; 1874-(2-((1-(3-(1,1-Difluoroethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidin-5-yl)morpholine; 1882-((1-(4-(Azetidin-1-yl)-3-(difluoromethyl)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidine; 1892-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]-5-fluoro-pyrazine; 1904-Chloro-2-[[1-[4-chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]pyrimidine; 1912-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]-4-fluoro-pyrimidine; 1922-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]-5-(2-fluoroethoxy)pyrimidine; 1932-[[1-[4-Chloro-3-(2-fluoroethoxy)phenyl]triazol-4-yl]methoxy]-5-methoxy-pyrimidine; 1942-[[1-[4-Fluoro-3-(3-fluoropropyl)phenyl]triazol-4-yl]methoxy]-5-methoxy-pyrimidine; 1952-[[1-[3-(3-Chloropropyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-5-methoxy-pyrimidine; 1962-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]-5-(3-fluoropropyl)pyrimidine; 2255-Chloro-2-[[1-(4-chlorophenyl)triazol-4-yl]methoxy]- pyrimidine; 2262-[[1-(4-Chlorophenyl)triazol-4-yl]methoxy]-5-(trifluoromethyl)pyrimidine; 2272-[[1-[4-Chlorophenyl)triazol-4-yl]methoxy]-5-(difluoromethoxy)pyrimidine; 2282-[[1-(3-Fluorophenyl)triazol-4-yl]methoxy]pyrimidine; 2295-Fluoro-2-[[1-(3-fluorophenyl)triazol-4-yl]methoxy]- pyrimidine; 2302-[[1-(3-Fluorophenyl)triazol-4-yl]methoxy]-5-methoxy- pyrimidine; 2315-Chloro-2-[[1-(3-fluorophenyl)triazol-4-yl]methoxy]- pyrimidine; 2322-[[1-(3-Fluorophenyl)triazol-4-yl]methoxy]-5- methyl-pyrimidine; 2335-Ethyl-2-[[1-(3-fluorophenyl)triazol-4-yl]methoxy]- pyrimidine; 2342-[[1-(3-Bromophenyl)triazol-4-yl]methoxy]-5-methyl- pyrimidine; 2352-[[1-(3-Bromophenyl)triazol-4-yl]methoxy]-4-methyl- pyrimidine; 2362-[[1-(o-Tolyl)triazol-4-yl]methoxy]pyrimidine; 2375-Fluoro-2-[[1-(o-tolyl)triazol-4-yl]methoxy]pyrimidine; 2385-Methoxy-2[[1-(o-tolyl)triazol-4-yl]methoxy]pyrimidine; 2395-Chloro-2-[[1-(o-tolyl)triazol-4-yl]methoxy]pyrimidine; 2405-Methyl-2-[[1-(o-tolyl)triazol-4-yl]methoxy]pyrimidine; 2415-Ethyl-2-[[1-(o-tolyl)triazol-4-yl]methoxy]pyrimidine; 2422-[[1-(m-Tolyl)triazol-4-yl]methoxy]pyrimidine; 2435-Methyl-2-[[1-(m-tolyl)triazol-4-yl]methoxy]pyrimidine; 2444-Methyl-2-[[1-(m-tolyl)triazol-4-yl]methoxy]pyrimidine; 2455-Ethyl-2-[[1-(m-tolyl)triazol-4-yl]methoxy]pyrimidine; 2465-Chloro-2-[[1-(m-tolyl)triazol-4-yl]methoxy]pyrimidine; 2475-Fluoro-2-[[1-(m-tolyl)triazol-4-yl]methoxy]pyrimidine; 2485-Methoxy-2-[[1-(m-tolyl)triazol-4-yl]methoxy]pyrimidine; 2492-[2-[[1-(m-Tolyl)triazol-4-yl]methoxy]pyrimidin-5- yl]propan-2-ol; 2504-(Methoxymethyl)-2-[[1-(m-tolyl)triazol-4-yl]methoxy]- pyrimidine; 2514,5-Dimethyl-2-[[1-(m-tolyl)triazol-4-yl]methoxy]pyrimidine; 2525-Fluoro-4-methyl-2-[[1-(m-tolyl)triazol-4-yl]methoxy]- pyrimidine; 2535-Chloro-4-methyl-2-[[1-(m-tolyl)triazol-4-yl]methoxy]- pyrimidine; 2545-Methyl-2-[[1-(m-tolyl)triazol-4-yl]methoxy]pyrimidin- 4-amine; 2551-[2-[[1-(m-Tolyl)triazol-4-yl]methoxy]pyrimidin-5- yl]ethanone; 2562-[[1-(p-Tolyl)triazol-4-yl]methoxy]pyrimidine; 2575-Fluoro-2-[[1-(p-tolyl)triazol-4-yl]methoxy]pyrimidine; 2585-Methoxy-2-[[1-(p-tolyl)triazol-4-yl]methoxy]pyrimidine; 2595-Chloro-2-[[1-(p-tolyl)triazol-4-yl]methoxy]pyrimidine; 2605-Methyl-2-[[1-(p-tolyl)triazol-4-yl]methoxy]pyrimidine; 2615-Ethyl-2-[[1-(p-tolyl)triazol-4-yl]methoxy]pyrimidine; 2622-[[1-(3-Isopropylphenyl)triazol-4-yl]methoxy]pyrimidine; 2635-Fluoro-2-[[1-(3-isopropylphenyl)triazol-4-yl]methoxy]- pyrimidine; 2642-[[1-(3-Isopropylphenyl)triazol-4-yl]methoxy]-5-methoxy- pyrimidine;265 5-Chloro-2-[[1-(3-isopropylphenyl)triazol-4-yl]methoxy]- pyrimidine;266 2-[[1-(3-Isopropylphenyl)triazol-4-yl]methoxy]-5- methyl-pyrimidine;267 5-Ethyl-2-[[1-(3-isopropylphenyl)triazol-4-yl]methoxy]- pyrimidine;268 2-[[1-[3-(Difluoromethyl)phenyl]triazol-4-yl]methoxy]-4-methyl-pyrimidine; 2692-[[1-[3-(Difluoromethyl)phenyl]triazol-4-yl]methoxy]-5-fluoro-pyrimidine; 2702-[[1-[3-(Difluoromethyl)phenyl]triazol-4-yl]methoxy]-4-isopropyl-pyrimidine; 2712-[[1-[3-(Difluoromethyl)phenyl]triazol-4-yl]methoxy]-4-(methoxymethyl)pyrimidine; 2722[2-[[1-[3-(Difluoromethyl)phenyl]triazol-4-yl]methoxy]-pyrimidin-5-yl]propan-2-ol; 2735-(Difluoromethyl)-2-[[1-[3-(difluoromethyl)phenyl]triazol-4-yl]methoxy]pyrimidine; 2744-(Difluoromethyl)-2-[[1-[3-(difluoromethyl)phenyl]triazol-4-yl]methoxy]pyrimidine; 2752-[[1-[3-(Difluoromethyl)phenyl]triazol-4-yl]methoxy]-5-(trifluoromethyl)pyrimidine; 2765-(Difluoromethoxy)-2-[[1-[3-difluoromethyl)phenyl]triazol-4-yl]methoxy]pyrimidine; 2772-[[1-[3-(Difluoromethyl)phenyl]triazol-4-yl]methoxy]-N,N-dimethyl-pyrimidin-4-amine; 2782-[[1-[3-(Difluoromethyl)phenyl]triazol-4-yl]methoxy]-5-fluoro-4-methyl-pyrimidine; 2795-Chloro-2-[[1-[3-(difluoromethyl)phenyl]triazol-4-yl]methoxy]-4-methyl-pyrimidine; 2802-Chloro-4[[1-[3-(difluoromethyl)phenyl]triazol-4-yl]methoxy]-5-methyl-pyrimidine; 2812-[[1-[3-(Difluoromethyl)phenyl]triazol-4-yl]methoxy]-N,N,5-trimethyl-pyrimidin-4-amine; 2825-Cyclopropyl-2-[[1-[3-(difluoromethyl)phenyl]triazol-4-yl]methoxy]pyrimidine; 2834-Cyclopropyl-2-[[1-[3-(difluoromethyl)phenyl]triazol-4-yl]methoxy]pyrimidine; 2842-[[1-[3-(Difluoromethyl)phenyl]triazol-4-yl]methoxy]-4-pyrrolidin-1-yl-pyrimidine; 2852-[[1-[3-(Difluoromethyl)phenyl]triazol-4-yl]methoxy]-4-(1-piperidyl)pyrimidine; 2865-Methyl-2-[[1-[3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]pyrimidine; 2875-Ethyl-2-[[1-[3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]pyrimidine; 2885-isopropyl-2-[[1-[3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]pyrimidine; 2895-(Difluoromethyl)-2-[[1-[3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]pyrimidine; 2904,5-Dimethyl-2-[[1-[3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]pyrimidine; 2915-Chloro-4-methyl-2-[[1-[3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]pyrimidine; 2922-[[1-[3-(1,1-Difluoroethyl)phenyl]triazol-4-yl]methoxy]- pyrimidine;293 5-Bromo-2-[[1-[3-(1,1-difluoroethyl)phenyl]triazol-4-yl]methoxy]pyrimidine; 2945-Chloro-2-[[1-[3-(1,1-difluoroethyl)phenyl]triazol-4-yl]methoxy]pyrimidine; 2952-[[1-[3-(1,1-Difluoroethyl)phenyl]triazol-4-yl]methoxy]-5-fluoro-pyrimidine; 2962-[[1-[3-(1,1-Difluoroethyl)phenyl]triazol-4-yl]methoxy]-4-methyl-pyrimidine; 2972-[[1-[3-(1,1-Difluoroethyl)phenyl]triazol-4-yl]methoxy]-5-methyl-pyrimidine; 298[2-[[1-[3-(1,1-Difluoroethyl)phenyl]triazol-4-yl]methoxy]-pyrimidin-5-yl]methanol; 299[2-[[1-[3-(1,1-Difluoroethyl)phenyl]triazol-4-yl]methoxy]-pyrimidin-4-yl]methanol; 3002-[[1-[3-(1,1-Difluoroethyl)phenyl]triazol-4-yl]methoxy]-4-(methoxymethyl)pyrimidine; 3012-[2-[[1-[3-(1,1-Difluoroethyl)phenyl]triazol-4-yl]methoxy]-pyrimidin-5-yl]propan-2-ol; 3022-[[1-[3-(1,1-Difluoroethyl)phenyl]triazol-4-yl]methoxy]-5-(difluoromethy)pyrimidine; 3032-[[1-[3-(1,1-Difluoroethyl)phenyl]triazol-4-yl]methoxy]-4-(difluoromethyl)pyrimidine; 3042-[[1-[3-(1,1-Difluoroethyl)phenyl]triazol-4-yl]methoxy]-4-(trifluoromethyl)pyrimidine; 305(R/S)-2-[2-[[1-[3-(1,1-Difluoroethyl)phenyl]triazol-4-yl]methoxy]pyrimidin-5-yl]-1,1,1-trifluoro-propan-2-ol; 3062-[[1-[3-(1,1-Difluoroethyl)phenyl]triazol-4-yl]methoxy]-5-methoxy-pyrimidine; 3072-[[1-[3-(1,1-Difluoroethyl)phenyl]triazol-4-yl]methoxy]-4-methoxy-pyrimidine; 3082-[[1-[3-(1,1-Difluoroethyl)phenyl]triazol-4-yl]methoxy]-5-(difluoromethoxy)pyrimidine; 3091-[2-[[1-[3-(1,1-Difluoroethyl)phenyl]triazol-4-yl]methoxy]-pyrimidin-5-yl]ethanone; 310(R/S)-1-[2-[[1-[3-(1,1-Difluoroethyl)phenyl]triazol-4-yl]methoxy]pyrimidin-5-yl]ethanol; 311(R/S)-2-[[1-[3-(1,1-Difluoroethyl)phenyl]triazol-4-yl]methoxy]-5-(1-methoxyethyl)pyrimidine; 3125-Chloro-2-[[1-[3-(1,1-difluoroethyl)phenyl]triazol-4-yl]methoxy]-4-methyl-pyrimidine; 3132-[[1-[3-(1,1-Difluoroethyl]phenyl]triazol-4-yl]methoxy]-5-fluoro-4-methyl-pyrimidine; 3142-[[1-[3-(1,1-Difluoroethyl)phenyl]triazol-4-yl]methoxy]-5-methyl-pyrimidin-4-amine; 3152-[[1-[3-(1,1-Difluoroethyl)phenyl]triazol-4-yl]methoxy]-5-fluoro-N-methyl-pyrimidin-4-amine; 3162-[[1-[3-(1,1-Difluoroethyl)phenyl]triazol-4-yl]methoxy]-pyrimidin-4-amine; 3172-[[1-[3-(1,1-Difluoroethyl)phenyl]triazol-4-yl]methoxy]-N-methyl-pyrimidin-4-amine; 3182-[[1-[3-(1,1-Difluoroethyl)phenyl]triazol-4-yl]methoxy]-N,N-dimethyl-pyrimidin-4-amine; 3195-Cyclopropyl-2-[[1-[3-(1,1-difluoroethyl)phenyl]triazol-4-yl]methoxy]pyrimidine; 3205-(Azetidin-1-yl)-2-[[1-[3-(1,1-difluomethyl)phenyl]triazol-4-yl]methoxy]pyrimidine; 3212-[[1-[3-(1,1-Difluoroethyl)phenyl]triazol-4-yl]methoxy]-5-(3-fluoroazetidin-1-yl)pyrimidine; 3222-[[1-[3-(1,1-Difluoromethyl)phenyl]triazol-4-yl]methoxy]-4-pyrrolidin-1-yl-pyrimidine; 3232-[[1-[3-(Difluoromethoxy)phenyl]triazol-4-yl]methoxy]- pyrimidine; 3242-[[1-[3-(Difluoromethoxy)phenyl]triazol-4-yl]methoxy]-5-fluoro-pyrimidine; 3252-[[1-[3-(Difluoromethoxy)phenyl]triazol-4-yl]methoxy]-5-methoxy-pyrimidine; 3265-Chloro-2[[1-[3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]pyrimidine; 3272-[[1-[3-(Difluoromethoxy)phenyl]triazol-4-yl]methoxy]-5-methyl-pyrimidine; 3282-[[1-[3-(Difluoromethoxy)phenyl]triazol-4-yl]methoxy]-5-ethyl-pyrimidine; 3292-[[1-[4-(Difluoromethoxy)phenyl]triazol-4-yl]methoxy]- pyrimidine; 3302-[[1-[4-(Difluoromethoxy)phenyl]triazol-4-yl]methoxy]-5-fluoro-pyrimidine; 3312-[[1-[4-(Difluoromethoxy)phenyl]triazol-4-yl]methoxy]-5-methoxy-pyrimidine; 3325-Chloro-2-[[1-[4-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]pyrimidine; 3332-[[1-[4-(Difluoromethoxy)phenyl]triazol-4-yl]methoxy]-5-methyl-pyrimidine; 3342-[[1-[4-(Difluoromethoxy)phenyl]triazol-4-yl]methoxy]-5-ethyl-pyrimidine; 3352-[[1-[4-(Trifluoromethoxy)phenyl]triazol-4-yl]methoxy]- pyrimidine; 3365-Fluoro-2-[[1-[4-(trifluoromethoxy)phenyl]triazol-4-yl]methoxy]pyrimidine; 3375-Methoxy-2-[[1-[4-(trifluoromethoxy)phenyl]triazol-4-yl]methoxy]pyrimidine; 3385-Chloro-2-[[1-[4-(trifluoromethoxy)phenyl]triazol-4-yl]methoxy]pyrimidine; 3395-Methyl-2-[[1-[4-(trifluoromethoxy)phenyl]triazol-4-yl]methoxy]pyrimidine; 3405-Ethyl-2-[[1-[4-(trifluoromethoxy)phenyl]triazol-4-yl]methoxy]pyrimidine; 3412-[[1-[3-(Trifluoromethoxy)phenyl]triazol-4-yl]methoxy]- pyrimidine; 3425-Methyl-2-[[1-[3-(trifluoromethoxy)phenyl]triazol-4-yl]methoxy]pyrimidine; 3435-Methyl-2-[[1-[3-(trifluoromethoxy)phenyl]triazol-4-yl]methoxy]pyrimidin-4-amine; 3441-[2-[[1-[3-(Trifluoromethoxy)phenyl]triazol-4-yl]methoxy]pyrimidin-5-yl]ethanone; 3452-[2-[[1-[3-(Trifluoromethoxy)phenyl]triazol-4-yl]methoxy]pyrimidin-5-yl]propan-2-ol; 3464-(Methoxymethyl)-2-[[1-[3-(trifluoromethoxy)phenyl]triazol-4-yl]methoxy]pyrimidine; 3474-Methyl-2-[[1-[3-(trifluoromethoxy)phenyl]triazol-4-yl]methoxy]pyrimidine; 3485-Fluoro-2-[[1-[3-(trifluoromethoxy)phenyl]triazol-4-yl]methoxy]pyrimidine; 3495-Methoxy-2-[[1-[3-(trifluoromethoxy)phenyl]triazol-4-yl]methoxy]pyrimidine; 3505-Chloro-2-[[1-[3-(trifluoromethoxy)phenyl]triazol-4-yl]methoxy]pyrimidine; 3515-Ethyl-2-[[1-[3-(trifluoromethoxy)phenyl]triazol-4-yl]methoxy]pyrimidine; 352N-Methyl-2-[[1-[3-(trifluoromethoxy)phenyl]triazol-4-yl]methoxy]pyrimidin-4-amine; 3532-[[1-[3-(Trifluoromethoxy)phenyl]triazol-4-yl]methoxy]-pyrimidin-4-amine; 3542-[[1-(2,2-Difluoro-1,3-benzodioxo1-5-yl)triazol-4-yl]methoxy]-5-methyl-pyrimidine; 3552-[[1-(2,2-Difluoro-1,3-benzodioxol-5-yl)triazol-4-yl]methoxy]pyrimidine; 3565-Chloro-2-[[1-(2,2-difluoro-1,3-benzodioxol-5-yl)triazol-4-yl]methoxy]pyrimidine; 3572-[[1-(2,2-Difluoro-1,3-benzodioxol-5-yl)triazol-4-yl]methoxy]-5-fluoro-4-methyl-pyrimidine; 3582-[[1-(2,2-Difluoro-1,3-benzodioxol-5-yl)triazol-4-yl]methoxy]-5-fluoro-pyrimidine; 3592-[[1-(2,2-Difluoro-1,3-benzodioxol-5-yl)triazol-4-yl]methoxy]-4,5-dimethyl-pyrimidine; 3602-[[1-(3,5-Dimethylphenyl)triazol-4-yl]methoxy]pyrimidine; 3612-[[1-(3,5-Dimethylphenyl)triazol-4-yl]methoxy]-5- fluoro-pyrimidine;362 2-[[1-(3,5-Dimethylphenyl)triazol-4-yl]methoxy]-5-methoxy-pyrimidine; 3635-Chloro-2-[[1-(3,5-dimethylphenyl)triazol-4-yl]- methoxy]pyrimidine;364 2-[[1-(3,5-Dimethylphenyl)triazol-4-yl]methoxy]-5-methyl-pyrimidine; 3652-[[1-(3,5-Dimethylphenyl)triazol-4-yl]methoxy]- 5-ethyl-pyrimidine; 3662-[(1-Indan-5-yltriazol-4-yl)methoxy]-5-methyl-pyrimidine; 3675-Chloro-2-[(1-indan-5-yltriazol-4-yl)methoxy]pyrimidine; 3682-[(1-Indan-5-yltriazol-4-yl)methoxy]-4-(methoxymethyl)- pyrimidine; 3692-[2-[(1-Indan-5-yltriazol-4-yl)methoxy]pyrimidin-5- yl]propan-2-ol; 3704-(Difluoromethyl)-2-[(1-indan-5-yltriazol-4-yl)methoxy]- pyrimidine;371 5-Chloro-2-[(1-indan-5-yltriazol-4-yl)methoxy]-4- methyl-pyrimidine;372 2-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]-methoxy]-4,5-dimethyl-pyrimidine; 3732-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]-methoxy]-5-isopropyl-pyrimidine; 3742-[(1R)-1-[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]ethoxy]pyrimidine; 3755-Chloro-2-[(1R)-1-[1-[4-chloro-3-(difluoromethoxy)phenyl]-triazol-4-yl]ethoxy]pyrimidine; 3762-[(1R)-1-[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]ethoxy]-5-methyl-pyrimidine; 3772-[(1R)-1-[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]ethoxy]-5-methoxy-pyrimidine; 3782-[(1S)-1-[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]ethoxy]pyrimidine; 3795-Chloro-2-[(1S)-1-[1-[4-chloro-3-(difluoromethoxy)phenyl]-triazol-4-yl]ethoxy]pyrimidine; 3802-[(1S)-1-[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]ethoxy]-5-methyl-pyrimidine; 3812-[(1S)-1-[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]ethoxy]-5-methoxy-pyrimidine; 3822-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]pyrimidin-4-amine; 383[2-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]pyrimidin-4-yl]methanol; 3842-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]-4-(methoxymethyl)pyrimidine; 3852-[2-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]pyrimidin-5-yl]propan-2-ol; 3862-((1-(4-Chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)-4-isopropoxypyrimidine; 387 Methyl2-((1-(4-chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidine-4-carboxylate; 3882-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]-N-(2,2-difluoroethyl)-5-fluoro-pyrimidin-4-amine; 3892-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]-5-fluoro-N-methyl-pyrimidin-4-amine; 3902-((1-(4-Chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)-5-fluoropyrimidin-4-amine; 3915-(Azetidin-1-yl)-2-((1-(4-chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidine; 3922-((1-(4-Chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)-5-(3-fluoroazetidin-1-yl)pyrimidine; 3932-((1-(4-Chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl]methoxy)-5-(3,3-difluoroazetidin-1-yl)pyrimidine; 3942-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]-6-fluoro-pyridine; 3952-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]-6-(trifluoromethy)pyridine; 3962-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]-5-methyl-pyrazine; 3972-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]-5-(2-thienyl)pyrazine; 3985-Bromo-2-[[1-[3-(difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyrimidine; 3992-[[1-[3-(Difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-4-(methoxymethyl)pyrimidine; 400[2-[[1-[3-(Difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyrimidin-4-yl]methanol; 4012-[2-[[1-[3-(Difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyrimidin-5-yl]propan-2-ol; 4024-(Difluoromethyl)-2-[[1-[3-(difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyrimidine; 4032-[[1-[3-(Difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-4-(trifluoromethyl)pyrimidine; 404(R/S)-2-[2-[[1-[3-(Difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyrimidin-5-yl]-1,1,1-trifluoro-propan-2-ol; 4055-(Difluoromethoxy)-2-[[1-[3-(difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyrimidine; 4065-Chloro-2-[[1-[3-(difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-4-methyl-pyrimidine; 4072-[[1-[3-(Difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-5-fluoro-4-methyl-pyrimidine; 4082-[[1-[3-(Difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-4,5-dimethyl-pyrimidine; 4092-[[1-[3-(Difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-N-methyl-pyrimidine-5-carboxamide; 4102-[[1-[3-(Difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-N,N-dimethyl-pyrimidine-4-carboxamide; 4112-[[1-[3-(Difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-4-methoxy-5-methyl-pyrimidine; 4122-[[1-[3-(Difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyrimidin-4-amine; 4132-[[1-[3-(Difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-N-methyl-pyrimidin-4-amine; 4142-[[1-[3-(Difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-5-fluoro-N-methyl-pyrimidin-4-amine; 4152-[[1-[3-(Difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-N,N-dimethyl-pyrimidin-4-amine; 4162-((1-(3-(Difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-5-(3-fluoroazetidin-1-yl)pyrimidine; 4175-(Azetidin-1-yl)-2-((1-(3-(difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl]methoxy)pyrimidine; 4182-((1-(3-(Difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-5-(3-methoxyazetidin-1-yl)pyrimidine; 4195-(3,3-Difluoroazetidin-1-yl)-2-((1-(3-(difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidine; 4202-((1-(3-(Difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-5-(3-fluoro-3-methylazetidin-1-yl)pyrimidine; 4212-((1-(3-(Difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-5-(3-(difluoromethyl)azetidin-1-yl)pyrimidine; 4222-((1-(3-(Difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-5-(3,3-difluoropyrrolidin-1-yl)pyrimidine; 4235-Cyclopropyl-2-[[1-[3-(difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyrimidine; 4242-[[1-[3-(Difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-4-(2-furyl)pyrimidine; 4252-[[1-[3-(Difluoromethyl)-4-fluoro-phenyl]-5-iodo-triazol-4-yl]methoxy]-5-methyl-pyrimidine; 426[3H]-2-((1-(3-(Difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl-5-t)methoxy)-5-methylpyrimidine; 4273-Fluoro-2-[[1-[4-fluoro-3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]pyridine; 4285-Chloro-2-[[1-[4-fluoro-3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]pyridine; 4292-[[1-[4-Fluoro-3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]-4-methyl-pyridine; 4302-[[1-[4-Fluoro-3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]-6-methyl-pyridine; 4312-[[1-[4-Fluoro-3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]-5-methyl-pyridine; 4322-[[1-[4-Fluoro-3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]-5-(trifluoromethyl)pyridine; 4332-[6-[[1-[4-Fluoro-3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]-3-pyridyl]propan-2-ol; 4342-[[1-[4-Fluoro-3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]pyrazine; 4352-[2-[[1-[4-Fluoro-3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]pyrimidin-5-yl]propan-2-ol; 4362-[[1-[4-Fluoro-3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]-5-(1-methoxy-1-methyl-ethyl)pyrimidine; 4372-[[1-[4-Fluoro-3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]-5-(methoxymethyl)pyrimidine; 4382-[[1-[4-Fluoro-3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]-4-(methoxymethyl)pyrimidine; 4395-(Difluoromethyl)-2-[[1-[4-fluoro-3-(trifluoromethyl)-phenyl]triazol-4-yl]methoxy]pyrimidine; 4404-(Difluoromethyl)-2-[[1-[4-fluoro-3-(trifluoromethyl)-phenyl]triazol-4-yl]methoxy]pyrimidine; 441(R/S)-1,1,1-Trifluoro-2-[2-[[1-[4-fluoro-3-(trifluoromethyl)-phenyl]triazol-4-yl]methoxy]pyrimidin-5-yl]propan-2-ol; 4422-[[1-[4-Fluoro-3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]-4-methoxy-pyrimidine; 4435-Ethoxy-2-[[1-[4-fluoro-3-(trifluoromethyl)phenyl]-triazol-4-yl]methoxy]pyrimidine; 4445-Chloro-2-[[1-[4-fluoro-3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]-4-methyl-pyrimidine; 4455-Fluoro-2-[[1-[4-fluoro-3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]-4-methyl-pyrimidine; 4462-[[1-[4-Fluoro-3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]-4,5-dimethyl-pyrimidine; 4471-[2-[[1-[4-Fluoro-3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]pyrimidin-5-yl]ethanone; 448(R/S)-1-[2-[[1-[4-Fluoro-3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]pyrimidin-5-yl]ethanol; 4492-[[1-[4-Fluoro-3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]-N-methyl-pyrimidin-4-amine; 4502-[[1-[4-Fluoro-3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]-N,N-dimethyl-pyrimidin-4-amine; 4515-Fluoro-2-[[1-[4-fluoro-3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]-N-methyl-pyrimidin-4-amine; 4522-[[1-[4-Fluoro-3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]-N-methyl-pyrimidine-5-carboxamide; 4535-Cyclopropyl-2-[[1-[4-fluoro-3-(trifluoromethyl)phenyl]-triazol-4-yl]methoxy]pyrimidine; 4545-Bromo-2-((1-(4-fluoro-3-(trifluoromethyl)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidine; 4552-((1-(4-Fluoro-3-(trifluoromethyl)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)-5-(3-fluoroazetidin-1-yl)pyrimidine; 4564-(2-((1-(4-Fluoro-3-(trifluoromethyl)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidin-5-yl)morpholine; 4575-(Azetidin-1-yl)-2-((1-(3-(trifluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-4-methylpyrimidine; 4582-((1-(3-(Trifluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-N-ethyl-4-methylpyrimidin-5-amine; 4592-((1-(3-(Trifluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-N-ethylpyrimidin-5-amine; 4602-((1-(3-(Trifluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-5-(3-methoxyazetidin-1-yl)pyrimidine; 4615-Chloro-2-[[1-[2-fluoro-3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]pyrimidine; 4624-[[1-(4-Fluoro-3-methyl-phenyl)triazol-4-yl]methoxy]-6-methyl-pyrimidine; 4635-Chloro-2-[[1-(3-fluoro-2-methyl-phenyl)triazol-4-yl]methoxy]pyrimidine; 4642-[[1-(3-Fluoro-2-methyl-phenyl)triazol-4-yl]methoxy]-5-methyl-pyrimidine; 4655-Fluoro-2-[[1-(3-fluoro-2-methyl-phenyl)triazol-4-yl]methoxy]-4-methyl-pyrimidine; 4662-[2-[[1-(3-Fluoro-2-methyl-phenyl)triazol-4-yl]methoxy]-pyrimidin-5-yl]propan-2-ol; 4672-[[1-(2-Fluoro-3-methyl-phenyl)triazol-4-yl]methoxy]-5-methyl-pyrimidine; 4685-Chloro-2-[[1-(2-fluoro-3-methyl-phenyl)triazol-4-yl]methoxy]pyrimidine; 4692-[[1-(2-Fluoro-3-methyl-phenyl)triazol-4-yl]methoxy]-5-(trifluoromethyl)pyrimidine; 4705-Chloro-2-[[1-(2-fluoro-3-methyl-phenyl)triazol-4-yl]methoxy]-4-methyl-pyrimidine; 4715-(Difluoromethoxy)-2-[[1-(2-fluoro-3-methyl-phenyl)triazol-4-yl]methoxy]pyrimidine; 4722-[[1-(4-Fluoro-3-methyl-phenyl)triazol-4-yl]methoxy]-pyrimidin-4-amine; 4732-[[1-(4-Fluoro-3-methyl-phenyl)triazol-4-yl]methoxy]- pyrimidine; 4745-Fluoro-2-[[1-(4-fluoro-3-methyl-phenyl)triazol-4-yl]methoxy]pyrimidine; 4752-[[1-(4-Fluoro-3-methyl-phenyl)triazol-4-yl]methoxy]-5-methoxy-pyrimidine; 4765-Chloro-2-[[1-(4-fluoro-3-methyl-phenyl)triazol-4-yl]methoxy]pyrimidine; 477 2-[[1-(4-Fluoro-3-methyl-phenyl)triazol-4-yl]methoxy]-5-methyl-pyrimidine; 4785-Ethyl-2-[[1-(4-fluoro-3-methyl-phenyl)triazol-4-yl]methoxy]pyrimidine; 4792-[[1-(4-Fluoro-3-methyl-phenyl)triazol-4-yl]methoxy]-4-(methoxymethyl)pyrimidine; 4802-[[1-(4-Fluoro-3-methyl-phenyl)triazol-4-yl]methoxy]-4,5-dimethyl-pyrimidine; 4815-Fluoro-2-[[1-(4-fluoro-3-methyl-phenyl)triazol-4-yl]methoxy]-4-methyl-pyrimidine; 4825-Chloro-2-[[1-(4-fluoro-3-methyl-phenyl)triazol-4-yl]methoxy]-4-methyl-pyrimidine; 4835-(2-Fluoroethoxy)-2-[[1-(4-fluoro-3-methyl-phenyl)triazol-4-yl]methoxy]pyrimidine; 4842-[[1-(2-Fluoro-5-methyl-phenyl)triazol-4-yl]methoxy]-5-methyl-pyrimidine; 4855-Chloro-2-[[1-(2-fluoro-5-methyl-phenyl)triazol-4-yl]methoxy]-4-methyl-pyrimidine; 4865-Fluoro-2-[[1-(2-fluoro-5-methyl-phenyl)triazol-4-yl]methoxy]-4-methyl-pyrimidine; 4875-Fluoro-2-[[1-(4-fluoro-2-methyl-phenyl)triazol-4-yl]methoxy]pyrimidine; 4882-[[1-(4-Fluoro-2-methyl-phenyl)triazol-4-yl]methoxy]-5-methoxy-pyrimidine; 4895-Chloro-2-[[1-(4-fluoro-2-methyl-phenyl)triazol-4-yl]methoxy]pyrimidine; 4902-[[1-(4-Fluoro-2-methyl-phenyl)triazol-4-yl]methoxy]-5-methyl-pyrimidine; 4915-Ethyl-2-[[1-(4-fluoro-2-methyl-phenyl)triazol-4-yl]methoxy]pyrimidine; 4922-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]-5-fluoro-pyrimidine; 4932-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]-5-fluoro-4-methyl-pyrimidine; 4945-Bromo-2-[[1-[3-(difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyrimidine; 4952-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]-4-ethyl-pyrimidine; 4962-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]-4-isopropyl-pyrimidine; 4972-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]-4-methoxy-pyrimidine; 498[2-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyrimidin-4-yl]methanol; 4992-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]-4-(methoxymethyl)pyrimidine; 5002-[2-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyrimidin-5-yl]propan-2-ol; 5012-[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyrimidin-4-amine; 5022-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyrimidin-5-amine; 5032-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]-N-methyl-pyrimidin-4-amine; 5042-((1-(3-(Difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-N-ethylpyrimidin-4-amine; 5052-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]-N,N-dimethyl-pyrimidin-4-amine; 5062-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]-4-phenyl-pyrimidine; 5072-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]-5-(3-fluoroazetidin-1-yl)pyrimidine; 5085-(3,3-Difluoroazetidin-1-yl)-2-[[1-[3-(difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyrimidine; 5094-(Azetidin-1-yl)-2-[[1-[3-(difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyrimidine; 5102-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]-4-(3-fluoroazetidin-1-yl)pyrimidine; 5114-(3,3-Difluoroazetidin-1-yl)-2-[[1-[3-(difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyrimidine; 512(R)-2-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]-4-[(3R)-3-fluoropyrrolidin-1-yl]pyrimidine; 5135-Chloro-2-[[1-[3-(difluoromethoxy)-4-fluoro-phenyl]-triazol-4-yl]methoxy]-4-methyl-pyrimidine; 5142-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]-5-methyl-pyrimidin-4-amine; 5152-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]-N,5-dimethyl-pyrimidin-4-amine; 5162-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]-N,N,5-trimethyl-pyrimidin-4-amine; 517N-(2,2-Difluoroethyl)-2-[[1-[3-(difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]-5-fluoro-pyrimidin-4-amine; 5182-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]-5-fluoro-N-methyl-pyrimidin-4-amine; 519N-Cyclopropyl-2-((1-(3-(difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-5-fluoropyrimidin-4-amine; 5201-(2-((1-(3-(Difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidin-4-yl)-N-methylmethanamine; 5212-[[1-[3-(Difluoromethoxy)-4-methyl-phenyl]triazol-4-yl]methoxy]-5-methyl-pyrimidin-4-amine; 5221-[2-[[1-[3-(Difluoromethoxy)-4-methyl-phenyl]triazol-4-yl]methoxy]pyrimidin-5-yl]ethanone; 5232-[[1-[3-(Difluoromethoxy)-4-methyl-phenyl]triazol-4-yl]methoxy]-4-methyl-pyrimidine; 5242-[[1-[3-(Difluoromethoxy)-4-methyl-phenyl]triazol-4-yl]methoxy]-5-methyl-pyrimidine; 5255-Bromo-2-[[1-[3-(difluoromethoxy)-4-methyl-phenyl]-triazol-4-yl]methoxy]pyrimidine; 5262-[2-[[1-[3-(Difluoromethoxy)-4-methyl-phenyl]triazol-4-yl]methoxy]pyrimidin-5-yl]propan-2-ol; 5272-[[1-[3-(Difluoromethoxy)-4-methyl-phenyl]triazol-4-yl]methoxy]-4-(methoxymethyl)pyrimidine; 5282-[[1-[3-(Difluoromethyl)phenyl]-5-methyl-triazol-4-yl]methoxy]-4,5-dimethyl-pyrimidine; 5295-Chloro-2-[[1-[3-(difluoromethyl)phenyl]-5-methyl-triazol-4-yl]methoxy]pyrimidine; 5302-[[1-[4-Chloro-3-(1,1-difluoroethyl)phenyl]triazol-4-yl]methoxy]-5-methyl-pyrimidine; 5312-[[1-[4-Chloro-3-(1,1-difluoroethyl)phenyl]triazol-4-yl]methoxy]-4-methyl-pyrimidine; 5322-[2-[[1-[4-Chloro-3-(1,1-difluoroethyl)phenyl]triazol-4-yl]methoxy]pyrimidin-5-yl]propan-2-ol; 533[2-[[1-[4-Chloro-3-(1,1-difluoroethyl)phenyl]triazol-4-yl]methoxy]pyrimidin-5-yl]methanol; 5342-[[1-[4-Chloro-3-(1,1-difluoroethyl)phenyl]triazol-4-yl]methoxy]-4-(methoxymethyl)pyrimidine; 5352-[[1-[4-Chloro-3-(1,1-difluoroethyl)phenyl]triazol-4-yl]methoxy]-5-(difluoromethy)pyrimidine; 5362-[[1-[4-Chloro-3-(1,1-difluoroethyl)phenyl]triazol-4-yl]methoxy]-4-(difluoromethy)pyrimidine; 5372-[[1-[4-Chloro-3-(1,1-difluoroethyl)phenyl]triazol-4-yl]methoxy]-5-(trifluoromethyl)pyrimidine; 5382-[[1-[4-Chloro-3-(1,1-difluoroethyl)phenyl]triazol-4-yl]methoxy]-4-(trifluoromethyl)pyrimidine; 539(R/S)-2-[2-[[1-[4-Chloro-3-(1,1-difluoroethyl)phenyl]-triazol-4-yl]methoxy]pyrimidin-5-yl]-1,1,1-trifluoro-propan-2-ol; 540[2-[[1-[4-Chloro-3-(1,1-difluoroethyl)phenyl]triazol-4-yl]methoxy]pyrimidin-4-yl]methanol; 5412-[[1-[4-Chloro-3-(1,1-difluoroethyl)phenyl]triazol-4-yl]methoxy]-4-methoxy-pyrimidine; 5422-[[1-[4-Chloro-3-(1,1-difluoroethyl)phenyl]triazol-4-yl]methoxy]-5-(difluoromethoxy)pyrimidine; 5435-Chloro-2-[[1-[4-chloro-3-(1,1-difluoroethyl)phenyl]-triazol-4-yl]methoxy]-4-methyl-pyrimidine; 5442-[[1-[4-Chloro-3-(1,1-difluoroethyl)phenyl]triazol-4-yl]methoxy]-5-fluoro-4-methyl-pyrimidine; 5452-[[1-[4-Chloro-3-(1,1-difluoroethyl)phenyl]triazol-4-yl]methoxy]-4,5-dimethyl-pyrimidine; 5462-[[1-[4-Chloro-3-(1,1-difluoroethyl)phenyl]triazol-4-yl]methoxy]-4,6-dimethyl-pyrimidine; 5472-[[1-[4-Chloro-3-(1,1-difluoroethyl)phenyl]triazol-4-yl]methoxy]pyrimidin-4-amine; 5482-[[1-[4-Chloro-3-(1,1-difluoroethyl)phenyl]triazol-4-yl]methoxy]-N-methyl-pyrimidin-4-amine; 5492-[[1-[4-Chloro-3-(1,1-difluoroethyl)phenyl]triazol-4-yl]methoxy]-5-fluoro-N-methyl-pyrimidin-4-amine; 5501-[2-[[1-[4-Chloro-3-(1,1-difluoroethyl)phenyl]triazol-4-yl]methoxy]pyrimidin-5-yl]ethanone; 551(R/S)-1-[2-[[1-[4-Chloro-3-(1,1-difluoroethyl)phenyl]-triazol-4-yl]methoxy]pyrimidin-5-yl]ethanol; 5522-[[1-[4-Chloro-3-(1,1-difluoroethyl)phenyl]triazol-4-yl]methoxy]-5-cyclopropyl-pyrimidine; 5532-[[1-[4-Chloro-3-(1,1-difluoroethyl)phenyl]triazol-4-yl]methoxy]-4-pyrrolidin-1-yl-pyrimidine; 5542-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyridine; 5552-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-3-fluoro-pyridine; 5562-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-6-methyl-pyridine; 5572-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-4-methyl-pyridine; 5582-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-5-methyl-pyridine; 5592-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-5-(trifluoromethyl)pyridine; 5606-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-2,3-dimethyl-pyridine; 5613-[[1-[3-(1,1-Difluomethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-2-methoxy-pyridine; 5622-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-5-(difluoromethyl)pyrimidine; 5632-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-4-(difluoromethyl)pyrimidine; 5642-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-4-(trifluoromethyl)pyrimidine; 565(R/S)-2-[2-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyrimidin-5-yl]-1,1,1-trifluoro-propan-2-ol; 5662-[2-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyrimidin-5-yl]propan-2-ol; 5672-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-5-(1-methoxy-1-methyl-ethyl)pyrimidine; 568[2-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyrimidin-4-yl]methanol; 5692-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-5-(methoxymethyl)pyrimidine; 5702-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-4-(methoxymethyl)pyrimidine; 571[2-[[1-[3-(1,1-difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyrimidin-5-yl]methanol; 5722-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-5-(difluoromethoxy)pyrimidine; 5732-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-4,5-dimethyl-pyrimidine; 5745-Chloro-2-[[1-[3-(1,1-difluoroethyl)-4-fluoro-phenyl]-triazol-4-yl]methoxy]-4-methyl-pyrimidine; 5752-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-5-fluoro-4-methyl-pyrimidine; 5762-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-5-methyl-pyrimidin-4-amine; 5772-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-N,5-dimethyl-pyrimidin-4-amine; 5782-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-5-fluoro-N-methyl-pyrimidin-4-amine; 5792-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-N,N,5-trimethyl-pyrimidin-4-amine; 5802-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyrimidin-4-amine; 5812-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-N-methyl-pyrimidin-4-amine; 5822-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-N,N-dimethyl-pyrimidin-4-amine; 5832-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyrimidine-5-carbonitrile; 5842-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-5-methylsulfonyl-pyrimidine; 5851-[2-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyrimidin-5-yl]ethanone; 586(R/S)-1-[2-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyrimidin-5-yl]ethanol; 5875-Cyclopropyl-2-[[1-[3-(1,1-difluoroethyl)-4-fluoro-phenyl]-triazol-4-yl]methoxy]pyrimidine; 5885-(Azetidin-1-yl)-2-[[1-[3-(1,1-difluoroethyl)-4-fluoro-phenyl]-triazol-4-yl]methoxy]pyrimidine; 5892-((1-(3-(1,1-Difluoroethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-5-(3-fluoroazetidin-1-yl)pyrimidine; 5902-((1-(3-(1,1-Difluoroethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-N,N-dimethylpyrimidin-5-amine; 5912-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-4-pyrrolidin-1-yl-pyrimidine; 5922-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-4-(1-piperidyl)pyrimidine; 5932-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]-5-methyl-triazol-4-yl]methoxy]-5-ethyl-pyrimidine; 5945-Cyclopropyl-2-[[1-[3-(1,1-difluoroethyl)-4-fluoro-phenyl]-5-methyl-triazol-4-yl]methoxy]pyrimidine; 5952-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]-5-methyl-triazol-4-yl]methoxy]-4,5-dimethyl-pyrimidine; 5965-Chloro-2-[[1-[3-(1,1-difluoroethyl)-4-fluoro-phenyl]-5-methyl-triazol-4-yl]methoxy]-4-methyl-pyrimidine; 5972-[[1-(3,4-Difluorophenyl)triazol-4-yl]methoxy]- pyrimidine; 5982-[[1-(3,4-Difluorophenyl)triazol-4-yl]methoxy]-5- fluoro-pyrimidine;599 2-[[1-(3,4-Difluorophenyl)triazol-4-yl]methoxy]-5-methoxy-pyrimidine; 6005-Chloro-2-[[1-(3,4-difluorophenyl)triazol-4-yl]methoxy]- pyrimidine;601 2-[[1-(3,4-Difluorophenyl)triazol-4-yl]methoxy]-5-methyl-pyrimidine; 602 2-[[1-(3,4-Difluorophenyl)triazol-4-yl]methoxy]-5-ethyl-pyrimidine; 6032-[[1-(2,5-Difluorophenyl)triazol-4-yl]methoxy]-5-methyl- pyrimidine;604 2-[2-[[1-(2,5-Difluorophenyl)triazol-4-yl]methoxy]-pyrimidin-5-yl]propan-2-ol; 6055-Chloro-2-[[1-(2,3-difluorophenyl)triazol-4-yl]methoxy]- pyrimidine;606 2-[[1-(2,3-Difluorophenyl)triazol-4-yl]methoxy]-5-fluoro-pyrimidine; 6072-[[1-(2,3-Difluorophenyl)triazol-4-yl]methoxy]pyrimidine; 6082-[2-[[1-(2,3-Difluorophenyl)triazol-4-yl]methoxy]-pyrimidin-5-yl]propan-2-ol; 6092-[[1-(2,3-Difluorophenyl)triazol-4-yl]methoxy]-5-fluoro-4-methyl-pyrimidine; 6102-[[1-(3-Chloro-2-fluoro-phenyl)triazol-4-yl]methoxy]-5-methyl-pyrimidine; 6112-[[1-(3-Chloro-2-fluoro-phenyl)triazol-4-yl]methoxy]- pyrimidine; 6125-Chloro-2-[[1-(3-chloro-2-fluoro-phenyl)triazol]-4-yl]methoxy]pyrimidine; 6132-[[1-(3-Chloro-2-fluoro-phenyl)triazol-4-yl]methoxy]-5-fluoro-4-methyl-pyrimidine; 6142-[[1-(3-Chloro-2-fluoro-phenyl)triazol-4-yl]methoxy]-5-fluoro-pyrimidine; 6152-[2-[[1-(3-Chloro-2-fluoro-phenyl)triazol-4-yl]methoxy]-pyrimidin-5-yl]propan-2-ol; 616[2-[[1-(3-Bromo-4-fluoro-phenyl)triazol-4-yl]methoxy]-pyrimidin-5-yl]methanol; 617[2-[[1-(3-Bromo-4-fluoro-phenyl)triazol-4-yl]methoxy]-pyrimidin-4-yl]methanol; 6182-[[1-(3-Bromo-4-fluoro-phenyl)triazol-4-yl]methoxy]-5-(2-fluoroethoxy)pyrimidine; 6192-[[1-(3-Chloro-4-fluoro-phenyl)triazol-4-yl]methoxy]- pyrimidine; 6202-[[1-(3-Chloro-4-fluoro-phenyl)triazol-4-yl]methoxy]-5-methyl-pyrimidine; 6212-[[1-(3-Chloro-4-fluoro-phenyl)triazol-4-yl]methoxy]-5-ethyl-pyrimidine; 6222-[[1-(3-Chloro-4-fluoro-phenyl)triazol-4-yl]methoxy]-4-(methoxymethyl)pyrimidine; 6232-[[1-[4-Chloro-3-(difluoromethyl)phenyl]triazol-4-yl]methoxy]-4-isopropyl-pyrimidine; 624[2-[[1-[4-Chloro-3-(difluoromethyl)phenyl]triazol-4-yl]methoxy]pyrimidin-5-yl]methanol; 625[2-[[1-[4-Chloro-3-(difluoromethyl)phenyl]triazol-4-yl]methoxy]pyrimidin-4-yl]methanol; 6262-[2-[[1-[4-Chloro-3-(difluoromethyl)phenyl]triazol-4-yl]methoxy]pyrimidin-5-yl]propan-2-ol; 6272-[[1-[4-Chloro-3-(difluoromethyl)phenyl]triazol-4-yl]methoxy]-4-(methoxymethyl)pyrimidine; 6282-[[1-[4-Chloro-3-(difluoromethyl)phenyl]triazol-4-yl]methoxy]-4-(difluoromethyl)pyrimidine; 6292-[[1-[4-Chloro-3-(difluoromethyl)phenyl]triazol-4-yl]methoxy]-N,N-dimethyl-pyrimidin-4-amine; 6302-[[1-[4-Chloro-3-(difluoromethyl)phenyl]triazol-4-yl]methoxy]-5-cyclopropyl-pyrimidine; 6312-[[1-[4-Chloro-3-(difluoromethyl)phenyl]triazol-4-yl]methoxy]-4-cyclopropyl-pyrimidine; 6322-[[1-[4-chloro-3-(difluoromethyl)phenyl]triazol-4-yl]methoxy]-5-methyl-pyrimidin-4-amine; 6332-[[1-[4-Chloro-3-(difluoromethyl)phenyl]triazol-4-yl]methoxy]-N,N,5-trimethyl-pyrimidin-4-amine; 6342-[[1-[4-Chloro-3-(difluoromethyl)phenyl]triazol-4-yl]methoxy]-4-pyrrolidin-1-yl-pyrimidine; 6352-[[1-[4-Chloro-3-(difluoromethyl)phenyl]triazol-4-yl]methoxy]-4-(1-piperidyl)pyrimidine; 6362-[[1-[4-Chloro-3-(difluoromethyl)phenyl]triazol-4-yl]methoxy]-5-(2-fluoroethoxy)pyrimidine; 6372-[[1-[4-Chloro-3-(difluoromethyl)phenyl]triazol-4-yl]methoxy]-5-(3-fluoropropyl)pyrimidine; 6382-((1-(4-(Azetidin-1-yl)-3-(difluoromethyl)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)-5-methylpyrimidine; 6392-[[1-(2,4-Difluoro-3-methyl-phenyl)triazol-4-yl]methoxy]-5-isopropyl-pyrimidine; 6402-[[1-(2,4-Difluoro-3-methyl-phenyl)triazol-4-yl]methoxy]-4-isopropyl-pyrimidine; 6415-(Difluoromethyl)-2-[[1-(2,4-difluoro-3-methyl-phenyl)triazol-4-yl]methoxy]pyrimidine; 6424-(Difluoromethyl)-2-[[1-(2,4-difluoro-3-methyl-phenyl)triazol-4-yl]methoxy]pyrimidine; 6432-[[1-(2,4-Difluoro-3-methyl-phenyl)triazol-4-yl]methoxy]-5-(trifluoromethyl)pyrimidine; 6442-[2-[[1-(2,4-Difluoro-3-methyl-phenyl)triazol-4-yl]methoxy]pyrimidin-5-yl]propan-2-ol; 6452-[[1-(2,4-Difluoro-3-methyl-phenyl)triazol-4-yl]methoxy]-4-(methoxymethyl)pyrimidine; 6465-(Difluoromethoxy)-2-[[1-(2,4-difluoro-3-methyl-phenyl)triazol-4-yl]methoxy]pyrimidine; 6475-Cyclopropyl-2-[[1-(2,4-difluoro-3-methyl-phenyl)triazol-4-yl]methoxy]pyrimidine; 6484-Cyclopropyl-2-[[1-(2,4-difluoro-3-methyl-phenyl)triazol-4-yl]methoxy]pyrimidine; 6492-[[1-(2,4-Difluoro-3-methyl-phenyl)triazol-4-yl]methoxy]-5-fluoro-4-methyl-pyrimidine; 6505-Chloro-2-[[1-(2,4-difluoro-3-methyl-phenyl)triazol-4-yl]methoxy]-4-methyl-pyrimidine; 6512-[[1-(2,4-Difluoro-3-methyl-phenyl)triazol-4-yl]methoxy]-5-methyl-pyrimidin-4-amine; 6522-[[1-[3-(Difluoromethyl)-2,4-difluoro-phenyl]triazol-4-yl]methoxy]-5-(trifluoromethyl)pyrimidine; 6535-Chloro-2-[[1-(2,4-difluoro-5-methyl-phenyl)triazol-4-yl]methoxy]pyrimidine; 6542-[[1-(2,4-Difluoro-5-methyl-phenyl)triazol-4-yl]methoxy]-5-methyl-pyrimidine; 6552-[[1-(2,4-Difluoro-5-methyl-phenyl)triazol-4-yl]methoxy]-5-ethyl-pyrimidine; 6565-(Difluoromethyl)-2-[[1-(2,4-difluoro-5-methyl-phenyl)triazol-4-yl]methoxy]pyrimidine; 6575-Chloro-2-[[1-(2,4-difluoro-5-methyl-phenyl)triazol-4-yl]-methoxy]-4-methyl-pyrimidine; 6585-Cyclopropyl-2-[[1-(2,4-difluoro-5-methyl-phenyl)triazol-4-yl]methoxy]pyrimidine; 6595-Chloro-2-[[1-(6-methyl-2-pyridyl)triazol-4-yl]methoxy]- pyrimidine;660 5-Ethyl-2-[[1-(6-methyl-2-pyridyl)triazol-4-yl]methoxy]- pyrimidine;661 5-Chloro-4-methyl-2-[[1-(6-methyl-2-pyridyl)triazol-4-yl]methoxy]pyrimidine; 6625-Methyl-2-[[1-(4-methyl-2-pyridyl)triazol-4-yl]methoxy]- pyrimidine;663 5-Ethyl-2-[[1-(4-methyl-2-pyridyl)triazol-4-yl]methoxy]- pyrimidine;664 5-Ethyl-2-[[1-(2-methyl-4-pyridyl)triazol-4-yl]methoxy]- pyrimidine;665 2-[[1-(2-Bromo-4-pyridyl)triazol-4-yl]methoxy]-5-ethyl- pyrimidine;666 5-Methyl-2-[[1-[2-(trifluoromethyl)-4-pyridyl]triazol-4-yl]methoxy]pyrimidine; 6675-Ethyl-2-[[1-[2-(trifluoromethyl)-4-pyridyl]triazol-4-yl]methoxy]pyrimidine; 6685-Fluoro-4-methyl-2-((1-(5-(trifluoromethyl)thiophen-2-yl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidine; 6695-Methoxy-2-((1-(5-(trifluoromethyl)thiophen-2-yl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidine; 6705-(Trifluoromethyl)-2-((1-(5-(trifluoromethyl)thiophen-2-yl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidine; 6712-((1-(3-(Difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-N-(oxetan-3-yl)pyrimidin-4-amine; 6725-(Azetidin-1-yl)-2-((1-(3-(difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyridine; 6732-((1-(3-(Difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-5-(3-fluoroazetidin-1-yl)pyridine; 6745-(3,3-Difluoroazetidin-1-yl)-2-((1-(3-(difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl]methoxy)pyridine; 6752-(Azetidin-1-yl)-6-((1-(3-(difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl]methoxy)pyridine; 6762-((1-(3-(Difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-6-(3-fluoroazetidin-1-yl)pyridine; 6772-(3,3-Difluoroazetidin-1-yl)-6-((1-(3-(difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl]methoxy)pyridine; 6784-(Azetidin-1-yl)-2-((1-(3-(difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl]methoxy)pyridine; 6792-((1-(3-(Difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-4-(3-fluoroazetidin-1-yl)pyridine; 6804-(3,3-Difluoroazetidin-1-yl)-2-((1-(3-(difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyridine; 6812-((1-(3-(Difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-4-(1H-pyrrol-2-yl)pyrimidine; 6822-((1-(3-(Difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-4-(1H-pyrazol-5-yl)pyrimidine; 6832-((1-(3-(Difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-5-(1H-pyrrol-2-yl)pyrimidine; 6842-((1-(3-(Difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-5-(1H-pyrazol-5-yl)pyrimidine; 6852-((1-(3-(Difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-N-ethyl-5-fluoropyrimidin-4-amine; 6862-((1-(3-(Difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-5-fluoro-N-(oxetan-3-yl)pyrimidin-4-amine; 687N-(3,3-Difluorocyclobutyl)-2-((1-(3-(difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-5-fluoropyrimidin- 4-amine;688 N-Cyclopropyl-2-((1-(3-(difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidin-4-amine; 689N-(3,3-Difluorocyclobutyl)-2-((1-(3-(difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidin-4-amine; 690N-Cyclopropyl-2-((1-(3-(difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidin-4-amine; 691N-Ethyl-2-((1-(3-(difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidin-4-amine; 6922-((1-(3-(Difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-4-(2-methyl-1H-imidazol-1-yl)pyrimidine; 6932-((1-(3-(Difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-5-(2-methyl-1H-imidazol-1-yl)pyrimidine; 6942-((1-(3-(Difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-5-(1H-pyrazol-5-yl)pyrimidine; 6952-((1-(3-(Difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-4-(1H-pyrazol-5-yl)pyrimidine; 6964-(1,1-Difluoroethyl)-2-((1-(3-(difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidine; 6974-((Difluoromethoxy)methyl)-2-((1-(3-(difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl]methoxy)pyrimidine; 6982-((1-(3-(Difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-5-(1H-pyrazol-1-yl)pyrimidine; 6992-((1-(3-(Difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-4-(1H-pyrazol-1-yl)pyrimidine; 700(E)-1-(2-((1-(3-(Difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidin-5-yl)ethan-1-one oxime; 7015-(1,1-Difluoroethyl)-2-((1-(3-(difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl]methoxy)pyrimidine; 702(Z)-1-(2-((1-(3-(Difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidin-4-yl)ethan-1-one oxime; 703(2-((1-(3-(Difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-5-fluoropyrimidin-4-yl)methanol; 7042-((1-(3-(Difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-4-((difluoromethoxy)methyl)-5-fluoropyrimidine; 7052-((1-(3-(Difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-4-((difluoromethoxy)methyl)pyrimidine; 7062-((1-(3-(Difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-5-fluoro-4-((trifluoromethoxy)methyl)pyrimidine; 7072-((1-(3-(Difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-4-((trifluoromethoxy)methyl)pyrimidine; 7082-((1-(3-(Difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-4-(methoxymethyl-d2)pyrimidine; 7092-((1-(3-(Difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-4-((methoxy-d3)methyl-d2)pyrimidine; 7102-((1-(3-(Difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-4-((methoxy-d3)methyl)pyrimidine; 7112-((1-(3-(Difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-4-(ethoxymethyl)pyrimidine; 7122-((1-(3-(Difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-4-(1-methoxyethyl)pyrimidine; 7131-(2-((1-(3-(Difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidin-4-yl)ethan-1-ol; 7142-((1-(3-(Difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-4-(2-methoxypropan-2-yl)pyrimidine; 7152-(2-((1-(3-(Difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidin-4-yl)propan-2-ol; 7164-((2,2-Difluoroethoxy)methyl)-2((1-(3-(difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidine;and pharmaceutically acceptable salts thereof.

A further embodiment of the current invention is a compound as shownbelow in Table 2.

Ex # Compound Name 2N-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methyl]pyridin-2-amine; 3N-[[1-[4-Fluoro-3-(trifluoromethyl)phenyl]triazol-4-yl]meth]pyrimidin-2-amine; 6N-((1-(3-(Difluoromethyl)phenyl)-1H-1,2,3-triazol-4-yl)methyl)pyrimidin-2-amine; 7N-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methyl]-1-methyl-imidazol-2-amine; 24N-[[1-[3-(Difuoromethyl)-4-fluoro-phenyl]triazol-4-yl]methyl]pyrimidin-2-amine; 36N-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methyl]pyrimidin-2-amine; 97N-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methyl]oxazol-2-amine; 98N-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methyl]pyrimdin-2-amine; 99N-[[1[3-(Difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methyl]-1-methyl-pyrazo-4-amine, 100N-[[1-[3-(Difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methyl]-1-methyl-pyrazol-3-amine; 101N-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]trazol-4-yl]methyl]-1-methyl-pyrazol-3-amine; 102N-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methyl]-1-methyl-pyrazol-4-amine; 109N-[[1-[4-Chloro-3-(difluoromethyl)phenyl]triazol-4-yl]methyl]pyrimidin-2-amine; 110N-[[1-[4-Chloro-3-(difluoromethyl)phenyl]triazol-4-yl]methyl]pyrimidin-4-amine; 144N-((1-(4-Chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methyl)-5-methylpyrimidin-2-amine; 145N-((1-(4-Chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methyl)-4,5-dimethylpyrimidin-2-amine; 1535-Chloro-N-[[1-[3-(difluoromethyl)phenyl]triazol-4-yl]methyl]pyrimidin-2-amine; 154N-[[1-[4-Chloro-3-(difluoromethyl)phenyl]triazol-4-yl]methyl]-5-methyl-pyrimidin-2-amine; 197N-[[1-[3-(Difluoromethyl)phenyl]triazol-4-yl]methyl]-5-fluoro-pyrimidin-2-amine; 198N-[[1-(4-Fluoro-3-methyl-phenyl)triazol-4-yl]methyl]-5-methyl-pyrimidin-2-amine; 1995-Chloro-N-[[1-(4-fluoro-3-methyl-phenyl)triazol-4-yl]methyl]-4-methyl-pyrimidin-2-amine; 2005-Chloro-N-[[1-[4-chloro-3-(difluoromethyl)phenyl]triazol-4-yl]methyl]pyrimidin-2-amine; 201N-[[1-[4-Chloro-3-(difluoromethyl)phenyl]triazol-4-yl]methyl]-4-methyl-pyrimidin-2-amine; 202N-[[1-[4-Chloro-3-(difluoromethyl)phenyl]triazol-4-yl]methyl]-5-ethyl-pyrimidin-2-amine; 203N-[[1-[4-Chloro-3-(difluoromethyl)phenyl]triazol-4-yl]methyl]-5-methoxy-pyrimidin-2-amine; 204N-[[1-[4-Chloro-3-(difluoromethy)phenyl]triazol-4-yl]methyl]-5-(difluoromethyl)pyrimidin-2-amine; 205N-[[1-[4-Chloro-3-(difluoromethyl)phenyl]triazol-4-yl]methyl]-5-(trifluoromethyl)pyrimidin-2-amine; 206N-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methyl]-5-methyl-pyrimidin-2-amine; 207N-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methyl]-5-ethyl-pyrimidin-2-amine; 208N-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methyl]-5-isopropyl-pyrimidin-2-amine; 2095-Cyclopropyl-N-[[1-[3-(1,1-difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methyl]pyrimidin-2-amine; 210N-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methyl]-4,5-dimethyl-pyrimidin-2-amine; 211N-[[1-[3-(Difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methyl]-5-methyl-pyrimidin-2-amine; 2125-Chloro-N-[[1-[3-(difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methyl]pyrimidin-2-amine; 213N-[[1-[3-(Difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methyl]-5-(trifluoromethyl)pyrimidin-2-amine; 2142-[2-[[1-[3-(Difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methylamino]pyrimidin-5-yl]propan-2-ol; 215N-((1-(3-(Difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methyl)pyridin-2-amine; 216N-((1-(3-(Difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methyl)-5-ethylpyrimidin-2-amine; 217N-((1-(3-(Difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methyl)-4,5-dimethylpyrimidin-2-amine; 2185-Chloro-N-((1-(3-(difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methyl)-4-methylpyrimidin-2-amine; 219N-((1-(3-(Difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methyl)-1-methyl-1H-pyrazol-5-amine; 220N-((1-(3-(Difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methyl)-1-methyl-1H-imidazol-2-amine; 221N-((1-(3-(Difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methyl)pyridin-2-amine; 222N-((1-(3-(Difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methyl)-5-methylpyrimidin-2-amine; 223N-((1-(3-(Difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methyl)-1-methyl-1H-pyrazol-5-amine; and 224N-[(1R)-1-[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]ethyl]-5-methyl-pyrimidin-2-amine;and pharmaceutically acceptable salts thereof.

A further embodiment of the current invention is a compound as shownbelow in Table 3.

Compound Name2-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]-5-methoxy-pyrimidine;2-[[1-[3-(Difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-5-methyl-pyrimidine;2-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]-5-methyl-pyrimidine;2-[[1-[4-Chloro-3-(difluoromethyl)phenyl]triazol-4-yl]methoxy]-4,5-dimethyl-pyrimidine;2-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]-5-(2-fluoroethoxy)pyrimidine;2-[[1-[4-Chloro-3-(2-fluoroethoxy)phenyl]triazol-4-yl]methoxy]-5-methoxy-pyrimidine;2-[[1-[3-(3-Chloropropyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-5-methoxy-pyrimidine;2-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]-5-(3-fluoropropyl)pyrimidine;[2-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]pyrimidin-4-yl]methanol;2-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]-4-(methoxymethyl)pyrimidine;5-Chloro-2-[[1-[3-(difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-4-methyl-pyrimidine; [2-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyrimidin-4-yl]methanol;2-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]-4-(methoxymethyl)pyrimidine;2-[2-[[1-[4-Chloro-3-(1,1-difluoroethyl)phenyl]triazol-4-yl]methoxy]pyrimidin-5-yl]propan-2-ol;5-(Azetidin-1-yl)-2[[1-[3-(1,1-difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyrimidine; and5-Fluoro-4-methyl-2-((1-(5-(trifluoromethyl)thiophen-2-yl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidine;and pharmaceutically acceptable salts thereof.

An additional embodiment of the invention is a pharmaceuticalcomposition comprising:

(A) an effective amount of at least one compound selected from compoundsof Formula (I):

wherein:

-   Ar¹ is selected from the group consisting of:    -   (a) phenyl substituted with one substituent selected from the        group consisting of: halo, C₁₋₆alkyl, C₁₋₆perhaloalkyl, and        OC₁₋₆perhaloalkyl; phenyl substituted with two or three        substituents each independently selected from the group        consisting of: halo, C₁₋₆alkyl, C₁₋₆perhaloalkyl, OC₁₋₆alkyl,        OC₁₋₆perhaloalkyl, C₃₋₆cycloalkyl, and azetidinyl;    -   (b) pyridinyl; pyridinyl substituted with one or two members        each independently selected from the group consisting of: halo,        CH₃, CF₃, and CF₂H; and    -   (c) thienyl substituted with CF₃;        1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl; or        2,3-dihydro-1H-inden-5-yl;-   R¹ is H, halo, or CH₃;-   R² is H or CH₃; and-   Ar³ is selected from the group consisting of:    -   (a) pyridinyl; pyridinyl substituted with one or two        substituents each independently selected from the group        consisting of: Cl, F, CH₃, OCH₃, CF₃, C(CH₃)₂OH; azetidin-1-yl;        3-fluoroazetidin-1-yl; and 3,3-difluoroazetidin-1-yl;    -   (b) pyridazinyl; pyridazinyl substituted with one or two        substituents each independently selected from the group        consisting of: CH₃, OCH₃, and CF₃;    -   (c) pyrimidin-4-yl; pyrimidin-4-yl substituted with one or two        substituents each independently selected from the group        consisting of: Cl, CH₃, CF₃, and OCH₃; pyrimidin-2-yl;        pyrimidin-2-yl substituted one or two members each independently        selected from the group consisting of: halo, C₁₋₆alkyl,        C₁₋₆alkyl substituted with OH or OCH₃, C(OH)(CH₃)(CF₃),        CH₂OCHF₂, CH₂OCF₃, CH₂OCH₂CH₃, CH(NH₂)CH₃, CH₂NH(CH₃),        C₁₋₆perhaloalkyl, OC₁₋₆alkyl, OC₁₋₆perhaloalkyl, C(═N—OH)(CH₃),        NH₂, NH(CH₃), N(CH₃)₂; NH(CH₂CH₃), NH(CH₂CHF₂), NH(cyclopropyl),        NH(difluorocyclobutyl), NH-oxetanyl, CN, C(═O)CH₃, C(═O)NH(CH₃),        C(═O)N(CH₃)₂, SO₂CH₃, CO₂CH₃, C(CH₃)(═N—OH), cyclopropyl,        azetidin-1-yl, 3-fluoroazetidin-1-yl, 3,3-difluoroazetidin-1-yl,        3-(difluoromethyl)azetidin-1-yl, 3-methoxyazetidin-1-yl,        3-fluoro-3-methyl-azetidin-1-yl, pyrrolidin-1-yl,        3-fluoropyrrolidin-1-yl, 3,3-difluoropyrrolidin-1-yl,        piperidin-1-yl, morpholinyl, 1H-pyrrol-2-yl, 2-furyl,        1H-pyrazol-4-yl, 1H-pyrazol-5-yl, 1H-pyrazol-1-yl,        2-methyl-1H-imidazol-1-yl, 1-methylpyrazol-3-yl, and phenyl;    -   (d) 5-fluoro-pyrazin-2-yl; 5-methylpyrazin-2-yl;        6-methylpyrazin-2-yl; pyrazin-4-yl; (2-thienyl)pyrazin-2-yl, and        2,3-dimethylpyrazin-5-yl; and    -   (e) 5-methyl-1H-imidazol-2-yl; 5-methylthiazol-2-yl;        and pharmaceutically acceptable salts of compounds of Formula        (I);

and (B) at least one pharmaceutically acceptable excipient.

An additional embodiment of the invention is a pharmaceuticalcomposition comprising:

(A) an effective amount of at least one compound selected from compoundsof Formula (II):

wherein:

-   Ar^(1′) is phenyl substituted with C₁₋₆perhaloalkyl; or phenyl    substituted with two substituents each independently selected from    the group consisting of: halo, C₁₋₃alkyl, C₁₋₃perhaloalkyl, and    OC₁₋₃perhaloalkyl;-   R² is H or CH₃; and-   Ar² is selected from the group consisting of:    -   (a) pyridin-2-yl; pyridazin-3-yl; pyrimidin-4-yl;        pyrimidin-2-yl; or pyrimidin-2-yl substituted with one or two        substituents each independently selected from the group        consisting of halo, C₁₋₃alkyl, C(CH₃)₂OH, C₁₋₃perhaloalkyl,        OCH₃, and cyclopropyl; and    -   (b) 1-methyl-imidazol-2-yl; oxazol-2-yl; 1-methyl-pyrazol-4-yl;        1-methyl-pyrazol-3-yl; or 1-methyl-1H-pyrazol-5-yl;        and pharmaceutically acceptable salts of compounds of Formula        (II);

and (B) at least one pharmaceutically acceptable excipient.

An additional embodiment of the invention is a pharmaceuticalcomposition comprising and effective amount of at least one compound ofFormula (IA) (as well as Formulas (IB), (IC), and (ID)), as well aspharmaceutically acceptable salts, N-oxides or solvates of compounds ofFormula (IA) (as well as Formulas (IB), (IC), and (ID)),pharmaceutically acceptable prodrugs of compounds of Formula (IA) (aswell as Formulas (IB), (IC), and (ID)), and pharmaceutically activemetabolites of Formula (IA) (as well as Formulas (IB), (IC), and (ID));and at least one pharmaceutically acceptable excipient.

An additional embodiment of the invention is a pharmaceuticalcomposition comprising and effective amount of at least one compound ofFormula (IIA) (as well as Formula (IIB)), as well as pharmaceuticallyacceptable salts, N-oxides or solvates of compounds of Formula (IIA) (aswell as Formula (IIB)), pharmaceutically acceptable prodrugs ofcompounds of Formula (IIA) (as well as Formula (IIB)), andpharmaceutically active metabolites of Formula (IIA) (as well as Formula(IIB)); and at least one pharmaceutically acceptable excipient.

An additional embodiment of the invention is a pharmaceuticalcomposition comprising and effective amount of at least one compound inTable 1 (as well Table 2 and Table 3), as well as pharmaceuticallyacceptable salts, N-oxides or solvates of compounds of Table 1 (as wellTable 2 and Table 3), pharmaceutically acceptable prodrugs of compoundsof Table 1 (as well Table 2 and Table 3), and pharmaceutically activemetabolites of Table 1 (as well Table 2 and Table 3); and at least onepharmaceutically acceptable excipient.

Also within the scope of the invention are enantiomers and diastereomersof the compounds of Formula (I) (as well as Formulas (IA), (IB), (IC),and (ID)). Also within the scope of the invention are thepharmaceutically acceptable salts, N-oxides or solvates of the compoundsof Formula (I) (as well as Formulas (IA), (IB), (IC), and (ID)). Alsowithin the scope of the invention are the pharmaceutically acceptableprodrugs of compounds of Formula (I) (as well as Formulas (IA), (IB),(IC), and (ID)), and pharmaceutically active metabolites of thecompounds of Formula (I) (as well as Formulas (IA), (IB), (IC), and(ID)).

Also within the scope of the invention are enantiomers and diastereomersof the compounds of Formula (II) (as well as Formulas (IIA) and (IB)).Also within the scope of the invention are the pharmaceuticallyacceptable salts, N-oxides or solvates of the compounds of Formula (II)(as well as Formulas (IIA) and (IB)). Also within the scope of theinvention are the pharmaceutically acceptable prodrugs of compounds ofFormula (II) (as well as Formulas (IIA) and (IB)), and pharmaceuticallyactive metabolites of the compounds of Formula (II) (as well as Formulas(IIA) and (IB)).

Also within the scope of the invention are isotopic variations ofcompounds of Formula (I) (as well as Formulas (IA), (IB), (IC), and(ID)), such as, e.g., deuterated compounds of Formula (I). Also withinthe scope of the invention are the pharmaceutically acceptable salts,N-oxides or solvates of the isotopic variations of the compounds ofFormula (I) (as well as Formulas (IA), (IB), (IC), and (ID)). Alsowithin the scope of the invention are the pharmaceutically acceptableprodrugs of the isotopic variations of the compounds of Formula (I) (aswell as Formulas (IA), (IB), (IC), and (ID)), and pharmaceuticallyactive metabolites of the isotopic variations of the compounds ofFormula (I) (as well as Formulas (IA), (IB), (IC), and (ID)).

Also within the scope of the invention are isotopic variations ofcompounds of Formula (II) (as well as Formulas (IIA) and (IB)), such as,e.g., deuterated compounds of Formula (II). Also within the scope of theinvention are the pharmaceutically acceptable salts, N-oxides orsolvates of the isotopic variations of the compounds of Formula (II) (aswell as Formulas (IIA) and (IB)). Also within the scope of the inventionare the pharmaceutically acceptable prodrugs of the isotopic variationsof the compounds of Formula (II) (as well as Formulas (IIA) and (IB)),and pharmaceutically active metabolites of the isotopic variations ofthe compounds of Formula (II) (as well as Formulas (IIA) and (IB)).

An additional embodiment of the invention is a method of treating asubject suffering from or diagnosed with a disease, disorder, or medicalcondition mediated by NR2B receptor activity, comprising administeringto a subject in need of such treatment an effective amount of at leastone compound selected from compounds of Formula (I):

wherein:

-   Ar¹ is selected from the group consisting of:    -   (a) phenyl substituted with one substituent selected from the        group consisting of: halo, C₁₋₆alkyl, C₁₋₆perhaloalkyl, and        OC₁₋₆perhaloalkyl; phenyl substituted with two or three        substituents each independently selected from the group        consisting of: halo, C₁₋₆alkyl, C₁₋₆perhaloalkyl, OC₁₋₆alkyl,        OC₁₋₆perhaloalkyl, C₃₋₆-cycloalkyl, and azetidinyl;    -   (b) pyridinyl; pyridinyl substituted with one or two members        each independently selected from the group consisting of: halo,        CH₃, CF₃, and CF₂H; and    -   (c) thienyl substituted with CF₃;        1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl; or        2,3-dihydro-1H-inden-5-yl;-   R¹ is H, halo, or CH₃;-   R² is H or CH₃; and-   Ar³ is selected from the group consisting of:    -   (a) pyridinyl; pyridinyl substituted with one or two        substituents each independently selected from the group        consisting of: Cl, F, CH₃, OCH₃, CF₃, C(CH₃)₂OH; azetidin-1-yl;        3-fluoroazetidin-1-yl; and 3,3-difluoroazetidin-1-yl;    -   (b) pyridazinyl; pyridazinyl substituted with one or two        substituents each independently selected from the group        consisting of: CH₃, OCH₃, and CF₃;    -   (c) pyrimidin-4-yl; pyrimidin-4-yl substituted with one or two        substituents each independently selected from the group        consisting of: Cl, CH₃, CF₃, and OCH₃; pyrimidin-2-yl;        pyrimidin-2-yl substituted one or two members each independently        selected from the group consisting of: halo, C₁₋₆alkyl,        C₁₋₆alkyl substituted with OH or OCH₃, C(OH)(CH₃)(CF₃),        CH₂OCHF₂, CH₂OCF₃, CH₂OCH₂CH₃, CH(NH₂)CH₃, CH₂NH(CH₃),        C₁₋₆perhaloalkyl, OC₁₋₆alkyl, OC₁₋₆perhaloalkyl, C(═N—OH)(CH₃),        NH₂, NH(CH₃), N(CH₃)₂; NH(CH₂CH₃), NH(CH₂CHF₂), NH(cyclopropyl),        NH(difluorocyclobutyl), NH-oxetanyl, CN, C(═O)CH₃, C(═O)NH(CH₃),        C(═O)N(CH₃)₂, SO₂CH₃, CO₂CH₃, C(CH₃)(═N—OH), cyclopropyl,        azetidin-1-yl, 3-fluoroazetidin-1-yl, 3,3-difluoroazetidin-1-yl,        3-(difluoromethyl)azetidin-1-yl, 3-methoxyazetidin-1-yl,        3-fluoro-3-methyl-azetidin-1-yl, pyrrolidin-1-yl,        3-fluoropyrrolidin-1-yl, 3,3-difluoropyrrolidin-1-yl,        piperidin-1-yl, morpholinyl, 1H-pyrrol-2-yl, 2-furyl,        1H-pyrazol-4-yl, 1H-pyrazol-5-yl, 1H-pyrazol-1-yl,        2-methyl-1H-imidazol-1-yl, 1-methylpyrazol-3-yl, and phenyl;    -   (d) 5-fluoro-pyrazin-2-yl; 5-methylpyrazin-2-yl;        6-methylpyrazin-2-yl; pyrazin-4-yl; (2-thienyl)pyrazin-2-yl, and        2,3-dimethylpyrazin-5-yl; and    -   (e) 5-methyl-1H-imidazol-2-yl; 5-methylthiazol-2-yl;        and pharmaceutically acceptable salts thereof, to a subject in        need thereof.

An additional embodiment of the invention is a method of treating asubject suffering from or diagnosed with a disease, disorder, or medicalcondition mediated by NR2B receptor activity, comprising administeringto a subject in need of such treatment an effective amount of at leastone compound selected from compounds of Formula (II):

wherein:

-   Ar^(1′) is phenyl substituted with C₁₋₃perhaloalkyl; or phenyl    substituted with two substituents each independently selected from    the group consisting of: halo, C₁₋₃alkyl, C₁₋₃perhaloalkyl, and    OC₁₋₃perhaloalkyl;-   R^(2′) is H or CH₃; and-   Ar² is selected from the group consisting of:    -   (a) pyridin-2-yl; pyridazin-3-yl; pyrimidin-4-yl;        pyrimidin-2-yl; or pyrimidin-2-yl substituted with one or two        substituents each independently selected from the group        consisting of halo, C₁₋₃alkyl, C(CH₃)₂OH, C₁₋₃perhaloalkyl,        OCH₃, and cyclopropyl; and    -   (b) 1-methyl-imidazol-2-yl; oxazol-2-yl; 1-methyl-pyrazol-4-yl;        1-methyl-pyrazol-3-yl; or 1-methyl-1H-pyrazol-5-yl;        and pharmaceutically acceptable salts thereof, to a subject in        need thereof.

An additional embodiment of the invention is a method of treating asubject suffering from or diagnosed with a disease, disorder, or medicalcondition mediated by NR2B receptor activity, comprising administeringto a subject in need of such treatment an effective amount of at leastone compound selected from compounds of Formula (I) (as well as (IA),(IB), (IC), (ID), (II), (IIA), and (IIB)), and pharmaceuticallyacceptable salts of all of the foregoing.

In preferred embodiments of the inventive method, the disease, disorder,or medical condition is selected from: neurologic and psychiatricdisorders including, but not limited to: (1) mood disorders and moodaffective disorders; (2) neurotic, stress-related and somatoformdisorders including anxiety disorders; (3) disorders of psychologicaldevelopment; (4) behavioral syndromes associated with physiologicaldisturbances and physical factors; (5) extrapyramidal and movementdisorders; (6) episodic and paroxysmal disorders, epilepsy; (7) pain;(8) forms of neurodegeneration; (9) cerebrovascular diseases, acute andchronic; and any sequelae of cerebrovascular diseases.

Examples of mood disorders and mood affective disorders that can betreated according to the present invention include, but are not limitedto, bipolar disorder I depressed, hypomanic, manic and mixed form;bipolar disorder II; depressive disorders, such as single depressiveepisode or recurrent major depressive disorder, minor depressivedisorder, treatment-resistant depression, depressive disorder withpostpartum onset, depressive disorders with psychotic symptoms;persistent mood disorders, such as cyclothymia, dysthymia, euthymia; andpremenstrual dysphoric disorder.

Examples of disorders belonging to the neurotic, stress-related andsomatoform disorders that can be treated according to the presentinvention include, but are not limited to, anxiety disorders, generalanxiety disorder, panic disorder with or without agoraphobia, specificphobia, social anxiety disorder, chronic anxiety disorders; obsessivecompulsive disorder; reaction to sever stress and adjustment disorders,such as post-traumatic stress disorder (PTSD); other neurotic disorderssuch as depersonalisation-derealisation syndrome.

Examples of disorders of psychological development that can be treatedaccording to the present invention include, but are not limited topervasive developmental disorders, including but not limited toAsperger's syndrome and Rett's syndrome, autistic disorders, childhoodautism and overactive disorder associated with mental retardation andstereotyped movements, specific developmental disorder of motorfunction, specific developmental disorders of scholastic skills.

Examples of behavioral syndromes associated with physiologicaldisturbances and physical factors according to the present inventioninclude, but are not limited to mental and behavioural disordersassociated with childbirth, including but not limited to postnatal(postpartum) and prenatal depression; eating disorders, including butnot limited to anorexia nervosa, bulimia nervosa, pica and binge eatingdisporder.

Examples of extrapyramidal and movement disorders that can be treatedaccording to the present invention include, but are not limited toParkinson's disease; second Parkinsonism, such as postencephaliticParkinsonism; Parkinsonism comprised in other disorders; Lewis bodydisease; degenerative diseases of the basal ganglia; otherextrapyramidal and movement disorders including but not limited totremor, essential tremor and drug-induced tremor, myoclonus, chorea anddrug-induced chorea, drug-induced tics and tics of organic origin,drug-induced acute dystonia, drug-induced tardive dyskinesia,L-dopa-induced dyskinesia; neuroleptic-induced movement disordersincluding but not limited to neuroleptic malignant syndrome (NMS),neuroleptic induced parkinsonism, neuroleptic-induced early onset oracute dyskinesia, neuroleptic-induced acute dystonia,neuroleptic-induced acute akathisia, neuroleptic-induced tardivedyskinesia, neuroleptic-induced tremor, restless leg syndrome, Stiff-mansyndrome.

Further examples of movement disorders with malfunction and/ordegeneration of basal ganglia that can be treated according to thepresent invention include, but are not limited to dystonia including butnot limited to focal dystonia, multiple-focal or segmental dystonia,torsion dystonia, hemispheric, generalised and tardive dystonia (inducedby psychopharmacological drugs). Focal dystonia include cervicaldystonia (torticolli), blepharospasm (cramp of the eyelid), appendiculardystonia (cramp in the extremities, like the writer's cramp),oromandibular dystonia and spasmodic dysphonia (cramp of the vocalcord);

Examples for episodic and paroxysmal disorders that can be treatedaccording to the present invention include, but are not limited toepilepsy, including localization-related (focal)(partial) idiopathicepilepsy and epileptic syndromes with seizures of localized onset,localization-related (focal)(partial) symptomatic epilepsy and epilepticsyndromes with simple partial seizures, localization-related(focal)(partial) symptomatic epilepsy and epileptic syndromes withcomplex partial seizures, generalized idiopathic epilepsy and epilepticsyndromes including but not limited to myoclonic epilepsy in infancy,neonatal convulsions (familial), childhood absence epilepsy(pyknolepsy), epilepsy with grand mal seizures on awakening, absenceepilepsy, myoclonic epilepsy (impulsive petit mal) and nonspecificatonic, clonic, myoclonic, tonic, tonic-clonic epileptic seizures.

Further examples of epilepsy that can be treated according to thepresent invention include, but are not limited to epilepsy withmyoclonic absences, myodonic-astatic seizures, infantile spasms,Lennox-Gastaut syndrome, Salaam attacks, symptomatic early myoclonicencephalopathy, West's syndrome, petit and grand mal seizures; statusepilepticus.

Examples of pain include, but are not limited to pain disorders relatedto psychological factors, such as persistent somatoform disorders;acute, chronic and chronic intractable pain, headache; acute and chronicpain related to physiological processes and physical disorders includingbut not limited to back pain, tooth pain, abdominal pain, low back pain,pain in joints; acute and chronic pain that is related to diseases ofthe musculoskeletal system and connective tissue including, but notlimited to rheumatism, myalgia, neuralgia and fibromyalgia; acute andchronic pain that is related to nerve, nerve root and plexus disorders,such as trigeminal pain, postzoster neuralgia, phantom limb syndromewith pain, carpal tunnel syndrome, lesion of sciatic nerve, diabeticmononeuropathy; acute and chronic pain that is related topolyneuropathies and other disorders of the peripheral nervous system,such as hereditary and idiopathic neuropathy, inflammatorypolyneuropathy, polyneuropathy induced by drugs, alcohol or toxicagents, polyneuropathy in neoplastic disease, diabetic polyneuropathy.

Examples of diseases that include forms of neurodegeneration include,but are not limited to, acute neurodegeneration, such as intracranialbrain injuries, such as stroke, diffuse and local brain injuries,epidural, subdural and subarachnoid haemorrhage, and chronicneurodegeneration, such as Alzheimer's disease, Huntington's disease,multiple sclerosis and ALS.

Examples of cerebrovascular diseases include, but are not limited to,subarachnoid haemorrhage, intracerebral haemorrhage and othernontraumatic intracranial haemorrhage, cerebral infarction, stroke,occlusion and stenosis or precerebral and cerebral arteries, notresulting in cerebral infarction, dissection of cerebral arteries,cerebral aneurysm, cerebral atherosclerosis, progressive vascularleukoencephalopathy, hypertensive encephalopathy, nonpyogenic thrombosisof intracranial venous system, cerebral arteritis, cerebral amyloidangiopathy and sequelae of cerebrovascular diseases.

In some embodiments, administration of a compound of the invention, orpharmaceutically acceptable salt thereof, is effective in preventing thedisease; for example, preventing a disease, condition or disorder in anindividual who may be predisposed to the disease, condition or disorderbut does not yet experience or display the pathology or symptomatologyof the disease.

Additional embodiments, features, and advantages of the invention willbe apparent from the following detailed description and through practiceof the invention.

The invention may be more fully appreciated by reference to thefollowing description, including the following glossary of terms and theconcluding examples. For the sake of brevity, the disclosures of thepublications, including patents, cited in this specification are hereinincorporated by reference.

As used herein, the terms “including”, “containing” and “comprising” areused herein in their open, non-limiting sense.

The term “alkyl” refers to a straight- or branched-chain alkyl grouphaving from 1 to 12 carbon atoms in the chain. Examples of alkyl groupsinclude methyl (Me, which also may be structurally depicted by thesymbol, “/”), ethyl (Et), n-propyl, isopropyl, butyl, isobutyl,sec-butyl, tert-butyl (tBu), pentyl, isopentyl, tert-pentyl, hexyl,isohexyl, and groups that in light of the ordinary skill in the art andthe teachings provided herein would be considered equivalent to any oneof the foregoing examples. The term C₁₋₃alkyl as used here refers to astraight- or branched-chain alkyl group having from 1 to 3 carbon atomsin the chain. The term C₁₋₆alkyl as used here refers to a straight- orbranched-chain alkyl group having from 1 to 6 carbon atoms in the chain.

The term “halo” represents chloro, fluoro, bromo or iodo.

The term “perhaloalkyl” or “haloalkyl” refers to a straight- orbranched-chain alkyl group having from 1 to 6 carbon atoms in the chainoptionally substituting hydrogens with halogens. The term“C₁₋₃perhaloalkyl” as used here refers to a straight- or branched-chainalkyl group having from 1 to 3 carbon atoms in the chain, optionallysubstituting hydrogens with halogens. The term “C₁₋₆perhaloalkyl” asused here refers to a straight- or branched-chain alkyl group havingfrom 1 to 6 carbon atoms in the chain, optionally substituting hydrogenswith halogens. Examples of “perhaloalkyl”, “haloalkyl” groups includetrifluoromethyl (CF₃), difluoromethyl (CF₂H), monofluoromethyl (CH₂F),pentafluoroethyl (CF₂CF₃), tetrafluoroethyl (CHFCF₃), monofluoroethyl(CH₂CH₂F), trifluoroethyl (CH₂CF₃), tetrafluorotrifluoromethylethyl(CF(CF₃)₂), chloropropyl (CH₂CH₂CH₂Cl), and groups that in light of theordinary skill in the art and the teachings provided herein would beconsidered equivalent to any one of the foregoing examples.

The term “cyano” refers to the group CN.

The term “cydoalkyl” refers to a saturated or partially saturated,monocyclic, fused polycydic, or spiro polycyclic carbocycle having from3 to 12 ring atoms per carbocycle. Illustrative examples of cydoalkylgroups include the following entities, in the form of properly bondedmoieties:

The term “phenyl” represents the following moiety:

The phenyl moiety can be attached through any one of the 1-, 2-, 3-4-,5-, or 6-position carbon atoms.

The term “thienyl” represents the following moiety:

The term “pyridinyl” or “pyridyl” represents the following moiety:

The pyridinyl or pyridyl moiety can be attached through any one of the2-, 3-, 4-, 5-, or 6-position carbon atoms.

The term “pyrimidinyl” represents the following moiety:

The pyrimidinyl moiety can be attached through any one of the 2-, 4-,5-, or 6-position carbon atoms.

The term “pyrazinyl” represents the following moiety:

The pyrazinyl moiety can be attached through any one of the 2-, 3-, 5-,or 6-position carbon atoms.

The term “pyridazinyl” represents the following moiety:

The pyridazinyl moiety can be attached through any one of the 3-, 4-,5-, or 6-position carbon atoms.

The term “pyrazolyl” represents the following moiety:

The pyrazolyl moiety can be attached through any one of the 1-, 2-, 3-,4-, or 5-position carbon atoms.

The term “piperidinyl” represents the following moiety:

When the piperidinyl moiety is a substituent, it can be attached throughany one of the 1-, 2-, 3-, 4-, 5-, or 6-position atoms, as permitted.

The term “pyrrolidinyl” represents the following moiety:

When the piperidinyl moiety is a substituent, it can be attached throughany one of the 1-, 2-, 3-, 4-, or 5-position atoms, as permitted.

The term “azetidinyl” represents a 4-membered heterocycloalkyl moietyhaving one ring nitrogen. When the azetidinyl moiety is a substituent,it can be attached through any carbon atom or through the nitrogen atom,as permitted.

The term “morpholinyl” represents the following moiety:

When the morpholinyl moiety is a substituent, it can be attached throughany one of the 2-, 3-, 4-, 5-, or 6-position atoms, as permitted.

The term “substituted” means that the specified group or moiety bearsone or more substituents. The term “unsubstituted” means that thespecified group bears no substituents. The term “optionally substituted”means that the specified group is unsubstituted or substituted by one ormore substituents. Where the term “substituted” is used to describe astructural system, the substitution is meant to occur at anyvalency-allowed position on the system. In cases where a specifiedmoiety or group is not expressly noted as being optionally substitutedor substituted with any specified substituent, it is understood thatsuch a moiety or group is intended to be unsubstituted.

The terms “para”, “meta”, and “ortho” have the meanings as understood inthe art. Thus, for example, a fully substituted phenyl group hassubstituents at both “ortho” (o) positions adjacent to the point ofattachment of the phenyl ring, both “meta” (m) positions, and the one“para” (p) position across from the point of attachment. To furtherclarify the position of substituents on the phenyl ring, the 2 differentortho positions will be designated as ortho and ortho′ and the 2different meta positions as meta and meta′ as illustrated below.

To provide a more concise description, some of the quantitativeexpressions given herein are not qualified with the term “about”. It isunderstood that, whether the term “about” is used explicitly or not,every quantity given herein is meant to refer to the actual given value,and it is also meant to refer to the approximation to such given valuethat would reasonably be inferred based on the ordinary skill in theart, including equivalents and approximations due to the experimentaland/or measurement conditions for such given value. Whenever a yield isgiven as a percentage, such yield refers to a mass of the entity forwhich the yield is given with respect to the maximum amount of the sameentity that could be obtained under the particular stoichiometricconditions. Concentrations that are given as percentages refer to massratios, unless indicated differently.

The terms “buffered” solution or “buffer” solution are used hereininterchangeably according to their standard meaning. Buffered solutionsare used to control the pH of a medium, and their choice, use, andfunction is known to those of ordinary skill in the art. See, forexample, G. D. Considine, ed., Van Nostrand's Encyclopedia of Chemistry,p. 261, 5^(th) ed. (2005), describing, inter alia, buffer solutions andhow the concentrations of the buffer constituents relate to the pH ofthe buffer. For example, a buffered solution is obtained by adding MgSO₄and NaHCO₃ to a solution in a 10:1 w/w ratio to maintain the pH of thesolution at about 7.5.

Any formula given herein is intended to represent compounds havingstructures depicted by the structural formula as well as certainvariations or forms. In particular, compounds of any formula givenherein may have asymmetric centers and therefore exist in differentenantiomeric forms. All optical isomers of the compounds of the generalformula, and mixtures thereof, are considered within the scope of theformula. Thus, any formula given herein is intended to represent aracemate, one or more enantiomeric forms, one or more diastereomericforms, one or more atropisomeric forms, and mixtures thereof.Furthermore, certain structures may exist as geometric isomers (i.e.,cis and trans isomers), as tautomers, or as atropisomers.

It is also to be understood that compounds that have the same molecularformula but differ in the nature or sequence of bonding of their atomsor the arrangement of their atoms in space are termed “isomers.”

Stereoisomers that are not mirror images of one another are termed“diastereomers” and those that are non-superimposable mirror images ofeach other are termed “enantiomers.” When a compound has an asymmetriccenter, for example, it is bonded to four different groups, and a pairof enantiomers is possible. An enantiomer can be characterized by theabsolute configuration of its asymmetric center and is described by theR- and S-sequencing rules of Cahn and Prelog, or by the manner in whichthe molecule rotates the plane of polarized light and designated asdextrorotatory or levorotatory (i.e., as (+)- or (−)-isomersrespectively). A chiral compound can exist as either an individualenantiomer or as a mixture thereof. A mixture containing equalproportions of the enantiomers is called a “racemic mixture.”

“Tautomers” refer to compounds that are interchangeable forms of aparticular compound structure, and that vary in the displacement ofhydrogen atoms and electrons. Thus, two structures may be in equilibriumthrough the movement of π electrons and an atom (usually H). Forexample, enols and ketones are tautomers because they are rapidlyinterconverted by treatment with either acid or base. Another example oftautomerism is the aci- and nitro-forms of phenyl nitromethane, that arelikewise formed by treatment with acid or base.

Tautomeric forms may be relevant to the attainment of the optimalchemical reactivity and biological activity of a compound of interest.

The compounds of this invention may possess one or more asymmetriccenters; such compounds can therefore be produced as individual (R)- or(S)-stereoisomers or as mixtures thereof.

Unless indicated otherwise, the description or naming of a particularcompound in the specification and claims is intended to include bothindividual enantiomers and mixtures, racemic or otherwise, thereof. Themethods for the determination of stereochemistry and the separation ofstereoisomers are well-known in the art.

Certain examples contain chemical structures that are depicted as anabsolute enantiomer but are intended to indicate enatiopure materialthat is of unknown configuration. In these cases (R*) or (S*) is used inthe name to indicate that the absolute stereochemistry of thecorresponding stereocenter is unknown. Thus, a compound designated as(R*) refers to an enantiopure compound with an absolute configuration ofeither (R) or (S). In cases where the absolute stereochemistry has beenconfirmed, the structures are named using (R) and (S).

The symbols

and

are used as meaning the same spatial arrangement in chemical structuresshown herein. Analogously, the symbols

and

are used as meaning the same spatial arrangement in chemical structuresshown herein.

Additionally, any formula given herein is intended to refer also tohydrates, solvates, and polymorphs of such compounds, and mixturesthereof, even if such forms are not listed explicitly. Certain compoundsof Formula (I) (as well as Formulas (IA), (IB), (IC), (ID), (II), (IIA),and (IIB)), or pharmaceutically acceptable salts of compounds of Formula(I) (as well as Formulas (IA), (IB), (IC), (ID), (II), (IIA), and (IIB))may be obtained as solvates. Solvates include those formed from theinteraction or complexation of compounds of the invention with one ormore solvents, either in solution or as a solid or crystalline form. Insome embodiments, the solvent is water and the solvates are hydrates.

In addition, certain crystalline forms of compounds of Formula (I) (aswell as Formulas (IA), (IB), (IC), (ID), (II), (IIA), and (IIB)) orpharmaceutically acceptable salts of compounds of Formula (I) (as wellas Formulas (IA), (IB), (IC), (ID), (II), (IIA), and (IIB)) may beobtained as co-crystals.

In other embodiments, pharmaceutically acceptable salts of compounds ofFormula (I) may be obtained in a crystalline form. In still otherembodiments, compounds of Formula (I) may be obtained in one of severalpolymorphic forms, as a mixture of crystalline forms, as a polymorphicform, or as an amorphous form. In other embodiments, compounds ofFormula (I) may convert in solution between one or more crystallineforms and/or polymorphic forms.

Reference to a compound herein stands for a reference to any one of: (a)the actually recited form of such compound, and (b) any of the forms ofsuch compound in the medium in which the compound is being consideredwhen named. For example, reference herein to a compound such as R—COOH,encompasses reference to any one of, for example, R—COOH_((s)),R—COOH_((sol)), and R—COO⁻ _((sol)). In this example, R—COOH_((s))refers to the solid compound, as it could be for example in a tablet orsome other solid pharmaceutical composition or preparation;R—COOH_((sol)) refers to the undissociated form of the compound in asolvent; and R—COO⁻ _((sol)) refers to the dissociated form of thecompound in a solvent, such as the dissociated form of the compound inan aqueous environment, whether such dissociated form derives fromR—COOH, from a salt thereof, or from any other entity that yields R—COO⁻upon dissociation in the medium being considered. In another example, anexpression such as “exposing an entity to compound of formula R—COOH”refers to the exposure of such entity to the form, or forms, of thecompound R—COOH that exists, or exist, in the medium in which suchexposure takes place. In still another example, an expression such as“reacting an entity with a compound of formula R—COOH” refers to thereacting of (a) such entity in the chemically relevant form, or forms,of such entity that exists, or exist, in the medium in which suchreacting takes place, with (b) the chemically relevant form, or forms,of the compound R—COOH that exists, or exist, in the medium in whichsuch reacting takes place. In this regard, if such entity is for examplein an aqueous environment, it is understood that the compound R—COOH isin such same medium, and therefore the entity is being exposed tospecies such as R—COOH_((aq)) and/or R—COO⁻ _((aq)), where the subscript“(aq)” stands for “aqueous” according to its conventional meaning inchemistry and biochemistry. A carboxylic acid functional group has beenchosen in these nomenclature examples; this choice is not intended,however, as a limitation but it is merely an illustration. It isunderstood that analogous examples can be provided in terms of otherfunctional groups, including but not limited to hydroxyl, basic nitrogenmembers, such as those in amines, and any other group that interacts ortransforms according to known manners in the medium that contains thecompound. Such interactions and transformations include, but are notlimited to, dissociation, association, tautomerism, solvolysis,including hydrolysis, solvation, including hydration, protonation, anddeprotonation. No further examples in this regard are provided hereinbecause these interactions and transformations in a given medium areknown by any one of ordinary skill in the art.

In another example, a zwitterionic compound is encompassed herein byreferring to a compound that is known to form a zwitterion, even if itis not explicitly named in its zwitterionic form. Terms such aszwitterion, zwitterions, and their synonyms zwitterionic compound(s) arestandard IUPAC-endorsed names that are well known and part of standardsets of defined scientific names. In this regard, the name zwitterion isassigned the name identification CHEBI:27369 by the Chemical Entities ofBiological Interest (ChEBI) dictionary of molecular entities. Asgenerally well known, a zwitterion or zwitterionic compound is a neutralcompound that has formal unit charges of opposite sign. Sometimes thesecompounds are referred to by the term “inner salts”. Other sources referto these compounds as “dipolar ions”, although the latter term isregarded by still other sources as a misnomer. As a specific example,aminoethanoic acid (the amino acid glycine) has the formula H₂NCH₂COOH,and it exists in some media (in this case in neutral media) in the formof the zwitterion ⁺H₃NCH₂COO⁻. Zwitterions, zwitterionic compounds,inner salts and dipolar ions in the known and well established meaningsof these terms are within the scope of this invention, as would in anycase be so appreciated by those of ordinary skill in the art. Becausethere is no need to name each and every embodiment that would berecognized by those of ordinary skill in the art, no structures of thezwitterionic compounds that are associated with the compounds of thisinvention are given explicitly herein. They are, however, part of theembodiments of this invention. No further examples in this regard areprovided herein because the interactions and transformations in a givenmedium that lead to the various forms of a given compound are known byany one of ordinary skill in the art.

Any formula given herein is also intended to represent unlabeled formsas well as isotopically labeled forms of the compounds. Isotopicallylabeled compounds have structures depicted by the formulas given hereinexcept that one or more atoms are replaced by an atom having a selectedatomic mass or mass number. Examples of isotopes that can beincorporated into compounds of the invention include isotopes ofhydrogen, carbon, nitrogen, oxygen, phosphorus, sulfur, fluorine,chlorine, and iodine such as ²H, ³H, ¹¹C, ¹³C, ¹⁴C, ¹⁵N, ¹⁸O, ¹⁷O, ³¹P,³²P, ³⁵S, ¹⁸F, ³⁶Cl, ¹²⁵I, respectively. Such isotopically labeledcompounds are useful in metabolic studies (preferably with ¹⁴C),reaction kinetic studies (with, for example deuterium (i.e., D or ²H);or tritium (i.e., T or ³H)), detection or imaging techniques [such aspositron emission tomography (PET) or single-photon emission computedtomography (SPECT)] including drug or substrate tissue distributionassays, or in radioactive treatment of patients. In particular, an ¹⁸For ¹¹C labeled compound may be particularly preferred for PET or SPECTstudies. Further, substitution with heavier isotopes such as deuterium(i.e., ²H) may afford certain therapeutic advantages resulting fromgreater metabolic stability, for example increased in vivo half-life orreduced dosage requirements. Isotopically labeled compounds of thisinvention and prodrugs thereof can generally be prepared by carrying outthe procedures disclosed in the schemes or in the examples andpreparations described below by substituting a readily availableisotopically labeled reagent for a non-isotopically labeled reagent.

When referring to any formula given herein, the selection of aparticular moiety from a list of possible species for a specifiedvariable is not intended to define the same choice of the species forthe variable appearing elsewhere. In other words, where a variableappears more than once, the choice of the species from a specified listis independent of the choice of the species for the same variableelsewhere in the formula, unless stated otherwise.

According to the foregoing interpretive considerations on assignmentsand nomenclature, it is understood that explicit reference herein to aset implies, where chemically meaningful and unless indicated otherwise,independent reference to embodiments of such set, and reference to eachand every one of the possible embodiments of subsets of the set referredto explicitly.

By way of a first example on substituent terminology, if substituent S¹_(example) is one of S₁ and S₂, and substituent S² _(example) is one ofS₃ and S₄, then these assignments refer to embodiments of this inventiongiven according to the choices S¹ _(example) is S₁ and S² _(example) isS₃; S¹ _(example) is S₁ and S² _(example) is S₄; S¹ _(example) is S₂ andS² _(example) is S₃; S¹ _(example) is S₂ and S² _(example) is S₄; andequivalents of each one of such choices. The shorter terminology “S¹_(example) is one of S₁ and S₂, and S² _(example) is one of S₃ and S₄”is accordingly used herein for the sake of brevity, but not by way oflimitation. The foregoing first example on substituent terminology,which is stated in generic terms, is meant to illustrate the varioussubstituent assignments described herein. The foregoing convention givenherein for substituents extends, when applicable, to members such as R¹,R^(1′), R², R^(2′), R⁴, R¹⁰, R¹¹, R¹², R¹³, R¹⁴, R¹⁵, R¹⁶, R¹⁷, R¹⁸,R¹⁹, R^(f), R^(g), R^(h), HAL, PG, LG, n, Ar¹, Ar^(1′), Ar², Ar³, andany other generic substituent symbol used herein.

Furthermore, when more than one assignment is given for any member orsubstituent, embodiments of this invention comprise the variousgroupings that can be made from the listed assignments, takenindependently, and equivalents thereof. By way of a second example onsubstituent terminology, if it is herein described that substituentS_(example) is one of S₁, S₂, and S₃, this listing refers to embodimentsof this invention for which S_(example) is S₁; S_(example) is S₂;S_(example) is S₃; S_(example) is one of S₁ and S₂; S_(example) is oneof S₁ and S₃; S_(example) is one of S₂ and S₃; S_(example) is one of S₁,S₂ and S₃; and S_(example) is any equivalent of each one of thesechoices. The shorter terminology “S_(example) is one of S₁, S₂, and S₃”is accordingly used herein for the sake of brevity, but not by way oflimitation. The foregoing second example on substituent terminology,which is stated in generic terms, is meant to illustrate the varioussubstituent assignments described herein. The foregoing convention givenherein for substituents extends, when applicable, to members such as R¹,R^(1′), R², R^(2′), R⁴, R¹⁰, R¹¹, R¹², R¹³, R¹⁴, R¹⁵, R¹⁶, R¹⁷, R¹⁸,R¹⁹, R^(f), R^(g), R^(h), HAL, PG, LG, n, Ar¹, Ar^(1′), Ar², Ar³ and anyother generic substituent symbol used herein.

The nomenclature “C_(i-j)” with j>i, when applied herein to a class ofsubstituents, is meant to refer to embodiments of this invention forwhich each and every one of the number of carbon members, from i to jincluding i and j, is independently realized. By way of example, theterm C₁₋₄ refers independently to embodiments that have one carbonmember (C₁), embodiments that have two carbon members (C₂), embodimentsthat have three carbon members (C₃), and embodiments that have fourcarbon members (C₄).

The term C_(n-m)alkyl refers to an aliphatic chain, whether straight orbranched, with a total number N of carbon members in the chain thatsatisfies n≤N≤m, with m>n. Any disubstituent referred to herein is meantto encompass the various attachment possibilities when more than one ofsuch possibilities are allowed. For example, reference to disubstituent-A-B—, where A≠B, refers herein to such disubstituent with A attached toa first substituted member and B attached to a second substitutedmember, and it also refers to such disubstituent with A attached to thesecond substituted member and B attached to the first substitutedmember.

The invention includes also pharmaceutically acceptable salts of thecompounds of Formula (I) (as well as Formulas (IA), (IB), (IC), (ID),(II), (IIA), and (IIB)), preferably of those described above and of thespecific compounds exemplified herein, and methods of treatment usingsuch salts.

The term “pharmaceutically acceptable” means approved or approvable by aregulatory agency of Federal or a state government or the correspondingagency in countries other than the United States, or that is listed inthe U. S. Pharmcopoeia or other generally recognized pharmacopoeia foruse in animals, and more particularly, in humans.

A “pharmaceutically acceptable salt” is intended to mean a salt of afree acid or base of compounds represented by Formula (I) (as well asFormulas (IA), (IB), (IC), (ID), (II), (IIA), and (IIB)) that arenon-toxic, biologically tolerable, or otherwise biologically suitablefor administration to the subject. It should possess the desiredpharmacological activity of the parent compound. See, generally, G. S.Paulekuhn, et al., “Trends in Active Pharmaceutical Ingredient SaltSelection based on Analysis of the Orange Book Database”, J. Med. Chem.,2007, 50:6665-72, S. M. Berge, et al., “Pharmaceutical Salts”, J PharmSci., 1977, 66:1-19, and Handbook of Pharmaceutical Salts, Properties,Selection, and Use, Stahl and Wermuth, Eds., Wiley-VCH and VHCA, Zurich,2002. Examples of pharmaceutically acceptable salts are those that arepharmacologically effective and suitable for contact with the tissues ofpatients without undue toxicity, irritation, or allergic response. Acompound of Formula (I) (as well as Formulas (IA), (IB), (IC), (ID),(II), (IIA), and (IIB)) may possess a sufficiently acidic group, asufficiently basic group, or both types of functional groups, andaccordingly react with a number of inorganic or organic bases, andinorganic and organic acids, to form a pharmaceutically acceptable salt.

Examples of pharmaceutically acceptable salts include sulfates,pyrosulfates, bisulfates, sulfites, bisulfites, phosphates,monohydrogen-phosphates, dihydrogenphosphates, metaphosphates,pyrophosphates, chlorides, bromides, iodides, acetates, propionates,decanoates, caprylates, acrylates, formates, isobutyrates, caproates,heptanoates, propiolates, oxalates, malonates, succinates, suberates,sebacates, fumarates, maleates, butyne-1,4-dioates, hexyne-1,6-dioates,benzoates, chlorobenzoates, methylbenzoates, dinitrobenzoates,hydroxybenzoates, methoxybenzoates, phthalates, sulfonates,xylenesulfonates, phenylacetates, phenylpropionates, phenylbutyrates,citrates, lactates, γ-hydroxybutyrates, glycolates, tartrates,methane-sulfonates, propanesulfonates, naphthalene-1-sulfonates,naphthalene-2-sulfonates, and mandelates.

When the compounds of Formula (I) (as well as Formulas (IA), (IB), (IC),(ID), (II), (IIA), and (IIB)) contain a basic nitrogen, the desiredpharmaceutically acceptable salt may be prepared by any suitable methodavailable in the art. For example, treatment of the free base with aninorganic acid, such as hydrochloric acid, hydrobromic acid, sulfuricacid, sulfamic acid, nitric acid, boric acid, phosphoric acid, and thelike, or with an organic acid, such as acetic acid, phenylacetic acid,propionic acid, stearic acid, lactic acid, ascorbic acid, maleic acid,hydroxymaleic acid, isethionic acid, succinic acid, valeric acid,fumaric acid, malonic acid, pyruvic acid, oxalic acid, glycolic acid,salicylic acid, oleic acid, palmitic acid, lauric acid, a pyranosidylacid, such as glucuronic acid or galacturonic acid, an alpha-hydroxyacid, such as mandelic acid, citric acid, or tartaric acid, an aminoacid, such as aspartic acid, glutaric acid or glutamic acid, an aromaticacid, such as benzoic acid, 2-acetoxybenzoic acid, naphthoic acid, orcinnamic acid, a sulfonic acid, such as laurylsulfonic acid,p-toluenesulfonic acid, methanesulfonic acid, ethanesulfonic acid, anycompatible mixture of acids such as those given as examples herein, andany other acid and mixture thereof that are regarded as equivalents oracceptable substitutes in light of the ordinary level of skill in thistechnology.

When the compound of Formula (I) (as well as Formulas (IA), (IB), (IC),(ID), (II), (IIA), and (IIB)) is an acid, such as a carboxylic acid orsulfonic acid, the desired pharmaceutically acceptable salt may beprepared by any suitable method, for example, treatment of the free acidwith an inorganic or organic base, such as an amine (primary, secondaryor tertiary), an alkali metal hydroxide, alkaline earth metal hydroxide,any compatible mixture of bases such as those given as examples herein,and any other base and mixture thereof that are regarded as equivalentsor acceptable substitutes in light of the ordinary level of skill inthis technology. Illustrative examples of suitable salts include organicsalts derived from amino acids, such as N-methyl-D-glucamine, lysine,choline, glycine and arginine, ammonia, carbonates, bicarbonates,primary, secondary, and tertiary amines, and cyclic amines, such astromethamine, benzylamines, pyrrolidines, piperidine, morpholine, andpiperazine, and inorganic salts derived from sodium, calcium, potassium,magnesium, manganese, iron, copper, zinc, aluminum, and lithium.

The invention also relates to pharmaceutically acceptable prodrugs ofthe compounds of Formula (I) (as well as Formulas (IA), (IB), (IC),(ID), (II), (IIA), and (IIB)), and treatment methods employing suchpharmaceutically acceptable prodrugs. The term “prodrug” means aprecursor of a designated compound that, following administration to asubject, yields the compound in vivo via a chemical or physiologicalprocess such as solvolysis or enzymatic cleavage, or under physiologicalconditions (e.g., a prodrug on being brought to physiological pH isconverted to the compound of Formula (I). A “pharmaceutically acceptableprodrug” is a prodrug that is non-toxic, biologically tolerable, andotherwise biologically suitable for administration to the subject.Illustrative procedures for the selection and preparation of suitableprodrug derivatives are described, for example, in “Design of Prodrugs”,ed. H. Bundgaard, Elsevier, 1986.

Exemplary prodrugs include compounds having an amino acid residue, or apolypeptide chain of two or more (e.g., two, three or four) amino acidresidues, covalently joined through an amide or ester bond to a freeamino, hydroxyl, or carboxylic acid group of a compound of Formula (I)(as well as Formulas (IA), (IB), (IC), (ID), (II), (IIA), and (IIB)).Examples of amino acid residues include the twenty naturally occurringamino acids, commonly designated by three letter symbols, as well as4-hydroxyproline, hydroxylysine, demosine, isodemosine,3-methylhistidine, norvalin, beta-alanine, gamma-aminobutyric acid,citrulline homocysteine, homoserine, omithine and methionine sulfone.

Additional types of prodrugs may be produced, for instance, byderivatizing free carboxyl groups of structures of Formula (I) (as wellas Formulas (IA), (IB), (IC), (ID), (II), (IIA), and (IIB)) as amides oralkyl esters. Examples of amides include those derived from ammonia,primary C₁₋₆alkyl amines and secondary di(C₁₋₆alkyl) amines. Secondaryamines include 5- or 6-membered heterocycloalkyl or heteroaryl ringmoieties. Examples of amides include those that are derived fromammonia, C₁₋₃alkyl primary amines, and di(C₁₋₂alkyl)amines. Examples ofesters of the invention include C₁₋₇alkyl, C₅₋₇cycloalkyl, phenyl, andphenyl(C₁₋₆alkyl) esters. Preferred esters include methyl esters.Prodrugs may also be prepared by derivatizing free hydroxy groups usinggroups including hemisuccinates, phosphate esters,dimethylaminoacetates, and phosphoryloxymethyloxycarbonyls, followingprocedures such as those outlined in Fleisher et al., Adv. Drug DeliveryRev. 1996, 19, 115-130. Carbamate derivatives of hydroxy and aminogroups may also yield prodrugs. Carbonate derivatives, sulfonate esters,and sulfate esters of hydroxy groups may also provide prodrugs.Derivatization of hydroxy groups as (acyloxy)methyl and (acyloxy)ethylethers, wherein the acyl group may be an alkyl ester, optionallysubstituted with one or more ether, amine, or carboxylic acidfunctionalities, or where the acyl group is an amino acid ester asdescribed above, is also useful to yield prodrugs. Prodrugs of this typemay be prepared as described in Robinson et al., J Med Chem. 1996, 39(1), 10-18. Free amines can also be derivatized as amides, sulfonamidesor phosphonamides. All of these prodrug moieties may incorporate groupsincluding ether, amine, and carboxylic acid functionalities.

The present invention also relates to pharmaceutically activemetabolites of the compounds of Formula (I) (as well as Formulas (IA),(IB), (IC), (ID), (II), (IIA), and (IIB)), which may also be used in themethods of the invention. A “pharmaceutically active metabolite” means apharmacologically active product of metabolism in the body of a compoundof Formula (I) (as well as Formulas (IA), (IB), (IC), (ID), (II), (IIA),and (IIB)) as applicable) or salt thereof. Prodrugs and activemetabolites of a compound may be determined using routine techniquesknown or available in the art. See, e.g., Bertolini, et al., J Med Chem.1997, 40, 2011-2016; Shan, et al., J Pharm Sci. 1997, 86 (7), 765-767;Bagshawe, Drug Dev Res. 1995, 34, 220-230; Bodor, Adv Drug Res. 1984,13, 224-331; Bundgaard, Design of Prodrugs (Elsevier Press, 1985); andLarsen, Design and Application of Prodrugs, Drug Design and Development(Krogsgaard-Larsen, et al., eds., Harwood Academic Publishers, 1991).

The compounds of Formula (I) (as well as Formulas (IA), (IB), (IC),(ID), (II), (IIA), and (IIB)) and their pharmaceutically acceptablesalts, pharmaceutically acceptable prodrugs, and pharmaceutically activemetabolites of the present invention are useful as modulators of theNR2B receptor in the methods of the invention. As such modulators, thecompounds may act as antagonists, agonists, or inverse agonists. Theterm “modulators” include both inhibitors and activators, where“inhibitors” refer to compounds that decrease, prevent, inactivate,desensitize, or down-regulate the NR2B receptor expression or activity,and “activators” are compounds that increase, activate, facilitate,sensitize, or up-regulate NR2B receptor expression or activity.

The term “treat”, “treatment” or “treating”, as used herein, is intendedto refer to administration of an active agent or composition of theinvention to a subject for the purpose of affecting a therapeutic orprophylactic benefit through modulation of NR2B receptor activity.Treating includes reversing, ameliorating, alleviating, inhibiting theprogress of, lessening the severity of, or preventing a disease,disorder, or condition, or one or more symptoms of such disease,disorder or condition mediated through modulation of NR2B receptoractivity. The term “subject” refers to a mammalian patient in need ofsuch treatment, such as a human.

Accordingly, the invention relates to methods of using the compoundsdescribed herein to treat subjects diagnosed with or suffering from adisease, disorder, or condition mediated by NR2B receptor activity, suchas: bipolar disorder I depressed, hypomanic, manic and mixed form;bipolar disorder II; depressive disorders, such as single depressiveepisode or recurrent major depressive disorder, minor depressivedisorder, treatment-resistant depression, depressive disorder withpostpartum onset, disruptive mood dysregulation disorder, depressivedisorders with psychotic symptoms; persistent mood disorders, such ascyclothymia, dysthymia, euthymia; and premenstrual dysphoric disorder,anxiety disorders, general anxiety disorder, panic disorder with orwithout agoraphobia, specific phobia, social anxiety disorder, chronicanxiety disorders; obsessive compulsive disorder; reaction to severstress and adjustment disorders, such as post traumatic stress disorder(PTSD); other neurotic disorders such as depersonalisation-derealisationsyndrome; pervasive developmental disorders, including but not limitedto Asperger's syndrome and Rett's syndrome, autistic disorders,childhood autism and overactive disorder associated with mentalretardation and stereotyped movements, specific developmental disorderof motor function, specific developmental disorders of scholasticskills; postnatal (postpartum) and prenatal depression; eatingdisorders, including but not limited to anorexia nervosa, bulimianervosa, pica and binge eating disorder; Parkinson's disease; secondParkinsonism, such as postencephalitic Parkinsonism; Parkinsonismcomprised in other disorders; Lewis body disease; degenerative diseasesof the basal ganglia; other extrapyramidal and movement disordersincluding but not limited to tremor, essential tremor and drug-inducedtremor, myoclonus, chorea and drug-induced chorea, drug-induced tics andtics of organic origin, drug-induced acute dystonia, drug-inducedtardive dyskinesia, L-dopa-induced dyskinesia; neuroleptic-inducedmovement disorders including but not limited to neuroleptic malignantsyndrome (NMS), neuroleptic induced parkinsonism, neuroleptic-inducedearly onset or acute dyskinesia, neuroleptic-induced acute dystonia,neuroleptic-induced acute akathisia, neuroleptic-induced tardivedyskinesia, neuroleptic-induced tremor; restless leg syndrome, Stiff-mansyndrome; dystonia including but not limited to focal dystonia,multiple-focal or segmental dystonia, torsion dystonia, hemispheric,generalised and tardive dystonia (induced by psychopharmacologicaldrugs). Focal dystonia include cervical dystonia (torticolli),blepharospasm (cramp of the eyelid), appendicular dystonia (cramp in theextremities, like the writer's cramp), oromandibular dystonia andspasmodic dysphonia (cramp of the vocal cord); epilepsy, includinglocalization-related (focal)(partial) idiopathic epilepsy and epilepticsyndromes with seizures of localized onset, localization-related(focal)(partial) symptomatic epilepsy and epileptic syndromes withsimple partial seizures, localization-related (focal)(partial)symptomatic epilepsy and epileptic syndromes with complex partialseizures, generalized idiopathic epilepsy and epileptic syndromesincluding but not limited to myoclonic epilepsy in infancy, neonatalconvulsions (familial), childhood absence epilepsy (pyknolepsy),epilepsy with grand mal seizures on awakening, absence epilepsy,myoclonic epilepsy (impulsive petit mal) and nonspecific atonic, clonic,myodonic, tonic, tonic-clonic epileptic seizures; epilepsy with myodonicabsences, myoclonic-astatic seizures, infantile spasms, Lennox-Gastautsyndrome, Salaam attacks, symptomatic early myoclonic encephalopathy,West's syndrome, petit and grand mal seizures; status epilepticus;persistent somatoform disorders; acute, chronic and chronic intractablepain, headache; acute and chronic pain related to physiologicalprocesses and physical disorders including but not limited to back pain,tooth pain, abdominal pain, low back pain, pain in joints; acute andchronic pain that is related to diseases of the musculoskeletal systemand connective tissue including, but not limited to rheumatism, myalgia,neuralgia and fibromyalgia; acute and chronic pain that is related tonerve, nerve root and plexus disorders, such as trigeminal pain,postzoster neuralgia, phantom limb syndrome with pain, carpal tunnelsyndrome, lesion of sciatic nerve, diabetic mononeuropathy; acute andchronic pain that is related to polyneuropathies and other disorders ofthe peripheral nervous system, such as hereditary and idiopathicneuropathy, inflammatory polyneuropathy, polyneuropathy induced bydrugs, alcohol or toxic agents, polyneuropathy in neoplastic disease,diabetic polyneuropathy; and acute neurodegeneration, such asintracranial brain injuries, such as stroke, diffuse and local braininjuries, epidural, subdural and subarachnoid haemorrhage, and chronicneurodegeneration, such as Alzheimer's disease, Huntington's disease,multiple sclerosis, and ALS; subarachnoid haemorrhage, intracerebralhaemorrhage and other nontraumatic intracranial haemorrhage, cerebralinfarction, stroke, occlusion and stenosis or precerebral and cerebralarteries, not resulting in cerebral infarction, dissection of cerebralarteries, cerebral aneurysm, cerebral atherosclerosis, progressivevascular leukoencephalopathy, hypertensive encephalopathy, nonpyogenicthrombosis of intracranial venous system, cerebral arteritis, cerebralamyloid angiopathy and sequelae of cerebrovascular diseases; glaucomaand other neuopathies; dementias, vascular demensia, Lewy body dementia,frontotemporal dementia, and HIV-dementia; vertigo and nystagmus;tinnitus; neuropsychiatric systemic lupus erythematosus; disruptive mooddysregulation disorder; schizophrenia spectrum disorder; and sleep/wakedisorders.

In treatment methods according to the invention, an effective amount ofa pharmaceutical agent according to the invention is administered to asubject suffering from or diagnosed as having such a disease, disorder,or condition. An “effective amount” means an amount or dose sufficientto generally bring about the desired therapeutic or prophylactic benefitin patients in need of such treatment for the designated disease,disorder, or condition. Effective amounts or doses of the compounds ofthe present invention may be ascertained by routine methods such asmodeling, dose escalation studies or clinical trials, and by taking intoconsideration routine factors, e.g., the mode or route of administrationor drug delivery, the pharmacokinetics of the compound, the severity andcourse of the disease, disorder, or condition, the subject's previous orongoing therapy, the subject's health status and response to drugs, andthe judgment of the treating physician. An example of a dose is in therange of from about 0.001 to about 200 mg of compound per kg ofsubject's body weight per day, preferably about 0.05 to 100 mg/kg/day,or about 1 to 35 mg/kg/day, in single or divided dosage units (e.g.,BID, TID, QID). For a 70-kg human, an illustrative range for a suitabledosage amount is from about 0.05 to about 7 g/day, or about 0.2 to about2.5 g/day.

Once improvement of the patient's disease, disorder, or condition hasoccurred, the dose may be adjusted for preventative or maintenancetreatment. For example, the dosage or the frequency of administration,or both, may be reduced as a function of the symptoms, to a level atwhich the desired therapeutic or prophylactic effect is maintained. Ofcourse, if symptoms have been alleviated to an appropriate level,treatment may cease. Patients may, however, require intermittenttreatment on a long-term basis upon any recurrence of symptoms.

In addition, the active agents of the invention may be used incombination with additional active ingredients in the treatment of theabove conditions. The additional active ingredients may beco-administered separately with an active agent of compounds of Table 1or included with such an agent in a pharmaceutical composition accordingto the invention. In an exemplary embodiment, additional activeingredients are those that are known or discovered to be effective inthe treatment of conditions, disorders, or diseases mediated by NR2Bactivity, such as another NR2B modulator or a compound active againstanother target associated with the particular condition, disorder, ordisease. The combination may serve to increase efficacy (e.g., byincluding in the combination a compound potentiating the potency oreffectiveness of an active agent according to the invention), decreaseone or more side effects, or decrease the required dose of the activeagent according to the invention.

The active agents of the invention are used, alone or in combinationwith one or more additional active ingredients, to formulatepharmaceutical compositions of the invention. A pharmaceuticalcomposition of the invention comprises: (a) an effective amount of atleast one active agent in accordance with the invention; and (b) apharmaceutically acceptable excipient.

A “pharmaceutically acceptable excipient” refers to a substance that isnon-toxic, biologically tolerable, and otherwise biologically suitablefor administration to a subject, such as an inert substance, added to apharmacological composition or otherwise used as a vehicle, carrier, ordiluent to facilitate administration of an agent and that is compatibletherewith. Examples of excipients include calcium carbonate, calciumphosphate, various sugars and types of starch, cellulose derivatives,gelatin, vegetable oils, and polyethylene glycols.

Delivery forms of the pharmaceutical compositions containing one or moredosage units of the active agents may be prepared using suitablepharmaceutical excipients and compounding techniques known or thatbecome available to those skilled in the art. The compositions may beadministered in the inventive methods by a suitable route of delivery,e.g., oral, parenteral, rectal, topical, or ocular routes, or byinhalation.

The preparation may be in the form of tablets, capsules, sachets,dragees, powders, granules, lozenges, powders for reconstitution, liquidpreparations, or suppositories. Preferably, the compositions areformulated for intravenous infusion, topical administration, or oraladministration.

For oral administration, the compounds of the invention can be providedin the form of tablets or capsules, or as a solution, emulsion, orsuspension. To prepare the oral compositions, the compounds may beformulated to yield a dosage of, e.g., from about 0.05 to about 100mg/kg daily, or from about 0.05 to about 35 mg/kg daily, or from about0.1 to about 10 mg/kg daily. For example, a total daily dosage of about5 mg to 5 g daily may be accomplished by dosing once, twice, three, orfour times per day.

Oral tablets may include a compound according to the invention mixedwith pharmaceutically acceptable excipients such as inert diluents,disintegrating agents, binding agents, lubricating agents, sweeteningagents, flavoring agents, coloring agents and preservative agents.Suitable inert fillers include sodium and calcium carbonate, sodium andcalcium phosphate, lactose, starch, sugar, glucose, methyl cellulose,magnesium stearate, mannitol, sorbitol, and the like. Exemplary liquidoral excipients include ethanol, glycerol, water, and the like. Starch,polyvinyl-pyrrolidone (PVP), sodium starch glycolate, microcrystallinecellulose, and alginic acid are suitable disintegrating agents. Bindingagents may include starch and gelatin. The lubricating agent, ifpresent, may be magnesium stearate, stearic acid or talc. If desired,the tablets may be coated with a material such as glyceryl monostearateor glyceryl distearate to delay absorption in the gastrointestinaltract, or may be coated with an enteric coating.

Capsules for oral administration include hard and soft gelatin capsules.To prepare hard gelatin capsules, compounds of the invention may bemixed with a solid, semi-solid, or liquid diluent. Soft gelatin capsulesmay be prepared by mixing the compound of the invention with water, anoil such as peanut oil or olive oil, liquid paraffin, a mixture of monoand di-glycerides of short chain fatty acids, polyethylene glycol 400,or propylene glycol.

Liquids for oral administration may be in the form of suspensions,solutions, emulsions or syrups or may be lyophilized or presented as adry product for reconstitution with water or other suitable vehiclebefore use. Such liquid compositions may optionally contain:pharmaceutically-acceptable excipients such as suspending agents (forexample, sorbitol, methyl cellulose, sodium alginate, gelatin,hydroxyethylcellulose, carboxymethylcellulose, aluminum stearate gel andthe like); non-aqueous vehicles, e.g., oil (for example, almond oil orfractionated coconut oil), propylene glycol, ethyl alcohol, or water;preservatives (for example, methyl or propyl p-hydroxybenzoate or sorbicacid); wetting agents such as lecithin; and, if desired, flavoring orcoloring agents.

The active agents of this invention may also be administered by non-oralroutes. For example, the compositions may be formulated for rectaladministration as a suppository. For parenteral use, includingintravenous, intramuscular, intraperitoneal, or subcutaneous routes, thecompounds of the invention may be provided in sterile aqueous solutionsor suspensions, buffered to an appropriate pH and isotonicity or inparenterally acceptable oil. Suitable aqueous vehicles include Ringer'ssolution and isotonic sodium chloride. Such forms will be presented inunit-dose form such as ampules or disposable injection devices, inmulti-dose forms such as vials from which the appropriate dose may bewithdrawn, or in a solid form or pre-concentrate that can be used toprepare an injectable formulation. Illustrative infusion doses may rangefrom about 1 to 1000 μg/kg/minute of compound, admixed with apharmaceutical carrier over a period ranging from several minutes toseveral days.

For topical administration, the compounds may be mixed with apharmaceutical carrier at a concentration of about 0.1% to about 10% ofdrug to vehicle. Another mode of administering the compounds of theinvention may utilize a patch formulation to affect transdermaldelivery. Compounds of the invention may alternatively be administeredin methods of this invention by inhalation, via the nasal or oralroutes, e.g., in a spray formulation also containing a suitable carrier.

Exemplary compounds useful in methods of the invention will now bedescribed by reference to the illustrative synthetic schemes for theirgeneral preparation below and the specific examples that follow.Artisans will recognize that, to obtain the various compounds herein,starting materials may be suitably selected so that the ultimatelydesired substituents will be carried through the reaction scheme with orwithout protection as appropriate to yield the desired product.Alternatively, it may be necessary or desirable to employ, in the placeof the ultimately desired substituent, a suitable group that may becarried through the reaction scheme and replaced as appropriate with thedesired substituent. Unless otherwise specified, the variables are asdefined above in reference to Formula (I). Reactions may be performedbetween the melting point and the reflux temperature of the solvent, andpreferably between 0° C. and the reflux temperature of the solvent.Reactions may be heated employing conventional heating or microwaveheating. Reactions may also be conducted in sealed pressure vesselsabove the normal reflux temperature of the solvent.

Abbreviations and acronyms used herein include the following: Table 4:

Term Acronym Acetonitrile ACN Aqueous aq Atmosphere atmtert-Butylcarbamoyl Boc, or BOCa Broad br Diatomaceous Earth Celite ®Diethylaminosulfur trifluoride DAST Di-tert-butyl azodicarboxylate DBAD1,8-Diazabicyclo[5.4.0]undec-7-ene DBU Dichloromethane DCMBis(2-methoxyethyl)aminosulfur trifluoride Deoxo-Fluor ®Diisopropylethylamine DIPEA, DIEA, or Hunig's base4-Dimethylaminopyridine DMAP 1,2-Dimethoxyethane DMEN,N-Dimethylformamide DMF Dimethylsulfoxide DMSO1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide EDCI; EDAC, or EDC Diethylether Ether, Et₂O Ethyl Acetate EtOAc, or EA Ethanol EtOH Electrosprayionization ESI Normal-phase silica gel chromatography FCC Grams g Hoursh Hydroxybenzotriazole HOBt High-pressure liquid chromatography HPLCHertz Hz Isopropyl alcohol iPrOH, IPA Lithium aluminum hydride LAH TermAcronym Liquid chromatography and mass spectrometry LCMS Lithiumbis(trimethylsilyl)amide LHMDS Molar M Mass to charge ratio m/zmeta-Chloroperoxybenzoic acid mCPBA Methyl Iodide Mel Methanol MeOHMilligrams mg Minute min Milliliter mL Microliter μL Millimoles mmolMass spectrometry MS Normal N Sodium tert-butoxide NaOt-Bu Nuclearmagnetic resonance NMR CF₃SO₃- or triflate OTf Palladium (II) acetatePd(OAc)₂ Palladium(II)bis(triphenylphosphine) dichloride Pd(PPh₃)₂Cl₂Tetrakis(triphenylphosphine)palladium(0) Pd(PPh₃)₄ [1,1′-Bis(di-tert-PdCl₂(dtbpf) or butylphosphino)ferrocene]dichloropalladium(II)Pd(dtbpf)₂Cl₂ [1,1'- Bis(diphenylphosphino)ferrocene]dichloropalladiumPdCl₂(dppf) or (II) Pd(dppf)₂Cl₂ Parts per million ppm Precipitate pptPolytetrafluoroethylene PTFE Retention time R_(t) Room temperature rtSaturated sat 1-Chloromethyl-4-fluoro-1,4- Selectfluor ®diazoniabicyclo[2.2.2]octane bis(tetrafluoroborate)[2-(Trimethylsilyl)ethoxy]methyl acetal SEM Supercritical FluidChromatography SFC Temperature T Tert-Butyl alcohol tBuOH, t-BuOHTetra-n-butylammonium fluoride TBAF Triethylamine TEA Trifluoroaceticacid TFA Tetrahydrofuran THF Thin layer chromatography TLC Volume inmilliliters of solvent per gram of V, or volumes substrate(Diethylamino)difluorosulfonium tetrafluoroborate XtalFluor ®

PREPARATIVE EXAMPLES

Exemplary compounds useful in methods of the invention will now bedescribed by reference to the illustrative synthetic schemes for theirgeneral preparation below and the specific examples to follow.

According to SCHEME A, a compound of formula (V) where HAL is Cl, andR¹⁰ is F, is oxidized under conditions known to one skilled in the art,to afford a compound of formula (VI). For example, reaction of acompound of formula (V), where HAL is Cl, and R¹⁰ is F, is oxidized withan oxidizing agent such as mCPBA, and the like, in a suitable solventsuch as DCM, and the like, at temperatures ranging from 0° C. to rt, toprovide a compound of formula (VI), where LG is SO₂CH₃.

Commercially available or synthetically accessible pyrimidines offormula (V), where HAL is Br, and R¹⁰ is H, are reacted in a metalmediated cross coupling with an amine of formula (VII), to provide acompound of formula (VIII). For example, a pyrimidine of formula (V),where HAL is Br, and R¹⁰ is H, is reacted with a palladium catalyst suchas Pd(OAc)₂, a ligand such as Xantphos, and the like, a base such asNaOtBu, and the like, an amine such as azetidine, 3-fluoroazetidine,3,3-difluoroazetidine, and the like, in a suitable solvent such astoluene, a temperatures ranging from 90-120° C., for a period of 2-5 h,to provide a compound of formula (VIII). A compound of formula (VIII),is oxidized, employing conditions previously described, to provide acompound of formula (IX).

Commercially available or synthetically accessible pyrimidines offormula (VI), where LG is Cl, R¹⁰ is H, and HAL is Cl, are reacted witha suitable nucleophile such as an amine of formula (VII) (wherein theamine is an alkylamine or heterocycloalkyl amine which is optionallysubstituted with one or more halogen members), with or without asuitable base such as TEA, in a suitable solvent such as DMF, THF, DCM,and the like, for a period of 1-6 h, to provide a compound of formula(IX), where NR¹¹R¹² is (N(C₁₋₆alkyl)₂) or heterocycloalkylamine and R¹⁰is H. In a preferred embodiment, the amine is azetidine,3-fluoroazetidine, 3,3-difluoroazetidine, pyrrolidine,3,3-difluoropyrrolidine piperidine, or morpholine, and the base is TEA.

According to SCHEME B, a compound of formula (Xa), where LG is Cl, R¹⁹is OH, or CH₂OH, is reacted with a silyl chloride reagent such astert-butyl(chloro)dimethylsilane, and the like, a base such asimidazole, in a solvent such as DCM and the like, to provide silyl ethercompound of formula (XI). Alternately a compound of formula (Xa) isalkylated with a suitable alkylating agent, such as1-fluoro-2-iodoethane, employing a base such as NaH, K₂CO₃, Na₂CO₃, TEA,Cs₂CO₃, and the like, in a suitable solvent such as DMF, ACN, DCM, attemperatures ranging from 0° C. to 85° C., to afford a compound offormula (XI), where R⁴ is O—C₁₋₆alkyl, CH₂O—C₁₋₆alkyl,O—C₁₋₆perhaloalkyl, or CH₂O—C₁₋₆perhaloalkyl, and LG is Cl.

A compound of formula (XI), where LG is SO₂CH₃ and R⁴ is CH₂O—C₁₋₆alkyl,CH₂O—C₁₋₆perhaloalkyl, and CH₂O-CD₃, may be prepared in two steps from acompound of formula (Xb) where R¹⁹ is CH₂OH. In a first step a compoundof formula (Xb) may be alkylated employing conditions previouslydescribed, with a suitable base such as NaH, K₂CO₃, and the like, and analkylating agent such as Et-I, CD₃-I,2-chloro-2,2-difluoro-1-phenylethan-1-one, and the like. In a secondstep, oxidation of the thiomethyl employing previously describedconditions, may provide a compound of formula (XI), where R⁴ isCH₂O—C₁₋₆alkyl, CH₂O—C₁₋₆perhaloalkyl, or CH₂O-CD₃, and LG is SO₂CH₃.

A compound of formula (XI), where R⁴ is CH₂O—C₁₋₆alkyl and LG is SO₂CH₃may also be prepared in three steps from a compound of formula (Xb)where R¹⁹ is C(═O)CH₃ or CO₂CH₃. In a first step, reduction of thekenone employing conditions known to one skilled in the art, for examplewith a reducing agent such as LiBH₄, LiBD₄, and the like, may provide acompound of formula (Xb), where R¹⁹ is CH₂OH. Subsequent alkylation andoxidation may provide a compound of formula (XI), where R⁴ isCH₂O—C₁₋₆alkyl and LG is SO₂CH₃. A compound of formula (Xb) mayadditionally be substituted with a halogen such as F.

A compound of formula (XI), where R⁴ is CH₂O—C₁₋₆alkyl and LG is SO₂CH₃may also be prepared in three steps from a compound of formula (Xb)where R¹⁹ is C(═O)CH₃. Reaction of the ketone with a reagent such asMeMgBr, employing conditions known to one skilled in the art, mayprovide a compound of formula (Xb), where R¹⁹ is C(CH₃)₂OH. Subsequentalkylation and oxidation may provide a compound of formula (XI), whereR⁴ is CH₂O—C₁₋₆alkyl and LG is SO₂CH₃.

A compound of formula (Xb), where R¹⁹ is C(CH₃)₂OH or CH₂OH may also bereacted with a silyl chloride reagent such astert-butyl(chloro)dimethylsilane, under conditions previously described.

According to SCHEME C, a compound of formula (XII), where LG is Cl, R¹⁴is H, F, or CH₃, R¹⁵ is C₁₋₆alkyl or C₁₋₆perhaloalkyl, is protected witha suitable nitrogen protecting group (PG) such as BOC(tert-butyloxycarbonyl), SEM (2-(trimethylsilyl)ethoxymethyl), and thelike, under conditions known to one skilled in the art, to provide acompound of formula (XIII).

According to SCHEME D, a compound of formula (XIV), where LG is Cl, andR¹⁴ is H, is reduced and subsequently protected in a one pot reaction toprovide a compound of formula (XV), where PG is BOC, and R¹⁷ is H. Forexample, 2-chloropyrimidine-4-carbonitrile, is reacted withdi-tert-butyl dicarbonate, Pd/C, under an atmosphere of H₂, in asuitable solvent such as EtOH, and the like, to provide tert-butyl((2-chloropyrimidin-4-yl)methyl)carbamate.

A compound of formula (XV) is also prepared from a compound of formula(XVII) in three steps. In a first step, a compound of formula (XVII),where R¹⁴ is H, is reacted in a reductive amination reaction with asuitable amine such as methyl amine, a reducing agent such asNaBH(OAc)₃, NaBH₄, and the like, in a solvent such as THF, DCM and thelike, for a period of 12-20 h. In a second step, the alkyl amine isprotected with a suitable nitrogen protecting group such as BOC,employing conditions previously described. In a third step, themethylthioether is oxidized employing conditions previously described toprovide a compound of formula (XV), where LG is SO₂CH₃, R¹⁷ is CH₃, andPG is BOC.

A compound of formula (XV), where LG is Cl, PG is BOC, and R¹⁷ is H, isalkylated employing conditions known to one skilled in the art. Forexample, alkylation with an alkyl halide agent such as MeI, and thelike, a base such as NaH, in a solvent such as THF, DMF, and the like,provides a compound of formula (XVI), where R¹⁸ is CH₃.

According to SCHEME E, 5-bromo-2-methoxypyrimidine is reacted in a metalmediated cross coupling with an alkyne such as prop-2-yn-1-ol, apalladium catalyst such as PdCl₂(PPh₃)₂, and the like, a base suchtrimethylamine, CuI, in a solvent such as DMF, and the like, to provide3-(2-methoxypyrimidin-5-yl)prop-2-yn-1-ol. The alkyne is reduced,employing conditions previously described, to afford3-(2-methoxypyrimidin-5-yl)propan-1-ol. The alcohol is protected with asuitable alkyl alcohol protecting group such as an alkyl tosylate. Forexample, 3-(2-methoxypyrimidin-5-yl)propan-1-ol is reacted with sulfonylchloride, a base such as TEA, trimethylamine, and the like, in a solventsuch DCM, for a period of 12-24 h, provides a compound of formula(XVIII). Fluorination of a compound of formula (XVIII), employing TBAF,in a solvent such as THF, provides5-(3-fluoropropyl)-2-methoxypyrimidine. A compound of formula (XIX) isprepared in two steps from 5-(3-fluoropropyl)-2-methoxypyrimidine. In afirst step, demethylation of the methyl ether is achieved withHCl/Dioxane, at a temperature of 100° C., for a period of 4-6 h.Chlorination of 5-(3-fluoropropyl)pyrimidin-2(1H)-one is achieved underchlorination conditions, for example, reaction with POCl₃, and the like,at temperatures ranging from 70-90° C., to afford a compound of formula(XIX), where LG is Cl.

According to SCHEME F, a compound of formula (XXII), where Ar¹ is asubstituted phenyl ring, is commercially available or syntheticallyaccessible from a compound of formula (XX), where R^(f) and R^(g) areselected from: H, OH, halo, C(O)C₁₋₃alkyl, CHO, C₁₋₃alkyl, OC₁₋₃alkyl,C₁₋₆perhaloalkyl, and OC₁₋₆perhaloalkyl. A compound of formula (XX),where R¹ is defined as above and R^(g) is OH, is alkylated with areagent such as chlorodifluoroacetate, MeI, and the like, in thepresence of a base, such as K₂CO₃, Cs₂CO₃, NaH, and the like, in asuitable solvent such as DMF, water, or a mixture thereof, attemperatures ranging from room temperature to 120° C., or conventionalheating, for a period of 2 to 5 h, to provide a compound of formula(XXI), where R^(f) is defined as above and R^(g) is OC₁₋₆alkyl orOC₁₋₆perhaloalkyl. In a preferred method, a compound of formula (XX),where R^(f) is Cl and R^(g) is OH, is alkylated withchlorodifluoroacetate, in the presence of a base, such as K₂CO₃, in asuitable solvent such as DMF, water, or a mixture thereof, at 100° C.,for 2.5 h, to afford compound of formula (XXI), where R^(f) is Cl, andR^(h) is OCF₂H. A compound of formula (XX), where R^(f) is defined asabove and R^(g) is CHO, is fluorinated with a fluorinating agent suchas, DAST, XtalFluor®, Deoxo-Fluor®, and the like, in a suitable solventsuch as DCM, and the like, at temperatures ranging from −78° C. to 50°C., for a period of 2-24 h. In a preferred method, a compound of formula(XX), where R^(f) is Cl and R^(g) is CHO, is reacted with the afluorinating agent such as DAST, in a solvent suitable solvent such asDCM, at room temperature, for 20 h, provides a compound of formula(XXI), where R^(f) is Cl and R^(h) is CF₂H.

A nitro compound of formula (XXI) is reduced, employing conditions knownto one skilled in the art, to provide a compound of formula (XXII),where Ar¹ is a substituted phenyl ring as defined in Formula (I). Anitro compound of formula (XX), where R^(f) and R^(g) are selected fromH, halo, C(O)C₁₋₄alkyl, C₁₋₄alkyl, OC₁₋₄alkyl, C₁₋₆perhaloalkyl, orOC₁₋₆perhaloalkyl, is reduced with a reducing agent, such as but notlimited to: Pd/C under an atmosphere of H₂ (balloon); Fe powder in asolution of HCl; Zn powder in a solution of aqueous NH₄Cl; in a suitablesolvent such as MeOH, EtOH, THF, acetone, and the like, at temperaturesranging from room temperature (23° C.) to about 50° C., for a period of30 minutes to 16 h, to afford a compound of formula (XXII). In apreferred method, a nitro compound of formula (XXI), where R^(f) is Cland R^(h) is OCF₂H, is reduced with Fe powder, concentrated HCl, in asolvent such as MeOH, at room temperature, for a period of about 2 h. Ina preferred method, a nitro compound of formula (XXI), where R^(f) is Cland R^(h) is CF₂H, is reduced with Zn powder, NH₄Cl, in a suitablesolvent such as acetone/water, at temperatures ranging from 0° C. to rt,for a period of 16 h.

According to SCHEME G, an azide compound of formula (XXIII) is preparedfrom a compound of formula (XXII) employing azidation conditions knownto one skilled in the art. In a preferred method, a compound of formula(XXII), where Ar¹ is a suitably substituted phenyl or pyridyl, in asuitable solvent such as iPrOH, THF, and the like, is treated with 6 NHCl in iPrOH, and reacted in flow, or conventional methods known to oneskilled in the art, with sodium nitrite in a suitable solvent such aswater, and sodium azide in a suitable solvent such as water,respectively, under acidic conditions (such as H₂SO₄, HCl, TFA, etc.) toafford an azide compound of formula (XXIII). Alternatively, aryl azidesof formula (XXIII) may be prepared employing conditions known to oneskilled in the art, for example, copper(II)-catalyzed conversion oforganoboron compounds; arenediazonium tosylates and sodium azide inwater at room temperature; S_(N)Ar reactions using sodium azide and ahalogenated aryl. A compound of formula (XXIII), were Ar¹ is a suitablysubstituted thiophene may be made according to the methods recitedabove.

A compound of formula (XXV), where R¹ is H, R² is H or CH₃, and Ar¹ is asuitably substituted phenyl or pyridyl, is obtained thru ametal-catalyzed azide-alkyne 1,3-dipolar cycloaddition reaction of acompound of formula (XXIII) and an alkyne of formula (XXIV), in thepresence of metal catalyst such as copper sulfate, (CuOTf)₂.C₆He,RuCp*Cl(PPh₃)₂, and the like, with or without a reducing agent such asL-sodium ascorbate and the like, in a solvent such as H₂O, tBuOH,isopropanol, dioxane, toluene, or a mixture thereof, at temperaturesranging from rt to 100° C., for a period of 30 min to 24 h. In apreferred method, the alkyne of formula (XXIV) where R¹ is H, R² is H orCH₃, is reacted with an azide compound of formula (XXIII), coppersulfate, L-sodium ascorbate, in tBuOH/H₂O, at room temperatureovernight. In an alternate method, the alkyne is N-propargylphthalimide.

A compound of formula (XXV), where Ar, is a suitably substituted phenylor pyridyl, can be prepared as described in B. Chattopadhyay et al. Org.Lett. 2010, 12, 2166-2169. One skilled in the art will recognize thatthe azide-alkyne cycloaddition can also be accomplished by methodsdescribed in H. Kolb et al. Angew. Chem. Int. Ed. 2001, 40, 2004-2021.

According to SCHEME H, a compound of formula (XXVI), where R¹ is CH₃,CF₂H, or CF₃, is reacted with an Ar¹-boronic acid, where Ar¹ is asuitably substituted phenyl ring, NaN₃, a transition metal catalyst suchas Cu(OAc)₂, Cu₂O, CuBr, or Cu powder, a base such as piperidine,trimethylamine, KzCO₃ and the like, in a solvent such as DMSO, THF, DMF,and water, at temperatures ranging from room temperature to 80° C., fora period of 2 to 24 h, to provide a compound of formula (XXVII).Alternately, the addition of NaI in the previously describedtransformation of a compound of formula (XXVI) to a compound of formula(XXVII) provides a compound of formula (XXV) where R¹ is I.

A compound of formula (XXVI), where R¹ is CH₃, CF₂H, or CF₃, is reactedwith an Ar¹—N₃ of formula (XXIII), where Ar¹ is a suitably substitutedphenyl ring, an amine catalyst such as diethylamine, piperidine,proline, triethylamine, and the like, in a solvent such as DMSO, toprovide a compound of formula (XXVII). Reduction of a compound offormula (XXVII), with a reducing agent, such as LiAlH₄, LiBH₄, and thelike, in a solvent such as THF, and the like, affords a compound offormula (XXV), where R¹ is H or CH₃ and R² is H.

Referring to SCHEME I, a compound of Formula (I), where Ar³ ispyrimidine, pyridine, or pyridazine substituted with one or twosubstituents, R¹ is H, and R² is H or CH₃, is obtained from a compoundof formula (XXV), by a S_(N)Ar, S_(N)2, or Mitsunobu reaction. Forexample, a compound of Formula (I) is obtained from a compound offormula (XXV), by S_(N)Ar reaction with LG-Ar³, where Ar³ is acommercially available or synthetically accessible heteroaromatic fiveor six membered ring, and LG is a suitable leaving group such as F, Cl,Br, I, SO₂Me, or OTf, in the presence of a base, such as NaH, K₂CO₃,Cs₂CO₃, and the like, in a solvent such as DMF, THF, ACN, and the like,at temperatures ranging from room temperature (about 23° C.) to about140° C., employing conventional or microwave heating. In a preferredmethod the base is NaH, the solvent is DMF and the reaction is performedat room temperature.

A compound of Formula (I), where Ar³ is pyrimidine, pyridine, orpyridazine substituted with one or two substituents, R¹ is H, and R² isH or CH₃, is also obtained from a compound of formula (XXV), by aMitsunobu reaction with a compound of Ar³—OH, where Ar³—OH is acommercially available or synthetically accessible heteroaromatic fiveor six membered ring selected from is pyrimidine, pyridine, orpyridazine substituted with one or two substituents. For example, acompound of formula (XXV), where R¹ is H, and R² is H or CH₃, is reactedwith Ar³—OH, where Ar³ is a commercially available or syntheticallyaccessible heteroaromatic five or six membered ring, PPh₃, and the like,a base such as DEAD, DCAD, DIAD, DBAD, and the like, in a suitablesolvent such as THF, DMF, and the like, at temperatures ranging fromroom temperature (about 23° C.) to about 50° C., to provide a compoundof Formula (I). In a preferred method, a compound of formula (XXV) isreacted with Ar³—OH, PPh₃, DBAD, in THF at room temperature to provide acompound of Formula (I).

A compound of Formula (I), where Ar^(1′) is pyrimidine, pyridine, orpyridazine substituted with one or two substituents, R¹ is H, and R² isH or CH₃, is also obtained in two steps from a compound of formula(XXV), by S_(N)2 reaction. In the first step, a chloro compound offormula (XXVIII) is prepared from a compound of formula (XXV) employingchlorination conditions known to one skilled in the art, such as thionylchloride, in a suitable solvent such as DCM, CHCl₃, and the like, attemperatures ranging from room temperature to about 50° C., for a periodof 30 min to 6 h. In the second step, a compound of Formula (I) isprepared by reacting a chloro compound of formula (XXVIII) with anucleophile such as Ar³—OH in a S_(N)2 reaction. For example, a chlorocompound of formula (XXVIII) is reacted with a nucleophile of formulaAr³—OH, where a Ar³—OH is a suitable commercially available orsynthetically accessible hydroxy-substituted heteroaryl compound, in thepresence of a base, such as NaH, K₂CO₃ and the like, in a solvent suchas DMF at temperatures ranging from room temperature (about 23° C.) toabout 50° C. to provide a compound of Formula (I). In a preferredmethod, the base is K₂CO₃, the solvent is DMF and the reaction isperformed at room temperature.

A compound of Formula (I) where Ar³ is substituted with Br, is reactedin a metal mediated cross coupling reaction to provide a compound ofFormula (I) where Ar³ is xx. For example, a compound of Formula (I),where Ar³ is substituted with Br or Cl, is reacted with a suitablysubstituted commercially available or synthetically accessible aryl orheteroaryl boronic acid, boronate ester, trimethylboroxine, and thelike, in the presence of a palladium catalyst such as XPhos PalladacydeGen. 3, PdCl₂(dtbpf), Pd(PPh₃)₄, PdCl₂(dppf), Pd(PPh₃)₂Cl₂, and thelike, a base such as K₃PO₄, aq. Na₂CO₃, Na₂CO₃, Cs₂CO₃, and the like, ina suitable solvent such as 1,2-dimethoxyethane, 1,4-dioxane, THF, DMF,water, or a mixture thereof, at a temperature ranging from 60 to 180°C., employing microwave or conventional heating, for a period of about30 min to 16 h, to provide a compound of Formula (I), where1-methylpyrazol-3-yl, 1H-pyrazol-4-yl, and the like.

In a similar fashion, a compound of Formula (I), where Ar¹ issubstituted with a suitable halogen such as Br, is reacted in a metalmediated cross coupling reaction with an alkylzinc halide,cyclallkylzinc halide such as cyclobutylzinc bromide, 2-propylzincbromide, and the like, a palladium catalyst such as Pd(t-Bu₃P)₂, and thelike, in a suitable solvent such as THF, at a temperature of about 50°C., for a period of 12-24 h, to provide a compound of Formula (I), whereAr¹ is substituted with C₁₋₆alkyl or C₃₋₆cycloalkyl.

In a similar fashion, a compound of Formula (I), where Ar¹ issubstituted with a suitable halogen such as Br, is reacted in a metalmediated cross coupling reaction with a suitably substitutedcommercially available or synthetically accessible boronic acid,potassium trifluoroborate, trimethylboroxine, and the like in thepresence of a palladium catalyst such as RuPhos-Pd-G3, and the like, ina suitable solvent such as 1,4-dioxane, with a suitable base such asK₂CO₃, potassium phosphate tribasic, and the like at a temperature ofabout 100° C., for a period of 12-24 h, to provide a compound of Formula(I), where Ar¹ is substituted with C₁₋₆alkyl or C₃₋₆cycloalkyl.

A compound of Formula (I), where Ar¹ is substituted with a suitablehalogen leaving group such as F, is reacted with a 4-6 memberedheterocycloalkyl such as azetidine, pyrrolidine, piperidine ormorpholine, a base such as DIPEA, and the like, in a suitable solventsuch as ACN, and the like, at temperatures ranging from 50-100° C., fora period of 12-24 h, to provide a compound of Formula (I), where Ar¹ issubstituted with 4-6 membered heterocycloalkyl.

A compound of Formula (I) where Ar¹ is substituted with an ester issaponified to a carboxylic acid using a base such as Cs₂CO₃, and thelike, in a suitable solvent such as ACN, and the like, at a temperatureof around 140° C. in a microwave reactor for 2 h, then the carboxylicacid is converted to an amide under conditions known to one skilled inthe art, to privde and compound of Formula (I).

Conversion of a compound of Formula (I), where Ar³ is a pyrazinesubstituted with Cl, to a compound of Formula (I), where Ar³ issubstituted with F, is achieved with CsF, in a solvent such as DMSO andthe like, a temperatures ranging from 90-110° C., for a period of 2-4 h.

Conversion of a compounds of Formula (I), where Ar³ is a pyrimidinesubstituted with Cl, to a compound of Formula (I), where Ar^(1′) issubstituted with. NH₂, is achieved with a solution of ammonia in MeOH,in a solvent such as THF, at a temperature around 100° C. undermicrowave irradiation for 8 h.

Referring to SCHEME J, a compound of Formula (II), where Ar² ispyrazole, oxazole, imidazole, pyrimidine, pyridine, or pyridazinesubstituted with one or two substituents, and R¹ and R² are H, isobtained from a compound of formula (XXVIII) by an S_(N)Ar, S_(N)2, ormetal mediated cross-coupling reaction.

A compound of Formula (II), where Ar² pyrimidine, pyridine, orpyridazine substituted with one or two substituents, and R¹ and R² areH, is obtained from a compound of formula (XXVIII) in two steps. In thefirst step, nucleophilic displacement of the chlorine in a compound offormula (XXVIII) with an amine, such as a solution of ammonia inmethanol, provides the corresponding primary amine compound of formula(XXIX). Alternatively, nucleophilic displacement of the chlorine in acompound of formula (XXVIII) with phthalimide followed by deprotectionusing hydrazine hydrate provides the corresponding primary aminecompound of formula (XXIX). In the second step, reaction of a compoundof formula (XXIX) in a S_(N)Ar reaction with Ar²-LG, where Ar² is acommercially available or synthetically accessible heteroaromatic fiveor six membered ring, and LG is a suitable leaving group such as F, Cl,Br, I, or OTf, in the presence of a base, such as NaH, Et₃N, K₂CO₃ andthe like, in a solvent such as EtOH and the like, at temperaturesranging from room temperature (about 23° C.) to about 200° C., employingconventional or microwave heating. In a preferred method the base isEt₃N, the solvent is EtOH and the reaction was heated in a microwavereactor at 120° C. for 2 h and then at 150° C. for 10 min.

A compound of Formula (II), where Ar² is imidazole, pyrazole,pyrimidine, pyridine, or pyridazine substituted with one or twosubstituents, and R¹ and R² are H, is also obtained from a compound offormula (XXIX), by a metal mediated cross-coupling reaction with Ar²-LG,where Ar² is a commercially available or synthetically accessibleheteroaromatic five or six membered ring, and LG is a suitable leavinggroup such as F, Cl, Br, I, or OTf, in the presence of a palladiumcatalyst such as Pd₂(dba)₃, Pd(OAc)₂, and the like, a phosphine ligandsuch as XPhos, tBuBrettPhos, and the like, a base such as KOtBu, LHMDS,and the like, in a suitable solvent such as toluene, DME, tBuOH, andDMF, at temperatures ranging from room temperature (about 23° C.) toabout 110° C. In a preferred method the palladium catalyst is Pd₂(dba)₃,the ligand is tBuXPhos, the base is KOtBu, and the solvent is tBuOH.

A compound of Formula (II), where Ar² is pyrazole, pyrimidine, pyridine,or pyridazine substituted with one or two substituents, and R¹ and R²are H, is obtained from a compound of formula (XXVIII), in a S_(N)2reaction with a compound of formula Ar²—NH₂. For example, a chlorocompound of formula (XXVIII) is reacted with a compound of formulaAr²—NH₂, where a Ar²—NH₂ is a suitable commercially available orsynthetically accessible amino-substituted heteroaryl compound, in thepresence of a base, such as NaH, K₂CO₃, TEA, and the like, in a solventsuch as DMF, EtOH, ACN and the like, at temperatures ranging from roomtemperature (about 23° C.) to about 100° C., for a period of about 3 hto 16 h, to provide a compound of Formula (II). In a preferred methodthe base is K₂CO₃, the solvent is DMF and the reaction is heated to 80°C.

Referring to SCHEME K, a compound of Formula (II), where Ar² pyridine,oxazole, pyrazole, and R¹ and R² are H, is obtained from a compound offormula (XXV) in two steps. In the first step, a compound of formula(XXV) is oxidized to an aldehyde of formula (XXX) employing oxidationconditions known to one skilled in the art, for example, DMP(Dess-Martin periodinane), SO₃-pyridine, Swem conditions [(COCl)₂, DMSO,Et₃N], PCC, and the like, in a solvent such as EtOAc, DMSO, DCM, and thelike, at temperatures ranging from about −78° C. to room temperature(about 23° C.). In a preferred method, a compound of formula (XXV) isoxidized to a compound of formula (XXX) with Dess-Martin periodinane, inDCM, at 20° C. for 4 hours. In the second step, a carbonyl compound offormula (XXX) is reacted with a compound of formula Ar²—NH₂, where aAr²—NH₂ is a suitable commercially available or synthetically accessibleamino-substituted heteroaryl compound, in a reductive aminationreaction, a suitable reducing agent such as NaBH₄, NaHB(OAc)₃, NaBH₃CNand the like in a solvent such as MeOH, DCM and the like, attemperatures ranging from room temperature (about 23° C.) to about 50°C., for a period of 8-24 h to provide a compound of Formula (II). In apreferred method, the reducing agent is NaHB(OAc)₃ and the solvent isDCM.

Compounds of Formula (I) (as well as Formula (II)) may be converted totheir corresponding salts using methods known to one of ordinary skillin the art. For example, an amine of Formula (I) (as well as Formula(II)) is treated with trifluoroacetic acid, HCl, or citric acid in asolvent such as Et₂O, CH₂Cl₂, THF, CH₃OH, chloroform, or isopropanol toprovide the corresponding salt form. Alternately, trifluoroacetic acidor formic acid salts are obtained as a result of reverse phase HPLCpurification conditions. Cyrstalline forms of pharmaceuticallyacceptable salts of compounds of Formula (I) (as well as Formula (II))may be obtained in crystalline form by recrystallization from polarsolvents (including mixtures of polar solvents and aqueous mixtures ofpolar solvents) or from non-polar solvents (including mixtures ofnon-polar solvents).

Where the compounds according to this invention have at least one chiralcenter, they may accordingly exist as enantiomers. Where the compoundspossess two or more chiral centers, they may additionally exist asdiastereomers. It is to be understood that all such isomers and mixturesthereof are encompassed within the scope of the present invention.

Compounds prepared according to the schemes described above may beobtained as single forms, such as single enantiomers, by form-specificsynthesis, or by resolution. Compounds prepared according to the schemesabove may alternately be obtained as mixtures of various forms, such asracemic (1:1) or non-racemic (not 1:1) mixtures. Where racemic andnon-racemic mixtures of enantiomers are obtained, single enantiomers maybe isolated using conventional separation methods known to one ofordinary skill in the art, such as chiral chromatography,recrystallization, diastereomeric salt formation, derivatization intodiastereomeric adducts, biotransformation, or enzymatic transformation.Where regioisomeric or diastereomeric mixtures are obtained, asapplicable, single isomers may be separated using conventional methodssuch as chromatography or crystallization.

The following specific examples are provided to further illustrate theinvention and various preferred embodiments.

EXAMPLES

In obtaining the compounds described in the examples below and thecorresponding analytical data, the following experimental and analyticalprotocols were followed unless otherwise indicated.

Unless otherwise stated, reaction mixtures were magnetically stirred atroom temperature (rt) under a nitrogen atmosphere. Where solutions were“dried,” they were generally dried over a drying agent such as Na₂SO₄ orMgSO₄. Where mixtures, solutions, and extracts were “concentrated”, theywere typically concentrated on a rotary evaporator under reducedpressure. Reactions under microwave irradiation conditions were carriedout in a Biotage Initiator or CEM (Microwave Reactor) Discoverinstrument.

For the reactions conducted under continuous flow conditions, “flowedthrough a LTF-VS mixer” refers to the use of a Chemyx Fusion 100 TouchSyringe Pump that is in line via 1/16″ PTFE tubing to a LTF-VS mixer(Little Things Factory GmbH (http://www.ltf-gmbh.com), unless otherwiseindicated.

Normal-phase silica gel chromatography (FCC) was performed on silica gel(SiO₂) using prepacked cartridges.

Preparative reverse-phase high performance liquid chromatography (RPHPLC) was performed on either:

Method A.

An Agilent HPLC with an Xterra Prep RP18 column (5 μM, 30×100 or 50×150mm) or an XBridge C18 OBD column (5 μM, 30×100 or 50×150 mm), and amobile phase of 5% ACN in 20 mM NH₄OH was held for 2 min, then agradient of 5-99% ACN over 15 min, then held at 99% ACN for 5 min, witha flow rate of 40 or 80 mL/min.

or

Method B.

A Shimadzu LC-8A Series HPLC with an Inertsil ODS-3 column (3 μm, 30×100mm, T=45° C.), mobile phase of 5% ACN in H₂O (both with 0.05% TFA) washeld for 1 min, then a gradient of 5-99% ACN over 6 min, then held at99% ACN for 3 min, with a flow rate of 80 mL/min.

or

Method C.

A Shimadzu LC-8A Series HPLC with an XBridge C18 OBD column (5 μm,50×100 mm), mobile phase of 5% ACN in H₂O (both with 0.05% TFA) was heldfor 1 min, then a gradient of 5-99% ACN over 14 min, then held at 99%ACN for 10 min, with a flow rate of 80 mL/min.

or

Method D.

A Gilson HPLC with an XBridge C18 column (5 μm, 100×50 mm), mobile phaseof 5-99% ACN in 20 mM NH₄OH over 10 min and then hold at 99 ACN for 2min, at a flow rate of 80 mL/min.

or

Method E.

A Shimadzu LC-8A Series HPLC with a Sunfire C18 OBD column 15 (5 μm,50×100 mm), mobile phase of 5% ACN in H2O (both with 0.05% TFA) was heldfor 1 min, then a gradient of 5-99% ACN over 14 min, then held at 99%ACN for 10 min, with a flow rate of 80 mL/min.

Preparative supercritical fluid high performance liquid chromatography(SFC) was performed either on a Jasco preparative SFC system, an APS1010 system from Berger instruments, or a SFC-PICLAB-PREP 200 (PICSOLUTION, Avignon, France). The separations were conducted at 100 to 150bar with a flow rate ranging from 40 to 60 mL/min. The column was heatedto 35 to 40° C.

Mass spectra (MS) were obtained on an Agilent series 1100 MSD usingelectrospray ionization (ESI) in positive mode unless otherwiseindicated. Calculated (calcd.) mass corresponds to the exact mass.

Nuclear magnetic resonance (NMR) spectra were obtained on Bruker modelDRX spectrometers. Definitions for multiplicity are as follows:s=singlet, d=doublet, t=triplet, q=quartet, m=multiplet, br=broad. Itwill be understood that for compounds comprising an exchangeable proton,said proton may or may not be visible on an NMR spectrum depending onthe choice of solvent used for running the NMR spectrum and theconcentration of the compound in the solution.

Chemical names were generated using ChemDraw Ultra 12.0, ChemDraw Ultra14.0 (CambridgeSoft Corp., Cambridge, Mass.) or ACD/Name Version 10.01(Advanced Chemistry).

Compounds designated as R* or S* are enantiopure compounds where theabsolute configuration was not determined.

Step A. 1-Chloro-2-(difluoromethoxy)-4-nitrobenzene

A mixture of 2-chloro-5-nitrophenol (10 g, 58 mmol), K₂CO₃ (9.4 g, 68mmol), and sodium chlorodifluoroacetate (18 g, 115 mmol) in DMF (192 mL)and H₂O (25 mL) was degassed with nitrogen for 5 minutes, and then thereaction mixture was heated to 100° C. for 2.5 h. The mixture was cooledto rt and 12 N HCl (17 mL) and H₂O (25 mL) was added. The mixture wasstirred at room temperature for 1 h. The resulting mixture was thencooled to 0° C., and an aqueous solution of 1 N NaOH (213 mL) was addedportion wise. The reaction mixture was diluted with H₂O and extractedwith Et₂O (2×). The organic layer was further washed with H₂O (1×),dried (Na₂SO₄), filtered, and concentrated under reduced pressure.Purification (FCC, SiO₂, 0-50% DCM in hexanes) afforded the titlecompound (12 g, 55 mmol, 95% yield). ¹H NMR (400 MHz, CDCl₃) δ 8.15-8.12(m, 1H), 8.08 (dd, J=8.8, 2.5 Hz, 1H), 7.65 (d, J=8.8 Hz, 1H), 6.65 (t,J=71.9 Hz, 1H).

Step B. 4-Chloro-3-(difluoromethoxy)aniline

To a solution of 1-chloro-2-(difluoromethoxy)-4-nitrobenzene (5 g, 22mmol) in methanol (72 mL) was added Fe powder (5 g, 89 mmol) followed bythe drop-wise addition of concentrated HCl (37% in H₂O, 19 mL). Thereaction mixture was stirred at room temperature for 2 h. The reactionwas quenched with ice water and basified with solid NaHCO₃. Celite® wasadded to the crude reaction mixture and stirred for 10 minutes. Theheterogeneous mixture was filtered over a pad of Celite@ and thefiltrate was concentrated under reduced pressure to remove MeOH. Theresultant aqueous layer was extracted with DCM (3×). The combinedorganics were concentrated under reduced pressure to yield the titlecompound (3.3 g) as a light orange oil, which was used without furtherpurification. MS (ESI) mass calcd. for C₇H₆ClF₂NO, 193.0; m/z found194.1 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃) δ 7.16 (d, J=8.6 Hz, 1H),6.68-6.28 (m, 3H), 3.77 (s, 2H).

Step C.(1-(4-Chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methanol

Two solutions, 4-chloro-3-(difluoromethoxy)aniline (2.5 g, 13 mmol) in 6N HCl (6N HCl in iPrOH, 8 mL) and iPrOH (19 mL), and sodium nitrite (1g, 15 mmol) in H₂O (12 mL) were flowed through a LTF-MS mixer (0.2 mL)at 1 mL/min and 0.4 mL/min, respectively. The outcome was mixed withsodium azide (1 g, 15 mmol) in H₂O (12 mL) at 0.4 mL/min in a T-pieceand flowed through a LTF-VS mixer (1 mL). The mixture was collected overK₂CO₃ (8.9 g, 65 mmol) in iPrOH (32 mL). The reaction mixture wasstirred for 10 minutes after completion, and then propargyl alcohol (0.9mL, 15 mmol), CuSO₄.5H₂O (322 mg, 1.29 mmol), and L-sodium ascorbate(256 mg, 1.29 mmol) were added to the crude reaction. The heterogeneousreaction mixture was stirred at rt overnight. The reaction was dilutedwith EtOAc, H₂O, and a saturated aqueous solution of NH₄Cl. The biphasicmixture was stirred for 5 min, and then the layers were separated andthe aqueous layer further extracted with EtOAc (3×). The combinedorganics were dried (Na₂SO₄), filtered, and concentrated under reducedpressure to afford a dark orange solid. Purification (FCC, SiO₂, 40-100%EtOAc in hexanes) gave the title compound (2.9 g, 10 mmol, 80% yield).MS (ESI) mass calcd. for C₁₀H₈ClF₂N₃O₂, 275.0; m/z found 276.0 [M+H]⁺.¹H NMR (400 MHz, CDCl₃) δ 8.04-7.94 (m, 1H), 7.74-7.67 (m, 1H),7.64-7.60 (m, 1H), 7.59-7.54 (m, 1H), 6.64 (t, J=72.5 Hz, 1H), 4.91 (s,2H).

Step A. 4-Azido-1-chloro-2-(difluoromethoxy)benzene

Two solutions, 4-chloro-3-(difluoromethoxy)aniline (Intermediate 1,product from Step B, 0.8 g, 4.1 mmol) in 6 N HCl (6N HCl in PrOH, 2.6mL) and iPrOH (6.4 mL), and sodium nitrite (342 mg, 4.96 mmol) in H₂O(12 mL) were flowed through a LTF-MS mixer (0.2 mL) at 1 ml/min and 0.4mL/min, respectively. The outcome was mixed with sodium azide (322 mg,4.96 mmol) in H₂O (4 mL) at 0.4 mL/min in a T-piece and flowed through aLTF-VS mixer (1 mL). The mixture was collected over K₂CO₃ (2.9 g, 21mmol) in H₂O (10 mL). The reaction mixture was stirred for 10 minutesafter completion. The crude reaction mixture was extracted with Et₂O(3×). The combined organics were dried (Na₂SO₄), filtered, andconcentrated to a dark orange oil. The title compound was used crude inthe next step without further purification.

Step B.R/S-1-(1-(4-Chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)ethan-1-ol

To a solution of the crude 4-azido-1-chloro-2-(difluoromethoxy)benzene(from Step A) 1:1 mixture of tBuOH/H₂O (14 mL) and 3-butyn-2-ol (0.37mL, 4.96 mmol) was added CuSO₄.5H₂O (103 mg, 0.413 mmol), and L-sodiumascorbate (82 mg, 0.413 mmol). The reaction mixture stirred at roomtemperature over the weekend. The reaction was diluted with EtOAc, H₂O,and a saturated aqueous solution of NH₄Cl. The biphasic mixture wasstirred for 5 min, and then the layers were separated and the aqueouslayer further extracted with EtOAc (3×). The combined organics weredried (Na₂SO₄), filtered, and concentrated to a dark orange solid.Purification (FCC, SiO₂, 30-100% EtOAc in hexanes) afforded the titlecompound (785 mg, 2.71 mmol, 66% yield). MS (ESI) mass calcd. forC₁₁H₁₀ClF₂N₃O₂, 289.0; m/z found 290.1 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃) δ7.97-7.88 (m, 1H), 7.73-7.66 (m, 1H), 7.63-7.58 (m, 1H), 7.58-7.54 (m,1H), 6.64 (t, J=72.6 Hz, 1H), 5.17 (q, J=6.5 Hz, 1H), 2.65 (s, 1H), 1.66(d, J=6.5 Hz, 3H).

Step A. 1-Chloro-2-(difluoromethyl)-4-nitrobenzene

To 2-chloro-5-nitrobenzaldehyde (3.08 g, 16.61 mmol) stirring in DCM (50mL) at rt was slowly added DAST (2.83 mL, 21.59 mmol), and the resultingsolution was stirred at rt for 20 h. The completed reaction was pouredover ice (100 g) and allowed to stir until all the ice was melted. Thelayers were separated and the aqueous layer was extracted with DCM (3×20mL). The combined organics were washed once with brine (20 mL), dried(Na₂SO₄), and then concentrated under reduced pressure. The resultingorange residue (3.4 g, 98%) was carried forward without purification. ¹HNMR (500 MHz, CDCl₃) δ 8.55 (d, J=2.5 Hz, 1H), 8.33-8.27 (m, 1H),7.67-7.62 (m, 1H), 6.98 (t, J=54.3 Hz, 1H).

Step B. 4-Chloro-3-(difluoromethyl)aniline

To a stirred mixture of 1-chloro-2-(difiuoromethyl)-4-nitrobenzene (3.31g, 15.95 mmol) and ammonium chloride (4.27 g, 79.73 mmol) in 5:1acetone:water (90 mL) at 0° C. was added zinc powder (10.43 g, 159.46mmol). The reaction was allowed to warm to rt and stirred for 16 h. Uponcompletion, the reaction was filtered through Celite@, concentratedunder reduced pressure, and then taken in up in EtOAc (50 mL) and H₂O(50 mL). The layers were separated and the organic layer was washed with1 M NaOH (3×15 mL), and then filtered again through Celite®. Theresulting solution was dried (Na₂SO₄), and concentrated under reducedpressure to afford an orange oil that solidified upon standing (2.29 g,78%). The material was carried forward crude without furtherpurification. MS (ESI): mass calcd. for C₇H₆ClF₂N, 177.0; m/z found,177.9 [M+H]⁺. ¹H NMR (500 MHz, CDCl₃) δ 7.19-7.13 (m, 1H), 6.94 (d,J=2.9 Hz, 1H), 6.87 (t, J=55.1 Hz, 1H), 6.73-6.67 (m, 1H).

To a solution of(1-(4-chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 1, 243 mg, 0.882 mmol) in DCM (2 mL) was added thionylchloride (2 mL). The reaction mixture was stirred at room temperaturefor 3 h. Upon completion the reaction mixture was poured over a solutionof ice water and K₂CO₃. The biphasic mixture was stirred until all ofthe ice melted and the layers separated. The aqueous layer was furtherextracted with DCM (3×). The combined organics were dried (Na₂SO₄),filtered, and concentrated under reduced pressure to give the titlecompound as a yellow solid (231 mg), which was used without furtherpurification. MS (ESI) mass calcd. for C₁₀H₇Cl₂F₂N₃O, 293.0; m/z found294.1 [M+H]⁺.

Step A. 4-Azido-1-fluoro-2-(trifluoromethyl)benzene

4-Fluoro-3-(trifluoromethyl)aniline (1 mL, 7.77 mmol) was added viasyringe to a cooled solution of TFA (6 mL)/H₂SO₄ (1.2 mL) at 0° C. Awhite ppt forms and the flask was removed from the ice bath and stirreduntil homogeneous (˜15 min). The resulting solution was placed back inthe ice bath and a solution of NaNO₂ (664 mg, 9.6 mmol) in water (5 mL)was added dropwise. After stirring for 30 min at 0° C. a solution ofNaN₃ (880 mg, 13.5 mmol) in water (5 mL) was then added slowly. Caution:gas evolution observed. After the addition was complete the reactionmixture was warmed to rt. and stirred for an additional 30 min. Etherwas added (75 mL) and the layers were separated. The organic layer wasplaced over aqueous NaHCO₃ (sat) and the acidic aqueous layer wasextracted (lx) with ether and the organic layers combined, washed withaqueous NaHCO₃ (sat), brine, dried (MgSO₄), filtered, and concentratedunder reduced pressure to afford the title compound which was used crudein the next step.

Step B.(1-(4-Fluoro-3-(trifluoromethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanol

To a solution of 4-azido-1-fluoro-2-(trifluoromethyl)benzene int-BuOH/water (20 mL; 1:1) was added prop-2-yn-1-ol (0.6 mL, 10.3 mmol);copper sulfate (195 mg, 0.78 mmol) and sodium ascorbate (152 mg, 0.77mmol). The resulting mixture was stirred at rt overnight. The reactionwas poured into water (200 mL) and extracted with EtOAc (3×50 mL). Thecombined organics were concentrated under reduced pressure. The residuewas loaded directly onto SiO₂ (DCM/w trace MeOH). Purification (FCC,SiO₂, DCM/EtOAc (10% MeOH) 0-70%) afforded the title compound as an offwhite solid (87%). ¹H NMR (500 MHz, CDCl₃) δ 8.02-7.98 (m, 2H),7.98-7.93 (m, 1H), 7.43-7.36 (m, 1H), 4.97-4.87 (m, 2H), 2.24 (t, J=6.0Hz, 1H).

Method A.

The title compound was prepared in a manner analogous to Intermediate 1.MS (ESI): mass calcd. for C₁₀H₈F₃N₃O₂, 259.1; m/z found, 260.1 [M+H]⁺.¹H NMR (400 MHz, CDCl₃) δ 2.44 (s, 1H), 4.91 (s, 2H), 6.65 (t, J=72.6Hz, 1H), 7.35 (t, J=9.2 Hz, 1H), 7.53-7.64 (m, 1H), 7.70 (dd, J=6.6, 2.7Hz, 1H), 7.97 (s, 1H).

Method B.

Step A. 3-(Difluoromethoxy)-4-fluoroaniline

To a suspension of 2-(difluoromethoxy)-1-fluoro-4-nitrobenzene (1.4 g,6.8 mmol) and Zn powder (4.0 g, 60.8 mmol) in acetone (31 mL) and water(3.1 mL) was added ammonium chloride (3.3 g, 60.8 mmol) at 0° C. Uponcompletion, the reaction mixture was filtered through a pad of Celite®and rinsed with MeOH. The filtrate was concentrated under vacuum.Purification (FCC, SiO₂, 0-10% EtOAc in hexanes) afforded (1.2 g, 6.6mmol, 97%). MS (ESI): mass calcd. for C₇H₆F₃NO, 177.0; m/z found, 178.1[M+H]⁺. ¹H NMR (400 MHz, DMSO-d₆) δ 7.10 (t, J=73.7 Hz, 1H), 6.99 (dd,J=10.8, 8.8 Hz, 1H), 6.49-6.45 (m, 1H), 6.39 (ddd, J=8.8, 3.8, 2.7 Hz,1H), 5.20 (s, 2H).

Step B. 4-Azido-2-(difluoromethoxy)-1-fluorobenzene

Sodium nitrite (1.3 M in H₂O, 6.4 mL, 8.3 mmol) was added dropwise to asolution of 3-(difluoromethoxy)-4-fluoroaniline (1.2 g, 6.6 mmol) in TFA(5.1 mL, 66.1 mmol) and H₂SO₄ (1.1 mL, 19.8 mmol) at 0° C. The mixturewas stirred at 0° C. for 30 min, and then sodium azide (1.3 M in H₂O,8.9 mL, 11.6 mmol) was added dropwise at 0° C. The mixture was stirredat 0° C. for 30 min. Then, the mixture was diluted with Et₂O. Theorganic layer was collected, washed with a saturated aqueous solution ofNaHCO₃ (until basic pH), dried (MgSO₄), filtered, and concentrated invacuo to yield title product. The title product was carried as is to thenext step.

Step C.(1-(3-(Difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol

CuSO₄ (91 mg, 0.6 mmol) and (+)-sodium ascorbate (114 mg, 0.6 mmol) wereadded to a stirred solution of4-azido-2-(difluoromethoxy)-1-fluorobenzene (1.2 g, 5.8 mmol) andpropargyl alcohol (0.4 mL, 7.5 mmol) in distilled water (7.3 mL) andisopropanol (5.7 mL) at room temperature. Upon completion, water (40 mL)was added to the reaction mixture. The reaction mixture was extractedusing EtOAc (3×60 mL). The combined organics were dried (MgSO₄),filtered, and concentrated under vacuum. Purification (FCC, SiO₂, 0-90%EtOAc in hexanes) afforded (1.3 g, 87%).

Method C.

Sodium azide (129 mg, 2.0 mmol) was added to a mixture of2-(3-(difluoromethoxy)-4-fluorophenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane(380 mg, 1.3 mmol) and CuOAc₂ (48 mg, 0.3 mmol) in DMSO (4.5 mL) at roomtemperature. After 3 hours, propargyl alcohol (0.12 mL, 2.0) was addedto the reaction mixture. After 16 h, water (20 mL) was added and themixture was extracted using EtOAc (3×30 mL). The combined organics weredried (MgSO₄), filtered, and concentrated under vacuum. Purification(FCC, SiO₂, 0-40% EtOAc in hexanes) afforded (14 mg, 0.05, mmol, 4%). MS(ESI): mass calcd. for C₁₀H₈F₃N₃O₂, 259.1; m/z found, 259.9 [M+H]⁺.

To a solution of(1-(3-(difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 6, 50 mg, 0.19 mmol) and 2-bromo-6-fluoropyridine (40.7mg, 0.23 mmol) in DMF (1.2 mL) at 0° C. was added NaH (60% dispersion inmineral oil, 9.2 mg, 0.23 mmol). The reaction mixture was stirred at 0°C. for 2 h then quenched by the addition of water. The resultingprecipitate was filtered to afford the title compound (75 mg, 93%) whichwas used crude without further purification. MS (ESI): mass calcd. forC₁₅H₁₀BrF₃N₄O₂, 413.99; m/z found, 414.0 [M+H]⁺.

The title compound was prepared in a manner analogous to Intermediate 1.MS (ESI): mass calcd. for C₁₀H₆ClF₂N₃O, 259.0; m/z found, 260.0 [M+H]⁺.¹H NMR (500 MHz, CDCl₃) δ 8.37 (s, 1H), 8.35 (d, J=2.6 Hz, 1H),8.25-8.19 (m, 1H), 7.97-7.93 (m, 1H), 7.34 (t, J=54.6 Hz, 1H), 5.25 (s,2H), 2.72 (s, 1H).

The title compound was prepared in a manner analogous to Intermediate 1.MS (ESI): mass calcd. for C₁₀H₆F₃N₃O, 243.1; m/z found, 244.1 [M+H]⁺. ¹HNMR (400 MHz, CDCl₃) δ 2.26 (br t, J=5.78 Hz, 1H) 4.91 (d, J=5.32 Hz,2H) 6.76-7.15 (m, 1H) 7.33 (t, J=9.02 Hz, 1H) 7.85-7.97 (m, 2H) 8.00 (s,1H).

The title compound was prepared in a manner analogous to Intermediate 1.MS (ESI): mass calcd. for C₁₀H₉F₂N₃O, 225.1; m/z found, 226.2 [M+H]⁺.Intermediate 11.(1-(3-(1,1-Difluoroethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol.

The title compound was prepared in a manner analogous to Intermediate 1.MS (ESI) mass calcd. for. C₁₁H₁₀F₃N₃O, 257.1; m/z found 258.0. ¹H NMR(400 MHz, CDCl₃) δ 7.98 (t, J=0.7 Hz, 1H), 7.95-7.87 (m, 1H), 7.87-7.78(m, 1H), 7.31 (dd, J=9.9, 8.9 Hz, 1H), 4.91 (d, J=0.7 Hz, 2H), 2.05 (td,J=18.6, 1.2 Hz, 3H).

The title compound was prepared in a manner analogous to Intermediate 1,Step C, using 3-(difluoromethyl)aniline. MS (ESI): mass calcd. ForC₁₀H₉F₂N₃O, 225.1; m/z found, 226.1 [M+H]⁺.

The title compound was prepared in a manner analogous to Intermediate 1,Step C, using 2,4-difluoro-5-methylaniline. MS (ESI): mass calcd. ForC₁₀H₉F₂N₃O, 225.1; m/z found, 226.1 [M+H]⁺.

The title compound was prepared in a manner analogous to Intermediate 1.MS (ESI): mass calcd. for C₉H₇BrFN₃O, 270.98; m/z found, 274.0 [M+H+2]⁺.

The title compound was prepared in a manner analogous to Intermediate 1.MS (ESI): mass calcd. for C₁₀H₁₀ClN₃O₂, 239.1; m/z found, 240.0 [M+H]⁺.¹H NMR (400 MHz, CDCl₃) δ 7.97 (s, 1H), 7.49 (d, J=8.5 Hz, 1H), 7.46 (d,J=2.3 Hz, 1H), 7.15 (dd, J=8.5, 2.4 Hz, 1H), 4.90 (s, 2H), 4.00 (s, 3H).

The title compound was prepared in a manner analogous to Intermediate 4.MS (ESI) mass calcd. for C₁₀H₉F₂N₃O, 225.1; m/z found 226.1.

4-(Chloromethyl)-1-(3-(difluoromethyl)phenyl)-1H-1,2,3-triazole(Intermediate 16, 309.0 mg, 1.27 mmol) was placed in a pressure flaskand then dissolved in NH₃ (7M in MeOH (13.73 mL, 7 M, 96.13 mmol). Theflask was sealed, and the reaction was stirred at 45° C. for 20 h. Thesolvent evaporated under reduced pressure. Purification (FCC, SiO₂, 0-8%MeOH in DCM) afforded the title compound (124.7 mg, 44%). MS (ESI): masscalcd. for C₁₀H₁₀F₂N₄, 224.1; m/z found, 225.0 [M+H]⁺. ¹H NMR (600 MHz,CD₃OD) δ 8.63 (s, 1H), 8.14-8.11 (m, 1H), 8.09-8.05 (m, 1H), 7.82-7.77(m, 1H), 7.77-7.73 (m, 1H), 6.97 (t, J=55.9 Hz, 1H), 4.26 (s, 2H).

The title compound was prepared in a manner analogous to Intermediate17. MS (ESI): mass calcd. for C₁₀H₉F₃N₄O, 258.1; m/z found, 259.0[M+H]⁺. ¹H NMR (400 MHz, DMSO-d₆) S ppm 4.20 (s, 2H) 7.45 (t, J=72.7 Hz,1H) 7.68-7.77 (m, 1H) 7.85 (dt, J=8.8, 3.4 Hz, 1H) 7.98 (dd, J=6.9, 2.7Hz, 1H) 8.64 (br s, 3H) 8.95 (s, 1H).

Step A.1-(4-Chloro-3-(difluoromethyl)phenyl)-4-(chloromethyl)-1H-1,2,3-triazole

To (1-(4-Chloro-3-(difluoromethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 8, 1.65 g, 6.3 mmol) stirring in DCM (16 mL) was slowlyadded SOCl₂ (4 mL, 55 mmol). The mixture was stirred at rt overnight,then poured into a mixture of ice water and K₂CO₃. After all the ice wasmelted, the layers were separated and the aqueous layer was extractedwith DCM (3×). The combined organic layers were washed with brine, dried(Na₂SO₄), then concentrated under reduced pressure to afford an orangesolid that was used without purification (1.66 g, 94%).

Step B.2-((1-(4-Chloro-3-(difluoromethyl)phenyl)-1H-1,2,3-triazol-4-yl)methyl)isoindoline-1,3-dione

To1-(4-chloro-3-(difluoromethyl)phenyl)-4-(chloromethyl)-1H-1,2,3-triazole(152 mg, 0.55 mmol) in DMF (2.7 mL) was added phthalimide (96 mg, 0.65mmol) followed by K₂CO₃ (226 mg, 1.6 mmol). The reaction was stirred at80° C. for 1 h, then cooled to rt and diluted with EtOAc and H₂O. Thelayers were separated and the aqueous layer was extracted with DCM (×3),then the combined organic layers were concentrated under reducedpressure to afford an orange solid that was used without purification.

Step C.(1-(4-Chloro-3-(difluoromethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanamine

To2-((1-(4-chloro-3-(difluoromethyl)phenyl)-1H-1,2,3-triazol-4-yl)methyl)isoindoline-1,3-dione(212 mg, 0.55 mmol) stirring in EtOH (5 mL) was added hydrazine hydrate(0.03 mL, 0.65 mmol) and the mixture was stirred at reflux (80° C.) for1 h. The reaction was cooled to rt and concentrated under reducedpressure. Purification (FCC, SiO₂, 10% 2 M NH₃ in MeOH/DCM 0-100%)afforded the title compound as pale yellow solid (116 mg, 82%). MS(ESI): mass calcd. for C₁₀H₉ClF₂N₄, 258.0; m/z found, 259.0 [M+H]⁺.

The title compound was prepared in a manner analogous to Intermediate19, steps A-C, using(1-(3-(1,1-difluoroethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 11) in step A. MS (ESI): mass calcd. for C₁₁H₁₁F₃N₄,256.1; m/z found, 257.1 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD) δ 8.48-8.43 (m,1H), 8.06 (dd, J=6.3, 2.8 Hz, 1H), 8.04-7.99 (m, 1H), 7.52-7.45 (m, 1H),4.02 (s, 2H), 2.07 (td, J=18.8, 1.1 Hz, 3H).

The title compound was prepared in a manner analogous to Intermediate19, Steps A-C, using(1-(3-(difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 9) in Step A. MS (ESI) mass calcd. for C₁₀H₉F₃N₄, 242.1;m/z found 243.0 [M+1].

The title compound was prepared in a manner analogous to Intermediate 2using 4-chloro-3-(difluoromethoxy)aniline and in Step A and(R)-(+)-3-butyn-2-ol in Step B. MS (ESI): mass calcd. forC₁₁H₁₀ClF₂N₃O₂, 289.7; m/z found, 290.1 [M+H]⁺. ¹H NMR (400 MHz,DMSO-d₆) δ 8.76 (s, 1H), 7.98 (d, J=2.3 Hz, 1H), 7.90-7.81 (m, 2H), 7.45(t, J=72.8 Hz, 1H), 5.44 (d, J=4.8 Hz, 1H), 4.92 (qd, J=6.5, 4.7 Hz,1H), 1.48 (d, J=6.5 Hz, 3H).

The title compound was prepared in a manner analogous to Intermediate 2using 4-chloro-3-(difluoromethoxy)aniline and in Step A and(S)-(+)-3-butyn-2-ol in Step B. MS (ESI): mass calcd. forC₁₁H₁₀ClF₂N₃O₂, 289.7; m/z found, 290.1 [M+H]⁺. ¹H NMR (400 MHz,DMSO-d₆) δ 8.75 (s, 1H), 7.98 (d, J=2.3 Hz, 1H), 7.91-7.79 (m, 2H), 7.45(t, J=72.8 Hz, 1H), 5.44 (d, J=4.8 Hz, 1H), 4.92 (qd, J=6.5, 4.6 Hz,1H), 1.47 (d, J=6.5 Hz, 3H).

The title compound was made analogous to Intermediate 19 using(R)-1-(1-(4-chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)ethan-1-ol(Intermediate 22) in step A.MS (ESI): mass calcd. for C₁₁H₁₁ClF₂N₄O,288.1; m/z found, 289.0 [M+H]⁺.

Step A. tert-butyl (5-(Trifluoromethyl)thiophen-2-yl)carbamate

To a solution of 5-(trifluoromethyl)thiophene-2-carboxylic acid (2.5 g,12.75 mmol) in tert-butyl alcohol (64 mL) was added triethylamine (1.78mL, 12.75 mmol) followed by diphenylphosphorylazide (2.75 mL, 12.75mmol). The resulting reaction mixture was heated to 90° C. and stirredovernight. The reaction was cooled to room temperature and the solventwas removed under reduced pressure. The resulting residue wasredissolved in ethyl acetate (50 mL) and washed with a saturated aqueoussolution of NaHCO₃, citric acid (10% aq) and brine. The combined organiclayers were dried (Na₂SO₄), filtered, and concentrated into a brown oilwhich was purified via FCC (using 5-20% ethyl acetate/hexanes) toprovide the desired product as a white solid (804 mg, 3.01 mmol, 23%).MS (ESI): mass calcd. for C₁₀H₁₂F₃NO₂S, 267.2; m/z found, 268.1 [M+H]⁺.¹H NMR (500 MHz, CDCl₃) δ 7.16-7.14 (m, 1H), 6.40-6.37 (m, 1H),1.55-1.50 (m, 9H).

Step B. 5-(Trifluoromethyl)thiophen-2-amine HCl salt

To a solution of tert-butyl (5-(trifluoromethyl)thiophen-2-yl)carbamate(804 mg, 3.01 mmol) in dioxane (8 mL) was added 4M HCl in dioxane (3.76mL, 15.04 mmol). The resulting reaction mixture was allowed to stirovernight at room temperature. The reaction mixture was subsequentlyconcentrated into a white solid (under reduced pressure), which waswashed with ether to provide the desired product (584 mg, 2.868 mmol,95.3%). Quantitative yield was assumed and the intermediate was usedwithout further purification. MS (ESI): mass calcd. for C₅H₄F₃NS, 203.6;m/z found, 204.1 [M+H]⁺. ¹H NMR (500 MHz, DMSO-d₆) δ 7.13-7.09 (m, 1H),5.90-5.84 (d, J=4.0 Hz, 1H).

Step C. 2-Azido-5-(trifluoromethyl)thiophene

To a solution of 5-(trifluoromethyl)thiophen-2-amine HCl salt (150 mg,0.74 mmol) in TFA (0.56 mL, 7.4 mmol), H₂SO₄ (0.118 mL, 2.21 mmol) andwater (4 mL) at 0° C. was slowly added a 1.3 M aq. solution of sodiumnitirite (0.71 mL, 0.92 mmol). The resulting reaction mixture wasstirred at 0° C. for 30 minutes and then a 1.3 M aq. solution of sodiumazide (0.992 mL, 1.29 mmol) in water (4 mL) was added dropwise. Thereaction mixture was stirred for an additional 30 minutes and thendiluted with ether (10 mL). The organic layer was isolated and washedwith saturated NaHCO₃ solution (until pH8), dried (Na₂SO₄), filtered,and concentrated under reduced pressure to yield the desired product(142 mg, 0.74 mmol). A quantitative yield was assumed and the crudematerial was carried forward without further purification.

Step D.(1-(5-(Trifluoromethyl)thiophen-2-yl)-1H-1,2,3-triazol-4-yl)methanol

To a solution of 2-azido-5-(trifluoromethyl)thiophene (150 mg, 0.78mmol) and propargyl alcohol (0.06 mL, 1.01 mmol) in isopropyl alcohol (1mL) and water (1 mL) at room temperature was added copper (II) sulfate(14 mg, 0.08 mmol), and sodium ascorbate (15 mg, 0.08 mmol). Theresulting reaction mixture was stirred for 3 hours then diluted withwater (10 mL) and extracted with ethyl acetate (3×20 mL). The combinedorganic layers were dried (MgSO₄), filtered, and concentrated underreduced pressure. Purification (FCC, SiO₂, 0-90% ethyl acetate inhexanes) afforded the title compound (94 mg, 0.38 mmol, 48%). MS (ESI):mass calcd. for C₈H₆F₃N₃OS, 249.2; m/z found, 250.1 [M+H]⁺. ¹H NMR (400MHz, CDCl₃) δ 8.06-7.86 (s, 1H), 7.46-7.32 (m, 1H), 7.23-7.10 (d, J=4.1Hz, 1H), 4.98-4.76 (s, 2H), 2.79-2.63 (s, 1H).

The title compound was prepared in a manner analogous to Intermediate19, steps A-C, using(1-(4-fluoro-3-methylphenyl)-1H-1,2,3-triazol-4-yl)methanol in Step A.MS (ESI): mass calcd. for C₁₀H₁₁FN₄, 206.1; m/z found, 207.0 [M+H]⁺.

Step A. 4-Azido-2-(difluoromethyl)-1-fluorobenzene

The title compound was prepared in a manner analogous to Intermediate 6,Method B, Steps A-B using 2-(difluoromethyl)-1-fluoro-4-nitrobenzene inStep A.

Step B.(1-(3-(Difluoromethyl)-4-fluorophenyl)-5-iodo-1H-1,2,3-triazol-4-yl)methanol

4-Azido-2-(difluoromethyl)-1-fluorobenzene (336 mg, 1.8 mmol),copper(II) perchlorate hexahydrate (1.3 g, 3.6 mmol) and NaI (1.1 g, 7.2mmol) were pre-mixed in ACN (8 mL). After 5 minutes, propargyl alcohol(0.14 mL, 2.3 mmol) and DBU (0.27 mL, 1.8 mmol) were added. Uponcompletion, the reaction mixture was diluted in DCM (40 mL) and NH₄OH(28% NH₃ in water, 50 mL) was added. The crude material was trituratedin DCM. The solids were collected by filtration, rinsed with DCM anddried under reduced pressure to yield the title compound (249 mg, 38%).MS (ESI): mass calcd. for C₁₀H₇F₃IN₃O, 369.0; m/z found, 369.8 [M+H]⁺.¹H NMR (400 MHz, DMSO-d₆) δ 7.93-7.85 (m, 2H), 7.74-7.66 (m, 1H), 7.32(t, J=53.9 Hz, 1H), 5.31 (t, J=5.4 Hz, 1H), 4.54 (d, J=5.4 Hz, 2H).

The title compound was prepared in a manner analogous to Intermediate 6,Method B, using 2-fluoro-1-nitro-3-(trifluoromethyl)benzene in Step A.MS (ESI): mass calcd. for C₁₀H₇F₄N₃O, 261.1; m/z found, 261.9 [M+H]⁺. ¹HNMR (500 MHz, DMSO-d₆) δ 8.56-8.54 (m, 1H), 8.21-8.15 (m, 1H), 8.02-7.98(m, 1H), 7.66 (tt, J=8.0, 1.0 Hz, 1H), 5.38 (t, J=5.7 Hz, 1H), 4.64 (dd,J=5.6, 0.8 Hz, 2H).

The title compound was prepared in a manner analogous to Intermediate 6,Method B, Steps B-C, using 2-fluoro-5-methylaniline in Step B. MS (ESI):mass calcd. for C₁₀H₁₀FN₃O, 207.1; m/z found, 208.0 [M+H]⁺. ¹H NMR (400MHz, DMSO-d₆) δ 8.40 (dt, J=2.2, 0.7 Hz, 1H), 7.66-7.61 (m, 1H),7.48-7.36 (m, 2H), 5.32 (t, J=5.6 Hz, 1H), 4.62 (d, J=5.2 Hz, 2H),2.40-2.37 (m, 3H).

The title compound was prepared in a manner analogous to Intermediate 6,Method B, using 3-(trifluoromethyl)aniline in Step B. MS (ESI): masscalcd. for C₁₀H₆F₃N₃O, 243.1; m/z found, 244.0 [M+H]⁺. ¹H NMR (500 MHz,DMSO-d₆) δ 8.88 (s, 1H), 8.31-8.25 (m, 2H), 7.88-7.82 (m, 2H), 5.38 (t,J=5.6 Hz, 1H), 4.63 (d, J=5.5 Hz, 2H).

The title compound was prepared in a manner analogous to Intermediate 6,Method B, Step B-C using 3-bromoaniline in Step B. ¹H NMR (300 MHz,CDCl₃) δ 7.97 (s, 1H), 7.94 (t, J=1.7 Hz, 1H), 7.68 (dd, J=8.1, 0.9 Hz,1H), 7.58 (d, J=8.6 Hz, 1H), 7.41 (t, J=8.1 Hz, 1H), 4.90 (s, 2H). OHwas not observed.

The title compound was prepared in a manner analogous to Intermediate 2using m-toluidine in Step A and propargyl alcohol in Step B. MS (ESI):mass calcd. for C₁₀H₁₁N₃O, 189.2; m/z found, 190.1 [M+H]⁺. ¹H NMR (500MHz, DMSO-d₆) δ 8.64 (d, J=0.7 Hz, 1H), 7.77-7.73 (m, 1H), 7.71-7.64 (m,1H), 7.46 (t, J=7.8 Hz, 1H), 7.29 (ddt, J=7.6, 1.7, 0.9 Hz, 1H), 5.31(t, J=5.6 Hz, 1H), 4.61 (dd, J=5.6, 0.7 Hz, 2H), 2.50 (p, J=1.9 Hz, 3H).

The title compound was prepared in a manner analogous to Intermediate 2using p-toluidine in Step A and propargyl alcohol in Step B. MS (ESI):mass calcd. for C₁₀H₁₁N₃O, 189.2; m/z found, 190.1 [M+H]⁺.

The title compound was prepared in a manner analogous to Intermediate 2using 4-(trifluoromethoxy)aniline in Step A and propargyl alcohol inStep B. MS (ESI): mass calcd. for C₁₀H₈F₃N₃O₂, 259.2; m/z found, 260.1[M+H]⁺.

The title compound was prepared in a manner analogous to Intermediate 2using 3-(trifluoromethoxy)aniline in Step A and propargyl alcohol inStep B. MS (ESI): mass calcd. for C₁₀H₆F₃N₃O₂, 259.2; m/z found, 260.1[M+H]⁺.

The title compound was prepared in a manner analogous to Intermediate 2using 3,5-dimethylaniline in Step A and propargyl alcohol in Step B. MS(ESI): mass calcd. for C₁₁H₁₃N₃O, 203.2; m/z found, 204.2 [M+H]⁺.

The title compound was prepared in a manner analogous to Intermediate 2using 4-fluoro-2-methylaniline in Step A and propargyl alcohol in StepB. MS (ESI): mass calcd. for C₁₀H₁₀FN₃O, 207.2; m/z found, 208.1 [M+H]⁺.

The title compound was prepared in a manner analogous to Intermediate 2using o-toluidine in Step A. MS (ESI): mass calcd. for C₁₀H₁₁N₃O, 189.2;m/z found, 190.1 [M+H]⁺.

The title compound was prepared in a manner analogous to Intermediate 2using 3,4-difluoroaniline in Step A and propargyl alcohol. MS (ESI):mass calcd. for C₉H₇F₂N₃O, 211.2; m/z found, 212.1 [M+H]⁺.

The title compound was prepared in a manner analogous to Intermediate 2using 4-fluoro-3-methylaniline in Step A and propargyl alcohol in StepB. MS (ESI): mass calcd. for C₁₀H₁₀FN₃O, 207.2; m/z found, 208.1 [M+H]⁺.

The title compound was prepared in a manner analogous to Intermediate 2using 3-fluoroaniline in Step A and propargyl alcohol in Step B. MS(ESI): mass calcd. for C₉H₈FN₃O, 193.2; m/z found, 194.1 [M+H]⁺.

The title compound was prepared in a manner analogous to Intermediate 2using 3-(difluoromethoxy)aniline in Step A and propargyl alcohol in StepB. MS (ESI): mass calcd. for C₁₀H₆F₂N₃O₂, 241.2; m/z found, 242.0[M+H]⁺.

The title compound was prepared in a manner analogous to Intermediate 2using 4-(difluoromethoxy)aniline in Step A and propargyl alcohol in StepB. MS (ESI): mass calcd. for C₁₀H₆F₂N₃O₂, 241.2; m/z found, 242.0[M+H]⁺.

The title compound was prepared in a manner analogous to Intermediate 2using 3-isopropylaniline in Step A and propargyl alcohol in Step B. MS(ESI): mass calcd. for C₁₀H₈F₂N₃O₂, 241.2; m/z found, 242.0 [M+H]⁺.

The title compound was prepared in a manner analogous to Intermediate 2using 2,2-difluoro-5-aminobenzodioxole in Step A and propargyl alcoholin Step B. MS (ESI): mass calcd. for C₁₀H₇F₂N₃O₃, 255.2; m/z found,256.1 [M+H]⁺. ¹H NMR (400 MHz, DMSO-d₆) δ 8.67 (d, J=0.7 Hz, 1H), 8.07(d, J=2.2 Hz, 1H), 7.78 (dd, J=8.7, 2.2 Hz, 1H), 7.64 (d, J=8.7 Hz, 1H),5.36 (t, J=5.5 Hz, 1H), 4.61 (dd, J=5.6, 0.7 Hz, 2H).

The title compound was prepared in a manner analogous to Intermediate 2using 3-chloro-2-fluoroaniline in Step A and propargyl alcohol in StepB. MS (ESI): mass calcd. for C₉H₇ClFN₃O, 227.6; m/z found, 228.0 [M+H]⁺.

The title compound was prepared in a manner analogous to Intermediate 2using 2,5-difluoroaniline in Step A and propargyl alcohol in Step B. MS(ESI): mass calcd. for C₉H₇F₂N₃O, 211.2; m/z found, 212.1 [M+H]⁺.

The title compound was prepared in a manner analogous to Intermediate 2using 2,3-difluoroaniline in Step A and propargyl alcohol in Step B. MS(ESI): mass calcd. for CH₇F₂N₃O, 211.2; m/z found, 212.1 [M+H]⁺.

The title compound was prepared in a manner analogous to Intermediate 2using 3-fluoro-2-methylaniline in Step A and propargyl alcohol in StepB. MS (ESI): mass calcd. for C₁₀H₁₀FN₃O, 207.2; m/z found, 208.1 [M+H]⁺.

The title compound was prepared in a manner analogous to Intermediate 2using 2-fluoro-3-methylaniline in Step A and propargyl alcohol in StepB. MS (ESI): mass calcd. for C₁₂H₁₃N₃O, 215.3; m/z found, 216.1 [M+H]⁺.

The title compound was prepared in a manner analogous to Intermediate 2using 5-aminoindan in Step A and propargyl alcohol in Step B. MS (ESI):mass calcd. for C₁₀H₁₀FN₃O, 207.2; m/z found, 208.1 [M+H]⁺.

The title compound was prepared in a manner analogous to Intermediate 1,Step C, using 3-(difluoromethoxy)-4-methylaniline. MS (ESI): mass calcd.for C₁₁H₁₁F₂N₃O₂, 255.1; m/z found, 256.0 [M+H]⁺.

To (2-chloropyrimidin-5-yl)methanol (946 mg, 6.5 mmol) stirring in DCM(38 mL) at rt was added imidazole (477 mg, 7 mmol) followed bytert-butyl(chloro)dimethylsilane (1 g, 6.9 mmol). The reaction wasstirred at rt for 30 mins, then diluted with water. The layers wereseparated and the aqueous layer was extracted with DCM (×3), dried(Na₂SO₄), and concentrated under reduced pressure. Purification (FCC,SiO₂, EtOAc/hexanes 0-10%) afforded the title compound as a clear,colorless oil that solidified upon standing (1.37 g, 81%). MS (ESI):mass calcd. for C₁₁H₁₉ClN₂OSi, 258.1; m/z found, 259.0 [M+H]⁺.

The title compound was prepared in a manner analogous to Intermediate 53using (2-chloropyrimidin-4-yl)methanol. MS (ESI): mass calcd. forC₁₁H₁₁ClN₂OSi, 258.1; m/z found, 259.0 [M+H]⁺.

A solution of 2-chloro-N-methylpyrimidin-4-amine (500 mg, 3.4 mmol),di-tert-butyl dicarbonate (1.49 mL, 6.9 mmol), TEA (0.96 mL, 6.9 mmol),DMAP (42.5 mg, 0.34 mmol) in THF (20 mL) was stirred at 70° C. for 3 h.The reaction mixture was cooled, and concentrated under reducedpressure. Purification (FCC, SiO₂, 0-20% EtOAc in hexanes) afforded thetitle compound (762 mg, 88%). MS (ESI): mass calcd. for C₁₀H₁₄ClN₃O₂,243.1; m/z found, 244.0 [M+H]⁺. ¹H NMR (500 MHz, DMSO-d₆) δ 8.51 (d,J=5.9 Hz, 1H), 7.94 (d, J=5.9 Hz, 1H), 3.33 (s, 3H), 1.52 (s, 9H).

The title compound was prepared in a manner analogous to Intermediate55, using 2-chloro-N,5-dimethylpyrimidin-4-amine. MS (ESI): mass calcd.for C₁₁H₁₆ClN₃O₂, 257.1; m/z found, 258.0 [M+H]⁺.

The title compound was prepared in a manner analogous to Intermediate55, using 2-chloro-N-(2,2-difluoroethyl)-5-fluoropyrimidin-4-amine. MS(ESI): mass calcd. for C₁₀H₁₃ClF₃N₃O₂, 311.1; m/z found, 312.1 [M+H]⁺.¹H NMR (400 MHz, DMSO-d₆) δ 8.92 (d, J=2.7 Hz, 1H), 6.47-6.15 (m, 1H),4.22 (td, J=14.8, 3.8 Hz, 2H), 1.44 (s, 9H).

A mixture of 2-chloropyrimidine-4-carbonitrile (1.5 g, 10.7 mmol),di-tert-butyl dicarbonate (2.8 mL, 12.9 mmol) and 10% Pd/C (572 mg, 0.5mmol) in EtOH (25 mL) was stirred at room temperature under a hydrogenatmosphere (1 atm, balloon). After 4 h, the reaction mixture wasfiltered through a pad of Celite®. The filtrate was concentrated undervacuum. Purification (FCC, SiO₂, 0-99% EtOAc) to yield title product(720 mg, 27%). MS (ESI): mass calcd. for C₁₀H₁₄ClN₃O₂, 243.7; m/z found,187.9 [M-t-Bu]⁺. ¹H NMR (400 MHz, DMSO-d₆) δ 8.72 (d, J=5.1 Hz, 1H),7.56 (t, J=6.2 Hz, 1H), 7.39 (d, J=5.1 Hz, 1H), 4.21 (d, J=6.0 Hz, 2H),1.40 (s, 9H).

A solution of 2-chloro-5-fluoro-N-methylpyrimidin-4-amine (500 mg, 3mmol), (2-(chloromethoxy)ethyl)trimethylsilane (0.8 mL, 4.6 mmol), DIPEA(0.8 mL, 4.6 mmol) in DMF (28 mL) was stirred at rt for 16 h. Additional(2-(chloromethoxy)ethyl)trimethylsilane (0.8 mL, 4.6 mmol), DIPEA (0.8mL, 4.6 mmol) was added and the reaction mixture was stirred for 6 h. Tothe reaction mixture was added brine (50 mL) and the reaction mix wasextracted with EtOAc (3×60 mL). The combined organics were dried(MgSO₄), filtered, and concentrated under reduced pressure. Purification(FCC, SiO₂, 0-90% EtOAc in hexanes) afforded the title compound (528 mg,58%). MS (ESI): mass calcd. for C₁₁H₁₉ClFN₃OSi, 291.1; m/z found, 292.1[M+H]⁺. ¹H NMR (500 MHz, DMSO-d₆) δ 8.27 (d, J=6.1 Hz, 1H), 4.97 (d,J=1.4 Hz, 2H), 3.55-3.51 (m, 2H), 3.17 (d, J=2.5 Hz, 3H), 0.90-0.85 (m,2H), −0.03-−0.05 (m, 9H).

The title compound was prepared in a manner analgous to Intermediate 59,using 2-chloro-N-ethylpyrimidin-4-amine. MS (ESI): mass calcd. forC₁₂H₂₂ClN₃OSi, 287.1; m/z found, 288.2 [M+H]⁺. ¹H NMR (400 MHz, DMSO-d₆)δ 8.13 (d, J=6.1 Hz, 1H), 6.79 (d, J=6.1 Hz, 1H), 4.92 (s, 2H),3.65-3.46 (m, 4H), 1.12 (t, J=7.1 Hz, 3H), 0.92-0.84 (m, 2H),−0.02-−0.05 (m, 9H).

Step A. N-methyl-1-(2-(methylthio)pyrimidin-4-yl)methanamine

Sodium triacetoxyborohydride (825 mg, 3.9 mmol) was added to a mixtureof 2-(methylthio)pyrimidine-4-carbaldehyde (300 mg, 1.9 mmol) and methylamine (2 M in MeOH, 1.3 mL, 2.5 mmol)) in THF (28 mL) at roomtemperature. After 16 hours, the reaction mixture was quenched with asaturated aqueous solution of NaHCO₃ (50 mL). The mixture was extractedusing EtOAc (3×75 mL). The combined organics were dried over MgSO₄,filtered and concentrated under vacuum. Purification (FCC, SiO₂, 0-90%EtOAc in hexanes followed by 0% DCM to 60% MeOH containing 10% 2 M NH₃in MeOH) afforded the title compound (67 mg, 20%). MS (ESI): mass calcd.for C₇H₁₁N₃S, 169.1; m/z found, 170.1 [M+H]⁺.

Step B. tert-Butyl methyl((2-(methylthio)pyrimidin-4-yl)methyl)carbamate

A mixture of N-methyl-1-(2-(methylthio)pyrimidin-4-yl)methanamine (239mg, 1.4 mmol), BOC-anhydride (0.9 mL, 4.2 mmol), DMAP (17 mg, 0.1 mmol),TEA (0.4 mL, 2.8 mmol) and THF (8 mL) was allowed to stir at roomtemperature. After 16 hours, water (30 mL) was added and the mixture wasextracted using DCM (3×50 mL). The combined organics were dried overMgSO₄, filtered and concentrated under vacuum. Purification (FCC, SiO₂,0-40% EtOAc in hexanes) afforded the title compound (151 mg, 40%). MS(ESI): mass calcd. for C₁₂H₁₉N₃O₂S, 269.1; m/z found, 270.1 [M+H]⁺. ¹HNMR (400 MHz, DMSO-d₆) δ 8.57 (d, J=5.1 Hz, 1H), 7.03-6.94 (m, 1H), 4.39(s, 2H), 2.89 (s, 3H), 1.48-1.21 (m, 9H).

Step C. tert-Butylmethyl((2-(methylsulfonyl)pyrimidin-4-yl)methyl)carbamate

mCPBA (276 mg, 1.2 mmol) was slowly added to a mixture of tert-butylmethyl((2-(methylthio)pyrimidin-4-yl)methyl)carbamate (151 mg, 0.6 mmol)in DCM (6 mL) at 0° C. After 3 hours, complete conversion was observed.The reaction mixture was quenched with saturated aqueous solution ofNaHCO₃(aq) (60 mL). The mixture was extracted with DCM (3×80 mL). Thecombined organics were dried over MgSO₄, filtered and concentrated undervacuum. Purification (FCC, SiO₂, 0-99% EtOAc in hexanes) afforded thetitle compound (132 mg, 78%). MS (ESI): mass calcd. for C₁₂H₁₉N₃O₄S,301.1; m/z found, 202.1 [M-tBu]⁺. ¹H NMR (400 MHz, DMSO-d₆) δ 9.05-8.99(m, 1H), 7.68-7.58 (m, 1H), 4.59 (s, 2H), 3.40 (s, 3H), 2.94 (s, 3H),1.51-1.19 (m, 9H).

Step A. 2-Chloro-N-(oxetan-3-yl)pyrimidin-4-amine

A mixture of 2,4-dichloropyrimidine (300 mg, 2.0 mmol),3-oxetanamine(147 mg, 2.0 mmol) and DIPEA (0.7 mL, 4.0 mmol) in DMF (17 mL) wasstirred at r.t. After 16 hours, conversion was observed. Water (20 mL)was added to the reaction mixture was extracted with EtOAc (3×30 mL).The combined organics were dried over MgSO₄, filtered and concentratedunder vacuum. Purification (FCC, SiO₂, 0-99% EtOAc in hexanes) affordedthe title compound. ¹H NMR (500 MHz, DMSO-d₆) δ 8.67-8.60 (m, 1H),8.04-7.92 (m, 1H), 6.57-6.38 (m, 1H), 4.98-4.87 (m, 1H), 4.80 (t, J=6.7Hz, 2H), 4.49-4.41 (m, 2H).

Step B.2-Chloro-N-(oxetan-3-yl)-N-((2-(trimethylsilyl)ethoxy)methyl)pyrimidin-4-amine

Under a nitrogen atmosphere was stirred a mixture of2-chloro-N-(oxetan-3-yl)pyrimidin-4-amine (374 mg, 2.0 mmol), DIPEA (0.7mL, 4.0 mmol) (2-(chloromethoxy)ethyl)trimethylsilane (0.7 mL, 4.0 mmol)and DMF (19 mL) at room temperature. After 16 hours, complete conversionwas observed. Water (20 mL) was added and the mixture was extractedusing EtOAc (3×30 mL). The combined organics were dried over MgSO₄,filtered and concentrated under vacuum. Purification (FCC, SiO₂, 0-99%EtOAc in hexanes) afforded the title compound (187 mg, 29%). MS (ESI):mass calcd. for C₁₃H₂₂ClN₃O₂Si, 315.1; m/z found, 316.1 [M+H]⁺. ¹H NMR(400 MHz, DMSO-d₆) 8.22 (d, J=6.1 Hz, 1H), 6.90-6.77 (m, 1H), 5.17-4.94(m, 3H), 4.79-4.73 (m, 2H), 4.70-4.64 (m, 2H), 3.57-3.51 (m, 2H),0.92-0.85 (m, 2H), −0.01-−0.04 (m, 9H).

Step A. 4-Chloro-3-(1,1-difluoroethyl)aniline

The title compound was prepared in a manner analogous to Intermediate 3,using 1-(2-chloro-5-nitrophenyl)ethan-1-one in step A and1-chloro-2-(1,1-difluoroethyl)-4-nitrobenzene in step B. MS (ESI) masscalcd. for C₈H₈ClF₂N₂O₂, 191.0; m/z found 192.0 [M+H]⁺. ¹H NMR (500 MHz,CDCl₃) δ 7.22-7.12 (m, 1H), 6.96-6.87 (d, J=2.8 Hz, 1H), 6.69-6.57 (m,1H), 3.86-3.64 (s, 2H), 2.09-1.92 (t, J=18.5 Hz, 3H).

Step B.(1-(4-Chloro-3-(1,1-difluoroethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanol

The title compound was prepared in a manner analogous to Intermediate 1,using 4-chloro-3-(1,1-difluoroethyl)aniline. MS (ESI) mass calcd. forC₁₁H₁₀ClF₂N₃O, 273.0; m/z found 274.0 [M+H]⁺. ¹H NMR (500 MHz, CDCl₃) δ8.07-7.92 (m, 2H), 7.90-7.74 (m, 1H), 7.68-7.56 (d, J=8.6 Hz, 1H),5.00-4.79 (s, 2H), 2.19-2.01 (t, J=18.5 Hz, 3H).

The title compound was prepared in a manner analgous to Intermediate 2,using 3-(1,1-difluoroethyl) aniline. MS (ESI): mass calcd. forC₁₁H₁₁F₂N₃O, 239.1; m/z found, 240.0 [M+H]⁺. 1H NMR (500 MHz, CDCl3) δ8.11-7.99 (s, 1H), 7.99-7.86 (s, 1H), 7.86-7.72 (m, 1H), 7.69-7.53 (m,2H), 5.00-4.83 (s, 2H), 2.08-1.88 (t, J=18.2 Hz, 3H).

To a solution of(1-(4-chloro-3-(difluoromethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 7, 25.3 mg, 0.097 mmol) in DMF (1.0 mL) at rt was addedNaH (60% dispersion in mineral oil) (11.7 mg, 0.29 mmol). The resultingreaction was stirred for 5 min before the addition of 2-chloropyrimidine(14.5 mg, 0.127 mmol). The reaction was stirred at rt for 20 h, and thenquenched by the addition of water (0.10 mL). The mixture was dilutedwith EtOAc (5 mL) and H₂O (5 mL). The layers were separated and theaqueous layer was extracted with EtOAc (3×5 mL). The combined organicswere washed with H₂O (1×5 mL), with brine (1×5 mL), dried (Na₂SO₄),filtered, and concentrated under reduced pressure. Purification (FCC,SiO₂, 0-60% EtOAc in hexanes) afforded the title compound (19.2 mg,58%). MS (ESI): mass calcd. for C₁₄H₁₀ClF₂N₅O, 337.1; m/z found, 338.0[M+H]⁺. ¹H NMR (400 MHz, CDCl₃) δ 8.58 (d, J=4.8 Hz, 2H), 8.18 (s, 1H),8.02-8.00 (m, 1H), 7.92-7.86 (m, 1H), 7.63-7.59 (m, 1H), 7.14-6.84 (m,2H), 5.71-5.65 (m, 2H).

Step A.1-(4-Chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazole-4-carbaldehyde

To a round bottom flask containing(1-(4-chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 1, 150 mg, 0.54 mmol) was added Dess-Martin periodinane(461.6 mg, 1.09 mmol) and DCM (20 mL). The flask was sealed underambient atmosphere and stirred rapidly at rt for 4 hours. The reactionwas quenched with saturated aqueous sodium bicarbonate (2.5 mL) and 10%aqueous sodium thiosulfate (2.5 mL). The biphasic mixture is stirredvigorously until the white milky organic phase became clear andcolorless (60 min). The layers were separated and aqueous layers wasextracted with DCM (1×). The combined organics were washed with brine,dried (Na₂SO₄), filtered, and concentrated under reduced pressure.Purification (FCC, SiO₂, 0-30% EtOAc in hexanes) afforded the titlecompound (140 mg, 94%) as an off white solid. MS (ESI) mass calcd. forC₁₀H₆ClF₂N₃O₂, 273.0; m/z found 274.1 [M+H]⁺.

Step B.N-((1-(4-Chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methyl)pyridin-2-amine

A solution of1-(4-chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazole-4-carbaldehyde(26 mg, 0.095 mmol) and 2-amino pyridine (10.7 mg, 0.114 mmol) in DCM (5mL) was charged with 1 N HCl in Et₂O (0.5 mL). The resulting solutionwas stirred at rt for 10 min then charged with NaHB(OAc)₃ (30 mg, 0.143mmol). The mixture was stirred at rt overnight. The completed reactionwas diluted with DCM (5 mL) and quenched with water. The layers wereseparated and aqueous layer was extracted with DCM (1×). The combinedorganics were washed with brine, dried (Na₂SO₄), filtered, andconcentrated under reduced pressure.

Purification (FCC, SiO₂, 0-10% 2M NH₃ in MeOH/DCM) afforded the titlecompound (16 mg, 48%). MS (ESI) mass calcd. for C₁₅H₁₂ClF₂N₅O, 351.1;m/z found 352.0. ¹H NMR (400 MHz, CDCl₃) δ 8.17-8.05 (m, 1H), 8.00 (s,1H), 7.69 (d, J=2.2 Hz, 1H), 7.63-7.43 (m, 3H), 6.86-6.42 (m, 3H), 5.67(s, 1H), 4.81-4.71 (m, 2H).

Example 3.N-[[1-[4-Fluoro-3-(trifluoromethyl)phenyl]triazol-4-yl]methyl]pyrimidin-2-amine

Step A.4-(Chloromethyl)-1-(4-fluoro-3-(trifluoromethyl)phenyl)-1H-1,2,3-triazole

To a suspension of(1-(4-fluoro-3-(trifluoromethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 5, 1.5 g, 5.7 mmol) in DCM (30 mL) in a flask equipped tovent into 2M Na₂CO₃ was added SOCl₂ (15 mL). The reaction turnedhomogeneous (˜5 min) and the clear solution was stirred at rt for 3 h.Concentration under reduced pressure afforded 1.5 g of the titlecompound as an off white solid, which was used without furtherpurification. ¹H NMR (500 MHz, CDCl₃) δ 8.05 (s, 1H), 8.00 (dd, J=5.8,2.7 Hz, 1H), 7.99-7.94 (m, 1H), 7.42 (t, J=9.1 Hz, 1H), 4.80 (s, 2H).

Step B.N-[[1-[4-Fluoro-3-(trifluoromethyl)phenyl]triazol-4-yl]methyl]pyrimidin-2-amine

A mixture of4-(chloromethyl)-1-(4-fluoro-3-(trifluoromethyl)phenyl)-1H-1,2,3-triazole(55 mg, 0.19 mmol), pyrimidin-2-amine (45 mg, 0.47 mmol), K₂CO₃ (130 mg,0.94 mmol) in DMF (1.5 mL) was heated in a 80° C. heating block for 24h. The mixture was poured into water (35 mL) and extracted with EtOAc.The solvent was removed under reduced pressure and the residue wasloaded onto SiO₂. Purification (FCC, SiO₂, hexanes/EtOAc 0-100%)afforded the title compound (13 mg, 19%). MS (ESI): mass calcd. forC₁₄H₁₀F₄N₆, 338.1; m/z found, 339.0 [M+H]⁺. ¹H NMR (500 MHz, CDCl₃) δ8.33 (d, J=4.8 Hz, 2H), 7.99-7.95 (m, 2H), 7.95-7.91 (m, 1H), 7.38 (t,J=9.1 Hz, 1H), 6.64-6.59 (m, 1H), 5.87-5.80 (m, 1H), 4.83 (d, J=6.2 Hz,2H).

Example 4.2-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyridine

To a solution of(1-(3-(difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 6, 180 mg, 0.69 mmol), pyridin-2-ol (66 mg, 0.69 mmol),and triphenylphosphine (182 mg, 0.69 mmol) in THF (4.5 mL) was addedDBAD (160 mg, 0.69 mmol). The resulting mixture was stirred at rt. for 3h. The solvent was removed under reduced pressure. Purification (FCC,SiO₂, heptane/EtOAc (0 to 80%) afforded the title compound (28 mg, 11%).MS (ESI): mass calcd. for C₁₅H₁₁F₃N₄O₂, 336.1; m/z found, 337.1 [M+H]⁺.¹H NMR (400 MHz, CDCl₃) δ 8.37-8.12 (m, 1H), 8.05 (s, 1H), 7.69 (dd,J=2.5, 6.7 Hz, 1H), 7.66-7.51 (m, 2H), 7.34 (t, J=9.2 Hz, 1H), 6.92(ddd, J=0.7, 5.2, 7.1 Hz, 1H), 6.85-6.40 (m, 2H), 5.60 (s, 2H).1-((1-(3-(Difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methyl)pyridin-2(1H)-onewas also obtained (75 mg, 32%).

Example 5.3-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]pyridine

To a solution of pyridin-3-ol (11 mg, 0.12 mmol) and K₂CO₃ (64 mg, 0.46mmol) in DMF (0.7 mL) was added a solution of1-(4-chloro-3-(difluoromethoxy)phenyl)-4-(chloromethyl)-1H-1,2,3-triazole(Intermediate 4, 41 mg, 0.14 mmol) in DMF (0.5 mL). The reaction mixturewas stirred at room temperature overnight. Upon completion, the reactionmixture was diluted with H₂O and EtOAc. The aqueous layer was furtherextracted with EtOAc (3×).

The combined organics were dried (Na₂SO₄), filtered, and concentratedunder reduced pressure. Purification (FCC, SiO₂, 0-100% EtOAc inhexanes) afforded title compound (24 mg, 58% yield). MS (ESI): masscalcd. for C₁₅H₁₁ClF₂N₄O₂, 352.1; m/z found, 353.0 [M+H]⁺. ¹H NMR (400MHz, CDCl₃) δ 8.42 (d, J=3.0 Hz, 1H), 8.27 (dd, J=4.6, 1.4 Hz, 1H),8.14-8.04 (m, 1H), 7.78-7.69 (m, 1H), 7.66-7.60 (m, 1H), 7.60-7.56 (m,1H), 7.40-7.33 (m, 1H), 7.31-7.21 (m, 1H), 6.64 (t, J=72.5 Hz, 1H), 5.34(s, 2H)

Example 6.N-((1-(3-(Difluoromethyl)phenyl-1H-1,2,3-triazol-4-yl)methyl)pyrimidin-2-amine

(1-(3-(Difluoromethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanamine(Intermediate 17, 32.4 mg, 0.145 mmol), 2-chloropyrimidine (21.5 mg,0.188 mmol), TEA (0.03 mL, 0.217 mmol), and EtOH (0.723 mL) werecombined in a microwave vial. The vial was purged with N₂, sealed, andheated in a microwave reactor at 120° C. for 2 h. Then at 150° C. for 10min. The crude reaction mixture was concentrated under reduced pressure.Purification (FCC, SiO₂, 0-8% MeOH in DCM) afforded the title compound(21.3 mg, 49%). MS (ESI): mass calcd. for C₁₄H₁₂F₂N₆, 302.1; m/z found,303.2 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃) δ 8.33 (d, J=4.8 Hz, 2H), 8.00 (s,1H), 7.92-7.82 (m, 2H), 7.68-7.55 (m, 2H), 6.72 (t, J=56.1 Hz, 1H), 6.61(t, J=4.8 Hz, 1H), 5.66 (s, 1H), 4.83 (d, J=6.2 Hz, 2H).

Example 7.N-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methyl]-1-methyl-imidazol-2-amine

To a solution of(1-(3-(difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanamine(Intermediate 18, 50 mg, 0.17 mmol) and 2-bromo-1-methyl-1H-imidazole intBuOH (4 mL) was added2-di-tert-butylphosphino-2′,4′,6′-triisopropylbiphenyl (14.4 mg, 0.033mmol), tris(dibenzylideneacetone)dipalladium(0) (15.5 mg, 0.017 mmol),and potassium tert-butoxide (76 mg, 0.68 mmol) under N₂ atmosphere. Themixture was stirred at 110° C. for 96 h. The resulting solids werefiltered off and the solvent was evaporated under reduced pressure.Purification (FCC, SiO₂, EtOAc/Heptane 0-100%; then MeOH/DCM 0-90%) thenfurther purified (RP HPLC; Stationary phase: C¹⁸ XBridge 30×100 mm 5μm), Mobile phase: Gradient from 81% 10 mM NH₄CO₃H pH 9 solution inWater, 19% CH₃CN to 64% 10 mM NH₄CO₃H pH 9 solution in Water, 36% CH₃CN)to afford the title compound (11 mg, 19%) as white solid. MS (ESI): masscalcd. for C₁₄H₁₃F₃N₆O, 338.1; m/z found, 339.1 [M+H]⁺. ¹H NMR (400 MHz,CDCl₃) δ 3.38 (s, 3H) 4.13-4.31 (m, 1H) 4.70 (d, J=6.24 Hz, 2H) 6.63 (t,J=72.83 Hz, 1H) 6.53 (d, J=1.39 Hz, 1H) 6.69 (d, J=1.39 Hz, 1H) 7.32 (t,J=9.25 Hz, 1H) 7.51-7.61 (m, 1H) 7.68 (dd, J=6.70, 2.54 Hz, 1H) 8.08 (s,1H).

Example 8.2-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]-6-methyl-pyridine

To a solution of2-bromo-6-((1-(3-(difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyridine(Intermediate 7, 75 mg, 0.18 mmol) in 1,4-dioxane (2 mL) was addedtrimethylboroxine (0.03 mL, 0.21 mmol), Cs₂CO₃ (118 mg, 0.36 mmol), and(2-dicydohexylphosphino-2′,4′,6′-triisopropyl-1,1′-biphenyl)[2-(2′-amino-1,1′-biphenyl)]palladium(II)methanesulfonate (15.3 mg, 0.018 mmol) to a sealed tube under N₂atmosphere. The mixture was heated to 120° C. for 12 min under microwaveirradiation. The mixture was concentrated under reduced pressure.Purification (FCC, SiO₂, EtOAc in heptane from 0-100%) afforded thetitle compound. The title compound was further purified (RP HPLC,Stationary phase: ¹⁸C XBridge 30×100 mm 5 μm), Mobile phase: Gradientfrom 90% 10 mM NH₄CO₃H pH 9 solution in Water, 10% CH₃CN to 0% 10 mMNH₄CO₃H pH 9 solution in Water, 100% CH₃CN) to afford the title compound(39 mg, 61%) HRMS=350.099. ¹H NMR (500 MHz, CDCl₃) δ ppm 2.49 (s, 3H)5.59 (s, 2H) 6.49-6.81 (m, 1H) 6.61 (d, J=8.1 Hz, 1H) 6.77 (d, J=7.2 Hz,1H) 7.35 (t, J=9.2 Hz, 1H) 7.49 (dd, J=8.2, 7.4 Hz, 1H) 7.59 (ddd,J=9.0, 3.9, 2.7 Hz, 1H) 7.70 (dd, J=6.4, 2.6 Hz, 1H) 8.04 (s, 1H)

Example 9.2-[[1-(3-Bromo-4-fluoro-phenyl)triazol-4-yl]methoxy]pyrimidine

The title compound was prepared in a manner analogous to Example 1 using(1-(3-bromo-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate14) and 2-chloropyrimidine. MS (ESI): mass calcd. for C₁₃H₉BrFN₅O,349.0; m/z found, 350.0 [M+H]⁺. ¹H NMR (600 MHz, CDCl₃) δ 8.57 (d, J=4.7Hz, 2H), 8.09-8.08 (m, 1H), 7.99 (dd, J=5.8, 2.7 Hz, 1H), 7.67 (ddd,J=8.9, 4.0, 2.6 Hz, 1H), 7.30-7.28 (m, 1H), 7.00 (t, J=4.8 Hz, 1H),5.68-5.65 (m, 2H).

Example 10.2-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]pyrimidine

The title compound was prepared in a manner analogous to Example 1 using(1-(4-chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 1) and 2-chloropyrimidine. MS (ESI): mass calcd. forC₁₄H₁₀ClF₂N₅O₂, 353.0; m/z found, 354.0 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃)δ 8.57 (d, J=4.8 Hz, 2H), 8.20-8.04 (m, 1H), 7.73-7.68 (m, 1H),7.65-7.60 (m, 1H), 7.59-7.55 (m, 1H), 7.03-6.90 (m, 1H), 6.64 (t, J=72.5Hz, 1H), 5.67 (s, 2H).

Example 11.2-[[1-[4-Chloro-3-(difluoromethyl)phenyl]triazol-4-yl]methoxy]pyridine

The title compound was prepared in a manner analogous to Example 1 using(1-(4-chloro-3-(difluoromethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 8) and 2-chloropyridine. MS (ESI): mass calcd. forC₁₅H₁₁ClF₂N₄O, 336.1; m/z found, 336.9 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃) δ8.21 (ddd, J=5.0, 2.0, 0.8 Hz, 1H), 8.12 (s, 1H), 8.02-7.99 (m, 1H),7.92-7.87 (m, 1H), 7.64-7.58 (m, 2H), 7.14-6.85 (m, 1H), 6.95-6.90 (m,1H), 6.81 (dt, J=8.3, 0.9 Hz, 1H), 5.64-5.57 (m, 2H).

Example 12.4-[[1-[4-Chloro-3-(difluoromethyl)phenyl]triazol-4-yl]methoxy]pyrimidine

The title compound was prepared in a manner analogous to Example 1 using(1-(4-chloro-3-(difluoromethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 8) and 4-chloropyrimidine. MS (ESI): mass calcd. forC₁₄H₁₀ClF₂N₅O, 337.1; m/z found, 338.0 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃) δ8.85 (s, 1H), 8.48 (d, J=5.8 Hz, 1H), 8.14 (s, 1H), 8.00 (d, J=2.7 Hz,1H), 7.93-7.85 (m, 1H), 7.66-7.58 (m, 1H), 7.00 (t, J=54.5 Hz, 1H), 6.81(dd, J=5.8, 1.2 Hz, 1H), 5.67 (s, 2H).

Example 13.4-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]pyrimidine

The title compound was prepared in a manner analogous to Example 1 using(1-(4-chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 1) and 4-chloropyrimidine. MS (ESI): mass calcd. forC₁₄H₁₀ClF₂N₅O₂, 353.0; m/z found, 354.0 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃)δ 8.83 (s, 1H), 8.47 (d, J=5.9 Hz, 1H), 8.10 (s, 1H), 7.73-7.67 (m, 1H),7.64-7.59 (m, 1H), 7.59-7.54 (m, 1H), 6.80 (dd, J=5.9, 1.2 Hz, 1H), 6.64(t, J=72.5 Hz, 1H), 5.65 (s, 2H)

Example 14.3-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]pyridazine

The title compound was prepared in a manner analogous to Example 1 using(1-(4-chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 1) and 3-chloropyridazine. MS (ESI): mass calcd. forC₁₄H₁₀ClF₂N₅O₂, 353.0; m/z found, 354.0 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃)δ 8.47 (d, J=5.9 Hz, 1H), 8.10 (s, 1H), 7.74-7.68 (m, 1H), 7.66-7.59 (m,1H), 7.59-7.54 (m, 1H), 6.80 (dd, J=5.9, 1.2 Hz, 1H), 6.64 (t, J=72.5Hz, 1H), 5.65 (s, 2H).

Example 15.2-[[1-(4-Chloro-3-methoxy-phenyl)triazol-4-yl]methoxy]pyrimidine

The title compound was prepared in a manner analogous to Example 1 using(1-(4-chloro-3-methoxyphenyl)-1H-1,2,3-triazol-4-yl)methanol and2-chloropyridine (Intermediate 15) and 2-chloropyrimidine. MS (ESI):mass calcd. for C₁₄H₁₂ClN₅O₂, 317.1; m/z found, 318.0 [M+H]⁺. ¹H NMR(400 MHz, CDCl₃) δ 8.57 (d, J=4.8 Hz, 2H), 8.13 (s, 1H), 7.49 (d, J=8.5Hz, 1H), 7.45 (d, J=2.4 Hz, 1H), 7.16 (dd, J=8.5, 2.4 Hz, 1H), 7.06-6.95(m, 1H), 5.67 (s, 2H), 3.99 (s, 3H)

Example 16.2-[[1-(3-Bromo-4-fluoro-phenyl)triazol-4-yl]methoxy]-5-methylpyrimidine

The title compound was prepared in a manner analogous to Example 1 using(1-(3-bromo-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate14) and 2-chloro-5-methylpyrimidine. MS (ESI): mass calcd. forC₁₄H₁₁BrFN₅O, 363.0; m/z found, 363.9 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃) δ8.38 (s, 2H), 8.07 (s, 1H), 7.98 (dd, J=5.8, 2.7 Hz, 1H), 7.67 (ddd,J=8.9, 4.0, 2.6 Hz, 1H), 7.30-7.27 (m, 1H), 5.63 (s, 2H), 2.26 (s, 3H).

Example 17.2-[[1-(3-Bromo-4-fluoro-phenyl)triazol-4-yl]methoxy]-4-methylpyrimidine

The title compound was prepared in a manner analogous to Example 1 using(1-(3-bromo-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate14) and 2-chloro-4-methylpyrimidine. MS (ESI): mass calcd. forC₁₄H₁₁BrFN₅O, 363.0; m/z found, 363.9 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃) δ8.40 (d, J=5.0 Hz, 1H), 8.08 (s, 1H), 7.99 (dd, J=5.8, 2.6 Hz, 1H), 7.66(ddd, J=8.8, 4.0, 2.6 Hz, 1H), 7.31-7.28 (m, 1H), 6.87 (d, J=5.0 Hz,1H), 5.65 (d, J=0.7 Hz, 2H), 2.50 (s, 3H).

Example 18.2-[[1-(3-Bromo-4-fluoro-phenyl)triazol-4-yl]methoxy]-4,6-dimethyl-pyrimidine

The title compound was prepared in a manner analogous to Example 1 using(1-(3-bromo-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate14) and 2-chloro-4,6-dimethylpyrimidine. MS (ESI): mass calcd. forC₁₅H₁₃BrFN₅O, 377.0; m/z found, 378.0 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃) δ8.08 (s, 1H), 7.99 (dd, J=5.8, 2.7 Hz, 1H), 7.66 (ddd, J=8.9, 4.0, 2.7Hz, 1H), 7.33-7.27 (m, 1H), 6.73 (s, 1H), 5.64 (d, J=0.8 Hz, 2H), 2.44(s, 6H).

Example 19.2-[[1-(3-Bromo-4-fluoro-phenyl)triazol-4-yl]methoxy]-5-fluoropyrimidine

The title compound was prepared in a manner analogous to Example 1 using(1-(3-bromo-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate14) and 2-chloro-5-fluoropyrimidine. MS (ESI): mass calcd. forC₁₃H₈BrF₂N₅O, 367.0; m/z found, 368.0 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃) δ8.43 (s, 2H), 8.07 (s, 1H), 7.98 (dd, J=5.8, 2.7 Hz, 1H), 7.67 (ddd,J=8.9, 4.0, 2.6 Hz, 1H), 7.29 (dd, J=8.9, 7.8 Hz, 1H), 5.63 (s, 2H).

Example 20.2-[[1-(4-Fluoro-3-methoxy-phenyl)triazol-4-yl]methoxy]pyrimidine

The title compound was prepared in a manner analogous to Example 1 using(1-(4-fluoro-3-methoxyphenyl)-1H-1,2,3-triazol-4-yl)methanol and2-chloropyrimidine. MS (ESI): mass calcd. for C₁₄H₁₂FN₅O₂, 301.1; m/zfound, 302.0 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃) δ 8.57 (d, J=4.8 Hz, 2H),8.09 (s, 1H), 7.46 (dd, J=7.4, 2.5 Hz, 1H), 7.23-7.12 (m, 2H), 7.05-6.94(m, 1H), 5.66 (s, 2H), 3.97 (s, 3H)

Example 21.2-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]-4-methyl-pyrimidine

The title compound was prepared in a manner analogous to Example 1 using(1-(4-chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 1) and 2-chloro-4-methylpyrimidine. MS (ESI): mass calcd.for C₁₅H₁₂ClF₂N₅O₂, 367.1; m/z found, 368.1 [M+H]⁺. ¹H NMR (400 MHz,CDCl₃) δ 8.39 (d, J=5.0 Hz, 1H), 8.13 (s, 1H), 7.74-7.65 (m, 1H),7.63-7.58 (m, 1H), 7.60-7.52 (m, 1H), 6.86 (d, J=5.0 Hz, 1H), 6.63 (t,J=72.5 Hz, 1H), 5.64 (s, 2H), 2.48 (s, 3H).

Example 22.2-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]-5-methyl-pyrimidine

The title compound was prepared in a manner analogous to Example 1 using(1-(4-chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 1) and 2-chloro-5-methylpyrimidine. MS (ESI): mass calcd.for C₅H₁₂ClF₂N₅O₂, 367.1; m/z found, 368.1 [M+H]⁺. ¹H NMR (400 MHz,CDCl₃) δ 8.37 (s, 2H), 8.12 (s, 1H), 7.75-7.67 (m, 1H), 7.64-7.58 (m,2H), 7.58-7.53 (m, 1H), 6.63 (t, J=72.6 Hz, 1H), 5.62 (s, 2H), 2.25 (s,3H).

Example 23.2-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]pyrazine

The title compound was prepared in a manner analogous to Example 1 using(1-(4-chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 1) and 2-fluoropyrazine. MS (ESI): mass calcd. forC₁₄H₁₀ClF₂N₅O₂, 353.0; m/z found, 354.1 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃)δ 8.30 (d, J=1.4 Hz, 1H), 8.19 (d, J=2.8 Hz, 1H), 8.13 (dd, J=2.8, 1.4Hz, 1H), 8.08 (s, 1H), 7.74-7.68 (m, 1H), 7.65-7.60 (m, 1H), 7.60-7.55(m, 1H), 6.64 (t, J=72.5 Hz, 1H), 5.61 (s, 2H).

Example 24.N-[[1-[3-(Difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methyl]pyrimidin-2-amine

The title compound was prepared in a manner analogous to Example 3, StepB, using(1-(3-(difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanamine(Intermediate 21) and 2-fluoropyrimidine. MS (ESI): mass calcd. forC₁₄H₁₁F₃N₆, 320.1; m/z found, 321.1 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃) δ4.82 (d, J=6.01 Hz, 2H), 5.80 (br s, 1H), 6.60 (t, J=4.62 Hz, 1H),6.75-7.15 (m, 1H), 7.30 (br t, J=8.90 Hz, 1H), 7.77-7.93 (m, 2H), 7.97(s, 1H), 8.33 (d, J=4.62 Hz, 2H).

Example 25.2-[[1-[3-(Difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyrimidine

The title compound was prepared in a manner analogous to Example 1 using(1-(3-(difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 9) and 2-chloropyrimidine. MS (ESI): mass calcd. forC₁₄H₁₀F₃N₅O, 321.1; m/z found, 322.1 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃)5.67 (s, 2H), 6.78-7.12 (m, 2H), 7.33 (t, J=9.0 Hz, 1H), 7.82-8.01 (m,2H), 8.14 (s, 1H), 8.58 (d, J=4.6 Hz, 2H).

Example 26.2-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]-5-methoxy-pyrimidine

The title compound was prepared in a manner analogous to Example 1 using(1-(4-chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 1) and 2-chloro-5-methoxypyrimidine. MS (ESI): mass calcd.for C₁₅H₁₂ClF₂N₅O₃, 383.1; m/z found, 384.1 [M+H]⁺. ¹H NMR (400 MHz,CDCl₃) δ 8.24 (s, 2H), 8.15-8.08 (m, 1H), 7.74-7.67 (m, 1H), 7.66-7.59(m, 1H), 7.59-7.55 (m, 1H), 6.63 (t, J=72.5 Hz, 1H), 5.61 (s, 2H), 3.88(s, 3H).

Example 27.2-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]-5-ethyl-pyrimidine

The title compound was prepared in a manner analogous to Example 1 using(1-(4-chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 1) and 2-chloro-5-ethylpyrimidine. MS (ESI): mass calcd.for C₁₆H₁₄ClF₂N₅O₂, 381.1; m/z found, 382.1 [M+H]⁺. ¹H NMR (400 MHz,CDCl₃) δ 0.40 (s, 2H), 8.21-8.00 (m, 1H), 7.79-7.67 (m, 1H), 7.64-7.59(m, 1H), 7.59-7.54 (m, 1H), 6.63 (t, J=72.5 Hz, 1H), 5.64 (s, 2H), 2.61(q, J=7.6 Hz, 2H), 1.26 (t, J=7.6 Hz, 3H)

Example 28.5-Chloro-2-[[1-[4-chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]pyrimidine

The title compound was prepared in a manner analogous to Example 1 using(1-(4-chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 1) and 2,5-dichloropyrimidine. MS (ESI): mass calcd. forC₁₄H₉Cl₁₂F₂N₅O₂, 387.0; m/z found, 388.1 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃)δ 8.51 (s, 2H), 8.16-8.02 (m, 1H), 7.73-7.68 (m, 1H), 7.65-7.60 (m, 1H),7.59-7.53 (m, 1H), 6.64 (t, J=72.5 Hz, 1H), 5.64 (s, 2H).

Example 29.2-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]-4-methoxy-pyrimidine

The title compound was prepared in a manner analogous to Example 1 using(1-(4-chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 1) and 2-chloro-4-methoxypyrimidine. MS (ESI): mass calcd.for C₁₅H₁₂ClF₂N₅O₃, 383.1; m/z found, 384.1 [M+H]⁺. ¹H NMR (400 MHz,CDCl₃) δ 8.22 (d, J=5.7 Hz, 1H), 8.12 (s, 1H), 7.75-7.68 (m, 1H),7.63-7.59 (m, 1H), 7.58-7.53 (m, 1H), 6.64 (t, J=72.5 Hz, 1H), 6.43 (d,J=5.7 Hz, 1H), 5.64 (s, 2H), 3.98 (s, 3H).

Example 30.2-[[1-[4-Chloro-3-(difluoromethyl)phenyl]triazol-4-yl]methoxy]-4-methyl-pyrimidine

The title compound was prepared in a manner analogous to Example 1 using(1-(4-chloro-3-(difluoromethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 8) and 2-chloro-4-methylpyrimidine. MS (ESI): mass calcd.for C₁₅H₁₂ClF₂N₅O, 351.1; m/z found, 352.1 [M+H]⁺. ¹H NMR (400 MHz,CDCl₃) δ 8.40 (d, J=5.0 Hz, 1H), 8.17 (s, 1H), 8.00 (d, J=2.5 Hz, 1H),7.90-7.86 (m, 1H), 7.60 (d, J=8.7 Hz, 1H), 7.12-6.84 (m, 2H), 5.65 (d,J=0.7 Hz, 2H), 2.49 (s, 3H).

Example 31.2-[[1-[4-Chloro-3-(difluoromethyl)phenyl]triazol-4-yl]methoxy]-5-methyl-pyrimidine

The title compound was prepared in a manner analogous to Example 1 using(1-(4-chloro-3-(difluoromethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 8) and 2-chloro-5-methylpyrimidine. MS (ESI): mass calcd.for C₁₅H₁₂ClF₂N₅O, 351.1; m/z found, 352.1 [M+H]⁺. ¹H NMR (500 MHz,CDCl₃) δ 8.38 (d, J=0.9 Hz, 2H), 8.16 (s, 1H), 8.00 (d, J=2.6 Hz, 1H),7.92-7.84 (m, 1H), 7.66-7.55 (m, 1H), 6.99 (t, J=54.6 Hz, 1H), 5.63 (d,J=0.7 Hz, 2H), 2.26 (s, 3H).

Example 32.2-[[1-[4-Chloro-3-(difluoromethyl)phenyl]triazol-4-yl]methoxy]-5-ethyl-pyrimidine

The title compound was prepared in a manner analogous to Example 1 using(1-(4-chloro-3-(difluoromethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 8) and 2-chloro-5-ethylpyrimidine, using THF instead ofDMF. MS (ESI): mass calcd. for C₁₆H₁₄ClF₂N₅O, 365.1; m/z found, 366.1[M+H]⁺. ¹H NMR (500 MHz, CDCl₃) δ 8.40 (s, 1H), 8.17 (d, J=0.7 Hz, 1H),8.01 (d, J=2.6 Hz, 1H), 7.92-7.86 (m, 1H), 7.63-7.59 (m, 1H), 6.99 (t,J=54.5 Hz, 1H), 5.65 (d, J=0.8 Hz, 2H), 2.61 (q, J=7.6 Hz, 3H), 1.27 (t,J=7.6 Hz, 3H).

Example 33.2-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyrimidine

The title compound was prepared in a manner analogous to Example 1 using(1-(3-(difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 6) and 2-fluoropyrimidine. MS (ESI): mass calcd. forC₁₄H₁₀F₃N₅O₂, 337.1; m/z found, 338.1 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃) δ8.58 (d, J=4.9 Hz, 2H), 8.12 (s, 1H), 7.70 (dd, J=2.7, 6.6 Hz, 1H),7.65-7.54 (m, 1H), 7.35 (t, J=9.1 Hz, 1H), 7.02 (t, J=4.7 Hz, 1H), 6.65(t, J=72.6 Hz, 1H), 5.66 (s, 2H).

Example 34.2-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]-5-methyl-pyrazine

The title compound was prepared in a manner analogous to Example 1 using(1-(4-chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 1) and 2-chloro-5-methylpyrazine. MS (ESI): mass calcd.for C₁₅H₁₂ClF₂N₅O₂, 367.1; m/z found, 368.1 [M+H]⁺. ¹H NMR (400 MHz,CDCl₃) δ 8.20 (d, J=1.5 Hz, 1H), 8.11-8.04 (m, 1H), 8.01-7.94 (m, 1H),7.74-7.68 (m, 1H), 7.65-7.58 (m, 1H), 7.59-7.55 (m, 1H), 6.64 (t, J=72.5Hz, 1H), 5.57 (s, 2H), 2.49 (s, 3H)

Example 35.2-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]-5-(difluoromethoxy)pyrimidine

The title compound was prepared in a manner analogous to Example 1 using(1-(4-chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 1) and 2-chloro-5-(difluoromethoxy)pyrimidine. MS (ESI):mass calcd. for C₁₅H₁₀ClF₄N₅O₃, 419.0; m/z found, 420.0 [M+H]⁺. ¹H NMR(400 MHz, CDCl₃) δ 8.45 (s, 2H), 8.12 (s, 1H), 7.75-7.69 (m, 1H),7.65-7.59 (m, 1H), 7.59-7.55 (m, 1H), 6.64 (t, J=72.5 Hz, 1H), 6.53 (t,J=71.9 Hz, 1H), 5.65 (s, 2H).

Example 36.N-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methyl]pyrimidin-2-amine

The title compound was prepared in a manner analogous to Example 6 using(1-(3-(difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanamine(Intermediate 18) and 2-fluoropyrimidine. MS (ESI): mass calcd. forC₁₄H₁₁F₃N₆O, 336.1; m/z found, 337.1 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃) δ8.33 (d, J=4.9 Hz, 2H), 7.93 (s, 1H), 7.67 (dd, J=2.5, 6.5 Hz, 1H), 7.56(ddd, J=2.7, 3.9, 9.0 Hz, 1H), 7.33 (t, J=9.2 Hz, 1H), 6.61 (s, 2H),5.81-5.57 (m, 1H), 4.82 (d, J=6.2 Hz, 2H)

Example 37.5-Chloro-2-[[1-(2,4-difluoro-3-methyl-phenyl)triazol-4-yl]methoxy]pyrimidine

The title compound was prepared in a manner analogous to Example 1 using(1-(2,4-difluoro-3-methylphenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 10) and 2,5-dichloropyrimidine. MS (ESI): mass calcd. forC₁₄H₁₀ClF₂N₅O, 337.1; m/z found, 338.1 [M+H]⁺. ¹H NMR (500 MHz, CDCl₃) δ8.50 (s, 2H), 8.13 (d, J=2.7 Hz, 1H), 7.73-7.66 (m, 1H), 7.07-6.99 (m,1H), 5.68-5.62 (m, 2H), 2.30 (t, J=2.0 Hz, 3H).

Example 38.2-[[1-(2,4-Difluoro-3-methyl-phenyl)triazol-4-yl]methoxy]-5-methyl-pyrimidine

The title compound was prepared in a manner analogous to Example 1 using(1-(2,4-difluoro-3-methylphenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 10) and 2-chloro-5-methylpyrimidine. MS (ESI): mass calcd.for C₁₅H₁₃F₂N₅O, 317.1; m/z found, 318.2 [M+H]⁺. ¹H NMR (500 MHz, CDCl₃)δ 8.38 (d, J=0.9 Hz, 2H), 8.15-8.11 (m, 1H), 7.69 (td, J=8.6, 5.7 Hz,1H), 7.02 (td, J=8.7, 1.8 Hz, 1H), 5.64 (d, J=0.6 Hz, 2H), 2.30 (t,J=2.0 Hz, 3H), 2.25 (t, J=0.7 Hz, 3H).

Example 39.2-[[1-(2,4-Difluoro-3-methyl-phenyl)triazol-4-yl]methoxy]-5-ethyl-pyrimidine

The title compound was prepared in a manner analogous to Example 1 using(1-(2,4-difluoro-3-methylphenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 10) and 2-chloro-5-ethylpyrimidine. MS (ESI): mass calcd.for C₁₆H₁₅F₂N₅O, 331.1; m/z found, 332.2 [M+H]⁺. ¹H NMR (500 MHz, CDCl₃)δ 8.39 (s, 2H), 8.14 (d, J=2.9 Hz, 1H), 7.73-7.66 (m, 1H), 7.02 (td,J=8.6, 1.9 Hz, 1H), 5.65 (d, J=0.7 Hz, 2H), 2.63-2.57 (m, 2H), 2.30 (t,J=2.0 Hz, 3H), 1.26 (t, J=7.6 Hz, 3H).

Example 40.2-[[1-(3-Bromo-4-fluoro-phenyl)triazol-4-yl]methoxy]-5-ethyl-pyrimidine

The title compound was prepared in a manner analogous to Example 1 using(1-(3-bromo-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate14) and 2-chloro-5-ethylpyrimidine, using THF instead of DMF. MS (ESI):mass calcd. for C₁₅H₁₃BrFN₅O, 377.0; m/z found, 380.1 [M+H]⁺. ¹H NMR(400 MHz, CDCl₃) δ 8.40 (s, 2H), 8.08 (s, 1H), 7.99 (dd, J=5.8, 2.7 Hz,1H), 7.67 (ddd, J=8.9, 4.1, 2.7 Hz, 1H), 7.31-7.27 (m, 1H), 5.64 (s,2H), 2.61 (q, J=7.6 Hz, 2H), 1.27 (t, J=7.6 Hz, 3H).

Example 41.2-[[1-(3-Bromo-4-fluoro-phenyl)triazol-4-yl]methoxy]-5-methoxy-pyrimidine

The title compound was prepared in a manner analogous to Example 1 using(1-(3-bromo-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate14) and 2-chloro-5-methoxypyrimidine. MS (ESI): mass calcd. forC₁₄H₁₁BrFN₅O₂, 379.0; m/z found, 380.0 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃) δ8.24 (s, 2H), 8.07 (s, 1H), 7.98 (dd, J=5.8, 2.7 Hz, 1H), 7.67 (ddd,J=8.9, 4.1, 2.6 Hz, 1H), 7.31-7.27 (m, 1H), 5.60 (d, J=0.7 Hz, 2H), 3.88(s, 3H).

Example 42.2-[[1-(3-Bromo-4-fluoro-phenyl)triazol-4-yl]methoxy]-5-chloropyrimidine

The title compound was prepared in a manner analogous to Example 1 using(1-(3-bromo-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate14) and 2,5-dichloropyrimidine, using THF instead of DMF. MS (ESI): masscalcd. for C₁₃H₈BrClFN₅O, 383.0; m/z found, 384.0 [M+H]⁺. ¹H NMR (400MHz, CDCl₃) δ 8.51 (s, 2H), 8.07 (s, 1H), 7.98 (dd, J=5.8, 2.7 Hz, 1H),7.67 (ddd, J=8.9, 4.0, 2.6 Hz, 1H), 7.29 (dd, J=9.0, 7.9 Hz, 1H), 5.64(d, J=0.7 Hz, 2H).

Example 43.2-[[1-(3-Bromo-4-fluoro-phenyl)triazol-4-yl]methoxy]-5-isopropylpyrimidine

The title compound was prepared in a manner analogous to Example 1 using(1-(3-bromo-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate14) and 2-chloro-5-isopropylpyrimidine, using THF instead of DMF. MS(ESI): mass calcd. for C₁₆H₁₅BrFN₅O, 391.0; m/z found, 392.1 [M+H]⁺. ¹HNMR (400 MHz, CDCl₃) δ 8.42 (d, J=0.5 Hz, 2H), 8.08 (s, 1H), 7.99 (dd,J=5.8, 2.7 Hz, 1H), 7.67 (ddd, J=8.9, 4.0, 2.7 Hz, 1H), 7.31-7.28 (m,1H), 5.64 (d, J=0.7 Hz, 2H), 2.97-2.87 (m, 1H), 1.30 (d, J=7.0 Hz, 6H)

Example 44.2-[[1-(3-Bromo-4-fluoro-phenyl)triazol-4-yl]methoxy]-5-(trifluoromethyl)pyrimidine

The title compound was prepared in a manner analogous to Example 1 using(1-(3-bromo-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate14) and 2-chloro-5-(trifluoromethyl)pyrimidine, using THF instead ofDMF. MS (ESI): mass calcd. for C₁₄H₈BrF₄N₅O, 417.0; m/z found, 418.0[M+H]⁺. ¹H NMR (400 MHz, CDCl₃) δ 8.82 (d, J=0.8 Hz, 2H), 8.09 (s, 1H),7.99 (dd, J=5.7, 2.7 Hz, 1H), 7.68 (ddd, J=8.9, 4.0, 2.6 Hz, 1H), 7.29(dd, J=8.9, 7.8 Hz, 1H), 5.73 (d, J=0.6 Hz, 2H).

Example 45.2-[[1-[4-Chloro-3-(difluoromethyl)phenyl]triazol-4-yl]methoxy]-5-(trifluoromethyl)pyrimidine

The title compound was prepared in a manner analogous to Example 1 using(1-(4-chloro-3-(difluoromethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 8) and 2-chloro-5-(trifluoromethyl)pyrimidine, using THFinstead of DMF. MS (ESI): mass calcd. for C₁₅H₉ClF₈N₅O, 405.0; m/zfound, 406.1 [M+H]⁺. ¹H NMR (500 MHz, CDCl3) δ 8.82 (d, J=0.8 Hz, 2H),8.18 (s, 1H), 8.01 (d, J=2.7 Hz, 1H), 7.89 (dd, J=8.7, 2.5 Hz, 1H), 7.62(d, J=8.6 Hz, 1H), 7.00 (t, J=54.5 Hz, 1H), 5.74 (d, J=0.7 Hz, 2H).

Example 46.2-[[1-[4-Chloro-3-(difluoromethyl)phenyl]triazol-4-yl]methoxy]-5-methoxy-pyrimidine

The title compound was prepared in a manner analogous to Example 1 using(1-(4-chloro-3-(difluoromethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 8) and 2-chloro-5-methoxypyrimidine, using THF instead ofDMF. MS (ESI): mass calcd. for C₁₅H₁₂ClF₂N₅O₂, 367.1; m/z found, 368.1[M+H]⁺. ¹H NMR (500 MHz, CDCl₃) δ 8.24 (s, 2H), 8.16 (s, 1H), 8.01 (d,J=2.6 Hz, 1H), 7.91-7.86 (m, 1H), 7.61 (dt, J=8.7, 1.2 Hz, 1H), 6.99 (t,J=54.6 Hz, 1H), 5.61 (d, J=0.7 Hz, 2H), 3.88 (s, 3H).

Example 47.5-Chloro-2-[[1-[4-chloro-3-(difluoromethyl)phenyl]triazol-4-yl]methoxy]pyrimidine

The title compound was prepared in a manner analogous to Example 1 using(1-(4-chloro-3-(difluoromethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 8) and 2,5-dichloropyrimidine, using THF instead of DMF.MS (ESI): mass calcd. for C₁₄H₉Cl₁₂F₂N₅O, 371.0; m/z found, 372.0[M+H]⁺. ¹H NMR (500 MHz, CDCl₃) δ 8.51 (s, 2H), 8.16 (s, 1H), 8.01 (d,J=2.6 Hz, 1H), 7.92-7.86 (m, 1H), 7.65-7.59 (m, 1H), 7.00 (t, J=54.5 Hz,1H), 5.65 (d, J=0.7 Hz, 2H).

Example 48.2-[[1-[4-Chloro-3-(difluoromethyl)phenyl]triazol-4-yl]methoxy]-5-isopropyl-pyrimidine

The title compound was prepared in a manner analogous to Example 1 using(1-(4-chloro-3-(difluoromethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 8) and 2-chloro-5-isopropylpyrimidine, using THF insteadof DMF. MS (ESI): mass calcd. for C₁₇H₁₆ClF₂N₅O, 379.1; m/z found, 380.1[M+H]⁺. ¹H NMR (500 MHz, CDCl₃) δ 8.43 (d, J=0.6 Hz, 2H), 8.17 (s, 1H),8.01 (d, J=2.6 Hz, 1H), 7.90-7.87 (m, 1H), 7.61 (d, J=8.7 Hz, 1H), 6.99(t, J=54.6 Hz, 1H), 5.65 (d, J=0.7 Hz, 2H), 2.97-2.88 (m, 1H), 1.30 (d,J=7.0 Hz, 6H).

Example 49.5-Chloro-2-[[1-[3-(difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyrimidine

The title compound was prepared in a manner analogous to Example 1 using(1-(3-(difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 9) and 2,5-dichloropyrimidine. MS (ESI): mass calcd. forC₁₄H₉ClF₃N₅O, 355.0; m/z found, 356.0 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃) δ5.66 (s, 2H), 6.96 (t, J=55.02 Hz, 1H), 7.34 (t, J=9.02 Hz, 1H),7.77-8.03 (m, 2H), 8.13 (s, 1H), 8.52 (s, 2H).

Example 50.2-[[1-[3-(Difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-5-(trifluoromethyl)pyrimidine

The title compound was prepared in a manner analogous to Example 1 using(1-(3-(difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 9) and 2-chloro-5-(trifluoromethyl)pyrimidine. MS (ESI):mass calcd. for C₁₅H₆F₆N₅O, 389.1; m/z found, 390.0 [M+H]⁺. ¹H NMR (400MHz, CDCl₃) δ 5.75 (s, 2H), 6.96 (t, J=54.56 Hz, 1H), 7.35 (t, J=9.02Hz, 1H), 7.76-8.05 (m, 2H), 8.16 (s, 1H), 8.83 (s, 2H)

Example 51.2-[[1-[3-(Difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-5-methyl-pyrimidine

The title compound was prepared in a manner analogous to Example 1 using(1-(3-(difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 9) and 2-chloro-5-methylpyrimidine, using THF instead ofDMF. MS (ESI): mass calcd. for C₁₅H₁₂F₃N₅O, 335.1; m/z found, 336.1[M+H]⁺. ¹H NMR (400 MHz, CDCl₃) δ 2.27 (s, 3H), 5.65 (s, 2H), 6.96 (t,J=54.56 Hz, 1H), 7.33 (t, J=8.90 Hz, 1H), 7.69-8.03 (m, 2H), 8.14 (s,1H), 8.39 (s, 2H).

Example 52.2-[[1-[3-(Difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-4-methyl-pyrimidine

The title compound was prepared in a manner analogous to Example 1 using(1-(3-(difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 9) and 2-chloro-4-methylpyrimidine, using THF instead ofDMF. MS (ESI): mass calcd. for C₁₅H₁₂F₃N₅O, 335.1; m/z found, 336.1[M+H]⁺. ¹H NMR (400 MHz, CDCl₃) δ 2.50 (s, 3H), 5.67 (s, 2H), 6.96 (t,J=54.56 Hz, 1H), 6.87 (d, J=4.85 Hz, 1H), 7.33 (t, J=9.02 Hz, 1H),7.86-7.93 (m, 1H), 7.96 (dd, J=5.66, 2.66 Hz, 1H), 8.15 (s, 1H), 8.41(d, J=4.85 Hz, 1H).

Example 53.(R/S)-2-[1-[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]ethoxy]pyrimidine

The title compound was prepared in a manner analogous to Example 1 usingR/S-1-(1-(4-chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)ethan-1-ol(Intermediate 2) and 2-chloropyrimidine. MS (ESI): mass calcd. forC₁₅H₁₂ClF₂N₅O₂, 367.1; m/z found, 368.0 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃)δ 8.54 (d, J=4.8 Hz, 2H), 8.10-8.02 (m, 1H), 7.72-7.64 (m, 1H),7.63-7.58 (m, 1H), 7.58-7.53 (m, 1H), 7.00-6.93 (m, 1H), 6.63 (t, J=72.5Hz, 1H), 6.51 (q, J=6.6 Hz, 1H), 1.85 (d, J=6.6 Hz, 3H).

Example 54.(R*)-2-[1-[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]ethoxy]pyrimidine

SFC Purification (Stationary phase: Chiralpak IF 5 μm 250×21 mm, Mobilephase: 20% methanol, 80% CO₂) Enantiomeric purity (SFC/Chiralpak IF):100%. Retention time: 5.40 min. MS (ESI): mass calcd. forC₁₅H₁₂ClF₂N₅O₂, 367.1; m/z found, 368.1 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃)δ 8.53 (d, J=4.8 Hz, 2H), 8.11-7.96 (m, 1H), 7.73-7.65 (m, 1H),7.61-7.57 (m, 1H), 7.57-7.52 (m, 1H), 7.01-6.91 (m, 1H), 6.63 (t, J=72.5Hz, 1H), 6.51 (q, J=6.6 Hz, 1H), 1.85 (d, J=6.6 Hz, 3H).

Example 55.(S*)-2-[1-[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]ethoxy]pyrimidine

SFC Purification (Stationary phase: Chiralpak IF 5 μm 250×21 mm, Mobilephase: 20% methanol, 80% CO₂) Enantiomeric purity (SFC/Chiralpak IF):99.6%. Retention time: 7.05 min. MS (ESI): mass calcd. forC₁₅H₁₂ClF₂N₅O₂, 367.1; m/z found, 368.1 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃)δ 8.54 (d, J=4.8 Hz, 2H), 8.11-7.97 (m, 1H), 7.75-7.65 (m, 1H),7.63-7.58 (m, 1H), 7.57-7.53 (m, 1H), 7.01-6.92 (m, 1H), 6.63 (t, J=72.5Hz, 1H), 6.51 (q, J=6.6 Hz, 1H), 1.85 (d, J=6.6 Hz, 3H).

Example 56.(R/S)-2-[1-[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]ethoxy]-5-methyl-pyrimidine

The title compound was prepared in a manner analogous to Example 1 usingR/S-1-(1-(4-chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)ethan-1-ol(Intermediate 2) and 2-chloro-5-methylpyrimidine. MS (ESI): mass calcd.for C₁₆H₁₄ClF₂N O₂, 381.1; m/z found, 382.0 [M+H]⁺. ¹H NMR (400 MHz,CDCl₃) δ 8.35 (s, 2H), 8.09-7.99 (m, 1H), 7.74-7.66 (m, 1H), 7.62-7.57(m, 1H), 7.57-7.52 (m, 1H), 6.84-6.42 (m, 2H), 2.24 (s, 3H), 1.84 (d,J=6.6 Hz, 3H). Example 56 was subjected to Chiral SFC purification[Stationary phase: Chiralpak IF (5 μm, 4.6×250 mm), Mobile phase of 25%MeOH: 75% CO₂] to provide the corresponding single enantiomers (Example57 and Example 58) where the absolute stereochemistry was notdetermined. The enantiomeric purity was confirmed by analytical SFCusing a Chiralpak IF column (5 μm 4.6×250 mm), mobile phase of 25% MeOH:75% CO₂, and a flow rate of 2 mL/min over 7 minutes (Temperature=35°C.). Elution was monitored following absorbance at 254 nm.

Example 57.(R*)-2-[1-[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]ethoxy]-5-methyl-pyrimidine

Enantiomeric purity (SFC/Chiralpak IF): 100%. Retention time: 5.93 min.MS (ESI): mass calcd. for C₁₆H₁₄ClF₂N₅O₂, 381.1; m/z found, 382.0[M+H]⁺. ¹H NMR (400 MHz, CDCl₃) δ 8.35 (s, 2H), 8.05-8.01 (m, 1H),7.71-7.66 (m, 1H), 7.62-7.57 (m, 1H), 7.57-7.51 (m, 1H), 6.82-6.41 (m,2H), 2.24 (s, 3H), 1.84 (d, J=6.6 Hz, 3H).

Example 58.(S*)-2-[1-[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]ethoxy]-5-methyl-pyrimidine

Enantiomeric purity (SFC/Chiralpak IF): 100%. Retention time: 8.74 min.MS (ESI): mass calcd. for C₁₆H₁₄ClF₂N₅O₂, 381.1; m/z found, 382.0[M+H]⁺. ¹H NMR (400 MHz, CDCl₃) δ 8.34 (s, 2H), 8.13-7.97 (m, 1H),7.73-7.65 (m, 1H), 7.60-7.57 (m, 1H), 7.57-7.52 (m, 1H), 6.84-6.39 (m,2H), 2.23 (s, 3H), 1.83 (d, J=6.6 Hz, 3H).

Example 59.(R/S)-2-[1-[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]ethoxy]-4-methyl-pyrimidine

The title compound was prepared in a manner analogous to Example 1 usingR/S-1-(1-(4-chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)ethan-1-ol(Intermediate 2) and 2-chloro-4-methylpyrimidine. MS (ESI): mass calcd.for C₁₆H₁₄ClF₂N₅O₂, 381.1; m/z found, 382.0 [M+H]⁺. ¹H NMR (500 MHz,CDCl₃) δ 8.36 (d, J=5.0 Hz, 1H), 8.04 (d, J=0.7 Hz, 1H), 7.70-7.65 (m,1H), 7.61-7.58 (m, 1H), 7.57-7.53 (m, 1H), 6.86-6.79 (m, 1H), 6.62 (t,J=72.5 Hz, 1H), 6.53 (q, J=6.6 Hz, 1H), 2.47 (s, 3H), 1.83 (d, J=6.6 Hz,3H)

Example 60.(R/S)-5-Chloro-2-[1-[1-[4-chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]ethoxy]pyrimidine

The title compound was prepared in a manner analogous to Example 1 usingR/S-1-(1-(4-chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)ethan-1-ol(Intermediate 2) and 2,5-dichloropyrimidine. MS (ESI): mass calcd. forC₁₅H₁₁Cl₂F₂N₅O₂, 401.0; m/z found, 402.0 [M+H]⁺. ¹H NMR (500 MHz, CDCl₃)δ 8.47 (s, 2H), 8.02 (d, J=0.7 Hz, 1H), 7.72-7.65 (m, 1H), 7.63-7.58 (m,1H), 7.57-7.52 (m, 1H), 6.63 (t, J=72.5 Hz, 1H), 6.44 (q, J=6.6 Hz, 1H),1.85 (d, J=6.6 Hz, 3H).

Example 61.5-Chloro-2-[[1-[3-(difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyrimidine

The title compound was prepared in a manner analogous to Example 1 using(1-(3-(difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 6) and 2,5-dichloropyrimidine, using THF instead of DMF.MS (ESI): mass calcd. for C₁₄H₉ClF₃N₅O₂, 371.0; m/z found, 372.1 [M+H]⁺.¹H NMR (400 MHz, CDCl₃) δ 2.01-2.06 (m, 1H), 4.08-4.15 (m, 1H), 5.64 (s,2H), 6.64 (t, J=72.36 Hz, 1H), 7.35 (t, J=9.13 Hz, 1H), 7.58 (ddd,J=8.90, 3.81, 2.77 Hz, 1H), 7.69 (dd, J=6.70, 2.54 Hz, 1H), 8.08 (s,1H), 8.51 (s, 2H)

Example 62.2-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]-5-(trifluoromethyl)pyrimidine

The title compound was prepared in a manner analogous to Example 1 using(1-(3-(difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 6) and 2-chloro-5-(trifluoromethyl)pyrimidine, using THFinstead of DMF. MS (ESI): mass calcd. for C₁₅H₉F₆N₅O₂, 405.1; m/z found,406.1 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃) δ 8.81 (s, 2H), 8.13 (s, 1H), 7.69(dd, J=2.4, 6.6 Hz, 1H), 7.59 (br d, J=9.0 Hz, 1H), 7.34 (t, J=9.2 Hz,1H), 6.65 (t, J=72.1 Hz, 1H), 5.72 (s, 2H).

Example 63.2-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]-5-methyl-pyrimidine

The title compound was prepared in a manner analogous to Example 1 using(1-(3-(difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 6) and 2-chloro-5-methylpyrimidine, using THF instead ofDMF. MS (ESI): mass calcd. for C₁₅H₁₂F₃N₅O₂, 351.1; m/z found, 352.1[M+H]⁺. ¹H NMR (400 MHz, CDCl₃) δ 8.38 (s, 2H), 8.09 (s, 1H), 7.69 (dd,J=2.5, 6.5 Hz, 1H), 7.58 (td, J=3.2, 8.9 Hz, 1H), 7.34 (t, J=9.2 Hz,1H), 6.64 (t, J=72.4 Hz, 1H), 5.83-5.41 (m, 2H), 2.26 (s, 3H)

Example 64.2-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]-4-methyl-pyrimidine

The title compound was prepared in a manner analogous to Example 1 using(1-(3-(difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 6) and 2-chloro-4-methylpyrimidine, using THF instead ofDMF. MS (ESI): mass calcd. for C₁₅H₁₂F₃N₅O₂, 351.1; m/z found, 352.1[M+H]⁺. ¹H NMR (400 MHz, CDCl₃) δ 8.40 (d, J=5.1 Hz, 1H), 8.11 (s, 1H),7.70 (dd, J=2.5, 6.5 Hz, 1H), 7.64-7.51 (m, 1H), 7.34 (t, J=9.2 Hz, 1H),6.87 (d, J=5.1 Hz, 1H), 6.65 (t, J=72.6 Hz, 1H), 5.66 (s, 2H), 2.50 (s,3H).

Example 65.2-[[1-[3-(Difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-5-(trifluoromethyl)pyridine

The title compound was prepared in a manner analogous to Example 1 using(1-(3-(difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 9) and 2-chloro-5-(trifluoromethyl)pyridine, using THFinstead of DMF. MS (ESI): mass calcd. for C₁₆H₁₀F₆N₄O, 388.1; m/z found,389.0 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃) δ 5.66 (s, 2H), 6.73-7.14 (m, 2H),7.33 (t, J=9.02 Hz, 1H), 7.81 (dd, J=8.67, 2.43 Hz, 1H), 7.86-7.99 (m,2H), 8.09 (s, 1H), 8.50 (s, 1H)

Example 66.2-[[1-[4-Chloro-3-(difluoromethyl)phenyl]triazol-4-yl]methoxy]-5-fluoro-pyrimidine

The title compound was prepared in a manner analogous to Example 1 using(1-(4-chloro-3-(difluoromethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 8) and 2-chloro-5-fluoropyrimidine, using THF instead ofDMF. MS (ESI): mass calcd. for C₁₄H₉ClF₃N₅O, 355.0; m/z found, 356.0[M+H]⁺. ¹H NMR (500 MHz, CDCl₃) δ 8.43 (s, 2H), 8.16 (s, 1H), 8.01 (d,J=2.6 Hz, 1H), 7.91-7.86 (m, 1H), 7.64-7.60 (m, 1H), 6.99 (t, J=54.6 Hz,1H), 5.64 (d, J=0.7 Hz, 2H).

Example 67.2-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-5-ethyl-pyrimidine

The title compound was prepared in a manner analogous to Example 1 using(1-(3-(1,1-difluoroethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 11) and 2-chloro-5-ethylpyrimidine, using THF instead ofDMF. MS (ESI): mass calcd. for C₁₇H₁₆F₃N₅O, 363.1; m/z found, 364.0[M+H]⁺. ¹H NMR (500 MHz, CDCl₃) δ 8.40 (s, 2H), 8.12 (t, J=0.7 Hz, 1H),7.92-7.87 (m, 1H), 7.86-7.80 (m, 1H), 7.34-7.28 (m, 1H), 5.74-5.55 (m,2H), 2.70-2.52 (m, 2H), 2.05 (t, J=18.6, 1.2 Hz, 3H), 1.27 (t, J=7.6 Hz,3H).

Example 68.2-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-5-methoxy-pyrimidine

The title compound was prepared in a manner analogous to Example 1 using(1-(3-(1,1-difluoroethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 11) and 2-chloro-5-methoxypyrimidine, using THF instead ofDMF. MS (ESI): mass calcd. for C₁₆H₁₄F₃N₅O₂, 365.1; m/z found, 366.0[M+H]⁺. ¹H NMR (500 MHz, CDCl₃) δ 8.24 (s, 2H), 8.11 (t, J=0.7 Hz, 1H),7.89 (dd, J=6.2, 2.8 Hz, 1H), 7.82 (s, 1H), 7.30 (dd, J=9.8, 8.8 Hz,1H), 5.61 (d, J=0.7 Hz, 2H), 3.88 (s, 3H), 2.05 (td, J=18.6, 1.2 Hz,3H).

Example 69.5-Chloro-2-[[1-[3-(1,1-difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyrimidine

The title compound was prepared in a manner analogous to Example 1 using(1-(3-(1,1-difluoroethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 11) and 2,5-dichloropyrimidine, using THF instead of DMF.MS (ESI): mass calcd. for C₁₅H₁₁ClF₃N₅O, 369.1; m/z found, 370.0 [M+H]⁺.¹H NMR (500 MHz, CDCl₃) δ 8.51 (s, 2H), 8.11 (t, J=0.7 Hz, 1H), 7.89(dd, J=6.2, 2.7 Hz, 1H), 7.84 (d, J=12.9 Hz, 1H), 7.31 (dd, J=9.8, 8.9Hz, 1H), 5.65 (d, J=0.7 Hz, 2H), 2.05 (td, J=18.6, 1.2 Hz, 3H).

Example 70.2-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-5-isopropyl-pyrimidine

The title compound was prepared in a manner analogous to Example 1 using(1-(3-(1,1-difluoroethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 11) and 2-chloro-5-isopropylpyrimidine, using THF insteadof DMF. MS (ESI): mass calcd. for C₁₅H₈F₃N₅O, 377.1; m/z found, 378.0[M+H]⁺. ¹H NMR (500 MHz, CDCl₃) δ 8.42 (d, J=0.5 Hz, 2H), 8.12 (t, J=0.7Hz, 1H), 7.90 (dd, J=6.2, 2.7 Hz, 1H), 7.87-7.81 (m, 1H), 7.35-7.27 (m,1H), 5.64 (s, 2H), 2.92 (t, J=7.0 Hz, 1H), 2.05 (td, J=18.6, 1.2 Hz,6H), 1.30 (d, J=7.0 Hz, 3H).

Example 71.2-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-5-(trifluoromethyl)pyrimidine

The title compound was prepared in a manner analogous to Example 1 using(1-(3-(1,1-difluoroethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 11) and 2-chloro-5-(trifluoromethyl)pyrimidine, using THFinstead of DMF. MS (ESI): mass calcd. for C₁₆H₁₁FN₅O, 403.1; m/z found,404.0 [M+H]⁺. ¹H NMR (500 MHz, CDCl₃) δ 8.85-8.78 (m, 2H), 8.13 (s, 1H),7.93-7.87 (m, 1H), 7.87-7.81 (m, 1H), 7.36-7.28 (m, 1H), 5.74 (s, 2H),2.05 (td, J=18.6, 1.2 Hz, 3H).

Example 72.5-Ethyl-2-[[1-[4-fluoro-3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]pyrimidine

The title compound was prepared in a manner analogous to Example 1 using(1-(4-fluoro-3-(trifluoromethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 5) and 2-chloro-5-ethylpyrimidine, using THF instead ofDMF. MS (ESI): mass calcd. for C₁₆H₁₃F₄N₅O, 367.1; m/z found, 368.1[M+H]⁺. ¹H NMR (500 MHz, CDCl₃) δ 8.40 (t, J=0.7 Hz, 2H), 8.14 (t, J=0.7Hz, 1H), 8.02-7.98 (m, 1H), 7.98-7.92 (m, 1H), 7.40 (t, J=9.1 Hz, 1H),5.65 (d, J=0.7 Hz, 2H), 2.70-2.54 (m, 2H), 1.27 (t, J=7.6 Hz, 3H)

Example 73.2-[[1-[4-Fluoro-3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]-5-methoxy-pyrimidine

The title compound was prepared in a manner analogous to Example 1 using(1-(4-fluoro-3-(trifluoromethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 5) and 2-chloro-5-methoxypyrimidine, using THF instead ofDMF. MS (ESI): mass calcd. for C₁₅H₁₁F₄N₅O₂, 369.1; m/z found, 370.0[M+H]⁺. ¹H NMR (500 MHz, CDCl₃) δ 8.24 (s, 2H), 8.16-8.09 (m, 1H),8.04-7.98 (m, 1H), 7.99-7.93 (m, 1H), 7.40 (t, J=9.2 Hz, 1H), 5.61 (s,2H), 3.88 (s, 3H).

Example 74.5-Chloro-2-[[1-[4-fluoro-3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]pyrimidine

The title compound was prepared in a manner analogous to Example 1 using(1-(4-fluoro-3-(trifluoromethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 5) and 2,5-dichloropyrimidine, using THF instead of DMF.MS (ESI): mass calcd. for C₁₄H₆ClF₄N₅O, 373.0; m/z found, 374.0 [M+H]⁺.¹H NMR (500 MHz, CDCl₃) δ 8.51 (s, 2H), 8.16-8.11 (m, 1H), 8.04-7.98 (m,1H), 7.98-7.92 (m, 1H), 7.41 (t, J=9.1 Hz, 1H), 5.65 (d, J=0.7 Hz, 2H).

Example 75.2-[[1-[4-Fluoro-3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]-5-isopropyl-pyrimidine

The title compound was prepared in a manner analogous to Example 1 using(1-(4-fluoro-3-(trifluoromethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 5) and 2-chloro-5-isopropylpyrimidine, using THF insteadof DMF. MS (ESI): mass calcd. for C₁₇H₁₅F₄N₅O, 381.1; m/z found, 382.0[M+H]⁺. ¹H NMR (500 MHz, CDCl₃) δ 8.43 (s, 2H), 8.16-8.13 (m, 1H),8.02-7.99 (m, 1H), 7.98-7.93 (m, 1H), 7.40 (t, J=9.1 Hz, 1H), 5.65 (s,2H), 2.98-2.85 (m, 1H), 1.30 (d, J=7.0 Hz, 6H).

Example 76.2-[[1-[4-Fluoro-3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]-5-(trifluoromethyl)pyrimidine

The title compound was prepared in a manner analogous to Example 1 using(1-(4-fluoro-3-(trifluoromethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 5) and 2-chloro-5-(trifluoromethyl)pyrimidine, using THFinstead of DMF. MS (ESI): mass calcd. for C₁₅H₈F₇N₅O, 407.1; m/z found,408.0 [M+H]⁺. ¹H NMR (500 MHz, CDCl₃) δ 8.86-8.79 (m, 2H), 8.15 (s, 1H),8.04-7.98 (m, 1H), 7.98-7.93 (m, 1H), 7.41 (t, J=9.1 Hz, 1H), 5.74 (d,J=0.7 Hz, 2H).

Example 77.2-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-5-methyl-pyrimidine

The title compound was prepared in a manner analogous to Example 1 using(1-(3-(1,1-difluoroethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 11) and 2-chloro-5-methylpyrimidine, using THF instead ofDMF. MS (ESI): mass calcd. for C₁₆H₁₄F₃N₅O, 349.1; m/z found, 350.1[M+H]⁺. ¹H NMR (400 MHz, CDCl₃) δ 8.38 (s, 2H), 8.12 (s, 1H), 7.97-7.78(m, 2H), 7.37-7.27 (m, 1H), 5.64 (d, J=2.9 Hz, 2H), 2.27 (d, J=2.7 Hz,3H), 2.17-1.94 (m, 3H).

Example 78.2-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyrimidine

The title compound was prepared in a manner analogous to Example 1 using(1-(3-(1,1-difluoroethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 11) and 2-chloropyrimidine, using THF instead of DMF. MS(ESI): mass calcd. for C₁₅H₁₂F₃N₅O, 335.1; m/z found, 336.0 [M+H]⁺. ¹HNMR (400 MHz, CDCl₃) δ 8.58 (d, J=4.7 Hz, 2H), 8.13 (d, J=1.1 Hz, 1H),7.93-7.87 (m, 1H), 7.88-7.79 (m, 1H), 7.36-7.27 (m, 1H), 7.01 (t, J=4.7Hz, 1H), 5.67 (d, J=0.9 Hz, 2H), 2.19-1.91 (m, 3H).

Example 79.2-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-4-methyl-pyrimidine

The title compound was prepared in a manner analogous to Example 1 using(1-(3-(1,1-difluoroethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 11) and 2-chloro-4-methylpyrimidine, using THF instead ofDMF. MS (ESI): mass calcd. for C₁₆H₁₄F₃N₅O, 349.1; m/z found, 350.1[M+H]⁺. ¹H NMR (400 MHz, CDCl₃) δ 8.41 (t, J=5.3 Hz, 1H), 8.13 (s, 1H),7.96-7.77 (m, 2H), 7.36-7.28 (m, 2H), 6.86 (d, J=5.3 Hz, 1H), 5.66 (d,J=3.5 Hz, 2H), 2.66-2.31 (m, 2H), 2.05 (t, J=18.3 Hz, 3H)

Example 80.2-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-5-fluoro-pyrimidine

The title compound was prepared in a manner analogous to Example 1 using(1-(3-(1,1-difluoroethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 11) and 2-chloro-5-fluoropyrimidine, using THF instead ofDMF. MS (ESI): mass calcd. for C₁₅H₁₁F₄N₅O, 353.1; m/z found, 354.0[M+H]⁺. ¹H NMR (400 MHz, CDCl₃) δ 8.43 (s, 2H), 8.11 (s, 1H), 7.92-7.87(m, 1H), 7.87-7.81 (m, 1H), 7.31 (t, J=9.4 Hz, 1H), 5.64 (s, 2H),2.16-1.96 (m, 3H).

Example 81.2-[[1-[4-Fluoro-3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]-5-methyl-pyrimidine

The title compound was prepared analogous to Example 155, using(1-(4-fluoro-3-(trifluoromethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 5) and 2-chloro-5-methylpyrimidine, using THF instead ofDMF. MS (ESI): mass calcd. for C₁₅H₁₁F₄N₅O, 353.1; m/z found, 354.0[M+H]⁺. ¹H NMR (400 MHz, CDCl₃) δ 8.39 (d, J=1.2 Hz, 2H), 8.13 (s, 1H),8.04-7.92 (m, 2H), 7.40 (t, J=9.2 Hz, 1H), 5.68-5.60 (m, 2H), 2.34-2.18(m, 3H).

Example 82.2-[[1-[4-Fluoro-3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]pyrimidine

The title compound was prepared analogous to Example 155, using(1-(4-fluoro-3-(trifluoromethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 5) and 2-chloropyrimidine, using THF instead of DMF. MS(ESI): mass calcd. for C₁₄H₉F₄N₅O, 339.1; m/z found, 340.0 [M+H]⁺. ¹HNMR (400 MHz, CDCl₃) δ 8.67-8.54 (m, 2H), 8.15 (s, 1H), 8.08-7.89 (m,2H), 7.40 (t, J=9.2 Hz, 1H), 7.01 (t, J=4.7 Hz, 1H), 5.68 (d, J=0.8 Hz,2H).

Example 83.2-[[1-[4-Fluoro-3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]-4-methyl-pyrimidine

The title compound was prepared analogous to Example 155, using(1-(4-fluoro-3-(trifluoromethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 5) and 2-chloro-4-methylpyrimidine, using THF instead ofDMF. MS (ESI): mass calcd. for C₁₅H₁₁F₄N₅O, 353.1; m/z found, 354.0[M+H]⁺. ¹H NMR (400 MHz, CDCl₃) δ 8.40 (d, J=5.2 Hz, 1H), 8.14 (s, 1H),8.08-7.90 (m, 2H), 7.40 (t, J=9.0 Hz, 1H), 6.87 (d, J=5.1 Hz, 1H), 5.66(d, J=0.8 Hz, 2H), 2.50 (d, J=2.5 Hz, 3H).

Example 84.5-Fuoro-2-[[1-[4-fluoro-3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]pyrimidine

The title compound was prepared analogous to Example 1, using(1-(4-fluoro-3-(trifluoromethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 5) and 2-chloro-5-fluoropyrimidine, using THF instead ofDMF. MS (ESI): mass calcd. for C₁₄H₆F₅N₅O, 357.1; m/z found, 358.0[M+H]⁺. ¹H NMR (400 MHz, CDCl₃) δ 8.44 (d, J=3.1 Hz, 2H), 8.13 (s, 1H),8.07-7.90 (m, 2H), 7.41 (t, J=9.3 Hz, 1H), 5.64 (d, J=3.0 Hz, 2H)

Example 85.2-[[1-(3-Bromo-4-fluoro-phenyl)triazol-4-yl]methoxy]-4,5-dimethyl-pyrimidine

The title compound was prepared in a manner analogous to Example 1 using(1-(3-bromo-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate14) and 2-chloro-4,5-dimethylpyrimidine, using THF instead of DMF. MS(ESI): mass calcd. for C₁₅H₁₃BrFN₅O, 377.0; m/z found, 378.0 [M+H]⁺. ¹HNMR (500 MHz, CDCl₃) δ 8.20 (s, 1H), 8.07 (s, 1H), 7.98 (dd, J=5.8, 2.7Hz, 1H), 7.66 (ddd, J=8.9, 4.1, 2.7 Hz, 1H), 7.30-7.27 (m, 1H), 5.62 (d,J=0.7 Hz, 2H), 2.44 (s, 3H), 2.20 (s, 3H).

Example 86.2-[[1-[4-Chloro-3-(difluoromethyl)phenyl]triazol-4-yl]methoxy]-4,5-dimethyl-pyrimidine

The title compound was prepared in a manner analogous to Example 1 using(1-(4-chloro-3-(difluoromethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 8) and 2-chloro-4,5-dimethylpyrimidine, using THF insteadof DMF. MS (ESI): mass calcd. for C₁₆H₁₄ClF₂N₅O, 365.1; m/z found, 366.0[M+H]⁺. ¹H NMR (500 MHz, CDCl₃) δ 8.22-8.20 (m, 1H), 8.17-8.16 (m, 1H),8.00 (d, J=2.6 Hz, 1H), 7.90-7.86 (m, 1H), 7.62-7.58 (m, 1H), 6.99 (t,J=54.6 Hz, 1H), 5.63 (d, J=0.8 Hz, 2H), 2.45 (s, 3H), 2.20 (s, 3H)

Example 87.2-[1-(4-Chloro-3-methoxy-phenyl)triazol-4-yl]methoxy)-5-methoxy-pyrimidine

The title compound was prepared in a manner analogous to Example 1 using(1-(4-chloro-3-methoxyphenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 15) and 2-chloro-5-methoxypyrimidine, using THF instead ofDMF. MS (ESI): mass calcd. for C₁₅H₁₄ClN₅O₃, 347.1; m/z found, 348.0[M+H]⁺. ¹H NMR (400 MHz, CDCl₃) δ 8.24 (s, 2H), 8.15-8.04 (m, 1H), 7.49(d, J=8.5 Hz, 1H), 7.45 (d, J=2.4 Hz, 1H), 7.16 (dd, J=8.5, 2.4 Hz, 1H),5.60 (s, 2H), 3.99 (s, 3H), 3.88 (s, 3H).

Example 88.2-[[1-(4-Chloro-3-methoxy-phenyl)triazol-4-yl]methoxy]-5-methyl-pyrimidine

The title compound was prepared in a manner analogous to Example 1 using(1-(4-chloro-3-methoxyphenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 15) and 2-chloro-5-methylpyrimidine, using THF instead ofDMF. MS (ESI): mass calcd. for C₁₅H₁₄ClN₅O₂, 331.1; m/z found, 332.1[M+H]⁺. ¹H NMR (400 MHz, CDCl₃) δ 8.38 (s, 2H), 8.23-8.08 (m, 1H), 7.49(d, J=8.5 Hz, 1H), 7.45 (d, J=2.3 Hz, 1H), 7.16 (dd, J=8.5, 2.4 Hz, 1H),5.63 (s, 2H), 3.99 (s, 3H), 2.26 (s, 3H).

Example 89.2-[[1-[3-(Difluoromethyl)phenyl]triazol-4-yl]methoxy]-5-methyl-pyrimidine

The title compound was prepared in a manner analogous to Example 1 using(1-(3-(difluoromethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 12) and 2-chloro-5-methylpyrimidine, using THF instead ofDMF. MS (ESI): mass calcd. for C₁₅H₁₃F₂N₅O, 317.1; m/z found, 318.0[M+H]⁺. ¹H NMR (500 MHz, CDCl₃) δ 8.38 (s, 2H), 8.17 (s, 1H), 7.92-7.89(m, 1H), 7.88-7.85 (m, 1H), 7.66-7.60 (m, 1H), 7.60-7.56 (m, 1H), 6.72(t, J=56.1 Hz, 1H), 5.64 (d, J=0.7 Hz, 2H), 2.28-2.23 (m, 3H).

Example 90.2-[[1-[3-(Difluoromethyl)phenyl]triazol-4-yl]methoxy]-5-methoxy-pyrimidine

The title compound was prepared in a manner analogous to Example 1 using(1-(3-(difluoromethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 12) and 2-chloro-5-methoxypyrimidine, using THF instead ofDMF. MS (ESI): mass calcd. for C₁₅H₁₃F₂N₅O₂, 333.1; m/z found, 334.0[M+H]⁺. ¹H NMR (500 MHz, CDCl₃) δ 8.23 (s, 2H), 8.16 (s, 1H), 7.91-7.89(m, 1H), 7.88-7.85 (m, 1H), 7.65-7.60 (m, 1H), 7.60-7.55 (m, 1H), 6.72(t, J=56.1 Hz, 1H), 5.61 (d, J=0.7 Hz, 2H), 3.87 (s, 3H).

Example 91.2-[[1-[3-(Difluoromethyl)phenyl]triazol-4-yl]methoxy]-5-ethyl-pyrimidine

The title compound was prepared in a manner analogous to Example 1 using(1-(3-(difluoromethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 12) and 2-chloro-5-ethylpyrimidine, using THF instead ofDMF. MS (ESI): mass calcd. for C₁₅H₁₅F₂N₅O, 331.1; m/z found, 332.1[M+H]⁺. ¹H NMR (500 MHz, CDCl₃) δ 8.38 (s, 2H), 8.17 (s, 1H), 7.91-7.88(m, 1H), 7.87-7.83 (m, 1H), 7.64-7.58 (m, 1H), 7.58-7.54 (m, 1H), 6.71(t, J=56.1 Hz, 1H), 5.63 (d, J=0.7 Hz, 2H), 2.59 (q, J=7.7 Hz, 2H), 1.24(t, J=7.6 Hz, 3H).

Example 92.5-Chloro-2-[[1-[3-(difluoromethyl)phenyl]triazol-4-yl]methoxy]pyrimidine

The title compound was prepared in a manner analogous to Example 1 using(1-(3-(difluoromethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 12) and 2,5-dichloropyrimidine, using THF instead of DMFMS (ESI): mass calcd. for C₁₄H₁₀ClF₂N₅O, 337.1; m/z found, 338.1 [M+H]⁺.¹H NMR (500 MHz, CDCl₃) δ 8.50 (s, 2H), 8.17 (s, 1H), 7.92-7.88 (m, 1H),7.88-7.85 (m, 1H), 7.66-7.61 (m, 1H), 7.61-7.57 (m, 1H), 6.72 (t, J=56.1Hz, 1H), 5.64 (d, J=0.6 Hz, 2H).

Example 93.2-[[1-[3-(Difluoromethyl)phenyl]triazol-4-yl]methoxy]pyrimidine

The title compound was prepared in a manner analogous to Example 1 using(1-(3-(difluoromethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 12) and 2-chloropyrimidine, using THF instead of DMF. MS(ESI): mass calcd. for C₁₄H₁₁F₂N₅O, 303.1; m/z found, 304.0 [M+H]⁺. ¹HNMR (500 MHz, CDCl₃) δ 8.56 (d, J=4.8 Hz, 2H), 8.18 (s, 1H), 7.91-7.89(m, 1H), 7.88-7.84 (m, 1H), 7.65-7.60 (m, 1H), 7.59-7.56 (m, 1H), 6.99(t, J=4.8 Hz, 1H), 6.72 (t, J=56.1 Hz, 1H), 5.66 (d, J=0.7 Hz, 2H)

Example 94.2-[[1-(5-Bromo-6-methyl-2-pyridyl)triazol-4-yl]methoxy]-5-methyl-pyrimidine

The title compound was prepared in a manner analogous to Example 1 using(1-(5-bromo-6-methylpyridin-2-yl)-1H-1,2,3-triazol-4-yl)methanol and2-chloro-5-methylpyrimidine, using THF instead of DMF. MS (ESI): masscalcd. for C₁₄H₁₃BrN₆O, 360.0; m/z found 361.0 [M+H]⁺. ¹H NMR (500 MHz,CDCl₃) δ 8.68 (s, 1H), 8.39-8.36 (m, 2H), 8.00-7.96 (m, 1H), 7.91-7.87(m, 1H), 5.63 (d, J=0.8 Hz, 2H), 2.68 (s, 3H), 2.25 (s, 3H).

Example 95.2-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]-5-fluoro-pyrimidine

The title compound was prepared in a manner analogous to Example 1 using(1-(4-chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 1) and 2-chloro-5-fluoropyrimidine. MS (ESI): mass calcd.for C₁₄H₉ClF₃N₅O₂, 371.0; m/z found, 372.1 [M+H]⁺. ¹H NMR (400 MHz,CDCl₃) δ 8.43 (s, 2H), 8.14-8.09 (m, 1H), 7.72-7.66 (m, 1H), 7.64-7.60(m, 1H), 7.59-7.54 (m, 1H), 6.64 (t, J=72.5 Hz, 1H), 5.63 (s, 2H).

Example 96.2-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]-5-(difluoromethyl)pyrimidine

The title compound was prepared in a manner analogous to Example 1 using(1-(4-chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 1) and 2-chloro-5-(difluoromethyl)pyrimidine. MS (ESI):mass calcd. for C₁₅H₁₀ClF₄N₅O₂, 403.1; m/z found, 404.0 [M+H]⁺. ¹H NMR(400 MHz, CDCl₃) δ 8.76-8.63 (m, 2H), 8.22-8.07 (m, 1H), 7.75-7.64 (m,1H), 7.64-7.60 (m, 1H), 7.59-7.54 (m, 1H), 6.73 (t, J=55.6 Hz, 1H), 6.64(t, J=72.5 Hz, 1H), 5.71 (s, 2H).

Example 97.N-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methyl]oxazol-2-amine

The title compound was prepared in a manner analogous to Example 2,using1-(4-chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazole-4-carbaldehydeand oxazol-2-amine. MS (ESI): mass calcd. for C₁₃H₁₀ClF₂N₅O₂, 341.0; m/zfound, 342.0 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃) δ 8.09-7.97 (m, 1H),7.74-7.64 (m, 1H), 7.65-7.51 (m, 2H), 7.22-7.14 (m, 1H), 6.87-6.40 (m,2H), 5.30 (s, 1H), 4.70 (d, J=5.7 Hz, 2H).

Example 98.N-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methyl]pyrimidin-2-amine

The title compound was prepared in a manner analogous Example 3, using1-(4-chloro-3-(difluoromethoxy)phenyl)-4-(chloromethyl)-1H-1,2,3-triazole(Intermediate 4) in Step A and pyrimidin-2-amine in Step B. MS (ESI):mass calcd. for C₁₄H₁₁ClF₂NO, 352.1; m/z found, 353.0 [M+H]⁺. ¹H NMR(400 MHz, CDCl₃) δ 8.33 (d, J=4.8 Hz, 2H), 8.00-7.92 (m, 1H), 7.72-7.68(m, 1H), 7.62-7.57 (m, 1H), 7.56-7.52 (m, 1H), 6.89-6.34 (m, 2H), 4.82(dd, J=6.2, 0.7 Hz, 2H).

Example 99.N-[[1-[3-(Difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methyl]-1-methyl-pyrazol-4-amine

The title compound was prepared in a manner analogous to Example 3,using(1-(3-(difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 9) in Step A and 1-methyl-1H-pyrazol-4-amine in Step B. MS(ESI): mass calcd. for C₁₄H₁₃F₃N₆, 322.1; m/z found, 323.1 [M+H]⁺. ¹HNMR (400 MHz, CDCl₃) δ 3.48 (br s, 1H), 3.80 (s, 3H), 4.37 (s, 2H),6.75-7.10 (m, 2H), 7.17 (s, 1H), 7.32 (br t, J=9.02 Hz, 1H), 7.75-8.05(m, 3H).

Example 100.N-[[1-[3-(Difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methyl]-1-methyl-pyrazol-3-amine

The title compound was prepared in a manner analogous to Example 3,using(1-(3-(difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 9) in Step A and 1-methyl-1H-pyrazol-3-amine in Step B. MS(ESI): mass calcd. for C₁₄H₁₃F₃N₆, 322.1; m/z found, 323.1 [M+H]⁺. ¹HNMR (400 MHz, CDCl₃) δ 3.74 (s, 3H), 4.18 (br s, 1H), 4.56 (br s, 2H),5.58 (br s, 1H), 6.75-7.20 (m, 2H), 7.31 (br t, J=9.02 Hz, 1H),7.72-8.17 (m, 3H)

Example 101.N-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methyl]-1-methyl-pyrazol-3-amine

The title compound was prepared in a manner analogous to Example 3,using(1-(3-(difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 6) in Step A and 1-methyl-1H-pyrazol-3-amine in Step B. MS(ESI): mass calcd. for C₁₄H₁₃F₃N₆O, 338.1; m/z found, 339.1 [M+H]⁺. ¹HNMR (400 MHz, CDCl₃) δ 7.91 (s, 1H), 7.67 (br d, J=4.2 Hz, 1H),7.61-7.48 (m, 1H), 7.33 (t, J=9.5 Hz, 1H), 7.12 (br d, J=1.6 Hz, 1H),6.64 (t, J=72.4 Hz, 1H), 5.57 (d, J=2.1 Hz, 1H), 4.55 (br s, 2H), 4.20(br s, 1H), 3.74 (s, 3H).

Example 102.N-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methyl]-1-methyl-pyrazol-4-amine

The title compound was prepared in a manner analogous to Example 3,using(1-(3-(difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 6) in Step A and 1-methyl-1H-pyrazol-4-amine in Step B. MS(ESI): mass calcd. for C₁₄H₁₃F₃N₆O, 338.1; m/z found, 339.1 [M+H]⁺. ¹HNMR (400 MHz, CDCl₃) δ 7.86 (s, 1H), 7.68 (br d, J=4.6 Hz, 1H),7.61-7.47 (m, 1H), 7.33 (s, 1H), 7.17 (s, 1H), 6.97 (s, 1H), 6.87-6.40(m, 1H), 4.36 (s, 2H), 3.80 (d, J=0.7 Hz, 3H)

Example 103.3-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]-2-methoxy-pyridine

The title compound was prepared in a manner analogous to Example 5 using1-(4-chloro-3-(difluoromethoxy)phenyl)-4-(chloromethyl)-1H-1,2,3-triazole(Intermediate 4) and 2-methoxypyridin-3-ol. MS (ESI): mass calcd. forC₁₆H₁₃ClF₂N₄O₃, 382.1; m/z found, 383.1 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃)δ 8.10 (s, 1H), 7.79 (dd, J=5.0, 1.5 Hz, 1H), 7.75-7.68 (m, 1H),7.66-7.59 (m, 1H), 7.58-7.53 (m, 1H), 7.30 (dd, J=7.8, 1.5 Hz, 1H), 6.85(dd, J=7.8, 5.0 Hz, 1H), 6.63 (t, J=72.5 Hz, 1H), 5.36 (s, 2H), 4.02 (s,3H).

Example 104.5-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]-2-methyl-pyridine

The title compound was prepared in a manner analogous to Example 5 using1-(4-chloro-3-(difluoromethoxy)phenyl)-4-(chloromethyl)-1H-1,2,3-triazole(Intermediate 4) and 6-methylpyridin-3-ol. MS (ESI): mass calcd. forC₁₆H₁₃ClF₂N₄O₂, 366.1; m/z found, 367.1 [M+H]⁺. ¹H NMR (400 MHz CDCl₃) δ8.29 (d, J=3.0 Hz, 1H), 8.08-7.98 (m, 1H), 7.74-7.70 (m, 1H), 7.66-7.61(m, 1H), 7.60-7.55 (m, 1H), 7.30-7.22 (m, 1H), 7.10 (d, J=8.5 Hz, 1H),6.64 (t, J=72.5 Hz, 1H), 5.31 (s, 2H), 2.50 (s, 3H)

Example 105.3-Chloro-2-[[1-[4-chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]pyridine

The title compound was prepared in a manner analogous to Example 5 using1-(4-chloro-3-(difluoromethoxy)phenyl)-4-(chloromethyl)-1H-1,2,3-triazole(Intermediate 4) and 3-chloropyridin-2-ol. MS (ESI): mass calcd. forC₁₅H₁₀Cl₁₂F₂N₄O₂, 386.0; m/z found, 387.0 [M+H]⁺. ¹H NMR (500 MHz,CDCl₃) δ 8.10 (dd, J=4.9, 1.7 Hz, 1H), 8.09-8.08 (m, 1H), 7.74-7.70 (m,1H), 7.67 (dd, J=7.6, 1.7 Hz, 1H), 7.64-7.59 (m, 1H), 7.59-7.55 (m, 1H),6.91 (dd, J=7.6, 4.9 Hz, 1H), 6.64 (t, J=72.6 Hz, 1H), 5.68 (s, 2H).

Example 106.5-Chloro-2-[[1-[4-chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]-3-methoxy-pyridine

The title compound was prepared in a manner analogous to Example 5 using1-(4-chloro-3-(difluoromethoxy)phenyl)-4-(chloromethyl)-1H-1,2,3-triazole(Intermediate 4) and 5-chloro-3-methoxypyridin-2-ol. MS (ESI): masscalcd. for C₁₆H₁₂ClF₂N₄O₃, 416.0; m/z found, 417.0 [M+H]⁺. ¹H NMR (400MHz, CDCl₃) δ 8.07 (s, 1H), 7.72 (d, J=2.2 Hz, 1H), 7.71-7.68 (m, 1H),7.62-7.58 (m, 1H), 7.57-7.53 (m, 1H), 7.06 (d, J=2.1 Hz, 1H), 6.63 (t,J=72.6 Hz, 1H), 5.64 (s, 2H), 3.86 (s, 3H)

Example 107.2-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]-3-fluoro-pyridine

The title compound was prepared in a manner analogous to Example 5 using1-(4-chloro-3-(difluoromethoxy)phenyl)-4-(chloromethyl)-1H-1,2,3-triazole(Intermediate 4) and 3-fluoropyridin-2-ol. MS (ESI): mass calcd. forC₁₅H₁₀ClF₃N₄O₂, 370.0; m/z found, 371.0 [M+H]⁺. ¹H NMR (500 MHz, CDCl₃)δ 8.17-8.06 (m, 1H), 7.97 (dd, J=5.0, 1.5 Hz, 1H), 7.72-7.70 (m, 1H),7.64-7.60 (m, 1H), 7.59-7.55 (m, 1H), 7.40-7.34 (m, 1H), 6.97-6.85 (m,1H), 6.64 (t, J=72.5 Hz, 1H), 5.68 (s, 2H).

Example 108.2-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]-3-methoxy-pyridine

The title compound was prepared in a manner analogous to Example 5 using1-(4-chloro-3-(difluoromethoxy)phenyl)-4-(chloromethyl)-1H-1,2,3-triazole(Intermediate 4) and 3-methoxypyridin-2-ol. MS (ESI): mass calcd. forC₁₆H₁₃ClF₂N₄O₃, 382.1; m/z found, 383.0 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃)δ 8.08 (s, 1H), 7.80-7.74 (m, 1H), 7.72-7.67 (m, 1H), 7.62-7.58 (m, 1H),7.57-7.53 (m, 1H), 7.12-7.07 (m, 1H), 6.93-6.87 (m, 1H), 6.63 (t, J=72.6Hz, 1H), 5.68 (s, 2H), 3.87 (s, 3H)

Example 109.N-[[1-[4-Chloro-3-(difluoromethyl)phenyl]triazol-4-yl]methyl]pyrimidin-2-amine

The title compound was prepared in a manner analogous to Example 6 using(1-(4-chloro-3-(difluoromethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanamine(Intermediate 19) and 2-chloropyrimidine. MS (ESI): mass calcd. forC₁₄H₁₁ClF₂N₆, 336.1; m/z found, 337.0 [M+H]⁺. ¹H NMR (500 MHz, CDCl₃) δ8.34 (d, J=4.8 Hz, 2H), 8.00 (s, 1H), 7.98 (d, J=2.6 Hz, 1H), 7.89-7.85(m, 1H), 7.61-7.57 (m, 1H), 6.98 (t, J=54.6 Hz, 1H), 6.61 (t, J=4.8 Hz,1H), 5.69 (s, 1H), 4.83 (dd, J=6.2, 0.7 Hz, 2H).

Example 110.N-[[1-[4-Chloro-3-(difluoromethyl)phenyl]triazol-4-yl]methyl]pyrimidin-4-amine

The title compound was prepared in a manner analogous to Example 6 using(1-(4-chloro-3-(difluoromethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanamine(Intermediate 19) and 4-chloropyrimidine. MS (ESI): mass calcd. forC₁₄H₁₁ClF₂N₆, 336.1; m/z found, 337.0 [M+H]⁺. ¹H NMR (500 MHz, CDCl₃) S8.65 (s, 1H), 8.20 (d, J=6.0 Hz, 1H), 8.02 (s, 1H), 8.00 (d, J=2.6 Hz,1H), 7.88-7.84 (m, 1H), 7.63-7.58 (m, 1H), 6.99 (t, J=54.5 Hz, 1H), 6.44(dd, J=6.0, 1.3 Hz, 1H), 5.54 (s, 1H), 4.81 (d, J=5.8 Hz, 2H).

Example 111.2-[[1-[3-(Difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyridine

The title compound was prepared in a manner analogous to Intermediate 7using(1-(3-(difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 9) and 2-fluoropyridine. MS (ESI): mass calcd. forC₁₅H₁₁F₃N₄O, 320.1; m/z found, 321.1 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃) δ5.62 (s, 2H), 6.73-7.15 (m, 3H), 7.33 (t, J=8.90 Hz, 1H), 7.55-7.73 (m,1H), 7.84-8.01 (m, 2H), 8.09 (s, 1H), 8.15-8.30 (m, 1H).

Example 112.5-Chloro-2-[[1-[3-(difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyridine

The title compound was prepared in a manner analogous to Intermediate 7using(1-(3-(difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 9) and 5-chloro-2-fluoropyridine. MS (ESI): mass calcd.for C₁₅H₁₀ClF₃N₄O, 354.0; m/z found, 355.1 [M+H]⁺. ¹H NMR (400 MHz,CDCl₃) δ 5.57 (s, 2H), 6.77 (d, J=8.8 Hz, 1H), 6.80-7.13 (m, 1H), 7.33(t, J=9.0 Hz, 1H), 7.56 (dd, J=8.8, 2.5 Hz, 1H), 7.84-7.98 (m, 2H), 8.07(s, 1H), 8.15 (d, J=2.5 Hz, 1H).

Example 113.2-[[1-[3-(Difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-6-methyl-pyridine

Step A.2-Bromo-6-((1-(3-(difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyridine

The title compound was prepared in a manner analogous to Intermediate 7using(1-(3-(difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 9) and 2-bromo-6-fluoropyridine.

Step B.2-[[1-[3-(Difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-6-methyl-pyridine

To a solution of2-bromo-6-((1-(3-(difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyridine(25 mg, 0.06 mmol), Cs₂CO₃ (41 mg, 0.12 mmol), in 1,4 dioxane (0.65 mL)was added 2,4,6-trimethyl-1,3,5,2,4,6-trioxatriborinane (0.01 mL, 0.07mmol) and(2-dicyclohexylphosphino-2′,4′,6′-triisopropyl-1,1′-biphenyl)[2-(2′-amino-1,1′-biphenyl)]palladium(II)methanesulfonate (Xphos Palladacycle Gen. 3) (5.3 mg, 0.006 mmol). Thereaction mixture was heated under microwave irradiation at 120° C. for12 minutes. The mixture was concentrated in vacuo. Purification (FCC,SiO₂, EtOAc in heptane from 0-100%). Purification (RP HPLC, Stationaryphase: C18 XBridge 30×100 mm 5 um, Mobile phase: Gradient from 90% 10 mMNH₄CO₃H pH 9 solution in Water, 10% CH₃CN to 0% 10 mM NH₄CO₃H pH 9solution in Water, 100% CH₃CN) afforded the title compound (46 mg, 68%).MS (ESI): mass calcd. for C₁₆H₁₃F₃N₄O, 334.1; m/z found, 335.1 [M+H]⁺.¹H NMR (400 MHz, CDCl₃) δ 2.49 (s, 3H), 5.60 (s, 2H), 6.61 (d, J=8.3 Hz,1H), 6.77 (d, J=7.4 Hz, 1H), 6.81-7.14 (m, 1H), 7.33 (t, J=9.0 Hz, 1H),7.49 (t, J=7.6 Hz, 1H), 7.83-7.99 (m, 2H), 8.08 (s, 1H).

Example 114.2-[[1-[3-(Difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-5-methyl-pyridine

The title compound was prepared in a manner analogous to Example 1 using(1-(3-(difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 9) and 2-fluoro-5-methylpyridine. MS (ESI): mass calcd.for C₁₆H₁₃F₃N₄O, 334.1; m/z found, 335.1 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃)δ 2.27 (s, 3H), 5.58 (s, 2H), 6.73 (d, J=8.3 Hz, 1H), 6.79-7.16 (m, 1H),7.33 (t, J=9.0 Hz, 1H), 7.43 (dd, J=8.4, 1.97 Hz, 1H), 7.84-7.97 (m,2H), 8.01 (s, 1H), 8.08 (s, 1H)

Example 115.2-[[1-[3-(Difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-4-methyl-pyridine

Step A.4-Bromo-2-((1-(3-(difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyridine

The title compound was prepared in a manner analogous to Intermediate 7using(1-(3-(difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 9) and 4-bromo-2-fluoropyridine.

Step B.2-[[1-[3-(Difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-4-methyl-pyridine

The title compound was prepared in a manner analogous to Example 113step B, using4-bromo-2-((1-(3-(difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyridine.MS (ESI): mass calcd. for C₁₆H₁₃F₃N₄O, 334.1; m/z found, 335.1 [M+H]⁺.¹H NMR (400 MHz, CDCl₃) δ 2.31 (s, 3H), 5.60 (s, 2H), 6.63 (s, 1H), 6.76(d, J=5.1 Hz, 1H), 6.80-7.12 (m, 1H), 7.33 (t, J=9.0 Hz, 1H), 7.80-7.98(m, 2H), 8.02-8.20 (m, 2H).

Example 116.2-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]-4-methyl-pyridine

Step A.4-Bromo-2-((1-(3-(difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyridine

The title compound was prepared in a manner analogous to Intermediate 7using(1-(3-(difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 6) and 4-bromo-2-fluoropyridine.

Step B.2-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]-4-methyl-pyridine

The title compound was prepared in a manner analogous to Example 113step B, using4-bromo-2-((1-(3-(difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyridine.MS (ESI): mass calcd. for C₁₆H₁₃F₃N₄O₂, 350.1; m/z found, 351.1 [M+H]⁺.¹H NMR (500 MHz, CDCl₃) δ 2.30 (s, 3H), 5.58 (s, 2H), 6.42-6.84 (m, 3H),7.33 (t, J=9.25 Hz, 1H), 7.58 (ddd, J=8.96, 3.90, 2.75 Hz, 1H), 7.68(dd, J=6.65, 2.60 Hz, 1H), 8.02 (s, 1H), 8.05 (d, J=5.20 Hz, 1H).

Example 117.5-Chloro-2-[[1-[3-(difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyridine

The title compound was prepared in a manner analgous to Example 1 using(1-(3-(difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 6) and 5-chloro-2-fluoropyridine. HRMS=370.044; ¹H NMR(500 MHz, CDCl₃) δ 5.57 (s, 2H), 6.46-6.87 (m, 2H), 7.35 (t, J=9.25 Hz,1H), 7.49-7.63 (m, 2H), 7.70 (dd, J=6.65, 2.60 Hz, 1H), 8.03 (s, 1H),8.15 (d, J=2.60 Hz, 1H).

Example 118.2-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]-5-methyl-pyridine

Step A.5-Chloro-2-((1-(3-(difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyridine

The title compound was prepared in a manner analogous to Intermediate 7using(1-(3-(difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 6) and 5-chloro-2-fluoropyridine.

Step B.2-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]-5-methyl-pyridine

The title compound was prepared in a manner analogous to Example 113step B, using5-chloro-2-((1-(3-(difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyridine.MS (ESI): mass calcd. for C₁₆H₁₃F₃N₄O₂, 350.1; m/z found, 351.1 [M+H]⁺.¹H NMR (500 MHz, CDCl₃) δ 2.26 (s, 3H), 5.56 (s, 2H), 6.44-6.81 (m, 2H),7.33 (t, J=9.25 Hz, 1H), 7.42 (dd, J=8.38, 2.02 Hz, 1H), 7.58 (ddd,J=8.81, 3.90, 2.89 Hz, 1H), 7.68 (dd, J=6.65, 2.60 Hz, 1H), 7.94-8.01(m, 1H), 8.03 (s, 1H).

Example 119.2-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]-5-(trifluoromethyl)pyridine

The title compound was prepared in a manner analogous to Intermediate 7using(1-(3-(difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 6) and 2-fluoro-5-(trifluoromethyl)pyridine. HRMS=404.070;¹H NMR (500 MHz, CDCl₃) δ 5.65 (s, 2H), 6.45-6.81 (m, 1H), 6.89 (d,J=8.96 Hz, 1H), 7.34 (t, J=9.25 Hz, 1H), 7.52-7.63 (m, 1H), 7.70 (dd,J=6.36, 2.60 Hz, 1H), 7.81 (dd, J=8.81, 2.17 Hz, 1H), 8.05 (s, 1H),8.37-8.58 (m, 1H).

Example 120-Example 152 may be prepared in a manner analogous to themethods described in the previous examples.

Example 120.5-Methyl-2-((1-(5-(trifluoromethyl)thiophen-2-yl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidine

MS (ESI): mass calcd. for C₁₃H₁₀F₃N₅OS, 341.06

Example 121.5-Methyl-2-((1-(4-(trifluoromethyl)thiophen-2-yl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidine

MS (ESI): mass calcd. for C₁₃H₁₀F₃N₅OS, 341.06

Example 122.2-((1-(3-(Difluoromethyl)-2-fluorophenyl-1H-1,2,3-triazol-4-yl)methoxy)-5-methylpyrimidine

MS (ESI): mass calcd. for C₁₅H₁₂F₃N₅O, 335.10

Example 123.2-((1-(4-Chlorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-5-methylpyrimidine

MS (ESI): mass calcd. for C₁₄H₁₂ClN₅O, 301.07

Example 124.2-((1-(4-Chloro-3-(oxetan-3-yl)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)-5-methylpyrimidine

MS (ESI): mass calcd. for C₁₇H₁₆ClN₅O₂, 357.10

Example 125.2-((1-(4-Chloro-3-(difluoromethyl)phenyl)-5-fluoro-1H-1,2,3-triazol-4-yl)methoxy)-5-methylpyrimidine

MS (ESI): mass calcd. for C15H11ClF3N5O, 369.06

Example 126.2-((1-(4-Chloro-3-(difluoromethyl)phenyl)-5-(trifluoromethyl)-1H-1,2,3-triazol-4-yl)methoxy)-5-methylpyrimidine

MS (ESI): mass calcd. for C₁₆H₁₁ClF₅N₅O, 419.06

Example 127.2-((1-(4-Chloro-3-(difluoromethyl)phenyl)-5-methyl-1H-1,2,3-triazol-4-yl)methoxy)-5-methylpyrimidine

MS (ESI): mass calcd. for C₁₆H₁₄ClF₂N₅O, 365.09

Example 128.2-((1-(4-Chloro-3-(difluoromethyl)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)-5-methylthiazole

MS (ESI): mass calcd. for C₁₄H₁₁ClF₂N₄OS, 356.03.

Example 129.1-(4-Chloro-3-(difluoromethyl)phenyl)-4-(((5-methyl-1H-imidazol-2-yl)oxy)methyl)-1H-1,2,3-triazole

MS (ESI): mass calcd. for C₁₄H₁₂ClF₂N₅O, 339.07

Example 130.2-((1-(4-Chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)-5-methylpyridine

MS (ESI): mass calcd. for C₁₆H₁₃ClF₂N₄O₂, 366.07

Example 131.2-((1-(4-Chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methoxy-6-methylpyridine

MS (ESI): mass calcd. for C₁₆H₁₃ClF₂N₄O₂, 366.07

Example 132.6-((1-(4-Chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)-2,3-dimethylpyridine

MS (ESI): mass calcd. for C₁₇H₁₅ClF₂N₄O₂, 380.09

Example 133.2-((1-(4-Chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)-6-methylpyrazine

MS (ESI): mass calcd. for C₁₅H₁₂ClF₂N₅O₂, 367.06

Example 134.5-((1-(4-Chloro-3-(difluoromethoxy)phenyl-1H-1,2,3-triazol-4-yl)methoxy)-2,3-dimethylpyrazine

MS (ESI): mass calcd. for C₁₆H₁₄ClF₂N₅O₂, 381.08

Example 135.5-((1-(4-Chloro-3-(difluoromethoxy)phenyl-1H-1,2,3-triazol-4-yl)methoxy)-2-methylpyrimidine

MS (ESI): mass calcd. for C₁₅H₁₂ClF₂N₅O₂, 367.06

Example 136.6-((1-(4-Chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)-3,4-dimethylpyridazine

MS (ESI): mass calcd. for C₁₆H₁₄ClF₂N₅O₂, 381.08

Example 137.3-((1-(4-Chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)-6-(trifluoromethyl)pyridazine

MS (ESI): mass calcd. for C₁₅H₉ClF₅N₅O₂, 421.04r

Example 138.3-((1-(4-Chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)-6-methoxypyridazine

MS (ESI): mass calcd. for C₁₅H₁₂ClF₂N₅O₃, 383.06

Example 139.4-((1-(4-Chloro-3-(difluoromethoxy)phenyl-1H-1,2,3-triazol-4-yl)methoxy-2-methylpyrimidine

MS (ESI): mass calcd. for C₁₅H₁₂ClF₂N₅O₂, 367.06

Example 140.4-((1-(4-Chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)-2-(trifluoromethyl)pyrimidine

MS (ESI): mass calcd. for C₁₅H₉ClF₅N₅O₂, 421.04

Example 141.4-((1-(4-Chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)-2-methoxypyrimidine

MS (ESI): mass calcd. for C₁₅H₁₂ClF₂N₅O₃, 383.06

Example 142.2-((1-(5-Chloro-6-(trifluoromethyl)pyridin-2-yl)-1H-1,2,3-triazol-4-yl)methoxy)-5-methylpyrimidine

MS (ESI): mass calcd. for C₁₄H₁₀ClF₃N₆O, 370.06

Example 143.2-((1-(2-(Difluoromethyl)pyridin-4-yl)-1H-1,2,3-triazol-4-yl)methoxy)-5-methylpyrimidine

MS (ESI): mass calcd. for C₁₄H₁₂F₂N₆O, 318.10

Example 144.N-((1-(4-Chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methyl)-5-methylpyrimidin-2-amine

MS (ESI): mass calcd. for C₁₅H₁₃ClF₂N₆O, 366.08

Example 145.N-((1-(4-Chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methyl)-4,5-dimethylpyrimidin-2-amine

MS (ESI): mass calcd. for C₁₆H₁₅CIF₂N₆O, 380.10

Example 146.3-((1-(4-Chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)-4-methoxypyridine.

MS (ESI): mass calcd. for C₁₆H₁₃CIF₂N₄O₃, 382.1

Example 147.4-Chloro-3-((1-(4-chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyridine

MS (ESI): mass calcd. for C₁₅H₁₀Cl₂F₂N₄O₂, 386.0

Example 148.4-((1-(3-(Difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)-5-methoxypyrimidine

MS (ESI): mass calcd. for C₁₅H₁₃F₂N₅O₃, 349.1

Example 149.2-((1-(3-(Difluoromethyl)phenyl)-5-1H-1,2,3-triazol-4-yl)methoxy)-5-methoxypyrimidine

MS (ESI): mass calcd. for C₁₆H₁₃F₂N₅O, 331.1

Example 150.5-Methyl-2-((1-(5-(trifluoromethyl)pyridin-2-yl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidine

MS (ESI): mass calcd. for C₁₆H₁₅F₂N₅O, 336.1

Example 151.2-((1-(5-Bromo-6-fluoropyridin-3-yl)-1H-1,2,3-triazol-4-yl)methoxy)-5-methylpyrimidine

MS (ESI): mass calcd. for C₁₃H₁₀BrFN₆O, 364.0

Example 152.5-Methyl-2-((1-(pyridin-4-yl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidine

MS (ESI): mass calcd. for C₁₃H₁₂N₆O, 268.1

Example 153:5-Chloro-N-[[1-[3-(difluoromethyl)phenyl]triazol-4-yl]methyl]pyrimidin-2-amine

To a solution of4-(chloromethyl)-1-(3-(difluoromethyl)phenyl)-1H-1,2,3-triazole (25 mg,0.103 mmol) and 2-amino-5-chloropyrimidine (17 mg, 0.13 mmol) in DMF(1.5 mL) was added K₂CO₃ (57 mg, 0.41 mmol). The resulting mixture wasstirred at 100° C. for 72 h. The reaction mixture was diluted with water(8 mL) and extracted with EtOAc (3×10 mL). The combined organics weredried over Na₂SO₄, filtered, and concentrated under reduced pressure.Purification (FCC, SiO₂, 0-80% EtOAc/hexanes) afforded the titlecompound (6.2 mg, 18%). MS (ESI): mass calcd. for C₁₄H₁₁ClF₂NS, 336.07;m/z found, 337.0 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃) δ 8.33-8.19 (m, 2H),8.03-7.95 (m, 1H), 7.91-7.80 (m, 2H), 7.68-7.54 (m, 2H), 6.72 (t, J=56.1Hz, 1H), 5.85 (s, 1H), 4.80 (dd, J=6.2, 0.6 Hz, 2H).

Example 154:N-[[1-[4-Chloro-3-(difluoromethyl)phenyl]triazol-4-yl]methyl]-5-methyl-pyrimidin-2-amine

A solution of(1-(4-chloro-3-(difluoromethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanamine(Intermediate 19) (35 mg, 0.14 mmol), 2-chloro-5-methylpyrimidine (22.6mg, 0.18 mmol), and triethylamine (0.06 mL, 0.4 mmol) in EtOH (1 mL) wassealed and heated in a microwave reactor for 1 h at 180° C., then 200°C. for 1 h. The mixture was concentrated under reduced pressure.Purification (FCC, SiO₂, MeOH/DCM 0-8%) afforded the title compound (8.3mg, 17%). MS (ESI): mass calcd. for C₁₅H₁₃ClF₂N₆, 350.1; m/z found,351.0 [M+H]⁺. ¹H NMR (500 MHz, CDCl₃) δ 8.19 (s, 2H), 7.99 (s, 1H), 7.97(d, J=2.6 Hz, 1H), 7.87 (dd, J=8.7, 2.6 Hz, 1H), 7.61-7.57 (m, 1H), 6.98(t, J=54.6 Hz, 1H), 5.69 (s, 1H), 4.81 (d, J=6.2 Hz, 2H), 2.16 (s, 3H).

Example 155:2-[[1-[3-(Difluoromethyl)phenyl]triazol-4-yl]methoxy]-4,5-dimethyl-pyrimidine

To a solution of(1-(3-(difluoromethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 12, 50 mg, 0.22 mmol) in THF (1 mL) was added NaH (60%dispersion in mineral oil, 26.6 mg, 0.67 mmol). The mixture was stirredfor 5 min, then 2-chloro-4,5-dimethylpyrimidine (38 mg, 0.27 mmol) wasadded. The reaction was stirred at rt overnight. The mixture wasquenched with H₂O, and diluted with EtOAc and H₂O. The layers wereseparated and the aqueous layer was extracted with EtOAc (3×). Thecombined organic layers were dried (Na₂SO₄) and concentrated underreduced pressure. Purification (FCC, SiO₂, EtOAc/hexanes 0-50%) affordedthe title compound (44 mg, 60%). MS (ESI): mass calcd. for C₁₆H₁₅F₂N₅O,331.1; m/z found, 332.1 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃) δ 8.23-8.12 (m,2H), 7.93-7.83 (m, 2H), 7.67-7.54 (m, 2H), 6.72 (t, J=56.0 Hz, 1H), 5.64(s, 2H), 2.44 (s, 3H), 2.20 (s, 3H).

Example 156:1-[2-[[1-[3-(Difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyrimidin-5-yl]ethanone

A solution of(1-(3-(difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 9, 110 mg, 0.41 mmol), Cs₂CO₃ (535.9 mg, 1.64 mmol), and1-(2-chloropyrimidin-5-yl)ethan-1-one (83.6 mg, 0.53 mmol) in ACN (0.02mL) was heated at 110° C. overnight. The reaction mixture was cooled,diluted with EtOAc, and washed with sat aq. NH₄Cl. The organic layer wasdried (Na₂SO₄), filtered, and concentrated under reduced pressure.Purification (FCC, SiO₂, 0-50% EtOAc in hexanes) afforded the titlecompound (12 mg, 8%). MS (ESI): mass calcd. for C₁₆H₁₂F₃N₅O₂, 363.1; m/zfound, 364.1 [M+H]⁺. ¹H NMR (500 MHz, CDCl₃) δ 9.14-9.05 (s, 2H),8.19-8.11 (s, 1H), 7.98-7.87 (m, 2H), 7.40-7.31 (m, 1H), 7.09-6.80 (t,J=54.6 Hz, 1H), 5.80-5.71 (s, 2H), 2.66-2.57 (s, 3H).

Example 157:(R/S)-1-[2-[[1-[3-(Difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyrimidin-5-yl]ethanol

A solution of1-(2-((1-(3-(difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidin-5-yl)ethan-1-one(Example 156, 14 mg, 0.04 mmol) in DCM/MeOH (15 mL/1 mL) is cool to 0°C. Sodium borohydride (4.4 mg, 0.12 mmol) was added in a single portionand the reaction mixture was stirred at 0° C. for 1 h. The completedreaction was quenched with water and extracted into DCM (5 mL×3). Theorganic layer is dried (Na₂SO₄), filtered, and concentrated.Purification (FCC, SiO₂, eluting with 0-3% MeOH in DCM) afforded thetitled compound (7 mg, 50%). MS (ESI): mass calcd. for C₁₆H₁₄F₃N₅O₂,365.1; m/z found, 366.0 [M+H]⁺. ¹H NMR (500 MHz, CDCl₃) δ 8.61-8.55 (s,2H), 8.17-8.13 (s, 1H), 7.98-7.93 (m, 1H), 7.93-7.87 (m, 1H), 7.37-7.29(m, 1H), 7.08-6.80 (t, J=54.6 Hz, 1H), 5.76-5.56 (d, J=0.7 Hz, 2H),5.10-4.86 (m, 1H), 1.64-1.50 (d, J=6.5 Hz, 3H). OH proton not observed.

Example 158:2-[[1-[4-Fluoro-3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]pyridine

A stirred suspension of(1-(4-fluoro-3-(trifluoromethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 5, 30 mg, 0.115 mmol), 2-chloropyridine (19.5 mg, 0.172mmol), Cs₂CO₃ (75 mg, 0.23 mmol) and 2-(di-tert-butylphosphino)biphenyl(69 mg, 0.23 mmol) in toluene (2 mL) was charged with palladium (II)acetate (3 mg, 0.012 mmol). The mixture was stirred at 120° C. for 4 hunder a nitrogen atmosphere. The completed reaction was filtered througha pad of diatomaceous earth and washed with EtOAc. The organics wereconcentrated under reduced pressure. Purification (FCC, SiO₂, 0-100%EtOAc in Hexanes) afforded the titled compound (18 mg, 47%). MS (ESI):mass calcd. for C₁₅H₁₀F₄N₄O, 338.1; m/z found, 339.0 [M+H]⁺. ¹H NMR (500MHz, CDCl₃) δ 8.23-8.18 (m, 1H), 8.09 (t, J=0.7 Hz, 1H), 8.03-7.97 (m,1H), 7.98-7.92 (m, 1H), 7.65-7.58 (m, 1H), 7.39 (t, J=9.1 Hz, 1H),6.95-6.89 (m, 1H), 6.85-6.78 (m, 1H), 5.61 (d, J=0.7 Hz, 2H).

Example 159:[2-[[1-[3-(Difluoromethyl)phenyl]triazol-4-yl]methoxy]pyrimidin-4-yl]methanol

Step A.4-(((tert-Butyldimethylsilyl)oxy)methyl)-2-((1-(3-(difluoromethyl)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidine

The title compound was prepared analogous to Example 155, using4-(((tert-butyldimethylsilyl)oxy)methyl)-2-chloropyrimidine(Intermediate 54).

Step B.[2-[[1-[3-(Difluoromethyl)phenyl]triazol-4-yl]methoxy]pyrimidin-4-yl]methanol

To a solution of4-(((tert-butyldimethylsilyl)oxy)methyl)-2-((1-(3-(difluoromethyl)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidine(78 mg, 0.17 mmol) in THF (2 mL) was added TBAF (1 M in THF, 0.2 mL, 0.2mmol). The reaction was stirred at rt for 15 minutes, then quenched witha saturated solution of NH₄Cl and diluted with EtOAc. The layers wereseparated and the organic layer was dried (Na₂SO₄) then concentratedunder reduced pressure. Purification (FCC, SiO₂, EtOAc/hexanes 0-80%)afforded the title compound (26 mg, 39%). MS (ESI): mass calcd. forC₁₅H₁₃F₂N₅O₂, 333.1; m/z found, 334.1 [M+H]⁺. ¹H NMR (500 MHz, CDCl₃) δ8.50 (d, J=5.0 Hz, 1H), 8.19 (s, 1H), 7.91-7.89 (m, 1H), 7.88-7.84 (m,1H), 7.65-7.60 (m, 1H), 7.60-7.56 (m, 1H), 7.02 (d, J=5.1 Hz, 1H), 6.72(t, J=56.1 Hz, 1H), 5.67 (d, J=0.7 Hz, 2H), 4.73 (d, J=4.5 Hz, 2H), 3.33(t, J=5.4 Hz, 1H)

Example 160:[2-[[1-[3-(Difluoromethyl)phenyl]triazol-4-yl]methoxy]pyrimidin-5-yl]methanol

The title compound was prepared analogous to Example 159, using5-(((tert-butyldimethylsilyl)oxy)methyl)-2-chloropyrimidine(Intermediate 53) in Step A. MS (ESI): mass calcd. for C₁₅H₁₃F₂N₅O₂,333.1; m/z found, 334.1 [M+H]⁺. ¹H NMR (500 MHz, CDCl₃) δ 8.54 (s, 2H),8.18 (s, 1H), 7.92-7.88 (m, 1H), 7.88-7.83 (m, 1H), 7.65-7.59 (m, 1H),7.58-7.55 (m, 1H), 6.71 (t, J=56.1 Hz, 1H), 5.63 (d, J=0.7 Hz, 2H), 4.67(s, 2H), 2.88 (s, 1H).

Example 161:2-[[1-[3-(Difluoromethyl)phenyl]triazol-4-yl]methoxy]-5-methyl-pyrimidin-4-amine

(1-(3-(Difluoromethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 12, 26 mg, 0.12 mmol),2-chloro-5-methylpyrimidin-4-amine(20 mg, 0.14 mmol), and Cs₂CO₃ (113 mg, 0.35 mmol) were dissolved in ACN(0.7 mL) in a microwave vial. The reaction was heated in a microwavereactor at 140° C. for 2 h. The reaction was cooled to rt, diluted withEtOAC and H₂O, then the layers were separated and the aqueous layer wasextracted with EtOAc (3×). The combined organic layers were dried(Na₂SO₄), and concentrated under reduced pressure. Purification (FCC,SiO₂, EtOAC/hexanes 0-70%) afforded the title compound (13.4 mg, 29%).MS (ESI): mass calcd. for C₁₅H₁₄F₂N₆O, 332.1; m/z found, 333.0 [M+H]⁺.¹H NMR (500 MHz, CDCl₃) δ 8.15 (s, 1H), 7.93-7.82 (m, 3H), 7.66-7.54 (m,2H), 6.71 (t, J=56.1 Hz, 1H), 5.55 (s, 2H), 5.02 (s, 2H), 2.07-1.99 (m,3H)

Example 162:2-[[1-[3-(Difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-N-methyl-pyrimidine-4-carboxamide

Step A:2-((1-(3-(difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidine-4-carboxylicacid

The title compound was prepared in a manner analogous to Example 161,using(1-(3-(difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 9) and methyl 2-chloropyrimidine-4-carboxylate. MS (ESI):mass calcd. for C₁₅H₁₀F₃N₅O₃, 335.1; m/z found, 366.0[M+H]⁺.

Step B:2-[[1-[3-(Difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-N-methyl-pyrimidine-4-carboxamide

To solution of2-((1-(3-(difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidine-4-carboxylicacid (15 mg, 0.041 mmol), methylamine (1.5 mg, 0.045 mmol), EDCl (16 mg,0.082 mmol), and HOBt (11 mg, 0.082 mmol) in DCM (3 mL) was added DIEA(21 μL, 0.123 mmol). The resulting mixture was stirred at rt overnight.The reaction mixture was diluted with DCM and washed with water andbrine. The organic layer was dried (Na₂SO₄), filtered, and concentratedunder reduced pressure. Purification (FCC, SiO₂, 0-80% EtOAc/Hexanes)afforded the title compound (6.1 mg, 39%). MS (ESI): mass calcd. forC₁₆H₁₃F₃N₆O₂, 378.1; m/z found, 379.0 [M+H]⁺. ¹H NMR (500 MHz, CDCl₃) δ8.77 (d, J=4.9 Hz, 1H), 8.17-8.09 (m, 2H), 7.98-7.92 (m, 1H), 7.93-7.86(m, 1H), 7.82-7.75 (m, 1H), 7.39-7.30 (m, 1H), 6.95 (t, J=54.6 Hz, 1H),5.70 (d, J=0.6 Hz, 2H), 3.06 (d, J=5.1 Hz, 3H).

Example 163: (R/S)1-[2-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyrimidin-4-yl]ethanamine

Step. A. (R/S) tert-Butyl (1-(2-chloropyrimidin-4-yl)ethyl)carbamate

Under a nitrogen atmosphere was added NaH (60% dispersion in mineraloil, 154 mg, 3.8 mmol) in small batches to a mixture of tert-butyl((2-chloropyrimidin-4-yl)methyl)carbamate (Intermediate 58, 720 mg, 3.0mmol) in DMF (50 mL) at room temperature. After 30 minutes, MeI (0.22mL, 3.5 mmol) was added at 0° C. After 16 h, complete conversion wasobserved. EtOAc (200 mL) was added. The mixture was washed with brine(1×350 mL). The organic was dried (MgSO₄), filtered, and concentratedunder vacuum. Purification (FCC, SiO₂, 0-99% EtOAc/hexanes) afforded thetitle compound (299 mg, 39%). MS (ESI): mass calcd. for C₁₁H₁₆ClN₃O₂,257.1; m/z found, 201.9 [M-t-Bu]⁺.

Step B. (R/S) tert-Butyl(1-(2-((1-(3-(difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidin-4-yl)ethyl)carbamate

The title compound was prepared in a manner analogous to Example 1 using(1-(3-(difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 6) and R/S tert-butyl(1-(2-chloropyrimidin-4-yl)ethyl)carbamate, using THF instead of DMF. MS(ESI): mass calcd. for C₂₁H₂₃F₃N₆O₄, 480.1; m/z found, 480.9 [M+H].

Step C. (R/S)1-[2-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyrimidin-4-yl]ethanamineas the trifluoroacetic acid salt

TFA (0.04 mL, 0.5 mmol) was added to a mixture of (R/S) tert-butyl(1-(2-((1-(3-(difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidin-4-yl)ethyl)carbamate(13 mg, 0.03 mmol) in DCM (5 mL). Upon completion, the reaction mixturewas concentrated under reduced pressure. Purification (HPLC METHOD E)afforded the title compound (3.6 mg, 35%). MS (ESI): mass calcd. forC₁₆H₁₅F₃N₆O₂, 380.1; m/z found, 381.0 [M+H]⁺. ¹H NMR (500 MHz, CD₂Cl₂)δ8.47 (d, J=5.1 Hz, 1H), 8.21 (s, 1H), 7.72 (dd, J=6.7, 2.6 Hz, 1H),7.60 (ddd, J=9.0, 3.9, 2.7 Hz, 1H), 7.37 (dd, J=9.7, 8.9 Hz, 1H), 7.03(d, J=5.0 Hz, 1H), 6.69 (t, J=72.8 Hz, 1H), 5.63-5.57 (m, 2H), 4.04 (q,J=6.8 Hz, 1H), 1.39 (d, J=6.7 Hz, 3H).

Example 164:5-Chloro-2-[[1-(4-fluorophenyl)triazol-4-yl]methoxy]pyrimidine. as theTrifluoroacetic Acid Salt

A microwave vial was charged with2-((1-(3-bromo-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-5-chloropyrimidine(Example 42, 25 mg, 0.07 mmol), azetidine (0.005 mL, 0.08 mmol),trans-bis(acetato)bis[o-(di-o-tolylphosphino)benzyl]dipalladium(II) (6mg, 0.007 mmol), molybdenum hexacarbonyl (17 mg, 0.07 mmol), DBU (0.01mL, 0.08 mmol) and THF (0.5 mL), purged with nitrogen, and heated to150° C. under microwave irradiation for 20 minutes. The reaction mixturewas concentrated under vacuum. Purification (FCC, SiO₂, 0-99% EtOAc inhexanes), followed by reversed phase HPLC (METHOD E) afforded the titlecompound (7 mg, 25%) as a by-product. MS (ESI): mass calcd. forC₁₃H₁₀ClFN₅O, 305.1; m/z found, 306.1 [M+H]⁺. ¹H NMR (500 MHz, DMSO-d₆)δ 8.89 (s, 1H), 8.77-8.75 (m, 2H), 7.98-7.93 (m, 2H), 7.49-7.42 (m, 2H),5.54 (s, 2H).

Example 165:5-(Azetidin-1-yl)-2-[[1-[3-(difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyrimidine

Step A. 5-(Azetidin-1-yl)-2-(methylthio)pyrimidine

A mixture of azetidine (0.03 mL, 0.5 mmol),5-bromo-2-(methylthio)pyrimidine (100 mg, 0.49 mmol), Xantphos(4,5-Bis(diphenylphosphino)-9,9-dimethylxanthene) (9.9 mg, 0.02 mmol),Pd(OAc)₂ (2 mg, 0.01 mmol) and NaOt-Bu (140 mg, 1.5 mmol) in toluene(1.7 mL) was heated at 110° C. After 3 h, the reaction mixture wascooled to room temperature and concentrated under vacuum. Purification(FCC, SiO₂, 0-99% EtOAc in hexanes) afforded the title compound (39 mg,44%). MS (ESI): mass calcd. for C₈H₁₁N₃S, 181.1; m/z found, 182.1[M+H]⁺. ¹H NMR (400 MHz, DMSO-d₆) δ 7.96 (s, 2H), 3.87 (t, J=7.3 Hz,4H), 2.45 (s, 3H), 2.40-2.32 (m, 2H).

Step B. 5-(Azetidin-1-yl)-2-(methylsulfonyl)pyrimidine

mCPBA (1.6 g, 7.3 mmol) was slowly added to a mixture of5-(azetidin-1-yl)-2-(methylthio)pyrimidine (531 mg, 2.9 mmol) in DCM (12mL) at 0° C. After 16 hours, the reaction mixture was quenched with asaturated aqueous solution of NaHCO₃ (60 mL). The mixture was extractedwith DCM (3×80 mL). The combined organics were dried (MgSO₄), filtered,and concentrated under vacuum. Purification (FCC, SiO₂, 0-99% EtOAc inhexanes) afforded the title compound (290 mg, 46%). MS (ESI): masscalcd. for C₅H₁₁N₃O₂S, 213.1; m/z found, 214.1 [M+H]⁺. ¹H NMR (500 MHz,DMSO-d₆) δ 8.10 (s, 2H), 4.08 (t, J=7.5 Hz, 4H), 3.24 (s, 3H), 2.48-2.40(m, 2H).

Step C.5-(Azetidin-1-yl)-2-[[1-[3-(difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyrimidine

The title compound was prepared in a manner analogous to Example 155using(1-(3-(difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 6) and using5-(azetidin-1-yl)-2-(methylsulfonyl)pyrimidine. MS (ESI): mass calcd.for C₁₇H₁₅F₃N₆O₂, 392.1; m/z found, 393.2 [M+H]⁺. ¹H NMR (400 MHz,DMSO-d₆) b 8.92 (s, 1H), 8.00 (dd, J=6.9, 2.6 Hz, 1H), 7.92 (s, 2H),7.87 (ddd, J=9.0, 4.0, 2.6 Hz, 1H), 7.68 (dd, J=10.2, 9.0 Hz, 1H), 7.39(t, J=72.8 Hz, 1H), 5.42 (s, 2H), 3.84 (t, J=7.2 Hz, 4H), 2.38-2.29 (m,2H).

Example 166:2-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]-4-(3,3-difluoropyrrolidin-1-yl)pyrimidine

Step A. 2-Chloro-4-(3,3-difluoropyrrolidin-1-yl)pyrimidine

A mixture of 2,4-dichloropyrimidine (500 mg, 3.4 mmol),3,3-difluoropyrrolidine hydrochloride (481 mg, 3.4 mmol) and TEA (0.56mL, 4.0 mmol) in DCM (23 mL) was stirred at rt. After 3 hours, water (50mL) was added to the reaction mixture. The mixture was extracted withEtOAc (3×75 mL). The combined organics were dried (MgSO₄), filtered, andconcentrated under vacuum. Purification (FCC, SiO₂, 0-100% EtOAc inhexanes) afforded the title compound (392 mg, 53%). MS (ESI): masscalcd. for C₈H₈ClF₂N₃, 219.0; m/z found, 220.0 [M+H]⁺. ¹H NMR (400 MHz,DMSO-d₆) δ 8.14 (d, J=6.0 Hz, 1H), 6.61 (br s, 1H), 3.89 (t, J=13.0 Hz,2H), 3.75-3.61 (m, 2H).

Step B.2-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]-4-(3,3-difluoropyrrolidin-1-yl)pyrimidine

The title compound was prepared in a manner analogous to Example 155using(1-(3-(difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 6) and 2-chloro-4-(3,3-difluoropyrrolidin-1-yl)pyrimidine.MS (ESI): mass calcd. for C₁₈H₁₅F₈N₆O₂, 442.1; m/z found, 442.9 [M+H]⁺.¹H NMR (400 MHz, DMSO-d₆) δ 8.92 (s, 1H), 8.09 (d, J=5.9 Hz, 1H), 8.00(dd, J=6.9, 2.6 Hz, 1H), 7.88 (ddd, J=9.0, 4.0, 2.6 Hz, 1H), 7.68 (dd,J=10.2, 9.0 Hz, 1H), 7.39 (t, J=72.8 Hz, 1H), 6.33-6.26 (m, 1H), 5.45(s, 2H), 3.97-3.83 (m, 2H), 3.74-3.59 (m, 2H).

Example 167:2-((1-(3-(Difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-5-fluoropyrimidin-4-amine

Step A: 4-Chloro-5-fluoro-2-(methylsulfonyl)pyrimidine

mCPBA (77%, 2.5 g, 11.2 mmol) was slowly added to a mixture of4-chloro-5-fluoro-2-(methylthio)pyrimidine (1.0 g, 5.6 mmol) in DCM (25mL) at 0° C. After 16 hours, the reaction mixture was quenched with asaturated aqueous solution of NaHCO₃ (60 mL). The mixture was extractedwith DCM (3×80 mL). The combined organics were dried (MgSO₄), filtered,and concentrated under vacuum. Purification (FCC, SiO₂, 0-99% EtOAc inhexanes) afforded the title compound (1.2 g, 98%). MS (ESI): mass calcd.for C₅H₄ClFN₂O₂S, 210.0; m/z found, 211.1 [M+H]⁺. ¹H NMR (400 MHz,DMSO-d₆) δ 9.26 (d, J=1.2 Hz, 1H), 3.43 (s, 3H).

Step B.4-Chloro-2-((1-(3-(difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-5-fluoropyrimidine

Under a nitrogen atmosphere was added((1-(3-(difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 6, 50 mg, 0.2 mmol) to a suspension of NaH (60% dispersionin mineral oil, 15 mg, 0.4 mmol) in THF (2.7 mL). After 5 minutes,4-chloro-5-fluoro-2-(methylsulfonyl)pyrimidine (49 mg, 0.2 mmol) wasadded at 0° C. Upon completion, brine (20 mL) was added and the mixturewas extracted with EtOAc (3×30 mL). The combined organics were dried(MgSO₄), filtered, and concentrated under vacuum. MS (ESI): mass calcd.for C₁₄H₈ClF₄N₅O₂, 389.0; m/z found, 390.1 [M+H]⁺.

Step C.2-((1-(3-(Difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-5-fluoropyrimidin-4-amine

A microwave vial was charged with4-chloro-2-((1-(3-(difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-5-fluoropyrimidine(75 mg, 0.2 mmol), ammonia (2M in MeOH, 1.9 mL, 3.9 mmol) and THF (1.9mL). The vial was heated to 100° C. under microwave irradiation for 8hours. The reaction mixture was concentrated under vacuum and the crudematerial was purified using reversed phase HPLC (Agilent, H₂O/NH₄OH:MeCNgradient) to afford the title compound (14.9 mg, 21%). MS (ESI): masscalcd. for C₁₄H₁₀F₄N₆O₂, 370.1; m/z found, 371.1 [M+H]⁺. ¹H NMR (500MHz, DMSO-d₆ δ 8.91 (s, 1H), 8.01-7.96 (m, 2H), 7.86 (ddd, J=9.0, 4.0,2.7 Hz, 1H), 7.68 (dd, J=10.2, 9.0 Hz, 1H), 7.55-7.23 (m, 3H), 5.35 (s,2H).

Example 168:2-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]-4-pyrrolidin-1-yl-pyrimidine.as the trifluoroacetic acid salt

The title compound was prepared in a manner analogous to Example 155using(1-(3-(difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 6) and 2-chloro-4-(pyrrolidin-1-yl)pyrimidine. MS (ESI):mass calcd. for C₁₈H₁₇F₃N₆O₂, 406.1; m/z found, 406.9 [M+H]⁺. ¹H NMR(400 MHz, DMSO-d₆) δ 8.97 (s, 1H), 8.07 (d, J=6.7 Hz, 1H), 8.00 (dd,J=6.9, 2.7 Hz, 1H), 7.90-7.85 (m, 1H), 7.70 (dd, J=10.2, 9.0 Hz, 1H),7.40 (t, J=72.7 Hz, 1H), 6.44 (d, J=6.7 Hz, 1H), 5.62 (s, 2H), 3.72-3.63(m, 2H), 2.08-1.90 (m, 4H).

Example 169:2-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]-4-(1-piperidyl)pyrimidine

The title compound was prepared in a manner analogous to Example 155using(1-(3-(difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 6) and 2-chloro-4-(piperidin-1-yl)pyrimidine. MS (ESI):mass calcd. for C₁₉H₁₉F₃N₆O₂, 420.2; m/z found, 421.0 [M+H]⁺. ¹H NMR(400 MHz, DMSO-d₆) δ 8.90 (s, 1H), 8.03-7.96 (m, 2H), 7.87 (ddd, J=9.0,4.0, 2.7 Hz, 1H), 7.68 (dd, J=10.2, 9.0 Hz, 1H), 7.39 (t, J=72.8 Hz,1H), 6.49 (d, J=6.2 Hz, 1H), 5.41 (s, 2H), 3.67-3.53 (m, 4H), 1.70-1.57(m, 2H), 1.54-1.42 (m, 4H).

Example 170:4-[2-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyrimidin-4-yl]morpholine

The title compound was prepared in a manner analogous to Example 155using(1-(3-(difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 6) and 4-(2-chloropyrimidin-4-yl) morpholine. MS (ESI):mass calcd. for C₁₈H₁₇F₃N₆O₃, 422.1; m/z found, 422.9 [M+H]⁺. ¹H NMR(400 MHz, DMSO-d₆) δ 8.91 (s, 1H), 8.07 (d, J=6.1 Hz, 1H), 8.00 (dd,J=6.9, 2.7 Hz, 1H), 7.87 (ddd, J=9.0, 4.0, 2.6 Hz, 1H), 7.68 (dd,J=10.2, 9.0 Hz, 1H), 7.39 (t, J=72.8 Hz, 1H), 6.52 (d, J=6.1 Hz, 1H),5.43 (s, 2H), 3.69-3.54 (m, 8H).

Example 171:2-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]-N-methyl-pyrimidin-4-amine

The title compound was prepared in a manner analogous to Example 163,Steps B-C, using(1-(4-chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 1) and tert-butyl(2-chloropyrimidin-4-yl)(methyl)carbamate (Intermediate 55). MS (ESI):mass calcd. for C₁₅H₁₃ClF₂N₆O₂, 382.1; m/z found, 383.1 [M+H]⁺. ¹H NMR(500 MHz, DMSO-d₆) δ 8.96 (s, 1H), 8.00-7.98 (m, 1H), 7.90-7.80 (m, 3H),7.60-7.28 (m, 2H), 6.15 (d, J=5.9 Hz, 1H), 5.41 (s, 2H), 2.82-2.73 (m,3H).

Example 172:2-[[1-[3-(Difluoromethyl)phenyl]-5-methyl-triazol-4-yl]methoxy]-5-methoxy-pyrimidine

Step A. 1-Azido-3-(difluoromethyl)benzene

Method A

Two solutions, 3-(difluoromethyl)aniline (1.0 g, 7.0 mmol) in 6 N HCl(6N HCl in iPrOH, 4.4 mL) and iPrOH (5 mL), and sodium nitrite (0.58 g,8.4 mmol) in H₂O (4 mL) were flowed through a LTF-MS mixer (0.2 mL) at 1mL/min and 0.4 mL/min, respectively. The outcome was mixed with sodiumazide (0.55 g, 8.4 mmol) in H₂O (4 mL) at 0.4 mL/min in a T-piece andflowed through a LTF-VS mixer (1 mL). The mixture was collected overKzCO₃ (4.8 g, 35 mmol) in iPrOH (140 mL). The reaction mixture wasextracted into ether and concentrated under reduced pressure. The cruderesidue was carried forward without purification.

Method B.

To 3-(difluoromethyl)aniline (1.47 g, 10.3 mmol) in a round bottom flaskwas slowly added H₂SO₄ (2 mL, 37.5 mmol) followed by TFA (10 mL, 130.7mmol). The reaction was cooled to 0° C., then a solution of NaNO₂ (1 g,15 mmol) in H₂O (10 mL) was added drop-wise with stirring. The reactionwas stirred at 0° C. for 40 minutes, then a solution of sodium azide(1.26 g, 19.4 mmol) in H₂O (10 mL) was added drop-wise. The reaction wasremoved from the ice bath and stirred at rt for 2 h. The mixture wasdiluted with diethyl ether and basified to pH 12 with a solution of LiOH(4 N). The layers were separated and the aqueous layer was extractedwith diethyl ether (3×). The combined organic layers were dried (Na₂SO₄)and concentrated under reduced pressure. The crude residue was carriedforward without purification.

Step B. Ethyl1-(3-(difluoromethyl)phenyl)-5-methyl-1H-1,2,3-triazole-4-carboxylate

To a solution of 1-azido-3-(difluoromethyl)benzene (0.59 g, 3.5 mmol) inDMSO (3.5 mL) was added ethyl acetoacetate (0.7 mL, 5.2 mmol) followedby dimethylamine (0.02 mL, 0.17 mmol). The vial was purged with N₂ thensealed and stirred at 70° C. overnight. The reaction was cooled to rtthen diluted with EtOAc and H₂O. The layers were separated and theaqueous layer was extracted with EtOAc (3×). The combined organic layerswere washed with H₂O (×5), then brine (×3), then dried (Na₂SO₄) andconcentrated under reduced pressure. Purification (FCC, SiO₂,EtOAc/hexanes 0-50%) afforded the title compound as a pale yellow oilthat solidified upon standing (67%). MS (ESI): mass calcd. forC₁₃H₁₃F₂N₃O₂, 281.1; m/z found, 282.0 [M+H]⁺.

Step C.(1-(3-(Difluoromethyl)phenyl)-5-methyl-1H-1,2,3-triazol-4-yl)methanol

To ethyl1-(3-(difluoromethyl)phenyl)-5-methyl-1H-1,2,3-triazole-4-carboxylate(395 mg, 1.4 mmol) stirring in THF at −78° C. was added LAH (1 M in THF,3.5 mL, 3.5 mmol) drop-wise. The reaction was stirred at −78° C. for 2h, then warmed to rt and stirred for 1 h. The reaction was cooled to 0°C. and quenched slowly with EtOAc, then the mixture was warmed to rt anddiluted with a saturated solution of L(+)-tartaric acid potassium sodiumsalt (Rochelle salt). The mixture was stirred vigorously for 1 h, thenthe layers were separated and the aqueous layer was extracted with EtOAc(3×). The combined organic layers were dried (Na₂SO₄) then concentratedunder reduced pressure to afford a yellow oil that was used withoutpurification (296 mg, 88%). MS (ESI) mass calcd. for C₁₁H₁₁F₂N₃O, 239.1;m/z found 240.0 [M+H]⁺. ¹H NMR (500 MHz, CDCl₃) δ 7.69-7.63 (m, 3H),7.63-7.57 (m, 1H), 6.73 (t, J=56.1 Hz, 1H), 4.83 (s, 2H), 2.40 (s, 3H).

Step D.2-[[1-[3-(Difluoromethyl)phenyl]-5-methyl-triazol-4-yl]methoxy]-5-methoxy-pyrimidine

To (1-(3-(difluoromethyl)phenyl)-5-methyl-1H-1,2,3-triazol-4-yl)methanol(45 mg, 0.19 mmol) stirring in THF (1 mL) was added NaH (60% dispersionin mineral oil, 22.6 mg, 0.56 mmol) and the reaction was stirred for 5min. 2-Chloro-5-methoxypyrimidine was then added and the reaction wasstirred at rt for 1 h. The reaction was quenched with H₂O, then dilutedwith EtOAc and H₂O. The layers were separated and the aqueous layer wasextracted with EtOAc (3×). The combined organic layers were washed withH₂O (1×), brine (IX), then dried (Na₂SO₄) and concentrated under reducedpressure. Purification (FCC, SiO₂, EtOAc/hexanes 0-60%) afforded thetitle compound (41 mg, 62%). MS (ESI): mass calcd. for C₁₆H₁₅F₂N₅O₂,347.1; m/z found, 348.0 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃) δ 8.24 (s, 2H),7.71-7.56 (m, 4H), 6.73 (t, J=56.1 Hz, 1H), 5.56 (s, 2H), 3.88 (s, 3H),2.45 (s, 3H).

Example 173:2-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]-5-methyl-triazol-4-yl]methoxy]-5-methyl-pyrimidine

Step A. 2-(1,1-Difluoroethyl)-1-fluoro-4-nitrobenzene

To a solution of 1-(2-fluoro-5-nitrophenyl)ethanone (3.0 g, 16.5 mmol)stirring in DCM (50 mL) at −78° C. was added DAST (10 mL, 75.7 mmol).The mixture was warmed to rt and stirred for 5 days. The reaction waspoured over ice, then the ice was allowed to melt and the layers wereseparated. The aqueous layer was extracted with DCM (2×), then thecombined organic layers were washed with brine, dried (Na₂SO₄),filtered, and concentrated under reduced pressure. Purification (FCC,SiO₂, EtOAc/hexanes 0-20%) afforded the title compound (2.73 g, 81%). ¹HNMR (500 MHz, CDCl₃) δ 8.49 (dd, J=6.3, 2.8 Hz, 1H), 8.35 (dt, J=8.9,3.5 Hz, 1H), 7.31 (t, J=9.3 Hz, 1H), 2.04 (t, J=18.5 Hz, 3H).

Step B. 3-(1,1-Difluoroethyl)-4-fluoroaniline

To 2-(1,1-difluoroethyl)-1-fluoro-4-nitrobenzene (1 g, 4.86 mmol)dissolved in EtOH (30 mL) was added 10% Pd/C (0.52 g, 0.49 mmol). Thereaction was placed under an atmosphere of hydrogen and stirred at rtovernight. The reaction mixture was filtered through a pad of Celite®,rinsing with EtOAc, and the filtrate was concentrated under vacuum toafford the title compound that was used without purification (863 mg,101%). MS (ESI): mass calcd. for C₅H₆F₃N, 175.1; m/z found, 176.1[M+H]⁺.

Step C. 4-Azido-2-(1,1-difluoroethyl)-1-fluorobenzene

To 3-(1,1-difluoroethyl)-4-fluoroaniline (854 mg, 4.9 mmol) in a roundbottom flask was slowly added H₂SO₄ (1 mL, 18.8 mmol) followed by TFA (5mL, 65.3 mmol). The reaction was cooled to 0° C., then a solution ofNaNO₂ (482 mg, 7 mmol) in H₂O (3 mL) was added drop-wise with stirring.The reaction was stirred at 0° C. for 15 minutes, then a solution ofsodium azide (594.3 mg, 9 mmol) in H₂O (6 mL) was added drop-wise. Thereaction was removed from the ice bath and stirred at rt for 30 min. Themixture was diluted with diethyl ether and basified to pH 12 with asolution of NaOH (3 N). The layers were separated and the aqueous layerwas extracted with diethyl ether (3×). The combined organic layers weredried (Na₂SO₄) and concentrated under reduced pressure. The cruderesidue was carried forward without purification.

Step D. Ethyl1-(3-(1,1-difluoroethyl)-4-fluorophenyl)-5-methyl-1H-1,2,3-triazole-4-carboxylate

To a solution of 4-azido-2-(1,1-difluoroethyl)-1-fluorobenzene (0.981 g,4.9 mmol) in DMSO (5 mL) was added ethyl acetoacetate (0.9 mL, 7.3 mmol)followed by dimethylamine (0.025 mL, 0.24 mmol). The vial was purgedwith N₂ then sealed and stirred at 70° C. for 2 days. The reaction wascooled to rt then diluted with EtOAc and H₂O. The layers were separatedand the aqueous layer was extracted with EtOAc (3×). The combinedorganic layers were washed with H₂O (5×), then brine (3×), then dried(Na₂SO₄) and concentrated under reduced pressure. Purification (FCC,SiO₂, EtOAc/hexanes 0-50%) afforded the title compound as a yellow oilthat solidified upon standing (1.32 g, 87%). MS (ESI): mass calcd. forC₁₄H₁₄F₃N₃O₂, 313.1; m/z found, 314.1 [M+H]⁺.

Step E.(1-(3-(1,1-difluoroethyl)-4-fluorophenyl)-5-methyl-1H-1,2,3-triazol-4-yl)methanol

To ethyl1-(3-(1,1-difluoroethyl)-4-fluorophenyl)-5-methyl-1H-1,2,3-triazole-4-carboxylate(537 mg, 1.7 mmol) stirring in THF at −78° C. was added LAH (1 M in THF,4.5 mL, 4.5 mmol) drop-wise. The reaction was stirred at −78° C. for 1h, then warmed to rt and stirred for 3 h. The reaction was cooled to 0°C. and quenched slowly with EtOAc, then the mixture was warmed to rt anddiluted with a saturated solution of potassium sodium tartratetetrahydrate. The mixture was stirred vigorously for 10 min, then thelayers were separated and the aqueous layer was extracted with EtOAc.The combined organic layers were washed with brine, then dried (Na₂SO₄)and concentrated under reduced pressure to afford a yellow oil that wasused without purification. MS (ESI) mass calcd. for C₁₂H₁₂F₃N₃O, 271.1;m/z found 272.1 [M+H]⁺

Step F.2-[[1-[3-(1,1-difluoroethyl)-4-fluoro-phenyl]-5-methyl-triazol-4-yl]methoxy]-5-methyl-pyrimidine

To(1-(3-(1,1-difluoroethyl)-4-fluorophenyl)-5-methyl-1H-1,2,3-triazol-4-yl)methanol(25 mg, 0.09 mmol) stirring in THF (0.8 mL) was added NaH (60%dispersion in mineral oil, 12.5 mg, 0.31 mmol) and the reaction wasstirred for 5 min. 2-Chloro-5-methylpyrimidine was then added and thereaction was stirred at rt overnight. The reaction was quenched withH₂O, then concentrated under a stream of air. Purification (FCC, SiO₂,EtOAc/hexanes 0-80%) afforded the title compound (20 mg, 60%). MS (ESI):mass calcd. for C₁₇H₁₆F₃N₅O, 363.1; m/z found, 364.0 [M+H]⁺. ¹H NMR (500MHz, CDCl₃) δ 8.37 (s, 2H), 7.66 (dd, J=6.3, 2.6 Hz, 1H), 7.53 (ddd,J=8.5, 4.1, 2.6 Hz, 1H), 7.32 (t, J=9.4 Hz, 1H), 5.56 (s, 2H), 2.42 (s,3H), 2.25 (s, 3H), 2.11-1.96 (m, 3H).

Example 174:5-Methyl-2-[[1-(6-methyl-2-pyridyl)triazol-4-yl]methoxy]pyrimidine

Step A. 5-Methyltetriazolo[1,5-a]pyridine

2-Methylpyridine N-oxide (400 mg, 3.7 mmol), diphenylphosphoryl azide (4mL, 18.6 mmol), and pyridine (0.6 mL, 7.4 mmol) were combined and purgedwith nitrogen, sealed, and stirred at 120° C. overnight. The mixture wascooled to rt, then loaded directly onto a silica gel column.Purification (FCC, SiO₂, 10% 2N NH₃ in MeOH/DCM 0-5%) afforded the titlecompound as a white solid (257 mg, 52%). MS (ESI): mass calcd. forC₆H₆N₄, 134.1; m/z found, 135.1 [M+H]⁺.

Step B. (1-(6-Methylpyridin-2-yl-1H-1,2,3-triazol-4-yl)methanol

To a solution of 5-methyltetriazolo[1,5-a]pyridine (257 mg, 1.9 mmol)and copper (I) trifluoromethanesulfonate benzene complex (96.4 mg, 0.19mmol) in toluene (7.7 mL) was added propargyl alcohol (0.13 mL, 2.3mmol). The vial was purged with nitrogen, then sealed and stirred at100° C. overnight. The mixture was diluted with DCM, washed with water(×1), brine (×1), then dried (Na₂SO₄) and concentrated under reducedpressure to afford a pale orange solid (191 mg, 53%). The crude productwas used without purification. MS (ESI): mass calcd. for CH₁₀N₄O, 190.1;m/z found, 191.1 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD) δ 8.68 (s, 1H),7.96-7.88 (m, 2H), 7.37-7.33 (m, 1H), 4.77 (d, J=0.7 Hz, 2H), 2.59 (s,3H).

Step C.5-Methyl-2-[[1-(6-methyl-2-pyridyl)triazol-4-yl]methoxy]pyrimidine

The title compound was prepared in a manner analgous to Example 1 using(1-(6-methylpyridin-2-yl)-1H-1,2,3-triazol-4-yl)methanol and2-chloro-5-methylpyrimidine, using THF instead of DMF. MS (ESI): masscalcd. for C₁₄H₁₄N₆O, 282.1; m/z found, 283.0 [M+H]⁺. ¹H NMR (400 MHz,CDCl₃) b 8.71 (s, 1H), 8.37 (d, J=0.8 Hz, 2H), 7.96 (d, J=8.1 Hz, 1H),7.76 (t, J=7.8 Hz, 1H), 7.17 (d, J=7.6 Hz, 1H), 5.63 (d, J=0.7 Hz, 2H),2.57 (s, 3H), 2.24 (s, 3H).

Example 175:5-Methyl-2-[[1-(2-methyl-4-pyridyl)triazol-4-yl]methoxy]pyrimidine

Step A. 4-Azido-2-methylpyridine

To 4-chloro-2-picoline hydrochloride (600 mg, 3.7 mmol) stirring in H₂O(2.5 mL) was added a solution of NaOH (1 M in H₂O) until the pH measured7. Sodium azide (476 mg, 7.3 mmol) was then added and the reaction washeated at reflux overnight. The reaction was cooled to rt then extractedwith ether (3×). The combined organic layers were dried (Na₂SO₄) andconcentrated under reduced pressure to afford a colorless oil that wasused without purification.

Step B. (1-(2-Methylpyridin-4-yl)-1H-1,2,3-triazol-4-yl)methanol

4-Azido-2-methylpyridine (491 mg, 3.7 mmol) was dissolved in a mixtureof tBuOH (4.5 mL) and H₂O (4.5 mL). Propargyl alcohol (0.26 mL, 4.4mmol) was then added, followed by copper (II) sulfate pentahydrate (91mg, 0.37 mmol) and L-sodium ascorbate (72.5 mg, 0.37 mmol). The reactionwas stirred at rt overnight, then diluted with NH₄OH (28% in H₂O) andH₂O. The layers were separated and the aqueous layer was extracted withEtOAc (6×) and DCM (3×). The combined organic layers were washed withbrine, dried (Na₂SO₄), and concentrated under reduced pressure to affordthe title compound that was used without purification (356 mg, 51%). MS(ESI): mass calcd. for C₉H₁₀N₄O, 190.1; m/z found, 191.1 [M+H]⁺. ¹H NMR(400 MHz, CD₃OD) δ 8.66 (s, 1H), 8.61 (d, J=5.7 Hz, 1H), 7.93-7.90 (m,1H), 7.83 (dd, J=5.8, 2.1 Hz, 1H), 4.80 (s, 2H), 2.67 (s, 3H).

Step C.5-Methyl-2-[[1-(2-methyl-4-pyridyl)triazol-4-yl]methoxy]pyrimidine

The title compound was prepared in a manner analgous to Example 1 using(1-(2-methylpyridin-4-yl)-1H-1,2,3-triazol-4-yl)methanol and2-chloro-5-methylpyrimidine, using THF instead of DMF. MS (ESI): masscalcd. for C₁₄H₁₄N₆O, 282.1; m/z found, 283.0 [M+H]⁺. ¹H NMR (400 MHz,CDCl₃) δ 8.65 (d, J=5.6 Hz, 1H), 8.38 (d, J=0.8 Hz, 2H), 8.21 (s, 1H),7.61 (d, J=2.1 Hz, 1H), 7.49 (ddd, J=5.4, 2.1, 0.7 Hz, 1H), 5.64 (d,J=0.7 Hz, 2H), 2.67 (s, 3H), 2.26 (s, 3H).

Example 176:5-Methyl-2-[[1-(5-methyl-3-pyridyl)triazol-4-yl]methoxy]pyrimidine

Step A. 3-Azido-5-methylpyridine

To 3-amino-5-methylpyridine (483 mg, 4.5 mmol) in a round bottom flaskwas slowly added H₂SO₄ (0.9 mL, 17.2 mmol) followed by TFA (4.6 mL, 59.9mmol). The reaction was cooled to 0° C., then a solution of NaNO₂ (442mg, 6.4 mmol) in H₂O (3 mL) was added drop-wise with stirring. Thereaction was stirred at 0° C. for 15 minutes, then a solution of sodiumazide (544 mg, 8.4 mmol) in H₂O (3 mL) was added drop-wise. The reactionwas removed from the ice bath and stirred at rt for 30 min. The mixturewas diluted with diethyl ether and basified to pH 12 with a solution ofNaOH (3 N). The layers were separated and the aqueous layer wasextracted with diethyl ether (3×). The combined organic layers weredried (Na₂SO₄) and concentrated under reduced pressure. The cruderesidue was carried forward without purification

Step B. (1-(5-Methylpyridin-3-yl)-1H-1,2,3-triazol-4-yl)methanol

To 3-azido-5-methylpyridine (599 mg, 4.5 mmol) dissolved in tBuOH (6 mL)and H₂O (6 mL) was added propargyl alcohol (0.3 mL, 5.2 mmol) followedby copper (II) sulfate pentahydrate (109 mg, 0.44 mmol) and L-sodiumascorbate (90 mg, 0.45 mmol). The reaction was stirred at rt overnight.In the morning LCMS indicated no conversion. The mixture was basified topH=8 with K₂CO₃ (approx. 200 mg, then stirred at rt for an additional 5h. The reaction was diluted with EtOAc and NH₄OH (28% in H₂O), then thelayers were separated and the aqueous layer was extracted with EtOAc(×3). The combined organic layers were dried (Na₂SO₄) and concentratedunder reduced pressure. Purification (FCC, SiO₂, MeOH/DCM 0-5%) affordedthe title compound (57.5 mg, 6.7%). MS (ESI): mass calcd. for C₉H₁₀N₄O,190.1; m/z found, 191.1 [M+H]⁺.

Step C.5-Methyl-2-[[1-(5-methyl-3-pyridyl)triazol-4-yl]methoxy]pyrimidine

The title compound was prepared in a manner analgous to Example 1 using(1-(5-methylpyridin-3-yl)-1H-1,2,3-triazol-4-yl) and2-chloro-5-methylpyrimidine using THF instead of DMF. MS (ESI): masscalcd. for C₁₄H₁₄N₆O, 282.1; m/z found, 283.0 [M+H]⁺. ¹H NMR (500 MHz,CDCl₃) δ 8.77 (d, J=2.4 Hz, 1H), 8.53 (d, J=1.8 Hz, 1H), 8.38 (s, 2H),8.19-8.13 (m, 1H), 7.97-7.94 (m, 1H), 5.65 (s, 2H), 2.47 (s, 3H), 2.26(s, 3H).

Example 177:2-[[1-(2-Bromo-4-pyridyl)triazol-4-yl]methoxy]-5-methyl-pyrimidine

The title compound was prepared in a manner analogous to Example 176,using 2-bromopyridin-4-amine in Step A. MS (ESI): mass calcd. forC₁₃H₁₁BrN₆O, 346.0; m/z found, 347.0 [M+H]⁺. ¹H NMR (400 MHz, CD₃OD) δ8.87 (s, 1H), 8.53 (d, J=5.5 Hz, 1H), 8.46 (s, 2H), 8.24 (d, J=2.0 Hz,1H), 8.01 (dd, J=5.6, 1.9 Hz, 1H), 5.60 (s, 2H), 2.27 (s, 3H)

Example 178:2-[2-[[1-(3-Cyclobutyl-4-fluoro-phenyl)triazol-4-yl]methoxy]pyrimidin-5-yl]propan-2-ol

Step A.2-(2-((1-(3-Bromo-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidin-5-yl)propan-2-ol

The title compound was prepared in a manner analogous to Example 1 using(1-(3-bromo-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate14) and 2-(2-chloropyrimidin-5-yl)propan-2-ol, using THF instead of DMF.MS (ESI): mass calcd. for C₁₆H₁₅BrN₅O₂, 407.0; m/z found, 408.0 [M+H]⁺.¹H NMR (500 MHz, CDCl₃) δ 8.67 (s, 2H), 8.09 (s, 1H), 7.99 (dd, J=5.8,2.7 Hz, 1H), 7.67 (ddd, J=8.8, 4.0, 2.7 Hz, 1H), 7.30-7.26 (m, 2H), 5.65(d, J=0.8 Hz, 2H), 1.63 (s, 6H).

Step B.2-[2-[[1-(3-Cyclobutyl-4-fluoro-phenyl)triazol-4-yl]methoxy]pyrimidin-5-yl]propan-2-ol

To a solution of2-(2-((1-(3-bromo-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidin-5-yl)propan-2-ol(30 mg, 0.07 mmol) in THF (1 mL) was added cyclobutylzinc bromide (0.5 Min THF, 0.3 mL, 0.15 mmol) and Pd(t-Bu₃P)₂ (1.9 mg, 0.004 mmol). Themixture was stirred at 50° C. overnight. The mixture was purified (FCC,SiO₂, MeOH/DCM 0-10%), however the product contained impurities. Thecompound was re-purified by basic HPLC (Gilson, waters Xbridge 50×150mm, 5-95% MeCN/20 mM NH₄OH over 15 min, 80 mL/min) to afford the titlecompound (15.8 mg, 56%). MS (ESI): mass calcd. for C₂₀H₂₂FN₅O₂, 383.2;m/z found, 384.1 [M+H]⁺. ¹H NMR (500 MHz, CDCl₃) δ 8.67 (s, 2H), 8.09(s, 1H), 7.61 (ddd, J=6.3, 2.7, 0.8 Hz, 1H), 7.46 (dddd, J=8.8, 4.2,2.7, 0.6 Hz, 1H), 7.11 (t, J=9.0 Hz, 1H), 5.65 (d, J=0.7 Hz, 2H),3.83-3.72 (m, 1H), 2.46-2.36 (m, 2H), 2.28-2.16 (m, 2H), 2.14-2.03 (m,1H), 1.96-1.87 (m, 1H), 1.62 (s, 6H).

Example 179:2-[2-[[1-(4-Fluoro-3-isopropyl-phenyl)triazol-4-yl]methoxy]pyrimidin-5-yl]propan-2-ol

The title compound was prepared in a manner analogous to Example 178step B, using2-(2-((1-(3-bromo-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidin-5-yl)propan-2-ol(Example 178, product from Step A) and 2-propylzinc bromide. MS (ESI):mass calcd. for C₁₉H₂₂FN₅O₂, 371.2; m/z found, 372.0 [M+H]⁺.

Example 180:2-[2-[[1-(3-Cyclopropyl-4-fluoro-phenyl)triazol-4-yl]methoxy]pyrimidin-5-yl]propan-2-ol

To a solution of2-(2-((1-(3-bromo-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidin-5-yl)propan-2-ol(Example 178, product from Step A, 42 mg, 0.1 mmol), K₂CO₃ (43 mg, 0.31mmol), and RuPhos-Pd-G3 (4.3 mg, 0.005 mmol) was in 1,4-dioxane (1 mL)and water (0.2 mL) was added cyclopropylboronic acid (19.3 mg, 0.23mmol). The vial was sealed and the reaction was stirred at 100° C.overnight. The reaction was diluted with water, capped with a septum,and left to stand at rt for 9 days. The mixture was then filteredthrough a plug of silica, rinsing with EtOAc and DCM, then concentratedunder reduced pressure. The residue was re-dissolved in MeOH, filteredthrough a 0.45 μm syringe, and purified by preparatory HPLC (Gilson,waters Xbridge 50×150 mm, 5-95% MeCN/20 mM NH₄OH over 15 min, 80mL/min). Fractions containing the pure product was frozen andlyophilized over 2 days to afford the title compound (8 mg, 21%). MS(ESI): mass calcd. for C₁₉H₂₀FN₅O₂, 369.2; m/z found, 370.0 [M+H]⁺. ¹HNMR (500 MHz, CDCl₃) δ 8.67 (s, 2H), 8.04 (s, 1H), 7.42 (ddd, J=8.8,4.2, 2.8 Hz, 1H), 7.28-7.27 (m, 1H), 7.14 (t, J=9.1 Hz, 1H), 5.65 (d,J=0.7 Hz, 2H), 2.15 (ddd, J=13.7, 8.6, 5.2 Hz, 1H), 1.76 (s, 1H), 1.63(s, 6H), 1.11-1.05 (m, 2H), 0.81 (dt, J=6.7, 4.8 Hz, 2H).

Example 181:2-[2-[[1-(4-Fluoro-3-methyl-phenyl)triazol-4-yl]methoxy]pyrimidin-5-yl]propan-2-ol

To a solution of2-(2-((1-(3-bromo-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidin-5-yl)propan-2-ol(Example 178, product from Step A, 42 mg, 0.1 mmol), K₂CO₃ (44 mg, 0.32mmol), and RuPhos-Pd-G3 (4.3 mg, 0.005 mmol) in 1,4-dioxane (1.05 mL)was added trimethylboroxine (0.04 mL, 0.3 mmol). The vial was sealed andthe reaction was stirred at 90° C. for 3 h. The mixture was thenfiltered through a plug of silica, rinsing with DCM, and concentratedunder reduced pressure. Purification (FCC, SiO₂, MeOH/DCM 0-10%)afforded the title compound (20.9 mg, 59%). MS (ESI): mass calcd. forC₁₇H₁₈FN₅O₂, 343.1; m/z found, 344.1 [M+H]⁺. ¹H NMR (500 MHz, CDCl₃) δ8.67 (s, 2H), 8.06 (s, 1H), 7.59 (ddd, J=6.5, 2.7, 0.9 Hz, 1H),7.50-7.45 (m, 1H), 7.14 (t, J=8.8 Hz, 1H), 5.66 (d, J=0.7 Hz, 2H), 2.37(d, J=2.0 Hz, 3H), 1.77 (s, 1H), 1.63 (s, 6H).

Example 182:2-[2-[[1-(3-Ethyl-4-fluoro-phenyl)triazol-4-yl]methoxy]pyrimidin-5-yl]propan-2-ol

A solution of2-(2-((1-(3-bromo-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidin-5-yl)propan-2-ol(Example 178, product from Step A, 32 mg, 0.08 mmol), potassiumethyltrifluoroborate (10.7 mg, 0.08 mmol), potassium phosphate tribasic(50 mg, 0.24 mmol), RuPhos-Pd-G3 (3.3, 0.004 mmol), in 1,4-dioxane (0.5mL), and water (0.2 mL) was purged with nitrogen, sealed and stirred at90° C. for 2 days. The reaction was filtered through a plug of silica,rinsing with EtOAc, then evaporated under reduced pressure. The residuewas dissolved in MeOH then purified by preparatory HPLC (Gilson, watersXbridge 50×150 mm, 5-95% MeCN/20 mM NH₄OH over 15 min, 80 mL/min), andthe fractions containing pure product were frozen and lyophilized over 2days to afford the title compound (5.7 mg, 20%). MS (ESI): mass calcd.for C₁₈H₂₀FN₅O₂, 357.2; m/z found, 358.0 [M+H]⁺. ¹H NMR (500 MHz, CDCl₃)δ 8.67 (s, 2H), 8.07 (s, 1H), 7.59 (dd, J=6.4, 2.7 Hz, 1H), 7.48 (ddd,J=8.8, 4.2, 2.8 Hz, 1H), 7.14 (t, J=8.9 Hz, 1H), 5.65 (s, 2H), 2.75 (q,J=8.0 Hz, 2H), 1.62 (s, 6H), 1.28 (t, J=7.6 Hz, 3H).

Example 183:5-Bromo-2-[[1-[3-(1,1-difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyrimidine

The title compound was prepared in a manner analogous to Example 153using(1-(3-(1,1-difluoroethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 11) and 5-bromo-2-chloropyrimidine, using ACN instead ofDMF. MS (ESI): mass calcd. for C₁₅H₁₁BrF₃N₅O, 413.0; m/z found, 414.0[M+H]⁺. ¹H NMR (500 MHz, CDCl₃) δ 8.66-8.54 (s, 2H), 8.15-8.09 (m, 1H),7.93-7.87 (m, 1H), 7.85-7.78 (m, 1H), 7.37-7.28 (m, 1H), 5.69-5.58 (m,2H), 2.14-1.94 (m, 3H).

Example 184:2-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-5-(1-methylpyrazol-3-yl)pyrimidine

In a vial a suspension of5-bromo-2-[[1-[3-(1,1-difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyrimidine(Example 183, 25 mg, 0.060 mmol),1-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole(15.07 mg, 0.072 mmol), Na₂CO₃ (20 mg, 0.181 mmol) and PdCl₂(dppf) (4mg, 0.006 mmol) in THF/H₂O (3 mL/0.3 mL) was capped and heated undermicrowave irradiation for 1.5 h at 100° C. The completed reaction wasdiluted with EtOAc and washed with water, brine, dried (Na₂SO₄),filtered, and concentrated under reduced pressure. Purification (FCC,SiO₂, eluting with 0-50% EtOAc in hexanes) afforded the title compound(13.8 mg, 55%). MS (ESI): mass calcd. for C₁₉H₁₆F₃N₇O, 415.1; m/z found,416.1 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃) δ 8.96-8.90 (s, 2H), 8.17-8.12 (s,1H), 7.94-7.87 (m, 1H), 7.87-7.79 (m, 1H), 7.46-7.39 (d, J=2.3 Hz, 1H),7.36-7.27 (t, J=9.4 Hz, 1H), 6.55-6.48 (d, J=2.3 Hz, 1H), 5.74-5.67 (d,J=0.7 Hz, 2H), 4.06-3.90 (s, 3H), 2.17-1.96 (m, 3H).

Example 185:2-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-5-(1H-pyrazol-4-yl)pyrimidine

Step A:2-((1-(3-(1,1-Difluoroethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-5-(1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-4-yl)pyrimidine

The title compound was prepared in an manner analogous to Example 184using5-bromo-2-[[1-[3-(1,1-difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyrimidine(Example 183) and1-(tetrahydro-2H-pyran-2-yl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole.MS (ESI): mass calcd. for C₂₃H₂₂F₃N₇O₂, 485.2; m/z found, 486.1 [M+H]⁺.

Step B:2-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-5-(1H-pyrazol-4-yl)pyrimidine

A solution of2-((1-(3-(1,1-difluoroethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-5-(1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-4-yl)pyrimidine(27 mg, 0.06 mmol) in MeOH (3 mL) was charged with 3M HCl (3 mL) andstirred at rt for 4 hours. The completed reaction was concentrated underreduced pressure and re-suspended in DCM. The organics were washed withsat. aq. NaHCO₃, water, then brine. The organics were dried (Na₂SO₄),filtered, and concentrated under reduced pressure. Purification (FCC,SiO₂, 0-3% MeOH in DCM) afforded the title compound (15.3 mg, 32%). MS(ESI): mass calcd. for C₁₈H₁₄F₃N₇O, 401.1; m/z found, 402.0 [M+H]⁺. ¹HNMR (400 MHz, CDCl₃) δ 8.73-8.68 (s, 2H), 8.36-8.32 (s, 1H), 7.99-7.94(m, 1H), 7.92-7.83 (m, 2H), 7.39-7.32 (t, J=9.4 Hz, 1H), 5.72-5.63 (s,2H), 3.40-3.32 (s, 2H), 2.15-1.97 (t, J=18.6 Hz, 2H).

Example 186:2-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-4-(1H-pyrazol-4-yl)pyrimidine

Step A:2-Chloro-4-(1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-4-yl)pyrimidine

To a flask with 2-chloro-4-(1H-pyrazol-4-yl)pyrimidine (284 mg, 1.6mmol) and 3,4-dihydro-2H-pyran (661 mg, 7.9 mmol) in THF (9 mL) wascharged with TFA (12 μL, 0.16 mmol) and stirred at 77° C. overnight. Thecompleted reaction was diluted with EtOAc and washed with water, brine,dried (Na₂SO₄), filtered, and concentrated under reduced pressure.Purification (FCC, SiO₂, 0-60% EtOAc in hexanes) afforded the titlecompound (360 mg, 86%). MS (ESI): mass calcd. for C₁₂H₁₃ClN₄O, 264.1;m/z found, 265.0 [M+H]⁺.

Step B:2-((1-(3-(1,1-Difluoroethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-4-(1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-4-yl)pyrimidine

The title compound was prepared in a manner analogous to Example 156using(1-(3-(1,1-difluoroethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 11) and2-chloro-4-(1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-4-yl)pyrimidine. MS(ESI): mass calcd. for C₂₃H₂₂F₃N₇O₂, 485.2; m/z found, 486.1 [M+H]⁺.

Step C.2-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-4-(1H-pyrazol-4-yl)pyrimidine

The title compound was prepared in a manner analogous to Example 185,step B, using2-((1-(3-(1,1-Difluoroethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-4-(1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-4-yl)pyrimidine.MS (ESI): mass calcd. for C₁₈H₁₄F₃N₇O, 401.1; m/z found, 402.0 [M+H]⁺.¹H NMR (500 MHz, CDCl₃) δ 8.52-8.44 (d, J=5.2 Hz, 1H), 8.25-8.17 (d,J=2.6 Hz, 3H), 7.96-7.87 (m, 1H), 7.89-7.80 (m, 1H), 7.36-7.26 (m, 1H),7.18-7.10 (d, J=5.2 Hz, 1H), 5.76-5.64 (s, 2H), 5.34-5.25 (s, 1H),2.11-1.98 (m, 3H).

Example 187:4-(2-((1-(3-(1,1-Difluoroethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidin-5-yl)morpholine

To a vial was added5-bromo-2-((1-(3-(1,1-difluoroethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidine(Example 183, 28 mg, 0.07 mmol), morpholine (0.01 mL, 0.08 mmol), NaOtBu(8 mg, 0.08 mmol),2-dicyclohexylphosphino-2′,6′-diisopropoxy-1,1′-biphenyl)[2-(2′-amino-1,1′-biphenyl)]palladium(II)methanesulfonate (RuPhos-Pd-G3) (6 mg, 0.01 mmol),2-dicyclohexylphosphino-2′,6′-diisopropoxybiphenyl (RuPhos) (4 mg, 0.01mmol) in THF (1 mL) under N₂. The resulting reaction mixture was sealedand heated to 85° C. then allowed to stir overnight. The reactionmixture was then cooled to room temperature, filtered through a pad ofCelite® and concentrated under reduced pressure. Purification (basicHPLC, Agilent prep system, Waters XBridge C18 5 μm 50×100 mm column,5-95% MeCN/20 nM NH₄OH over 22 min at 80 mL/min) afforded the titlecompound (13 mg, 45%). MS (ESI): mass calcd. for C₁₉H₁₉F₃N₆O₂, 420.3;m/z found, 421.1 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃) δ 8.18-8.14 (s, 2H),8.06-8.03 (s, 1H), 7.85-7.80 (m, 1H), 7.79-7.73 (m, 1H), 7.27-7.20 (m,1H), 5.57-5.50 (s, 2H), 3.85-3.77 (m, 4H), 3.08-3.00 (m, 4H), 2.05-1.90(m, 3H).

Example 188:2-((1-(4-(Azetidin-1-yl)-3-(difluoromethyl)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidine

To a solution of2-((1-(3-(difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidine(Example 25, 30 mg, 0.09 mmol) in ACN (2 mL) was added azetidine (5.3mg, 0.09 mmol) and DIPEA (30 mg, 0.23 mmol). The resulting reactionmixture was heated to 90° C. and allowed to stir overnight. The reactionmixture was cooled to room temperature and diluted with EtOAc thenwashed with NH₄Cl solution. The organic layer was isolated, dried(MgSO₄), filtered, and concentrated under reduced pressure. Purification(FCC, SiO₂, 0-100% ethyl acetate in hexanes) afforded the title compound(19 mg, 0.05 mmol, 57%). MS (ESI): mass calcd. for C₁₇H₁₆F₂N₆O, 358.3;m/z found, 359.1 [M+H]⁺. ¹H NMR (500 MHz, CDCl₃) δ 8.58-8.54 (d, J=4.7Hz, 2H), 8.05-8.01 (t, J=0.7 Hz, 1H), 7.75-7.70 (d, J=2.5 Hz, 1H),7.67-7.62 (m, 1H), 7.00-6.96 (m, 1H), 6.90-6.65 (m, 1H), 6.57-6.53 (d,J=8.9 Hz, 1H), 5.68-5.62 (d, J=0.6 Hz, 2H), 4.14-4.08 (m, 4H), 2.45-2.36(m, 2H).

Example 189:2-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]-5-fluoro-pyrazine

Step A.2-Chloro-5-((1-(4-chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyrazine

The title compound was prepared in a manner analogous to Example 1 using(1-(3-(difluoromethoxy)-4-chlorophenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 1) and 2,4-dichloropyrazine. MS (ESI): mass calcd. forC₁₄H₉Cl₁₂F₂N₅O₂, 387.0; m/z found, 388.0 [M+H]⁺.

Step B.2-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]-5-fluoro-pyrazine

To a solution of2-chloro-5-((1-(4-chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyrazine(42 mg, 0.108 mmol) in DMSO (0.8 mL) was added CsF (164 mg, 1.1 mmol).The mixture was heated in a sealed reaction vessel to 100° C. for 2.5 h.The reaction mixture was cooled to rt, then diluted with water, ACN andfew drops of HCl (1M, aq). Purification (semi-prep RP-HPLC, equippedwith Phenomenex C18 Gemini 5 um, 250×4.6 mm; 5-95% Acetonitrile in waterwith 0.1% TFA addition) afforded the title compound (8 mg, 20%) afterfree base with NaHCO₃ (aq). MS (ESI): mass calcd. for C₁₄H₉ClF₃N₅O₂,371.0; m/z found, 372.0 [M+H]⁺. ¹H NMR (400 MHz, CD₃CN) δ 8.47-8.36 (m,1H), 8.27-8.19 (m, 1H), 8.10 (dd, J=8.2, 0.7 Hz, 1H), 7.82-7.67 (m, 3H),7.12 (t, J=76 Hz, 1H), 5.59 (s, 2H).

Example 190:4-Chloro-2-[[1-[4-chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]pyrimidine

To a solution of2-((1-(4-chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidin-4-amine(Example 382, 25 mg, 0.068 mmol) in ACN (1 mL) at rt, were addedisopentyl nitrite (0.0137 ml, 0.1 mmol) and copper(II) chloride (9.6 mg,1.071 mmol). The mixture was heated to reflux for 3 hours The reactionmixture was diluted with water (5 mL) and few drops of HCl, filteredthrough a syringe filter (0.25 um). Purification (semi-prep HPLC (95% to5% Water in MeCN with 0.1% TFA addition, Phenomenex C18 Gemini, 5 um,250×4.6 mm)), afforded the title compound which was free based byneutralization with NaHCO₃ (aq) and extraction with EtOAc to afford thetitle compound (7 mg, 27%). MS (ESI): mass calcd. for C₁₄H₉Cl₁₂F₂N₅O₂,387.0; m/z found, 388.1 [M+H]⁺. ¹H NMR (400 MHz, CD₃CN) δ 8.55-8.48 (m,1H), 8.45 (t, J=1.3 Hz, 1H), 7.82-7.68 (m, 3H), 7.24-7.16 (m, 1H), 6.94(t, J=60 Hz, 1H), 5.63 (s, 1H).

Example 191:2-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]-4-fluoro-pyrimidine

The title compound was prepared in a manner analgous to Example 189,Step B, using4-chloro-2-((1-(4-chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidine(Example 190) using MeCN instead of DMSO. MS (ESI): mass calcd. forC₁₄H₉ClF₃N₅O₂, 371.0; m/z found, 372.1 [M+H]⁺. 1H NMR (500 MHz, CDCl₃) δ8.59 (dd, J=11.5, 5.5 Hz, 1H), 8.15 (s, 1H), 7.73 (d, J=2.1 Hz, 1H),7.66-7.62 (m, 1H), 7.61-7.56 (m, 1H), 6.69 (dd, J=5.5, 2.6 Hz, 1H), 6.66(t, J=72.5 Hz, 1H).

Example 192:2-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]-5-(2-fluoroethoxy)pyrimidine

Step A. 2-Chloro-5-(2-fluoroethoxy)pyrimidine

To a mixture of 2-chloropyrimidin-5-ol (1 g, 7.6 mmol) and1-fluoro-2-iodoethane (1.73 g, 9.9 mmol) in DMF (2.9 mL) was addedCs₂CO₃ (3.2 g, 9.9 mmol). The mixture was stirred vigorously for 3 h.The reaction mixture was diluted with EtOAc (20 mL) and filtered, andthe solid was washed with EtOAc (20 mL). The filtrate was washed withwater (3×30 mL) and dried (Na₂SO₄) and concentrated. Purification (FCC,SiO₂, DCM/EtOAc) afforded the title compound as a white solid (847 mg,62.6%). MS (ESI): mass calcd. for C₆H₆ClFN₂O, 176.0; m/z found, 171.1[M+H]⁺.

Step B.2-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]-5-(2-fluoroethoxy)pyrimidine

The title compound was prepared in a manner analogous to Example 1 using(1-(4-chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 1) (41.2 mg, 0.15 mmol) and2-chloro-5-(2-fluoroethoxy)pyrimidine. MS (ESI): mass calcd. forC₁₆H₁₃ClF₃N₅O₃, 415.1; m/z found, 416.1[M+H]⁺. ¹H NMR (500 MHz, CD₃OD) δ8.56 (s, 1H), 8.34 (s, 2H), 7.83 (s, 1H), 7.75-7.66 (m, 3H), 6.87 (m,1H), 5.59 (s, 2H), 4.81-4.80 (m, 1H), 4.71-4.70 (m, 1H), 4.36-4.34 (m,1H), 4.30-4.29 (m, 1H).

Example 193:2-[[1-[4-Chloro-3-(2-fluoroethoxy)phenyl]triazol-4-yl]methoxy]-5-methoxy-pyrimidine

Step A. 2-Chloro-5-(4-(hydroxymethyl)-1H-1,2,3-triazol-1-yl)phenol

A mixture of(1-(4-chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 1) (110 mg, 0.4 mmol) and tBuOK (134 mg, 1.2 mmol) in dryDMSO was stirred at rt for 15 h. The reaction was quenched by addingacetic acid (3 mL). The mixture was subjected to C18 reversed phase HPLCpurification (TFA buffered MeCN/water) to afford the title compound as awhite solid (18 mg, 20%). MS (ESI): mass calcd. for C₉H₈ClN₃O₂, 225.0;m/z found, 226.1[M+H]⁺.

Step B.(1-(4-Chloro-3-(2-fluoroethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methanol

To 2-chloro-5-(4-(hydroxymethyl)-1H-1,2,3-triazol-1-yl)phenol (18 mg,0.08 mg) and Cs₂CO₃ (65 mg, 0.2 mmol) in DMF (0.8 mL) was added1-fluoro-2-iodoethane (16.6 mg, 0.096 mmol). The mixture was stirred atrt for 3 h, and then diluted with EtOAc (30 mL), washed with water 3×20mL), dried (Na₂SO₄), and concentrated. Purification (FCC, SiO₂,DCM/EtOAc) afforded the title compound (19 mg, 87%). MS (ESI): masscalcd. for C₁₁H₁₁ClFN₃O₂, 271.0; m/z found, 272.1[M+H]⁺.

Step C.2-[[1-[4-Chloro-3-(2-fluoroethoxy)phenyl]triazol-4-yl]methoxy]-5-methoxy-pyrimidine

The title compound was prepared in a manner analogous to Example 1 using(1-(4-chloro-3-(2-fluoroethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methanoland 2-chloro-5-methoxypyrimidine. MS (ESI): mass calcd. forC₁₆H₁₅ClFN₅O₃, 379.1; m/z found, 380.1 [M+H]⁺. ¹H NMR (600 MHz, CD₃OD) δ8.39 (s, 1H), 8.25 (s, 2H), 7.52 (t, J=1.1 Hz, 2H), 7.31 (dd, J=8.5, 2.4Hz, 1H), 5.56 (s, 2H), 4.87-4.83 (m, 1H), 4.80-4.75 (m, 1H), 4.43-4.39(m, 1H), 4.39-4.33 (m, 1H), 3.88 (s, 2H).

Example 194:2-[[1-[4-Fluoro-3-(3-fluoropropyl)phenyl]triazol-4-yl]methoxy]-5-methoxy-pyrimidine

Step A.(E)-2-((1-(4-Fluoro-3-(3-((tetrahydro-2H-pyran-2-yl)oxy)prop-1-en-1-yl)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)-5-methoxypyrimidine

A mixture of2-((1-(3-bromo-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-5-methoxypyrimidine(Example 41, 80 mg, 0.21 mmol),(E)-4,4,5,5-tetramethyl-2-(3-((tetrahydro-2H-pyran-2-yl)oxy)prop-1-en-1-yl)-1,3,2-dioxaborolane(84 mg, 0.31 mmol), Pd(PPh₃)₄(12 mg, 0.01 mmol), and Na₂CO₃ solution(1.0 M, 0.63 mL, 0.62 mmol) in a microwave tube was heated at 110° C.for 20 min under microwave irradiation. The reaction mixture was dilutedwith EtOAc (10 mL) and washed with water (2×10 mL). The organic phasewas dried (Na₂SO₄), filtered, and concentrated under reduced pressure.Purification (FCC, SiO₂, hexane/EtOAc) afforded the title compound (68mg, 73.2%). MS (ESI): mass calcd. for C₂₂H₂₄FN₅O₄, 441.2; m/z found,442.3 [M+H]⁺.

Step B.2-((1-(4-Fluoro-3-(3-((tetrahydro-2H-pyran-2-yl)oxy)propyl)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)-5-methoxypyrimidine

A solution of(E)-2-((1-(4-fluoro-3-(3-((tetrahydro-2H-pyran-2-yl)oxy)prop-1-en-1-yl)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)-5-methoxypyrimidine(22 mg, 0.05 mmol) in MeOH (10 mL) was purged with nitrogen. Pd/C (10%,30 mg) was added. The mixture was purged with hydrogen twice. Themixture was stirred under hydrogen atmosphere at rt for 15 min. Themixture was filtered and the filtrate was concentrated. Purification(FCC, SiO₂, hexane/EtOAc) afforded the title compound (22 mg, 99%). MS(ESI): mass calcd. for C₂₂H₂₂FN₅O₄, 443.2; m/z found, 444.3 [M+H]⁺.

Step C.3-(2-Fluoro-5-(4-(((5-methoxypyrimidin-2-yl)oxy)methyl)-1H-1,2,3-triazol-1-yl)phenyl)propan-1-ol

To2-((1-(4-fluoro-3-(3-((tetrahydro-2H-pyran-2-yl)oxy)propyl)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)-5-methoxypyrimidine(22 mg, 0.05 mmol) in MeOH (10 mL) was added concentrated HCl dropwiseat rt. The mixture was stirred at rt for 15 min. To the mixture wasadded 0.1 mL of water and the volatiles were removed under reducedpressure and dried under high vacuum. Purification (FCC, SiO₂,DCM/methanol) afforded the title compound. mass calcd. for C₁₇H₁₈FN₅O₃,359.1; m/z found, 360.2 [M+H]⁺.

Step D.2-((1-(4-Fluoro-3-(3-fluoropropyl)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)-5-methoxypyrimidine

To3-(2-fluoro-5-(4-(((5-methoxypyrimidin-2-yl)oxy)methyl)-1H-1,2,3-triazol-1-yl)phenyl)propan-1-ol(21 mg, 0.058 mmol) in 0.2 mL of DCM at −78° C. was added(diethylamino)sulfur trifluoride (0.072 mL, 0.6 mmol) with stirring. Thereaction was allowed to warm slowly to rt with stirring and concentratedunder reduced pressure. Purification (semi-prep RP-HPLC (95% to 5% Waterin MeCN with 0.1% TFA addition, Phenomenex C18 Gemini, 5 um, 250×4.6 mm)afforded the title compound (1.2 mg, 6%) and2-[[1-[3-(3-chloropropyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-5-methoxy-pyrimidine.MS (ESI): mass calcd. for C₁₇H₁₇F₂N₅O₂, 361.1; m/z found, 362.2 [M+H]⁺.¹H NMR (400 MHz, CD₃OD) δ 8.50 (s, 1H), 8.23 (s, 2H), 7.70 (dd, J=6.4,2.8 Hz, 1H), 7.65-7.58 (m, 1H), 7.19 (t, J=9.1 Hz, 1H), 5.45 (s, 2H),4.45 (t, J=5.9 Hz, 1H), 4.33 (t, J=5.9 Hz, 1H), 3.80 (s, 3H), 2.78 (t,J=7.9 Hz, 2H).

Example 195:2-[[1-[3-(3-Chloropropyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-5-methoxy-pyrimidine

The title compound was obtained as a by-product from the synthesis ofExample 194, step D. (1.3 mg, 6%). MS (ESI): mass calcd. forC₁₇H₁₇ClFN₅O₂, 377.1; m/z found, 378.1 [M+H]⁺. ¹H NMR (400 MHz, CD₃OD) δ8.62 (s, 1H), 8.35 (s, 2H), 7.82 (dd, J=6.3, 2.7 Hz, 1H), 7.78-7.71 (m,1H), 7.31 (t, J=9.1 Hz, 1H), 5.57 (s, 2H), 3.92 (s, 3H), 3.64 (t, J=6.4Hz, 2H), 2.94 (t, J=7.6 Hz, 2H), 2.15 (ddd, J=7.7, 6.3, 1.3 Hz, 2H)

Example 196:2-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]-5-(3-fluoropropyl)pyrimidine

Step A: 3-(2-Methoxypyrimidin-5-yl)prop-2-yn-1-ol

To a degassed solution of 5-bromo-2-methoxypyrimidine (4.0 g, 21 mmol),trimethylamine (5.9 mL, 42 mmol), PdCl₂(PPh₃)₂(1.5 g, 2.1 mmol) and CuI(0.4 g, 2.1 mmol) in DMF (33 mL) was added prop-2-yn-1-ol (3.1 mL, 53mmol) was added. The reaction was sealed and heated at 90° C. for 4hours. The reaction was diluted with brine and extracted with EtOAc (50mL×3). The combined organics were dried, filtered, concentrated underreduced pressure. Purification (FCC, SiO₂, hexanes/EtOAc; 4:1) affordedthe title compound (1.8 g, 52%) MS (ESI): mass calcd. for C₈H₈N₂O₂,164.1; m/z found, [M+H]⁺ 165.1.

Step B: 3-(2-Methoxypyrimidin-5-yl)propan-1-ol

An ethanol solution (65 mL) of 3-(2-methoxypyrimidin-5-yl)prop-2-yn-1-ol(1.8 g, 11 mmol) was added to Pd/C (10% wt, 583 mg). The reactionmixture was stirred under hydrogen atmosphere (1 atm) for 3 hours. Thereaction mixture was filtered through diatomaceous earth andconcentrated under reduced pressure to afford the title compound (1.5 g,81%) MS (ESI): mass calcd. for C₈H₁₂N₂O₂, 168.1; m/z found, [M+H]⁺169.1.

Step C: 3-(2-Methoxypyrimidin-5-yl)propyl 4-methylbenzenesulfonate

To a solution of 3-(2-methoxypyrimidin-5-yl)propan-1-ol (450 mg, 2.7mmol) in DCM (17 mL), were added trimethylamine (1.1 mL, 8.0 mmol) andsulfonyl chloride (1.02 g, 5.35 mmol). The reaction mixture was stirredat rt overnight. The reaction was diluted with NaHCO₃ (aq, 25 mL) andthe aqueous layers were extracted with EtOAc (30 mL×3). The combinedorganic extracts was dried, filtered, and concentrated under reducedpressure. Purification (FCC, SiO₂, hexanes/EtOAc; 5:1) afforded thetitle compound (540 mg, 63%) MS (ESI): mass calcd. for C₁₅H₁₈N₂O₄S,322.1; m/z found, [M+H]⁺ 323.1.

Step D: 5-(3-Fluoropropyl)-2-methoxypyrimidine

To a solution of 3-(2-methoxypyrimidin-5-yl)propyl4-methylbenzenesulfonate (750 mg, 2.3 mmol) in THF (10 mL) was addedTBAF (1.0 M in THF, 3.5 mL, 3.5 mmol). The reaction mixture was heatedto 60° C. for 30 min. The reaction mixture was concentrated underreduced pressure. The crude product was diluted with EtOAc (50 mL),washed with NaHCO₃ (aq, 30 mL) and brine (30 mL). The combined organicswere dried, filtered, and concentrated under reduced pressure.Purification (FCC, SiO₂, hexanes EtOAc; 5:1) afforded the title compound(290 mg, 73%) MS (ESI): mass calcd. for C₈H₁₁FN₂O, 170.1; m/z found,[M+H]⁺ 171.1.

Step E: 5-(3-Fluoropropyl)pyrimidin-2(1H)-one hydrochloride salt

A solution of 5-(3-fluoropropyl)-2-methoxypyrimidine (250 mg, 1.47 mmol)in HCl (4M in dioxane, 1.1 mL, 4.4 mmol) and water (0.26 mL, 14.7 mmol)was heated to 100° C. for 5 hours. The mixture was concentrated underreduced pressure to afford the title compound as a white HCl salt whichwas used in next step without further purification. MS (ESI): masscalcd. for C₇H₉FN₂O, 156.1; m/z found, [M+H]⁺ 157.1.

Step F. 2-Chloro-5-(3-fluoropropyl)pyrimidine

A mixture of 5-(3-fluoropropyl)pyrimidin-2(1H)-one hydrochloride (120mg, 0.62 mmol) in POCl₃ (2 mL) was heated at 95° C. for 20 h. Thereaction mixture was cooled and concentrated under reduced pressure. Theresidue was diluted with EtOAc (30 mL) and washed with NaHCO₃ (aq, sat.3×20 mL). The organics were dried, filtered, and concentrated underreduced pressure. Purification (FCC, SiO₂, hexane/EtOAc) afforded thetitle compound (66 mg, 66%). MS (ESI): mass calcd. for C₇H₆ClFN₂, 174.0;m/z found, 175.0 [M+H]⁺.

Step G.2-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]-5-(3-fluoropropyl)pyrimidine

The title compound was prepared in a manner analogous to Example 1 using(1-(4-chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 1) and 2-chloro-5-(3 fluoropropyl)pyrimidine. MS (ESI):mass calcd. for C₁₇H₁₅ClF₃N₅O₂, 413.1; m/z found, 414.1 [M+H]⁺. ¹H NMR(400 MHz, CDCl₃) δ 8.45 (s, 2H), 8.17 (s, 1H), 7.74 (d, J=2.2 Hz, 1H),7.67-7.56 (m, 2H), 6.68 (t, J=72.5 Hz, 1H), 5.67 (d, J=0.7 Hz, 2H), 4.57(t, J=5.7 Hz, 1H), 4.46 (t, J=5.7 Hz, 1H), 2.76 (t, J=7.7 Hz, 2H),2.15-1.92 (m, 2H).

Example 197:N-[[1-[3-(Difluoromethyl)phenyl]triazol-4-yl]methyl]-5-fluoro-pyrimidin-2-amine

The title compound was prepared in a manner analogous to Example 153using 2-amino-5-fluoropyrimidine. MS (ESI): mass calcd. for C₁₄H₁₁F₃N₆,320.1; m/z found, 321.0 [M+H]⁺. ¹H NMR (500 MHz, CDCl₃) δ 8.23 (d, J=2.2Hz, 2H), 7.99 (s, 1H), 7.98-7.77 (m, 2H), 7.70-7.53 (m, 2H), 6.72 (t,J=56.1 Hz, 1H), 5.73 (s, 1H), 4.79 (d, J=6.4 Hz, 2H).

Example 198:N-[[1-(4-Fluoro-3-methyl-phenyl)triazol-4-yl]methyl]-5-methyl-pyrimidin-2-amine

The title compound was prepared in a manner analogous to Example 6,using (1-(4-fluoro-3-methylphenyl)-1H-1,2,3-triazol-4-yl)methanamine(Intermediate 26) and 2-chloro-5-methylpyrimidine. MS (ESI): mass calcd.for C₁₅H₁₅FN₆, 298.1; m/z found, 299.0 [M+H]⁺. ¹H NMR (400 MHz, DMSO-d₆)δ 8.52-8.50 (m, 1H), 8.18-8.14 (m, 2H), 7.88-7.83 (m, 1H), 7.75-7.69 (m,1H), 7.40-7.30 (m, 2H), 4.58 (d, J=6.1 Hz, 2H), 2.34-2.29 (m, 3H),2.08-2.04 (m, 3H).

Example 199:5-Chloro-N-[[1-(4-fluoro-3-methyl-phenyl)triazol-4-yl]methyl]-4-methyl-pyrimidin-2-amine

The title compound was prepared in a manner analogous to Example 6,using (1-(4-fluoro-3-methylphenyl)-1H-1,2,3-triazol-4-yl)methanamine(Intermediate 26) and 2,5-dichloro-4-methylpyrimidine. MS (ESI): masscalcd. for C₁₅H₁₄ClFN₆, 332.1; m/z found, 332.9 [M+H]⁺. ¹H NMR (400 MHz,DMSO-d₆) δ 8.54 (s, 1H), 8.25 (s, 1H), 7.88-7.79 (m, 2H), 7.76-7.70 (m,1H), 7.35 (t, J=9.1 Hz, 1H), 4.59 (d, J=6.0 Hz, 2H), 2.36 (s, 3H), 2.32(d, J=2.0 Hz, 3H).

Example 200:5-Chloro-N-[[1-[4-chloro-3-(difluoromethyl)phenyl]triazol-4-yl]methyl]pyrimidin-2-amine

The title compound was prepared in a manner analogous to Example 154using 2,5-dichloropyrimidine. MS (ESI): mass calcd. for C₁₄H₁₀Cl₁₂F₂N₆,370.0; m/z found, 371.0 [M+H]⁺. ¹H NMR (500 MHz, CDCl₃) δ 8.26 (s, 2H),8.00-7.95 (m, 2H), 7.90-7.83 (m, 1H), 7.62-7.55 (m, 1H), 6.98 (t, J=54.5Hz, 1H), 5.88 (t, J=6.4 Hz, 1H), 4.79 (d, J=6.1 Hz, 2H).

Example 201:N-[[1-[4-Chloro-3-(difluoromethyl)phenyl]triazol-4-yl]methyl]-4-methyl-pyrimidin-2-amine

The title compound was prepared in a manner analogous to Example 154using, using 2-chloro-4-methylpyrimidine. MS (ESI): mass calcd. forC₁₅H₁₃ClF₂N₆, 350.1; m/z found, 351.1 [M+H]⁺. ¹H NMR (500 MHz, CDCl₃) δ8.20 (d, J=5.0 Hz, 1H), 8.01 (s, 1H), 7.99-7.95 (m, 1H), 7.88-7.83 (m,1H), 7.63-7.55 (m, 1H), 6.98 (t, J=54.5 Hz, 1H), 6.52 (d, J=5.0 Hz, 1H),6.12 (s, 1H), 4.85 (d, J=6.1 Hz, 2H), 2.39 (s, 3H).

Example 202:N-[[1-[4-Chloro-3-(difluoromethyl)phenyl]triazol-4-yl]methyl]-5-ethyl-pyrimidin-2-amine

The title compound was prepared in a manner analogous to Example 154using 2-chloro-5-ethylpyrimidine. MS (ESI): mass calcd. forC₁₅H₁₅ClF₂N₆, 364.1; m/z found, 365.1 [M+H]⁺. ¹H NMR (500 MHz, CDCl₃) δ8.26 (s, 2H), 8.11 (s, 1H), 7.99 (d, J=2.5 Hz, 1H), 7.85 (dd, J=8.7, 2.5Hz, 1H), 7.58 (d, J=8.7 Hz, 1H), 7.10 (s, 1H), 6.97 (t, J=54.5 Hz, 1H),4.89 (d, J=5.5 Hz, 2H), 2.54 (q, J=7.6 Hz, 2H), 1.23 (t, J=7.6 Hz, 3H).

Example 203:N-[[1-[4-Chloro-3-(difluoromethyl)phenyl]triazol-4-yl]methyl]-5-methoxy-pyrimidin-2-amine

The title compound was prepared in a manner analogous to Example 154using 2-chloro-5-methoxypyrimidine. MS (ESI): mass calcd. forC₁₅H₁₃ClF₂N₆O, 366.1; m/z found, 367.0 [M+H]⁺. ¹H NMR (500 MHz, CDCl₃) δ8.10 (s, 2H), 7.99-7.96 (m, 2H), 7.89-7.83 (m, 1H), 7.61-7.57 (m, 1H),6.98 (t, J=54.5 Hz, 1H), 5.55-5.42 (m, 1H), 4.78 (d, J=6.2 Hz, 2H), 3.81(s, 3H)

Example 204:N-[[1-[4-Chloro-3-(difluoromethyl)phenyl]triazol-4-yl]methyl]-5-(difluoromethyl)pyrimidin-2-amine

The title compound was prepared in a manner analogous to Example 154using 2-chloro-5-difluoromethylpyrimidine. MS (ESI): mass calcd. forC₁₅H₁₁ClF₄N₆, 386.1; m/z found, 387.0 [M+H]⁺. ¹H NMR (500 MHz, CDCl₃) δ8.45 (s, 2H), 8.02-7.99 (m, 1H), 7.98 (d, J=2.5 Hz, 1H), 7.89-7.84 (m,1H), 7.60 (dd, J=8.6, 1.0 Hz, 1H), 6.99 (t, J=54.5 Hz, 1H), 6.59 (t,J=56.0 Hz, 1H), 6.05 (s, 1H), 4.86 (d, J=6.2 Hz, 2H).

Example 205:N-[[1-[4-Chloro-3-(difluoromethyl)phenyl]triazol-4-yl]methyl]-5-(trifluoromethyl)pyrimidin-2-amine

The title compound was prepared in a manner analogous to Example 154using 2-chloro-5-trifluoromethylpyrimidine. MS (ESI): mass calcd. forC₁₅H₁₀ClF₅N₆, 404.1; m/z found, 405.0 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃) δ8.54 (s, 2H), 8.02 (s, 1H), 7.98 (d, J=2.6 Hz, 1H), 7.90-7.84 (m, 1H),7.63-7.56 (m, 1H), 6.98 (t, J=54.5 Hz, 1H), 6.43-6.31 (m, 1H), 4.87 (d,J=6.0 Hz, 2H).

Example 206:N-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methyl]-5-methyl-pyrimidin-2-amine

The title compound was prepared in a manner analogous to Example 154using(1-(3-(1,1-difluoroethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanamine(Intermediate 20). MS (ESI): mass calcd. for C₁₆H₁₅F₃N₆, 348.1; m/zfound, 349.0 [M+H]⁺. ¹H NMR (400 MHz, CD₃OD) δ 8.46-8.44 (m, 1H), 8.20(d, J=0.7 Hz, 2H), 8.07-8.03 (m, 1H), 8.02-7.96 (m, 1H), 7.46 (t, J=9.7Hz, 1H), 4.74 (s, 2H), 2.16 (s, 3H), 2.06 (td, J=18.7, 1.1 Hz, 3H).

Example 207:N-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methyl]-5-ethyl-pyrimidin-2-amine

The title compound was prepared in a manner analogous to Example 154using(1-(3-(1,1-difluoroethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanamine(Intermediate 20) and 2-chloro-5-ethylpyrimidine. MS (ESI): mass calcd.for C₁₇H₁₇F₃N₆, 362.1; m/z found, 363.1 [M+H]⁺. ¹H NMR (400 MHz, CD₃OD)δ 8.45 (s, 1H), 8.22 (s, 2H), 8.07-7.95 (m, 2H), 7.45 (t, J=9.6 Hz, 1H),4.74 (s, 2H), 2.52 (q, J=7.6 Hz, 2H), 2.14-1.99 (m, 3H), 1.21 (t, J=7.6Hz, 3H).

Example 208:N-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methyl]-5-isopropyl-pyrimidin-2-amine

The title compound was prepared in a manner analogous to Example 154using(1-(3-(1,1-difluoroethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanamine(Intermediate 20) and 2-chloro-4-isopropylpyrimidine. MS (ESI): masscalcd. for C₁₈H₁₉F₃N₆, 376.2; m/z found, 377.2 [M+H]⁺. ¹H NMR (400 MHz,CD₃OD) δ 8.46 (s, 1H), 8.25 (s, 2H), 8.07-8.03 (m, 1H), 8.02-7.97 (m,1H), 7.46 (t, J=9.6 Hz, 1H), 4.75 (d, J=0.7 Hz, 2H), 2.89-2.78 (m, 1H),2.06 (td, J=18.7, 1.1 Hz, 3H), 1.27 (d, J=7.0 Hz, 6H).

Example 209:5-Cyclopropyl-N-[[1-[3-(1,1-difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methyl]pyrimidin-2-amine

The title compound was prepared in a manner analogous to Example 154using(1-(3-(1,1-difluoroethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanamine(Intermediate 20) and 2-chloro-4-cyclopropylpyrimidine. MS (ESI): masscalcd. for C₁₈H₁₇F₃N₆, 374.1; m/z found, 375.1 [M+H]⁺. ¹H NMR (400 MHz,CD₃OD) δ 8.45 (s, 1H), 8.15 (s, 2H), 8.07-8.02 (m, 1H), 8.02-7.95 (m,1H), 7.46 (t, J=9.6 Hz, 1H), 4.74 (s, 2H), 2.13-1.99 (m, 3H), 1.84-1.73(m, 1H), 0.99-0.88 (m, 2H), 0.68-0.60 (m, 2H).

Example 210:N-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methyl]-4,5-dimethyl-pyrimidin-2-amine

The title compound was prepared in a manner analogous to Example 154using(1-(3-(1,1-difluoroethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanamine(Intermediate 20) and 2-chloro-4,5-dimethylpyrimidine. MS (ESI): masscalcd. for C₁₇H₁₇F₃N₆, 362.1; m/z found, 363.1 [M+H]⁺. ¹H NMR (400 MHz,CD₃OD) δ 8.44 (s, 1H), 8.07-7.96 (m, 3H), 7.49-7.42 (m, 1H), 4.74 (s,2H), 2.35 (s, 3H), 2.14-2.11 (m, 3H), 2.11-2.00 (m, 3H).

Example 211:N-[[1-[3-(Difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methyl]-5-methyl-pyrimidin-2-amine

The title compound was prepared in a manner analogous to Example 154using(1-(3-(difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanamine(Intermediate 21) and 2-chloro-5-methylpyrimidine. MS (ESI): mass calcd.for C₁₅H₁₃F₃N₆, 334.1; m/z found, 335.1 [M+H]⁺. ¹H NMR (500 MHz, CDCl₃)δ 8.19-8.16 (m, 2H), 7.96-7.94 (m, 1H), 7.92-7.86 (m, 2H), 7.30 (t,J=9.0 Hz, 1H), 6.94 (t, J=54.7 Hz, 1H), 5.52 (s, 1H), 4.87-4.75 (m, 2H),2.21-2.07 (m, 3H).

Example 212:5-Chloro-N-[[1-[3-(difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methyl]pyrimidin-2-amine

The title compound was prepared in a manner analogous to Example 154using(1-(3-(difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanamine(Intermediate 21) and 2,5-dichloropyrimidine. MS (ESI): mass calcd. forC₁₄H₁₀ClF₃N₆, 354.1; m/z found, 355.0 [M+H]⁺. ¹H NMR (500 MHz, CDCl₃) δ8.27 (s, 2H), 7.97-7.94 (m, 1H), 7.94-7.85 (m, 2H), 7.31 (t, J=9.0 Hz,1H), 6.94 (t, J=54.5 Hz, 1H), 5.73 (s, 1H), 4.79 (d, J=6.4 Hz, 2H).

Example 213:N-[[1-[3-(Difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methyl]-5-(trifluoromethyl)pyrimidin-2-amine

The title compound was prepared in a manner analogous to Example 154using(1-(3-(difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanamine(Intermediate 21) and 2-chloro-5-trifluoromethylpyrimidine. MS (ESI):mass calcd. for C₁₅H₁₀F₆N₆, 388.1; m/z found, 389.0 [M+H]⁺. ¹H NMR (500MHz, CDCl₃) δ 8.54 (s, 2H), 7.98 (s, 1H), 7.95-7.85 (m, 2H), 7.32 (t,J=9.0 Hz, 1H), 6.95 (t, J=54.6 Hz, 1H), 6.16 (s, 1H), 4.86 (d, J=6.5 Hz,2H).

Example 214:2-[2-[[1-[3-(Difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methylamino]pyrimidin-5-yl]propan-2-ol

The title compound was prepared in a manner analogous to Example 154using(1-(3-(difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanamine(Intermediate 21) and 2-(2-chloropyrimidin-5-yl)propan-2-ol. MS (ESI):mass calcd. for C₁₇H₁₇F₃N₆O, 378.1; m/z found, 379.0 [M+H]⁺. ¹H NMR (500MHz, CDCl₃) δ 8.47 (s, 2H), 7.99-7.94 (m, 1H), 7.94-7.86 (m, 2H), 7.31(t, J=9.0 Hz, 1H), 6.94 (t, J=54.6 Hz, 1H), 5.66 (s, 1H), 4.87-4.77 (m,2H), 1.58 (s, 6H).

Example 215.N-((1-(3-(Difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methyl)pyridin-2-amine

A mixture of(1-(3-(difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanamine(Intermediate 21) (69 mg, 0.29 mmol), 2-iodopyridine (0.03 mL, 0.29mmol), cuprous iodide (27.1 mg, 0.14 mmol),1-(5,6,7,8-tetrahydroquinolin-8-yl)ethan-1-one (0.045 mL, 0.29 mmol),and Cs₂CO₃ (185.6 mg, 0.57 mmol) in DMF (0.9 mL) under N₂ in a sealedtube was stirred at rt for 16 h. The mixture was concentrated un vacuo.Purification (FCC, EtOAc/heptane from 0-100%) and re-purification (HPLC,Stationary phase: C18 XBridge 30×100 mm 5 um), Mobile phase: Gradientfrom 90% 10 mM NH₄CO₃H pH 9 solution in Water, 10% CH₃CN to 0% 10 mMNH₄CO₃H pH 9 solution in Water, 100% CH₃CN) afforded the title compound(12 mg, 13%). MS (ESI): mass calcd. for C₁₅H₁₂F₃N₆, 319.1; m/z found,320.1 [M+H]⁺. ¹H NMR (500 MHz, CDCl₃) δ 4.77 (d, J=5.49 Hz, 2H), 5.06(br s, 1H), 6.49 (dt, J=8.4, 0.9 Hz, 1H), 6.64 (ddd, J=7.2, 5.0, 0.9 Hz,1H), 6.77-7.09 (m, 1H), 7.31 (t, J=9.1 Hz, 1H), 7.43 (ddd, J=8.5, 6.9,1.9 Hz, 1H), 7.82-7.91 (m, 1H), 7.93 (dd, J=5.6, 2.8 Hz, 1H), 7.96 (s,1H), 8.08-8.26 (m, 1H).

Example 216:N-((1-(3-(Difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methyl)-5-ethylpyrimidin-2-amine

The title compound was prepared in a manner analogous to Example 153using(1-(3-(difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanamine(Intermediate 21) and 2-chloro-5-ethylpyrimidine. MS (ESI): mass calcd.for C₁₆H₁₅F₃N₆, 348.1; m/z found, 349.0 [M+H]⁺. ¹H NMR (300 MHz,DMSO-d₆) δ 8.62 (s, 1H), 8.13 (s, 2H), 8.11-7.97 (m, 2H), 7.55 (t, J=9.4Hz, 1H), 7.45-6.88 (m, 2H), 4.53 (d, J=6.0 Hz, 2H), 2.35 (q, J=7.5 Hz,2H), 1.05 (t, J=7.6 Hz, 3H).

Example 217:N-((1-(3-(Difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methyl)-4,5-dimethylpyrimidin-2-amine

The title compound was prepared in a manner analogous to Example 153using(1-(3-(difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanamine(Intermediate 21) and 2-chloro-4,5-dimethylpyrimidine. MS (ESI): masscalcd. for C₁₆H₁₅F₃N₆, 348.1; m/z found, 349.0 [M+H]⁺. ¹H NMR (300 MHz,DMSO-d₆) δ 8.66 (s, 1H), 8.15 (dd, J=12.0, 4.6 Hz, 2H), 7.99 (s, 1H),7.62 (t, J=9.4 Hz, 1H), 7.29 (t, J=72.0, 1H), 7.24 (t, J=5.8 Hz, 1H),4.59 (d, J=6.0 Hz, 2H), 2.24 (s, 3H), 2.03 (s, 3H).

Example 218:5-Chloro-N-((1-(3-(difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methyl)-4-methylpyrimidin-2-amine

The title compound was prepared in a manner analogous to Example 153using(1-(3-(difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanamine(Intermediate 21) and 2,5-dichloro-4-methylpyrimidine. MS (ESI): masscalcd. for C₁₅H₁₂ClF₃N₆, 368.1; m/z found, 369.0 [M+H]⁺. ¹H NMR (300MHz, DMSO-d₆) δ 8.70 (s, 1H), 8.24 (s, 1H), 8.15 (dd, J=10.6, 4.7 Hz,2H), 7.84 (t, J=5.6 Hz, 1H), 7.63 (t, J=9.4 Hz, 1H), 7.29 (t, J=53.9 Hz,1H), 4.60 (d, J=5.9 Hz, 2H), 2.36 (s, 3H).

Example 219:N-((1-(3-(Difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methyl)-1-methyl-1H-pyrazol-5-amine

Step A.1-(3-(Difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazole-4-carbaldehyde

To a solution of(1-(3-(difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 9) (50 mg, 0.21 mmol) and sodium acetate (50.6 mg, 0.62mmol) stirring in DCM (2 mL) was added pyridinium chlorochromate (PCC)(88.6 mg, 0.41 mmol), and the mixture was stirred at rt for 2 h. Thesuspension was filtered and the solvent removed under vacuum. The crudeproduct was used without purification.

Step B.N-((1-(3-(Difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methyl)-1-methyl-1H-pyrazol-5-amine

To1-(3-(Difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazole-4-carbaldehyde(42 mg, 0.17 mmol) and 1-methyl-1H-pyrazol-5-amine (18.9 mg, 0.19 mmol)stirring in MeOH (2.2 mL) and AcOH (0.2 mL) was added NaBH₃CN, and themixture was stirred at rt for 90 min. The suspension was filtered andthe solvent was removed under vacuum. The residue was purified by HPLC((Stationary phase: C18 XBridge 30×100 mm 5 um), Mobile phase: Gradientfrom 74% 10 mM NH₄CO₃H pH 9 solution in Water, 26% CH₃CN to 58% 10 mMNH₄CO₃H pH 9 solution in Water, 42% CH₃CN)) to afford the product (12mg, 18%). MS (ESI): mass calcd. for C₁₄H₁₃F₃N₆, 322.1; m/z found, 323.1[M+H]⁺. ¹H NMR (500 MHz, CDCl₃) δ 8.20-7.75 (m, 3H), 7.45-7.29 (m, 1H),7.58-7.29 (m, 1H), 7.17-6.77 (m, 1H), 5.59 (s, 1H), 4.49 (s, 2H), 4.03(br s, 1H), 3.68 (s, 3H).

Example 220:N-((1-(3-(Difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methyl)-1-methyl-1H-imidazol-2-amine

The title compound was prepared in a manner analogous to Example 7 using(1-(3-(difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanamine(Intermediate 21). MS (ESI): mass calcd. for C₁₄H₁₃F₃N₆, 322.1; m/zfound, 323.1 [M+H]⁺. 1H NMR (500 MHz, CDCl₃) δ 8.12 (s, 1H), 7.95 (dd,J=2.9, 5.8 Hz, 1H), 7.92-7.82 (m, 1H), 7.31 (t, J=9.0 Hz, 1H), 6.95 (t,J=54.6 Hz, 1H), 6.71 (d, J=1.7 Hz, 1H), 6.54 (d, J=1.4 Hz, 1H), 4.72 (d,J=6.4 Hz, 2H), 4.19 (br t, J=6.1 Hz, 1H), 3.39 (s, 3H).

Example 221:N-((1-(3-(Difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methyl)pyridin-2-amine

The title compound was prepared in a manner analogous to Example 215using(1-(3-(difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanamine(Intermediate 18). MS (ESI): mass calcd. for C₁₅H₁₂F₃N₅O, 335.1; m/zfound, 336.1 [M+H]⁺. 1H NMR (500 MHz, CDCl₃) δ 4.75 (d, J=6.1 Hz, 2H)5.05 (br s, 1H) 6.38-6.87 (m, 3H) 7.32 (t, J=9.3 Hz, 1H) 7.42 (ddd,J=8.5, 6.9, 1.9 Hz, 1H) 7.50-7.61 (m, 1H) 7.67 (dd, J=6.7, 2.6 Hz, 1H)7.9 (s, 1H) 8.07-8.26 (m, 1H).

Example 222:N-((1-(3-(Difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methyl)-5-methylpyrimidin-2-amine

The title compound was prepared in a manner analogous to Example 153using(1-(3-(difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanamine(Intermediate 18) and 2-chloro-5-methylpyrimidine. MS (ESI): mass calcd.for C₁₅H₁₃F₃N₆O, 350.1; m/z found, 350.9 [M+H]⁺. ¹H NMR (300 MHz,DMSO-d₆) δ 8.63 (s, 1H), 8.17 (s, 2H), 8.04-7.90 (m, 1H), 7.91-7.77 (m,1H), 7.64 (t, J=9.6 Hz, 1H), 7.46-7.35 (m, 1H), 7.38 (t, J=72.5 Hz, 1H),4.59 (d, J=6.0 Hz, 2H), 2.06 (s, 3H).

Example 223:N-((1-(3-(Difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methyl)-1-methyl-1H-pyrazol-5-amine

The title compound was prepared in a manner analogous to Example 219using(1-(3-(difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanamine(Intermediate 18) in step A. MS (ESI): mass calcd. for C₁₄H₁₃F₃N₆O,338.1; m/z found, 339.1 [M+H]⁺. ¹H NMR (500 MHz, CDCl₃) δ 7.88 (s, 1H),7.69 (dd, J=2.5, 6.5 Hz, 1H), 7.62-7.53 (m, 1H), 7.35 (t, J=9.2 Hz, 1H),7.30 (d, J=1.2 Hz, 1H), 6.65 (t, J=72.8 Hz, 1H), 5.57 (d, J=1.7 Hz, 1H),4.48 (s, 2H), 3.95 (br s, 1H), 3.68 (s, 3H).

Example 224:N-[(1R)-1-[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]ethyl]-5-methyl-pyrimidin-2-amine

The title compound was prepared in a manner analogous to Example 154using(R)-1-(1-(4-chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)ethan-1-amine(Intermediate 24) and 2-chloro-5-methylpyrimidine. MS (ESI): mass calcd.for C₁₆H₁₅ClF₂N₆O, 380.1; m/z found, 381.0 [M+H]⁺. ¹H NMR (500 MHz,CDCl₃) δ 8.17-8.11 (d, J=0.8 Hz, 2H), 7.87-7.82 (s, 1H), 7.69-7.65 (d,J=2.3 Hz, 1H), 7.61-7.51 (m, 2H), 6.78-6.45 (t, J=72.6 Hz, 1H),5.46-5.36 (m, 2H), 2.17-2.10 (t, J=0.7 Hz, 3H), 1.77-1.68 (d, J=6.6 Hz,3H).

Example 225:5-Chloro-2-[[1-(4-chlorophenyl)triazol-4-yl]methoxy]pyrimidine

The title compound was prepared analogous to Example 155, using(1-(4-chlorophenyl)-1H-1,2,3-triazol-4-yl)methanol and2,5-dichloropyrimidine. MS (ESI): mass calcd. for C₁₃H₉Cl₁₂N₅O, 321.0;m/z found, 322.0 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃) δ 8.49 (s, 2H), 8.09(s, 1H), 7.71-7.63 (m, 2H), 7.53-7.45 (m, 2H), 5.62 (d, J=0.7 Hz, 2H).

Example 226:2-[[1-(4-Chlorophenyl)triazol-4-yl]methoxy]-5-(trifluoromethyl)pyrimidine

The title compound was prepared analogous to Example 155, using(1-(4-chlorophenyl)-1H-1,2,3-triazol-4-yl)methanol and2-chloro-5-trifluoromethylpyrimidine. MS (ESI): mass calcd. forC₁₄H₉ClF₃N₅O, 355.0; m/z found, 356.0 [M+H]⁺. ¹H NMR (500 MHz, CDCl₃) δ8.82 (d, J=0.8 Hz, 2H), 8.11 (s, 1H), 7.71-7.66 (m, 2H), 7.54-7.49 (m,2H), 5.73 (d, J=0.7 Hz, 2H).

Example 227:2-[[1-(4-Chlorophenyl)triazol-4-yl]methoxy]-5-(difluoromethoxy)pyrimidine

The title compound was prepared analogous to Example 155, using(1-(4-chlorophenyl)-1H-1,2,3-triazol-4-yl)methanol and2-chloro-5-(difluoromethoxy)pyrimidine. MS (ESI): mass calcd. forC₁₄H₁₀ClF₂N₅O₂, 353.0; m/z found, 354.0 [M+H]⁺. ¹H NMR (500 MHz, CDCl₃)δ 8.46 (s, 2H), 8.12 (s, 1H), 7.73-7.68 (m, 2H), 7.55-7.50 (m, 2H), 6.55(t, J=71.9 Hz, 1H), 5.67 (d, J=0.7 Hz, 2H).

Example 228: 2-[[1-(3-Fluorophenyl)triazol-4-yl]methoxy]pyrimidine

The title compound was prepared in a manner analogous to Example 1 using(1-(3-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 41) and2-chloropyrimidine. MS (ESI): mass calcd. for C₁₃H₁₀FN₅O, 271.1; m/zfound, 272.1 [M+H]⁺. ¹H NMR (500 MHz, DMSO-d₆) δ 8.98 (s, 1H), 8.66 (d,J=4.8 Hz, 2H), 7.87 (dt, J=10.0, 2.3 Hz, 1H), 7.82 (ddd, J=8.0, 2.0, 0.8Hz, 1H), 7.66 (td, J=8.3, 6.3 Hz, 1H), 7.36 (tdd, J=8.6, 2.6, 0.9 Hz,1H), 7.20 (t, J=4.8 Hz, 1H), 5.54 (d, J=0.6 Hz, 2H).

Example 229:5-Fluoro-2-[[1-(3-fluorophenyl)triazol-4-yl]methoxy]pyrimidine

The title compound was prepared in a manner analogous to Example 1 using(1-(3-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 41) and2-chloro-5-fluoropyrimidine. MS (ESI): mass calcd. for C₁₃H₉F₂N₅O,289.1; m/z found, 290.1 [M+H]⁺. ¹H NMR (500 MHz, DMSO-d₆) δ 8.97 (d,J=0.6 Hz, 1H), 8.75 (d, J=0.7 Hz, 2H), 7.86 (dt, J=10.0, 2.3 Hz, 1H),7.82 (ddd, J=8.1, 2.1, 0.9 Hz, 1H), 7.66 (td, J=8.3, 6.3 Hz, 1H), 7.36(tdd, J=8.5, 2.5, 0.9 Hz, 1H), 5.52 (d, J=0.6 Hz, 2H).

Example 230:2-[[1-(3-Fluorophenyl)triazol-4-yl]methoxy]-5-methoxy-pyrimidine

The title compound was prepared in a manner analogous to Example 1 using(1-(3-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 41) and2-chloro-5-methoxypyrimidine. MS (ESI): mass calcd. for C₁₄H₁₂FN₅O₂,301.1; m/z found, 302.1 [M+H]⁺. ¹H NMR (500 MHz, DMSO-d₆) δ 8.96 (d,J=0.6 Hz, 1H), 8.41 (s, 2H), 7.91-7.78 (m, 2H), 7.65 (td, J=8.2, 6.3 Hz,1H), 7.36 (tdd, J=8.5, 2.5, 0.9 Hz, 1H), 5.47 (d, J=0.5 Hz, 2H), 3.86(s, 3H).

Example 231:5-Chloro-2-[[1-(3-fluorophenyl)triazol-4-yl]methoxy]pyrimidine

The title compound was prepared in a manner analogous to Example 1 using(1-(3-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 41) and2,5-dichloropyrimidine. MS (ESI): mass calcd. for C₁₃H₉ClFN₅O, 305.0;m/z found, 306.0 [M+H]⁺. ¹H NMR (500 MHz, DMSO-d₆) δ 8.97 (d, J=0.7 Hz,1H), 8.77 (s, 2H), 7.86 (dt, J=10.0, 2.3 Hz, 1H), 7.82 (ddd, J=8.1, 2.1,0.9 Hz, 1H), 7.66 (td, J=8.3, 6.3 Hz, 1H), 7.36 (tdd, J=8.5, 2.5, 0.9Hz, 1H), 5.55 (d, J=0.5 Hz, 2H).

Example 232:2-[[1-(3-Fluorophenyl)triazol-4-yl]methoxy]-5-methyl-pyrimidine

The title compound was prepared in a manner analogous to Example 1 using(1-(3-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 41) and2-chloro-5-methylpyrimidine. MS (ESI): mass calcd. for C₁₄H₁₂FN₅O,285.1; m/z found, 286.1 [M+H]⁺. ¹H NMR (400 MHz, DMSO-d₆) δ 8.97 (s,1H), 8.49 (d, J=0.9 Hz, 2H), 7.87 (dt, J=10.0, 2.3 Hz, 1H), 7.82 (ddd,J=8.1, 2.2, 0.9 Hz, 1H), 7.65 (td, J=8.2, 6.2 Hz, 1H), 7.36 (tdd, J=8.5,2.5, 0.9 Hz, 1H), 5.50 (s, 2H), 2.21 (s, 3H).

Example 233:5-Ethyl-2-[[1-(3-fluorophenyl)triazol-4-yl]methoxy]pyrimidine

The title compound was prepared in a manner analogous to Example 1 using(1-(3-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 41) and2-chloro-5-ethylpyrimidine. MS (ESI): mass calcd. for C₁₅H₁₄FN₅O, 299.1;m/z found, 300.2 [M+H]⁺. ¹H NMR (400 MHz, DMSO-d₆) δ 8.97 (s, 1H), 8.53(s, 2H), 7.87 (dt, J=10.0, 2.3 Hz, 1H), 7.82 (ddd, J=8.1, 2.0, 0.9 Hz,1H), 7.65 (td, J=8.2, 6.2 Hz, 1H), 7.36 (tdd, J=8.5, 2.5, 0.9 Hz, 1H),5.50 (s, 2H), 2.57 (q, J=7.6 Hz, 2H), 1.19 (t, J=7.6 Hz, 3H).

Example 234:2-[[1-(3-Bromophenyl)triazol-4-yl]methoxy]-5-methyl-pyrimidine

The title compound was prepared in a manner analogous to Example 1 using(1-(3-bromophenyl)-1H-1,2,3-triazol-4-yl)methanol and2-chloro-5-methylpyrimidine. MS (ESI): mass calcd. for C₁₄H₁₂BrN₅O,345.0; m/z found, 348.0 [M+H]⁺. ¹H NMR (300 MHz, CDCl₃) δ 8.38 (s, 2H),8.11 (s, 1H), 7.96-7.91 (m, 1H), 7.68 (dd, J=8.1, 1.0 Hz, 1H), 7.57 (dd,J=8.0, 0.5 Hz, 1H), 7.39 (t, J=8.1 Hz, 1H), 5.63 (s, 2H), 2.26 (s, 3H).

Example 235:2-[[1-(3-Bromophenyl)triazol-4-yl]methoxy]-4-methyl-pyrimidine

The title compound was prepared in a manner analogous to Example 1 using(1-(3-bromophenyl)-1H-1,2,3-triazol-4-yl)methanol and2-chloro-4-methylpyrimidine. MS (ESI): mass calcd. for C₁₄H₁₂BrN₅O,345.0; m/z found, 347.9 [M+H]⁺. ¹H NMR (300 MHz, CDCl₃) δ 8.40 (d, J=5.0Hz, 1H), 8.12 (s, 1H), 7.94 (s, 1H), 7.68 (d, J=8.0 Hz, 1H), 7.57 (d,J=8.1 Hz, 1H), 7.40 (t, J=8.1 Hz, 1H), 6.86 (d, J=5.0 Hz, 1H), 5.65 (s,2H), 2.49 (s, 3H).

Example 236: 2-[[1-(o-Tolyl)triazol-4-yl]methoxy]pyrimidine

The title compound was prepared in a manner analogous to Example 1 using(1-(2-methylphenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 38) and2-chloropyrimidine. MS (ESI): mass calcd. for C₁₄H₁₃N₅O, 267.1; m/zfound, 268.1 [M+H]⁺. ¹H NMR (500 MHz, DMSO-d₆) δ 8.66 (d, J=4.8 Hz, 2H),8.60 (s, 1H), 7.52-7.39 (m, 4H), 7.20 (t, J=4.8 Hz, 1H), 5.53 (s, 2H),2.15 (s, 3H).

Example 237: 5-Fluoro-2-[[1-(o-tolyl)triazol-4-yl]methoxy]pyrimidine

The title compound was prepared in a manner analogous to Example 1 using(1-(2-methylphenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 38) and2-chloro-5-fluoropyrimidine. MS (ESI): mass calcd. for C₁₄H₁₂FN₅O,285.1; m/z found, 286.1 [M+H]⁺. ¹H NMR (500 MHz, DMSO-d₆) δ 8.75 (d,J=0.7 Hz, 2H), 8.60 (s, 1H), 7.55-7.35 (m, 4H), 5.51 (s, 2H), 2.15 (s,3H).

Example 238: 5-Methoxy-2-[[1-(o-tolyl)triazol-4-yl]methoxy]pyrimidine

The title compound was prepared in a manner analogous to Example 1 using(1-(2-methylphenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 38) and2-chloro-5-methoxypyrimidine. MS (ESI): mass calcd. for C₁₅H₁₅N₅O₂,297.1; m/z found, 298.1[M+H]⁺. ¹H NMR (500 MHz, DMSO-d₆) δ 8.57 (s, 1H),8.41 (s, 2H), 7.59-7.37 (m, 4H), 5.46 (s, 2H), 3.86 (s, 3H), 2.15 (s,3H).

Example 239: 5-Chloro-2-[[1-(o-tolyl)triazol-4-yl]methoxy]pyrimidine

The title compound was prepared in a manner analogous to Example 1 using(1-(2-methylphenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 38) and2,5-dichloropyrimidine. MS (ESI): mass calcd. for C₁₄H₁₂ClN₅O, 301.1;m/z found, 302.1 [M+H]⁺. ¹H NMR (500 MHz, DMSO-d₆) δ 8.76 (s, 2H), 8.61(s, 1H), 7.56-7.36 (m, 4H), 5.54 (s, 2H), 2.15 (s, 3H).

Example 240: 5-Methyl-2-[[1-(o-tolyl)triazol-4-yl]methoxy]pyrimidine

The title compound was prepared in a manner analogous to Example 1 using(1-(2-methylphenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 38) and2-chloro-5-methylpyrimidine. MS (ESI): mass calcd. for C₁₅H₁₅N₅O, 281.1;m/z found, 282.2 [M+H]⁺. ¹H NMR (500 MHz, DMSO-d₆) δ 8.58 (s, 1H), 8.49(d, J=0.8 Hz, 2H), 7.56-7.37 (m, 4H), 5.49 (s, 2H), 2.21 (d, J=0.8 Hz,3H), 2.15 (s, 3H).

Example 241: 5-Ethyl-2-[[1-(o-tolyl)triazol-4-yl]methoxy]pyrimidine

The title compound was prepared in a manner analogous to Example 1 using(1-(2-methylphenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 38) and2-chloro-5-ethylpyrimidine. MS (ESI): mass calcd. for C₁₆H₁₇N₅O, 295.1;m/z found, 296.1[M+H]⁺. ¹H NMR (500 MHz, DMSO-d₆) δ 8.58 (s, 1H), 8.52(d, J=0.6 Hz, 2H), 7.55-7.37 (m, 4H), 5.50 (s, 2H), 2.57 (q, J=7.6 Hz,2H), 2.15 (s, 3H), 1.19 (t, J=7.6 Hz, 3H).

Example 242: 2-[[1-(m-Tolyl)triazol-4-yl]methoxy]pyrimidine

The title compound was prepared in a manner analogous to Example 1 using(1-(m-Tolyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 32) and2-chloropyrimidine. MS (ESI): mass calcd. for C₁₄H₁₃N₅O, 267.1; m/zfound, 268.1[M+H]⁺. ¹H NMR (500 MHz, DMSO-d₆) δ 8.89 (s, 1H), 8.66 (d,J=4.7 Hz, 2H), 7.76 (td, J=1.8, 0.9 Hz, 1H), 7.70 (dt, J=7.9, 1.6 Hz,1H), 7.48 (t, J=7.8 Hz, 1H), 7.32 (ddt, J=7.6, 1.7, 0.9 Hz, 1H), 7.20(t, J=4.8 Hz, 1H), 5.52 (s, 2H), 2.42 (d, J=0.7 Hz, 3H)

Example 243: 5-Methyl-2-[[1-(m-tolyl)triazol-4-yl]methoxy]pyrimidine

The title compound was prepared in a manner analogous to Example 1 using(1-(m-tolyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 32) and2-chloro-5-methylpyrimidine. MS (ESI): mass calcd. for C₁₅H₁₅N₅O, 281.1;m/z found, 282.2 [M+H]⁺. ¹H NMR (400 MHz, DMSO-d₆) δ 8.87 (s, 1H), 8.49(d, J=0.9 Hz, 2H), 7.75 (d, J=1.9 Hz, 1H), 7.69 (dd, J=8.0, 2.2 Hz, 1H),7.47 (t, J=7.8 Hz, 1H), 7.37-7.26 (m, 1H), 5.49 (s, 2H), 2.41 (s, 3H),2.21 (s, 3H).

Example 244: 4-Methyl-2-[[1-(m-tolyl)triazol-4-yl]methoxy]pyrimidine

The title compound was prepared in a manner analogous to Example 1 using(1-(m-tolyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 32) and2-chloro-4-methylpyrimidine. MS (ESI): mass calcd. for C₁₅H₁₅N₅O, 281.1;m/z found, 282.2 [M+H]⁺. ¹H NMR (400 MHz, DMSO-d₆) δ 8.87 (s, 1H), 8.49(d, J=5.0 Hz, 1H), 7.76 (d, J=2.1 Hz, 1H), 7.70 (dd, J=8.0, 2.1 Hz, 1H),7.48 (t, J=7.8 Hz, 1H), 7.32 (d, J=7.6 Hz, 1H), 7.07 (d, J=4.9 Hz, 1H),5.50 (s, 2H), 2.42 (d, J=5.7 Hz, 6H).

Example 245: 5-Ethyl-2-[[1-(m-tolyl)triazol-4-yl]methoxy]pyrimidine

The title compound was prepared in a manner analogous to Example 1 using(1-(m-tolyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 32) and2-chloro-5-ethylpyrimidine. MS (ESI): mass calcd. for C₁₆H₁₇N₅O, 295.1;m/z found, 296.1[M+H]⁺. ¹H NMR (500 MHz, DMSO-d₆) δ 8.87 (s, 1H), 8.53(d, J=0.6 Hz, 2H), 7.79-7.73 (m, 1H), 7.70 (ddt, J=8.2, 1.7, 0.8 Hz,1H), 7.47 (t, J=7.9 Hz, 1H), 7.31 (ddt, J=7.7, 1.8, 0.9 Hz, 1H),5.55-5.41 (m, 2H), 2.57 (q, J=7.6 Hz, 2H), 2.41 (s, 3H), 1.19 (t, J=7.6Hz, 3H).

Example 246: 5-Chloro-2-[[1-(m-tolyl)triazol-4-yl]methoxy]pyrimidine

The title compound was prepared in a manner analogous to Example 1 using(1-(m-tolyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 32) and2,5-dichloropyrimidine. MS (ESI): mass calcd. for C₁₄H₁₂ClN₅O, 301.1;m/z found, 302.1 [M+H]⁺. ¹H NMR (500 MHz, DMSO-d₆) δ 8.88 (s, 1H), 8.77(s, 2H), 7.75 (dq, J=2.2, 1.1 Hz, 1H), 7.72-7.66 (m, 1H), 7.48 (t, J=7.8Hz, 1H), 7.32 (ddt, J=7.6, 1.7, 0.8 Hz, 1H), 5.53 (d, J=0.6 Hz, 2H),2.42 (d, J=0.7 Hz, 3H).

Example 247: 5-Fluoro-2-[[1-(m-tolyl)triazol-4-yl]methoxy]pyrimidine

The title compound was prepared in a manner analogous to Example 1 using(1-(m-tolyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 32) and2-chloro-5-fluoropyrimidine. MS (ESI): mass calcd. for C₁₄H₁₂FN₅O,285.1; m/z found, 286.1 [M+H]⁺. ¹H NMR (500 MHz, DMSO-d₆) δ 8.88 (s,1H), 8.75 (d, J=0.7 Hz, 2H), 7.75 (tq, J=1.5, 0.7 Hz, 1H), 7.69 (ddt,J=8.1, 2.3, 0.9 Hz, 1H), 7.48 (t, J=7.8 Hz, 1H), 7.32 (ddt, J=7.6, 1.8,0.9 Hz, 1H), 5.51 (s, 2H), 2.42 (d, J=0.7 Hz, 3H)

Example 248: 5-Methoxy-2-[[1-(m-tolyl)triazol-4-yl]methoxy]pyrimidine

The title compound was prepared in a manner analogous to Example 1 using(1-(m-tolyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 32) and2-chloro-5-methoxypyrimidine. MS (ESI): mass calcd. for C₁₅H₁₅N₅O₂,297.1; m/z found, 298.2 [M+H]⁺. ¹H NMR (500 MHz, DMSO-d₆) δ 8.86 (s,1H), 8.41 (s, 2H), 7.75 (d, J=1.9 Hz, 1H), 7.69 (dd, J=8.1, 2.2 Hz, 1H),7.47 (t, J=7.8 Hz, 1H), 7.31 (ddt, J=7.6, 1.8, 0.9 Hz, 1H), 5.46 (s,2H), 3.86 (s, 3H), 2.42 (s, 3H).

Example 249:2-[2-[[1-(m-Tolyl)triazol-4-yl]methoxy]pyrimidin-5-yl]propan-2-ol

The title compound was prepared in a manner analogous to Example 1 using(1-(m-tolyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 32) and2-(2-chloropyrimidin-5-yl)propan-2-ol. MS (ESI): mass calcd. forC₁₇H₁₉N₅O₂, 325.2; m/z found, 326.3 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD) δ8.72 (d, J=3.0 Hz, 2H), 8.64 (d, J=2.9 Hz, 1H), 7.68 (d, J=2.0 Hz, 1H),7.62 (dd, J=8.1, 2.2 Hz, 1H), 7.44 (t, J=7.8 Hz, 1H), 7.31 (d, J=7.7 Hz,1H), 4.89 (d, J=2.8 Hz, 2H), 2.45 (s, 3H), 1.58 (d, J=3.2 Hz, 6H).

Example 250:4-(Methoxymethyl)-2-[[1-(m-tolyl)triazol-4-yl]methoxy]pyrimidine

The title compound was prepared in a manner analogous to Example 1 using(1-(m-tolyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 32) and2-chloro-4-(methoxymethyl)pyrimidine. MS (ESI): mass calcd. forC₁₆H₁₇N₅O₂, 311.1; m/z found, 312.2 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD) δ8.62 (s, 1H), 8.56 (dd, J=5.1, 1.4 Hz, 1H), 7.65 (d, J=2.0 Hz, 1H), 7.60(dd, J=8.1, 2.1 Hz, 1H), 7.42 (t, J=7.8 Hz, 1H), 7.29 (d, J=7.7 Hz, 1H),7.20 (d, J=5.1 Hz, 1H), 5.59 (s, 2H), 4.50 (s, 2H), 3.48 (m, J=1.5 Hz,3H), 2.43 (s, 3H).

Example 251: 4,5-Dimethyl-2-[[1-(m-tolyl)triazol-4-yl]methoxy]pyrimidine

The title compound was prepared in a manner analogous to Example 1 using(1-(m-tolyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 32) and2-chloro-4,5-dimethylpyrimidine. MS (ESI): mass calcd. for C₁₆H₁₇N₅O,295.1; m/z found, 296.1 [M+H]⁺. ¹H NMR (400 MHz, DMSO-d₆) δ 8.85 (s,1H), 8.30 (d, J=1.0 Hz, 1H), 7.75 (d, J=2.1 Hz, 1H), 7.69 (d, J=8.1 Hz,1H), 7.47 (t, J=7.8 Hz, 1H), 7.35-7.28 (m, 1H), 5.46 (s, 2H), 2.41 (s,3H), 2.39 (s, 3H), 2.16 (s, 3H).

Example 252:5-Fluoro-4-methyl-2-[[1-(m-tolyl)triazol-4-yl]methoxy]pyrimidine

The title compound was prepared in a manner analogous to Example 1 using(1-(m-tolyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 32) and2-chloro-4-methyl-5-fluoropyrimidine. MS (ESI): mass calcd. forC₁₅H₁₄FN₅O, 299.1; m/z found, 300.2 [M+H]⁺. ¹H NMR (400 MHz, DMSO-d₆) δ8.86 (s, 1H), 8.56 (d, J=1.5 Hz, 1H), 7.76 (d, J=2.1 Hz, 1H), 7.69 (dd,J=7.9, 2.2 Hz, 1H), 7.48 (td, J=7.8, 5.0 Hz, 1H), 7.32 (d, J=7.5 Hz,1H), 5.48 (s, 2H), 2.44 (d, J=2.6 Hz, 3H), 2.42 (s, 3H)

Example 253:5-Chloro-4-methyl-2-[[1-(m-tolyl)triazol-4-yl]methoxy]pyrimidine

The title compound was prepared in a manner analogous to Example 1 using(1-(m-tolyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 32) and2,5-dichloro-4-methylpyrimidine. MS (ESI): mass calcd. for C₁₅H₁₄ClN₅O,315.1; m/z found, 316.1 [M+H]⁺. ¹H NMR (500 MHz, DMSO-d₆) δ 8.88 (s,1H), 8.63 (d, J=1.3 Hz, 1H), 7.76 (s, 1H), 7.69 (d, J=8.2 Hz, 1H), 7.48(t, J=7.7 Hz, 1H), 7.32 (d, J=7.8 Hz, 1H), 5.51 (s, 2H), 2.43 (d, J=8.5Hz, 6H).

Example 254:5-Methyl-2-[[1-(m-tolyl)triazol-4-yl]methoxy]pyrimidin-4-amine

The title compound was prepared in a manner analogous to Example 1 using(1-(m-tolyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 32) and2-chloro-5-methylpyrimidin-4-amine. MS (ESI): mass calcd. for C₁₅H₁₆N₆O,296.1; m/z found, 297.2 [M+H]⁺. ¹H NMR (500 MHz, DMSO-d₆) δ 8.84 (s,1H), 7.78-7.72 (m, 2H), 7.69 (d, J=8.6 Hz, 1H), 7.47 (t, J=7.8 Hz, 1H),7.37-7.25 (m, 1H), 6.76 (s, 2H), 5.33 (s, 2H), 2.41 (s, 3H), 1.92 (d,J=0.9 Hz, 3H).

Example 255:1-[2-[[1-(m-Tolyl)triazol-4-yl]methoxy]pyrimidin-5-yl]ethanone

The title compound was prepared in a manner analogous to Example 1 using(1-(m-tolyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 32) and1-(2-chloropyrimidin-5-yl)ethan-1-one. MS (ESI): mass calcd. forC₁₆H₁₅N₅O₂, 309.1; m/z found, 310.1 [M+H]⁺. ¹H NMR (400 MHz, CD₃OD) δ9.17 (s, 2H), 8.68 (s, 1H), 7.71 (s, 1H), 7.65 (d, J=8.2 Hz, 1H), 7.47(t, J=7.9 Hz, 1H), 7.35 (d, J=7.6 Hz, 1H), 5.74 (s, 2H), 2.62 (d, J=3.2Hz, 3H), 2.48 (s, 3H).

Example 256: 2-[[1-(p-Tolyl)triazol-4-yl]methoxy]pyrimidine

The title compound was prepared in a manner analogous to Example 1 using(1-(p-tolyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 33) and2-chloropyrimidine. MS (ESI): mass calcd. for C₁₄H₁₃N₅O, 267.1; m/zfound, 268.1 [M+H]⁺. ¹H NMR (500 MHz, DMSO-d₆) δ 8.86 (s, 1H), 8.66 (d,J=4.8 Hz, 2H), 7.85-7.73 (m, 2H), 7.47-7.35 (m, 2H), 7.20 (t, J=4.8 Hz,1H), 5.52 (s, 2H), 2.38 (s, 3H).

Example 257: 5-Fluoro-2-[[1-(p-tolyl)triazol-4-yl]methoxy]pyrimidine

The title compound was prepared in a manner analogous to Example 1 using(1-(p-tolyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 33) and2-chloro-5-fluoropyrimidine. MS (ESI): mass calcd. for C₁₄H₁₂FN₅O,285.1; m/z found, 286.1 [M+H]⁺. ¹H NMR (500 MHz, DMSO-d₆) δ 8.86 (s,1H), 8.74 (d, J=0.7 Hz, 2H), 7.84-7.72 (m, 2H), 7.44-7.34 (m, 2H),5.57-5.43 (m, 2H), 2.38 (s, 3H).

Example 258: 5-Methoxy-2-[[1-(p-tolyl)triazol-4-yl]methoxy]pyrimidine

The title compound was prepared in a manner analogous to Example 1 using(1-(p-tolyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 33) and2-chloro-5-methoxypyrimidine. MS (ESI): mass calcd. for C₁₅H₁₅N₅O₂,297.1; m/z found, 298.1 [M+H]⁺. ¹H NMR (500 MHz, DMSO-d₆) δ 8.84 (s,1H), 8.41 (s, 2H), 7.88-7.72 (m, 2H), 7.46-7.30 (m, 2H), 5.45 (d, J=0.5Hz, 2H), 3.86 (s, 3H), 2.38 (s, 3H).

Example 259: 5-Chloro-2-[[1-(p-tolyl)triazol-4-yl]methoxy]pyrimidine

The title compound was prepared in a manner analogous to Example 1 using(1-(p-tolyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 33) and2,5-dichloropyrimidine. MS (ESI): mass calcd. for C₁₄H₁₂ClN₅O, 301.1;m/z found, 302.1 [M+H]⁺. ¹H NMR (500 MHz, DMSO-d₆) δ 8.86 (s, 1H), 8.76(s, 2H), 7.84-7.69 (m, 2H), 7.44-7.29 (m, 2H), 5.53 (d, J=0.5 Hz, 2H),2.38 (s, 3H).

Example 260: 5-Methyl-2-[[1-(p-tolyl)triazol-4-yl]methoxy]pyrimidine

The title compound was prepared in a manner analogous to Example 1 using(1-(p-tolyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 33) and2-chloro-5-methylpyrimidine. MS (ESI): mass calcd. for C₁₅H₁₅N₅O, 281.1;m/z found, 282.2 [M+H]⁺. ¹H NMR (500 MHz, DMSO-d₆) δ 8.84 (d, J=0.7 Hz,1H), 8.49 (q, J=0.7 Hz, 2H), 7.84-7.70 (m, 2H), 7.45-7.36 (m, 2H), 5.48(d, J=0.5 Hz, 2H), 2.38 (s, 3H), 2.21 (d, J=0.8 Hz, 3H).

Example 261: 5-Ethyl-2-[[1-(p-tolyl)triazol-4-yl]methoxy]pyrimidine

The title compound was prepared in a manner analogous to Example 1 using(1-(p-tolyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 33) and2-chloro-5-ethylpyrimidine. MS (ESI): mass calcd. for C₁₅H₁₇N₅O, 295.1;m/z found, 296.1 [M+H]⁺. ¹H NMR (500 MHz, DMSO-d) δ 8.85 (s, 1H), 8.52(d, J=0.6 Hz, 2H), 7.85-7.73 (m, 2H), 7.44-7.33 (m, 2H), 5.54-5.29 (m,2H), 2.63-2.53 (m, 2H), 2.38 (s, 3H), 1.19 (t, J=7.6 Hz, 3H).

Example 262: 2-[[1-(3-Isopropylphenyl)triazol-4-yl]methoxy]pyrimidine

The title compound was prepared in a manner analogous to Example 1 using(1-(3-isopropylphenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 44)and 2-chloropyrimidine. MS (ESI): mass calcd. for C₁₆H₁₇N₅O, 295.1; m/zfound, 296.1 [M+H]⁺. ¹H NMR (400 MHz, DMSO-d₆) δ 8.93 (s, 1H), 8.67 (d,J=4.8 Hz, 2H), 7.78 (t, J=2.0 Hz, 1H), 7.71 (ddd, J=8.1, 2.4, 1.1 Hz,1H), 7.51 (t, J=7.9 Hz, 1H), 7.42-7.33 (m, 1H), 7.20 (t, J=4.8 Hz, 1H),5.53 (s, 2H), 3.01 (p, J=7.0 Hz, 1H), 1.26 (d, J=6.9 Hz, 6H).

Example 263:5-Fluoro-2-[[1-(3-isopropylphenyl)triazol-4-yl]methoxy]pyrimidine

The title compound was prepared in a manner analogous to Example 1 using(1-(3-isopropylphenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 44)and 2-chloro-5-fluoropyrimidine. MS (ESI): mass calcd. for C₁₆H₁₆FN₅O,313.1; m/z found, 314.1 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD) δ 8.65 (s, 1H),8.57 (s, 2H), 7.72 (t, J=2.1 Hz, 1H), 7.64 (ddd, J=8.0, 2.3, 1.1 Hz,1H), 7.49 (t, J=7.9 Hz, 1H), 7.44-7.34 (m, 1H), 5.59 (s, 2H), 3.03 (p,J=6.9 Hz, 1H), 1.31 (d, J=6.9 Hz, 6H).

Example 264:2-[[1-(3-Isopropylphenyl)triazol-4-yl]methoxy]-5-methoxy-pyrimidine

The title compound was prepared in a manner analogous to Example 1 using(1-(3-isopropylphenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 44)and 2-chloro-5-methoxypyrimidine. MS (ESI): mass calcd. for C₁₇H₉N₅O₂,325.2; m/z found, 326.1 [M+H]⁺. ¹H NMR (400 MHz, DMSO-d₆) δ 8.90 (s,1H), 8.41 (s, 2H), 7.78 (t, J=2.0 Hz, 1H), 7.71 (ddd, J=8.0, 2.3, 1.1Hz, 1H), 7.51 (t, J=7.9 Hz, 1H), 7.42-7.35 (m, 1H), 5.46 (s, 2H), 3.86(s, 3H), 3.01 (p, J=6.9 Hz, 1H), 1.26 (d, J=6.9 Hz, 6H).

Example 265:5-Chloro-2-[[1-(3-isopropylphenyl)triazol-4-yl]methoxy]pyrimidine

The title compound was prepared in a manner analogous to Example 1 using(1-(3-isopropylphenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 44)and 2,5-dichloropyrimidine. MS (ESI): mass calcd. for C₁₆H₁₆ClN₅O,329.1; m/z found, 330.0 [M+H]⁺. ¹H NMR (400 MHz, DMSO-d) δ 8.92 (s, 1H),8.77 (d, J=0.8 Hz, 2H), 7.77 (d, J=2.0 Hz, 1H), 7.74-7.66 (m, 1H), 7.51(t, J=7.8 Hz, 1H), 7.39 (d, J=7.6 Hz, 1H), 5.54 (s, 2H), 3.00 (h, J=6.9Hz, 1H), 1.31-1.14 (m, 6H).

Example 266:2-[[1-(3-Isopropylphenyl)triazol-4-yl]methoxy]-5-methyl-pyrimidine

The title compound was prepared in a manner analogous to Example 1 using(1-(3-isopropylphenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 44)and 2-chloro-5-methylpyrimidine. MS (ESI): mass calcd. for C₁₇H₁₉N₅O,309.2; m/z found, 310.2 [M+H]⁺. ¹H NMR (400 MHz, DMSO-d₆) δ 8.91 (s,1H), 8.49 (s, 2H), 7.78 (t, J=2.0 Hz, 1H), 7.75-7.69 (m, 1H), 7.51 (t,J=7.8 Hz, 1H), 7.38 (d, J=7.7 Hz, 1H), 5.49 (s, 2H), 3.01 (p, J=6.7 Hz,1H), 2.21 (s, 3H), 1.26 (d, J=6.9 Hz, 6H).

Example 267:5-Ethyl-2-[[1-(3-isopropylphenyl)triazol-4-yl]methoxy]pyrimidine

The title compound was prepared in a manner analogous to Example 1 using(1-(3-isopropylphenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 44)and 2-chloro-5-ethylpyrimidine. MS (ESI): mass calcd. for C₁₈H₂₁N₅O,323.2; m/z found, 324.2 [M+H]⁺. ¹H NMR (400 MHz, DMSO-d₆) δ 8.92 (s,1H), 8.53 (s, 2H), 7.78 (t, J=2.1 Hz, 1H), 7.75-7.69 (m, 1H), 7.51 (t,J=7.9 Hz, 1H), 7.43-7.36 (m, 1H), 5.50 (s, 2H), 3.02 (q, J=6.9 Hz, 1H),2.57 (q, J=7.6 Hz, 2H), 1.26 (d, J=6.9 Hz, 6H), 1.19 (t, J=7.6 Hz, 3H)

Example 268:2-[[1-[3-(Difluoromethyl)phenyl]triazol-4-yl]methoxy]-4-methyl-pyrimidine

The title compound was prepared analogous to Example 155, using2-chloro-4-methylpyrimidine. MS (ESI): mass calcd. for C₁₅H₁₃F₂N₅O,317.1; m/z found, 318.0 [M+H]⁺. ¹H NMR (600 MHz, CDCl₃) δ 8.40 (d, J=4.9Hz, 1H), 8.17 (s, 1H), 7.92-7.89 (m, 1H), 7.89-7.85 (m, 1H), 7.66-7.61(m, 1H), 7.61-7.56 (m, 1H), 6.86 (d, J=5.0 Hz, 1H), 6.73 (t, J=56.2 Hz,1H), 5.67 (d, J=0.8 Hz, 2H), 2.49 (s, 3H).

Example 269:2-[[1-[3-(Difluoromethyl)phenyl]triazol-4-yl]methoxy]-5-fluoro-pyrimidine

The title compound was prepared analogous to Example 155, using2-chloro-5-fluoropyrimidine. MS (ESI): mass calcd. for C₁₄H₁₀F₃N₅O,321.1; m/z found, 322.0 [M+H]⁺. ¹H NMR (600 MHz, CDCl₃) δ 8.43 (s, 2H),8.18-8.15 (m, 1H), 7.93-7.85 (m, 2H), 7.67-7.57 (m, 2H), 6.73 (t, J=56.1Hz, 1H), 5.65 (d, J=0.7 Hz, 2H).

Example 270:2-[[1-[3-(Difluoromethyl)phenyl]triazol-4-yl]methoxy-4-isopropyl-pyrimidine

The title compound was prepared analogous to Example 155, using2-chloro-4-isopropylpyrimidine. MS (ESI): mass calcd. for C₁₇H₁₇F₂N₅O,345.1; m/z found, 346.0 [M+H]⁺. ¹H NMR (500 MHz, CDCl₃) δ 8.43 (d, J=5.1Hz, 1H), 8.18 (s, 1H), 7.92-7.89 (m, 1H), 7.88-7.84 (m, 1H), 7.65-7.60(m, 1H), 7.59-7.55 (m, 1H), 6.86 (d, J=5.1 Hz, 1H), 6.72 (t, J=56.1 Hz,1H), 5.66 (d, J=0.8 Hz, 2H), 2.96 (hept, J=6.9 Hz, 1H), 1.29 (d, J=6.9Hz, 6H).

Example 271:2-[[1-[3-(Difluoromethyl)phenyl]triazol-4-yl]methoxy]-4-(methoxymethyl)]pyrimidine

The title compound was prepared analogous to Example 155, using2-chloro-4-(methoxymethyl)pyrimidine. MS (ESI): mass calcd. forC₁₆H₁₅F₂N₅O₂, 347.1; m/z found, 348.0 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃) δ8.54 (d, J=5.0 Hz, 1H), 8.20 (s, 1H), 7.93-7.84 (m, 2H), 7.67-7.56 (m,2H), 7.15 (d, J=5.1 Hz, 1H), 6.72 (t, J=56.1 Hz, 1H), 5.66 (d, J=0.7 Hz,2H), 4.50 (d, J=0.7 Hz, 2H), 3.49 (s, 3H).

Example 272:2-[2-[[1-[3-(Difluoromethyl)phenyl]triazol-4-yl]methoxy]pyrimidin-5-yl]propan-2-ol

The title compound was prepared analogous to Example 155, using2-(2-chloropyrimidin-5-yl)propan-2-ol. MS (ESI): mass calcd. forC₁₇H₁₇F₂N₅O₅₂, 361.1; m/z found, 362.1 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃) δ8.68 (s, 2H), 8.18 (s, 1H), 7.94-7.84 (m, 2H), 7.68-7.56 (m, 2H), 6.73(t, J=56.1 Hz, 1H), 5.67 (d, J=0.7 Hz, 2H), 1.63 (s, 6H).

Example 273:5-(Difluoromethyl)-2-[[1-[3-(difluoromethyl)phenyl]triazol-4-yl]methoxy]pyrimidine

The title compound was prepared analogous to Example 155, using2-chloro-5-difluoromethylpyrimidine. MS (ESI): mass calcd. forC₁₅H₁₁F₄N₅O, 353.1; m/z found, 354.0 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃) δ8.72 (s, 2H), 8.18 (s, 1H), 7.94-7.85 (m, 2H), 7.69-7.57 (m, 2H),6.89-6.57 (m, 2H), 5.73 (s, 2H).

Example 274:4-(Difluoromethyl)-2-[[1-[3-(difluoromethyl)phenyl]triazol-4-yl]methoxy]pyrimidine

The title compound was prepared analogous to Example 155, using2-chloro-4-difluoromethylpyrimidine. MS (ESI): mass calcd. forC₁₅H₁₁F₄N₅O, 353.1; m/z found, 354.0 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃) δ8.76 (d, J=4.9 Hz, 1H), 8.21 (s, 1H), 7.94-7.84 (m, 2H), 7.63 (dt,J=16.0, 7.7 Hz, 2H), 7.30 (d, J=4.9 Hz, 1H), 6.88-6.34 (m, 2H), 5.71 (d,J=0.7 Hz, 2H)

Example 275:2-[[1-[3-(Difluoromethyl)phenyl]triazol-4-yl]methoxy]-5-(trifluoromethyl)pyrimidine

The title compound was prepared analogous to Example 155, using2,-chloro-5-trifluoromethylpyrimidine. MS (ESI): mass calcd. forC₁₅H₁₀F₈N₅O, 371.1; m/z found, 372.0 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃) δ8.82 (d, J=0.8 Hz, 2H), 8.19 (s, 1H), 7.94-7.85 (m, 2H), 7.71-7.57 (m,2H), 6.73 (t, J=56.1 Hz, 1H), 5.75 (s, 2H).

Example 276:5-(Difluoromethoxy)-2-[[1-[3-(difluoromethyl)phenyl]triazol-4-yl]methoxy]pyrimidine

The title compound was prepared analogous to Example 155, using2-chloro-5-difluoromethoxypyrimidine. MS (ESI): mass calcd. forC₁₅H₁₁F₄N₅O₂, 369.1; m/z found, 370.0 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃) δ8.48-8.43 (m, 2H), 8.21-8.14 (m, 1H), 7.96-7.84 (m, 2H), 7.69-7.57 (m,2H), 6.89-6.34 (m, 2H), 5.67 (d, J=0.7 Hz, 2H).

Example 277:2-[[1-[3-(Difluoromethyl)phenyl]triazol-4-yl]methoxy]-N,N-dimethyl-pyrimidin-4-amine

The title compound was prepared analogous to Example 155, using2-chloro-N,N-dimethylpyrimidin-4-amine. MS (ESI): mass calcd. forC₁₆H₁₆F₂N₆O, 346.1; m/z found, 347.1 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃) δ8.15 (s, 1H), 8.03 (d, J=6.1 Hz, 1H), 7.92-7.88 (m, 1H), 7.89-7.83 (m,1H), 7.66-7.55 (m, 2H), 6.72 (t, J=56.1 Hz, 1H), 6.13 (d, J=6.1 Hz, 1H),5.62 (d, J=0.8 Hz, 2H), 3.11 (s, 6H).

Example 278:2-[[1-[3-(Difluoromethyl)phenyl]triazol-4-yl]methoxy]-5-fluoro-4-methyl-pyrimidine

The title compound was prepared analogous to Example 155, using2-chloro-5-fluoro-4-methylpyrimidine. MS (ESI): mass calcd. forC₁₅H₁₂F₃N₅O, 335.1; m/z found, 336.1 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃) δ8.26 (d, J=1.2 Hz, 1H), 8.16 (s, 1H), 7.93-7.85 (m, 2H), 7.67-7.57 (m,2H), 6.73 (t, J=56.1 Hz, 1H), 5.62 (d, J=0.7 Hz, 2H), 2.49 (d, J=2.5 Hz,3H).

Example 279:5-Chloro-2-[[1-[3-(difluoromethyl)phenyl]triazol-4-yl]methoxy]-4-methyl-pyrimidine

The title compound was prepared analogous to Example 155, using2,5-dichloro-4-methylpyrimidine. MS (ESI): mass calcd. forC₁₅H₁₂ClF₂N₅O, 351.1; m/z found, 352.1 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃) δ8.38 (s, 1H), 8.16 (s, 1H), 7.93-7.84 (m, 2H), 7.68-7.56 (m, 2H), 6.73(t, J=56.1 Hz, 1H), 5.64 (d, J=0.7 Hz, 2H), 2.56 (s, 3H).

Example 280:2-Chloro-4-[[1-[3-(difluoromethyl)phenyl]triazol-4-yl]methoxy]-5-methyl-pyrimidine

The title compound was prepared analogous to Example 155, using2,4-dichloro-5-methylpyrimidine. MS (ESI): mass calcd. forC₁₅H₁₂ClF₂N₅O, 351.1; m/z found, 352.0 [M+H]⁺. ¹H NMR (600 MHz, CDCl₃) δ8.24-8.19 (m, 1H), 8.17-8.14 (m, 1H), 7.95-7.91 (m, 1H), 7.89-7.85 (m,1H), 7.68-7.63 (m, 1H), 7.62-7.60 (m, 1H), 6.74 (t, J=56.1 Hz, 1H), 5.67(d, J=0.5 Hz, 2H), 2.14 (d, J=0.9 Hz, 3H).

Example 281:2-[[1-[3-(Difluoromethyl)phenyl]triazol-4-yl]methoxy]-N,N,5-trimethyl-pyrimidin-4-amine

The title compound was prepared analogous to Example 155, using2-chloro-N,N,5-trimethylpyrimidin-4-amine. MS (ESI): mass calcd. forC₁₇H₁₅F₂N₆O, 360.2; m/z found, 361.0 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃) δ8.15 (s, 1H), 7.90 (s, 1H), 7.87-7.82 (m, 1H), 7.67-7.53 (m, 2H), 6.72(t, J=56.1 Hz, 1H), 5.59 (s, 2H), 3.13 (s, 6H), 2.25 (s, 3H).

Example 282:5-Cyclopropyl-2-[[1-[3-(difluoromethyl)phenyl]triazol-4-yl]methoxy]pyrimidine

The title compound was prepared analogous to Example 155, using2-chloro-5-cyclopropylpyrimidine. MS (ESI): mass calcd. for C₁₇H₁₅F₂N₅O,343.1; m/z found, 344.1 [M+H]⁺. ¹H NMR (500 MHz, CDCl₃) δ 8.74 (d, J=1.4Hz, 2H), 8.58 (s, 1H), 8.34-8.31 (m, 1H), 8.30-8.27 (m, 1H), 8.08-8.02(m, 1H), 8.02-7.97 (m, 1H), 7.14 (t, J=56.1 Hz, 1H), 6.06 (s, 2H),2.29-2.21 (m, 1H), 1.47-1.41 (m, 2H), 1.15-1.09 (m, 2H).

Example 283:4-Cyclopropyl-2-[[1-[3-(difluoromethyl)phenyl]triazol-4-yl]methoxy]pyrimidine

The title compound was prepared analogous to Example 155, using2-chloro-4-cyclopropylpyrimidine. MS (ESI): mass calcd. for C₁₇H₁₅F₂N₅O,343.1; m/z found, 344.1 [M+H]⁺. ¹H NMR (500 MHz, CDCl₃) δ 8.31 (dd,J=5.1, 1.1 Hz, 1H), 8.15 (s, 1H), 7.92-7.89 (m, 1H), 7.88-7.84 (m, 1H),7.66-7.61 (m, 1H), 7.60-7.57 (m, 1H), 6.86 (dd, J=5.2, 1.0 Hz, 1H), 6.72(t, J=56.1 Hz, 1H), 5.61 (s, 2H), 1.96 (ttd, J=8.0, 4.7, 1.0 Hz, 1H),1.22-1.17 (m, 2H), 1.10-1.06 (m, 2H)

Example 284:2-[[1-[3-(Difluoromethyl)phenyl]triazol-4-yl]methoxy]-4-pyrrolidin-1-yl-pyrimidine

The title compound was prepared analogous to Example 155, using2-chloro-4-cyclopropylpyrimidine 2-chloro-4-(pyrrolidin-1-yl)pyrimidine.MS (ESI): mass calcd. for C₁₈H₁₈F₂N₆O, 372.2; m/z found, 373.0 [M+H]⁺.¹H NMR (400 MHz, CDCl₃) δ 8.16 (s, 1H), 8.00 (s, 1H), 7.90 (s, 1H),7.88-7.83 (m, 1H), 7.66-7.56 (m, 2H), 6.72 (t, J=56.1 Hz, 1H), 6.00 (d,J=5.9 Hz, 1H), 5.62 (s, 2H), 3.63 (s, 2H), 3.42-3.27 (m, 2H), 2.11-1.89(m, 4H).

Example 285:2-[[1-[3-(Difluoromethyl)phenyl]triazol-4-yl]methoxy]-4-(1-piperidyl)pyrimidine

The title compound was prepared analogous to Example 155, using2-chloro-4-(piperidin-1-yl)pyrimidine. MS (ESI): mass calcd. forC₁₉H₂₀F₂N₆O, 386.2; m/z found, 387.1 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃) δ8.15 (s, 1H), 8.01 (d, J=6.1 Hz, 1H), 7.90 (s, 1H), 7.89-7.83 (m, 1H),7.67-7.54 (m, 2H), 6.72 (t, J=56.1 Hz, 1H), 6.19 (d, J=6.2 Hz, 1H), 5.59(d, J=0.8 Hz, 2H), 3.71-3.56 (m, 4H), 1.75-1.56 (m, 6H).

Example 286:5-Methyl-2-[[1-[3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]pyrimidine

The title compound was prepared in a manner analogous to Example 155using (1-(3-(trifluoromethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 30) and 2-chloro-5-methylpyrimidine. MS (ESI): mass calcd.for C₁₅H₁₂F₃N₅O, 335.1; m/z found, 335.9 [M+H]⁺. ¹H NMR (400 MHz,DMSO-d₆) δ 9.10 (s, 1H), 8.51-8.49 (m, 2H), 8.33-8.26 (m, 2H), 7.92-7.82(m, 2H), 5.52 (s, 2H), 2.22 (t, J=0.8 Hz, 3H).

Example 287:5-Ethyl-2-[[1-[3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]pyrimidine

The title compound was prepared in a manner analogous to Example 155using (1-(3-(trifluoromethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 30) and 2-chloro-5-ethylpyrimidine. MS (ESI): mass calcd.for C₁₆H₁₄F₃N₅O, 349.1; m/z found, 349.9 [M+H]⁺. ¹H NMR (500 MHz,DMSO-d₆) δ 9.10 (s, 1H), 8.54-8.52 (m, 2H), 8.32-8.30 (m, 1H), 8.30-8.26(m, 1H), 7.90-7.83 (m, 2H), 5.52 (s, 2H), 2.58 (q, J=7.6 Hz, 2H), 1.19(t, J=7.6 Hz, 3H).

Example 288:5-Isopropyl-2-[[1-[3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]pyrimidine

The title compound was prepared in a manner analogous to Example 155using (1-(3-(trifluoromethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 30) and 2-chloro-5-isopropylpyrimidine. MS (ESI): masscalcd. for C₁₇H₁₆F₃N₅O, 363.1; m/z found, 363.9 [M+H]⁺. ¹H NMR (500 MHz,DMSO-d₆) δ 9.10 (s, 1H), 8.58-8.56 (m, 2H), 8.32-8.30 (m, 1H), 8.30-8.26(m, 1H), 7.91-7.82 (m, 2H), 5.53 (s, 2H), 2.98-2.87 (m, 1H), 1.24 (d,J=7.0 Hz, 6H).

Example 289:5-(Difluoromethyl)-2-[[1-[3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]pyrimidine

The title compound was prepared in a manner analogous to Example 155using (1-(3-(trifluoromethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 30) and 2-chloro-5-(difluoromethyl)pyrimidine. MS (ESI):mass calcd. for C₁₅H₁₀F₈N₅O, 371.1; m/z found, 371.9 [M+H]⁺. ¹H NMR (500MHz, DMSO-d₆) δ 9.13 (s, 1H), 8.91-8.90 (m, 2H), 8.32-8.30 (m, 1H),8.29-8.26 (m, 1H), 7.91-7.83 (m, 2H), 7.16 (t, J=55.0 Hz, 1H), 5.63 (s,2H).

Example 290:4,5-Dimethyl-2-[[1-[3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]pyrimidine

The title compound was prepared in a manner analogous to Example 155using (1-(3-(trifluoromethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 30) and 2-chloro-4,5-dimethylpyrimidine. MS (ESI): masscalcd. for C₁₆H₁₄F₃N₅O, 349.1; m/z found, 349.9 [M+H]⁺. ¹H NMR (500 MHz,DMSO-d₆) δ 9.08 (s, 1H), 8.33-8.25 (m, 3H), 7.90-7.82 (m, 2H), 5.50 (s,2H), 2.39 (s, 3H), 2.16 (s, 3H).

Example 291:5-Chloro-4-methyl-2-[[1-[3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]pyrimidine

The title compound was prepared in a manner analogous to Example 155using (1-(3-(trifluoromethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 30) and 2,5-dichloro-4-methylpyrimidine. MS (ESI): masscalcd. for C₁₅H₁₁ClF₃N₅O, 369.1; m/z found, 369.9 [M+H]⁺. ¹H NMR (500MHz, DMSO-d₆) δ 9.09 (s, 1H), 8.63 (s, 1H), 8.31-8.29 (m, 1H), 8.29-8.26(m, 1H), 7.90-7.82 (m, 2H), 5.54 (s, 2H), 2.51 (s, 3H).

Example 292:2-[[1-[3-(1,1-Difluoroethyl)phenyl]triazol-4-yl]methoxy]pyrimidine

The title compound was prepared analogous to Example 155, using(1-(3-(1,1-difluoroethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 64) and 2-chloropyrimidine. MS (ESI): mass calcd. forC₁₅H₁₃F₂N₅O, 317.1; m/z found, 318.0 [M+H]⁺. ¹H NMR (500 MHz, CDCl₃) δ8.58 (d, J=4.8 Hz, 2H), 8.25-8.08 (m, 1H), 7.94-7.86 (m, 1H), 7.86-7.74(m, 1H), 7.70-7.51 (m, 2H), 7.01 (t, J=4.8 Hz, 1H), 5.68 (d, J=0.7 Hz,2H), 1.98 (t, J=18.2 Hz, 3H).

Example 293:5-Bromo-2-[[1-[3-(1,1-difluoroethyl)phenyl]triazol-4-yl]methoxy]pyrimidine

The title compound was prepared in a manner analogous to Example 153using (1-(3-(1,1-difluoroethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 64) and 5-bromo-2-chloropyrimidine, using ACN instead ofDMF. MS (ESI): mass calcd. for C₁₅H₁₂BrF₂N₅O, 395.0; m/z found, 396.0[M+H]⁺. ¹H NMR (400 MHz, CDCl₃) δ 8.62-8.55 (s, 2H), 8.19-8.13 (s, 1H),7.92-7.85 (m, 1H), 7.85-7.78 (m, 1H), 7.64-7.57 (m, 2H), 5.69-5.61 (d,J=0.7 Hz, 2H), 2.19-1.78 (t, J=18.2 Hz, 3H).

Example 294:5-Chloro-2-[[1-[3-(1,1-difluoroethyl)phenyl]triazol-4-yl]methoxy]pyrimidine

The title compound was prepared analogous to Example 155, using(1-(3-(1,1-difluoroethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 64) and 2,5-dichloropyrimidine. MS (ESI): mass calcd. forC₁₅H₁₂ClF₂N₅O, 351.1; m/z found, 352.0 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃) δ8.51 (s, 2H), 8.18-8.13 (m, 1H), 7.91-7.87 (m, 1H), 7.84-7.79 (m, 1H),7.65-7.55 (m, 2H), 5.73-5.60 (m, 2H), 1.98 (t, J=18.2 Hz, 3H).

Example 295:2-[[1-[3-(1,1-Difluoroethyl)phenyl]triazol-4-yl]methoxy]-5-fluoro-pyrimidine

The title compound was prepared analogous to Example 155, using(1-(3-(1,1-difluoroethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 64) and 2-chloro-5-fluoropyrimidine. MS (ESI): mass calcd.for C₁₅H₁₂F₃N₅O, 335.1; m/z found, 336.0 [M+H]⁺. ¹H NMR (500 MHz, CDCl₃)δ 8.43 (s, 2H), 8.20-8.13 (m, 1H), 7.91-7.86 (m, 1H), 7.87-7.76 (m, 1H),7.66-7.57 (m, 2H), 5.64 (d, J=0.7 Hz, 2H), 1.98 (t, J=18.2 Hz, 3H)

Example 296:2-[[1-[3-(1,1-Difluoroethyl)phenyl]triazol-4-yl]methoxy]-4-methyl-pyrimidine

The title compound was prepared analogous to Example 155, using(1-(3-(1,1-difluoroethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 64) and 2-chloro-4-methylpyrimidine. MS (ESI): mass calcd.for C₁₆H₁₅F₂N₅O, 331.1; m/z found, 332.1 [M+H]⁺. ¹H NMR (500 MHz, CDCl₃)δ 8.40 (d, J=5.0 Hz, 1H), 8.23-8.12 (m, 1H), 7.95-7.86 (m, 1H),7.86-7.75 (m, 1H), 7.66-7.54 (m, 2H), 6.92-6.81 (m, 1H), 5.67 (d, J=0.8Hz, 2H), 2.50 (s, 3H), 1.98 (t, J=18.2 Hz, 3H).

Example 297:2-[[1-[3-(1,1-Difluoroethyl)phenyl]triazol-4-yl]methoxy]-5-methyl-pyrimidine

The title compound was prepared analogous to Example 155, using(1-(3-(1,1-difluoroethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 64) and 2-chloro-5-methylpyrimidine. MS (ESI): mass calcd.for C₁₆H₁₅F₂N₅O, 331.1; m/z found, 332.1 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃)δ 8.48-8.30 (m, 2H), 8.16 (s, 1H), 7.95-7.84 (m, 1H), 7.85-7.75 (m, 1H),7.68-7.52 (m, 2H), 5.64 (d, J=0.6 Hz, 2H), 2.26 (s, 3H), 1.97 (t, J=18.2Hz, 3H).

Example 298:[2-[[1-[3-(1,1-Difluoroethyl)phenyl]triazol-4-yl]methoxy]pyrimidin-5-yl]methanol

The title compound was prepared in a manner analogous to Example 159,Steps A-B using(1-(3-(1,1-difluoroethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 64) and5-(((tert-butyldimethylsilyl)oxy)methyl)-2-chloropyrimidine(Intermediate 53) in Step A. MS (ESI): mass calcd. for C₁₆H₁₅F₂N₅O₂,347.1; m/z found, 348.0 [M+H]⁺. ¹H NMR (500 MHz, CDCl₃) δ 8.60-8.52 (s,2H), 8.22-8.15 (s, 1H), 7.92-7.86 (m, 1H), 7.84-7.77 (m, 1H), 7.65-7.53(m, 2H), 5.71-5.57 (m, 2H), 4.77-4.64 (s, 2H), 2.71-2.48 (s, 1H),2.02-1.92 (t, J=18.2 Hz, 3H).

Example 299:[2-[[1-[3-(1,1-Difluoroethyl)phenyl]triazol-4-yl]methoxy]pyrimidin-4-yl]methanol

The title compound was prepared in a manner analogous to Example 159,Steps A-B using(1-(3-(1,1-difluoroethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 64) and4-(((tert-butyldimethylsilyl)oxy)methyl)-2-chloropyrimidine(Intermediate 54) in Step A. MS (ESI): mass calcd. for C₁₆H₁₅F₂N₅O₂,347.1; m/z found, 348.1 [M+H]⁺. ¹H NMR (500 MHz, CDCl₃) δ 8.56-8.48 (d,J=5.0 Hz, 1H), 8.23-8.15 (m, 1H), 7.93-7.85 (m, 1H), 7.86-7.76 (m, 1H),7.65-7.54 (m, 2H), 7.07-6.96 (m, 1H), 5.71-5.64 (m, 2H), 4.78-4.68 (d,J=0.7 Hz, 2H), 2.02-1.92 (t, J=18.2 Hz, 3H).

Example 300:2-[[1-[3-(1,1-Difluoroethyl)phenyl]triazol-4-yl]methoxy]-4-(methoxymethyl)pyrimidine

The title compound was prepared analogous to Example 155, using(1-(3-(1,1-difluoroethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 64) and 2-chloro-4-(methoxymethyl)pyrimidine. MS (ESI):mass calcd. for C₁₇H₁₇F₂N₅O₂, 361.1; m/z found, 362.1 [M+H]⁺. ¹H NMR(400 MHz, CDCl₃) δ 8.55 (d, J=5.0 Hz, 1H), 8.20 (t, J=0.7 Hz, 1H),7.91-7.87 (m, 1H), 7.86-7.78 (m, 1H), 7.64-7.56 (m, 2H), 7.16 (dt,J=5.0, 0.8 Hz, 1H), 5.67 (d, J=0.7 Hz, 2H), 4.60-4.40 (m, 2H), 3.50 (s,3H), 1.97 (t, J=18.2 Hz, 3H).

Example 301:2-[2-[[1-[3-(1,1-Difluoroethyl)phenyl]triazol-4-yl]methoxy]pyrimidin-5-yl]propan-2-ol

The title compound was prepared analogous to Example 155, using(1-(3-(1,1-difluoroethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 64) and 2-(2-chloropyrimidin-5-yl)propan-2-ol. MS (ESI):mass calcd. for C₁₈H₁₉F₂N₅O₂, 375.2; m/z found, 376.0 [M+H]⁺. ¹H NMR(500 MHz, CDCl₃) δ 8.68 (s, 2H), 8.21-8.15 (m, 1H), 7.92-7.86 (m, 1H),7.86-7.79 (m, 1H), 7.63-7.56 (m, 2H), 5.67 (d, J=0.7 Hz, 2H), 2.12-1.88(m, 3H), 1.63 (s, 6H).

Example 302:2-[[1-[3-(1,1-Difluoroethyl)phenyl]triazol-4-yl]methoxy]-5-(difluoromethyl)pyrimidine

The title compound was prepared analogous to Example 155, using(1-(3-(1,1-difluoroethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 64) and 2-chloro-5-(difluoromethyl)pyrimidine. MS (ESI):mass calcd. for C₁₆H₁₃F₄N₅O, 367.1; m/z found, 368.1 [M+H]⁺. ¹H NMR (400MHz, CDCl₃) δ 8.77-8.66 (m, 2H), 8.25-8.11 (m, 1H), 7.96-7.87 (m, 1H),7.87-7.77 (m, 1H), 7.66-7.55 (m, 2H), 6.73 (t, J=55.6 Hz, 1H), 5.73 (d,J=0.7 Hz, 2H), 1.98 (t, J=18.2 Hz, 3H).

Example 303:2-[[1-[3-(1,1-Difluoroethyl)phenyl]triazol-4-yl]methoxy]-4-(difluoromethyl)pyrimidine

The title compound was prepared analogous to Example 155, using(1-(3-(1,1-difluoroethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 64) and 2-chloro-4-(difluoromethyl)pyrimidine. MS (ESI):mass calcd. for C₁₆H₁₃F₄N₅O, 367.1; m/z found, 368.1 [M+H]⁺. ¹H NMR (500MHz, CDCl₃) δ 8.76 (d, J=4.9 Hz, 1H), 8.25-8.16 (m, 1H), 7.92-7.86 (m,1H), 7.86-7.77 (m, 1H), 7.67-7.56 (m, 2H), 7.34-7.28 (m, 1H), 6.65-6.37(m, 1H), 5.71 (d, J=1.3 Hz, 2H), 2.09-1.85 (m, 3H).

Example 304:2-[[1-[3-(1,1-Difluoroethyl)phenyl]triazol-4-yl]methoxy]-4-(trifluoromethyl)pyrimidine

The title compound was prepared analogous to Example 155, using(1-(3-(1,1-difluoroethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 64) and 2-chloro-4-(trifluoromethyl)pyrimidine. MS (ESI):mass calcd. for C₁₆H₁₂F₅N₅O, 385.1; m/z found, 386.0 [M+H]⁺. ¹H NMR (400MHz, CDCl₃) δ 8.83 (d, J=4.9 Hz, 1H), 8.22 (t, J=0.7 Hz, 1H), 7.89 (d,J=1.0 Hz, 1H), 7.86-7.75 (m, 1H), 7.65-7.57 (m, 2H), 7.34 (d, J=4.9 Hz,1H), 5.73 (d, J=0.6 Hz, 2H), 1.98 (t, J=18.2 Hz, 3H).

Example 305:(R/S)-2-[2-[[1-[3-(1,1-Difluoroethyl)phenyl]triazol-4-yl]methoxy]pyrimidin-5-yl]-1,1,1-trifluoro-propan-2-ol

The title compound was prepared in a manner analogous to Example 153using (1-(3-(1,1-difluoroethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 64) and2-(2-chloropyrimidin-5-yl)-1,1,1-trifluoropropan-2-ol, using ACN insteadof DMF. MS (ESI): mass calcd. for C₁₈H₁₆F₅N₅O₂, 429.1; m/z found, 430.0[M+H]⁺. ¹H NMR (500 MHz, CDCl₃) δ 8.78-8.72 (s, 2H), 8.21-8.16 (t, J=0.7Hz, 1H), 7.92-7.86 (s, 1H), 7.85-7.78 (m, 1H), 7.65-7.56 (m, 2H),5.72-5.65 (d, J=0.7 Hz, 2H), 2.70-2.59 (s, 1H), 2.04-1.92 (t, J=18.2 Hz,3H), 1.86-1.81 (m, 3H).

Example 306:2-[[1-[3-(1,1-Difluoroethyl)phenyl]triazol-4-yl]methoxy]-5-methoxy-pyrimidine

The title compound was prepared analogous to Example 155, using(1-(3-(1,1-difluoroethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 64) and 2-chloro-5-methoxypyrimidine. MS (ESI): masscalcd. for C₁₆H₁₅F₂N₅O₂, 347.1; m/z found, 348.0 [M+H]⁺. ¹H NMR (500MHz, CDCl₃) δ 8.24 (s, 2H), 8.20-8.11 (m, 1H), 7.93-7.87 (m, 1H),7.84-7.77 (m, 1H), 7.67-7.53 (m, 2H), 5.62 (d, J=0.7 Hz, 2H), 3.88 (s,3H), 1.97 (t, J=18.2 Hz, 3H).

Example 307:2-[[1-[3-(1,1-Difluoroethyl)phenyl]triazol-4-yl]methoxy]-4-methoxy-pyrimidine

The title compound was prepared analogous to Example 155, using(1-(3-(1,1-difluoroethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 64) and 2-chloro-4-methoxypyrimidine. MS (ESI): masscalcd. for C₁₆H₁₅F₂N₅O₂, 347.1; m/z found, 348.0 [M+H]⁺. ¹H NMR (400MHz, CDCl₃) δ 8.23 (d, J=5.7 Hz, 1H), 8.16 (t, J=0.7 Hz, 1H), 7.92-7.86(m, 1H), 7.86-7.77 (m, 1H), 7.64-7.56 (m, 2H), 6.43 (d, J=5.8 Hz, 1H),5.66 (d, J=0.7 Hz, 2H), 3.99 (s, 3H), 1.98 (t, J=18.2 Hz, 3H).

Example 308:2-[[1-[3-(1,1-Difluoroethyl)phenyl]triazol-4-yl]methoxy]-5-(difluoromethoxy)pyrimidine

The title compound was prepared analogous to Example 155, using(1-(3-(1,1-difluoroethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 64) and 2-chloro-5-(difluoromethoxy)pyrimidine. MS (ESI):mass calcd. for C₁₆H₁₃F₄N₅O₂, 383.1; m/z found, 384.0 [M+H]⁺. ¹H NMR(400 MHz, CDCl₃) δ 8.45 (s, 2H), 8.17 (s, 1H), 7.93-7.87 (m, 1H),7.87-7.76 (m, 1H), 7.68-7.55 (m, 2H), 6.53 (t, J=71.9 Hz, 1H), 5.67 (d,J=0.7 Hz, 2H), 1.98 (t, J=18.2 Hz, 3H).

Example 309:1-[2-[[1-[3-(1,1-Difluoroethyl)phenyl]triazol-4-yl]methoxy]pyrimidin-5-yl]ethanone

The title compound was prepared analogous to Example 155, using(1-(3-(1,1-difluoroethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 64) and 1-(2-chloropyrimidin-5-yl)ethan-1-one. MS (ESI):mass calcd. for C₁₇H₁₅F₂N₅O₂, 359.1; m/z found, 360.1 [M+H]⁺. ¹H NMR(400 MHz, CDCl₃) δ 9.16-9.05 (s, 2H), 8.24-8.16 (s, 1H), 7.93-7.88 (d,J=2.0 Hz, 1H), 7.86-7.78 (m, 1H), 7.66-7.57 (m, 2H), 5.83-5.73 (d, J=0.9Hz, 2H), 2.67-2.55 (s, 3H), 2.06-1.90 (t, J=18.2 Hz, 3H).

Example 310:(R/S)-1-[2-[[1-[3-(1,1-Difluoroethyl)phenyl]triazol-4-yl]methoxy]pyrimidin-5-yl]ethanol

The title compound was prepared in a manner analogous to Example 157using1-(2-((1-(3-(1,1-difluoroethyl)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidin-5-yl)ethan-1-one(Example 309). MS (ESI): mass calcd. for C₁₇H₁₇F₂N₅O₂, 361.1; m/z found,362.1 [M+H]⁺. ¹H NMR (500 MHz, CDCl₃) δ 8.64-8.52 (s, 2H), 8.26-8.10 (s,1H), 7.93-7.85 (m, 1H), 7.84-7.77 (m, 1H), 7.66-7.54 (m, 2H), 5.72-5.57(d, J=0.7 Hz, 2H), 5.03-4.88 (m, 1H), 2.23-2.10 (s, 1H), 2.07-1.88 (t,J=18.3 Hz, 3H), 1.61-1.52 (d, J=6.5 Hz, 3H).

Example 311:(R/S)-2-[[1-[3-(1,1-Difluoroethyl)phenyl]triazol-4-yl]methoxy]-5-(1-methoxyethyl)pyrimidine

To a solution of1-(2-((1-(3-(1,1-difluoroethyl)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidin-5-yl)ethan-1-ol(Example 310, 21 mg, 0.06 mmol) in ACN was added NaH (7 mg, 0.17 mmol)followed by iodomethane (82 mg, 0.58 mmol). The resulting suspension wasstirred at rt for 2 h. The completed reaction was diluted with EtOAc andwashed with water, brine and dried (Na₂SO₄), filtered, and concentratedunder reduced pressure. Purification (FCC, SiO₂, 0-3% MeOH in DCM)afforded the titled compound (9.6 mg, 44%). MS (ESI): mass calcd. forC₁₈H₁₉F₂N₅O₂, 375.2; m/z found, 376.0 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃) δ8.57-8.48 (s, 2H), 8.24-8.15 (t, J=0.7 Hz, 1H), 7.92-7.86 (m, 1H),7.86-7.78 (m, 1H), 7.67-7.53 (m, 2H), 5.72-5.64 (d, J=0.7 Hz, 2H),4.40-4.29 (m, 1H), 3.35-3.21 (s, 3H), 2.08-1.88 (t, J=18.2 Hz, 3H),1.54-1.43 (d, J=6.5 Hz, 3H).

Example 312:5-Chloro-2-[[1-[3-(1,1-difluoroethyl)phenyl]triazol-4-yl]methoxy]-4-methyl-pyrimidine

The title compound was prepared analogous to Example 155, using(1-(3-(1,1-difluoroethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 64) and 2,5-dichloro-4-methylpyrimidine. MS (ESI): masscalcd. for C₁₆H₁₄ClF₂N₅O, 365.1; m/z found, 366.0 [M+H]⁺. ¹H NMR (400MHz, CDCl₃) δ 8.39 (s, 1H), 8.17-8.14 (m, 1H), 7.90-7.87 (m, 1H),7.84-7.79 (m, 1H), 7.62-7.57 (m, 2H), 5.64 (d, J=0.7 Hz, 2H), 2.57 (s,3H), 1.98 (t, J=18.2 Hz, 3H).

Example 313:2-[[1-[3-(1,1-Difluoroethyl)phenyl]triazol-4-yl]methoxy]-5-fluoro-4-methyl-pyrimidine

The title compound was prepared analogous to Example 155, using(1-(3-(1,1-difluoroethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 64) and 2-chloro-5-fluoro-4-methylpyrimidine. MS (ESI):mass calcd. for C₁₆H₁₄F₃N₅O, 349.1; m/z found, 350.1 [M+H]⁺. ¹H NMR (400MHz, CDCl₃) δ 8.26 (d, J=1.2 Hz, 1H), 8.16 (s, 1H), 7.89 (s, 1H),7.86-7.77 (m, 1H), 7.68-7.53 (m, 2H), 5.62 (d, J=0.7 Hz, 2H), 2.50 (d,J=2.5 Hz, 3H), 1.98 (t, J=18.2 Hz, 3H).

Example 314:2-[[1-[3-(1,1-Difluoroethyl)phenyl]triazol-4-yl]methoxy]-5-methyl-pyrimidin-4-amine

The title compound was prepared in a manner analogous to Example 153using (1-(3-(1,1-difluoroethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 64) and 2-chloro-5-methylpyrimidin-4-amine, using ACNinstead of DMF. MS (ESI): mass calcd. for C₁₆H₁₆F₂N₆O, 346.1; m/z found,347.1 [M+H]⁺. ¹H NMR (500 MHz, CDCl₃) δ 8.19-8.13 (s, 1H), 7.94-7.86 (m,2H), 7.85-7.75 (m, 1H), 7.63-7.55 (m, 2H), 5.62-5.51 (s, 2H), 5.08-4.91(s, 2H), 2.05-2.02 (s, 3H), 2.02-1.93 (t, J=18.2 Hz, 3H).

Example 315:2-[[1-[3-(1,1-Difluoroethyl)phenyl]triazol-4-yl]methoxy]-5-fluoro-N-methyl-pyrimidin-4-amine

The title compound was prepared in a manner analogous to Example 163,Steps B-C using(1-(3-(1,1-difluoroethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 64) and2-chloro-5-fluoro-N-methyl-N-((2-(trimethylsilyl)ethoxy)methyl)pyrimidin-4-amine(Intermediate 59) in step A. MS (ESI): mass calcd. for C₁₆H₁₅F₃N₆O,364.1; m/z found, 365.1 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃) δ 8.17-8.12 (t,J=0.7 Hz, 1H), 7.92-7.86 (m, 1H), 7.85-7.77 (m, 2H), 7.64-7.56 (m, 2H),5.61-5.55 (d, J=0.7 Hz, 2H), 5.15-5.10 (s, 1H), 3.11-3.05 (d, J=5.0 Hz,3H), 2.00-1.90 (m, 3H).

Example 316:2-[[1-[3-(1,1-Difluoroethyl)phenyl]triazol-4-yl]methoxy]pyrimidin-4-amine

The title compound was prepared in a manner analogous to Example 153using (1-(3-(1,1-difluoroethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 64) and 2-chloropyrimidin-4-amine, using ACN instead ofDMF. MS (ESI): mass calcd. for C₁₅H₁₄F₂N₆O, 332.1; m/z found, 333.1[M+H]⁺. ¹H NMR (400 MHz, CDCl₃) δ 8.22-8.11 (t, J=0.7 Hz, 1H), 8.09-7.99(d, J=5.7 Hz, 1H), 7.94-7.84 (m, 1H), 7.84-7.76 (m, 1H), 7.65-7.52 (m,2H), 6.22-6.07 (d, J=5.7 Hz, 1H), 5.65-5.50 (d, J=0.8 Hz, 2H), 5.29-5.12(s, 2H), 2.04-1.88 (t, J=18.2 Hz, 3H).

Example 317:2-[[1-[3-(1,1-Difluoroethyl)phenyl]triazol-4-yl]methoxy]-N-methyl-pyrimidin-4-amine

The title compound was prepared in a manner analogous to Example 163,Steps B-C using tert-butyl (2-chloropyrimidin-4-yl)(methyl)carbamate(Intermediate 55) and(1-(3-(1,1-difluoroethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 64). MS (ESI): mass calcd. for C₁₆H₁₆F₂N₆O, 346.1; m/zfound, 347.0 [M+H]⁺. ¹H NMR (500 MHz, CDCl₃) δ 8.18-8.13 (t, J=0.7 Hz,1H), 8.07-7.98 (s, 1H), 7.92-7.86 (dt, J=3.0, 1.1 Hz, 1H), 7.85-7.78 (m,1H), 7.63-7.55 (m, 2H), 6.07-6.02 (d, J=5.9 Hz, 1H), 5.64-5.58 (d, J=0.8Hz, 2H), 5.09-4.83 (s, 1H), 3.08-2.85 (m, 3H), 2.12-1.82 (t, J=18.2 Hz,3H).

Example 318:2-[[1-[3-(1,1-Difluoroethyl)phenyl]triazol-4-yl]methoxy]-N,N-dimethyl-pyrimidin-4-amine

The title compound was prepared analogous to Example 155, using(1-(3-(1,1-difluoroethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 64) and 2-chloro-N,N-dimethylpyrimidin-4-amine. MS (ESI):mass calcd. for C₁₇H₁₈F₂N₆O, 360.2; m/z found, 361.0 [M+H]⁺. ¹H NMR (500MHz, CDCl₃) δ 8.19-8.12 (t, J=0.8 Hz, 1H), 8.06-8.00 (d, J=6.1 Hz, 1H),7.94-7.87 (t, J=2.1 Hz, 1H), 7.84-7.77 (m, 1H), 7.63-7.55 (m, 2H),6.16-6.09 (d, J=6.1 Hz, 1H), 5.64-5.59 (d, J=0.8 Hz, 2H), 3.25-2.97 (s,6H), 2.08-1.90 (m, 3H).

Example 319:5-Cyclopropyl-2-[[1-[3-(1,1-difluoroethyl)phenyl]triazol-4-yl]methoxy]pyrimidine

The title compound was prepared analogous to Example 155, using(1-(3-(1,1-difluoroethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 64) and 2-chloro-5-cyclopropylpyrimidine. MS (ESI): masscalcd. for C₁₈H₁₇F₂N₅O, 357.1; m/z found, 358.0 [M+H]⁺. ¹H NMR (400 MHz,CDCl₃) δ 8.32 (d, J=0.5 Hz, 2H), 8.17-8.15 (m, 1H), 7.90-7.87 (m, 1H),7.81 (d, J=6.4 Hz, 1H), 7.63-7.57 (m, 2H), 5.64 (d, J=0.7 Hz, 2H), 1.97(t, J=18.2 Hz, 3H), 1.89-1.77 (m, 1H), 1.07-0.98 (m, 2H), 0.75-0.64 (m,2H).

Example 320:5-(Azetidin-1-yl)-2-[[1-[3-(1,1-difluoroethyl)phenyl]triazol-4-yl]methoxy]pyrimidine

The title compound was prepared in a manner analogous to Example 165,Steps A-C, using5-bromo-2-((1-(3-(1,1-difluoroethyl)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidine(Example 293) and azetidine in Step A. MS (ESI): mass calcd. forC₁₈H₁₈F₂N₆O, 372.2; m/z found, 373.1 [M+H]⁺. ¹H NMR (500 MHz, CDCl₃) δ8.16-8.13 (t, J=0.7 Hz, 1H), 7.91-7.87 (m, 1H), 7.84-7.79 (s, 3H),7.64-7.54 (m, 2H), 5.62-5.55 (d, J=0.8 Hz, 2H), 3.97-3.86 (t, J=7.2 Hz,4H), 2.50-2.39 (m, 2H), 2.04-1.88 (t, J=18.2 Hz, 3H).

Example 321:2-[[1-[3-(1,1-Difluoroethyl)phenyl]triazol-4-yl]methoxy]-5-(3-fluoroazetidin-1-yl)pyrimidine

The title compound was prepared in a manner analogous to Example 165,Steps A-C, using5-bromo-2-((1-(3-(1,1-difluoroethyl)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidine(Example 293) and 3-fluoroazetidine in Step A. MS (ESI): mass calcd. forC₁₈H₁₇F₃N₆O, 390.1; m/z found, 391.1 [M+H]⁺. ¹H NMR (500 MHz, CDCl₃) δ8.17-8.12 (t, J=0.7 Hz, 1H), 7.91-7.86 (m, 3H), 7.85-7.77 (m, 1H),7.64-7.55 (m, 2H), 5.62-5.56 (d, J=0.8 Hz, 2H), 5.56-5.34 (m, 1H),4.29-4.18 (m, 2H), 4.06-3.94 (m, 2H), 2.04-1.91 (t, J=18.2 Hz, 3H).

Example 322:2-[[1-[3-(1,1-Difluoroethyl)phenyl]triazol-4-yl]methoxy]-4-pyrrolidin-1-yl-pyrimidine

The title compound was prepared in a manner analogous to Example 153using (1-(3-(1,1-difluoroethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 64) and 2-chloro-4-(pyrrolidin-1-yl)pyrimidine using ACNinstead of DMF. MS (ESI): mass calcd. for C₁₀H₂₀F₂N₆O, 386.2; m/z found,387.1 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃) δ 8.17-8.14 (s, 1H), 8.02-7.98 (d,J=5.9 Hz, 1H), 7.91-7.87 (m, 1H), 7.84-7.77 (m, 1H), 7.62-7.55 (m, 2H),6.06-5.95 (d, J=6.0 Hz, 1H), 5.68-5.55 (d, J=0.8 Hz, 2H), 3.76-3.54 (m,2H), 3.47-3.27 (m, 2H), 2.10-1.88 (m, 7H).

Example 323:2-[[1-[3-(Difluoromethoxy)phenyl]triazol-4-yl]methoxy]pyrimidine

The title compound was prepared in a manner analogous to Example 1 using(1-(3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 42) and 2-chloropyrimidine. MS (ESI): mass calcd. forC₁₄H₁₁F₂N₅O₂, 319.1; m/z found, 320.1 [M+H]⁺. ¹H NMR (400 MHz, DMSO-d₆)δ 8.99 (s, 1H), 8.66 (d, J=4.8 Hz, 2H), 7.86-7.76 (m, 2H), 7.66 (t,J=8.2 Hz, 1H), 7.48 (d, J=73.5 Hz, 1H), 7.31 (dd, J=7.9, 2.4 Hz, 1H),7.24-7.14 (m, 1H), 5.54 (s, 2H).

Example 324:2-[[1-[3-(Difluoromethoxy)phenyl]triazol-4-yl]methoxy]-5-fluoro-pyrimidine

The title compound was prepared in a manner analogous to Example 1 using(1-(3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 42) and 2-chloro-5-fluoropyrimidine. MS (ESI): mass calcd.for C₁₄H₁₀F₃N₅O₂, 337.1; m/z found, 338.1 [M+H]⁺. ¹H NMR (400 MHz,DMSO-d₆) δ 8.98 (s, 1H), 8.75 (d, J=0.7 Hz, 2H), 7.82 (ddd, J=8.1, 2.1,0.9 Hz, 1H), 7.79 (t, J=2.2 Hz, 1H), 7.66 (t, J=8.2 Hz, 1H), 7.60-7.17(m, 2H), 5.52 (s, 2H).

Example 325:2-[[1-[3-(Difluoromethoxy)phenyl]triazol-4-yl]methoxy]-5-methoxy-pyrimidine

The title compound was prepared in a manner analogous to Example 1 using(1-(3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 42) and 2-chloro-5-methoxypyrimidine. MS (ESI): masscalcd. for C₁₅H₁₃F₂N₅O₃, 349.1; m/z found, 350.1 [M+H]⁺. ¹H NMR (400MHz, DMSO-d₆) δ 8.96 (s, 1H), 8.41 (s, 2H), 7.83 (dd, J=8.1, 2.2 Hz,1H), 7.79 (t, J=2.2 Hz, 1H), 7.66 (t, J=8.2 Hz, 1H), 7.59-7.16 (m, 2H),5.47 (s, 2H), 3.86 (s, 3H).

Example 326:5-Chloro-2-[[1-[3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]pyrimidine

The title compound was prepared in a manner analogous to Example 1 using(1-(3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 42) and 2,5-dichloropyrimidine. MS (ESI): mass calcd. forC₁₄H₁₀ClF₂N₅O₂, 353.0; m/z found, 354.0 [M+H]⁺. ¹H NMR (500 MHz,DMSO-d₆) δ 8.98 (s, 1H), 8.77 (s, 2H), 7.82 (ddd, J=8.1, 2.1, 0.9 Hz,1H), 7.79 (t, J=2.2 Hz, 1H), 7.66 (t, J=8.2 Hz, 1H), 7.56-7.23 (m, 2H),5.79-5.32 (m, 2H).

Example 327:2-[[1-[3-(Difluoromethoxy)phenyl]triazol-4-yl]methoxy]-5-methyl-pyrimidine

The title compound was prepared in a manner analogous to Example 1 using(1-(3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 42) and 2-chloro-5-methylpyrimidine. MS (ESI): mass calcd.for C₁₅H₁₃F₂N₅O₂, 333.1; m/z found, 334.1 [M+H]⁺. ¹H NMR (500 MHz,DMSO-d₆) δ 8.97 (s, 1H), 8.49 (d, J=0.8 Hz, 2H), 7.83 (ddd, J=8.1, 2.1,0.9 Hz, 1H), 7.79 (t, J=2.2 Hz, 1H), 7.66 (t, J=8.2 Hz, 1H), 7.56-7.22(m, 2H), 5.62-5.21 (m, 2H), 2.21 (d, J=0.8 Hz, 3H).

Example 328:2-[[1-[3-(Difluoromethoxy)phenyl]triazol-4-yl]methoxy]-5-ethyl-pyrimidine

The title compound was prepared in a manner analogous to Example 1 using(1-(3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 42) and 2-chloro-5-ethylpyrimidine. MS (ESI): mass calcd.for C₁₆H₁₅F₂N₅O₂, 347.1; m/z found, 348.2 [M+H]⁺. ¹H NMR (500 MHz,DMSO-d₆) δ 8.98 (d, J=0.6 Hz, 1H), 8.53 (d, J=0.6 Hz, 2H), 7.83 (ddd,J=8.1, 2.1, 0.9 Hz, 1H), 7.79 (t, J=2.2 Hz, 1H), 7.66 (t, J=8.2 Hz, 1H),7.55-7.19 (m, 2H), 5.67-5.35 (m, 2H), 2.62-2.54 (m, 2H), 1.19 (t, J=7.6Hz, 3H).

Example 329:2-[[1-[4-(Difluoromethoxy)phenyl]triazol-4-yl]methoxy]pyrimidine

The title compound was prepared in a manner analogous to Example 1 using(1-(4-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 43) and 2-chloropyrimidine. MS (ESI): mass calcd. forC₁₄H₁₁F₂N₅O₂, 319.1; m/z found, 320.1 [M+H]⁺. ¹H NMR (500 MHz, DMSO-d₆)δ 8.92 (d, J=0.6 Hz, 1H), 8.66 (d, J=4.8 Hz, 2H), 8.05-7.91 (m, 2H),7.52-7.16 (m, 4H), 5.53 (d, J=0.5 Hz, 2H).

Example 330:2-[[1-[4-(Difluoromethoxy)phenyl]triazol-4-yl]methoxy]-5-fluoro-pyrimidine

The title compound was prepared in a manner analogous to Example 1 using(1-(4-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 43) and 2-chloro-5-fluoropyrimidine. MS (ESI): mass calcd.for C₁₄H₁₀F₃N₅O₂, 337.1; 338.1 [M+H]⁺. ¹H NMR (500 MHz, DMSO-d₆) δ 8.91(s, 1H), 8.75 (d, J=0.7 Hz, 2H), 8.01-7.92 (m, 2H), 7.52-7.17 (m, 3H),5.52 (s, 2H).

Example 331:2-[[1-[4-(Difluoromethoxy)phenyl]triazol-4-yl]methoxy]-5-methoxy-pyrimidine

The title compound was prepared in a manner analogous to Example 1 using(1-(4-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 43) and 2-chloro-5-methoxypyrimidine. MS (ESI): masscalcd. for C₁₅H₁₃F₂N₅O₃, 349.1; m/z found, 350.1 [M+H]⁺. ¹H NMR (500MHz, DMSO-d₆) δ 8.89 (s, 1H), 8.41 (s, 2H), 8.02-7.94 (m, 2H), 7.53-7.16(m, 3H), 5.46 (d, J=0.6 Hz, 2H), 3.86 (s, 3H).

Example 332:5-Chloro-2-[[1-[4-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]pyrimidine

The title compound was prepared in a manner analogous to Example 1 using(1-(4-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 43) and 2,5-dichloropyrimidine. ¹H NMR (500 MHz, DMSO-d₆)δ 8.91 (s, 1H), 8.77 (s, 2H), 8.01-7.93 (m, 2H), 7.53-7.16 (m, 3H),5.59-5.49 (m, 2H).

Example 333:2-[[1-[4-(Difluoromethoxy)phenyl]triazol-4-yl]methoxy]-5-methyl-pyrimidine

The title compound was prepared in a manner analogous to Example 1 using(1-(4-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 43) and 2-chloro-5-methylpyrimidine. ¹H NMR (500 MHz,DMSO-d₆) δ 8.90 (s, 1H), 8.49 (d, J=0.8 Hz, 2H), 8.04-7.90 (m, 2H),7.55-7.16 (m, 3H), 5.49 (s, 2H), 2.21 (d, J=0.8 Hz, 3H).

Example 334:2-[[1-[4-(Difluoromethoxy)phenyl]triazol-4-yl]methoxy]-5-ethyl-pyrimidine

The title compound was prepared in a manner analogous to Example 1 using(1-(4-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 43) and 2-chloro-5-ethylpyrimidine. ¹H NMR (500 MHz,DMSO-d₆) δ 8.90 (s, 1H), 8.53 (t, J=0.6 Hz, 2H), 8.01-7.88 (m, 2H),7.54-7.16 (m, 3H), 5.50 (d, J=0.6 Hz, 2H), 2.57 (q, J=7.6 Hz, 2H), 1.19(t, J=7.6 Hz, 3H).

Example 335:2-[[1-[4-(Trifluoromethoxy)phenyl]triazol-4-yl]methoxy]pyrimidine

The title compound was prepared in a manner analogous to Example 1 using(1-(4-(trifluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 34) and 2-chloropyrimidine. MS (ESI): mass calcd. forC₁₄H₁₀F₃N₅O₂, 337.1; m/z found, 338.1 [M+H]⁺. ¹H NMR (500 MHz, DMSO-d₆)δ 8.97 (s, 1H), 8.66 (d, J=4.8 Hz, 2H), 8.12-7.99 (m, 2H), 7.69-7.58 (m,2H), 7.20 (t, J=4.8 Hz, 1H), 5.61-5.39 (m, 2H).

Example 336:5-Fluoro-2-[[1-[4-(trifluoromethoxy)phenyl]triazol-4-yl]methoxy]pyrimidine

The title compound was prepared in a manner analogous to Example 1 using(1-(4-(trifluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 34) and 2-chloro-5-fluoropyrimidine. MS (ESI): mass calcd.for C₁₄H₉F₄N₅O₂, 355.1; m/z found, 356.0 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD)δ 8.74 (s, 1H), 8.57 (s, 2H), 8.03-7.94 (m, 2H), 7.57-7.44 (m, 2H), 5.44(s, 2H).

Example 337:5-Methoxy-2-[[1-[4-(trifluoromethoxy)phenyl]triazol-4-yl]methoxy]pyrimidine

The title compound was prepared in a manner analogous to Example 1 using(1-(4-(trifluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 34) and 2-chloro-5-methoxypyrimidine. MS (ESI): masscalcd. for C₁₅H₁₂F₃N₅O₃, 367.1; m/z found, 368.1 [M+H]⁺. ¹H NMR (500MHz, DMSO-d₆) δ 8.94 (s, 1H), 8.41 (s, 2H), 8.11-8.00 (m, 2H), 7.68-7.54(m, 2H), 5.51-5.43 (m, 2H), 3.86 (s, 3H).

Example 338:5-Chloro-2-[[1-[4-(trifluoromethoxy)phenyl]triazol-4-yl]methoxy]pyrimidine

The title compound was prepared in a manner analogous to Example 1 using(1-(4-(trifluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 34) and 2,5-dichloropyrimidine. MS (ESI): mass calcd. forC₁₄H₉ClF₃N₅O₂, 371.0; m/z found, 372.0 [M+H]⁺. ¹H NMR (500 MHz, DMSO-d₆)δ 8.96 (s, 1H), 8.77 (s, 2H), 8.10-8.01 (m, 2H), 7.67-7.55 (m, 2H), 5.55(d, J=0.6 Hz, 2H).

Example 339:5-Methyl-2-[[1-[4-(trifluoromethoxy)phenyl]triazol-4-yl]methoxy]pyrimidine

The title compound was prepared in a manner analogous to Example 1 using(1-(4-(trifluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 34) and 2-chloro-5-methylpyrimidine. MS (ESI): mass calcd.for C₁₅H₁₂F₃N₅O₂, 351.1; m/z found, 352.1 [M+H]⁺. ¹H NMR (500 MHz,DMSO-d₆) δ 8.95 (s, 1H), 8.49 (d, J=0.7 Hz, 2H), 8.12-8.02 (m, 2H),7.70-7.56 (m, 2H), 5.50 (s, 2H), 2.21 (t, J=0.8 Hz, 3H).

Example 340:5-Ethyl-2-[[1-[4-(trifluoromethoxy)phenyl]triazol-4-yl]methoxy]pyrimidine

The title compound was prepared in a manner analogous to Example 1 using(1-(4-(trifluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 34) and 2-chloro-5-ethylpyrimidine. MS (ESI): mass calcd.for C₁₆H₁₄F₃N₅O₂, 365.1; m/z found, 366.2 [M+H]⁺. ¹H NMR (500 MHz,DMSO-d₆) δ 8.96 (s, 1H), 8.53 (s, 2H), 8.16-7.97 (m, 2H), 7.70-7.51 (m,2H), 5.58-5.41 (m, 2H), 2.57 (q, 2H), 1.19 (t, J=7.6 Hz, 3H).

Example 341:2-[[1-[3-(Trifluoromethoxy)phenyl]triazol-4-yl]methoxy]pyrimidine

The title compound was prepared in a manner analogous to Example 1 using(1-(3-(trifluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 35) and 2-chloropyrimidine. ¹H NMR (500 MHz, DMSO-d) δ9.03 (s, 1H), 8.67 (d, J=4.8 Hz, 2H), 8.05-7.92 (m, 2H), 7.75 (t, J=8.2Hz, 1H), 7.52 (d, J=8.3 Hz, 1H), 7.20 (t, J=4.8 Hz, 1H), 5.54 (s, 2H).

Example 342:5-Methyl-2-[[1-[3-(trifluoromethoxy)phenyl]triazol-4-yl]methoxy]pyrimidine

The title compound was prepared in a manner analogous to Example 1 using(1-(3-(trifluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 35) and 2-chloro-5-methylpyrimidine. MS (ESI): mass calcd.for C₁₅H₁₂F₃N₅O₂, 351.1; m/z found, 352.1 [M+H]⁺. ¹H NMR (400 MHz,DMSO-d₆) δ 9.02 (s, 1H), 8.49 (d, J=0.8 Hz, 2H), 8.04-7.96 (m, 2H),7.78-7.68 (m, 1H), 7.52 (ddt, J=8.3, 2.3, 1.2 Hz, 1H), 5.50 (s, 2H),2.21 (d, J=0.8 Hz, 3H).

Example 343:5-Methyl-2-[[1-[3-(trifluoromethoxy)phenyl]triazol-4-yl]methoxy]pyrimidin-4-amine

The title compound was prepared in a manner analogous to Example 1 using(1-(3-(trifluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 35) and 2-chloro-5-methylpyrimidin-4-amine. MS (ESI): masscalcd. for C₁₅H₁₃F₃N₆O₂, 366.1; m/z found, 367.1 [M+H]⁺. ¹H NMR (500MHz, DMSO-d₆) δ 8.99 (s, 1H), 8.04-7.95 (m, 2H), 7.79-7.70 (m, 2H),7.54-7.49 (m, 1H), 6.76 (s, 2H), 5.35 (s, 2H), 1.92 (d, J=0.9 Hz, 3H).

Example 344:1-[2-[[1-[3-(Trifluoromethoxy)phenyl]triazol-4-yl]methoxy]pyrimidin-5-yl]ethanone

The title compound was prepared in a manner analogous to Example 1 using(1-(3-(trifluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 35) and 1-(2-chloropyrimidin-5-yl)ethan-1-one. MS (ESI):mass calcd. for C₁₆H₁₂F₃N₅O₃, 379.1; m/z found, 380.1 [M+H]⁺. ¹H NMR(500 MHz, DMSO-d₆) δ 9.16 (s, 2H), 9.06 (s, 1H), 8.04-7.99 (m, 2H),7.80-7.71 (m, 1H), 7.57-7.47 (m, 1H), 5.66 (s, 2H), 2.60 (s, 3H).

Example 345:2-[2-[[1-[3-(Trifluoromethoxy)phenyl]triazol-4-yl]methoxy]pyrimidin-5-yl]propan-2-ol

The title compound was prepared in a manner analogous to Example 1 using(1-(3-(trifluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 35) and 2-(2-chloropyrimidin-5-yl)propan-2-ol. MS (ESI):mass calcd. for C₁₇H₁₆F₃N₅O₃, 395.1; m/z found, 396.1 [M+H]⁺. ¹H NMR(500 MHz, CD₃OD) δ 8.76 (s, 1H), 8.72 (s, 2H), 7.94-7.85 (m, 2H), 7.69(t, J=8.2 Hz, 1H), 7.43 (ddt, J=8.3, 2.3, 1.1 Hz, 1H), 5.62 (s, 2H),1.57 (s, 6H).

Example 346:4-(Methoxymethyl)-2-[[1-[3-(trifluoromethoxy)phenyl]triazol-4-yl]methoxy]pyrimidine

The title compound was prepared in a manner analogous to Example 1 using(1-(3-(trifluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 35) and 2-chloro-4-(methoxymethyl)pyrimidine. MS (ESI):mass calcd. for C₁₆H₁₄F₃N₅O₃, 381.1; m/z found, 382.1 [M+H]⁺. ¹H NMR(400 MHz, CD₃OD) δ 8.84-8.72 (m, 1H), 8.59 (s, 1H), 7.90 (d, J=9.3 Hz,2H), 7.71 (d, J=7.9 Hz, 1H), 7.45 (s, 1H), 7.23 (s, 1H), 5.63 (d, J=5.4Hz, 2H), 4.68-4.42 (m, 2H), 3.62-3.44 (m, 3H).

Example 347:4-Methyl-2-[[1-[3-(trifluoromethoxy)phenyl]triazol-4-yl]methoxy]pyrimidine

The title compound was prepared in a manner analogous to Example 1 using(1-(3-(trifluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 35) and 2-chloro-4-methylpyrimidine. MS (ESI): mass calcd.for C₁₅H₁₂F₃N₅O₂, 351.1; m/z found, 352.1[M+H]⁺. ¹H NMR (500 MHz,DMSO-d₆) δ 9.02 (s, 1H), 8.49 (d, J=5.0 Hz, 1H), 8.07-7.98 (m, 2H), 7.75(t, J=8.2 Hz, 1H), 7.58-7.51 (m, 1H), 7.08 (d, J=4.9 Hz, 1H), 5.52 (s,2H), 2.43 (s, 3H).

Example 348:5-Fluoro-2-[[1-[3-(trifluoromethoxy)phenyl]triazol-4-yl]methoxy]pyrimidine

The title compound was prepared in a manner analogous to Example 1 using(1-(3-(trifluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 35) and 2-chloro-5-fluoropyrimidine. MS (ESI): mass calcd.for C₁₄H₉F₄N₅O₂, 355.1; m/z found, 256.1 [M+H]⁺. ¹H NMR (500 MHz,DMSO-d₆) δ 9.03 (s, 1H), 8.75 (d, J=0.7 Hz, 2H), 8.05-7.96 (m, 2H),7.80-7.71 (m, 1H), 7.53 (ddq, J=8.3, 2.2, 1.1 Hz, 1H), 5.53 (d, J=0.6Hz, 2H)

Example 349:5-Methoxy-2-[[1-[3-(trifluoromethoxy)phenyl]triazol-4-yl]methoxy]pyrimidine

The title compound was prepared in a manner analogous to Example 1 using(1-(3-(trifluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 35) and 2-chloro-5-methoxypyrimidine. MS (ESI): masscalcd. for C₁₅H₁₂F₃N₅O₃, 367.1; m/z found, 368.1 [M+H]⁺. ¹H NMR (500MHz, DMSO-d₆) δ 9.01 (s, 1H), 8.41 (s, 2H), 8.05-7.96 (m, 2H), 7.75 (t,J=8.2 Hz, 1H), 7.52 (d, J=8.2 Hz, 1H), 5.48 (s, 2H), 3.86 (s, 3H).

Example 350:5-Chloro-2-[[1-[3-(trifluoromethoxy)phenyl]triazol-4-yl]methoxy]pyrimidine

The title compound was prepared in a manner analogous to Example 1 using(1-(3-(trifluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 35) and 2,5-dichloropyrimidine. MS (ESI): mass calcd. forC₁₄H₉ClF₃N₅O₂, 371.0; m/z found, 372.0 [M+H]⁺. ¹H NMR (500 MHz, DMSO-d₆)δ 9.02 (s, 1H), 8.77 (s, 2H), 8.05-7.95 (m, 2H), 7.81-7.70 (m, 1H), 7.53(ddt, J=8.3, 2.2, 1.1 Hz, 1H), 5.55 (s, 2H).

Example 351:5-Ethyl-2-[[1-[3-(trifluoromethoxy)phenyl]triazol-4-yl]methoxy]pyrimidine

The title compound was prepared in a manner analogous to Example 1 using(1-(3-(trifluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 35) and 2-chloro-5-ethylpyrimidine. MS (ESI): mass calcd.for C₁₆H₁₄F₃N₅O₂, 365.1; m/z found, 366.2 [M+H]⁺. ¹H NMR (500 MHz,DMSO-d₆) δ 9.03 (s, 1H), 8.53 (d, J=0.8 Hz, 2H), 8.08-7.91 (m, 2H),7.80-7.69 (m, 1H), 7.52 (ddt, J=8.3, 2.2, 1.1 Hz, 1H), 5.52 (s, 2H),2.58 (q, J=7.6 Hz, 2H), 1.19 (t, J=7.6 Hz, 3H).

Example 352:N-Methyl-2-[[1-[3-(trifluoromethoxy)phenyl]triazol-4-yl]methoxy]pyrimidin-4-amine

The title compound was prepared in a manner analogous to Example 163,Steps B-C, using tert-butyl (2-chloropyrimidin-4-yl)(methyl)carbamate(Intermediate 55) and(1-(3-(trifluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 35). MS (ESI): mass calcd. for C₁₅H₁₃F₃N₆O₂, 366.1; m/zfound, 367.4 [M+H]⁺. ¹H NMR (400 MHz, CD₃OD) δ 8.69 (s, 1H), 7.97-7.84(m, 2H), 7.80 (s, 1H), 7.69 (dd, J=10.2, 6.3 Hz, 1H), 7.51-7.37 (m, 2H),6.20-6.05 (m, 1H), 5.53 (s, 2H), 2.92 (s, 3H).

Example 353:2-[[1-[3-(Trifluoromethoxy)phenyl]triazol-4-yl]methoxy]pyrimidin-4-amine

The title compound was prepared in a manner analogous to Example 153using (1-(3-(trifluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 35) and 2-chloropyrimidin-4-amine. MS (ESI): mass calcd.for C₁₄H₁₁F₃N₆O₂, 352.1; m/z found, 353.3[M+H]⁺. ¹H NMR (400 MHz, CD₃OD)δ 8.72 (s, 1H), 7.95-7.82 (m, 3H), 7.69 (dd, J=9.7, 6.9 Hz, 1H),7.48-7.34 (m, 1H), 6.17 (d, J=5.9 Hz, 1H), 5.48 (d, J=3.7 Hz, 2H).

Example 354:2-[[1-(2,2-Difluoro-1,3-benzodioxol-5-yl)triazol-4-yl]methoxy]-5-methyl-pyrimidine

The title compound was prepared in a manner analogous to Example 1 using(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 45) and 2-chloro-5-methylpyrimidine. MS (ESI): mass calcd.for C₁₅H₁₁F₂N₅O₃, 347.1; m/z found, 348.0 [M+H]⁺. ¹H NMR (400 MHz,DMSO-d₆) δ 8.88 (s, 1H), 8.49 (d, J=0.9 Hz, 2H), 8.08 (d, J=2.2 Hz, 1H),7.79 (dd, J=8.8, 2.2 Hz, 1H), 7.65 (d, J=8.7 Hz, 1H), 5.49 (s, 2H), 2.21(d, J=0.7 Hz, 3H).

Example 355:2-[[1-(2,2-Difluoro-1,3-benzodioxol-5-yl)triazol-4-yl]methoxy]pyrimidine

The title compound was prepared in a manner analogous to Example 1 using(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 45) and 2-chloropyrimidine. MS (ESI): mass calcd. forC₁₄H₉F₂N₅O₃, 333.1; m/z found, 334.1 [M+H]⁺. ¹H NMR (400 MHz, DMSO-d₆) δ8.91 (s, 1H), 8.67 (d, J=4.8 Hz, 2H), 8.09 (d, J=2.2 Hz, 1H), 7.80 (dd,J=8.7, 2.2 Hz, 1H), 7.65 (d, J=8.7 Hz, 1H), 7.20 (t, J=4.8 Hz, 1H), 5.54(s, 2H).

Example 356:5-Chloro-2-[[1-(2,2-difluoro-1,3-benzodioxol-5-yl)triazol-4-yl]methoxy]pyrimidine

The title compound was prepared in a manner analogous to Example 1 using(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 45) and 2,5-dichloropyrimidine. MS (ESI): mass calcd. forC₁₄H₈ClF₂N₅O₃, 367.0; m/z found, 368.0 [M+H]⁺. ¹H NMR (400 MHz, DMSO-ds)δ 8.89 (s, 1H), 8.77 (s, 2H), 8.08 (d, J=2.2 Hz, 1H), 7.79 (dd, J=8.8,2.2 Hz, 1H), 7.65 (d, J=8.8 Hz, 1H), 5.54 (s, 2H).

Example 357:2-[[1-(2,2-Difluoro-1,3-benzodioxol-5-yl)triazol-4-yl]methoxy]-5-fluoro-4-methyl-pyrimidine

The title compound was prepared in a manner analogous to Example 1 using(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 45) and 2-chloro-5-fluoro-4-methylpyrimidine. MS (ESI):mass calcd. for C₁₅H₁₀F₃N₅O₃, 365.1; m/z found, 366.0 [M+H]⁺. ¹H NMR(400 MHz, DMSO-d₆) δ 8.88 (s, 1H), 8.56 (d, J=1.6 Hz, 1H), 8.08 (d,J=2.2 Hz, 1H), 7.79 (dd, J=8.7, 2.2 Hz, 1H), 7.65 (d, J=8.8 Hz, 1H),5.49 (s, 2H), 2.44 (d, J=2.6 Hz, 3H).

Example 358:2-[[1-(2,2-Difluoro-1,3-benzodioxol-5-yl)triazol-4-yl]methoxy]-5-fluoro-pyrimidine

The title compound was prepared in a manner analogous to Example 1 using(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 45) and 2-chloro-5-fluoropyrimidine. MS (ESI): mass calcd.for C₁₄H₆F₃N₅O₃, 351.1; m/z found, 352.1 [M+H]⁺. ¹H NMR (400 MHz,DMSO-d₆) δ 8.89 (s, 1H), 8.75 (d, J=0.6 Hz, 2H), 8.08 (d, J=2.2 Hz, 1H),7.79 (dd, J=8.8, 2.2 Hz, 1H), 7.65 (d, J=8.7 Hz, 1H), 5.52 (s, 2H).

Example 359:2-[[1-(2,2-Difluoro-1,3-benzodioxol-5-yl)triazol-4-yl]methoxy]-4,5-dimethyl-pyrimidine

The title compound was prepared in a manner analogous to Example 1 using(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 45) and 2-chloro-4,5-dimethylpyrimidine. MS (ESI): masscalcd. for C₁₆H₁₃F₂N₅O₃, 361.1; m/z found, 362.1 [M+H]⁺. ¹H NMR (400MHz, DMSO-d₆) δ 8.87 (s, 1H), 8.30 (s, 1H), 8.08 (d, J=2.2 Hz, 1H), 7.79(dd, J=8.8, 2.2 Hz, 1H), 7.65 (d, J=8.7 Hz, 1H), 5.47 (s, 2H), 2.39 (s,3H), 2.16 (s, 3H).

Example 360: 2-[[1-(3,5-Dimethylphenyl)triazol-4-yl]methoxy]pyrimidine

The title compound was prepared in a manner analogous to Example 1 using(1-(3,5-dimethylphenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 36)and 2-chloropyrimidine. MS (ESI): mass calcd. for C₁₅H₁₅N₅O, 281.1; m/zfound, 282.2 [M+H]⁺. ¹H NMR (500 MHz, DMSO-d₆) δ 8.85 (s, 1H), 8.66 (d,J=4.8 Hz, 2H), 7.59-7.44 (m, 2H), 7.20 (t, J=4.8 Hz, 1H), 7.13 (td,J=1.5, 0.8 Hz, 1H), 5.52 (s, 2H), 2.37 (d, J=0.8 Hz, 6H).

Example 361:2-[[1-(3,5-Dimethylphenyl)triazol-4-yl]methoxy]-5-fluoro-pyrimidine

The title compound was prepared in a manner analogous to Example 1 using(1-(3,5-dimethylphenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 36)and 2-chloro-5-fluoropyrimidine. MS (ESI): mass calcd. for C₁₅H₁₄FN₅O,299.1; m/z found, 300.1 [M+H]⁺. ¹H NMR (500 MHz, DMSO-d₆) δ 8.84 (s,1H), 8.75 (d, J=0.6 Hz, 2H), 7.54 (dt, J=1.4, 0.7 Hz, 2H), 7.14 (dq,J=1.8, 0.8 Hz, 1H), 5.50 (s, 2H), 2.37 (d, J=0.7 Hz, 6H).

Example 362:2-[[1-(3,5-Dimethylphenyl)triazol-4-yl]methoxy]-5-methoxy-pyrimidine

The title compound was prepared in a manner analogous to Example 1 using(1-(3,5-dimethylphenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 36)and 2-chloro-5-methoxypyrimidine. MS (ESI): mass calcd. for C₁₆H₁₇N₅O₂,311.1; m/z found, 312.2 [M+H]⁺. ¹H NMR (500 MHz, DMSO-d₆) δ 8.82 (s,1H), 8.41 (s, 2H), 7.54 (dt, J=1.5, 0.7 Hz, 2H), 7.13 (tt, J=1.7, 0.8Hz, 1H), 5.45 (d, J=0.6 Hz, 2H), 3.86 (s, 3H), 2.37 (d, J=0.7 Hz, 6H).

Example 363:5-Chloro-2-[[1-(3,5-dimethylphenyl)triazol-4-yl]methoxy]pyrimidine

The title compound was prepared in a manner analogous to Example 1 using(1-(3,5-dimethylphenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 36)and 2,5-dichloropyrimidine. MS (ESI): mass calcd. for C₁₅H₁₄ClN₅O,315.1; m/z found, 316.1 [M+H]⁺. ¹H NMR (500 MHz, DMSO-d₆) δ 8.85 (s,1H), 8.77 (s, 2H), 7.54 (dd, J=1.4, 0.8 Hz, 2H), 7.14 (tt, J=1.6, 0.8Hz, 1H), 5.53 (d, J=0.5 Hz, 2H), 2.37 (q, J=0.7 Hz, 6H).

Example 364:2-[[1-(3,5-Dimethylphenyl)triazol-4-yl]methoxy]-5-methyl-pyrimidine

The title compound was prepared in a manner analogous to Example 1 using(1-(3,5-dimethylphenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 36)and 2-chloro-5-methylpyrimidine. MS (ESI): mass calcd. for C₁₆H₁₇N₅O,295.1; m/z found, 296.1 [M+H]⁺. ¹H NMR (500 MHz, DMSO-d₆) δ 8.83 (s,1H), 8.49 (d, J=0.8 Hz, 2H), 7.54 (dd, J=1.5, 0.8 Hz, 2H), 7.18-7.06 (m,1H), 5.48 (s, 2H), 2.37 (d, J=0.7 Hz, 6H), 2.21 (t, J=0.7 Hz, 3H).

Example 365:2-[[1-(3,5-Dimethylphenyl)triazol-4-yl]methoxy]-5-ethyl-pyrimidine

The title compound was prepared in a manner analogous to Example 1 using(1-(3,5-dimethylphenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 36)and 2-chloro-5-ethylpyrimidine. MS (ESI): mass calcd. for C₁₇H₁₉N₅O,309.2; m/z found, 310.2 [M+H]⁺. ¹H NMR (500 MHz, DMSO-d₆) δ 8.84 (s,1H), 8.53 (s, 2H), 7.54 (dt, J=1.5, 0.7 Hz, 2H), 7.13 (tt, J=1.6, 0.8Hz, 1H), 5.49 (s, 2H), 2.57 (q, J=7.6 Hz, 2H), 1.19 (t, J=7.6 Hz, 3H).

Example 366: 2-[(1-Indan-5-yltriazol-4-yl)methoxy]-5-methyl-pyrimidine

The title compound was prepared in a manner analogous to Example 1 using(1-(2,3-dihydro-1H-inden-5-yl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 51) and 2-chloro-5-methylpyrimidine. MS (ESI): mass calcd.for C₁₇H₁₇N₅O, 307.1; m/z found, 308.1 [M+H]⁺. ¹H NMR (400 MHz, DMSO-d₆)δ 8.82 (s, 1H), 8.49 (d, J=0.9 Hz, 2H), 7.74 (d, J=2.0 Hz, 1H), 7.63(dd, J=8.1, 2.2 Hz, 1H), 7.41 (d, J=8.1 Hz, 1H), 5.47 (s, 2H), 2.94 (dt,J=12.9, 7.4 Hz, 4H), 2.21 (s, 3H), 2.14-2.00 (m, 2H).

Example 367: 5-Chloro-2-[(1-indan-5-yltriazol-4-yl)methoxy]pyrimidine

The title compound was prepared in a manner analogous to Example 1 using(1-(2,3-dihydro-1H-inden-5-yl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 51) and 2,5-dichloropyrimidine. MS (ESI): mass calcd. forC₁₆H₁₄ClN₅O, 327.1; m/z found, 328.1 [M+H]⁺. ¹H NMR (400 MHz, DMSO-d₆) δ8.83 (s, 1H), 8.76 (s, 2H), 7.74 (d, J=2.1 Hz, 1H), 7.63 (dd, J=8.1, 2.2Hz, 1H), 7.41 (d, J=8.1 Hz, 1H), 5.52 (s, 2H), 2.94 (dt, J=12.6, 7.4 Hz,4H), 2.08 (p, J=7.5 Hz, 2H).

Example 368:2-[(1-Indan-5-yltriazol-4-yl)methoxy]-4-(methoxymethyl)pyrimidine

The title compound was prepared in a manner analogous to Example 1 using(1-(2,3-dihydro-1H-inden-5-yl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 51) and 2-chloro-4-(methoxymethyl)pyrimidine. MS (ESI):mass calcd. for C₁₈H₁₉N₅O₂, 337.2; m/z found, 338.1 [M+H]⁺. ¹H NMR (400MHz, DMSO-d₆) δ 8.82 (s, 1H), 8.64 (d, J=5.0 Hz, 1H), 7.74 (d, J=2.0 Hz,1H), 7.63 (dd, J=8.1, 2.2 Hz, 1H), 7.42 (d, J=8.1 Hz, 1H), 7.20-7.16 (m,1H), 5.50 (s, 2H), 4.47 (d, J=0.7 Hz, 2H), 3.40 (s, 3H), 2.94 (dt,J=14.1, 7.3 Hz, 4H), 2.14-2.03 (m, 2H).

Example 369:2-[2-[(1-Indan-5-yltriazol-4-yl)methoxy]pyrimidin-5-yl]propan-2-ol

The title compound was prepared in a manner analogous to Example 1 using(1-(2,3-dihydro-1H-inden-5-yl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 51) and 2-(2-chloropyrimidin-5-yl)propan-2-ol. MS (ESI):mass calcd. for C₁₀H₂₁N₅O₂, 351.2; m/z found, 352.2 [M+H]⁺. ¹H NMR (400MHz, DMSO-d₆) δ 8.83 (s, 1H), 8.69 (s, 2H), 7.75 (d, J=2.0 Hz, 1H), 7.64(dd, J=8.1, 2.3 Hz, 1H), 7.41 (d, J=8.1 Hz, 1H), 5.50 (s, 2H), 5.30 (s,1H), 2.94 (dt, J=13.9, 7.5 Hz, 4H), 2.14-2.04 (m, 2H), 1.46 (s, 6H)

Example 370:4-(Difluoromethyl)-2-[(1-indan-5-yltriazol-4-yl)methoxy]pyrimidine

The title compound was prepared in a manner analogous to Example 1 using(1-(2,3-dihydro-1H-inden-5-yl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 51) and 2-chloro-4-(difluoromethyl)pyrimidine. MS (ESI):mass calcd. for C H₁₅F₂N₅O, 343.1; m/z found, 344.1[M+H]⁺. ¹H NMR (500MHz, DMSO-d₆) δ 8.90 (d, J=4.9 Hz, 1H), 8.84 (s, 1H), 7.74 (d, J=2.0 Hz,1H), 7.63 (dt, J=8.1, 1.3 Hz, 1H), 7.46 (d, J=4.9 Hz, 1H), 7.42 (d,J=8.1 Hz, 1H), 6.96 (t, J=54.1 Hz, 1H), 5.57 (s, 2H), 2.94 (dt, J=15.3,7.4 Hz, 4H), 2.08 (p, J=7.5 Hz, 2H).

Example 371:5-Chloro-2-[(1-indan-5-yltriazol-4-yl)methoxy]-4-methyl-pyrimidine

The title compound was prepared in a manner analogous to Example 1 using(1-(2,3-dihydro-1H-inden-5-yl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 51) and 2,5-dichloro-4-methylpyrimidine. MS (ESI): masscalcd. for C₁₇H₁₆ClN₅O, 341.1; m/z found, 342.0 [M+H]⁺. ¹H NMR (500 MHz,DMSO-d₆) δ 8.82 (s, 1H), 8.62 (s, 1H), 7.74 (d, J=2.0 Hz, 1H), 7.63 (dd,J=8.1, 2.1 Hz, 1H), 7.41 (d, J=8.1 Hz, 1H), 5.50 (s, 2H), 2.94 (dt,J=15.4, 7.4 Hz, 4H), 2.51 (s, 5H), 2.08 (p, J=7.5 Hz, 2H).

Example 372:2-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]-4,5-dimethyl-pyrimidine

The title compound was prepared in a manner analogous to Example 1 using(1-(4-chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methanoland 2-chloro-4,5-dimethylpyrimidine. MS (ESI): mass calcd. forC₁₆H₁₄ClF₂N₅O₂, 381.1; m/z found, 382.1 [M+H]⁺. ¹H NMR (500 MHz,DMSO-d₆) δ 8.98 (s, 1H), 8.30 (d, J=0.8 Hz, 1H), 7.99 (dd, J=2.2, 0.7Hz, 1H), 7.91-7.82 (m, 2H), 7.45 (t, J=72.8 Hz, 1H), 5.54-5.37 (m, 2H),2.38 (s, 3H), 2.16 (s, 3H).

Example 373:2-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]-5-isopropyl-pyrimidine

The title compound was prepared in a manner analogous to Example 1 using(1-(4-chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methanoland 2-chloro-5-isopropylpyrimidine. MS (ESI): mass calcd. forC₁₇H₁₆ClF₂N₅O₂, 395.1; m/z found, 396.2 [M+H]⁺. ¹H NMR (500 MHz,DMSO-d₆) δ 9.01 (s, 1H), 8.56 (s, 2H), 7.99 (d, J=2.2 Hz, 1H), 7.95-7.81(m, 2H), 7.45 (t, J=72.8 Hz, 1H), 5.52 (s, 2H), 2.93 (p, J=7.0 Hz, 1H),1.24 (d, J=6.9 Hz, 6H).

Example 374:2-[(1R)-1-[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]ethoxy]pyrimidine

The title compound was prepared in a manner analogous to Example 1 using(R)-1-(1-(4-chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)ethan-1-ol(Intermediate 22) and 2-chloropyrimidine. MS (ESI): mass calcd. forC₅H₁₂ClF₂N₅O₂, 367.1; m/z found, 368.1 [M+H]⁺. ¹H NMR (400 MHz, CD₃OD) δ8.66 (d, J=3.4 Hz, 1H), 8.58 (d, J=4.7 Hz, 2H), 7.86 (d, J=4.1 Hz, 1H),7.81-7.61 (m, 2H), 7.29-6.75 (m, 1H), 6.48 (dt, J=9.5, 4.6 Hz, 1H), 1.82(dd, J=6.7, 3.4 Hz, 3H).

Example 375:5-Chloro-2-[(1R)-1-[1-[4-chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]ethoxy]pyrimidine

The title compound was prepared in a manner analogous to Example 1 using(R)-1-(1-(4-chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)ethan-1-ol(Intermediate 22) and 2,5-dichloropyrimidine. MS (ESI): mass calcd. forC₁₅H₁₁Cl₁₂F₂N₅O₂, 401.0; m/z found, 402.0[M+H]⁺. ¹H NMR (500 MHz, CD₃OD)δ 8.67 (d, J=0.6 Hz, 1H), 8.58 (d, J=1.2 Hz, 2H), 7.86 (d, J=2.3 Hz,1H), 7.82-7.66 (m, 2H), 7.02 (t, J=72.8 Hz, 1H), 6.41 (dt, J=7.1, 6.3Hz, 1H), 1.83 (d, J=6.7 Hz, 3H).

Example 376:2-[(1R)-1-[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]ethoxy]-5-methyl-pyrimidine

The title compound was prepared in a manner analogous to Example 1 using(R)-1-(1-(4-chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)ethan-1-ol(Intermediate 22) and 2-chloro-5-methylpyrimidine. MS (ESI): mass calcd.for C₁₅H₁₄ClF₂N₅O₂, 381.1; m/z found, 382.1 [M+H]⁺. ¹H NMR (500 MHz,DMSO-d₆) δ 8.96 (d, J=0.6 Hz, 1H), 8.46 (d, J=0.8 Hz, 2H), 7.97 (d,J=2.3 Hz, 1H), 7.91-7.80 (m, 2H), 7.43 (t, J=72.8 Hz, 1H), 6.34 (q,J=6.6 Hz, 1H), 2.19 (d, J=0.8 Hz, 3H), 1.73 (d, J=6.6 Hz, 3H).

Example 377:2-[(1R)-1-[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]ethoxy]-5-methoxy-pyrimidine

The title compound was prepared in a manner analogous to Example 1 using(R)-1-(1-(4-chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)ethan-1-ol(Intermediate 22) and 2-chloro-5-methoxypyrimidine. MS (ESI): masscalcd. for C₁₆H₁₄ClF₂N₅O₃, 397.1; m/z found, 398.1 [M+H]⁺. ¹H NMR (500MHz, CD₃OD) δ 8.64 (d, J=0.6 Hz, 1H), 8.30 (s, 2H), 7.86 (d, J=2.3 Hz,1H), 7.80-7.65 (m, 2H), 7.02 (t, J=72.8 Hz, 1H), 6.36 (dt, J=6.8, 6.3Hz, 1H), 3.88 (s, 3H), 1.80 (d, J=6.6 Hz, 3H).

Example 378:2-[(1S)-1-[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]ethoxy]pyrimidine

The title compound was prepared in a manner analogous to Example 1 using(S)-1-(1-(4-chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)ethan-1-ol(Intermediate 23) (Intermediate 23) and 2-chloropyrimidine. MS (ESI):mass calcd. for C₁₅H₁₂ClF₂N₅O₂, 367.1; m/z found, 368.0 [M+H]⁺. ¹H NMR(500 MHz, DMSO-d₆) δ 8.99 (d, J=0.6 Hz, 1H), 8.63 (d, J=4.8 Hz, 2H),7.98 (d, J=2.3 Hz, 1H), 7.92-7.80 (m, 2H), 7.43 (t, J=72.8 Hz, 1H), 7.16(t, J=4.8 Hz, 1H), 6.39 (q, J=6.5 Hz, 1H), 1.75 (d, J=6.6 Hz, 3H).

Example 379:5-Chloro-2-[(1S)-1-[1-[4-chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]ethoxy]pyrimidine

The title compound was prepared in a manner analogous to Example 1 using(S)-1-(1-(4-chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)ethan-1-ol(Intermediate 23) and 2,5-dichloropyrimidine. MS (ESI): mass calcd. forC₁₅H₁Cl₂F₂N₅O₂, 401.0; m/z found, 402.0[M+H]⁺. ¹H NMR (400 MHz, CD₃OD) δ8.67 (s, 1H), 8.59 (s, 2H), 7.87 (d, J=2.5 Hz, 1H), 7.80-7.65 (m, 2H),7.02 (t, J=72.8 Hz, 1H), 6.41 (q, J=6.5 Hz, 1H), 1.90-1.72 (m, 3H).

Example 380:2-[(1S)-1-[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]ethoxy]-5-methyl-pyrimidine

The title compound was prepared in a manner analogous to Example 1 using(S)-1-(1-(4-chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)ethan-1-ol(Intermediate 23) and 2-chloro-5-methylpyrimidine. ¹H NMR (400 MHz,DMSO-d₆) δ 8.96 (s, 1H), 8.46 (d, J=0.8 Hz, 2H), 7.97 (d, J=2.1 Hz, 1H),7.93-7.78 (m, 2H), 7.43 (t, J=72.8 Hz, 1H), 6.34 (q, J=6.6 Hz, 1H), 2.19(d, J=0.7 Hz, 3H), 1.73 (d, J=6.6 Hz, 3H).

Example 381:2-[(1S)-1-[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]ethoxy]-5-methoxy-pyrimidine

The title compound was prepared in a manner analogous to Example 1 using(S)-1-(1-(4-chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)ethan-1-ol(Intermediate 23) and 2-chloro-5-methoxypyrimidine. MS (ESI): masscalcd. for C₁₆H₁₄ClF₂N₅O₃, 397.1; m/z found, 398.1 [M+H]⁺. ¹H NMR (400MHz, CD₃OD) δ 8.64 (s, 1H), 8.30 (s, 2H), 7.80 (d, J=48.2 Hz, 3H), 7.02(t, J=72.2 Hz, 1H), 6.36 (s, 1H), 3.88 (s, 3H), 1.81 (s, 3H).

Example 382:2-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]pyrimidin-4-amine

The title compound was prepared in a manner analogous to Example 155using(1-(4-chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 1) and 2-chloropyrimidin-4-amine. MS (ESI): mass calcd.for C₁₄H₁₁ClF₂N₅O₂, 368.1; m/z found, 369.1 [M+H]⁺. ¹H NMR (500 MHz,DMSO-d₆) δ 8.97-8.95 (m, 1H), 7.99-7.97 (m, 1H), 7.90 (d, J=5.8 Hz, 1H),7.88-7.83 (m, 2H), 7.44 (t, J=72.8 Hz, 1H), 6.90 (s, 2H), 6.11 (d, J=5.8Hz, 1H), 5.38 (s, 2H).

Example 383:[2-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]pyrimidin-4-yl]methanol

Step A. 2-Chloro-4-(((2-(trimethylsilyl)ethoxy)methoxy)methyl)pyrimidine

The title compound was prepared in a manner analogous to Intermediate59, using (2-chloropyrimidin-4-yl)methanol and(2-(chloromethoxy)ethyl)trimethylsilane. ¹H NMR (400 MHz, DMSO-d₆) δ8.77 (d, J=5.0 Hz, 1H), 7.60-7.55 (m, 1H), 4.77 (s, 2H), 4.65-4.62 (m,2H), 3.64-3.56 (m, 2H), 0.87-0.80 (m, 2H), 0.00-−0.03 (s, 9H).

Step B.[2-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]pyrimidin-4-yl]methanol

The title compound was prepared in a manner analogous to Example 163,Steps B-C, using(1-(4-chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 1) andchloro-4-(((2-(trimethylsilyl)ethoxy)methoxy)methyl)pyrimidine and usingTHF instead of DMF in Step B. MS (ESI): mass calcd. for C₁₅H₁₂ClF₂N₅O₃,383.1; m/z found, 384.1 [M+H]⁺. ¹H NMR (400 MHz, DMSO-d₆) δ 9.00 (s,1H), 8.62 (d, J=5.0 Hz, 1H), 8.00-7.97 (m, 1H), 7.89-7.83 (m, 2H), 7.44(t, J=72.8 Hz, 1H), 7.25-7.23 (m, 1H), 5.63 (t, J=5.7 Hz, 1H), 5.53 (s,2H), 4.51 (d, J=5.3 Hz, 2H).

Example 384:2-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]-4-(methoxymethyl)pyrimidine

The title compound was prepared in a manner analogous to Example 155using 2-chloro-4-(methoxymethyl)pyrimidine and(1-(4-chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 1). MS (ESI): mass calcd. for C₁₆H₁₄ClF₂N₅O₃, 397.1; m/zfound, 398.1 [M+H]⁺. ¹H NMR (500 MHz, DMSO-d₆) δ 9.00-8.99 (m, 1H), 8.64(d, J=5.0 Hz, 1H), 7.99-7.97 (m, 1H), 7.89-7.83 (m, 2H), 7.44 (t, J=72.8Hz, 1H), 7.18 (dt, J=5.0, 0.7 Hz, 1H), 5.54 (s, 2H), 4.49-4.46 (m, 2H),3.40 (s, 3H)

Example 385:2-[2-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]pyrimidin-5-yl]propan-2-ol

The title compound was prepared in a manner analogous to Example 153using(1-(3-(difluoromethoxy)-4-chlorophenyl)-1H-1,2,3-triazol-4-yl)methanoland 2-(2-chloropyrimidin-5-yl)propan-2-ol, using ACN instead of DMF. MS(ESI): mass calcd. for C₁₇H₁₆ClF₂N₅O₃, 411.1; m/z found, 412.0 [M+H]⁺.¹H NMR (500 MHz, CDCl₃) δ 8.79-8.61 (s, 2H), 8.16-8.10 (s, 1H),7.74-7.68 (d, J=2.2 Hz, 1H), 7.66-7.54 (m, 2H), 6.80-6.46 (t, J=72.5 Hz,2H), 5.71-5.61 (s, 2H), 1.65-1.59 (s, 6H).

Example 386:2-((1-(4-Chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)-4-isopropoxypyrimidine

The title compound was prepared in a manner analogous to Example 155using 2-chloro-4-isopropoxypyrimidine and(1-(4-chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 1). MS (ESI): mass calcd. for C₁₇H₁₆ClF₂N₅O₃, 411.1; m/zfound, 412.1 [M+H]⁺. ¹H NMR (400 MHz, DMSO-d₆) δ 9.00 (s, 1H), 8.31 (d,J=5.7 Hz, 1H), 8.01-7.97 (m, 1H), 7.90-7.83 (m, 2H), 7.44 (t, J=72.8 Hz,1H), 6.53 (d, J=5.7 Hz, 1H), 5.51 (s, 2H), 5.33-5.25 (m, 1H), 1.29 (d,J=6.2 Hz, 6H).

Example 387: Methyl2-((1-(4-chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidine-4-carboxylate

The title compound was prepared in a manner analogous to Example 155using methyl 2-chloropyrimidine-4-carboxylate and(1-(4-chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 1). MS (ESI): mass calcd. for C₁₆H₁₂ClF₂N₅O₄, 411.1; m/zfound, 412.1 [M+H]⁺.

Example 388:2-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]-N-(2,2-difluoroethyl)-5-fluoro-pyrimidin-4-amine.as the Trifluoroacetic Acid Salt

The title compound was prepared in a manner analogous to Example 163,Steps B-C using tert-butyl(2-chloro-5-fluoropyrimidin-4-yl)(2,2-difluoroethyl)carbamate(Intermediate 57) and(1-(4-chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 1). MS (ESI): mass calcd. for C₁₆H₁₂ClF₅N₆O₂, 450.1; m/zfound, 451.1 [M+H]⁺. ¹H NMR (400 MHz, DMSO-d₆) δ 8.97 (s, 1H), 8.19-8.12(m, 1H), 8.07 (d, J=3.3 Hz, 1H), 8.00-7.97 (m, 1H), 7.90-7.82 (m, 2H),7.44 (t, J=72.8 Hz, 1H), 6.33-5.99 (m, 1H), 5.42 (s, 2H).

Example 389:2-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]-5-fluoro-N-methyl-pyrimidin-4-amine.as the Trifluoroacetic Acid Salt

The title compound was prepared in a manner analogous to Example 163,Steps B-C, using(1-(4-chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 1) and2-chloro-5-fluoro-N-methyl-N-((2-(trimethylsilyl)ethoxy)methyl)pyrimidin-4-amine(Intermediate 59) in Step A. MS (ESI): mass calcd. for C₁₅H₁₂ClF₃N₆O₂,400.1; m/z found, 401.1 [M+H]⁺. ¹H NMR (500 MHz, DMSO-d₆) δ 8.98 (s,1H), 8.01-7.84 (m, 5H), 7.46 (t, J=72.8 Hz, 1H), 5.43 (s, 2H), 2.87 (d,J=4.6 Hz, 3H).

Example 390:2-((1-(4-Chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)-5-fluoropyrimidin-4-amine

Step A.4-Chloro-2-((1-(4-chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)-5-fluoropyrimidine

The title compound was prepared in a manner analogous to Example 167using 4-chloro-5-fluoro-2-(methylsulfonyl)pyrimidine and(1-(4-chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 1) in Step B. MS (ESI): mass calcd. for C₁₄H₈Cl₂F₃N₅O₂,405.0; m/z found, 406.0 [M+H]⁺.

Step B.2-((1-(4-Chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)-5-fluoropyrimidin-4-amine

The title compound was prepared in a manner analogous to Example 167,Step C. MS (ESI): mass calcd. for C₁₄H₁₀ClF₃N₆O₂, 386.1; m/z found,387.1 [M+H]⁺. ¹H NMR (400 MHz, DMSO-do) δ 8.96 (s, 1H), 8.00-7.96 (m,2H), 7.89-7.83 (m, 2H), 7.44 (t, J=72.8 Hz, 1H), 7.34 (s, 2H), 5.36 (s,2H).

Example 391:5-(Azetidin-1-yl)-2-((1-(4-chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidine

The title compound was prepared in a manner analogous to Example 165,Steps A-C using(1-(4-chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 1) in Step C. MS (ESI): mass calcd. for C₁₇H₁₅ClF₂N₅O₂,408.1; m/z found, 409.1 [M+H]⁺. ¹H NMR (400 MHz, DMSO-d₆) δ 8.98-8.96(m, 1H), 8.00-7.97 (m, 1H), 7.92 (s, 2H), 7.89-7.83 (m, 2H), 7.45 (t,J=72.8 Hz, 1H), 5.45-5.41 (m, 2H), 3.84 (t, J=7.2 Hz, 4H), 2.39-2.29 (m,2H).

Example 392:2-((1-(4-Chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)-5-(3-fluoroazetidin-1-yl)pyrimidine

The title compound was prepared in a manner analogous to Example 165,Steps A-C using 3-fluoroazetidine in Step A and(1-(4-chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 1) in Step C. MS (ESI): mass calcd. for C₁₇H₁₄ClF₃N₆O₂,426.1; m/z found, 427.1 [M+H]⁺. ¹H NMR (400 MHz, DMSO-d₆) δ 8.97 (s,1H), 8.03-7.96 (m, 3H), 7.90-7.82 (m, 2H), 7.44 (t, J=72.8 Hz, 1H),5.60-5.38 (m, 3H), 4.25-4.14 (m, 2H), 4.00-3.88 (m, 2H).

Example 393:2-((1-(4-Chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)-5-(3,3-difluoroazetidin-1-yl)pyrimidine

The title compound was prepared in a manner analogous to Example 165,Steps A-C using 3,3-difluoroazetidine in Step A and(1-(4-chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 1) in Step C. MS (ESI): mass calcd. for C₁₇H₁₃ClF₄N₆O₂,444.1; m/z found, 445.1 [M+H]⁺. ¹H NMR (400 MHz, DMSO-d₆) δ 8.98 (s,1H), 8.09 (s, 2H), 8.00-7.97 (m, 1H), 7.90-7.83 (m, 2H), 7.44 (t, J=72.8Hz, 1H), 5.46 (s, 2H), 4.34 (t, J=12.3 Hz, 4H).

Example 394:2-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4-yl]methoxy]-6-fluoro-pyridine

The title compound was prepared in a manner analogous to Example 155using(1-(4-chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 1) and 2,6-difluoropyridine. MS (ESI): mass calcd. forC₁₅H₁₀ClF₃N₄O₂, 370.0; m/z found, 371.0 [M+H]⁺. ¹H NMR (500 MHz, CD₃CN)δ 8.42 (s, 1H), 7.84 (q, J=8.1 Hz, 1H), 7.80-7.76 (m, 1H), 7.76-7.67 (m,2H), 6.93 (t, J=73.0 Hz, 1H), 6.70 (ddd, J=53.8, 7.9, 2.0 Hz, 2H), 5.50(s, 2H).

Example 395:2-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]-6-(trifluoromethyl)pyridine

The title compound was prepared in a manner analogous to Example 155using(1-(4-chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 6) and 2-fluoro-6-(trifluoromethyl)pyridine. MS (ESI):mass calcd. for C₁₆H₁₀F₆N₄O₂, 404.1; m/z found, 404.9 [M+H]⁺. ¹H NMR(500 MHz, DMSO-d₆) δ 8.92 (s, 1H), 8.04-8.00 (m, 1H), 7.98 (dd, J=6.9,2.6 Hz, 1H), 7.85 (ddd, J=9.0, 3.9, 2.6 Hz, 1H), 7.69 (dd, J=10.2, 9.0Hz, 1H), 7.56-7.24 (m, 2H), 7.23-7.20 (m, 1H), 5.53 (s, 2H)

Example 396:2-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]-5-methyl-pyrazine

The title compound was prepared in a manner analogous to Example 155using(1-(4-chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 6) and using 2-chloro-5-methylpyrazine. MS (ESI): masscalcd. for C₁₅H₁₂F₃N₅O₂, 351.1; m/z found, 351.9 [M+H]⁺. ¹H NMR (500MHz, DMSO-d₆) δ 8.95 (s, 1H), 8.25 (d, J=1.4 Hz, 1H), 8.14-8.12 (m, 1H),7.99 (dd, J=6.9, 2.6 Hz, 1H), 7.87 (ddd, J=9.0, 3.9, 2.6 Hz, 1H), 7.68(dd, J=10.2, 9.0 Hz, 1H), 7.39 (t, J=72.8 Hz, 1H), 5.50 (s, 2H), 2.42(s, 3H).

Example 397:2-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]-5-(2-thienyl)pyrazine

The title compound was prepared in a manner analogous to Example 155using(1-(4-chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 6) and using 2-chloro-5-(thiophen-2-yl)pyrazine. MS (ESI):mass calcd. for C₁₈H₁₂F₃N₅O₂S, 419.1; m/z found, 419.9 [M+H]⁺. ¹H NMR(500 MHz, DMSO-d₆) δ 8.97 (s, 1H), 8.83 (d, J=1.4 Hz, 1H), 8.34 (d,J=1.4 Hz, 1H), 8.00 (dd, J=6.9, 2.6 Hz, 1H), 7.87 (ddd, J=9.0, 3.9, 2.6Hz, 1H), 7.79 (dd, J=3.6, 1.1 Hz, 1H), 7.69 (dd, J=10.2, 9.0 Hz, 1H),7.65 (dd, J=5.1, 1.1 Hz, 1H), 7.39 (t, J=72.7 Hz, 1H), 7.19 (dd, J=5.1,3.6 Hz, 1H), 5.58 (s, 2H).

Example 398:5-Bromo-2-[[1-[3-(difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyrimidine

The title compound was prepared in a manner analogous to Example 1 using(1-(3-(difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 9) and 5-bromo-2-chloropyrimidine. MS (ESI): mass calcd.for C₁₄H₉BrF₃N₅O, 399.0; m/z found, 399.9 [M+H]⁺. ¹H NMR (300 MHz,DMSO-de δ 9.00 (s, 1H), 8.82 (s, 2H), 8.18 (dd, J=12.7, 4.6 Hz, 2H),7.66 (t, J=9.3 Hz, 1H), 7.31 (t, J=53.9 Hz, 1H), 5.54 (s, 2H).

Example 399:2-[[1-[3-(Difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-4-(methoxymethyl)pyrimidine

The title compound was prepared in a manner analogous to Example 155using(1-(3-(difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 9) and 2-chloro-4-(methoxymethyl)pyrimidine. MS (ESI):mass calcd. for C₁₆H₁₄F₃N₅O₂, 365.1; m/z found, 366.0 [M+H]⁺. ¹H NMR(400 MHz, CDCl₃) δ 8.55 (d, J=5.0 Hz, 1H), 8.17 (s, 1H), 7.98-7.85 (m,2H), 7.33 (s, 1H), 7.16 (d, J=5.1 Hz, 1H), 7.10-6.79 (m, 1H), 5.66 (d,J=0.7 Hz, 2H), 4.50 (d, J=0.8 Hz, 2H), 3.50 (s, 3H).

Example 400:[2-[[1-[3-(Difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyrimidin-4-yl]methanol

The title compound was prepared in a manner analogous to Example 159,Steps A-B using(1-(3-(difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 9) and4-(((tert-butyldimethylsilyl)oxy)methyl)-2-chloropyrimidine(Intermediate 54) in Step A. MS (ESI): mass calcd. for C₁₅H₁₂F₃N₅O₂,351.1; m/z found, 352.0 [M+H]⁺. ¹H NMR (500 MHz, CDCl₃) δ 8.56-8.45 (d,J=5.0 Hz, 1H), 8.20-8.11 (s, 1H), 7.99-7.93 (dd, J=5.8, 2.7 Hz, 1H),7.93-7.87 (ddd, J=8.1, 4.2, 2.9 Hz, 1H), 7.37-7.29 (tt, J=9.0, 1.1 Hz,1H), 7.10-6.79 (m, 2H), 5.74-5.63 (m, 2H), 4.81-4.66 (m, 2H).

Example 401:2-[2-[[1-[3-(Difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyrimidin-5-yl]propan-2-ol

The title compound was prepared in a manner analogous to Example 155using(1-(3-(difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 9) and 2-(2-chloropyrimidin-5-yl)propan-2-ol. MS (ESI):mass calcd. for C₁₇H₆F₃N₅O₂, 379.1; m/z found, 380.1 [M+H]⁺. ¹H NMR (500MHz, CDCl₃) δ 8.68 (s, 2H), 8.17-8.13 (m, 1H), 7.98-7.88 (m, 2H),7.37-7.29 (m, 1H), 6.95 (t, J=54.6 Hz, 1H), 5.67 (d, J=0.7 Hz, 2H), 1.63(s, 6H).

Example 402:4-(Difluoromethyl)-2-[[1-[3-(difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyrimidine

The title compound was prepared in a manner analogous to Example 155using(1-(3-(difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 9) and 2-chloro-4-(difluoromethyl)pyrimidine. MS (ESI):mass calcd. for C₁₅H₁₀F₈N₅O, 371.1; m/z found, 372.0 [M+H]⁺. ¹H NMR (500MHz, CDCl₃) δ 8.79-8.74 (m, 1H), 8.20-8.15 (m, 1H), 7.97-7.93 (m, 1H),7.93-7.87 (m, 1H), 7.38-7.28 (m, 2H), 7.09-6.83 (m, 1H), 6.63-6.37 (m,1H), 5.75-5.68 (m, 2H).

Example 403:2-[[1-[3-(Difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-4-(trifluoromethyl)pyrimidine

The title compound was prepared in a manner analogous to Example 155using(1-(3-(1,1-difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanoland 2-chloro-4-trifluoromethylpyrimidine. MS (ESI): mass calcd. forC₁₅H₉F₆N₅O, 389.1; m/z found, 390.0 [M+H]⁺. ¹H NMR (500 MHz, CDCl₃) δ8.83 (d, J=4.8 Hz, 1H), 8.19 (t, J=0.6 Hz, 1H), 7.98-7.85 (m, 2H),7.39-7.30 (m, 2H), 6.95 (t, J=54.6 Hz, 1H), 5.72 (d, J=0.6 Hz, 2H).

Example 404:(R/S)-2-[2-[[1-[3-(Difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyrimidin-5-yl]-1,1,1-trifluoro-propan-2-ol

The title compound was prepared in a manner analogous to Example 153using(1-(3-(difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 9) and2-(2-chloropyrimidin-5-yl)-1,1,1-trifluoropropan-2-ol, using ACN insteadof DMF. MS (ESI): mass calcd. for C₁₇H₁₃FN₅O₂, 433.1; m/z found, 434.0[M+H]⁺. ¹H NMR (500 MHz, CDCl₃) δ 8.78-8.71 (s, 2H), 8.16-8.12 (t, J=0.7Hz, 1H), 7.98-7.93 (d, J=5.4 Hz, 1H), 7.93-7.87 (m, 1H), 7.38-7.29 (t,J=9.0 Hz, 1H), 7.08-6.79 (t, J=54.6 Hz, 1H), 5.73-5.67 (d, J=0.7 Hz,2H), 2.59-2.51 (s, 1H), 1.87-1.80 (m, 3H).

Example 405:5-(Difluoromethoxy)-2-[[1-[3-(difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyrimidine

The title compound was prepared in a manner analogous to Example 155using(1-(3-(difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 9) and 2-chloro-5-(difluoromethoxy)pyrimidine. MS (ESI):mass calcd. for C₁₅H₁₀F₈N₅O₂, 387.1; m/z found, 388.0 [M+H]⁺. ¹H NMR(500 MHz, CDCl₃) δ 8.45 (t, J=0.8 Hz, 2H), 8.14 (t, J=0.7 Hz, 1H),8.01-7.86 (m, 2H), 7.33 (t, J=9.0 Hz, 1H), 6.95 (t, J=54.6 Hz, 1H), 6.53(t, J=71.9 Hz, 1H), 5.66 (d, J=0.7 Hz, 2H).

Example 406:5-Chloro-2-[[1-[3-(difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-4-methyl-pyrimidine

The title compound was prepared in a manner analogous to Example 155using(1-(3-(difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 9) and 2,5-dichloro-4-methylpyrimidine. MS (ESI): masscalcd. for C₁₅H₁₁ClF₃N₅O, 369.1; m/z found, 370.0 [M+H]⁺. ¹H NMR (500MHz, CDCl₃) δ 8.39 (s, 2H), 8.12 (s, 1H), 7.99-7.86 (m, 2H), 7.39-7.29(m, 1H), 6.95 (t, J=54.6 Hz, 1H), 5.64 (d, J=0.7 Hz, 2H), 2.57 (s, 3H).

Example 407:2-[[1-[3-(Difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-5-fluoro-4-methyl-pyrimidine

The title compound was prepared in a manner analogous to Example 155using(1-(3-(difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 9) and 2-chloro-5-fluoro-4-methylpyrimidine. MS (ESI):mass calcd. for C₁₅H₁₁F₄N₅O, 353.1; m/z found, 354.0 [M+H]⁺. ¹H NMR (400MHz, CDCl₃) δ 8.26 (d, J=1.2 Hz, 1H), 8.12 (t, J=0.7 Hz, 1H), 7.97-7.87(m, 2H), 7.33 (t, J=9.0 Hz, 1H), 6.95 (t, J=54.6 Hz, 1H), 5.62 (d, J=0.7Hz, 2H), 2.50 (d, J=2.5 Hz, 3H).

Example 408:2-[[1-[3-(Difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-4,5-dimethyl-pyrimidine

The title compound was prepared in a manner analogous to Example 155using(1-(3-(difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 9) and 2-chloro-4,5-dimethylpyrimidine. MS (ESI): masscalcd. for C₁₆H₁₄F₃N₅O, 349.1; m/z found, 350.1 [M+H]⁺. ¹H NMR (400 MHz,CDCl₃) δ 8.21 (d, J=0.9 Hz, 1H), 8.13 (t, J=0.8 Hz, 1H), 7.98-7.85 (m,2H), 7.32 (s, 1H), 6.95 (t, J=54.6 Hz, 1H), 5.66-5.59 (m, 2H), 2.45 (s,3H), 2.20 (s, 3H)

Example 409:2-[[1-[3-(Difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-N-methyl-pyrimidine-5-carboxamide

The title compound was prepared in a manner analogous to Example 153using(1-(3-(difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 9) and 2-chloro-N-methylpyrimidine-5-carboxamide, usingACN instead of DMF. MS (ESI): mass calcd. for C₁₆H₁₃F₃N₆O₂, 378.1; m/zfound, 379.1 [M+H]⁺. ¹H NMR (500 MHz, CDCl₃) δ 9.05-8.95 (m, 2H),8.42-8.34 (d, J=0.9 Hz, 1H), 8.05-8.00 (m, 1H), 8.00-7.91 (m, 1H),7.40-7.35 (m, 1H), 7.12-6.85 (t, J=54.5 Hz, 1H), 5.76-5.66 (s, 2H),3.03-2.87 (m, 3H).

Example 410:2-[[1-[3-(Difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-N,N-dimethyl-pyrimidine-4-carboxamide

The title compound was prepared in a manner analogous to Example 162,Steps A-B, using dimethylamine in Step B. MS (ESI): mass calcd. forC₁₇H₁₅F₃N₆O₂, 392.1; m/z found, 393.0 [M+H]⁺. ¹H NMR (500 MHz, CDCl₃) δ8.69 (d, J=4.9 Hz, 1H), 8.21 (s, 1H), 7.98 (dd, J=5.9, 2.6 Hz, 1H),7.94-7.86 (m, 1H), 7.37-7.29 (m, 1H), 7.22 (d, J=4.9 Hz, 1H), 6.95 (t,J=54.6 Hz, 1H), 5.72-5.62 (m, 2H), 3.14 (s, 3H), 3.09 (s, 3H).

Example 411:2-[[1-[3-(Difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-4-methoxy-5-methyl-pyrimidine

The title compound was prepared in a manner analogous to Example 153using(1-(3-(difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 9) and 2-chloro-4-methoxy-5-methylpyrimidine, using ACNinstead of DMF. MS (ESI): mass calcd. for C₁₆H₁₄F₃N₅O₂, 365.1; m/zfound, 366.1 [M+H]⁺. ¹H NMR (500 MHz, CDCl₃) δ 8.14-8.10 (s, 1H),8.05-8.00 (d, J=1.2 Hz, 1H), 7.97-7.92 (dd, J=5.8, 2.6 Hz, 1H),7.92-7.86 (m, 1H), 7.36-7.29 (m, 1H), 7.08-6.82 (t, J=54.6 Hz, 1H),5.64-5.60 (d, J=0.6 Hz, 2H), 4.07-3.90 (s, 3H), 2.12-2.02 (m, 3H).

Example 412:2-[[1-[3-(Difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyrimidin-4-amine

The title compound was prepared in a manner analogous to Example 153using(1-(3-(difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 9) and 2-chloropyrimidin-4-amine, using ACN instead ofDMF. MS (ESI): mass calcd. for C₁₄H₁₁F₃N₆O, 336.1; m/z found, 337.0[M+H]⁺. ¹H NMR (400 MHz, CDCl₃) δ 8.17-8.09 (s, 1H), 8.09-8.01 (m, 1H),7.99-7.84 (m, 2H), 7.38-7.28 (m, 1H), 7.10-6.76 (t, J=54.6 Hz, 1H),6.19-6.09 (m, 1H), 5.63-5.54 (m, 2H), 5.08-4.89 (s, 2H).

Example 413:2-[[1-[3-(Difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-N-methyl-pyrimidin-4-amine

The title compound was prepared in a manner analogous to Example 163,Steps B-C using tert-butyl (2-chloropyrimidin-4-yl)(methyl)carbamate(Intermediate 55) and(1-(3-(difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 9). MS (ESI): mass calcd. for C₁₅H₁₃F₃N₆O, 350.1; m/zfound, 351.0 [M+H]⁺. ¹H NMR (500 MHz, CDCl₃) δ 8.14-8.10 (s, 1H),8.07-7.98 (d, J=7.4 Hz, 1H), 7.98-7.92 (m, 1H), 7.93-7.85 (m, 1H),7.36-7.28 (m, 1H), 7.07-6.81 (t, J=54.6 Hz, 1H), 6.08-6.02 (d, J=5.9 Hz,1H), 5.64-5.55 (s, 2H), 5.14-4.91 (m, 1H), 3.04-2.86 (d, J=4.8 Hz, 3H).

Example 414:2-[[1-[3-(Difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-5-fluoro-N-methyl-pyrimidin-4-amine

The title compound was prepared in a manner analogous to 163, Steps B-Cusing(1-(3-(difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 9) and2-chloro-5-fluoro-N-methyl-N-((2-(trimethylsilyl)ethoxy)methyl)pyrimidin-4-amine(Intermediate 59) in Step A. MS (ESI): mass calcd. for C₁₅H₁₂F₄N₆O,368.1; m/z found, 369.0 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃) δ 8.16-8.09 (d,J=0.8 Hz, 1H), 7.98-7.92 (m, 1H), 7.92-7.86 (m, 1H), 7.85-7.78 (m, 1H),7.37-7.28 (m, 1H), 7.11-6.77 (t, J=54.6 Hz, 1H), 5.64-5.50 (m, 2H),5.26-5.01 (s, 1H), 3.14-2.98 (m, 3H).

Example 415:2-[[1-[3-(Difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-N,N-dimethyl-pyrimidin-4-amine

The title compound was prepared in a manner analogous to Example 155using(1-(3-(difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 9) and 2-chloro-N,N-dimethylpyrimidin-4-amine. MS (ESI):mass calcd. for C₁₆H₁₅F₃N₆O, 364.1; m/z found, 365.1 [M+H]⁺. ¹H NMR (500MHz, CDCl₃) δ 8.14-8.09 (t, J=0.8 Hz, 1H), 8.06-8.01 (d, J=6.1 Hz, 1H),7.97-7.92 (m, 1H), 7.92-7.86 (m, 1H), 7.35-7.28 (m, 1H), 7.08-6.81 (t,J=54.6 Hz, 1H), 6.16-6.08 (d, J=6.1 Hz, 1H), 5.64-5.58 (d, J=0.8 Hz,2H), 3.21-3.04 (s, 6H).

Example 416:2-((1-(3-(Difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-5-(3-fluoroazetidin-1-yl)pyrimidine

The title compound was made in an analogous manner to Example 187 using5-bromo-2-((1-(4-fluoro-3-(difluoromethyl)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidine(Example 398) and 3-fluoroazetidine hydrochloride. MS (ESI): mass calcd.for C₁₇H₁₄F₄N₆O, 394.3; m/z found, 395.1 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃)δ 8.18-8.15 (s, 1H), 8.00-7.97 (m, 1H), 7.97-7.92 (m, 1H), 7.92-7.89 (s,2H), 7.40-7.33 (m, 1H), 7.14-6.84 (m, 1H), 5.67-5.61 (s, 2H), 5.60-5.39(m, 1H), 4.34-4.22 (m, 2H), 4.11-3.98 (m, 2H).

Example 417:5-(Azetidin-1-yl)-2-((1-(3-(difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidine

The title compound was made in an analogous manner to Example 187 using5-bromo-2-((1-(4-fluoro-3-(difluoromethyl)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidine(Example 398) and azetidine. MS (ESI): mass calcd. for C₁₇H₁₅F₃N₆O,376.3; m/z found, 377.1 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃) δ 8.18-8.12 (s,1H), 8.01-7.97 (m, 1H), 7.96-7.91 (m, 1H), 7.88-7.83 (s, 2H), 7.40-7.32(m, 1H), 7.14-6.83 (t, J=54.6 Hz, 1H), 5.66-5.58 (s, 2H), 4.02-3.87 (m,4H), 2.55-2.43 (m, 2H).

Example 418:2-((1-(3-(Difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-5-(3-methoxyazetidin-1-yl)pyrimidine

The title compound was made in an analogous manner to Example 187 using5-bromo-2-((1-(4-fluoro-3-(difluoromethyl)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidine(Example 398) and 3-methoxyazetidine hydrochloride. MS (ESI): masscalcd. for Cl₁H₁₇F₃N₆O₂, 406.3; m/z found, 407.1 [M+H]⁺. ¹H NMR (500MHz, CDCl₃) δ 8.12-8.09 (s, 1H), 7.97-7.92 (m, 1H), 7.92-7.87 (m, 1H),7.86-7.81 (s, 2H), 7.35-7.29 (m, 1H), 7.07-6.81 (m, 1H), 5.62-5.56 (d,J=0.7 Hz, 2H), 4.43-4.36 (m, 1H), 4.19-4.11 (m, 2H), 3.79-3.68 (m, 2H),3.37-3.31 (s, 3H).

Example 419:5-(3,3-Difluoroazetidin-1-yl)-2-((1-(3-(difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidine

The title compound was made in an analogous manner to Example 187 using5-bromo-2-((1-(4-fluoro-3-(difluoromethyl)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidine(Example 398) and 3,3-difluoroazetidine hydrochloride. MS (ESI): masscalcd. for C₁₇H₁₃F₈N₆O, 412.3; m/z found, 413.1 [M+H]⁺. ¹H NMR (500 MHz,CDCl₃) δ 8.13-8.11 (s, 1H), 7.96-7.93 (m, 1H), 7.93-7.88 (s, 3H),7.36-7.30 (m, 1H), 7.07-6.82 (m, 1H), 5.62-5.57 (d, J=0.8 Hz, 2H),4.33-4.22 (m, 4H).

Example 420:2-((1-(3-(Difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-5-(3-fluoro-3-methylazetidin-1-yl)pyrimidine

The title compound was made in an analogous manner to Example 187 using5-bromo-2-((1-(4-fluoro-3-(difluoromethyl)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidine(Example 398) and 3-fluoro-3-methylazetidine hydrochloride. MS (ESI):mass calcd. for C₁₈H₁₆F₄N₆O, 408.3; m/z found, 409.1 [M+H]⁺. ¹H NMR (500MHz, CDCl₃) δ 8.13-8.10 (t, J=0.7 Hz, 1H), 7.96-7.92 (m, 1H), 7.92-7.88(m, 1H), 7.88-7.85 (s, 2H), 7.35-7.29 (m, 1H), 7.06-6.83 (t, J=54.6 Hz,1H), 5.62-5.56 (d, J=0.7 Hz, 2H), 4.06-3.98 (m, 2H), 3.98-3.89 (m, 2H),1.76-1.67 (d, J=21.8 Hz, 3H).

Example 421:2-((1-(3-(Difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-5-(3-(difluoromethyl)azetidin-1-yl)pyrimidine

The title compound was made in an analogous manner to Example 187 using5-bromo-2-((1-(4-fluoro-3-(difluoromethyl)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidine(Example 398) and 3-(difluoromethyl)azetidine hydrochloride. MS (ESI):mass calcd. for C₁₈H₁₅F₈N₆O, 426.3; m/z found, 427.1 [M+H]⁺. ¹H NMR (500MHz, CDCl₃) δ 8.13-8.09 (m, 1H), 7.96-7.93 (dd, J=5.8, 2.8 Hz, 1H),7.92-7.87 (m, 1H), 7.87-7.83 (s, 2H), 7.35-7.29 (m, 1H), 7.07-6.83 (t,J=54.6 Hz, 1H), 6.20-5.94 (m, 1H), 5.61-5.56 (d, J=0.8 Hz, 2H),4.07-4.00 (m, 2H), 3.94-3.89 (dd, J=7.6, 5.3 Hz, 2H), 3.26-3.14 (m, 1H).

Example 422:2-((1-(3-(Difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-5-(3,3-difluoropyrrolidin-1-yl)pyrimidine

The title compound was made in an analogous manner to Example 187 using5-bromo-2-((1-(4-fluoro-3-(difluoromethyl)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidine(Example 398) and 3,3-difluoropyrrolidine hydrochloride. MS (ESI): masscalcd. for C₁₈H₁₅F₈N₆O, 426.3; m/z found, 427.1 [M+H]⁺. ¹H NMR (500 MHz,CDCl₃) δ 8.15-8.11 (d, J=0.8 Hz, 1H), 7.99-7.95 (m, 3H), 7.94-7.89 (m,1H), 7.37-7.31 (m, 1H), 7.09-6.84 (m, 1H), 5.63-5.60 (s, 2H), 3.72-3.63(m, 2H), 3.58-3.52 (m, 2H), 2.60-2.50 (m, 2H)

Example 423:5-Cyclopropyl-2-[[1-[3-(difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyrimidine

The title compound was prepared in a manner analogous to Example 155using(1-(3-(difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 9) and 2-chloro-5-cyclopropylpyrimidine. MS (ESI): masscalcd. for C₁₇H₁₄F₃N₅O, 361.1; m/z found, 362.1 [M+H]⁺. ¹H NMR (400 MHz,CDCl₃) δ 8.32 (d, J=0.6 Hz, 2H), 8.12 (t, J=0.7 Hz, 1H), 7.96-7.87 (m,2H), 7.32 (t, J=9.0 Hz, 1H), 6.95 (t, J=54.6 Hz, 1H), 5.63 (d, J=0.7 Hz,2H), 1.88-1.78 (m, 1H), 1.07-0.99 (m, 2H), 0.75-0.64 (m, 2H).

Example 424:2-[[1-[3-(Difluoromethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-4-(2-furyl)pyrimidine

The title compound was prepared in a manner analogous to Example 153using(1-(3-(difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 9) and 2-chloro-4-(furan-2-yl)pyrimidine, using ACNinstead of DMF. MS (ESI): mass calcd. for C₁₈H₁₂F₃N₅O₂, 387.1; m/zfound, 388.1 [M+H]⁺. ¹H NMR (500 MHz, CDCl₃) δ 8.62-8.52 (d, J=5.1 Hz,1H), 8.25-8.15 (s, 1H), 7.98-7.93 (m, 1H), 7.92-7.87 (m, 1H), 7.66-7.58(m, 1H), 7.39-7.28 (m, 3H), 7.08-6.80 (t, J=54.6 Hz, 1H), 6.64-6.56 (m,1H), 5.76-5.67 (s, 2H)

Example 425:2-[[1-[3-(Difluoromethyl)-4-fluoro-phenyl]-5-iodo-triazol-4-yl]methoxy]-5-methyl-pyrimidine

The title compound was prepared in a manner analogous to Example 155using(1-(3-(difluoromethyl)-4-fluorophenyl)-5-iodo-1H-1,2,3-triazol-4-yl)methanol(Intermediate 27) and 2-chloro-5-methylpyrimidine. MS (ESI): mass calcd.for C₁₅H₁₁F₃IN₅O, 461.0; m/z found, 461.8 [M+H]⁺. ¹H NMR (400 MHz,DMSO-d₆) δ 8.51-8.49 (m, 2H), 7.99-7.91 (m, 2H), 7.75-7.67 (m, 1H), 7.33(t, J=53.9 Hz, 1H), 5.44 (s, 2H), 2.22 (s, 3H).

Example 426:[3H]-2-((1-(3-(Difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl-5-t)methoxy)-5-methylpyrimidine

A solution of2-((1-(3-(difluoromethyl)-4-fluorophenyl)-5-iodo-1H-1,2,3-triazol-4-yl)methoxy)-5-methylpyrimidine(Example 425, 5 mg, 0.01 mmol), Pd/C 10% (9 mg, 0.008 mmol), DMF (1 ml),DIPEA (0.018 mL, 0.1 mmol), and tritium gas (760 mm Hg) was stirred for30 minutes. The resulting product was dissolved in ethanol and filtered.The labile tritium was removed by rotovap three times. Purification(HPLC-C-18 column using gradient A: 0.1% TFA, B: 100% CH₃CN, A to 100% Bin 60 min., U.V. 250 nm, flow 6 ml/min) afforded the title compound.

Example 427:3-Fluoro-2-[[1-[4-fluoro-3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]pyridine

The title compound was prepared analogous to Example 158 using2-chloro-3-fluoropyridine. MS (ESI): mass calcd. for C₁₅H₉F₈N₄O, 356.1;m/z found, 357.0 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃) δ 8.11 (s, 1H),8.04-7.92 (m, 3H), 7.44-7.33 (m, 2H), 6.95-6.88 (m, 1H), 5.69 (d, J=0.7Hz, 2H).

Example 428:5-Chloro-2-[[1-[4-fluoro-3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]pyridine

The title compound was prepared analogous to Example 158 using 2,5-dichloropyridine. MS (ESI): mass calcd. for C₁₅H₉ClF₄N₄O, 372.0; m/zfound, 373.0 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃) δ 8.16-8.12 (m, 1H),8.10-8.04 (m, 1H), 8.03-7.91 (m, 2H), 7.60-7.53 (m, 1H), 7.40 (t, J=9.1Hz, 1H), 6.81-6.72 (m, 1H), 5.57 (d, J=0.6 Hz, 2H).

Example 429:2-[[1-[4-Fluoro-3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]-4-methyl-pyridine

The title compound was prepared analogous to Example 158 using2-chloro-4-methylpyridine. MS (ESI): mass calcd. for C₁₆H₁₂F₄N₄O, 352.1;m/z found, 353.0 [M+H]⁺. ¹H NMR (500 MHz, CDCl₃) δ 8.08-8.03 (m, 2H),8.00-7.97 (m, 1H), 7.97-7.92 (m, 1H), 7.39 (t, J=9.1 Hz, 1H), 6.75 (d,J=5.2 Hz, 1H), 6.62 (d, J=1.4 Hz, 1H), 5.59 (d, J=0.7 Hz, 2H), 2.31 (s,3H).

Example 430:2-[[1-[4-Fluoro-3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]-6-methyl-pyridine

The title compound was prepared analogous to Example 158 using2-chloro-6-methylpyridine. MS (ESI): mass calcd. for C₁₆H₁₂F₄N₄O, 352.1;m/z found, 353.1 [M+H]⁺. ¹H NMR (500 MHz, CDCl₃) δ 8.07 (t, J=0.7 Hz,1H), 8.02-7.98 (m, 1H), 7.97-7.92 (m, 1H), 7.52-7.46 (m, 1H), 7.39 (t,J=9.1 Hz, 1H), 6.88-6.70 (m, 1H), 6.68-6.54 (m, 1H), 5.60 (d, J=0.7 Hz,2H), 2.48 (t, J=0.7 Hz, 3H).

Example 431:2-[[1-[4-Fluoro-3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]-5-methyl-pyridine

The title compound was prepared analogous to Example 158 using2-chloro-5-methylpyridine. MS (ESI): mass calcd. for C₁₆H₁₂F₄N₄O, 352.1;m/z found, 353.1 [M+H]⁺. ¹H NMR (500 MHz, CDCl₃) δ 8.09-8.05 (m, 1H),8.03-7.97 (m, 2H), 7.98-7.93 (m, 1H), 7.45-7.36 (m, 2H), 6.72 (d, J=8.4Hz, 1H), 5.69-5.48 (m, 2H), 2.26 (s, 3H).

Example 432:2-[[1-[4-Fluoro-3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]-5-(trifluoromethyl)pyridine

The title compound was prepared analogous to Example 158 using2-chloro-5-trifluoromethylpyridine. MS (ESI): mass calcd. forC₁₅H₆F₇N₄O, 406.1; m/z found, 407.1 [M+H]⁺. ¹H NMR (500 MHz, CDCl₃) δ8.50 (d, J=1.3 Hz, 1H), 8.09 (t, J=0.6 Hz, 1H), 8.03-7.98 (m, 1H),7.98-7.93 (m, 1H), 7.85-7.78 (m, 1H), 7.40 (t, J=9.1 Hz, 1H), 6.91-6.88(m, 1H), 5.66 (d, J=0.6 Hz, 2H).

Example 433:2-[6-[[1-[4-Fluoro-3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]-3-pyridyl]propan-2-ol

The title compound was prepared analogous to Example 158 using2-(6-chloropyridin-3-yl)propan-2-ol. MS (ESI): mass calcd. forC₁₈H₁₆F₄N₄O₂, 396.1; m/z found, 397.0 [M+H]⁺. ¹H NMR (500 MHz, CDCl₃) δ8.34-8.27 (m, 1H), 8.10 (s, 1H), 8.03-7.98 (m, 1H), 7.98-7.93 (m, 1H),7.80-7.72 (m, 1H), 7.39 (t, J=9.1 Hz, 1H), 6.78 (dd, J=8.6, 0.8 Hz, 1H),5.59 (s, 2H), 1.60 (s, 6H).

Example 434:2-[[1-[4-Fluoro-3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]pyrazine

The title compound was prepared analogous to Example 155, using(1-(3-(trifluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanoland 2-chloropyrazine. MS (ESI): mass calcd. for C₁₄H₉F₄N₅O, 339.1; m/zfound, 340.0 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃) δ 8.38-8.27 (m, 1H),8.30-8.07 (m, 2H), 8.07-7.93 (m, 2H), 7.41 (t, J=9.6 Hz, 1H), 7.26 (s,1H), 5.62 (s, 2H).

Example 435:2-[2-[[1-[4-Fluoro-3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]pyrimidin-5-yl]propan-2-ol

The title compound was prepared analogous to Example 155, using(1-(3-(trifluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanoland 2-(2-chloropyrimidin-5-yl)propan-2-ol. MS (ESI): mass calcd. forC₁₇H₁₅F₄N₅O₂, 397.1; m/z found, 398.1 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃) δ8.68 (s, 2H), 8.15 (s, 1H), 7.99 (d, J=20.7 Hz, 2H), 7.50-7.28 (m, 1H),5.82-5.58 (m, 2H), 1.78-1.44 (m, 6H).

Example 436:2-[[1-[4-Fluoro-3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]-5-(1-methoxy-1-methyl-ethyl)pyrimidine

The title compound was prepared in a manner analogous to Example 311using2-(2-((1-(4-fluoro-3-(trifluoromethyl)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidin-5-yl)propan-2-ol(Example 435). MS (ESI): mass calcd. for C₁₇H₁₇F₄N₅O₂, 411.1; m/z found,412.1 [M+H]⁺. ¹H NMR (500 MHz, CDCl₃) δ 8.64-8.53 (s, 2H), 8.20-8.13 (t,J=0.7 Hz, 1H), 8.03-7.99 (m, 1H), 7.98-7.94 (m, 1H), 7.46-7.36 (t, J=9.1Hz, 1H), 5.72-5.63 (d, J=0.7 Hz, 2H), 3.16-3.08 (s, 3H), 1.59-1.51 (s,6H).

Example 437:2-[[1-[4-Fluoro-3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]-5-(methoxymethyl)pyrimidine

The title compound was prepared in a manner analogous to Example 153using(1-(4-fluoro-3-(trifluoromethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 5) and 2-chloro-5-(methoxymethyl)pyrimidine, using ACNinstead of DMF. MS (ESI): mass calcd. for C₁₆H₁₃F₄N₅O₂, 383.1; m/zfound, 384.1 [M+H]⁺. ¹H NMR (500 MHz, CDCl₃) δ 8.60-8.48 (s, 2H),8.21-8.10 (m, 1H), 8.02-7.98 (m, 1H), 7.98-7.92 (m, 1H), 7.46-7.35 (t,J=9.1 Hz, 1H), 5.74-5.61 (d, J=0.8 Hz, 2H), 4.50-4.33 (s, 2H), 3.49-3.36(s, 3H).

Example 438:2-[[1-[4-Fluoro-3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]-4-(methoxymethyl)pyrimidine

The title compound was prepared analogous to Example 155, using(1-(4-fluoro-3-(trifluoromethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 5) and 2-chloro-4-(methoxymethyl)pyrimidine. MS (ESI):mass calcd. for C₁₆H₁₃F₄N₅O₂, 383.1; m/z found, 384.0 [M+H]⁺. ¹H NMR(400 MHz, CDCl₃) δ 8.55 (d, J=5.0 Hz, 1H), 8.17 (t, J=0.8 Hz, 1H),8.03-7.98 (m, 1H), 7.98-7.92 (m, 1H), 7.40 (t, J=9.2 Hz, 1H), 7.16 (dt,J=5.0, 0.7 Hz, 1H), 5.66 (d, J=0.7 Hz, 2H), 4.50 (d, J=0.7 Hz, 2H), 3.50(s, 3H)

Example 439:5-(Difluoromethyl)-2-[[1-[4-fluoro-3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]pyrimidine

The title compound was prepared analogous to Example 155, using(1-(4-fluoro-3-(trifluoromethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 5). MS (ESI): mass calcd. for C₁₅H₉F₆N₅O, 389.1; m/zfound, 390.0 [M+H]⁺. ¹H NMR (500 MHz, CDCl₃) δ 8.72 (t, J=1.3 Hz, 2H),8.15 (t, J=0.7 Hz, 1H), 8.04-7.98 (m, 1H), 7.99-7.92 (m, 1H), 7.41 (t,J=9.1 Hz, 1H), 6.73 (t, J=55.6 Hz, 1H), 5.72 (d, J=0.7 Hz, 2H).

Example 440:4-(Difluoromethyl)-2-[[1-[4-fluoro-3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]pyrimidine

The title compound was prepared analogous to Example 155, using(1-(4-fluoro-3-(trifluoromethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 5) and 2-chloro-4-(difluoromethyl)pyrimidine. MS (ESI):mass calcd. for C₁₅H₉F₆N₅O, 389.1; m/z found, 390.0 [M+H]⁺. ¹H NMR (500MHz, CDCl₃) δ 8.77 (d, J=5.0 Hz, 1H), 8.18 (s, 1H), 8.05-7.98 (m, 1H),7.98-7.92 (m, 1H), 7.41 (t, J=9.0 Hz, 1H), 7.31 (d, J=5.0 Hz, 1H), 6.51(t, J=54.7 Hz, 1H), 5.71 (d, J=0.9 Hz, 2H)

Example 441:(R/S)-1,1,1-Trifluoro-2-[2-[[1-[4-fluoro-3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]pyrimidin-5-yl]propan-2-ol

The title compound was prepared in a manner analogous to Example 153using(1-(4-fluoro-3-(trifluoromethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 5) and2-(2-chloropyrimidin-5-yl)-1,1,1-trifluoropropan-2-ol, using ACN insteadof DMF. MS (ESI): mass calcd. for C₁₇H₁₂F₇N₅O₂, 451.1; m/z found, 452.0[M+H]⁺. ¹H NMR (500 MHz, CDCl₃) δ 8.78-8.73 (s, 2H), 8.18-8.11 (s, 1H),8.05-7.98 (m, 1H), 7.98-7.92 (d, J=9.0 Hz, 1H), 7.45-7.37 (t, J=9.1 Hz,1H), 5.73-5.66 (d, J=0.7 Hz, 2H), 2.68-2.60 (d, J=17.8 Hz, 1H),1.85-1.81 (d, J=1.1 Hz, 3H).

Example 442:2-[[1-[4-Fluoro-3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]-4-methoxy-pyrimidine

The title compound was prepared analogous to Example 155, using(1-(3-(trifluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 5) and 2-chloro-4-methoxypyrimidine. MS (ESI): mass calcd.for C₁₅H₁₁F₄N₅O₂, 369.1; m/z found, 370.0 [M+H]⁺. ¹H NMR (400 MHz,CDCl₃) δ 8.23 (d, J=5.7 Hz, 1H), 8.14 (s, 1H), 8.08-7.87 (m, 2H), 7.40(t, J=9.1 Hz, 1H), 6.44 (d, J=5.9 Hz, 1H), 5.66 (s, 2H), 3.99 (s, 3H).

Example 443:5-Ethoxy-2-[[1-[4-fluoro-3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]pyrimidine

The title compound was prepared analogous to Example 155, using(1-(4-fluoro-3-(trifluoromethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 5) and 2-chloro-5-ethoxypyrimidine. MS (ESI): mass calcd.for C₁₆H₁₃F₄N₅O₂, 383.1; m/z found, 384.0 [M+H]⁺. ¹H NMR (400 MHz,CDCl₃) δ 8.23 (s, 2H), 8.12 (s, 1H), 8.06-7.91 (m, 2H), 7.40 (t, J=9.2Hz, 1H), 5.61 (d, J=0.7 Hz, 2H), 4.09 (q, J=7.0 Hz, 2H), 1.44 (t, J=6.9Hz, 3H).

Example 444:5-Chloro-2-[[1-[4-fluoro-3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]-4-methyl-pyrimidine

The title compound was prepared analogous to Example 155, using(1-(3-(trifluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 5) and 2,5 dichloro-4-methylpyrimidine. MS (ESI): masscalcd. for C₁₅H₁₀ClF₄N₅O, 387.1; m/z found, 388.0 [M+H]⁺. ¹H NMR (400MHz, CDCl₃) δ 8.39 (s, 1H), 8.13 (s, 1H), 8.11-7.90 (m, 2H), 7.41 (t,J=9.1 Hz, 1H), 5.64 (d, J=3.5 Hz, 2H), 2.68-2.50 (m, 3H).

Example 445:5-Fluoro-2-[[1-[4-fluoro-3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]-4-methyl-pyrimidine

The title compound was prepared analogous to Example 155, using(1-(4-fluoro-3-(trifluoromethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 5) and 2-chloro-5-fluoro-4-methylpyrimidine. MS (ESI):mass calcd. for C₁₅H₁₀F₈N₅O, 371.1; m/z found, 372.0 [M+H]⁺. ¹H NMR (400MHz, CDCl₃) δ 8.26 (d, J=1.2 Hz, 1H), 8.12 (t, J=0.7 Hz, 1H), 8.06-7.90(m, 2H), 7.40 (t, J=9.1 Hz, 1H), 5.62 (d, J=0.7 Hz, 2H), 2.50 (d, J=2.5Hz, 3H).

Example 446:2-[[1-[4-Fluoro-3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]-4,5-dimethyl-pyrimidine

The title compound was prepared analogous to Example 155, using(1-(4-fluoro-3-(trifluoromethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 5) and 2-chloro-4,5-dimethylpyrimidine. MS (ESI): masscalcd. for C₁₆H₁₃F₄N₅O, 367.1; m/z found, 368.1 [M+H]⁺. ¹H NMR (400 MHz,CDCl₃) δ 8.19-8.10 (m, 1H), 8.06-7.89 (m, 2H), 7.40 (t, J=9.1 Hz, 1H),6.74 (s, 1H), 5.65 (d, J=0.8 Hz, 2H), 2.44 (d, J=0.5 Hz, 6H).

Example 447:1-[2-[[1-[4-Fluoro-3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]pyrimidin-5-yl]ethanone

The title compound was prepared analogous to Example 155, using(1-(4-fluoro-3-(trifluoromethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 5) and 1-(2-chloropyrimidin-5-yl)ethan-1-one. MS (ESI):mass calcd. for C₁₆H, F₄N₅O₂, 381.1; m/z found, 382.0 [M+H]⁺. ¹H NMR(400 MHz, CDCl₃) δ 9.19-9.07 (d, J=1.8 Hz, 2H), 8.22-8.11 (s, 1H),8.07-7.91 (m, 2H), 7.47-7.37 (t, J=9.1 Hz, 1H), 5.82-5.71 (s, 2H),2.73-2.52 (s, 3H).

Example 448:(R/S)-1-[2-[[1-[4-Fluoro-3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]pyrimidin-5-yl]ethanol

The title compound was prepared in a manner analogous to Example 157using1-(2-((1-(4-fluoro-3-(trifluoromethyl)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidin-5-yl)ethan-1-one(Example 447). MS (ESI): mass calcd. for C₁₆H₁₃F₄N₅O₂, 383.1; m/z found,384.1 [M+H]⁺. ¹H NMR (500 MHz, CDCl₃) δ 8.62-8.53 (s, 2H), 8.19-8.13 (s,1H), 8.04-7.99 (m, 1H), 7.99-7.92 (m, 1H), 7.44-7.35 (t, J=9.1 Hz, 1H),5.69-5.59 (d, J=0.8 Hz, 2H), 5.02-4.88 (m, 1H), 2.41-2.17 (s, 1H),1.62-1.49 (d, J=6.5 Hz, 3H).

Example 449:2-[[1-[4-Fluoro-3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]-N-methyl-pyrimidin-4-amine

The title compound was prepared in a manner analogous to Example 163,Steps B-C using tert-butyl (2-chloropyrimidin-4-yl)(methyl)carbamate(Intermediate 55) and(1-(4-fluoro-3-(trifluoromethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 5). MS (ESI): mass calcd. for C₁₅H₁₂F₄N₆O, 368.1; m/zfound, 369.0 [M+H]⁺. ¹H NMR (500 MHz, CDCl₃) δ 8.23-8.09 (s, 1H),8.09-7.99 (m, 2H), 7.98-7.89 (dt, J=8.8, 3.4 Hz, 1H), 7.46-7.34 (t,J=9.2 Hz, 1H), 6.17-5.99 (d, J=6.0 Hz, 1H), 5.69-5.54 (s, 2H), 5.34-5.08(s, 1H), 3.05-2.91 (d, J=4.4 Hz, 3H).

Example 450:2-[[1-[4-Fluoro-3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]-N,N-dimethyl-pyrimidin-4-amine

The title compound was prepared analogous to Example 155, using(1-(4-fluoro-3-(trifluoromethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 5) and 2-chloro-N,N-dimethylpyrimidin-4-amine. MS (ESI):mass calcd. for C₁₆H₁₄F₄N₅O, 382.1; m/z found, 383.1 [M+H]⁺. ¹H NMR (400MHz, CDCl₃) δ 8.17-8.12 (s, 1H), 8.08-7.98 (t, J=6.7 Hz, 2H), 7.98-7.90(m, 1H), 7.44-7.33 (t, J=9.1 Hz, 1H), 6.17-6.10 (d, J=6.1 Hz, 1H),5.64-5.58 (d, J=0.8 Hz, 2H), 3.19-3.06 (s, 6H).

Example 451:5-Fluoro-2-[[1-[4-fluoro-3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]-N-methyl-pyrimidin-4-amine

The title compound was prepared in a manner analogous to Example 163,Steps B-C using(1-(4-fluoro-3-(trifluoromethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 5) and2-chloro-5-fluoro-N-methyl-N-((2-(trimethylsilyl)ethoxy)methyl)pyrimidin-4-amine(Intermediate 59) in step A. MS (ESI): mass calcd. for C₁₅H₁₁F₈N₆O,386.1; m/z found, 387.0 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃) δ 8.17-8.10 (s,1H), 8.06-7.98 (m, 1H), 7.98-7.89 (m, 1H), 7.85-7.78 (d, J=3.0 Hz, 1H),7.46-7.34 (t, J=9.0 Hz, 1H), 5.62-5.54 (d, J=0.8 Hz, 2H), 5.20-5.04 (s,1H), 3.20-2.96 (m, 3H).

Example 452:2-[[1-[4-Fluoro-3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]-N-methyl-pyrimidine-5-carboxamide

The title compound was prepared in a manner analogous to Example 153using(1-(4-fluoro-3-(trifluoromethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 5) and 2-chloro-N-methylpyrimidine-5-carboxamide, usingACN instead of DMF. MS (ESI): mass calcd. for C₁₆H₁₂F₄N₆O₂, 396.1; m/zfound, 397.0 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃) δ 9.00-8.98 (s, 2H),8.44-8.38 (s, 1H), 8.12-8.07 (m, 1H), 8.07-8.00 (m, 1H), 7.49-7.41 (t,J=9.2 Hz, 1H), 5.77-5.67 (s, 2H), 3.03-2.90 (s, 3H).

Example 453:5-Cyclopropyl-2-[[1-[4-fluoro-3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]pyrimidine

The title compound was prepared analogous to Example 155, using(1-(4-fluoro-3-(trifluoromethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 5) and 2-chloro-5-cyclopropylpyrimidine. MS (ESI): masscalcd. for C₁₇H₁₃F₄N₅O, 379.1; m/z found, 380.0 [M+H]⁺. ¹H NMR (400 MHz,CDCl₃) δ 8.32 (d, J=0.6 Hz, 2H), 8.14-8.12 (m, 1H), 8.02-7.98 (m, 1H),7.98-7.92 (m, 1H), 7.40 (t, J=9.1 Hz, 1H), 5.64 (d, J=0.7 Hz, 2H),1.90-1.76 (m, 1H), 1.09-0.97 (m, 2H), 0.75-0.65 (m, 2H)

Example 454:5-Bromo-2-((1-(4-fluoro-3-(trifluoromethyl)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidine

The title compound was made analogous to Example 156, using(1-(4-fluoro-3-(trifluoromethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 5) and 2,5-dibromopyrimidine. MS (ESI): mass calcd. forC₁₄H₈BrF₄N₅O, 418.3; m/z found, 419.1 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃) b8.67-8.61 (s, 2H), 8.20-8.15 (s, 1H), 8.07-8.02 (m, 1H), 8.02-7.96 (m,1H), 7.48-7.40 (m, 1H), 5.72-5.65 (d, J=0.6 Hz, 2H).

Example 455:2-((1-(4-Fluoro-3-(trifluoromethyl)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)-5-(3-fluoroazetidin-1-yl)pyrimidine

The title compound was made in an analogous manner to Example 187 using5-bromo-2-((1-(4-fluoro-3-(trifluoromethyl)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidine(Example 454) and 3-fluoroazetidine hydrochloride. MS (ESI): mass calcd.for C₁₇H₁₃F₅N₆O, 412.3; m/z found, 413.1 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃)δ 8.08-8.02 (s, 1H), 7.96-7.90 (m, 1H), 7.90-7.84 (m, 1H), 7.82-7.76 (s,2H), 7.37-7.27 (m, 1H), 5.54-5.49 (m, 2H), 5.48-5.26 (m, 1H), 4.23-4.11(m, 2H), 3.99-3.84 (m, 2H).

Example 456:4-(2-((1-(4-Fluoro-3-(trifluoromethyl)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidin-5-yl)morpholine

The title compound was made in an analogous manner to Example 187 using5-bromo-2-((1-(4-fluoro-3-(trifluoromethyl)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidine(Example 454). MS (ESI): mass calcd. for C₁₈H₁₆F₄N₆O₂, 424.3; m/z found,425.1 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃) δ 8.19-8.13 (s, 2H), 8.07-8.04 (s,1H), 7.95-7.91 (m, 1H), 7.91-7.85 (m, 1H), 7.36-7.29 (m, 1H), 5.57-5.51(s, 2H), 3.85-3.76 (m, 4H), 3.08-3.00 (m, 4H).

Example 457:5-(Azetidin-1-yl)-2-((1-(3-(trifluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-4-methylpyrimidine

The title compound was made in an analogous manner to Example 187 using5-chloro-2-((1-(4-fluoro-3-(trifluoromethyl)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)-4-methylpyrimidine(Example 444) and azetidine. MS (ESI): mass calcd. for C₁₈H₁₆F₄N₆O,408.3; m/z found, 409.1 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃) δ 8.18-8.15 (s,1H), 8.06-8.02 (m, 1H), 8.01-7.96 (m, 1H), 7.76-7.72 (s, 1H), 7.47-7.40(m, 1H), 5.66-5.59 (s, 2H), 3.96-3.88 (m, 4H), 2.44-2.42 (s, 3H),2.42-2.36 (m, 2H).

Example 458:2-((1-(3-(Trifluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-N-ethyl-4-methylpyrimidin-5-amine

The title compound was made in an analogous manner to Example 187 using5-chloro-2-((1-(4-fluoro-3-(trifluoromethyl)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)-4-methylpyrimidine(Example 444) and ethylamine. MS (ESI): mass calcd. for C₁₇H₁₆F₄N₆O,396.3; m/z found, 397.1 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃) δ 8.19-8.15 (s,1H), 8.07-8.02 (dd, J=5.8, 2.7 Hz, 1H), 8.01-7.95 (m, 1H), 7.86-7.84 (s,1H), 7.47-7.39 (m, 1H), 5.65-5.59 (s, 2H), 3.26-3.17 (m, 2H), 3.16-3.08(s, 1H), 2.42-2.38 (s, 3H), 1.39-1.33 (m, 3H).

Example 459:2-((1-(3-(Trifluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-N-ethylpyrimidin-5-amine

The title compound was made in an analogous manner to Example 187 using5-bromo-2-((1-(4-fluoro-3-(trifluoromethyl)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidine(Example 454) and ethylamine. MS (ESI): mass calcd. for C₁₆H₁₄F₄N₆O,382.3; m/z found, 383.1 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃) δ 8.06-8.04 (s,1H), 7.95-7.92 (m, 1H), 7.92-7.91 (s, 2H), 7.90-7.85 (m, 1H), 7.35-7.28(m, 1H), 5.53-5.49 (s, 2H), 3.31-3.20 (s, 1H), 3.14-3.04 (m, 2H),1.24-1.20 (m, 3H).

Example 460:2-((1-(3-(Trifluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-5-(3-methoxyazetidin-1-yl)pyrimidine

The title compound was made in an analogous manner to Example 187 using5-bromo-2-((1-(4-fluoro-3-(trifluoromethyl)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidine(Example 454) and 3-methoxyazetidine hydrochloride. MS (ESI): masscalcd. for C₁₈H₁₆F₄N₆O₂, 424.3; m/z found, 425.1 [M+H]⁺. ¹H NMR (400MHz, CDCl₃) δ 8.14-8.10 (s, 1H), 8.02-7.98 (m, 1H), 7.98-7.92 (m, 1H),7.86-7.82 (s, 2H), 7.43-7.36 (m, 1H), 5.63-5.53 (s, 2H), 4.42-4.34 (m,1H), 4.18-4.11 (m, 2H), 3.77-3.70 (m, 2H), 3.38-3.29 (s, 3H).

Example 461:5-Chloro-2-[[1-[2-fluoro-3-(trifluoromethyl)phenyl]triazol-4-yl]methoxy]pyrimidine

The title compound was prepared in a manner analogous to Example 155using 2,5-dichloropyrimidine and(1-(2-fluoro-3-(trifluoromethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 28). MS (ESI): mass calcd. for C₁₄H₈ClF₄N₅O, 373.0; m/zfound, 373.9 [M+H]⁺. ¹H NMR (400 MHz, DMSO-d₆) δ 8.82 (d, J=2.1 Hz, 1H),8.77 (s, 2H), 8.25-8.17 (m, 1H), 8.05-7.99 (m, 1H), 7.70-7.64 (m, 1H),5.57 (s, 2H).

Example 462:4-[[1-(4-Fluoro-3-methyl-phenyl)triazol-4-yl]methoxy]-6-methyl-pyrimidine

The title compound was prepared in a manner analogous to Example 155using (1-(4-fluoro-3-methylphenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 40) and 4-chloro-6-methylpyrimidine. MS (ESI): mass calcd.for C₁₅H₁₄FN₅O, 299.1; m/z found, 300.0 [M+H]⁺. ¹H NMR (400 MHz,DMSO-d₆) δ 8.85 (s, 1H), 8.72 (d, J=1.1 Hz, 1H), 7.90-7.86 (m, 1H),7.78-7.72 (m, 1H), 7.38 (t, J=9.1 Hz, 1H), 6.88-6.86 (m, 1H), 5.55 (s,2H), 2.39 (s, 3H), 2.34 (d, J=2.1 Hz, 3H).

Example 463:5-Chloro-2-[[1-(3-fluoro-2-methyl-phenyl)triazol-4-yl]methoxy]pyrimidine

The title compound was prepared in a manner analogous to Example 1 using(1-(3-fluoro-2-methylphenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 49) and 2,5-dichloropyrimidine. MS (ESI): mass calcd. forC₁₄H₁₁ClFN₅O, 319.1; m/z found, 320.1 [M+H]⁺. ¹H NMR (500 MHz, DMSO-d₆)δ 8.77 (s, 2H), 8.65 (s, 1H), 7.52-7.41 (m, 2H), 7.38-7.33 (m, 1H), 5.54(s, 2H), 2.25-1.93 (m, 3H).

Example 464:2-[[1-(3-Fluoro-2-methyl-phenyl)triazol-4-yl]methoxy]-5-methyl-pyrimidine

The title compound was prepared in a manner analogous to Example 1 using(1-(3-fluoro-2-methylphenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 49) and 2-chloro-5-methylpyrimidine. MS (ESI): mass calcd.for C₁₅H₁₄FN₅O, 299.1; m/z found, 300.2 [M+H]⁺. ¹H NMR (500 MHz,DMSO-d₆) δ 8.63 (s, 1H), 8.49 (d, J=0.8 Hz, 2H), 7.51-7.41 (m, 2H), 7.35(dd, J=6.8, 1.9 Hz, 1H), 5.49 (s, 2H), 2.21 (d, J=0.8 Hz, 3H), 2.05 (d,J=2.2 Hz, 3H).

Example 465:5-Fluoro-2-[[1-(3-fluoro-2-methyl-phenyl)triazol-4-yl]methoxy]-4-methyl-pyrimidine

The title compound was prepared in a manner analogous to Example 1 using(1-(3-fluoro-2-methylphenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 49) and 2-chloro-5-fluoro-4-methylpyrimidine. MS (ESI):mass calcd. for C₁₅H₁₃F₂N₅O, 317.1; m/z found, 318.1 [M+H]⁺. ¹H NMR (500MHz, CD₃OD) δ 8.41-8.35 (m, 2H), 7.42 (td, J=8.2, 5.9 Hz, 1H), 7.32 (td,J=8.9, 8.3, 1.3 Hz, 1H), 7.26 (dd, J=7.9, 1.3 Hz, 1H), 5.58 (d, J=1.8Hz, 2H), 2.48 (d, J=2.6 Hz, 3H), 2.09 (d, J=2.2 Hz, 3H).

Example 466:2-[2-[[1-(3-Fluoro-2-methyl-phenyl)triazol-4-yl]methoxy]pyrimidin-5-yl]propan-2-ol

The title compound was prepared in a manner analogous to Example 1 using(1-(3-fluoro-2-methylphenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 49) and 2-(2-chloropyrimidin-5-yl)propan-2-ol. MS (ESI):mass calcd. for C₁₇H₁₈FN₅O₂, 343.1; m/z found, 344.1 [M+H]⁺. ¹H NMR (500MHz, DMSO-d₆) δ 8.69 (s, 2H), 8.65 (d, J=4.5 Hz, 1H), 7.53-7.42 (m, 2H),7.36 (d, J=7.4 Hz, 1H), 5.52 (s, 2H), 5.32 (s, 1H), 2.07 (s, 3H), 1.47(d, J=6.6 Hz, 6H).

Example 467:2-[[1-(2-Fluoro-3-methyl-phenyl)triazol-4-yl]methoxy]-5-methyl-pyrimidine

The title compound was prepared in a manner analogous to Example 1 using(1-(2-fluoro-3-methylphenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 50) and 2-chloro-5-methylpyrimidine. MS (ESI): mass calcd.for C₁₅H₁₄FN₅O, 299.1; m/z found, 300.1[M+H]⁺. ¹H NMR (500 MHz, DMSO-d₆)δ 8.66 (d, J=2.0 Hz, 1H), 8.49 (t, J=0.7 Hz, 2H), 7.68-7.60 (m, 1H),7.55-7.45 (m, 1H), 7.33 (t, J=7.8 Hz, 1H), 5.50 (s, 2H), 2.36 (d, J=2.3Hz, 3H), 2.21 (t, J=0.7 Hz, 3H).

Example 468:5-Chloro-2-[[1-(2-fluoro-3-methyl-phenyl)triazol-4-yl]methoxy]pyrimidine

The title compound was prepared in a manner analogous to Example 1 using(1-(2-fluoro-3-methylphenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 50) and 2,5-dichloropyrimidine. MS (ESI): mass calcd. forC₁₄H₁₁ClFN₅O, 319.1; m/z found, 320.1 [M+H]⁺. ¹H NMR (500 MHz, DMSO-d₆)δ 8.77 (s, 2H), 8.69 (d, J=2.1 Hz, 1H), 7.63 (td, J=7.6, 1.8 Hz, 1H),7.57-7.46 (m, 1H), 7.33 (td, J=7.8, 1.0 Hz, 1H), 5.55 (s, 2H), 2.36 (d,J=2.2 Hz, 3H).

Example 469:2-[[1-(2-Fluoro-3-methyl-phenyl)triazol-4-yl]methoxy]-5-(trifluoromethyl)pyrimidine

The title compound was prepared in a manner analogous to Example 1 using(1-(2-fluoro-3-methylphenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 50) and 2-chloro-5-(trifluoromethyl)pyrimidine. MS (ESI):mass calcd. for C₁₅H₁₁F₄N₅O, 353.1; m/z found, 354.0 [M+H]⁺. ¹H NMR (500MHz, DMSO-d₆) δ 9.12 (q, J=0.8 Hz, 2H), 8.73 (d, J=2.1 Hz, 1H),7.68-7.60 (m, 1H), 7.51 (tdd, J=7.0, 1.8, 0.9 Hz, 1H), 7.33 (td, J=7.8,1.0 Hz, 1H), 5.66 (s, 2H), 2.36 (d, J=2.1 Hz, 3H).

Example 470:5-Chloro-2-[[1-(2-fluoro-3-methyl-phenyl)triazol-4-yl]methoxy]-4-methyl-pyrimidine

The title compound was prepared in a manner analogous to Example 1 using(1-(2-fluoro-3-methylphenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 50) and 2,5-dichloro-4-methylpyrimidine. MS (ESI): masscalcd. for C₁₅H₁₃ClFN₅O, 333.1; m/z found, 334.1 [M+H]⁺. ¹H NMR (500MHz, DMSO-d₆) δ 8.68 (d, J=2.1 Hz, 1H), 8.62 (d, J=1.5 Hz, 1H), 7.63 (t,J=7.5 Hz, 1H), 7.51 (t, J=7.3 Hz, 1H), 7.33 (t, J=7.8 Hz, 1H), 5.53 (d,J=1.5 Hz, 2H), 2.50 (m, 3H), 2.36 (d, J=2.1 Hz, 3H).

Example 471:5-(Difluoromethoxy)-2-[[1-(2-fluoro-3-methyl-phenyl)triazol-4-yl]methoxy]pyrimidine

The title compound was prepared in a manner analogous to Example 1 using(1-(2-fluoro-3-methylphenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 50) and 2-chloro-5-(difluoromethoxy)pyrimidine. MS (ESI):mass calcd. for C₁₅H₁₂F₃N₅O₂, 351.1; m/z found, 352.1 [M+H]⁺. ¹H NMR(400 MHz, DMSO-d₆) δ 8.70 (d, J=2.1 Hz, 1H), 8.65 (s, 2H), 7.68-7.59 (m,1H), 7.55-7.47 (m, 1H), 7.45-7.03 (m, 2H), 5.54 (s, 2H), 2.36 (d, J=2.2Hz, 3H).

Example 472:2-[[1-(4-Fluoro-3-methyl-phenyl)triazol-4-yl]methoxy]pyrimidin-4-amine

The title compound was prepared in a manner analogous to Example 1 using(1-(4-fluoro-3-methylphenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 40) and 2-chloropyrimidin-4-amine. MS (ESI): mass calcd.for C₁₄H₁₃FN₆O, 300.1; m/z found, 301.1 [M+H]⁺. ¹H NMR (500 MHz,DMSO-d₆) δ 8.82 (s, 1H), 7.89 (t, J=6.4 Hz, 2H), 7.75 (dt, J=7.6, 3.4Hz, 1H), 7.38 (t, J=9.1 Hz, 1H), 6.92 (s, 2H), 6.11 (d, J=5.7 Hz, 1H),5.35 (s, 2H), 2.33 (d, J=2.0 Hz, 3H).

Example 473:2-[[1-(4-Fluoro-3-methyl-phenyl)triazol-4-yl]methoxy]pyrimidine

The title compound was prepared in a manner analogous to Example 1 using(1-(4-fluoro-3-methylphenyl)-1H-1,2,3-triazol-4-yl)methanol and2-chloropyrimidine. MS (ESI): mass calcd. for C₁₄H₁₂FN₅O, 285.1; m/zfound, 286.1 [M+H]⁺. ¹H NMR (600 MHz, DMSO-d₆) δ 8.87 (s, 1H), 8.67 (d,J=4.8 Hz, 2H), 7.90 (ddd, J=6.7, 2.8, 0.9 Hz, 1H), 7.81-7.71 (m, 1H),7.38 (t, J=9.1 Hz, 1H), 7.20 (t, J=4.8 Hz, 1H), 5.52 (s, 2H), 2.33 (d,J=2.0 Hz, 3H).

Example 474:5-Fluoro-2-[[1-(4-fluoro-3-methyl-phenyl)triazol-4-yl]methoxy]pyrimidine

The title compound was prepared in a manner analogous to Example 1 using(1-(4-fluoro-3-methylphenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 40) and 2-chloro-5-fluoropyrimidine. MS (ESI): mass calcd.for C₁₄H₁₁F₂N₅O, 303.1; m/z found, 304.1 [M+H]⁺. ¹H NMR (600 MHz,DMSO-d₆) δ 8.86 (s, 1H), 8.75 (d, J=0.6 Hz, 2H), 7.93-7.85 (m, 1H), 7.76(dt, J=7.9, 3.6 Hz, 1H), 7.39 (t, J=9.1 Hz, 1H), 5.51 (s, 2H), 2.33 (d,J=2.1 Hz, 3H).

Example 475:2-[[1-(4-Fluoro-3-methyl-phenyl)triazol-4-yl]methoxy]-5-methoxy-pyrimidine

The title compound was prepared in a manner analogous to Example 1 using(1-(4-fluoro-3-methylphenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 40) and 2-chloro-5-methoxypyrimidine. MS (ESI): masscalcd. for C₁₅H₁₄FN₅O₂, 315.1; m/z found, 316.1 [M+H]⁺. ¹H NMR (600 MHz,DMSO-d₆) δ 8.84 (s, 1H), 8.41 (s, 2H), 7.89 (dd, J=6.6, 2.7 Hz, 1H),7.76 (dt, J=8.4, 3.6 Hz, 1H), 7.38 (t, J=9.1 Hz, 1H), 5.45 (s, 2H), 3.86(s, 3H), 2.33 (d, J=2.1 Hz, 3H).

Example 476:5-Chloro-2-[[1-(4-fluoro-3-methyl-phenyl)triazol-4-yl]methoxy]pyrimidine

The title compound was prepared in a manner analogous to Example 1 using(1-(4-fluoro-3-methylphenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 40) and 2,5-dichloropyrimidine. MS (ESI): mass calcd. forC₁₄H₁₁ClFN₅O, 319.1; m/z found, 320.0 [M+H]⁺. ¹H NMR (600 MHz, DMSO-d₆)δ 8.86 (s, 1H), 8.77 (s, 2H), 7.95-7.86 (m, 1H), 7.76 (dt, J=7.5, 3.6Hz, 1H), 7.39 (t, J=9.1 Hz, 1H), 5.53 (s, 2H), 2.33 (d, J=2.0 Hz, 3H)

Example 477:2-[[1-(4-Fluoro-3-methyl-phenyl)triazol-4-yl]methoxy]-5-methyl-pyrimidine

The title compound was prepared in a manner analogous to Example 1 using(1-(4-fluoro-3-methylphenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 40) and 2-chloro-5-methylpyrimidine. MS (ESI): mass calcd.for C₁₅H₁₄FN₅O, 299.1; m/z found, 300.2 [M+H]⁺. ¹H NMR (600 MHz,DMSO-d₆) δ 8.85 (s, 1H), 8.49 (d, J=0.8 Hz, 2H), 7.89 (ddd, J=6.6, 2.8,0.9 Hz, 1H), 7.83-7.71 (m, 1H), 7.38 (t, J=9.1 Hz, 1H), 5.48 (s, 2H),2.33 (d, J=2.0 Hz, 3H), 2.21 (t, J=0.8 Hz, 3H).

Example 478:5-Ethyl-2-[[1-(4-fluoro-3-methyl-phenyl)triazol-4-yl]methoxy]pyrimidine

The title compound was prepared in a manner analogous to Example 1 using(1-(4-fluoro-3-methylphenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 40) and 2-chloro-5-ethylpyrimidine. MS (ESI): mass calcd.for C₁₆H₁₆FN₅O, 313.1; m/z found, 314.1 [M+H]⁺. ¹H NMR (600 MHz,DMSO-d₆) δ 8.86 (s, 1H), 8.53 (s, 2H), 7.90 (dd, J=6.8, 2.7 Hz, 1H),7.76 (dt, J=8.2, 3.6 Hz, 1H), 7.38 (t, J=9.1 Hz, 1H), 5.49 (s, 2H), 2.57(q, J=7.6 Hz, 2H), 2.33 (d, J=2.0 Hz, 3H), 1.19 (t, J=7.6 Hz, 3H).

Example 479:2-[[1-(4-Fluoro-3-methyl-phenyl)triazol-4-yl]methoxy]-4-(methoxymethyl)pyrimidine

The title compound was prepared in a manner analogous to Example 1 using(1-(4-fluoro-3-methylphenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 40) and 2-chloro-4-(methoxymethyl)pyrimidine. MS (ESI):mass calcd. for C₁₆H₁₆FN₅O₂, 329.1; m/z found, 330.0[M+H]⁺. ¹H NMR (400MHz, DMSO-d₆) δ 8.85 (s, 1H), 8.64 (d, J=5.0 Hz, 1H), 7.88 (ddd, J=6.5,2.7, 0.9 Hz, 1H), 7.75 (ddd, J=8.9, 4.3, 3.0 Hz, 1H), 7.38 (t, J=9.1 Hz,1H), 7.24-7.12 (m, 1H), 5.51 (s, 2H), 4.47 (d, J=0.7 Hz, 2H), 3.40 (s,3H), 2.33 (d, J=2.1 Hz, 3H).

Example 480:2-[[1-(4-Fluoro-3-methyl-phenyl)triazol-4-yl]methoxy]-4,5-dimethyl-pyrimidine

The title compound was prepared in a manner analogous to Example 1 using(1-(4-fluoro-3-methylphenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 40) and 2-chloro-4,5-dimethylpyrimidine. MS (ESI): masscalcd. for C₁₆H₁₆FN₅O, 313.1; m/z found, 314.1 [M+H]⁺. ¹H NMR (400 MHz,DMSO-d₆) δ 8.82 (s, 1H), 8.30 (s, 1H), 7.89 (dd, J=6.7, 2.9 Hz, 1H),7.75 (dt, J=7.5, 3.5 Hz, 1H), 7.38 (t, J=9.1 Hz, 1H), 5.46 (s, 2H), 2.38(s, 3H), 2.33 (d, J=2.0 Hz, 3H), 2.16 (s, 3H).

Example 481:5-Fluoro-2-[[1-(4-fluoro-3-methyl-phenyl)triazol-4-yl]methoxy]-4-methyl-pyrimidine

The title compound was prepared in a manner analogous to Example 1 using(1-(4-fluoro-3-methylphenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 40) and 2-chloro-5-fluoro-4-methylpyrimidine. MS (ESI):mass calcd. for C₁₅H₁₃F₂N₅O, 317.1; m/z found, 318.0 [M+H]⁺. ¹H NMR (400MHz, DMSO-d₆) δ 8.84 (s, 1H), 8.56 (d, J=1.5 Hz, 1H), 7.88 (dd, J=6.8,2.9 Hz, 1H), 7.75 (dt, J=8.1, 3.8 Hz, 1H), 7.38 (t, J=9.1 Hz, 1H), 5.48(s, 2H), 2.44 (d, J=2.5 Hz, 3H), 2.33 (d, J=2.0 Hz, 3H).

Example 482:5-Chloro-2-[[1-(4-fluoro-3-methyl-phenyl)triazol-4-yl]methoxy]-4-methyl-pyrimidine

The title compound was prepared in a manner analogous to Example 1 using(1-(4-fluoro-3-methylphenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 40) and 2,5-dichloro-4-methylpyrimidine. MS (ESI): masscalcd. for C₁₅H₁₃ClFN₅O, 333.1; m/z found, 334.1 [M+H]⁺. ¹H NMR (400MHz, DMSO-d₆) δ 8.84 (s, 1H), 8.62 (s, 1H), 7.88 (dd, J=6.8, 2.8 Hz,1H), 7.75 (dt, J=8.9, 3.6 Hz, 1H), 7.38 (t, J=9.1 Hz, 1H), 5.51 (s, 2H),2.51 (m, J=1.3 Hz, 3H), 2.33 (d, J=2.2 Hz, 3H).

Example 483:5-(2-Fluoroethoxy)-2-[[1-(4-fluoro-3-methyl-phenyl)triazol-4-yl]methoxy]pyrimidine

The title compound was prepared in a manner analogous to Example 192,Steps A-B, using(1-(4-fluoro-3-methylphenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 40) in Step B. MS (ESI): mass calcd. for C₁₆H₁₅F₂N₅O₂,347.1; m/z found, 348.2 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃) δ 8.29 (s, 2H),8.05 (s, 1H), 7.64-7.53 (m, 1H), 7.51-7.42 (m, 1H), 7.14 (t, J=8.8 Hz,1H), 5.60 (d, J=0.8 Hz, 2H), 4.88-4.76 (m, 1H), 4.76-4.65 (m, 1H),4.36-4.27 (m, 1H), 4.27-4.18 (m, 1H), 2.36 (d, J=2.0 Hz, 3H).

Example 484:2-[[1-(2-Fluoro-5-methyl-phenyl)triazol-4-yl]methoxy]-5-methyl-pyrimidine

The title compound was prepared in a manner analogous to Example 155using (1-(2-fluoro-5-methylphenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 29) and 2-chloro-5-methylpyrimidine. MS (ESI): mass calcd.for C₁₅H₁₄FN₅O, 299.1; m/z found, 300.0 [M+H]⁺. ¹H NMR (500 MHz,DMSO-d₆) δ 8.67 (d, J=2.0 Hz, 1H), 8.51-8.47 (m, 2H), 7.68-7.64 (m, 1H),7.48-7.38 (m, 2H), 5.49 (s, 2H), 2.38 (s, 3H), 2.21 (t, J=0.8 Hz, 3H).

Example 485:5-Chloro-2-[[1-(2-fluoro-5-methyl-phenyl)triazol-4-yl]methoxy]-4-methyl-pyrimidine

The title compound was prepared in a manner analogous to Example 155using (1-(2-fluoro-5-methylphenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 29) and 2,5-dichloro-4-methylpyrimidine. MS (ESI): masscalcd. for C₁₅H₁₃ClFN₅O, 333.1; m/z found, 333.9 [M+H]⁺. ¹H NMR (500MHz, DMSO-d6) δ 8.69 (d, J=2.0 Hz, 1H), 8.62 (s, 1H), 7.68-7.64 (m, 1H),7.48-7.39 (m, 2H), 5.52 (s, 2H), 2.38 (s, 3H).

Example 486:5-Fluoro-2-[[1-(2-fluoro-5-methyl-phenyl)triazol-4-yl]methoxy]-4-methyl-pyrimidine

The title compound was prepared in a manner analogous to Example 155using (1-(2-fluoro-5-methylphenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 29) and 2-chloro-5-fluoro-4-methylpyrimidine. MS (ESI):mass calcd. for C₁₅H₁₃F₂N₅O, 317.1; m/z found, 317.9 [M+H]⁺. ¹H NMR (500MHz, DMSO-d₆) δ 8.68 (d, J=2.0 Hz, 1H), 8.57 (d, J=1.5 Hz, 1H),7.68-7.64 (m, 1H), 7.48-7.38 (m, 2H), 5.49 (s, 2H), 2.44 (d, J=2.5 Hz,3H), 2.38 (s, 3H).

Example 487:5-Fluoro-2-[[1-(4-fluoro-2-methyl-phenyl)triazol-4-yl]methoxy]pyrimidine

The title compound was prepared in a manner analogous to Example 1 using(1-(4-fluoro-2-methylphenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 37) and 2-chloro-5-fluoropyrimidine. MS (ESI): mass calcd.for C₁₄H₁₁F₂N₅O, 303.1; m/z found, 304.1 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD)δ 8.56 (d, J=0.6 Hz, 2H), 8.35 (d, J=0.5 Hz, 1H), 7.42 (dd, J=8.7, 5.2Hz, 1H), 7.22 (ddd, J=9.3, 2.9, 0.9 Hz, 1H), 7.14 (dddd, J=8.7, 8.0,2.9, 0.7 Hz, 1H), 5.60 (d, J=0.5 Hz, 2H), 2.16 (s, 3H).

Example 488:2-[[1-(4-Fluoro-2-methyl-phenyl)triazol-4-yl]methoxy]-5-methoxy-pyrimidine

The title compound was prepared in a manner analogous to Example 1 using(1-(4-fluoro-2-methylphenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 37) and 2-chloro-5-methoxypyrimidine. MS (ESI): masscalcd. for C₁₅H₁₄FN₅O₂, 315.1; m/z found, 316.1 [M+H]⁺. ¹H NMR (400 MHz,DMSO-d₆) δ 8.56 (s, 1H), 8.41 (s, 2H), 7.51 (dd, J=8.7, 5.4 Hz, 1H),7.39 (dd, J=9.6, 2.9 Hz, 1H), 7.26 (td, J=8.5, 2.9 Hz, 1H), 5.46 (s,2H), 3.86 (s, 3H), 2.13 (s, 3H).

Example 489:5-Chloro-2-[[1-(4-fluoro-2-methyl-phenyl)triazol-4-yl]methoxy]pyrimidine

The title compound was prepared in a manner analogous to Example 1 using(1-(4-fluoro-2-methylphenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 37) and 2,5-dichloropyrimidine. MS (ESI): mass calcd. forC₁₄H₁₁ClFN₅O, 319.1; m/z found, 320.0 [M+H]⁺.

Example 490:2-[[1-(4-Fluoro-2-methyl-phenyl)triazol-4-yl]methoxy]-5-methyl-pyrimidine

The title compound was prepared in a manner analogous to Example 1 using(1-(4-fluoro-2-methylphenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 37) and 2-chloro-5-methylpyrimidine. MS (ESI): mass calcd.for C₁₅H₁₄FN₅O, 299.1; m/z found, 300.2[M+H]⁺. ¹H NMR (500 MHz, CD₃OD) δ8.43 (d, J=0.9 Hz, 2H), 8.34 (s, 1H), 7.41 (dd, J=8.7, 5.2 Hz, 1H), 7.20(dd, J=9.5, 3.1 Hz, 1H), 7.12 (td, J=8.4, 2.9 Hz, 1H), 5.58 (s, 2H),2.25 (d, J=0.8 Hz, 3H), 2.15 (s, 3H).

Example 491:5-Ethyl-2-[[1-(4-fluoro-2-methyl-phenyl)triazol-4-yl]methoxy]pyrimidine

The title compound was prepared in a manner analogous to Example 1 using(1-(4-fluoro-2-methylphenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 37) and 2-chloro-5-ethylpyrimidine. MS (ESI): mass calcd.for C₁₆H₁₆FN₅O, 313.1; m/z found, 314.1 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD)δ 8.45 (d, J=0.7 Hz, 2H), 8.35 (s, 1H), 7.41 (dd, J=8.7, 5.2 Hz, 1H),7.20 (ddd, J=9.3, 2.9, 0.8 Hz, 1H), 7.12 (dddd, J=8.8, 8.0, 2.9, 0.7 Hz,1H), 5.68-5.47 (m, 2H), 2.62 (q, J=7.6 Hz, 2H), 2.15 (s, 3H), 1.24 (t,J=7.6 Hz, 3H).

Example 492:2-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]-5-fluoro-pyrimidine

The title compound was prepared in a manner analogous to Example 155using(1-(3-(difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 6) and 2-chloro-5-fluoropyrimidine. MS (ESI): mass calcd.for C₁₄H₉F₄N₅O₂, 355.1; m/z found, 355.9 [M+H]⁺. ¹H NMR (500 MHz,DMSO-d₆) δ 8.96 (s, 1H), 8.76-8.74 (m, 2H), 8.00 (dd, J=6.9, 2.6 Hz,1H), 7.87 (ddd, J=9.0, 4.0, 2.7 Hz, 1H), 7.68 (dd, J=10.2, 9.0 Hz, 1H),7.39 (t, J=72.8 Hz, 1H), 5.52 (s, 2H).

Example 493:2-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]-5-fluoro-4-methyl-pyrimidine

The title compound was prepared in a manner analogous to Example 155using(1-(3-(difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 6) and 2-chloro-5-fluoro-4-methylpyrimidine. MS (ESI):mass calcd. for C₁₅H₁₁F₄N₅O₂, 369.1; m/z found, 369.9 [M+H]⁺. ¹H NMR(500 MHz, DMSO-d₆) δ 8.94 (s, 1H), 8.57 (d, J=1.5 Hz, 1H), 8.00 (dd,J=6.9, 2.6 Hz, 1H), 7.87 (ddd, J=9.0, 3.9, 2.7 Hz, 1H), 7.68 (dd,J=10.2, 9.0 Hz, 1H), 7.39 (t, J=72.8 Hz, 1H), 5.50 (s, 2H), 2.44 (d,J=2.6 Hz, 3H).

Example 494:5-Bromo-2-[[1-[3-(difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyrimidine

The title compound was prepared in a manner analogous to Example 155using(1-(3-(difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 6) and 5-bromo-2-chloropyrimidine. MS (ESI): mass calcd.for C₁₄H₉BrF₃N₅O₂, 415.0; m/z found, 416 [M+H]⁺. ¹H NMR (300 MHz,DMSO-do δ 8.95 (s, 1H), 8.81 (s, 2H), 7.99 (dd, J=6.8, 2.1 Hz, 1H),7.92-7.82 (m, 1H), 7.68 (t, J=9.6 Hz, 1H), 7.39 (t, J=72.8 Hz, 1H), 5.54(s, 2H).

Example 495:2-f[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]-4-ethyl-pyrimidine

The title compound was prepared in a manner analogous to Example 155using(1-(3-(difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 6) and 2-chloro-4-ethylpyrimidine. MS (ESI): mass calcd.for C₁₆H₁₄F₃N₅O₂, 365.1; m/z found, 365.9 [M+H]⁺. ¹H NMR (400 MHz,DMSO-d₆) δ 8.95 (s, 1H), 8.51 (d, J=5.0 Hz, 1H), 8.00 (dd, J=6.9, 2.6Hz, 1H), 7.88 (ddd, J=9.0, 4.0, 2.6 Hz, 1H), 7.68 (dd, J=10.2, 9.0 Hz,1H), 7.39 (t, J=72.8 Hz, 1H), 7.08 (d, J=5.0 Hz, 1H), 5.52 (s, 2H), 2.71(q, J=7.6 Hz, 2H), 1.22 (t, J=7.6 Hz, 3H).

Example 496:2-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]-4-isopropyl-pyrimidine

The title compound was prepared in a manner analogous to Example 155using(1-(3-(difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 6) and 2-chloro-4-isopropylpyrimidine. MS (ESI): masscalcd. for C₁₇H₁₆F₃N₅O₂, 379.1; m/z found, 379.9 [M+H]⁺. ¹H NMR (400MHz, DMSO-d₆) δ 8.95 (s, 1H), 8.53 (d, J=5.1 Hz, 1H), 8.00 (dd, J=6.9,2.6 Hz, 1H), 7.88 (ddd, J=9.0, 3.9, 2.6 Hz, 1H), 7.68 (dd, J=10.2, 9.0Hz, 1H), 7.39 (t, J=72.8 Hz, 1H), 7.10 (d, J=5.1 Hz, 1H), 5.52 (s, 2H),2.95 (hept, J=7.0 Hz, 1H), 1.22 (d, J=6.9 Hz, 6H).

Example 497:2-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]-4-methoxy-pyrimidine.as the Trifluoroacetic Acid Salt

The title compound was prepared in a manner analogous to Example 155using(1-(3-(difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 6) and 2-chloro-4-methoxypyrimidine. MS (ESI): mass calcd.for C₁₅H₁₂F₃N₅O₃, 367.1; m/z found, 368.2 [M+H]⁺. ¹H NMR (400 MHz,DMSO-d₆) δ 8.96 (s, 1H), 8.34 (d, J=5.7 Hz, 1H), 8.01 (dd, J=6.9, 2.6Hz, 1H), 7.88 (ddd, J=9.0, 4.0, 2.6 Hz, 1H), 7.69 (dd, J=10.2, 9.0 Hz,1H), 7.40 (t, J=72.7 Hz, 1H), 6.62 (d, J=5.7 Hz, 1H), 5.53 (s, 2H), 3.91(s, 3H)

Example 498:[2-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyrimidin-4-yl]methanol

The title compound was prepared in a manner analogous to Example 163,Steps B-C, using(1-(3-(difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 6) and2-chloro-4-(((2-(trimethylsilyl)ethoxy)methoxy)methyl)pyrimidine(Example 383, product from Step A). MS (ESI): mass calcd. forC₁₅H₁₂F₃N₅O₃, 367.1; m/z found, 368.1 [M+H]⁺. ¹H NMR (400 MHz, DMSO-d) δ8.94 (s, 1H), 8.62 (d, J=5.0 Hz, 1H), 8.00 (dd, J=7.0, 2.6 Hz, 1H), 7.87(ddd, J=9.0, 4.0, 2.6 Hz, 1H), 7.68 (dd, J=10.2, 9.0 Hz, 1H), 7.39 (t,J=72.8 Hz, 1H), 7.26-7.22 (m, 1H), 5.63 (t, J=5.8 Hz, 1H), 5.52 (s, 2H),4.51 (d, J=5.7 Hz, 2H).

Example 499:2-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]-4-(methoxymethyl)pyrimidine

The title compound was prepared in a manner analogous to Example 155using(1-(3-(difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 6) and 2-chloro-4-(methoxymethyl)pyrimidine. MS (ESI):mass calcd. for C₁₆H₁₄F₃N₅O₃, 381.1; m/z found, 381.9 [M+H]⁺. ¹H NMR(400 MHz, DMSO-d₆) δ 8.95 (s, 1H), 8.64 (d, J=5.0 Hz, 1H), 8.00 (dd,J=6.9, 2.6 Hz, 1H), 7.90-7.84 (m, 1H), 7.69 (dd, J=10.2, 9.0 Hz, 1H),7.40 (t, J=72.8 Hz, 1H), 7.20-7.17 (m, 1H), 5.53 (s, 2H), 4.48 (s, 2H),3.41 (s, 3H)

Example 500:2-[2-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyrimidin-5-yl]propan-2-ol

The title compound was prepared in a manner analogous to Example 153using(1-(3-(difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanoland 2-(2-chloropyrimidin-5-yl)propan-2-ol, using ACN instead of DMF. MS(ESI): mass calcd. for C₁₇H₁₆F₃N₅O₃, 395.1; m/z found, 396.0 [M+H]⁺. ¹HNMR (500 MHz, CDCl₃) δ 8.70-8.65 (s, 2H), 8.12-8.08 (t, J=0.7 Hz, 1H),7.71-7.67 (dd, J=6.6, 2.6 Hz, 1H), 7.61-7.55 (m, 1H), 7.38-7.30 (t,J=9.2 Hz, 1H), 6.80-6.48 (t, J=72.6 Hz, 1H), 5.72-5.61 (d, J=0.7 Hz,2H), 1.70-1.60 (s, 6H).

Example 501:2-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyrimidin-4-amine

The title compound was prepared in a manner analogous to Example 155using(1-(3-(difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 6) and 2-chloropyrimidin-4-amine. MS (ESI): mass calcd.for C₁₄H₁₁F₃N₆O₂, 352.1; m/z found, 352.9 [M+H]⁺. ¹H NMR (400 MHz,DMSO-d₆) δ 8.91 (s, 1H), 7.99 (dd, J=6.9, 2.6 Hz, 1H), 7.91-7.83 (m,2H), 7.68 (dd, J=10.2, 9.0 Hz, 1H), 7.39 (t, J=72.8 Hz, 1H), 6.92 (s,2H), 6.11 (d, J=5.7 Hz, 1H), 5.37 (s, 2H).

Example 502:2-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyrimidin-5-amine

The title compound was prepared in a manner analogous to Example 155using(1-(3-(difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 6) and 2-chloropyrimidin-5-amine. MS (ESI): mass calcd.for C₁₄H₁₁F₃N₆O₂, 352.1; m/z found, 352.9 [M+H]⁺. ¹H NMR (400 MHz,CD₂Cl₂) δ 8.17-8.01 (m, 3H), 7.73-7.67 (m, 1H), 7.62-7.55 (m, 1H),7.40-7.32 (m, 1H), 6.68 (t, J=72.8 Hz, 1H), 5.50 (s, 2H).

Example 503:2-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]-N-methyl-pyrimidin-4-amine

The title compound was prepared in a manner analogous to Example 163,Steps B-C using tert-butyl (2-chloropyrimidin-4-yl)(methyl)carbamate(Intermediate 55) and(1-(3-(difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 6) in Step A. MS (ESI): mass calcd. for C₁₅H₁₃F₃N₆O₂,366.1; m/z found, 366.9 [M+H]⁺. ¹H NMR (500 MHz, DMSO-d₆) δ 8.90 (s,1H), 8.00 (dd, J=7.0, 2.6 Hz, 1H), 7.89-7.79 (m, 2H), 7.67 (dd, J=10.2,9.0 Hz, 1H), 7.55-7.22 (m, 2H), 6.14 (d, J=5.9 Hz, 1H), 5.40 (s, 2H),2.81-2.74 (m, 3H).

Example 504:2-((1-(3-(Difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-N-ethylpyrimidin-4-amine

The title compound was prepared in a manner analogous to Example 163Steps B-C, using(1-(3-(difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 6) and2-chloro-N-ethyl-N-((2-(trimethylsilyl)ethoxy)methyl)pyrimidin-4-amine(Intermediate 60) in Step A. MS (ESI): mass calcd. for C₁₆H₁₅F₃N₆O₂,380.1; m/z found, 381.2 [M+H]⁺. ¹H NMR (400 MHz, DMSO-d₆) δ 8.91 (s,1H), 8.00 (dd, J=6.9, 2.6 Hz, 1H), 7.90-7.80 (m, 2H), 7.68 (dd, J=10.2,9.0 Hz, 1H), 7.59-7.20 (m, 2H), 6.13 (d, J=5.9 Hz, 1H), 5.39 (s, 2H),1.11 (t, J=7.2 Hz, 3H).

Example 505:2-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]-N,N-dimethyl-pyrimidin-4-amine

The title compound was prepared in a manner analogous to Example 155using(1-(3-(difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 6) and 2-chloro-N,N-dimethylpyrimidin-4-amine. MS (ESI):mass calcd. for C₁₆H₁₅F₃N₅O₂, 380.1; m/z found, 380.9 [M+H]⁺. ¹H NMR(400 MHz, DMSO-d₆) δ 8.91 (s, 1H), 8.03-7.98 (m, 2H), 7.88 (ddd, J=9.0,4.0, 2.6 Hz, 1H), 7.68 (dd, J=10.2, 9.0 Hz, 1H), 7.39 (t, J=72.8 Hz,1H), 6.36 (d, J=6.1 Hz, 1H), 5.43 (s, 2H), 3.05 (s, 6H).

Example 506:2-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]-4-phenyl-pyrimidine

The title compound was prepared in a manner analogous to Example 155using(1-(3-(difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 6) and(1-(3-(difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 6) and 2-chloro-4-phenylpyrimidine. MS (ESI): mass calcd.for C₂₀H₁₄F₃N₅O₂, 413.1; m/z found, 413.9 [M+H]⁺. ¹H NMR (500 MHz,DMSO-d₆) δ 9.00 (s, 1H), 8.72 (d, J=5.2 Hz, 1H), 8.25-8.21 (m, 2H), 8.01(dd, J=6.9, 2.6 Hz, 1H), 7.88 (ddd, J=9.0, 4.0, 2.7 Hz, 1H), 7.78 (d,J=5.2 Hz, 1H), 7.68 (dd, J=10.2, 9.0 Hz, 1H), 7.61-7.23 (m, 4H), 5.65(s, 2H).

Example 507:2-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]-5-(3-fluoroazetidin-1-yl)pyrimidine

The title compound was prepared in a manner analogous to Example 165using 3-fluoroazetidine hydrochloride in Step A. MS (ESI): mass calcd.for C₁₇H₁₄F₄N₄O₂, 410.1; m/z found, 411.2 [M+H]⁺. ¹H NMR (400 MHz,DMSO-d₆) δ 8.92 (s, 1H), 8.02-7.98 (m, 3H), 7.87 (ddd, J=9.0, 4.0, 2.7Hz, 1H), 7.68 (dd, J=10.2, 9.0 Hz, 1H), 7.39 (t, J=72.8 Hz, 1H),5.59-5.38 (m, 3H), 4.26-4.14 (m, 2H), 4.00-3.88 (m, 2H).

Example 508:5-(3,3-Difluoroazetidin-1-yl)-2-[[1-[3-(difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyrimidine

The title compound was prepared in a manner analogous to Example 165using 3,3-difluoroazetidine hydrochloride in Step A. MS (ESI): masscalcd. for C₁₇H₁₃F₈N₆O₂, 428.1; m/z found, 429.2 [M+H]⁺. ¹H NMR (400MHz, DMSO-d₆) δ 8.93 (s, 1H), 8.08 (s, 2H), 8.00 (dd, J=6.9, 2.6 Hz,1H), 7.87 (ddd, J=9.0, 4.0, 2.7 Hz, 1H), 7.68 (dd, J=10.2, 9.0 Hz, 1H),7.39 (t, J=72.8 Hz, 1H), 5.45 (s, 2H), 4.34 (t, J=12.3 Hz, 4H)

Example 509:4-(Azetidin-1-yl)-2-[[1-[3-(difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyrimidine

The title compound was prepared in a manner analogous to Example 166using azetidine in Step A. MS (ESI): mass calcd. for C₁₇H₁₅F₃N₆O₂,392.1; m/z found, 392.9 [M+H]⁺. ¹H NMR (500 MHz, DMSO-d) δ 8.89 (s, 1H),8.02-7.98 (m, 2H), 7.87 (ddd, J=9.0, 3.9, 2.7 Hz, 1H), 7.67 (dd, J=10.2,9.0 Hz, 1H), 7.39 (t, J=72.8 Hz, 1H), 6.04 (d, J=5.8 Hz, 1H), 5.40 (s,2H), 4.02 (t, J=7.6 Hz, 4H), 2.39-2.31 (m, 2H).

Example 510:2-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]-4-(3-fluoroazetidin-1-yl)pyrimidine

The title compound was prepared in a manner analogous to Example 166using 3-fluoroazetidine hydrochloride in Step A. MS (ESI): mass calcd.for C₁₇H₁₄F₄N₆O₂, 410.1; m/z found, 410.9 [M+H]⁺. ¹H NMR (500 MHz,DMSO-d₆) δ 8.90 (s, 1H), 8.06 (d, J=5.8 Hz, 1H), 8.00 (dd, J=6.9, 2.6Hz, 1H), 7.87 (ddd, J=9.0, 4.0, 2.7 Hz, 1H), 7.67 (dd, J=10.2, 9.0 Hz,1H), 7.39 (t, J=72.8 Hz, 1H), 6.16 (d, J=5.8 Hz, 1H), 5.60-5.41 (m, 3H),4.41-4.31 (m, 2H), 4.14-4.04 (m, 2H).

Example 511:4-(3,3-Difluoroazetidin-1-yl)-2-[[1-[3-(difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyrimidine

The title compound was prepared in a manner analogous to Example 166using 3,3-difluoroazetidine hydrochloride in Step A. MS (ESI): masscalcd. for C₁₇H₁₃F₈N₅O₂, 428.1; m/z found, 428.9 [M+H]⁺. ¹H NMR (400MHz, DMSO-d₆) δ 8.92 (s, 1H), 8.15 (d, J=5.7 Hz, 1H), 8.02-7.98 (m, 1H),7.90-7.85 (m, 1H), 7.68 (dd, J=10.2, 9.0 Hz, 1H), 7.39 (t, J=72.8 Hz,1H), 6.28 (d, J=5.8 Hz, 1H), 5.45 (s, 2H), 4.49 (t, J=12.4 Hz, 4H).

Example 512:(R)-2-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]-4-[(3R)-3-fluoropyrrolidin-1-yl]pyrimidine

The title compound was prepared in a manner analogous to Example 166using (R)-3-fluoropyrrolidine hydrochloride in Step A. MS (ESI): masscalcd. for C₁₈H₁₆F₄N₆O₂, 424.1; m/z found, 424.9 [M+H]⁺. ¹H NMR (500MHz, DMSO-d₆) δ 8.91 (s, 1H), 8.04 (d, J=5.9 Hz, 1H), 8.00 (dd, J=6.9,2.6 Hz, 1H), 7.87 (ddd, J=9.0, 4.0, 2.7 Hz, 1H), 7.67 (dd, J=10.2, 9.0Hz, 1H), 7.39 (t, J=72.8 Hz, 1H), 6.30-6.19 (m, 1H), 5.55-5.34 (m, 3H),3.95-3.36 (m, 4H), 2.35-2.02 (m, 2H).

Example 513:5-Chloro-2-[[1-[3-(difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]-4-methyl-pyrimidine

The title compound was prepared in a manner analogous to Example 155using(1-(3-(difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 6) and 2,5-dichloro-4-methylpyrimidine. MS (ESI): masscalcd. for C₁₅H₁₁ClF₃N₅O₂, 385.1; m/z found, 385.9 [M+H]⁺. ¹H NMR (500MHz, DMSO-d₆) δ 8.94 (s, 1H), 8.62 (s, 1H), 8.01-7.97 (m, 1H), 7.90-7.84(m, 1H), 7.72-7.64 (m, 1H), 7.39 (t, J=72.8 Hz, 1H), 5.53 (s, 2H).

Example 514:2-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]-5-methyl-pyrimidin-4-amine.as the Trifluoroacetic Acid Salt

The title compound was prepared in a manner analogous to Example 155using(1-(3-(difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 6) and 2-chloro-5-methylpyrimidin-4-amine. MS (ESI): masscalcd. for C₁₅H₁₃F₃N₆O₂, 366.1; m/z found, 366.9 [M+H]⁺. ¹H NMR (400MHz, DMSO-d₆) δ 9.03 (s, 1H), 7.99-7.95 (m, 1H), 7.95-7.92 (m, 1H),7.88-7.82 (m, 1H), 7.72 (dd, J=10.2, 9.0 Hz, 1H), 7.39 (t, J=72.7 Hz,1H), 5.59 (s, 2H), 2.02-1.97 (m, 3H).

Example 515:2-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]-N,5-dimethyl-pyrimidin-4-amine

The title compound was prepared in a manner analogous to Example 163,Steps B-C using tert-butyl(2-chloro-5-methylpyrimidin-4-yl)(methyl)carbamate (Intermediate 56) and(1-(3-(difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 6) in Step A. MS (ESI): mass calcd. for C₁₆H₁₅F₃N₆O₂,380.1; m/z found, 381.2 [M+H]⁺. ¹H NMR (500 MHz, DMSO-d₆) δ 8.95 (s,1H), 7.99 (dd, J=6.9, 2.7 Hz, 1H), 7.87 (ddd, J=9.0, 3.9, 2.6 Hz, 1H),7.84-7.82 (m, 1H), 7.69 (dd, J=10.2, 9.0 Hz, 1H), 7.39 (t, J=72.7 Hz,1H), 5.63 (s, 2H), 3.01 (d, J=4.5 Hz, 3H), 2.00-1.97 (m, 3H).

Example 516:2-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]-N,N,5-trimethyl-pyrimidin-4-amine

The title compound was prepared in a manner analogous to Example 155using(1-(3-(difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 6) and 2-chloro-N,N,5-trimethylpyrimidin-4-amine. MS(ESI): mass calcd. for C₁₇H₁₇F₃N₆O₂, 394.1; m/z found, 395.0 [M+H]⁺. ¹HNMR (400 MHz, DMSO-d₆) δ 8.90 (s, 1H), 8.00 (dd, J=6.9, 2.7 Hz, 1H),7.87 (ddd, J=9.0, 4.0, 2.6 Hz, 1H), 7.84-7.82 (m, 1H), 7.67 (dd, J=10.2,9.0 Hz, 1H), 7.39 (t, J=72.8 Hz, 1H), 5.40 (s, 2H), 3.07 (s, 6H), 2.22(d, J=0.9 Hz, 3H).

Example 517:N-(2,2-Difluoroethyl)-2-[[1-[3-(difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]-5-fluoro-pyrimidin-4-amine.as the Trifluoroacetic Acid Salt

The title compound was prepared in a manner analogous to Example 163,Steps B-C using tert-butyl(2-chloro-5-fluoropyrimidin-4-yl)(2,2-difluoroethyl)carbamate(Intermediate 57) and(1-(3-(difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 6) in Step A. MS (ESI): mass calcd. for C₁₆H₁₂F₈N₆O₂,434.1; m/z found, 435.2 [M+H]⁺. ¹H NMR (400 MHz, DMSO-d₆) δ 8.92 (s,1H), 8.19-8.12 (m, 1H), 8.07 (d, J=3.3 Hz, 1H), 8.00 (dd, J=6.9, 2.6 Hz,1H), 7.88 (ddd, J=9.0, 3.9, 2.6 Hz, 1H), 7.69 (dd, J=10.2, 9.0 Hz, 1H),7.40 (t, J=72.8 Hz, 1H), 6.34-6.00 (m, 1H), 5.42 (s, 2H).

Example 518:2-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]-5-fluoro-N-methyl-pyrimidin-4-amine.as the Trifluoroacetic Acid Salt

The title compound was prepared in a manner analogous to Example 163,Steps B-C, using(1-(3-(difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 6) and2-chloro-5-fluoro-N-methyl-N-((2-(trimethylsilyl)ethoxy)methyl)pyrimidin-4-amine(Intermediate 59) in Step A. MS (ESI): mass calcd. for C₁₅H₁₂F₄N₆O₂,384.1; m/z found, 385.1 [M+H]⁺. ¹H NMR (500 MHz, DMSO-d₆) δ 8.91 (s,1H), 8.01-7.97 (m, 2H), 7.94-7.85 (m, 2H), 7.68 (dd, J=10.2, 9.0 Hz,1H), 7.39 (t, J=72.8 Hz, 1H), 5.43 (s, 2H), 2.87 (d, J=4.6 Hz, 3H).

Example 519:N-Cyclopropyl-2-((1-(3-(difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-5-fluoropyrimidin-4-amine

The title compound was prepared in a manner analogous to Example 167using4-chloro-2-((1-(3-(difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-5-fluoropyrimidineand cyclopropylamine in Step C. MS (ESI): mass calcd. for C₁₇H₁₄F₄N₆O₂,411.1; m/z found, 410.1 [M+H]⁺. ¹H NMR (400 MHz, DMSO-d₆) δ 8.91 (s,1H), 8.00 (dd, J=6.9, 2.6 Hz, 1H), 7.95 (d, J=3.5 Hz, 1H), 7.90-7.84 (m,2H), 7.68 (dd, J=10.2, 9.0 Hz, 1H), 7.39 (t, J=72.8 Hz, 1H), 5.40 (s,2H), 2.85-2.75 (m, 1H), 0.74-0.67 (m, 2H), 0.60-0.53 (m, 2H).

Example 520:1-(2-((1-(3-(Difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidin-4-yl)-N-methylmethanamine

The title compound was prepared in a manner analogous to Example 163,Steps B-C, using tert-butylmethyl((2-(methylsulfonyl)pyrimidin-4-yl)methyl)carbamate (Intermediate61) and(1-(3-(difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 6). MS (ESI): mass calcd. for C₁₆H₁₅F₃N₆O₂, 380.1; m/zfound, 381.1 [M+H]⁺. ¹H NMR (500 MHz, DMSO-d₆) δ 8.97 (s, 1H), 8.57 (d,J=5.0 Hz, 1H), 8.00 (dd, J=6.9, 2.6 Hz, 1H), 7.87 (ddd, J=9.0, 4.0, 2.6Hz, 1H), 7.68 (dd, J=10.2, 9.0 Hz, 1H), 7.39 (t, J=72.8 Hz, 1H), 7.21(d, J=5.0 Hz, 1H), 5.52 (s, 2H), 3.69 (s, 2H), 2.29 (s, 3H).

Example 521:2-[[1-[3-(Difluoromethoxy)-4-methyl-phenyl]triazol-4-yl]methoxy]-5-methyl-pyrimidin-4-amine

The title compound was prepared in a manner analogous to Example 1 using(1-(3-(difluoromethoxy)-4-methylphenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 52) and 2-chloro-4-amino-5-methylpyrimidine. MS (ESI):mass calcd. for C₁₆H₁₆F₂N₆O₂, 362.1; m/z found, 363.2[M+H]⁺. ¹H NMR (400MHz, DMSO-d₆) δ 8.88 (s, 1H), 7.93-7.66 (m, 2H), 7.61-7.10 (m, 3H), 6.76(s, 2H), 5.35 (s, 2H), 2.29 (s, 3H), 1.92 (s, 3H).

Example 522:1-[2-[[1-[3-(Difluoromethoxy)-4-methyl-phenyl]triazol-4-yl]methoxy]pyrimidin-5-yl]ethanone

The title compound was prepared in a manner analogous to Example 1 using(1-(3-(difluoromethoxy)-4-methylphenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 52) and 1-(2-chloropyrimidin-5-yl)ethan-1-one. MS (ESI):mass calcd. for C₁₇H₁₅F₂N₅O₃, 375.1; m/z found, 376.1 [M+H]⁺. ¹H NMR(400 MHz, DMSO-d₆) δ 9.15 (s, 2H), 8.97 (s, 1H), 7.79-7.67 (m, 2H),7.60-7.13 (m, 2H), 5.65 (s, 2H), 2.59 (s, 3H), 2.30 (s, 3H).

Example 523:2-[[1-[3-(Difluoromethoxy)-4-methyl-phenyl]triazol-4-yl]methoxy]-4-methyl-pyrimidine

The title compound was prepared in a manner analogous to Example 1 using(1-(3-(difluoromethoxy)-4-methylphenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 52) and 2-chloro-4-methylpyrimidine. MS (ESI): mass calcd.for C₁₆H₁₅F₂N₅O₂, 347.1; m/z found, 348.0 [M+H]⁺. ¹H NMR (400 MHz,DMSO-d₆) δ 8.92 (s, 1H), 8.49 (d, J=4.8 Hz, 1H), 7.80-7.67 (m, 2H),7.57-7.14 (m, 2H), 7.07 (d, J=5.1 Hz, 1H), 5.51 (s, 2H), 2.43 (s, 3H),2.30 (s, 3H).

Example 524:2-[[1-[3-(Difluoromethoxy)-4-methyl-phenyl]triazol-4-yl]methoxy]-5-methyl-pyrimidine

The title compound was prepared in a manner analogous to Example 1 using(1-(3-(difluoromethoxy)-4-methylphenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 52) and 2-chloro-5-methylpyrimidine. MS (ESI): mass calcd.for C₁₆H₁₅F₂N₅O₂, 347.1; m/z found, 348.0 [M+H]⁺. ¹H NMR (400 MHz,DMSO-d₆) δ 8.93 (d, J=2.7 Hz, 1H), 8.50 (d, J=7.9 Hz, 2H), 7.84-7.68 (m,2H), 7.61-7.10 (m, 2H), 5.50 (d, J=2.5 Hz, 2H), 2.30 (s, 2H), 2.21 (s,2H).

Example 525:5-Bromo-2-[[1-[3-(difluoromethoxy)-4-methyl-phenyl]triazol-4-yl]methoxy]pyrimidine

The title compound was prepared in a manner analogous to Example 1 using(1-(3-(difluoromethoxy)-4-methylphenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 52) and 2-chloro-5-bromopyrimidine. MS (ESI): mass calcd.for C₁₅H₁₂BrF₂N₅O₂, 411.0; m/z found, 412.1 [M+H]⁺. ¹H NMR (400 MHz,CD₃OD) δ 8.71 (s, 2H), 8.68 (s, 1H), 7.69 (d, J=2.1 Hz, 1H), 7.65 (dd,J=8.2, 2.2 Hz, 1H), 7.50 (d, J=8.2 Hz, 1H), 6.97 (t, J=73.6 Hz, 1H),5.62 (s, 2H), 2.37 (s, 3H)

Example 526:2-[2-[[1-[3-(Difluoromethoxy)-4-methyl-phenyl]triazol-4-yl]methoxy]pyrimidin-5-yl]propan-2-ol

The title compound was prepared in a manner analogous to Example 1 using(1-(3-(difluoromethoxy)-4-methylphenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 52) and 2-(2-chloropyrimidin-5-yl)propan-2-ol. MS (ESI):mass calcd. for C₁₈H₁₉F₂N₅O₃, 391.1; m/z found, 392.1 [M+H]⁺.

Example 527:2-[[1-[3-(Difluoromethoxy)-4-methyl-phenyl]triazol-4-yl]methoxy]-4-(methoxymethyl)pyrimidine

The title compound was prepared in a manner analogous to Example 1 using(1-(3-(difluoromethoxy)-4-methylphenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 52) and 2-chloro-4-(methoxymethyl)pyrimidine. MS (ESI):mass calcd. for C₁₇H₁₇F₂N₅O₃, 377.1; m/z found, 378.2 [M+H]⁺. ¹H NMR(400 MHz, CD₃OD) δ 8.67 (s, 1H), 8.59 (d, J=5.1 Hz, 1H), 7.71-7.57 (m,2H), 7.49 (d, J=8.3 Hz, 1H), 7.23 (d, J=5.1 Hz, 1H), 6.98 (t, J=73.7 Hz,1H), 5.62 (s, 2H), 4.53 (s, 2H), 3.50 (s, 3H), 2.37 (s, 3H).

Example 528:2-[[1-[3-(Difluoromethyl)phenyl]-5-methyl-triazol-4-yl]methoxy]-4,5-dimethyl-pyrimidine

The title compound was prepared in a manner analogous to Example 172,Steps A through D, using 2-chloro-4,5-dimethylpyrimidine in Step D. MS(ESI): mass calcd. for C₁₇H₁₇F₂N₅O, 345.1; m/z found, 346.0 [M+H]⁺. ¹HNMR (400 MHz, CDCl₃) δ 8.19 (d, J=0.9 Hz, 1H), 7.71-7.56 (m, 4H), 6.73(t, J=56.1 Hz, 1H), 5.57 (s, 2H), 2.44 (s, 3H), 2.43 (s, 3H), 2.19 (s,3H).

Example 529:5-Chloro-2-[[1-[3-(difluoromethyl)phenyl]-5-methyl-triazol-4-yl]methoxy]pyrimidine

The title compound was prepared in a manner analogous to Example 172,Steps A through D, using 2,5-dichloropyrimidine in Step D. MS (ESI):mass calcd. for C₁₅H₁₂ClF₂N₅O, 351.1; m/z found, 352.0 [M+H]⁺. ¹H NMR(400 MHz, CDCl₃) δ 8.50 (s, 2H), 7.72-7.54 (m, 4H), 6.73 (t, J=56.1 Hz,1H), 5.59 (s, 2H), 2.45 (s, 3H).

Example 530:2-[[1-[4-Chloro-3-(1,1-difluoroethyl)phenyl]triazol-4-yl]methoxy]-5-methyl-pyrimidine

The title compound was prepared in a manner analogous to Example 155using(1-(4-chloro-3-(1,1-difluoroethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 63) and 2-chloro-5-methylpyrimidine. MS (ESI): mass calcd.for C₁₆H₁₄ClF₂N₅O, 365.1; m/z found, 366.0 [M+H]⁺. ¹H NMR (400 MHz,CDCl₃) δ 8.38 (d, J=0.8 Hz, 2H), 8.20-8.09 (m, 1H), 7.97 (d, J=2.6 Hz,1H), 7.84-7.76 (m, 1H), 7.65-7.58 (m, 1H), 5.64 (d, J=0.7 Hz, 2H), 2.26(t, J=0.7 Hz, 3H), 2.09 (t, J=18.5 Hz, 3H).

Example 531:2-[[1-[4-Chloro-3-(1,1-difluoroethyl)phenyl]triazol-4-yl]methoxy]-4-methyl-pyrimidine

The title compound was prepared in a manner analogous to Example 155using(1-(4-chloro-3-(1,1-difluoroethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 63) and 2-chloro-4-methylpyrimidine. MS (ESI): mass calcd.for C₁₆H₁₄ClF₂N₅O, 365.1; m/z found, 366.0 [M+H]⁺. ¹H NMR (400 MHz,CDCl₃) δ 8.40 (d, J=5.0 Hz, 1H), 8.16 (s, 1H), 7.97 (d, J=2.6 Hz, 1H),7.85-7.74 (m, 1H), 7.61 (d, J=8.6 Hz, 1H), 6.92-6.80 (m, 1H), 5.66 (d,J=0.7 Hz, 2H), 2.56-2.43 (m, 3H), 2.18-1.97 (m, 3H).

Example 532:2-[2-[[1-[4-Chloro-3-(1,1-difluoroethyl)phenyl]triazol-4-yl]methoxy]pyrimidin-5-yl]propan-2-ol

The title compound was prepared in a manner analogous to Example 155using(1-(4-chloro-3-(1,1-difluoroethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 63) and 2-(2-chloropyrimidin-5-yl)propan-2-ol. MS (ESI):mass calcd. for C₁₈H₁₈ClF₂N₅O₂, 409.1; m/z found, 410.1 [M+H]⁺. ¹H NMR(500 MHz, CDCl₃) δ 8.68 (d, J=1.4 Hz, 2H), 8.20-8.13 (m, 1H), 7.98 (d,J=2.5 Hz, 1H), 7.84-7.74 (m, 1H), 7.61 (d, J=8.6 Hz, 1H), 5.67 (t, J=0.9Hz, 2H), 2.20-1.99 (m, 3H), 1.70-1.59 (m, 6H).

Example 533:[2-[[1-[4-Chloro-3-(1,1-difluoroethyl)phenyl]triazol-4-yl]methoxy]pyrimidin-5-yl]methanol

The title compound was prepared in a manner analogous to Example 159,Steps A-B using(1-(4-chloro-3-(1,1-difluoroethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 63) and5-(((tert-butyldimethylsilyl)oxy)methyl)-2-chloropyrimidine(Intermediate 53) in Step A. MS (ESI): mass calcd. for C₁₆H₁₄ClF₂N₅O₂,381.1; m/z found, 382.0 [M+H]⁺. ¹H NMR (500 MHz, CDCl₃) δ 8.60-8.54 (s,2H), 8.18-8.12 (t, J=0.7 Hz, 1H), 8.00-7.94 (d, J=2.6 Hz, 1H), 7.83-7.75(m, 1H), 7.65-7.57 (m, 1H), 5.70-5.63 (d, J=0.7 Hz, 2H), 4.75-4.66 (m,2H), 2.16-2.03 (t, J=18.5 Hz, 3H), 1.90-1.57 (s, 1H).

Example 534:2-[[1-[4-Chloro-3-(1,1-difluoroethyl)phenyl]triazol-4-yl]methoxy]-4-(methoxymethyl)pyrimidine

The title compound was prepared in a manner analogous to Example 155using(1-(4-chloro-3-(1,1-difluoroethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 63) and 2-chloro-4-(methoxymethyl)pyrimidine. MS (ESI):mass calcd. for C₁₇H₁₆ClF₂N₅O₂, 395.1; m/z found, 396.0 [M+H]⁺. ¹H NMR(400 MHz, CDCl₃) δ 8.55 (d, J=5.0 Hz, 1H), 8.18 (t, J=0.7 Hz, 1H), 7.97(d, J=2.6 Hz, 1H), 7.82-7.76 (m, 1H), 7.61 (d, J=8.6 Hz, 1H), 7.16 (d,J=5.0 Hz, 1H), 5.66 (d, J=0.7 Hz, 2H), 4.50 (d, J=0.7 Hz, 2H), 3.50 (s,3H), 2.29-1.90 (m, 3H)

Example 535:2-[[1-[4-Chloro-3-(1,1-difluoroethyl)phenyl]triazol-4-yl]methoxy]-5-(difluoromethyl)pyrimidine

The title compound was prepared in a manner analogous to Example 155using(1-(4-chloro-3-(1,1-difluoroethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 63) and 2-chloro-4-difluoromethylpyrimidine. MS (ESI):mass calcd. for C₁₅H₁₂ClF₄N₅O, 401.1; m/z found, 402.0 [M+H]⁺. ¹H NMR(400 MHz, CDCl₃) δ 8.75-8.68 (m, 2H), 8.16 (s, 1H), 7.97 (d, J=2.7 Hz,1H), 7.84-7.76 (m, 1H), 7.62 (d, J=8.6 Hz, 1H), 6.73 (t, J=55.6 Hz, 1H),5.72 (d, J=0.7 Hz, 2H), 2.09 (t, J=18.5 Hz, 3H).

Example 536:2-[[1-[4-Chloro-3-(1,1-difluoroethyl)phenyl]triazol-4-yl]methoxy]-4-(difluoromethyl)pyrimidine

The title compound was prepared in a manner analogous to Example 155using(1-(4-chloro-3-(1,1-difluoroethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 63) and 2-chloro-4-(difluoromethyl)pyrimidine. MS (ESI):mass calcd. for C₁₆H₁₂ClF₄N₅O, 401.1; m/z found, 402.0 [M+H]⁺. ¹H NMR(500 MHz, CDCl₃) δ 8.76 (d, J=4.9 Hz, 1H), 8.19 (s, 1H), 8.07-7.93 (m,1H), 7.87-7.74 (m, 1H), 7.62 (d, J=8.7 Hz, 1H), 7.31 (d, J=5.0 Hz, 1H),6.51 (t, J=54.7 Hz, 1H), 5.71 (s, 2H), 2.20-1.99 (m, 3H)

Example 537:2-[[1-[4-Chloro-3-(1,1-difluoroethyl)phenyl]triazol-4-yl]methoxy]-5-(trifluoromethyl)pyrimidine

The title compound was prepared in a manner analogous to Example 155using(1-(4-chloro-3-(1,1-difluoroethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 63) and 2-chloro-5-trifluoromethylpyrimidine. MS (ESI):mass calcd. for C₁₆H₁₁ClF₅N₅O, 419.1; m/z found, 420.0 [M+H]⁺. ¹H NMR(400 MHz, CDCl₃) δ 8.89-8.76 (m, 2H), 8.23-8.08 (m, 1H), 7.97 (d, J=2.6Hz, 1H), 7.85-7.75 (m, 1H), 7.70-7.57 (m, 1H), 5.74 (d, J=0.7 Hz, 2H),2.09 (t, J=18.5 Hz, 3H).

Example 538:2-[[1-[4-Chloro-3-(1,1-difluoroethyl)phenyl]triazol-4-yl]methoxy]-4-(trifluoromethyl)pyrimidine

The title compound was prepared in a manner analogous to Example 155using(1-(4-chloro-3-(1,1-difluoroethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 63) and 2-chloro-4-trifluoromethylpyrimidine. MS (ESI):mass calcd. for C₁₆H₁₁ClF₅N₅O, 419.1; m/z found, 420.0 [M+H]⁺. ¹H NMR(400 MHz, CDCl₃) δ 8.83 (d, J=4.8 Hz, 1H), 8.21 (s, 1H), 7.97 (d, J=2.6Hz, 1H), 7.79 (dd, J=8.6, 2.6 Hz, 1H), 7.62 (d, J=8.6 Hz, 1H), 7.34 (d,J=4.9 Hz, 1H), 5.72 (d, J=0.7 Hz, 2H), 2.09 (t, J=18.5 Hz, 3H).

Example 539:(R/S)-2-[2-[[1-[4-Chloro-3-(1,1-difluoroethyl)phenyl]triazol-4-yl]methoxy]pyrimidin-5-yl]-1,1,1-trifluoro-propan-2-ol

The title compound was prepared in a manner analogous to Example 153using(1-(4-chloro-3-(1,1-difluoroethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 63) and2-(2-chloropyrimidin-5-yl)-1,1,1-trifluoropropan-2-ol, using ACN insteadof DMF. MS (ESI): mass calcd. for C₁₈H₁₅ClF₅N₅O₂, 463.1; m/z found,464.0 [M+H]⁺. ¹H NMR (500 MHz, CDCl₃) δ 8.77-8.71 (s, 2H), 8.20-8.13 (s,1H), 8.01-7.95 (d, J=2.6 Hz, 1H), 7.83-7.75 (m, 1H), 7.64-7.58 (d, J=8.6Hz, 1H), 5.72-5.65 (d, J=0.8 Hz, 2H), 2.16-2.03 (t, J=18.5 Hz, 3H),1.87-1.78 (m, 3H).

Example 540:[2-[[1-[4-Chloro-3-(1,1-difluoroethyl)phenyl]triazol-4-yl]methoxy]pyrimidin-4-yl]methanol

The title compound was prepared in a manner analogous to Example 159,Steps A-B using(1-(4-chloro-3-(1,1-difluoroethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 63) and4-(((tert-butyldimethylsilyl)oxy)methyl)-2-chloropyrimidine(Intermediate 54) in Step A. MS (ESI): mass calcd. for C₁₆H₁₄ClF₂N₅O₂,381.1; m/z found, 382.0 [M+H]⁺. ¹H NMR (500 MHz, CDCl₃) δ 8.55-8.48 (d,J=5.0 Hz, 1H), 8.21-8.12 (s, 1H), 8.00-7.95 (d, J=2.6 Hz, 1H), 7.84-7.75(m, 1H), 7.65-7.57 (d, J=8.6 Hz, 1H), 7.07-6.98 (d, J=5.0 Hz, 1H),5.73-5.62 (d, J=0.7 Hz, 2H), 4.80-4.68 (d, J=0.7 Hz, 2H), 2.18-1.99 (m,3H)

Example 541:2-[[1-[4-Chloro-3-(1,1-difluoroethyl)phenyl]triazol-4-yl]methoxy]-4-methoxy-pyrimidine

The title compound was prepared in a manner analogous to Example 155using(1-(4-chloro-3-(1,1-difluoroethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 63) and 2-chloro-4-methoxypyrimidine. MS (ESI): masscalcd. for C₁₆H₁₄ClF₂N₅O₂, 381.1; m/z found, 382.0 [M+H]⁺. ¹H NMR (400MHz, CDCl₃) δ 8.23 (d, J=5.7 Hz, 1H), 8.15 (s, 1H), 7.97 (d, J=2.6 Hz,1H), 7.86-7.73 (m, 1H), 7.61 (d, J=8.6 Hz, 1H), 6.43 (d, J=5.7 Hz, 1H),5.65 (d, J=0.7 Hz, 2H), 3.99 (s, 3H), 2.20-1.99 (m, 3H).

Example 542:2-[[1-[4-Chloro-3-(1,1-difluoroethyl)phenyl]triazol-4-yl]methoxy]-5-(difluoromethoxy)pyrimidine

The title compound was prepared in a manner analogous to Example 155using(1-(4-chloro-3-(1,1-difluoroethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 63) and 2-chloro-5-difluoromethoxypyrimidine. MS (ESI):mass calcd. for C₁₅H₁₂ClF₄N₅O₂, 417.1; m/z found, 418.0 [M+H]⁺. ¹H NMR(400 MHz, CDCl₃) δ 8.53-8.41 (m, 2H), 8.15 (s, 1H), 7.98 (d, J=2.6 Hz,1H), 7.80 (dd, J=8.6, 2.6 Hz, 1H), 7.62 (d, J=8.6 Hz, 1H), 6.53 (t,J=71.9 Hz, 1H), 5.66 (d, J=0.7 Hz, 2H), 2.09 (t, J=18.5 Hz, 3H).

Example 543:5-Chloro-2-[[1-[4-chloro-3-(1,1-difluoroethyl)phenyl]triazol-4-yl]methoxy]-4-methyl-pyrimidine

The title compound was prepared in a manner analogous to Example 155using(1-(4-chloro-3-(1,1-difluoroethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 63) and 2,5-dichloro-4-methylpyrimidine. MS (ESI): masscalcd. for C₁₆H₁₃Cl₂F₂N₅O, 399.0; m/z found, 400.0 [M+H]⁺. ¹H NMR (400MHz, CDCl₃) δ 8.39 (s, 1H), 8.14 (s, 1H), 7.97 (d, J=2.6 Hz, 1H), 7.79(dd, J=8.6, 2.6 Hz, 1H), 7.61 (d, J=8.6 Hz, 1H), 5.69-5.57 (m, 2H), 2.57(s, 3H), 2.09 (t, J=18.5 Hz, 3H).

Example 544:2-[[1-[4-Chloro-3-(1,1-difluoroethyl)phenyl]triazol-4-yl]methoxy]-5-fluoro-4-methyl-pyrimidine

The title compound was prepared in a manner analogous to Example 155using(1-(4-chloro-3-(1,1-difluoroethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 63) and 2-chloro-5-fluoro-4-methylpyrimidine. MS (ESI):mass calcd. for C₁₆H₁₃ClF₃N₅O, 383.1; m/z found, 384.0 [M+H]⁺. ¹H NMR(400 MHz, CDCl₃) δ 8.26 (d, J=1.2 Hz, 1H), 8.14 (t, J=0.7 Hz, 1H), 7.97(d, J=2.6 Hz, 1H), 7.86-7.75 (m, 1H), 7.61 (d, J=8.6 Hz, 1H), 5.62 (d,J=0.7 Hz, 2H), 2.50 (d, J=2.5 Hz, 3H), 2.09 (t, J=18.5 Hz, 3H).

Example 545:2-[[1-[4-Chloro-3-(1,1-difluoroethyl)phenyl]triazol-4-yl]methoxy]-4,5-dimethyl-pyrimidine

The title compound was prepared in a manner analogous to Example 155using(1-(4-chloro-3-(1,1-difluoroethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 63) and 2-chloro-4,5-dimethylpyrimidine. MS (ESI): masscalcd. for C₁₇H₁₆ClF₂N₅O, 379.1; m/z found, 380.1 [M+H]⁺. ¹H NMR (400MHz, CDCl₃) δ 8.20 (d, J=0.9 Hz, 1H), 8.15 (s, 1H), 7.97 (d, J=2.6 Hz,1H), 7.79 (dd, J=8.6, 2.6 Hz, 1H), 7.61 (d, J=8.6 Hz, 1H), 5.63 (d,J=0.8 Hz, 2H), 2.44 (s, 3H), 2.20 (s, 3H), 2.09 (t, J=18.5 Hz, 3H).

Example 546:2-[[1-[4-Chloro-3-(1,1-difluoroethyl)phenyl]triazol-4-yl]methoxy]-4,6-dimethyl-pyrimidine

The title compound was prepared in a manner analogous to Example 155using(1-(4-chloro-3-(1,1-difluoroethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 63) and 2-chloro-4,6-dimethylpyrimidine. MS (ESI): masscalcd. for C₁₇H₁₆ClF₂N₅O, 379.1; m/z found, 380.1 [M+H]⁺. ¹H NMR (400MHz, CDCl₃) δ 8.16 (t, J=0.8 Hz, 1H), 7.97 (d, J=2.6 Hz, 1H), 7.79 (dd,J=8.6, 2.6 Hz, 1H), 7.61 (d, J=8.7 Hz, 1H), 6.73 (s, 1H), 5.65 (d, J=0.8Hz, 2H), 2.52-2.31 (m, 6H), 2.09 (t, J=18.5 Hz, 3H).

Example 547:2-[[1-[4-Chloro-3-(1,1-difluoroethyl)phenyl]triazol-4-yl]methoxy]pyrimidin-4-amine

The title compound was prepared in a manner analogous to Example 153using(1-(4-chloro-3-(1,1-difluoroethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 63) and 2-chloropyrimidin-4-amine, using ACN instead ofDMF. MS (ESI): mass calcd. for C₁₅H₁₃ClF₂N₆O, 366.1; m/z found, 367.0[M+H]⁺. ¹H NMR (400 MHz, CDCl₃) δ 8.21-8.11 (t, J=0.8 Hz, 1H), 8.11-8.02(d, J=5.7 Hz, 1H), 8.00-7.95 (d, J=2.6 Hz, 1H), 7.86-7.72 (m, 1H),7.66-7.54 (d, J=8.6 Hz, 1H), 6.25-6.00 (d, J=5.7 Hz, 1H), 5.70-5.44 (d,J=0.7 Hz, 2H), 5.20-4.99 (s, 2H), 2.21-1.96 (t, J=18.5 Hz, 3H).

Example 548:2-[[1-[4-Chloro-3-(1,1-difluoroethyl)phenyl]triazol-4-yl]methoxy]-N-methyl-pyrimidin-4-amine

The title compound was prepared in a manner analogous to Example 163,Steps B-C using tert-butyl (2-chloropyrimidin-4-yl)(methyl)carbamate(Intermediate 55) and(1-(4-chloro-3-(1,1-difluoroethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 63). MS (ESI): mass calcd. for C₁₆H₁₅ClF₂N₆O, 380.1; m/zfound, 381.0 [M+H]⁺. ¹H NMR (500 MHz, CDCl₃) δ 8.20-8.16 (s, 1H),8.07-7.96 (m, 2H), 7.82-7.76 (m, 1H), 7.64-7.57 (d, J=8.6 Hz, 1H),6.10-6.07 (d, J=5.9 Hz, 1H), 5.67-5.57 (s, 2H), 5.40-5.26 (s, 1H),3.05-2.91 (s, 3H), 2.18-2.00 (t, J=18.5 Hz, 3H).

Example 549:2-[[1-[4-Chloro-3-(1,1-difluoroethyl)phenyl]triazol-4-yl]methoxy]-5-fluoro-N-methyl-pyrimidin-4-amine

The title compound was prepared in a manner analogous to Example 163,Steps B-C using(1-(4-chloro-3-(1,1-difluoroethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 63) and2-chloro-5-fluoro-N-methyl-N-((2-(trimethylsilyl)ethoxy)methyl)pyrimidin-4-amine(Intermediate 59) in step A. MS (ESI): mass calcd. for C₁₅H₁₄ClF₃N₆O,398.1; m/z found, 399.0 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃) δ 8.16-8.11 (s,1H), 8.01-7.94 (d, J=2.6 Hz, 1H), 7.86-7.73 (m, 2H), 7.66-7.56 (d, J=8.6Hz, 1H), 5.63-5.51 (s, 2H), 5.19-5.03 (s, 1H), 3.15-3.04 (d, J=5.0 Hz,3H), 2.21-1.97 (m, 3H).

Example 550:1-[2-[[1-[4-Chloro-3-(1,1-difluoroethyl)phenyl]triazol-4-yl]methoxy]pyrimidin-5-yl]ethanone

The title compound was prepared in a manner analogous to Example 155using(1-(4-chloro-3-(1,1-difluoroethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 63) and 1-(2-chloropyrimidin-5-yl)ethan-1-one. MS (ESI):mass calcd. for C₁₇H₁₄ClF₂N₅O₂, 393.1; m/z found, 394.0 [M+H]⁺. ¹H NMR(400 MHz, CDCl₃) δ 9.18-9.05 (m, 2H), 8.25-8.14 (s, 1H), 8.04-7.92 (m,1H), 7.88-7.75 (m, 1H), 7.70-7.58 (m, 1H), 5.83-5.70 (m, 2H), 2.69-2.57(m, 3H), 2.23-2.00 (m, 3H).

Example 551:(R/S)-1-[2-[[1-[4-Chloro-3-(1,1-difluoroethyl)phenyl]triazol-4-yl]methoxy]pyrimidin-5-yl]ethanol

The title compound was prepared in a manner analogous to Example 157using1-(2-((1-(4-chloro-3-(1,1-difluoroethyl)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidin-5-yl)ethan-1-one(Example 550). MS (ESI): mass calcd. for C₁₇H₁₆ClF₂N₅O₂, 395.1; m/zfound, 396.0 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃) δ 8.62-8.55 (d, J=0.6 Hz,2H), 8.18-8.14 (t, J=0.7 Hz, 1H), 8.00-7.96 (d, J=2.6 Hz, 1H), 7.83-7.76(m, 1H), 7.65-7.57 (d, J=8.6 Hz, 1H), 5.71-5.62 (d, J=0.8 Hz, 2H),5.03-4.92 (q, J=6.5 Hz, 1H), 2.20-2.01 (t, J=18.4 Hz, 3H), 1.62-1.50 (d,J=6.5 Hz, 3H).

Example 552:2-[[1-[4-Chloro-3-(1,1-difluoroethyl)phenyl]triazol-4-yl]methoxy]-5-cyclopropyl-pyrimidine

The title compound was prepared in a manner analogous to Example 155using(1-(4-chloro-3-(1,1-difluoroethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 63) and 2-chloro-5-cyclopropylpyrimidine. MS (ESI): masscalcd. for C₁₈H₁₆ClF₂N₅O, 391.1; m/z found, 392.1 [M+H]⁺. ¹H NMR (400MHz, CDCl₃) δ 8.32 (d, J=0.5 Hz, 2H), 8.14 (t, J=0.7 Hz, 1H), 7.97 (d,J=2.6 Hz, 1H), 7.83-7.77 (m, 1H), 7.61 (d, J=8.6 Hz, 1H), 5.63 (d, J=0.7Hz, 2H), 2.09 (t, J=18.5 Hz, 3H), 1.88-1.78 (m, 1H), 1.07-0.98 (m, 2H),0.74-0.67 (m, 2H)

Example 553:2-[[1-[4-Chloro-3-(1,1-difluoroethyl)phenyl]triazol-4-yl]methoxy]-4-pyrrolidin-1-yl-pyrimidine

The title compound was prepared in a manner analogous to Example 153using(1-(4-chloro-3-(1,1-difluoroethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 63) and 2-chloro-4-(pyrrolidin-1-yl)pyrimidine, using ACNinstead of DMF. MS (ESI): mass calcd. for C₁₉H₁₉ClF₂N₆O, 420.1; m/zfound, 421.0 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃) δ 8.16-8.11 (t, J=0.7 Hz,1H), 8.02-7.98 (d, J=5.9 Hz, 1H), 7.98-7.96 (d, J=2.6 Hz, 1H), 7.82-7.74(dd, J=8.6, 2.7 Hz, 1H), 7.64-7.55 (d, J=8.6 Hz, 1H), 6.03-5.97 (d,J=5.9 Hz, 1H), 5.63-5.57 (d, J=0.8 Hz, 2H), 3.72-3.53 (m, 2H), 3.43-3.26(m, 2H), 2.17-1.92 (m, 7H).

Example 554:2-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyridine

The title compound was prepared in a manner analogous to Example 158using(1-(3-(1,1-difluoroethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 11) and 2-chloropyridine. MS (ESI): mass calcd. forC₁₆H₁₃F₃N₄O, 334.1; m/z found, 335.1 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃) δ8.29-8.12 (m, 1H), 8.13-7.99 (m, 1H), 7.96-7.80 (m, 2H), 7.68-7.53 (m,1H), 7.42-7.22 (m, 1H), 7.05-6.70 (m, 2H), 5.72-5.50 (m, 2H), 2.23-1.82(m, 3H)

Example 555:2-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-3-fluoro-pyridine

The title compound was prepared in a manner analogous to Example 158using(1-(3-(1,1-difluoroethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 11) and 2-chloro-3-fluoropyridine. MS (ESI): mass calcd.for C₁₆H₁₂F₄N₄O, 352.1; m/z found, 353.1 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃)δ 8.11 (s, 1H), 8.02-7.96 (m, 1H), 7.95-7.87 (m, 1H), 7.88-7.81 (m, 1H),7.43-7.26 (m, 2H), 6.98-6.87 (m, 1H), 5.68 (d, J=2.0 Hz, 2H), 2.05 (t,J=18.4, 1.6 Hz, 3H).

Example 556:2-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-6-methyl-pyridine

The title compound was prepared in a manner analogous to Example 158using(1-(3-(1,1-difluoroethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 11) and 2-chloro-6-methylpyridine. MS (ESI): mass calcd.for C₁₇H₁₅F₃N₄O, 348.1; m/z found, 349.1 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃)δ 8.09-8.03 (m, 1H), 7.93-7.85 (m, 1H), 7.86-7.78 (m, 1H), 7.54-7.41 (m,1H), 7.36-7.26 (m, 1H), 6.81-6.73 (m, 1H), 6.64-6.51 (m, 1H), 5.59 (d,J=0.7 Hz, 2H), 2.48 (t, J=0.6 Hz, 3H), 2.05 (td, J=18.6, 1.2 Hz, 3H).

Example 557:2-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-4-methyl-pyridine

The title compound was prepared in a manner analogous to Example 158using(1-(3-(1,1-difluoroethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 11) and 2-chloro-4-methylpyridine. MS (ESI): mass calcd.for C₁₇H₁₅F₃N₄O, 348.1; m/z found, 349.0 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃)δ 8.15-8.01 (m, 1H), 7.97-7.76 (m, 2H), 7.39-7.22 (m, 2H), 6.83-6.58 (m,2H), 5.68-5.49 (m, 2H), 2.31 (s, 3H), 2.20-1.90 (m, 3H).

Example 558:2-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-5-methyl-pyridine

The title compound was prepared in a manner analogous to Example 158using(1-(3-(1,1-difluoroethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 11) and 2-chloro-5-methylpyridine. MS (ESI): mass calcd.for C₁₇H₁₅F₃N₄O, 348.1; m/z found, 349.0 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃)δ 8.13-8.04 (m, 1H), 8.05-7.96 (m, 1H), 7.96-7.75 (m, 2H), 7.49-7.35 (m,1H), 7.36-7.21 (m, 1H), 6.81-6.63 (m, 1H), 5.57 (d, J=4.0 Hz, 2H), 2.27(d, J=3.6 Hz, 3H), 2.05 (t, 3H).

Example 559:2-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-5-(trifluoromethyl)pyridine

The title compound was prepared in a manner analogous to Example 158using(1-(3-(1,1-difluoroethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 11) and 2-chloro-5-trifluoromethylpyridine. MS (ESI): masscalcd. for C₁₇H₁₂F₆N₄O, 402.1; m/z found, 403.0 [M+H]⁺. ¹H NMR (400 MHz,CDCl₃) δ 8.60-8.39 (m, 1H), 8.23-8.02 (m, 1H), 8.01-7.74 (m, 2H),7.43-7.22 (m, 2H), 7.03-6.84 (m, 1H), 5.65 (s, 2H), 2.05 (t, J=18.4 Hz,3H).

Example 560:6-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-2,3-dimethyl-pyridine

The title compound was prepared in a manner analogous to Example 158using(1-(3-(1,1-difluoroethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 11) and 2-chloro-5,6-dimethylpyridine. MS (ESI): masscalcd. for C₁₈H₁₇F₃N₄O, 362.1; m/z found, 363.1 [M+H]⁺. ¹H NMR (400 MHz,CDCl₃) δ 8.06 (s, 1H), 7.98-7.76 (m, 2H), 7.42-7.26 (m, 2H), 6.64-6.51(m, 1H), 5.57 (d, J=2.5 Hz, 2H), 2.43 (s, 3H), 2.20 (s, 3H), 2.03 (t,3H).

Example 561:3-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-2-methoxy-pyridine

The title compound was prepared in a manner analogous to Example 153,using4-(chloromethyl)-1-(3-(1,1-difluoroethyl)-4-fluorophenyl)-1H-1,2,3-triazole(Intermediate 20, product from Step A) and 2-methoxypyridin-3-ol (24 mg,0.189 mmol) and stirred at rt overnight. MS (ESI): mass calcd. forC₁₇H₁₅F₃N₄O₂, 364.1; m/z found, 365.1 [M+H]⁺. ¹H NMR (500 MHz, CDCl₃) δ8.09 (t, J=0.7 Hz, 1H), 7.92-7.88 (m, 1H), 7.86-7.80 (m, 1H), 7.81-7.77(m, 1H), 7.34-7.28 (m, 2H), 6.91-6.78 (m, 1H), 5.46-5.28 (m, 2H), 4.03(s, 3H), 2.05 (t, J=18.6, 1.2 Hz, 3H).

Example 562:2-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-5-(difluoromethyl)pyrimidine

The title compound was prepared in a manner analogous to Example 155using(1-(3-(1,1-difluoroethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 11) and 2-chloro-5-(difluoromethyl)pyrimidine. MS (ESI):mass calcd. for C₁₆H₁₂F₈N₅O, 385.1; m/z found, 386.1 [M+H]⁺. ¹H NMR (500MHz, CDCl₃) δ 8.76-8.67 (m, 2H), 8.13 (s, 1H), 7.94-7.87 (m, 1H),7.87-7.81 (m, 1H), 7.32 (t, J=9.4 Hz, 1H), 6.73 (t, J=55.6 Hz, 1H),5.78-5.68 (m, 2H), 2.12-1.96 (m, 3H).

Example 563:2-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-4-(difluoromethyl)pyrimidine

The title compound was prepared in a manner analogous to Example 155using(1-(3-(1,1-difluoroethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 11) and 2-chloro-4-(difluoromethyl)pyrimidine. MS (ESI):mass calcd. for C₁₆H₁₂F₅N₅O, 385.1; m/z found, 386.1 [M+H]⁺. ¹H NMR (500MHz, CDCl₃) δ 8.76 (d, J=4.9 Hz, 1H), 8.16 (t, J=0.7 Hz, 1H), 7.93-7.87(m, 1H), 7.87-7.79 (m, 1H), 7.36-7.28 (m, 2H), 6.50 (t, J=54.7 Hz, 1H),5.70 (d, J=0.7 Hz, 2H), 2.05 (td, J=18.6, 1.1 Hz, 3H)

Example 564:2-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-4-(trifluoromethyl)pyrimidine

The title compound was prepared in a manner analogous to Example 155using(1-(3-(1,1-difluoroethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 11) and 2-chloro-3-trifluoromethylpyrimidine. MS (ESI):mass calcd. for C₁₆H₁₁F₆N₅O, 403.1; m/z found, 404.0 [M+H]⁺. ¹H NMR (400MHz, CDCl₃) δ 8.83 (d, J=4.8 Hz, 1H), 8.18 (s, 1H), 7.95-7.86 (m, 1H),7.87-7.78 (m, 1H), 7.38-7.28 (m, 2H), 5.78-5.66 (m, 2H), 2.05 (t,J=18.6, 1.2 Hz, 3H).

Example 565:(R/S)-2-[2-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyrimidin-5-yl]-1,1,1-trifluoro-propan-2-ol

The title compound was prepared in a manner analogous to Example 153using(1-(3-(1,1-difluoroethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 11) and2-(2-chloropyrimidin-5-yl)-1,1,1-trifluoropropan-2-ol, using ACN insteadof DMF. MS (ESI): mass calcd. for C₁₈H₁₅F₆N₅O₂, 447.1; m/z found, 448.0[M+H]⁺. ¹H NMR (500 MHz, CDCl₃) δ 8.79-8.70 (s, 2H), 8.17-8.08 (t, J=0.7Hz, 1H), 7.94-7.88 (m, 1H), 7.88-7.78 (m, 1H), 7.35-7.27 (m, 1H),5.74-5.65 (d, J=0.7 Hz, 2H), 2.77-2.56 (s, 1H), 2.11-1.99 (m, 3H),1.86-1.79 (m, 3H)

Example 566:2-[2-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyrimidin-5-yl]propan-2-ol

The title compound was prepared in a manner analogous to Example 155using(1-(3-(1,1-difluoroethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 11) and 2-(2-chloropyrimidin-5-yl)propan-2-ol. MS (ESI):mass calcd. for C₁₈H₁₈F₃N₅O₂, 393.1; m/z found, 394.0 [M+H]⁺. ¹H NMR(500 MHz, CDCl₃) δ 8.68 (s, 2H), 8.13 (s, 1H), 7.95-7.79 (m, 2H),7.37-7.27 (m, 1H), 5.67 (d, J=0.7 Hz, 2H), 2.15-1.97 (m, 3H), 1.63 (s,6H).

Example 567:2-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-5-(1-methoxy-1-methyl-ethyl)pyrimidine

The title compound was prepared in a manner analogous to Example 311using2-(2-((1-(3-(1,1-difluoroethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidin-5-yl)propan-2-ol(Example 566). MS (ESI): mass calcd. for C₁₀H₂₀F₃N₅O₂, 407.2; m/z found,408.1 [M+H]⁺. ¹H NMR (500 MHz, CDCl₃) δ 8.62-8.56 (s, 2H), 8.16-8.09 (t,J=0.7 Hz, 1H), 7.93-7.87 (m, 1H), 7.87-7.80 (m, 1H), 7.35-7.28 (m, 1H),5.72-5.63 (d, J=0.7 Hz, 2H), 3.18-3.09 (s, 3H), 2.14-1.97 (m, 3H),1.56-1.55 (s, 6H)

Example 568:[2-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyrimidin-4-yl]methanol

The title compound was prepared in a manner analogous to Example 159,Steps A-B using(1-(3-(1,1-difluoroethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 11) and4-(((tert-butyldimethylsilyl)oxy)methyl)-2-chloropyrimidine(Intermediate 54) in Step A. MS (ESI): mass calcd. for C₁₆H₁₄F₃N₅O₂,365.1; m/z found, 366.1 [M+H]⁺. ¹H NMR (500 MHz, CDCl₃) δ 8.60-8.43 (d,J=5.0 Hz, 1H), 8.19-8.11 (s, 1H), 7.95-7.87 (dd, J=6.2, 2.7 Hz, 1H),7.87-7.76 (m, 1H), 7.34-7.28 (m, 1H), 7.07-6.94 (d, J=5.0 Hz, 1H),5.74-5.62 (d, J=0.7 Hz, 2H), 4.84-4.67 (d, J=0.8 Hz, 2H), 2.15-1.92 (m,3H).

Example 569:2-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-5-(methoxymethyl)pyrimidine

The title compound was prepared in a manner analogous to Example 153using(1-(3-(1,1-difluoroethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 11) and 2-chloro-5-(methoxymethyl)pyrimidine, using ACNinstead of DMF. MS (ESI): mass calcd. for C₁₇H₁₆F₃N₅O₂, 379.1; m/zfound, 380.1 [M+H]⁺. ¹H NMR (500 MHz, CDCl₃) δ 8.56-8.52 (s, 2H),8.14-8.09 (t, J=0.7 Hz, 1H), 7.92-7.87 (m, 1H), 7.87-7.78 (m, 1H),7.35-7.27 (m, 1H), 5.70-5.64 (d, J=0.7 Hz, 2H), 4.45-4.37 (s, 2H),3.45-3.39 (s, 3H), 2.12-1.97 (m, 3H)

Example 570:2-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-4-(methoxymethyl)pyrimidine

The title compound was prepared in a manner analogous to Example 155using (1-(3-(1,1-difluoroethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanoland 2-chloro-4-(methoxymethyl)pyrimidine. MS (ESI): mass calcd. forC₁₇H₁₆F₃N₅O₂, 379.1; m/z found, 380.1 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃) δ8.55 (d, J=5.0 Hz, 1H), 8.15 (t, J=0.8 Hz, 1H), 7.92-7.86 (m, 1H),7.86-7.80 (m, 1H), 7.31 (t, J=10.0, 8.8 Hz, 1H), 7.16 (d, J=5.1 Hz, 1H),5.66 (d, J=0.7 Hz, 2H), 4.50 (d, J=0.7 Hz, 2H), 3.50 (s, 3H), 2.05 (t,J=18.6, 1.2 Hz, 3H).

Example 571:[2-[[1-[3-(1,1-difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyrimidin-5-yl]methanol

The title compound was prepared in a manner analogous to Example 159,Steps A-B using(1-(3-(1,1-difluoroethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 11) and5-(((tert-butyldimethylsilyl)oxy)methyl)-2-chloropyrimidine(Intermediate 53) in Step A. MS (ESI): mass calcd. for C₁₆H₁₄F₃N₅O₂,365.1; m/z found, 366.1 [M+H]⁺. ¹H NMR (500 MHz, CDCl₃) δ 8.61-8.56 (s,2H), 8.15-8.10 (t, J=0.7 Hz, 1H), 7.93-7.86 (m, 1H), 7.86-7.81 (m, 1H),7.34-7.27 (m, 1H), 5.70-5.65 (d, J=0.7 Hz, 2H), 4.75-4.67 (m, 2H),2.16-1.95 (m, 3H)

Example 572:2-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-5-(difluoromethoxy)pyrimidine

The title compound was prepared in a manner analogous to Example 155using(1-(3-(1,1-difluoroethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 11) and 2-chloro-5-(difluoromethoxy)pyrimidine. MS (ESI):mass calcd. for C₁₆H₁₂F₅N₅O₂, 401.1; m/z found, 402.0 [M+H]⁺. ¹H NMR(500 MHz, CDCl₃) δ 8.45 (s, 2H), 8.12 (s, 1H), 7.92-7.88 (m, 1H),7.87-7.80 (m, 1H), 7.31 (t, J=9.4 Hz, 1H), 6.53 (t, J=71.9 Hz, 1H), 5.66(d, J=0.7 Hz, 2H), 2.05 (t, J=18.6, 1.2 Hz, 3H).

Example 573:2-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-4,5-dimethyl-pyrimidine

The title compound was prepared in a manner analogous to Example 155using(1-(3-(1,1-difluoroethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 11) and 2-chloro-4,5-dimethylpyrimidine. MS (ESI): masscalcd. for C₁₇H₁₆F₃N₅O, 363.1; m/z found, 364.0 [M+H]⁺. ¹H NMR (500 MHz,CDCl₃) δ 8.20 (d, J=1.0 Hz, 1H), 8.12 (d, J=0.7 Hz, 1H), 7.91-7.87 (m,1H), 7.86-7.80 (m, 1H), 7.30 (t, J=9.4 Hz, 1H), 5.73-5.55 (m, 2H), 2.44(s, 3H), 2.20 (s, 3H), 2.05 (td, J=18.5, 1.2 Hz, 3H).

Example 574:5-Chloro-2-[[1-[3-(1,1-difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-4-methyl-pyrimidine

The title compound was prepared in a manner analogous to Example 155using(1-(3-(1,1-difluoroethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 11) and 2,5-dichloro-4-methylpyrimidine. MS (ESI): masscalcd. for C₁₆H₁₃ClF₃N₅O, 383.1; m/z found, 384.0 [M+H]⁺. ¹H NMR (500MHz, CDCl₃) δ 8.39 (s, 1H), 8.15-8.07 (m, 1H), 7.89 (dd, J=6.2, 2.7 Hz,1H), 7.87-7.80 (m, 1H), 7.31 (t, J=9.4 Hz, 1H), 5.73-5.56 (m, 2H),2.68-2.52 (m, 3H), 2.15-1.91 (m, 3H).

Example 575:2-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-5-fluoro-4-methyl-pyrimidine

The title compound was prepared in a manner analogous to Example 155using(1-(3-(1,1-difluoroethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 11) and 2-chloro-5-fluoro-4-methylpyrimidine. MS (ESI):mass calcd. for C₁₆H₁₃F₄N₅O, 367.1; m/z found, 368.1 [M+H]⁺. ¹H NMR (400MHz, CDCl₃) δ 8.26 (d, J=1.2 Hz, 1H), 8.11 (t, J=0.7 Hz, 1H), 7.94-7.86(m, 1H), 7.86-7.78 (m, 1H), 7.31 (t, J=9.4 Hz, 1H), 5.62 (d, J=0.8 Hz,2H), 2.49 (d, J=2.5 Hz, 3H), 2.05 (td, J=18.7, 1.2 Hz, 3H).

Example 576:2-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-5-methyl-pyrimidin-4-amine

The title compound was prepared in a manner analogous to Example 153using (1-(3-(I,1-difluoroethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 11) and 2-chloro-5-methylpyrimidin-4-amine, using ACNinstead of DMF. MS (ESI): mass calcd. for C₁₆H₁₅F₃N₆O, 364.1; m/z found,365.1 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃) δ 8.16-8.05 (m, 1H), 7.93-7.87 (m,1H), 7.86-7.80 (m, 1H), 7.37-7.27 (m, 2H), 5.56 (d, J=0.8 Hz, 2H),4.98-4.81 (m, 2H), 2.15-1.94 (m, 6H).

Example 577:2-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-N,5-dimethyl-pyrimidin-4-amine

Step A: tert-Butyl(2-((1-(3-(1,1-difluoroethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidin-4-yl)(methyl)carbamate

The title compound was prepared in a manner analogous to Example 153using(1-(3-(1,1-difluoroethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 11) and tert-butyl(2-chloro-5-methylpyrimidin-4-yl)(methyl)carbamate, using ACN instead ofDMF. MS (ESI): mass calcd. for C₂₂H₂₅F₃N₆O₅, 478.2; m/z found, 479.1[M+H]⁺.

Step B: tert-Butyl(2-((1-(3-(1,1-difluoroethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidin-4-yl)(methyl)carbamate

To a vial with tert-butyl(2-((1-(3-(1,1-difluoroethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-5-methylpyrimidin-4-yl)(methyl)carbamatein DCM (3 mL) was added TFA (0.5 mL). The reaction mixture was stirredat rt overnight. The completed reaction was concentrated under reducedpressure. Purification (FCC, SiO₂, eluting with 0-3% 2M NH₃ in MeOH inDCM) afforded the title compound (17.9 mg, 41%) over the two stepprocess. MS (ESI): mass calcd. for C₁₇H₁₇F₃N₆O, 378.1; m/z found, 379.0[M+H]⁺. ¹H NMR (500 MHz, CDCl₃) δ 8.14-8.08 (t, J=0.8 Hz, 1H), 7.92-7.87(m, 1H), 7.85-7.79 (m, 1H), 7.79-7.76 (d, J=1.1 Hz, 1H), 7.34-7.27 (m,1H), 5.64-5.56 (d, J=0.7 Hz, 2H), 4.75-4.59 (s, 1H), 3.13-3.03 (d, J=4.8Hz, 3H), 2.10-1.99 (m, 3H), 1.99-1.95 (d, J=1.0 Hz, 3H).

Example 578:2-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-5-fluoro-N-methyl-pyrimidin-4-amine

The title compound was prepared in a manner analogous to Example 163,Steps B-C using(1-(3-(1,1-difluoroethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 11) and2-chloro-5-fluoro-N-methyl-N-((2-(trimethylsilyl)ethoxy)methyl)pyrimidin-4-amine(Intermediate 59) in Step A. MS (ESI): mass calcd. for C₁₆H₁₄F₄N₆O,382.1; m/z found, 383.0 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃) δ 8.14-8.07 (d,J=2.4 Hz, 1H), 7.95-7.87 (m, 1H), 7.86-7.78 (m, 2H), 7.36-7.22 (m, 1H),5.61-5.52 (d, J=2.4 Hz, 2H), 5.22-5.08 (s, 1H), 3.16-3.02 (m, 3H),2.17-1.90 (m, 3H).

Example 579:2-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-N,N,5-trimethyl-pyrimidin-4-amine

The title compound was prepared in a manner analogous to Example 153using(1-(3-(1,1-difluoroethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 11) and 2-chloro-N,N,5-trimethylpyrimidin-4-amine, usingACN instead of DMF. MS (ESI): mass calcd. for C₁₈H₁₉F₃N₅O, 392.2; m/zfound, 393.1 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃) δ 8.10 (s, 1H), 7.92-7.87(m, 1H), 7.86-7.79 (m, 2H), 7.33-7.27 (m, 1H), 5.58 (s, 2H), 3.13 (s,6H), 2.25 (s, 3H), 2.13-1.96 (m, 3H).

Example 580:2-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyrimidin-4-amine

The title compound was prepared in a manner analogous to Example 153using(1-(3-(1,1-difluoroethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 11) and 2-chloropyrimidin-4-amine, using ACN instead ofDMF. MS (ESI): mass calcd. for C₁₅H₁₃F₃N₅O, 350.1; m/z found, 351.0[M+H]⁺. ¹H NMR (400 MHz, CDCl₃) δ 8.26-7.99 (m, 2H), 7.99-7.68 (m, 2H),7.49-7.03 (m, 1H), 6.36-5.98 (m, 1H), 5.75-5.49 (d, J=3.0 Hz, 2H),5.20-4.89 (s, 2H), 2.28-1.91 (m, 3H).

Example 581:2-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-N-methyl-pyrimidin-4-amine

The title compound was prepared in a manner analogous to Example 163,Steps B-C using tert-butyl (2-chloropyrimidin-4-yl)(methyl)carbamate(Intermediate 55) and(1-(3-(1,1-difluoroethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 11). MS (ESI): mass calcd. for C₁₆H₁₅F₃N₅O, 364.1; m/zfound, 365.1 [M+H]⁺. ¹H NMR (500 MHz, CDCl₃) δ 8.17-8.05 (s, 1H),8.09-7.95 (s, 1H), 7.96-7.87 (m, 1H), 7.87-7.76 (m, 1H), 7.38-7.27 (m,1H), 6.15-5.98 (d, J=5.7 Hz, 1H), 5.71-5.51 (s, 2H), 5.27-4.95 (s, 1H),3.05-2.86 (d, J=4.8 Hz, 3H), 2.12-1.93 (m, 3H).

Example 582:2-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-N,N-dimethyl-pyrimidin-4-amine

The title compound was prepared in a manner analogous to Example 155using(1-(3-(1,1-difluoroethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 11) and 2-chloro-N,N-dimethylpyrimidin-4-amine. MS (ESI):mass calcd. for C₁₇H₁₇F₃N₆O, 378.1; m/z found, 379.0 [M+H]⁺. ¹H NMR (400MHz, CDCl₃) δ 8.15-8.08 (t, J=0.8 Hz, 1H), 8.07-7.98 (d, J=6.0 Hz, 1H),7.94-7.86 (m, 1H), 7.86-7.78 (m, 1H), 7.34-7.26 (m, 1H), 6.18-6.08 (d,J=6.1 Hz, 1H), 5.66-5.54 (d, J=0.7 Hz, 2H), 3.22-3.03 (s, 6H), 2.15-1.95(m, 3H).

Example 583:2-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyrimidine-5-carbonitrile

The title compound was prepared in a manner analogous to Example 153using(1-(3-(1,1-difluoroethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 11) and 2-chloro-5-cyanopyrimidine, using ACN instead ofDMF, employing microwave heating at 140° C. for 90 min. MS (ESI): masscalcd. for C₁₆H₁₁F₃N₆O, 360.1; m/z found, 361.0 [M+H]⁺. ¹H NMR (400 MHz,CDCl₃) δ 8.85 (s, 2H), 8.16-8.09 (m, 1H), 7.92-7.86 (m, 1H), 7.86-7.81(m, 1H), 7.38-7.29 (m, 1H), 5.74 (d, J=0.6 Hz, 2H), 2.17-1.91 (m, 3H).

Example 584:2-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-5-methylsulfonyl-pyrimidine

The title compound was prepared in a manner analogous to Example 153using (1-(3-(1,i-difluoroethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 11) and 2-chloro-5-(methylsulfonyl)pyrimidine, using ACNinstead of DMF. MS (ESI): mass calcd. for C₁₆H₁₄F₃N₅O₃S, 413.1; m/zfound, 414.0 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃) δ 9.05 (s, 2H), 8.21-8.05(m, 1H), 7.92-7.88 (m, 1H), 7.87-7.81 (m, 1H), 7.33 (t, J=9.3 Hz, 1H),5.84-5.68 (m, 2H), 3.15 (s, 3H), 2.18-1.92 (m, 3H).

Example 585:1-[2-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyrimidin-5-yl]ethanone

The title compound was prepared in a manner analogous to Example 155using(1-(3-(1,1-difluoroethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 11) and 1-(2-chloropyrimidin-5-yl)ethan-1-one. MS (ESI):mass calcd. for C₁₇H₁₄F₃N₅O₂, 377.1; m/z found, 378.0 [M+H]⁺. ¹H NMR(400 MHz, CDCl₃) δ 9.15-9.06 (s, 2H), 8.19-8.10 (s, 1H), 7.94-7.87 (m,1H), 7.87-7.80 (m, 1H), 7.38-7.28 (m, 1H), 5.81-5.71 (m, 2H), 2.65-2.55(s, 3H), 2.16-1.94 (m, 3H)

Example 586:(R/S)-1-[2-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyrimidin-5-yl]ethanol

The title compound was prepared in a manner analogous to Example 157using1-(2-((1-(3-(1,1-difluoroethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidin-5-yl)ethan-1-one(Example 585). MS (ESI): mass calcd. for C₁₇H₁₁F₃N₅O₂, 379.1; m/z found,380.1 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃) δ 8.61-8.52 (s, 2H), 8.17-8.10 (s,1H), 7.93-7.86 (m, 1H), 7.86-7.79 (m, 1H), 7.35-7.28 (m, 1H), 5.69-5.60(d, J=0.7 Hz, 2H), 5.03-4.92 (m, 1H), 2.12-1.97 (m, 3H), 1.61-1.50 (d,J=6.5 Hz, 3H).

Example 587:5-Cyclopropyl-2-[[1-[3-(1,1-difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyrimidine

The title compound was prepared in a manner analogous to Example 155using(1-(3-(1,1-difluoroethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 11) and 2-chloro-5-cyclopropylpyrimidine. MS (ESI): masscalcd. for C₁₈H₁₆F₃N₅O, 375.1; m/z found, 376.0 [M+H]⁺. ¹H NMR (400 MHz,CDCl₃) δ 8.34-8.29 (m, 2H), 8.13-8.08 (m, 1H), 7.92-7.86 (m, 1H),7.86-7.79 (m, 1H), 7.34-7.27 (m, 1H), 5.63 (d, J=0.7 Hz, 2H), 2.16-1.94(m, 3H), 1.91-1.74 (m, 1H), 1.09-0.97 (m, 2H), 0.78-0.63 (m, 2H)

Example 588:5-(Azetidin-1-yl)-2-[[1-[3-(1,1-difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyrimidine

The title compound was prepared in a manner analogous to Example 165,Step A, using5-bromo-2-[[1-[3-(1,1-difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]pyrimidine(Example 183) and azetidine. MS (ESI): mass calcd. for C₁₈H₁₇F₃N₆O,390.1; m/z found, 391.0 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃) δ 8.12-8.07 (t,J=0.7 Hz, 1H), 7.93-7.87 (m, 1H), 7.87-7.78 (s, 3H), 7.35-7.27 (m, 1H),5.62-5.54 (d, J=0.7 Hz, 2H), 3.98-3.86 (t, J=7.2 Hz, 4H), 2.53-2.39 (m,2H), 2.16-1.97 (m, 3H).

Example 589:2-((1-(3-(1,1-Difluoroethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-5-(3-fluoroazetidin-1-yl)pyrimidine

The title compound was made in an analogous manner to Example 187 using3-fluoroazetidine hydrochloride. MS (ESI): mass calcd. for C₁₈H₁₆F₄N₆O,408.3; m/z found, 409.1 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃) δ 8.05-8.02 (s,1H), 7.84-7.80 (m, 1H), 7.80-7.79 (s, 2H), 7.78-7.73 (m, 1H), 7.26-7.20(m, 1H), 5.54-5.49 (s, 2H), 5.49-5.28 (m, 1H), 4.23-4.11 (m, 2H),3.98-3.86 (m, 2H), 2.05-1.91 (m, 3H).

Example 590:2-((1-(3-(1,1-Difluoroethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-N,N-dimethylpyrimidin-5-amine

The title compound was made in an analogous manner to Example 187 usingdimethylamine hydrochloride. MS (ESI): mass calcd. for C₁₇H₁₇F₃N₆O,378.3; m/z found, 379.1 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃) δ 8.05-8.03 (m,1H), 8.03-8.01 (s, 2H), 7.84-7.80 (dd, J=6.3, 2.7 Hz, 1H), 7.78-7.73 (m,1H), 7.26-7.20 (m, 1H), 5.53-5.50 (d, J=0.7 Hz, 2H), 2.89-2.83 (s, 6H),2.05-1.90 (m, 3H).

Example 591:2-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-4-pyrrolidin-1-yl-pyrimidine

The title compound was prepared in a manner analogous to Example 153using(1-(3-(1,1-difluoroethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 11) and 2-chloro-4-(pyrrolidin-1-yl)pyrimidine, using ACNinstead of DMF. MS (ESI): mass calcd. for C₁₉H₁₉F₃N₆O, 404.2; m/z found,405.1 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃) δ 8.12-8.08 (t, J=0.8 Hz, 1H),8.02-7.96 (m, 1H), 7.91-7.86 (m, 1H), 7.84-7.79 (m, 1H), 7.33-7.27 (m,1H), 6.04-5.96 (d, J=6.0 Hz, 1H), 5.65-5.57 (d, J=0.8 Hz, 2H), 3.80-3.22(d, J=110.6 Hz, 4H), 2.13-1.94 (m, 7H).

Example 592:2-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-4-(1-piperidyl)pyrimidine

The title compound was prepared in a manner analogous to Example 153using(1-(3-(1,1-difluoroethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 11) and 2-chloro-4-(piperidin-1-yl)pyrimidine, using ACNinstead of DMF. MS (ESI): mass calcd. for C₂₀H₂₁F₃N₆O, 418.2; m/z found,419.1 [M+H]⁺. ¹H NMR (500 MHz, CDCl₃) δ 8.15-8.07 (s, 1H), 8.07-7.97 (d,J=6.1 Hz, 1H), 7.95-7.86 (m, 1H), 7.86-7.78 (m, 1H), 7.34-7.27 (m, 1H),6.22-6.15 (d, J=6.2 Hz, 1H), 5.61-5.54 (d, J=0.8 Hz, 2H), 3.73-3.53 (s,4H), 2.13-1.98 (m, 3H), 1.75-1.65 (m, 2H), 1.65-1.56 (m, 4H).

Example 593:2-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]-5-methyl-triazol-4-yl]methoxy]-5-ethyl-pyrimidine

The title compound was prepared in a manner analogous to Example 173,Steps A through F, using 2-chloro-5-ethylpyrimidine in Step F. MS (ESI):mass calcd. for C₁₈H₁₈F₃N₅O, 377.1; m/z found, 378.1 [M+H]⁺. ¹H NMR (500MHz, CDCl₃) δ 8.39 (s, 2H), 7.66 (dd, J=6.3, 2.6 Hz, 1H), 7.57-7.51 (m,1H), 7.32 (t, J=9.3 Hz, 1H), 5.57 (s, 2H), 2.60 (q, J=7.6 Hz, 2H), 2.42(s, 3H), 2.04 (td, J=18.6, 1.1 Hz, 3H), 1.25 (t, J=7.6 Hz, 3H).

Example 594:5-Cyclopropyl-2-[[1-[3-(1,1-difluoroethyl)-4-fluoro-phenyl]-5-methyl-triazol-4-yl]methoxy]pyrimidine

The title compound was prepared in a manner analogous to Example 173,Steps A through F, using 2-chloro-5-cyclopropylpyrimidine in Step F. MS(ESI): mass calcd. for C₁₉H₁₈F₃N₅O, 389.1; m/z found, 390.1 [M+H]⁺. ¹HNMR (500 MHz, CDCl₃) δ 8.30 (s, 2H), 7.66 (dd, J=6.3, 2.6 Hz, 1H),7.55-7.51 (m, 1H), 7.34-7.29 (m, 1H), 5.56 (s, 2H), 2.41 (s, 3H), 2.04(td, J=18.6, 1.1 Hz, 3H), 1.82 (tt, J=8.5, 5.1 Hz, 1H), 1.04-0.97 (m,2H), 0.73-0.63 (m, 2H).

Example 595:2-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]-5-methyl-triazol-4-yl]methoxy]-4,5-dimethyl-pyrimidine

The title compound was prepared in a manner analogous to Example 173,Steps A through F, using 2-chloro-4,5-dimethylpyrimidine in Step F. MS(ESI): mass calcd. for C₁₈H₁₈F₃N₅O, 377.1; m/z found, 378.0 [M+H]⁺. ¹HNMR (500 MHz, CDCl₃) δ 8.19 (s, 1H), 7.66 (dd, J=6.4, 2.6 Hz, 1H), 7.53(ddd, J=8.6, 4.1, 2.8 Hz, 1H), 7.35-7.29 (m, 1H), 5.56 (s, 2H),2.45-2.40 (m, 6H), 2.19 (s, 3H), 2.04 (td, J=18.6, 1.2 Hz, 3H).

Example 596:5-Chloro-2-[[1-[3-(1,1-difluoroethyl)-4-fluoro-phenyl]-5-methyl-triazol-4-yl]methoxy]-4-methyl-pyrimidine

The title compound was prepared in a manner analogous to Example 173,Steps A through F, using 2,5-dichloro-4-methylpyrimidine in Step F. MS(ESI): mass calcd. for C₁₇H₁₅ClF₃N₅O, 397.1; m/z found 398.0 [M+H]⁺. ¹HNMR (500 MHz, CDCl₃) δ 8.37 (s, 1H), 7.66 (dd, J=6.3, 2.6 Hz, 1H), 7.53(ddd, J=8.6, 4.1, 2.7 Hz, 1H), 7.33 (t, J=9.3 Hz, 1H), 5.56 (s, 2H),2.55 (s, 3H), 2.42 (s, 3H), 2.04 (td, J=18.6, 1.2 Hz, 3H).

Example 597: 2-[[1-(3,4-Difluorophenyl)triazol-4-yl]methoxy]pyrimidine

The title compound was prepared in a manner analogous to Example 1 using(1-(3,4-difluorophenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 39)and 2-chloropyrimidine. MS (ESI): mass calcd. for C₁₃H₉F₂N₅O, 289.1; m/zfound, 290.1 [M+H]⁺. ¹H NMR (500 MHz, DMSO-d₆) δ 8.94 (d, J=0.6 Hz, 1H),8.66 (d, J=4.8 Hz, 2H), 8.13 (ddd, J=11.4, 7.0, 2.7 Hz, 1H), 7.83 (dddd,J=9.0, 4.1, 2.6, 1.6 Hz, 1H), 7.71 (dt, J=10.4, 8.8 Hz, 1H), 7.20 (t,J=4.8 Hz, 1H), 5.53 (d, J=0.6 Hz, 2H).

Example 598:2-[[1-(3,4-Difluorophenyl)triazol-4-yl]methoxy]-5-fluoro-pyrimidine

The title compound was prepared in a manner analogous to Example 1 using(1-(3,4-difluorophenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 39)and 2-chloro-5-fluoropyrimidine. MS (ESI): mass calcd. for C₁₃H₆F₃N₅O,307.1; m/z found, 308.0 [M+H]. ¹H NMR (500 MHz, DMSO-d₆) δ 8.93 (s, 1H),8.75 (d, J=0.6 Hz, 2H), 8.13 (ddd, J=11.5, 7.0, 2.7 Hz, 1H), 7.83 (dt,J=8.3, 2.9 Hz, 1H), 7.71 (dt, J=10.4, 8.8 Hz, 1H), 5.52 (s, 2H).

Example 599:2-[[1-(3,4-Difluorophenyl)triazol-4-yl]methoxy]-5-methoxy-pyrimidine

The title compound was prepared in a manner analogous to Example 1 using(1-(3,4-difluorophenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 39)and 2-chloro-5-methoxypyrimidine. MS (ESI): mass calcd. forC₁₄H₁₁F₂N₅O₂, 319.1; m/z found, 320.1 [M+H]⁺. ¹H NMR (500 MHz, DMSO-d₆)δ 8.92 (s, 1H), 8.41 (s, 2H), 8.13 (ddd, J=11.4, 7.0, 2.6 Hz, 1H), 7.83(dddd, J=9.0, 4.1, 2.6, 1.6 Hz, 1H), 7.71 (dt, J=10.4, 8.8 Hz, 1H), 5.47(d, J=0.6 Hz, 2H), 3.86 (s, 3H).

Example 600:5-Chloro-2-[[1-(3,4-difluorophenyl)triazol-4-yl]methoxy]pyrimidine

The title compound was prepared in a manner analogous to Example 1 using(1-(3,4-difluorophenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 39)and 2,5-dichloropyrimidine. MS (ESI): mass calcd. for C₁₃H₈ClF₂N₅O,323.0; m/z found, 324.0 [M+H]⁺. ¹H NMR (500 MHz, DMSO-d₆) δ 8.93 (s,1H), 8.77 (s, 2H), 8.13 (ddd, J=11.5, 7.0, 2.7 Hz, 1H), 7.83 (dtt,J=8.1, 2.6, 1.5 Hz, 1H), 7.71 (dt, J=10.4, 8.8 Hz, 1H), 5.54 (d, J=0.5Hz, 2H)

Example 601:2-[[1-(3,4-Difluorophenyl)triazol-4-yl]methoxy]-5-methyl-pyrimidine

The title compound was prepared in a manner analogous to Example 1 using(1-(3,4-difluorophenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 39)and 2-chloro-5-methylpyrimidine. MS (ESI): mass calcd. for C₁₄H₁₁F₂N₅O,303.1; m/z found, 304.1 [M+H]⁺. ¹H NMR (500 MHz, DMSO-d₆) δ 8.93 (d,J=0.6 Hz, 1H), 8.49 (d, J=0.8 Hz, 2H), 8.13 (ddd, J=11.5, 7.0, 2.7 Hz,1H), 7.83 (dddd, J=9.1, 4.1, 2.6, 1.6 Hz, 1H), 7.71 (dt, J=10.3, 8.8 Hz,1H), 5.49 (d, J=0.6 Hz, 2H), 2.21 (d, J=0.8 Hz, 3H).

Example 602:2-[[1-(3,4-Difluorophenyl)triazol-4-yl]methoxy]-5-ethyl-pyrimidine

The title compound was prepared in a manner analogous to Example 1 using(1-(3,4-difluorophenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 39)and 2-chloro-5-ethylpyrimidine. MS (ESI): mass calcd. for C₁₅H₁₃F₂N₅O,317.1; m/z found, 318.2 [M+H]⁺. ¹H NMR (500 MHz, DMSO-d₆) δ 8.93 (s,1H), 8.52 (d, J=0.6 Hz, 2H), 8.13 (ddd, J=11.5, 7.1, 2.7 Hz, 1H),7.87-7.80 (m, 1H), 7.71 (dt, J=10.4, 8.8 Hz, 1H), 5.50 (d, J=0.6 Hz,2H), 2.62-2.54 (m, 2H), 1.19 (t, J=7.6 Hz, 3H).

Example 603:2-[[1-(2,5-Difluorophenyl)triazol-4-yl]methoxy]-5-methyl-pyrimidine

The title compound was prepared in a manner analogous to Example 1 using(1-(2,5-difluorophenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 47)and 2-chloro-5-methylpyrimidine. MS (ESI): mass calcd. for C₁₄H₁₁F₂N₅O,303.1; m/z found, 304.1 [M+H]⁺. ¹H NMR (500 MHz, DMSO-d₆) δ 8.73 (s,1H), 8.49 (d, J=1.0 Hz, 2H), 7.85 (s, 1H), 7.66 (td, J=9.9, 4.9 Hz, 1H),7.51 (s, 1H), 5.50 (s, 2H), 2.21 (d, J=0.9 Hz, 3H).

Example 604:2-[2-[[1-(2,5-Difluorophenyl)triazol-4-yl]methoxy]pyrimidin-5-yl]propan-2-ol

The title compound was prepared in a manner analogous to Example 1 using(1-(2,5-difluorophenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 47)and 2-(2-chloropyrimidin-5-yl)propan-2-ol. MS (ESI): mass calcd. forC₁₆H₁₅F₂N₅O₂, 347.1; m/z found, 348.0 [M+H]⁺. ¹H NMR (500 MHz, DMSO-d₆)δ 8.73 (s, 1H), 8.69 (d, J=1.1 Hz, 1H), 7.92-7.81 (m, 1H), 7.66 (td,J=9.7, 4.6 Hz, 1H), 7.52 (d, J=8.5 Hz, 1H), 5.53 (s, 2H), 5.32 (s, 1H),1.47 (s, 6H).

Example 605:5-Chloro-2-[[1-(2,3-difluorophenyl)triazol-4-yl]methoxy]pyrimidine

The title compound was prepared in a manner analogous to Example 1 using(1-(2,3-difluorophenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 48)and 2,5-dichloropyrimidine. MS (ESI): mass calcd. for C₁₃H₈ClF₂N₅O,323.0; m/z found, 324.0 [M+H]⁺. ¹H NMR (500 MHz, DMSO-d₆) δ 8.86-8.66(m, 2H), 7.71 (s, 2H), 7.48 (s, 1H), 5.56 (d, J=1.5 Hz, 2H).

Example 606:2-[[1-(2,3-Difluorophenyl)triazol-4-yl]methoxy]-5-fluoro-pyrimidine

The title compound was prepared in a manner analogous to Example 1 using(1-(2,3-difluorophenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 48)and 2-chloro-5-fluoropyrimidine. MS (ESI): mass calcd. for C₁₃H₈F₃N₅O,307.1; m/z found, 308.0 [M+H]⁺. ¹H NMR (400 MHz, DMSO-d₆) δ 8.83-8.70(m, 3H), 7.69 (dddd, J=11.8, 8.9, 5.5, 1.6 Hz, 2H), 7.54-7.42 (m, 1H),5.54 (s, 2H).

Example 607: 2-[[1-(2,3-Difluorophenyl)triazol-4-yl]methoxy]pyrimidine

The title compound was prepared in a manner analogous to Example 1 using(1-(2,3-difluorophenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 48)and 2-chloropyrimidine. MS (ESI): mass calcd. for C₁₃H₉F₂N₅O, 289.1; m/zfound, 290.1 [M+H]⁺. ¹H NMR (400 MHz, DMSO-d₆) δ 8.77 (d, J=2.0 Hz, 1H),8.66 (d, J=4.8 Hz, 2H), 7.76-7.64 (m, 2H), 7.53-7.43 (m, 1H), 7.20 (t,J=4.8 Hz, 1H), 5.55 (s, 2H).

Example 608:2-[2-[[1-(2,3-Difluorophenyl)triazol-4-yl]methoxy]pyrimidin-5-yl]propan-2-ol

The title compound was prepared in a manner analogous to Example 1 using(1-(2,3-difluorophenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 48)and 2-(2-chloropyrimidin-5-yl)propan-2-ol. MS (ESI): mass calcd. forC₁₆H₁₅F₂N₅O₂, 347.1; m/z found, 348.2 [M+H]⁺. ¹H NMR (400 MHz, CD₃OD) δ8.70 (s, 2H), 8.58 (d, J=2.4 Hz, 1H), 7.68 (ddt, J=8.1, 6.3, 1.8 Hz,1H), 7.49 (dddd, J=10.1, 8.8, 7.3, 1.7 Hz, 1H), 7.40 (tdd, J=8.4, 5.2,2.0 Hz, 1H), 5.63 (d, J=2.5 Hz, 2H), 1.56 (d, J=2.7 Hz, 6H).

Example 609:2-[[1-(2,3-Difluorophenyl)triazol-4-yl]methoxy]-5-fluoro-4-methyl-pyrimidine

The title compound was prepared in a manner analogous to Example 1 using(1-(2,3-difluorophenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate 48)and 2-chloro-5-fluoro-4-methylpyrimidine. MS (ESI): mass calcd. forC₁₄H₁₀F₃N₅O, 321.1; m/z found, 322.1 [M+H]⁺. ¹H NMR (400 MHz, DMSO-d₆) δ8.92-8.50 (m, 2H), 7.79-7.63 (m, 2H), 7.48 (s, 1H), 5.49 (d, J=12.0 Hz,2H), 2.37 (s, 3H).

Example 610:2-[[1-(3-Chloro-2-fluoro-phenyl)triazol-4-yl]methoxy]-5-methyl-pyrimidine

The title compound was prepared in a manner analogous to Example 1 using(1-(3-chloro-2-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 46) and 2-chloro-5-methylpyrimidine. MS (ESI): mass calcd.for C₁₄H₁₁ClFN₅O, 319.1; m/z found, 320.0 [M+H]⁺. ¹H NMR (500 MHz,CD₃OD) δ 8.55 (d, J=2.5 Hz, 1H), 8.45 (t, J=0.8 Hz, 2H), 7.81 (ddd,J=8.2, 6.6, 1.6 Hz, 1H), 7.69 (ddd, J=8.3, 6.8, 1.6 Hz, 1H), 7.40 (td,J=8.2, 1.6 Hz, 1H), 5.60 (d, J=0.6 Hz, 2H), 2.27 (t, J=0.8 Hz, 3H).

Example 611:2-[[1-(3-Chloro-2-fluoro-phenyl)triazol-4-yl]methoxy]pyrimidine

The title compound was prepared in a manner analogous to Example 1 using(1-(3-chloro-2-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 46) and 2-chloropyrimidine. MS (ESI): mass calcd. forC₁₃H₉ClFN₅O, 305.0; m/z found, 306.0 [M+H]⁺. ¹H NMR (500 MHz, DMSO-d₆) δ8.78 (d, J=2.3 Hz, 1H), 8.67 (dd, J=4.8, 1.6 Hz, 2H), 7.92-7.79 (m, 2H),7.57-7.43 (m, 1H), 7.28-7.15 (m, 1H), 5.55 (d, J=1.5 Hz, 2H).

Example 612:5-Chloro-2-[[1-(3-chloro-2-fluoro-phenyl)triazol-4-yl]methoxy]pyrimidine

The title compound was prepared in a manner analogous to Example 1 using(1-(3-chloro-2-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 46) and 2,5-dichloropyrimidine. MS (ESI): mass calcd. forC₁₃H₈Cl₁₂FN₅O, 339.0; m/z found, 341.0 [M+H]⁺. ¹H NMR (500 MHz, DMSO-d₆)δ 8.78 (d, J=5.8 Hz, 2H), 7.84 (q, J=8.0, 7.6 Hz, 3H), 7.58-7.40 (m,1H), 5.56 (s, 2H)

Example 613:2-[[1-(3-Chloro-2-fluoro-phenyl)triazol-4-yl]methoxy]-5-fluoro-4-methyl-pyrimidine

The title compound was prepared in a manner analogous to Example 1 using(1-(3-chloro-2-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 46) and 2-chloro-5-fluoro-4-methylpyrimidine. MS (ESI):mass calcd. for C₁₄H₁₀ClF₂N₅O, 337.1; m/z found, 338.0 [M+H]⁺. ¹H NMR(500 MHz, DMSO-d₆) δ 8.76 (d, J=2.2 Hz, 1H), 8.57 (d, J=1.6 Hz, 1H),7.84 (dt, J=7.9, 6.4 Hz, 2H), 7.53-7.45 (m, 1H), 5.51 (s, 2H), 2.44 (d,J=2.6 Hz, 3H).

Example 614:2-[[1-(3-Chloro-2-fluoro-phenyl)triazol-4-yl]methoxy]-5-fluoro-pyrimidine

The title compound was prepared in a manner analogous to Example 1 using(1-(3-chloro-2-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 46) and 2-chloro-5-fluoropyrimidine. MS (ESI): mass calcd.for C₁₃H₈ClF₂N₅O, 323.0; m/z found, 324.0 [M+H]⁺. ¹H NMR (500 MHz,CD₃OD) δ 8.57 (d, J=4.1 Hz, 3H), 7.81 (ddd, J=8.2, 6.6, 1.7 Hz, 1H),7.69 (ddd, J=8.4, 6.7, 1.6 Hz, 1H), 7.41 (td, J=8.2, 1.7 Hz, 1H), 5.61(s, 2H).

Example 615:2-[2-[[1-(3-Chloro-2-fluoro-phenyl)triazol-4-yl]methoxy]pyrimidin-5-yl]propan-2-ol

The title compound was prepared in a manner analogous to Example 1 using(1-(3-chloro-2-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 46) and 2-(2-chloropyrimidin-5-yl)propan-2-ol. MS (ESI):mass calcd. for C₁₆H₁₅ClFN₅O₂, 363.1; m/z found, 364.1 [M+H]⁺. ¹H NMR(500 MHz, DMSO-d₆) δ 8.77 (d, J=2.1 Hz, 1H), 8.69 (s, 2H), 7.84 (dddd,J=11.7, 8.3, 6.8, 1.6 Hz, 2H), 7.48 (td, J=8.2, 1.5 Hz, 1H), 5.53 (s,2H), 5.32 (s, 1H), 1.46 (s, 6H).

Example 616:[2-[[1-(3-Bromo-4-fluoro-phenyl)triazol-4-yl]methoxy]pyrimidin-5-yl]methanol

The title compound was prepared analogous to Example 160, steps A-B,using (1-(3-bromo-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 14) in step A. MS (ESI): mass calcd. for C₁₄H₁₁BrFN₅O₂,379.0; m/z found, 380.0 [M+H]⁺. ¹H NMR (500 MHz, CDCl₃) δ 8.55 (s, 2H),8.09 (s, 1H), 7.98 (dd, J=5.8, 2.6 Hz, 1H), 7.66 (ddd, J=8.9, 4.0, 2.7Hz, 1H), 7.29-7.25 (m, 1H), 5.64 (d, J=0.7 Hz, 2H), 4.69 (s, 2H).

Example 617:[2-[[1-(3-Bromo-4-fluoro-phenyl)triazol-4-yl]methoxy]pyrimidin-4-yl]methanol

The title compound was prepared analogous to Example 159, steps A-B,using (1-(3-bromo-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 14) in step A. MS (ESI): mass calcd. for C₁₄H₁₁BrFN₅O₂,379.0; m/z found, 380.0 [M+H]⁺. ¹H NMR (500 MHz, CDCl₃) δ 8.51 (d, J=5.0Hz, 1H), 8.09 (s, 1H), 7.98 (dd, J=5.8, 2.7 Hz, 1H), 7.66 (ddd, J=8.8,4.0, 2.6 Hz, 1H), 7.29-7.26 (m, 1H), 7.02 (d, J=5.0 Hz, 1H), 5.66 (d,J=0.7 Hz, 2H), 4.75-4.70 (m, 2H), 3.25 (s, 1H).

Example 618:2-[[1-(3-Bromo-4-fluoro-phenyl)triazol-4-yl]methoxy]-5-(2-fluoroethoxy)pyrimidine

The title compound was prepared in a manner analogous to Example 192,Steps A-B, using1-(3-bromo-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol (Intermediate14) in Step B. MS (ESI): mass calcd. for C₁₅H₁₂BrF₂N₅O₂, 411.0; m/zfound, 412.0 [M+H]⁺. ¹H NMR (400 MHz, CD₃OD) δ 8.37 (s, 1H), 8.32 (s,2H), 8.09 (dd, J=5.8, 2.7 Hz, 1H), 7.78 (ddd, J=8.9, 4.2, 2.7 Hz, 1H),7.35 (dd, J=8.9, 7.9 Hz, 1H), 5.59 (s, 2H), 4.86-4.79 (m, 1H), 4.75-4.68(m, 1H), 4.38-4.32 (m, 1H), 4.31-4.25 (m, 1H).

Example 619:2-[[1-(3-Chloro-4-fluoro-phenyl)triazol-4-yl]methoxy]pyrimidine

The title compound was prepared analogous to Example 155, using(1-(3-chloro-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol and2-chloropyrimidine. MS (ESI): mass calcd. for C₁₃H₉ClFN₅O, 305.0; m/zfound, 306.0 [M+H]⁺. ¹H NMR (500 MHz, CDCl₃) δ 8.57 (d, J=4.7 Hz, 2H),8.11-8.06 (m, 1H), 7.84 (dd, J=6.2, 2.7 Hz, 1H), 7.62 (ddd, J=8.9, 4.0,2.7 Hz, 1H), 7.31 (t, J=8.6 Hz, 1H), 7.00 (t, J=4.8 Hz, 1H), 5.66 (d,J=0.7 Hz, 2H).

Example 620:2-[[1-(3-Chloro-4-fluoro-phenyl)triazol-4-yl]methoxy]-5-methyl-pyrimidine

The title compound was prepared analogous to Example 155, using(1-(3-chloro-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol and2-chloro-5-methylpyrimidine. MS (ESI): mass calcd. for C₁₄H₁₁ClFN₅O,319.1; m/z found, 320.0 [M+H]⁺. ¹H NMR (500 MHz, CDCl₃) δ 8.38 (d, J=0.7Hz, 2H), 8.07 (s, 1H), 7.84 (dd, J=6.3, 2.7 Hz, 1H), 7.61 (ddd, J=8.9,4.0, 2.7 Hz, 1H), 7.30 (t, J=8.6 Hz, 1H), 5.63 (d, J=0.7 Hz, 2H), 2.26(s, 3H).

Example 621:2-[[1-(3-Chloro-4-fluoro-phenyl)triazol-4-yl]methoxy]-5-ethyl-pyrimidine

The title compound was prepared analogous to Example 155, using(1-(3-chloro-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol and2-chloro-5-ethylpyrimidine. MS (ESI): mass calcd. for C₁₅H₁₃ClFN₅O,333.1; m/z found, 334.0 [M+H]⁺. ¹H NMR (500 MHz, CDCl₃) δ 8.39 (s, 2H),8.08 (s, 1H), 7.84 (dd, J=6.2, 2.7 Hz, 1H), 7.61 (ddd, J=8.9, 4.0, 2.7Hz, 1H), 7.30 (t, J=8.6 Hz, 1H), 5.63 (s, 2H), 2.60 (q, J=7.6 Hz, 2H),1.26 (t, J=7.6 Hz, 3H).

Example 622:2-[[1-(3-Chloro-4-fluoro-phenyl)triazol-4-yl]methoxy]-4-(methoxymethyl)pyrimidine

The title compound was prepared analogous to Example 155, using(1-(3-chloro-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol and2-chloro-4-(methoxymethyl)pyrimidine. MS (ESI): mass calcd. forC₁₅H₁₃ClFN₅O₂, 349.1; m/z found, 350.0 [M+H]⁺. ¹H NMR (500 MHz, CDCl₃) δ8.54 (d, J=5.0 Hz, 1H), 8.11 (s, 1H), 7.84 (dd, J=6.2, 2.7 Hz, 1H), 7.61(ddd, J=8.9, 3.9, 2.7 Hz, 1H), 7.30 (t, J=8.6 Hz, 1H), 7.15 (d, J=5.0Hz, 1H), 5.65 (s, 2H), 4.50 (s, 2H), 3.50 (s, 3H).

Example 623:2-[[1-[4-Chloro-3-(difluoromethyl)phenyl]triazol-4-yl]methoxy]-4-isopropyl-pyrimidine

The title compound was prepared analogous to Example 155, using(1-(4-chloro-3-(difluoromethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 8) and 2-chloro-4-isopropylpyrimidine. MS (ESI): masscalcd. for C₁₇H₁₆ClF₂N₅O, 379.1; m/z found, 380.1 [M+H]⁺. ¹H NMR (500MHz, CDCl₃) δ 8.43 (d, J=5.1 Hz, 1H), 8.18 (s, 1H), 8.00 (d, J=2.6 Hz,1H), 7.89-7.86 (m, 1H), 7.62-7.57 (m, 1H), 7.11-6.85 (m, 2H), 5.66 (s,2H), 2.97 (hept, J=6.9 Hz, 1H), 1.30 (d, J=6.9 Hz, 6H).

Example 624:[2-[[1-[4-Chloro-3-(difluoromethyl)phenyl]triazol-4-yl]methoxy]pyrimidin-5-yl]methanol

The title compound was prepared analogous to Example 160, steps A-B,using(1-(4-chloro-3-(difluoromethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 8) in step A. MS (ESI): mass calcd. for C₁₅H₁₂ClF₂N₅O₂,367.1; m/z found, 368.0 [M+H]⁺. ¹H NMR (500 MHz, CDCl₃) δ 8.58 (s, 2H),8.17 (s, 1H), 8.01 (d, J=2.6 Hz, 1H), 7.89 (dd, J=8.7, 2.6 Hz, 1H),7.66-7.56 (m, 1H), 6.99 (t, J=54.5 Hz, 1H), 5.68 (d, J=0.7 Hz, 2H), 4.71(d, J=5.6 Hz, 2H), 1.78 (t, J=5.5 Hz, 1H).

Example 625:[2-[[1-[4-Chloro-3-(difluoromethyl)phenyl]triazol-4-yl]methoxy]pyrimidin-4-yl]methanol

The title compound was prepared analogous to Example 159, Steps A-B,using(1-(4-chloro-3-(difluoromethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 8) in Step A. MS (ESI): mass calcd. for C₅H₁₂ClF₂N₅O₂,367.1; m/z found, 368.0 [M+H]⁺. ¹H NMR (500 MHz, CDCl₃) δ 8.51 (d, J=5.0Hz, 1H), 8.19 (s, 1H), 8.00 (d, J=2.6 Hz, 1H), 7.92-7.83 (m, 1H),7.64-7.56 (m, 1H), 7.11-6.85 (m, 2H), 5.67 (s, 2H), 4.72 (s, 2H).

Example 626:2-[2-[[1-[4-Chloro-3-(difluoromethyl)phenyl]triazol-4-yl]methoxy]pyrimidin-5-yl]propan-2-ol

The title compound was prepared analogous to Example 155, using(1-(4-chloro-3-(difluoromethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 8) and 2-(2-chloropyrimidin-5-yl)propan-2-ol. MS (ESI):mass calcd. for C₁₇H₁₆ClF₂N₅O₂, 395.1; m/z found, 396.0 [M+H]⁺. ¹H NMR(400 MHz, CDCl₃) δ 8.66 (s, 2H), 8.19 (s, 1H), 8.01 (d, J=2.6 Hz, 1H),7.88 (dd, J=8.7, 2.6 Hz, 1H), 7.60 (dd, J=8.6, 1.2 Hz, 1H), 6.98 (t,J=54.5 Hz, 1H), 5.65-5.63 (m, 2H), 1.61 (s, 6H).

Example 627:2-[[1-[4-Chloro-3-(difluoromethyl)phenyl]triazol-4-yl]methoxy]-4-(methoxymethyl)pyrimidine

The title compound was prepared analogous to Example 155, using(1-(4-chloro-3-(difluoromethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 8) and 2-chloro-4-(methoxymethyl)pyrimidine. MS (ESI):mass calcd. for C₁₆H₁₄ClF₂N₅O₂, 381.1; m/z found, 382.0 [M+H]⁺. ¹H NMR(400 MHz, CDCl₃) δ 8.55 (d, J=5.0 Hz, 1H), 8.21 (s, 1H), 8.00 (d, J=2.6Hz, 1H), 7.91-7.86 (m, 1H), 7.63-7.58 (m, 1H), 7.15 (d, J=5.0 Hz, 1H),6.99 (t, J=54.5 Hz, 1H), 5.66 (s, 2H), 4.50 (s, 2H), 3.50 (s, 3H).

Example 628:2-[[1-[4-Chloro-3-(difluoromethyl)phenyl]triazol-4-yl]methoxy]-4-(difluoromethyl)pyrimidine

The title compound was prepared analogous to Example 155, using(1-(4-chloro-3-(difluoromethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 8) and 2-chloro-4-difluoromethylpyrimidine. MS (ESI): masscalcd. for C₁₅H₁₀ClF₄N₅O, 387.1; m/z found, 388.0 [M+H]⁺. ¹H NMR (400MHz, CDCl₃) δ 8.76 (d, J=4.9 Hz, 1H), 8.20 (s, 1H), 8.01 (d, J=2.6 Hz,1H), 7.91-7.85 (m, 1H), 7.64-7.57 (m, 1H), 7.30 (d, J=4.9 Hz, 1H), 6.99(t, J=54.5 Hz, 1H), 6.50 (t, J=54.7 Hz, 1H), 5.71 (d, J=0.6 Hz, 2H).

Example 629:2-[[1-[4-Chloro-3-(difluoromethyl)phenyl]triazol-4-yl]methoxy]-N,N-dimethyl-pyrimidin-4-amine

The title compound was prepared analogous to Example 155, using(1-(4-chloro-3-(difluoromethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 8) and 2-chloro-N,N-dimethylpyrimidin-4-amine. MS (ESI):mass calcd. for C₁₆H₁₅ClF₂N₆O, 380.1; m/z found, 381.0 [M+H]⁺. ¹H NMR(400 MHz, CDCl₃) δ 8.15 (s, 1H), 8.06-7.98 (m, 2H), 7.91-7.82 (m, 1H),7.60 (dt, J=8.7, 1.2 Hz, 1H), 6.99 (t, J=54.6 Hz, 1H), 6.13 (d, J=6.1Hz, 1H), 5.61 (d, J=0.8 Hz, 2H), 3.11 (s, 6H).

Example 630:2-[[1-[4-Chloro-3-(difluoromethyl)phenyl]triazol-4-yl]methoxy]-5-cyclopropyl-pyrimidine

The title compound was prepared analogous to Example 155, using(1-(4-chloro-3-(difluoromethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 8) and 2-chloro-5-cyclopropylpyrimidine. MS (ESI): masscalcd. for C₁₇H₁₄ClF₂N₅O, 377.1; m/z found, 378.0 [M+H]⁺. ¹H NMR (500MHz, CDCl₃) δ 8.32 (s, 2H), 8.16 (s, 1H), 8.00 (d, J=2.6 Hz, 1H),7.91-7.87 (m, 1H), 7.64-7.58 (m, 1H), 6.99 (t, J=54.5 Hz, 1H), 5.64 (s,2H), 1.83 (tt, J=8.4, 5.1 Hz, 1H), 1.02 (ddd, J=8.3, 6.4, 4.8 Hz, 2H),0.70 (ddd, J=7.3, 5.7, 4.4 Hz, 2H).

Example 631:2-[[1-[4-Chloro-3-(difluoromethyl)phenyl]triazol-4-yl]methoxy]-4-cyclopropyl-pyrimidine

The title compound was prepared analogous to Example 155, using(1-(4-chloro-3-(difluoromethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 8) and 2-chloro-4-cyclopropylpyrimidine. MS (ESI): masscalcd. for C₁₇H₁₄ClF₂N₅O, 377.1; m/z found, 378.0 [M+H]⁺. ¹H NMR (500MHz, CDCl₃) δ 8.32-8.29 (m, 1H), 8.16-8.12 (m, 1H), 8.02-7.98 (m, 1H),7.89-7.84 (m, 1H), 7.60 (dd, J=8.5, 1.2 Hz, 1H), 7.10-6.84 (m, 2H), 5.60(s, 2H), 2.00-1.90 (m, 1H), 1.22-1.16 (m, 2H), 1.08 (ddd, J=6.7, 3.0,1.6 Hz, 2H).

Example 632:2-[[1-[4-chloro-3-(difluoromethyl)phenyl]triazol-4-yl]methoxy]-5-methyl-pyrimidin-4-amine

The title compound was prepared in a manner analogous to Example 161,using(1-(4-chloro-3-(difluoromethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 8). (ESI): mass calcd. for C₁₅H₁₃ClF₂N₆O, 366.1; m/zfound, 366.9 [M+H]⁺. ¹H NMR (500 MHz, CDCl₃) δ 8.15 (d, J=1.2 Hz, 1H),8.00 (d, J=2.6 Hz, 1H), 7.92-7.84 (m, 2H), 7.62-7.56 (m, 1H), 6.98 (t,J=54.6 Hz, 1H), 5.60-5.54 (m, 2H), 4.91 (s, 2H), 2.07-2.01 (m, 3H).

Example 633:2-[[1-[4-Chloro-3-(difluoromethyl)phenyl]triazol-4-yl]methoxy]-N,N,5-trimethyl-pyrimidin-4-amine

The title compound was prepared analogous to Example 155, using(1-(4-chloro-3-(difluoromethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 8) and 2-chloro-N,N,5-trimethylpyrimidin-4-amine. MS(ESI): mass calcd. for C₁₇H₁₇ClF₂N₅O, 394.1; m/z found, 395.1 [M+H]⁺. ¹HNMR (400 MHz, CDCl₃) δ 8.14 (s, 1H), 8.04-7.97 (m, 1H), 7.90-7.80 (m,2H), 7.62-7.56 (m, 1H), 6.99 (t, J=54.6 Hz, 1H), 5.59 (s, 2H), 3.13 (s,6H), 2.25 (s, 3H).

Example 634:2-[[1-[4-Chloro-3-(difluoromethyl)phenyl]triazol-4-yl]methoxy]-4-pyrrolidin-1-yl-pyrimidine

The title compound was prepared analogous to Example 155, using(1-(4-chloro-3-(difluoromethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 8) and 2-chloro-4-(pyrrolidin-1-yl)pyrimidine. MS (ESI):mass calcd. for C₁₈H₁₇ClF₂N₆O, 406.1; m/z found, 407.0 [M+H]⁺. ¹H NMR(400 MHz, CDCl₃) δ 8.15 (s, 1H), 8.03-7.98 (m, 2H), 7.90-7.84 (m, 1H),7.60 (dt, J=8.6, 1.2 Hz, 1H), 6.99 (t, J=54.6 Hz, 1H), 6.00 (d, J=6.0Hz, 1H), 5.61 (d, J=0.8 Hz, 2H), 3.62 (s, 2H), 3.35 (s, 2H), 2.00 (s,4H).

Example 635:2-[[1-[4-Chloro-3-(difluoromethyl)phenyl]triazol-4-yl]methoxy]-4-(1-piperidyl)pyrimidine

The title compound was prepared analogous to Example 155, using(1-(4-chloro-3-(difluoromethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 8) and 2-chloro-4-(piperidin-1-yl)pyrimidine. MS (ESI):mass calcd. for C₁₉H₁₉ClF₂N₆O, 420.1; m/z found, 421.0 [M+H]⁺. ¹H NMR(400 MHz, CDCl₃) δ 8.15 (s, 1H), 8.06-7.96 (m, 2H), 7.91-7.80 (m, 1H),7.68-7.52 (m, 1H), 6.98 (t, J=54.6 Hz, 1H), 6.19 (d, J=6.1 Hz, 1H), 5.58(s, 2H), 3.73-3.48 (m, 4H), 1.73-1.56 (m, 6H).

Example 636:2-[[1-[4-Chloro-3-(difluoromethyl)phenyl]triazol-4-yl]methoxy]-5-(2-fluoroethoxy)pyrimidine

The title compound was prepared in a manner analogous to Example 192,Steps A-B, using(1-(4-chloro-3-(difluoromethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 8) in Step B. MS (ESI): mass calcd. for C₁₆H₁₃ClF₃N₅O₂,399.1; m/z found, 400.1 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃) δ 8.29 (s, 2H),8.16 (s, 1H), 8.01 (d, J=2.5 Hz, 1H), 7.89 (dd, J=8.7, 2.7 Hz, 1H), 7.61(d, J=8.7 Hz, 1H), 6.99 (t, J=54.5 Hz, 1H), 5.62 (d, J=0.7 Hz, 2H),4.90-4.77 (m, 1H), 4.76-4.66 (m, 1H), 4.37-4.27 (m, 1H), 4.27-4.18 (m,1H). ¹⁹F NMR (376 MHz, CDCl₃) δ −115.87 (s), −116.02 (s).

Example 637:2-[[1-[4-Chloro-3-(difluoromethyl)phenyl]triazol-4-yl]methoxy]-5-(3-fluoropropyl)pyrimidine

The title compound was prepared in a manner analogous to Example 196,Steps A-G, using(1-(4-chloro-3-(difluoromethyl)phenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 8) in step G. MS (ESI): mass calcd. for C₁₇H₁₅ClF₃N₅O,397.1; m/z found, 398.1 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃) δ 8.42 (s, 2H),8.18 (s, 1H), 8.01 (d, J=2.7 Hz, 1H), 7.92-7.86 (m, 1H), 7.61 (d, J=8.7Hz, 1H), 6.99 (t, J=54.5 Hz, 1H), 5.65 (d, J=0.7 Hz, 1H), 4.55 (t, J=5.7Hz, 0H), 4.43 (t, J=5.7 Hz, 0H), 2.78-2.63 (m, 1H), 2.10-1.92 (m, 1H)

Example 638:2-((1-(4-(Azetidin-1-yl)-3-(difluoromethyl)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)-5-methylpyrimidine

Made in an analogous manner to Example 188 using2-((1-(3-(difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-5-methylpyrimidine(Example 51). MS (ESI): mass calcd. for C₁₈H₁₈F₂N₅O, 372.3; m/z found,373.1 [M+H]⁺. ¹H NMR (500 MHz, CDCl₃) δ 8.41-8.34 (d, J=0.9 Hz, 2H),8.05-8.00 (s, 1H), 7.74-7.70 (d, J=2.5 Hz, 1H), 7.67-7.62 (m, 1H),6.91-6.64 (m, 1H), 6.58-6.51 (d, J=8.8 Hz, 1H), 5.64-5.58 (d, J=0.6 Hz,2H), 4.15-4.07 (m, 4H), 2.45-2.35 (m, 2H), 2.29-2.21 (m, 3H).

Example 639:2-[[1-(2,4-Difluoro-3-methyl-phenyl)triazol-4-yl]methoxy]-5-isopropyl-pyrimidine

The title compound was prepared analogous to Example 155, using(1-(2,4-difluoro-3-methylphenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 10) and 2-chloro-5-isopropylpyrimidine. MS (ESI): masscalcd. for C₁₇H₁₇F₂N₅O, 345.1; m/z found, 346.0 [M+H]⁺. ¹H NMR (400 MHz,CDCl₃) δ 8.42 (s, 2H), 8.14 (d, J=2.8 Hz, 1H), 7.74-7.65 (m, 1H), 7.02(td, J=8.8, 1.8 Hz, 1H), 5.65 (d, J=0.7 Hz, 2H), 2.91 (hept, J=6.8 Hz,1H), 2.30 (t, J=2.0 Hz, 3H), 1.29 (d, J=7.0 Hz, 6H).

Example 640:2-[[1-(2,4-Difluoro-3-methyl-phenyl)triazol-4-yl]methoxy]-4-isopropyl-pyrimidine

The title compound was prepared analogous to Example 155, using(1-(2,4-difluoro-3-methylphenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 10) and 2-chloro-4-isopropylpyrimidine. MS (ESI): masscalcd. for C₁₇H₁₇F₂N₅O, 345.1; m/z found, 346.0 [M+H]⁺. ¹H NMR (500 MHz,CDCl₃) δ 8.42 (d, J=5.1 Hz, 1H), 8.13 (d, J=2.9 Hz, 1H), 7.71-7.64 (m,1H), 7.04-6.97 (m, 1H), 6.85 (d, J=5.1 Hz, 1H), 5.66 (d, J=0.7 Hz, 2H),2.95 (hept, J=6.9 Hz, 1H), 2.28 (t, J=2.0 Hz, 3H), 1.28 (d, J=6.9 Hz,6H).

Example 641:5-(Difluoromethyl)-2-[[1-(2,4-difluoro-3-methyl-phenyl)triazol-4-yl]methoxy]pyrimidine

The title compound was prepared analogous to Example 155, using(1-(2,4-difluoro-3-methylphenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 10) and 2-chloro-5-difluoromethylpyrimidine. MS (ESI):mass calcd. for C₁₅H₁₁F₄N₅O, 353.1; m/z found, 354.0 [M+H]⁺. ¹H NMR (400MHz, CDCl₃) δ 8.71 (t, J=1.2 Hz, 2H), 8.15 (d, J=2.8 Hz, 1H), 7.74-7.66(m, 1H), 7.03 (td, J=8.6, 1.8 Hz, 1H), 6.72 (t, J=55.6 Hz, 1H), 5.72 (s,2H), 2.30 (t, J=2.1 Hz, 3H).

Example 642:4-(Difluoromethyl)-2-[[1-(2,4-difluoro-3-methyl-phenyl)triazol-4-yl]methoxy]pyrimidine

The title compound was prepared analogous to Example 155, using(1-(2,4-difluoro-3-methylphenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 10) and 2-chloro-4-difluoromethylpyrimidine. MS (ESI):mass calcd. for C₁₅H₁₁F₄N₅O, 353.1; m/z found, 354.0 [M+H]⁺. ¹H NMR (400MHz, CDCl₃) δ 8.75 (d, J=4.9 Hz, 1H), 8.16 (d, J=2.8 Hz, 1H), 7.75-7.64(m, 1H), 7.29 (d, J=4.9 Hz, 1H), 7.10-6.96 (m, 1H), 6.49 (t, J=54.7 Hz,1H), 5.71 (s, 2H), 2.30 (t, J=2.1 Hz, 3H).

Example 643:2-[[1-(2,4-Difluoro-3-methyl-phenyl)triazol-4-yl]methoxy]-5-(trifluoromethyl)pyrimidine

The title compound was prepared analogous to Example 155, using(1-(2,4-difluoro-3-methylphenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 10) and 2-chloro-5-trifluoromethylpyrimidine. MS (ESI):mass calcd. for C₁₅H₁₀F₅N₅O, 371.1; m/z found, 372.0 [M+H]⁺. ¹H NMR (400MHz, CDCl₃) δ 8.81 (d, J=0.9 Hz, 2H), 8.16 (d, J=2.8 Hz, 1H), 7.70 (td,J=8.7, 5.6 Hz, 1H), 7.03 (td, J=8.7, 1.8 Hz, 1H), 5.74 (s, 2H), 2.30 (t,J=2.1 Hz, 3H).

Example 644:2-[2-[[1-(2,4-Difluoro-3-methyl-phenyl)triazol-4-yl]methoxy]pyrimidin-5-yl]propan-2-ol

The title compound was prepared analogous to Example 155, using(1-(2,4-difluoro-3-methylphenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 10) and 2-(2-chloropyrimidin-5-yl)propan-2-ol. MS (ESI):mass calcd. for C₁₇H₁₇F₂N₅O₅₂, 361.1; m/z found, 362.1 [M+H]⁺. ¹H NMR(400 MHz, CDCl₃) δ 8.67 (s, 2H), 8.14 (d, J=2.8 Hz, 1H), 7.69 (td,J=8.6, 5.7 Hz, 1H), 7.02 (td, J=8.7, 1.9 Hz, 1H), 5.67 (s, 2H), 2.30 (s,3H), 1.62 (s, 6H).

Example 645:2-[[1-(2,4-Difluoro-3-methyl-phenyl)triazol-4-yl]methoxy]-4-(methoxymethyl)pyrimidine

The title compound was prepared analogous to Example 155, using(1-(2,4-difluoro-3-methylphenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 10) and 2-chloro-4-(methoxymethyl)pyrimidine. MS (ESI):mass calcd. for C₁₅H₁₅F₂N₅O₂, 347.1; m/z found, 348.0 [M+H]⁺. ¹H NMR(400 MHz, CDCl₃) δ 8.54 (d, J=5.0 Hz, 1H), 8.14 (d, J=2.8 Hz, 1H), 7.68(dddd, J=9.1, 8.4, 5.7, 0.8 Hz, 1H), 7.14 (dt, J=5.0, 0.7 Hz, 1H), 7.01(td, J=8.7, 1.8 Hz, 1H), 5.65 (d, J=0.7 Hz, 2H), 4.49 (d, J=0.7 Hz, 2H),3.49 (s, 3H), 2.29 (t, J=2.1 Hz, 3H).

Example 646:5-(Difluoromethoxy)-2-[[1-(2,4-difluoro-3-methyl-phenyl)triazol-4-yl]methoxy]pyrimidine

The title compound was prepared analogous to Example 155, using(1-(2,4-difluoro-3-methylphenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 10) and 2-chloro-5-(difluoromethoxy)pyrimidine. MS (ESI):mass calcd. for C₁₅H₁₁F₄N₅O₂, 369.1; m/z found, 370.1 [M+H]⁺. ¹H NMR(400 MHz, CDCl₃) δ 8.44 (s, 2H), 8.14 (d, J=2.7 Hz, 1H), 7.74-7.65 (m,1H), 7.02 (td, J=8.7, 1.8 Hz, 1H), 6.52 (t, J=71.9 Hz, 1H), 5.66 (d,J=0.6 Hz, 2H), 2.30 (t, J=2.1 Hz, 3H).

Example 647:5-Cyclopropyl-2-[[1-(2,4-difluoro-3-methyl-phenyl)triazol-4-yl]methoxy]pyrimidine

The title compound was prepared analogous to Example 155, using(1-(2,4-difluoro-3-methylphenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 10) and 2-chloro-5-cyclopropylpyrimidine. MS (ESI): masscalcd. for C₁₇H₁₅F₂N₅O, 343.1; m/z found, 344.1 [M+H]⁺. ¹H NMR (500 MHz,CDCl₃) δ 8.31 (s, 2H), 8.12 (d, J=2.8 Hz, 1H), 7.68 (td, J=8.7, 5.7 Hz,1H), 7.01 (td, J=8.7, 1.8 Hz, 1H), 5.63 (s, 2H), 2.29 (t, J=2.0 Hz, 3H),1.82 (tt, J=8.4, 5.1 Hz, 1H), 1.01 (ddd, J=8.4, 6.4, 4.9 Hz, 2H),0.72-0.66 (m, 2H).

Example 648:4-Cyclopropyl-2-[[1-(2,4-difluoro-3-methyl-phenyl)triazol-4-yl]methoxy]pyrimidine

The title compound was prepared analogous to Example 155, using(1-(2,4-difluoro-3-methylphenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 10) and 2-chloro-4-cyclopropylpyrimidine. MS (ESI): masscalcd. for C₁₇H₁₅F₂N₅O, 343.1; m/z found, 344.1 [M+H]⁺. ¹H NMR (500 MHz,CDCl₃) δ 8.29 (d, J=5.1 Hz, 1H), 8.10 (d, J=2.7 Hz, 1H), 7.68 (td,J=8.7, 5.7 Hz, 1H), 7.01 (td, J=8.7, 1.8 Hz, 1H), 6.85 (d, J=5.1 Hz,1H), 5.60 (s, 2H), 2.29 (t, J=2.1 Hz, 3H), 1.94 (tt, J=8.1, 4.6 Hz, 1H),1.22-1.16 (m, 2H), 1.10-1.03 (m, 2H).

Example 649:2-[[1-(2,4-Difluoro-3-methyl-phenyl)triazol-4-yl]methoxy]-5-fluoro-4-methyl-pyrimidine

The title compound was prepared analogous to Example 155, using(1-(2,4-difluoro-3-methylphenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 10) and 2-chloro-5-fluoro-4-methylpyrimidine. MS (ESI):mass calcd. for C₁₅H₁₂F₃N₅O, 335.1; m/z found, 336.0 [M+H]⁺. ¹H NMR (400MHz, CDCl₃) δ 8.25 (d, J=1.2 Hz, 1H), 8.13 (d, J=2.7 Hz, 1H), 7.76-7.64(m, 1H), 7.06-6.95 (m, 1H), 5.67-5.57 (m, 2H), 2.49 (d, J=2.5 Hz, 3H),2.30 (t, J=2.0 Hz, 3H).

Example 650:5-Chloro-2-[[1-(2,4-difluoro-3-methyl-phenyl)triazol-4-yl]methoxy]-4-methyl-pyrimidine

The title compound was prepared analogous to Example 155, using(1-(2,4-difluoro-3-methylphenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 10) and 2,5-dichloro-4-methylpyrimidine. MS (ESI): masscalcd. for C₁₅H₁₂ClF₂N₅O, 351.1; m/z found, 352.0 [M+H]⁺. ¹H NMR (400MHz, CDCl₃) δ 8.38 (s, 1H), 8.13 (d, J=2.6 Hz, 1H), 7.76-7.63 (m, 1H),7.06-6.99 (m, 1H), 5.66-5.60 (m, 2H), 2.56 (s, 3H), 2.30 (t, J=2.0 Hz,3H).

Example 651:2-[[1-(2,4-Difluoro-3-methyl-phenyl)triazol-4-yl]methoxy]-5-methyl-pyrimidin-4-amine

The title compound was prepared in a manner analogous to Example 161,using (1-(2,4-difluoro-3-methylphenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 10). MS (ESI): mass calcd. for C₁₅H₁₄F₂N₆O, 332.1; m/zfound, 333.1 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD) δ 8.46 (d, J=2.3 Hz, 1H),7.72 (s, 1H), 7.65 (td, J=8.6, 5.6 Hz, 1H), 7.15 (td, J=8.8, 1.8 Hz,1H), 5.46 (s, 2H), 2.30 (t, J=2.0 Hz, 3H), 1.99 (s, 3H).

Example 652:2-[[1-[3-(Difluoromethyl)-2,4-difluoro-phenyl]triazol-4-yl]methoxy]-5-(trifluoromethyl)pyrimidine

Step A.1-(3-(Difluoromethyl)-2,4-difluorophenyl)-1H-1,2,3-triazol-4-yl)methanol

The title compound was prepared in a manner analogous to Intermediate 5using 3-(difluoromethyl)-2,4-difluoroaniline in step A, and1-azido-3-(difluoromethyl)-2,4-difluorobenzene and a reactiontemperature of 60° C. in step B.

Step B.2-[[1-[3-(Difluoromethyl)-2,4-difluoro-phenyl]triazol-4-yl]methoxy]-5-(trifluoromethyl)pyrimidine

The title compound was prepared analogous to Example 155, using(1-(3-(difluoromethyl)-2,4-difluorophenyl)-1H-1,2,3-triazol-4-yl)methanoland 2-chloro-5-trifluoromethylpyrimidine. MS (ESI): mass calcd. forC₁₅H₆F₇N₅O, 407.1; m/z found, 408.0 [M+H]⁺. ¹H NMR (500 MHz, CDCl₃) δ8.82 (s, 2H), 8.22 (d, J=2.7 Hz, 1H), 8.14-8.05 (m, 1H), 7.24-7.16 (m,1H), 7.00 (t, J=52.9 Hz, 1H), 5.74 (s, 2H).

Example 653:5-Chloro-2-[[1-(2,4-difluoro-5-methyl-phenyl)triazol-4-yl]methoxy]pyrimidine

The title compound was prepared analogous to Example 155, using(1-(2,4-difluoro-5-methylphenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 13) and 2,5-dichloropyrimidine. MS (ESI): mass calcd. forC₁₄H₁₀ClF₂N₅O, 337.1; m/z found, 338.0 [M+H]⁺. ¹H NMR (500 MHz, CDCl₃) δ8.49 (s, 2H), 8.14 (d, J=2.5 Hz, 1H), 7.77 (t, J=8.0 Hz, 1H), 7.00 (t,J=9.7 Hz, 1H), 5.63 (s, 2H), 2.32 (s, 3H).

Example 654:2-[[1-(2,4-Difluoro-5-methyl-phenyl)triazol-4-yl]methoxy]-5-methyl-pyrimidine

The title compound was prepared analogous to Example 155, using(1-(2,4-difluoro-5-methylphenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 13) and 2-chloro-5-methylpyrimidine. MS (ESI): mass calcd.for C₁₅H₁₃F₂N₅O, 317.1; m/z found, 318.1 [M+H]⁺. ¹H NMR (500 MHz, CDCl₃)δ 8.37 (s, 2H), 8.14 (d, J=2.7 Hz, 1H), 7.77 (t, J=8.0 Hz, 1H), 6.99(dd, J=10.6, 8.9 Hz, 1H), 5.63 (s, 2H), 2.32 (s, 3H), 2.25 (s, 3H).

Example 655:2-[[1-(2,4-Difluoro-5-methyl-phenyl)triazol-4-yl]methoxy]-5-ethyl-pyrimidine

The title compound was prepared analogous to Example 155, using(1-(2,4-difluoro-5-methylphenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 13) and 2-chloro-5-ethylpyrimidine. MS (ESI): mass calcd.for C₁₆H₁₅F₂N₅O, 331.1; m/z found, 332.1 [M+H]⁺. ¹H NMR (500 MHz, CDCl₃)δ 8.38 (s, 2H), 8.14 (d, J=2.8 Hz, 1H), 7.80-7.74 (m, 1H), 6.98 (dd,J=10.6, 8.9 Hz, 1H), 5.63 (d, J=0.6 Hz, 2H), 2.59 (q, J=7.6 Hz, 2H),2.36-2.25 (m, 3H), 1.25 (t, J=7.6 Hz, 3H).

Example 656:5-(Difluoromethyl)-2-[[1-(2,4-difluoro-5-methyl-phenyl)triazol-4-yl]methoxy]pyrimidine

The title compound was prepared analogous to Example 155, using(1-(2,4-difluoro-5-methylphenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 13) and 2-chloro-5-difluoromethylpyrimidine. MS (ESI):mass calcd. for C₁₅H₁₁F₄N₅O, 353.1; m/z found, 354.0 [M+H]⁺. ¹H NMR (500MHz, CDCl₃) δ 8.70 (s, 2H), 8.16 (d, J=2.7 Hz, 1H), 7.77 (t, J=7.5 Hz,1H), 7.00 (dd, J=10.7, 8.9 Hz, 1H), 6.72 (t, J=55.6 Hz, 1H), 5.71 (d,J=0.7 Hz, 2H), 2.37-2.26 (m, 3H).

Example 657:5-Chloro-2-[[1-(2,4-difluoro-5-methyl-phenyl)triazol-4-yl]methoxy]-4-methyl-pyrimidine

The title compound was prepared analogous to Example 155, using(1-(2,4-difluoro-5-methylphenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 13) and 2,5-dichloro-4-methylpyrimidine. MS (ESI): masscalcd. for C₁₅H₁₂ClF₂N₅O, 351.1; m/z found, 352.0 [M+H]⁺. ¹H NMR (500MHz, CDCl₃) δ 8.36 (s, 1H), 8.14 (d, J=2.7 Hz, 1H), 7.82-7.70 (m, 1H),6.99 (dd, J=10.6, 8.9 Hz, 1H), 5.62 (s, 2H), 2.55 (s, 3H), 2.33-2.29 (m,3H).

Example 658:5-Cyclopropyl-2-[[1-(2,4-difluoro-5-methyl-phenyl)triazol-4-yl]methoxy]pyrimidine

The title compound was prepared analogous to Example 155, using(1-(2,4-difluoro-5-methylphenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 13) and 2-chloro-5-cyclopropylpyrimidine. MS (ESI): masscalcd. for C₁₇H₁₅F₂N₅O, 343.1; m/z found, 344.1 [M+H]⁺. ¹H NMR (500 MHz,CDCl₃) δ 8.31 (s, 2H), 8.14 (d, J=2.7 Hz, 1H), 7.77 (t, J=7.8 Hz, 1H),6.99 (dd, J=10.6, 8.9 Hz, 1H), 5.63 (s, 2H), 2.33-2.31 (m, 3H), 1.82(tt, J=8.5, 5.2 Hz, 1H), 1.04-0.99 (m, 2H), 0.69 (dt, J=6.4, 4.9 Hz, 2H)

Example 659:5-Chloro-2-[[1-(6-methyl-2-pyridyl)triazol-4-yl]methoxy]pyrimidine

The title compound was prepared in a manner analogous to Example 174,steps A-C, using 2,5-dichloropyrimidine in step C. MS (ESI): mass calcd.for C₁₃H₁₁ClN₅O, 302.1; m/z found, 303.0 [M+H]⁺. ¹H NMR (500 MHz, CDCl₃)δ 8.71 (s, 1H), 8.49 (s, 2H), 7.96 (d, J=8.1 Hz, 1H), 7.77 (t, J=7.8 Hz,1H), 7.18 (d, J=7.6 Hz, 1H), 5.64 (d, J=0.7 Hz, 2H), 2.57 (s, 3H).

Example 660:5-Ethyl-2-[[1-(6-methyl-2-pyridyl)triazol-4-yl]methoxy]pyrimidine

The title compound was prepared in a manner analogous to Example 174,steps A-C, using 2-chloro-5-ethylpyrimidine in step C. MS (ESI): masscalcd. for C₁₅H₁₆N₆O, 296.1; m/z found, 297.1 [M+H]⁺. ¹H NMR (400 MHz,CDCl₃) δ 8.71 (s, 1H), 8.39 (d, J=0.6 Hz, 2H), 7.96 (d, J=8.1 Hz, 1H),7.76 (t, J=7.8 Hz, 1H), 7.17 (d, J=7.5 Hz, 1H), 5.64 (d, J=0.7 Hz, 2H),2.65-2.53 (m, 5H), 1.25 (t, J=7.6 Hz, 3H).

Example 661:5-Chloro-4-methyl-2-[[1-(6-methyl-2-pyridyl)triazol-4-yl]methoxy]pyrimidine

The title compound was prepared in a manner analogous to Example 174,Steps A-C, using 2,5-dichloro-4-methylpyrimidine in Step C. MS (ESI):mass calcd. for C₁₄H₁₃ClN₆O, 316.1; m/z found, 317.1 [M+H]⁺. ¹H NMR (500MHz, CDCl₃) δ 8.71 (s, 1H), 8.38 (s, 1H), 7.97 (d, J=8.1 Hz, 1H), 7.77(t, J=7.8 Hz, 1H), 7.18 (d, J=7.3 Hz, 1H), 5.63 (d, J=0.7 Hz, 2H), 2.57(s, 3H), 2.56 (s, 3H).

Example 662:5-Methyl-2-[[1-(4-methyl-2-pyridyl)triazol-4-yl]methoxy]pyrimidine

The title compound was prepared analogous to Example 174, steps A-C,using 4-methylpyridine N-oxide in Step A,7-methyltetriazolo[1,5-a]pyridine in Step B, and(1-(4-methylpyridin-2-yl)-1H-1,2,3-triazol-4-yl)methanol in Step C. MS(ESI): mass calcd. for C₁₄H₁₄N₆O, 282.1; m/z found, 283.0 [M+H]⁺. ¹H NMR(500 MHz, CDCl₃) δ 8.66 (s, 1H), 8.37 (s, 2H), 8.32 (d, J=5.0 Hz, 1H),8.04-7.98 (m, 1H), 7.17-7.12 (m, 1H), 5.63 (s, 2H), 2.47 (s, 3H), 2.24(s, 3H).

Example 663:5-Ethyl-2-[[1-(4-methyl-2-pyridyl)triazol-4-yl]methoxy]pyrimidine

The title compound was prepared analogous to Example 174, Steps A-C,using 4-methylpyridine N-oxide in Step A,7-methyltetriazolo[1,5-a]pyridine in Step B, and(1-(4-methylpyridin-2-yl)-1H-1,2,3-triazol-4-yl)methanol and2-chloro-5-ethylpyrimidine in Step C. MS (ESI): mass calcd. forC₁₅H₁₆N₆O, 296.1; m/z found, 297.1 [M+H]⁺. ¹H NMR (500 MHz, CDCl₃) δ8.69-8.64 (m, 1H), 8.40-8.37 (m, 2H), 8.33 (d, J=5.0 Hz, 1H), 8.04-8.01(m, 1H), 7.17-7.12 (m, 1H), 5.67-5.60 (m, 2H), 2.59 (q, J=7.4 Hz, 2H),2.47 (s, 3H), 1.25 (t, J=7.6 Hz, 3H)

Example 664:5-Ethyl-2-[[1-(2-methyl-4-pyridyl)triazol-4-yl]methoxy]pyrimidine

The title compound was prepared analogous to Example 175, steps A-C,using 2-chloro-5-ethylpyrimidine in step C. MS (ESI): mass calcd. forC₁₅H₁₆N₆O, 296.1; m/z found, 297.1 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃) δ8.65 (d, J=5.5 Hz, 1H), 8.40 (s, 2H), 8.21 (s, 1H), 7.61 (d, J=2.1 Hz,1H), 7.51-7.47 (m, 1H), 5.65 (s, 2H), 2.67 (s, 3H), 2.61 (q, J=7.6 Hz,2H), 1.27 (t, J=7.6 Hz, 3H).

Example 665:2-[[1-(2-Bromo-4-pyridyl)triazol-4-yl]methoxy]-5-ethyl-pyrimidine

The title compound was prepared analogous to Example 177, steps A-C,using 2-chloro-5-ethylpyrimidine in step C. MS (ESI): mass calcd. forC₁₄H₁₃BrN₆O, 360.0; m/z found, 361.0 [M+H]⁺. ¹H NMR (400 MHz, CD₃OD) δ8.88 (s, 1H), 8.53 (d, J=5.5 Hz, 1H), 8.48 (s, 2H), 8.24 (d, J=2.0 Hz,1H), 8.01 (dd, J=5.5, 2.1 Hz, 1H), 5.61 (s, 2H), 2.64 (q, J=7.7 Hz, 2H),1.26 (t, J=7.6 Hz, 3H).

Example 666:5-Methyl-2-[[1-[2-(trifluoromethyl)-4-pyridyl]triazol-4-yl]methoxy]pyrimidine

The title compound was prepared in a manner analogous to Example 177,steps A-C, using 4-amino-2-(trifluoromethyl)pyridine in step A,4-azido-2-(trifluoromethyl)pyridine in step B, and(1-(2-(trifluoromethyl)pyridin-4-yl)-1H-1,2,3-triazol-4-yl)methanol instep C. MS (ESI): mass calcd. for C₁₄H₁₁F₃N₆O, 336.1; m/z found, 337.1[M+H]⁺. ¹H NMR (500 MHz, CDCl₃) δ 8.90 (d, J=5.4 Hz, 1H), 8.39 (d, J=0.8Hz, 2H), 8.30-8.28 (m, 1H), 8.12 (d, J=2.1 Hz, 1H), 7.92 (dd, J=5.4, 2.0Hz, 1H), 5.66 (d, J=0.8 Hz, 2H), 2.27 (s, 3H).

Example 667:5-Ethyl-2-[[1-[2-(trifluoromethyl)-4-pyridyl]triazol-4-yl]methoxy]pyrimidine

The title compound was prepared in a manner analogous to Example 177,Steps A-C, using 4-amino-2-(trifluoromethyl)pyridine in step A,4-azido-2-(trifluoromethyl)pyridine in step B, and(1-(2-(trifluoromethyl)pyridin-4-yl)-1H-1,2,3-triazol-4-yl)methanol and2-chloro-5-ethylpyrimidine in step C. MS (ESI): mass calcd. forC₁₅H₁₃F₃N₆O, 350.1; m/z found, 351.1 [M+H]⁺. ¹H NMR (500 MHz, CDCl₃) δ8.90 (d, J=5.4 Hz, 1H), 8.42-8.39 (m, 2H), 8.30 (t, J=0.7 Hz, 1H), 8.13(d, J=2.0 Hz, 1H), 7.92 (dd, J=5.4, 2.1 Hz, 1H), 5.67 (d, J=0.8 Hz, 2H),2.62 (q, J=7.7 Hz, 2H), 1.27 (t, J=7.6 Hz, 3H).

Example 668:5-Fluoro-4-methyl-2-((1-(5-(trifluoromethyl)thiophen-2-yl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidine

The title compound was prepared in a manner analogous to Example 155using(1-(5-(trifluoromethyl)thiophen-2-yl)-1H-1,2,3-triazol-4-yl)methanol and2-chloro-5-fluoro-4-methylpyrimidine. MS (ESI): mass calcd. forC₁₃H₉F₄N₅OS, 359.3; m/z found, 360.1 [M+H]⁺. ¹H NMR (500 MHz, CDCl₃) δ8.28-8.23 (s, 1H), 8.11-8.05 (s, 1H), 7.42-7.37 (m, 1H), 7.19-7.15 (m,1H), 5.62-5.57 (s, 2H), 2.53-2.45 (d, J=2.4 Hz, 3H).

Example 669:5-Methoxy-2-((1-(5-(trifluoromethyl)thiophen-2-yl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidine

The title compound was prepared in a manner analogous to Example 155using(1-(5-(trifluoromethyl)thiophen-2-yl)-1H-1,2,3-triazol-4-yl)methanol and2-chloro-5-methoxypyrimidine. MS (ESI): mass calcd. for C₁₃H₁₀F₃N₅O₂S,357.3; m/z found, 358.1 [M+H]⁺. ¹H NMR (500 MHz, CDCl₃) δ 8.26-8.22 (s,2H), 8.09-8.06 (d, J=0.9 Hz, 1H), 7.40-7.37 (m, 1H), 7.19-7.15 (m, 1H),5.62-5.56 (s, 2H), 3.91-3.85 (m, 3H).

Example 670:5-(Trifluoromethyl)-2-((1-(5-(trifluoromethyl)thiophen-2-yl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidine

The title compound was prepared in a manner analogous to Example 155using(1-(5-(trifluoromethyl)thiophen-2-yl)-1H-1,2,3-triazol-4-yl)methanol and2-chloro-5-(trifluoromethyl)pyrimidine. MS (ESI): mass calcd. forC₁₃H₁₇F₆N₅OS, 395.3; m/z found, 396.1 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃) δ8.85-8.80 (d, J=0.9 Hz, 2H), 8.12-8.09 (m, 1H), 7.42-7.38 (m, 1H),7.22-7.17 (m, 1H), 5.74-5.70 (d, J=0.7 Hz, 2H).

Example 671:2-((1-(3-(Difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-N-(oxetan-3-yl)pyrimidin-4-amine

The title compound was prepared in a manner analogous to Example 159,using(1-(3-(difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanoland2-chloro-N-(oxetan-3-yl)-N-((2-(trimethylsilyl)ethoxy)methyl)pyrimidin-4-amine(Intermediate 62) in Step A. MS (ESI): mass calcd. for C₁₇H₁₅F₃N₆O₃,408.1; m/z found, 409.2 [M+H]⁺. ¹H NMR (500 MHz, DMSO-d₆) δ 8.91 (s,1H), 8.26-8.17 (m, 1H), 8.00 (dd, J=7.0, 2.6 Hz, 1H), 7.97-7.91 (m, 1H),7.87 (ddd, J=8.9, 3.9, 2.6 Hz, 1H), 7.68 (dd, J=10.2, 9.0 Hz, 1H), 7.40(t, J=72.8 Hz, 1H), 6.24-6.16 (m, 1H), 5.38 (s, 2H), 5.00-4.86 (m, 1H),4.79 (t, J=6.7 Hz, 2H), 4.45 (t, J=6.1 Hz, 2H).

Examples 672-689, 693-698, 700-716 may be prepared in a manner analogousto the previously described examples.

Example 672:5-(Azetidin-1-yl)-2-((1-(3-(difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyridine

MS (ESI): mass calcd. for C₁₈H₁₆F₃N₅O₂, 391.1

Example 673:2-((1-(3-(Difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-5-(3-fluoroazetidin-1-yl)pyridine

MS (ESI): mass calcd. for C₁₈H₁₅F₄N₅O₂, 409.1

Example 674:5-(3,3-Difluoroazetidin-1-yl)-2-((1-(3-(difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyridine

MS (ESI): mass calcd. for C₁₈H₁₄F₅N₅O₂, 427.1

Example 675:2-(Azetidin-1-yl)-6-((1-(3-(difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyridine

MS (ESI): mass calcd. for C₁₈H₁₆F₃N₅O₂, 391.1

Example 676:2-((1-(3-(Difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-6-(3-fluoroazetidin-1-yl)pyridine

MS (ESI): mass calcd. for C₁₈H₁₅F₄N₅O₂, 409.1

Example 677:2-(3,3-Difluoroazetidin-1-yl)-6-((1-(3-(difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyridine

MS (ESI): mass calcd. for C₁₈H₁₄F₅N₅O₂, 427.1

Example 678:4-(Azetidin-1-yl)-2-((1-(3-(difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyridine

Example 679:2-((1-(3-(Difluoromethoxy)-4-fluorophenyl-1H-1,2,3-triazol-4-yl)methoxy)-4-(3-fluoroazetidin-1-yl)pyridine

MS (ESI): mass calcd. for C₁₈H₁₅F₄N₅O₂, 409.1

Example 680:4-(3,3-Difluoroazetidin-1-yl)-2-((1-(3-(difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyridine

MS (ESI): mass calcd. for C₁₈H₁₄F₅N₅O₂, 427.1

Example 681:2-((1-(3-(Difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-4-(1H-pyrrol-2-yl)pyrimidine

MS (ESI): mass calcd. for C₁₈H₁₃F₃N₆O₂, 402.1

Example 682:2-((1-(3-(Difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-4-(1H-pyrazol-5-yl)pyrimidine

MS (ESI): mass calcd. for C₁₇H₁₂F₃N₇O₂, 403.1

Example 683:2-((1-(3-(Difluoromethoxy)-4-fluorophenyl-1H-1,2,3-triazol-4-yl)methoxy)-5-(1H-pyrrol-2-yl)pyrimidine

MS (ESI): mass calcd. for C₁₈H₁₃F₃N₆O₂, 402.1

Example 684:2-((1-(3-(Difluoromethoxy)-4-fluorophenyl-1H-1,2,3-triazol-4-yl)methoxy)-5-(1H-pyrazol-5-yl)pyrimidine

MS (ESI): mass calcd. for C₁₇H₁₂F₃N₇O₂, 403.1

Example 685:2-((1-(3-(Difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-N-ethyl-5-fluoropyrimidin-4-amine

MS (ESI): mass calcd. for C₁₆H₁₄F₄N₆O₂, 398.1

Example 686:2-((1-(3-Difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-5-fluoro-N-(oxetan-3-yl)pyrimidin-4-amine

MS (ESI): mass calcd. for C₁₇H₁₄F₄N₆O₃, 426.1

Example 687:N-(3,3-Difluorocyclobutyl)-2-((1-(3-(difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-5-fluoropyrimidin-4-amine

MS (ESI): mass calcd. for C₁₈H₁₄F₆N₆O₂, 460.1

Example 688:N-Cyclopropyl-2-((1-(3-(difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidin-4-amine

MS (ESI): mass calcd. for C₁₇H₁₅F₃N₆O₂, 392.1

Example 689:N-(3,3-Difluorocyclobutyl)-2-((1-(3-(difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidin-4-amine

MS (ESI): mass calcd. for C₁₈H₁₅F₈N₆O₂, 442.1

Example 690:N-Cyclopropyl-2-((1-(3-(difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidin-4-amine

The title compound was prepared in a manner analogous to Example 1 using(1-(3-(difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 9) and 2-chloro-N-cycloproplypyrimidine-4-amine. MS (ESI):mass calcd. for C₁₇H₁₅F₃N₆O, 376.1; m/z found, 377.1 [M+H]⁺. ¹H NMR (500MHz, CDCl₃) δ 8.16-8.09 (m, 2H), 7.96-7.92 (m, 1H), 7.92-7.86 (m, 1H),7.35-7.29 (m, 1H), 7.08-6.79 (t, J=54.6 Hz, 1H), 6.44-6.33 (s, 1H),5.59-5.53 (d, J=0.8 Hz, 2H), 5.43-5.32 (s, 1H), 2.66-2.51 (s, 1H),0.93-0.76 (m, 2H), 0.66-0.54 (m, 2H).

Example 691:N-Ethyl-2-((1-(3-(difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidin-4-amine

The title compound was prepared in a manner analogous to Example 171,Steps A-B,(1-(3-(difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 9) and2-chloro-N-ethyl-N-((2-(trimethylsilyl)ethoxy)methyl)pyrimidin-4-amine(Intermediate 60) in Step A. MS (ESI): mass calcd. for C₁₈H₂₁F₃N₆O,394.2; m/z found, 365.1 [M+H]⁺. ¹H NMR (500 MHz, CDCl₃) δ 8.15-8.10 (s,1H), 8.09-7.97 (d, J=11.8 Hz, 1H), 7.97-7.92 (d, J=5.5 Hz, 1H),7.92-7.87 (s, 1H), 7.36-7.28 (t, J=9.0 Hz, 1H), 7.08-6.82 (t, J=54.6 Hz,1H), 6.07-5.99 (d, J=5.8 Hz, 1H), 5.63-5.54 (s, 2H), 5.00-4.81 (s, 1H),3.48-3.29 (m, 2H), 1.30-1.22 (t, J=7.1 Hz, 3H).

Example 692:2-((1-(3-(Difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-4-(2-methyl-1H-imidazol-1-yl)pyrimidine

The title compound was prepared in a manner analogous to Example 1 using(1-(3-(difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 9) and 2-chloro-4-(2-methyl-1H-imidazol-1-yl)pyrimidine.MS (ESI): mass calcd. for C₁₈H₁₄F₃N₇O, 401.1; m/z found, 402.1 [M+H]⁺.¹H NMR (500 MHz, CDCl₃) δ 8.48-8.42 (d, J=5.7 Hz, 1H), 8.12-8.06 (s,1H), 7.97-7.93 (d, J=5.3 Hz, 1H), 7.93-7.88 (m, 2H), 7.39-7.30 (t, J=8.9Hz, 1H), 7.09-6.83 (m, 2H), 6.78-6.61 (m, 1H), 5.78-5.62 (s, 2H),2.96-2.80 (s, 3H).

Example 693:2-((1-(3-(Difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-5-(2-methyl-1H-imidazol-1-yl)pyrimidine

MS (ESI): mass calcd. for C₁₈H₁₄F₃N₇O, 401.1

Example 694:2-((1-(3-(Difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-5-(1H-pyrazol-5-yl)pyrimidine

MS (ESI): mass calcd. for C₁₇H₁₂F₃N₇O, 387.1

Example 695:2-((1-(3-(Difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-4-(1H-pyrazol-5-yl)pyrimidine

MS (ESI): mass calcd. for C₁₇H₁₂F₃N₇O, 387.1

Example 696:4(1,1-Difluoroethyl)-2-((1-(3-(difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidine

MS (ESI): mass calcd. for C₁₆H₁₂F₅N₅O, 385.1

Example 697:4-((Difluoromethoxy)methyl)-2-((1-(3-(difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidine

MS (ESI): mass calcd. for C₁₆H₁₂F₅N₅O₂, 401.1

Example 698:2-((1-(3-(Difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-5-(1H-pyrazol-1-yl)pyrimidine

MS (ESI): mass calcd. for C₁₇H₁₂F₃N₇O, 387.1

Example 699:2-((1-(3-(Difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-4-(1H-pyrazol-1-yl)pyrimidine

The title compound was prepared in a manner analogous to Example 1 using(1-(3-(difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methanol(Intermediate 9) and 2-chloro-4-(pyrazol-1-yl)pyrimidine. MS (ESI): masscalcd. for C₁₇H₁₂F₃N₇O, 387.1; m/z found, 388.0 [M+H]⁺. ¹H NMR (500 MHz,CDCl₃) δ 8.66-8.60 (m, 1H), 8.60-8.54 (d, J=5.5 Hz, 1H), 8.21-8.13 (s,1H), 8.00-7.93 (m, 1H), 7.93-7.85 (m, 1H), 7.84-7.77 (m, 1H), 7.65-7.56(d, J=5.5 Hz, 1H), 7.37-7.30 (m, 1H), 7.10-6.81 (t, J=54.6 Hz, 1H),6.56-6.47 (m, 1H), 5.76-5.67 (m, 2H).

Example 700:(E)-1-(2-((1-(3-(Difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidin-5-yl)ethan-1-oneoxime

MS (ESI): mass calcd. for C₁₆H₁₃F₃N₈O₂, 378.1

Example 701:5-(1,1-Difluoroethyl)-2-((1-(3-(difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidine

MS (ESI): mass calcd. for C₁₆H₁₂F₅N₅O, 385.1

Example 702:(Z)-1-(2-((1-(3-(Difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidin-4-yl)ethan-1-oneoxime

MS (ESI): mass calcd. for C₁₆H₁₃F₃N₆O₂, 378.1

Example 703:(2-((1-(3-(Difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-5-fluoropyrimidin-4-yl)methanol

MS (ESI): mass calcd. for C₁₅H₁₁F₄N₅O₃, 385.1

Example 704:2-((1-(3-(Difluoromethoxy)-4-fluorophenyl-1H-1,2,3-triazol-4-yl)methoxy)-4-((difluoromethoxy)methyl)-5-fluoropyrimidine

MS (ESI): mass calcd. for C₁₆H₁₁F₆N₅O₃, 435.1

Example 705:2-((1-(3-(Difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-4-((difluoromethoxy)methyl)pyrimidine

MS (ESI): mass calcd. for C₁₆H₁₂F₅N₅O₃, 417.1

Example 706:2-((1-(3-(Difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-5-fluoro-4-((trifluoromethoxy)methyl)pyrimidine

MS (ESI): mass calcd. for C₁₀H₁₀F₇N₅O₃, 453.1

Example 707:2-((1-(3-(Difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-4-((trifluoromethoxy)methyl)pyrimidine

MS (ESI): mass calcd. for C₁₆H₁₁F₆N₅O₃, 435.1

Example 708:2-((1-(3-(Difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-4-(methoxymethyl-d2)pyrimidine

MS (ESI): mass calcd. for C₁₆H₁₂D₂F₃N₅O₃, 383.1

Example 709:2-((1-(3-(Difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-4-((methoxy-d3)methyl-d2)pyrimidine

MS (ESI): mass calcd. for C₁₆H₉D₅F₃N₅O₃, 386.1

Example 710:2-((1-(3-(Difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-4-((methoxy-d3)methyl)pyrimidine

MS (ESI): mass calcd. for C₁₆H₁₁D₃F₃N₅O₃, 384.1

Example 711:2-((1-(3-(Difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-4-(ethoxymethyl)pyrimidine

MS (ESI): mass calcd. for C₁₇H₁₆F₃N₅O₃, 395.1

Example 712:2-((1-(3-(Difluoromethoxy)-4-fluorophenyl-1H-1,2,3-triazol-4-yl)methoxy)-4-(1-methoxyethyl)pyrimidine

MS (ESI): mass calcd. for C₁₇H₁₆F₃N₅O₃, 395.1

Example 713:1-(2-((1-(3-(Difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidin-4-yl)ethan-1-ol

MS (ESI): mass calcd. for C₁₆H₁₄F₃N₅O₃, 381.1

Example 714:2-((1-(3-(Difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-4-(2-methoxypropan-2-yl)pyrimidine

MS (ESI): mass calcd. for C₁₈H₁₈F₃N₅O₃, 409.1

Example 715:2-(2-((1-(3-(Difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidin-4-yl)propan-2-ol

MS (ESI): mass calcd. for C₁₇H₁₆F₃N₅O₃, 395.1

Example 716:4-((2,2-Difluoroethoxy)methyl)-2-((1-(3-(difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidine

MS (ESI): mass calcd. for C₁₇H₁₄F₅N₅O₃, 431.1

Biological Assays

Effects of Test Articles on Cloned Human NR1/NR2B Ion Channels Expressedin Mammalian Cells

NMDA receptors are ion channels that are highly permeable to Ca²⁺ ions,rendering it possible to monitor NMDA receptor function using cell-basedcalcium flux assay. In this assay, co-agonists glutamate and glycine areadded to cells heterologously expressing human GluN1/GluN2B NMDAreceptors to initiate cellular Ca²⁺ influx. The time course of thechanges in intracellular calcium is measured using a fluorescent dye anda FLIPR (Fluorometric Imaging Plate Reader) device.

Twenty four hours before measurements, the expression of the NMDAreceptors in the stable cell line is induced with Tet-On induciblesystem in the presence of a non-selective NMDA receptor blocker. On theday of the experiment, cell culture media is carefully washed and thecells are loaded with Calcium 5 Dye Kit (Molecular Devices) in dyeloading buffer containing 149 mM NaCl, 4 mM KCl, 2 mM CaCl₂, and 1.5 mMMgCl₂, 10 mM HEPES and 5 mM D-glucose; pH 7.4. After 1 h incubation atthe room temperature, the dye is washed away with the assay buffer (149mM NaCl (standard assay) or 150 mM (HTS assay), 4 mM KCl (standardassay) or 3 mM (HTS assay), 2 mM CaCl₂, 0.01 mM EDTA, 10 mM HEPES and 5mM D-glucose; pH 7.4) In the FLIPR TETRA reader, various concentrationsof the test compounds are added to the cells for 5 min whilefluorescence is monitored to detect potential agonist activity. Next,co-agonists, glutamate and glycine are added for another 5 minutes. Theconcentration of glutamate corresponding to ˜EC₈₀ (standard assay) orEC₄₀ (HTS assay) is used to maximize the assay's signal window or theability to detect NMDA receptor antagonists and negative allostericmodulators, respectively. A saturating concentration (10 μM) of glycineis also present in the assay. A non-selective NMDA receptor antagonist,(+)MK-801 is used as a positive control for antagonist activity. Thefluorescent signal in the presence of test compounds is quantified andnormalized to the signal defined by the appropriate control wells.

TABLE 5 NR2B IC₅₀ (μM) standard Ex #. Compound Name assay 12-((1-(4-Chloro-3-(difluoromethyl)phenyl)-1H-1,2,3- 0.049triazol-4-yl)methoxy)pyrimidine; 2N-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4- 0.213yl]methyl]pyridin-2-amine; 3N-[[1-[4-Fluoro-3-(trifluoromethyl)phenyl]triazol-4- 2.800yl]methyl]pyrimidin-2-amine; 42-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4- 0.392yl]methoxy]pyridine; 53-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4- 0.333yl]methoxy]pyridine; 6N-((1-(3-(Difluoromethyl)phenyl)-1H-1,2,3-triazol-4- 10.573yl)methyl)pyrimidin-2-amine; 7N-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4- 1.870yl]methyl]-1-methyl-imidazol-2-amine; 82-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4- 0.022yl]methoxy]-6-methyl-pyridine; 92-[[1-(3-Bromo-4-fluoro-phenyl)triazol-4- 0.020 yl]methoxy]pyrimidine;10 2-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4- 0.010yl]methoxy]pyrimidine; 112-[[1-[4-Chloro-3-(difluoromethyl)phenyl]triazol-4- 1.200yl]methoxy]pyridine; 124-[[1-[4-Chloro-3-(difluoromethyl)phenyl]triazol-4- 2.230yl]methoxy]pyrimidine; 134-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4- 0.879yl]methoxy]pyrimidine; 143-[[144-Chloro-3-(difluoromethoxy)phenyl]triazol-4- 0.401yl]methoxy]pyridazine; 15 2-[[1-(4-Chloro-3-methoxy-phenyl)triazol-4-0.699 yl]methoxy]pyrimidine; 162-[[1-(3-Bromo-4-fluoro-phenyl)triazol-4-yl]methoxy]- 0.0015-methyl-pyrimidine; 172-[[1-(3-Bromo-4-fluoro-phenyl)triazol-4-yl]methoxy]- 0.0104-methyl-pyrimidine; 182-[[1-(3-Bromo-4-fluoro-phenyl)triazol-4-yl]methoxy]- 0.0824,6-dimethyl-pyrimidine; 192-[[1-(3-Bromo-4-fluoro-phenyl)triazol-4-yl]methoxy]- 0.0565-fluoro-pyrimidine; 20 2-[[1-(4-Fluoro-3-methoxy-phenyl)triazol-4-1.000 yl]methoxy]pyrimidine; 212-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4- 0.002yl]methoxy]-4-methyl-pyrimidine; 222-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4- 0.002yl]methoxy]-5-methyl-pyrimidine; 232-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4- 0.456yl]methoxy]pyrazine; 24N-[[1-[3-(Difluoromethyl)-4-fluoro-phenyl]triazol-4- 0.824yl]methyl]pyrimidin-2-amine; 252-[[1-[3-(Difluoromethyl)-4-fluoro-phenyl]triazol-4- 0.050yl]methoxy]pyrimidine; 262-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4- 0.003yl]methoxy]-5-methoxy-pyrimidine; 272-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4- 0.009yl]methoxy]-5-ethyl-pyrimidine; 28 5-Chloro-2-[[1-[4-chloro-3- 0.002(difluoromethoxy)phenyl]triazol-4- yl]methoxy]pyrimidine; 292-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4- 0.011yl]methoxy]-4-methoxy-pyrimidine; 302-[[1-[4-Chloro-3-(difluoromethyl)phenyl]triazol-4- 0.004yl]methoxy]-4-methyl-pyrimidine; 312-[[1-[4-Chloro-3-(difluoromethyl)phenyl]triazol-4- 0.001yl]methoxy]-5-methyl-pyrimidine; 322-[[1-[4-Chloro-3-(difluoromethyl)phenyl]triazol-4- 0.002yl]methoxy]-5-ethyl-pyrimidine; 332-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4- 0.018yl]methoxy]pyrimidine; 342-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4- 0.159yl]methoxy]-5-methyl-pyrazine; 352-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4- 0.006yl]methoxy]-5-(difluoromethoxy)pyrimidine; 36N-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4- 0.351yl]methyl]pyrimidin-2-amine; 375-Chloro-2[[1-(2,4-difluoro-3-methyl-phenyl)triazol-4- 0.053yl]methoxy]pyrimidine; 38 2-[[1-(2,4-Difluoro-3-methyl-phenyl)triazol-4-0.027 yl]methoxy]-5-methyl-pyrimidine; 392-[[1-(2,4-Difluoro-3-methyl-phenyl)triazol-4- 0.015yl]methoxy]-5-ethyl-pyrimidine; 402-[[1-(3-Bromo-4-fluoro-phenyl)triazol-4-yl]methoxy]- 0.0015-ethyl-pyrimidine; 412-[[1-(3-Bromo-4-fluoro-phenyl)triazol-4-yl]methoxy]- 0.0005-methoxy-pyrimidine; 422-[[1-(3-Bromo-4-fluoro-phenyl)triazol-4-yl]methoxy]- 0.0035-chloro-pyrimidine; 432-[[1-(3-Bromo-4-fluoro-phenyl)triazol-4-yl]methoxy]- 0.0055-isopropyl-pyrimidine; 442-[[1-(3-Bromo-4-fluoro-phenyl)triazol-4-yl]methoxy]- 0.0055-(trifluoromethyl)pyrimidine; 452-[[1-[4-Chloro-3-(difluoromethyl)phenyl]triazol-4- 0.004yl]methoxy]-5-(trifluoromethyl)pyrimidine; 462-[[1-[4-Chloro-3-(difluoromethyl)phenyl]triazol-4- 0.001yl]methoxy]-5-methoxy-pyrimidine; 47 5-Chloro-2-[[1-[4-chloro-3- 0.003(difluoromethyl)phenyl]triazol-4- yl]methoxy]pyrimidine; 482-[[1-[4-Chloro-3-(difluoromethyl)phenyl]triazol-4- 0.008yl]methoxy]-5-isopropyl-pyrimidine; 495-Chloro-2-[[1-[3-(difluoromethy)-4-fluoro- 0.003phenyl]triazol-4-yl]methoxy]pyrimidine; 502-[[1-[3-(Difluoromethyl)-4-fluoro-phenyl]triazol-4- 0.007yl]methoxy]-5-(trifluoromethyl)pyrimidine; 512-[[1-[3-(Difluoromethyl)-4-fluoro-phenyl]triazol-4- 0.001yl]methoxy]-5-methyl-pyrimidine; 522-[[1-[3-(Difluoromethyl)-4-fluoro-phenyl]triazol-4- 0.008yl]methoxy]-4-methyl-pyrimidine; 53 (R/S)-2-[1-[1-[4-Chloro-3- 0.026(difluoromethoxy)pheny]triazol-4-yl]ethoxy]pyrimidine; 54(R*)-2-[1-[1-[4-Chloro-3- 4.640(difluoromethoxy)phenyl]triazol-4-yl]ethoxy]pyrimidine; 55(S*)-2-[1-[1-[4-Chloro-3- 0.008(difluoromethoxy)phenyl]triazol-4-yl]ethoxy]pyrimidine; 56(R/S)-2-[1-[1-[4-Chloro-3- 0.028(difluoromethoxy)phenyl]triazol-4-yl]ethoxy]-5-methyl- pyrimidine; 57(R*)-2-[1-[1-[4-Chloro-3- 0.338(difluoromethoxy)phenyl]triazol-4-yl]ethoxy]-5-methyl- pyrimidine; 58(S*)-2-[1-[1-[4-Chloro-3- 0.007(difluoromethoxy)phenyl]triazol-4-yl]ethoxy]-5-methyl- pyrimidine; 59(R/S)-2-[1-[1-[4-Chloro-3- 0.040(difluoromethoxy)phenyl]triazol-4-yl]ethoxy]-4-methyl- pyrimidine; 60(R/S)-5-Chloro-2-[1-[1-[4-chloro-3- 0.032(difluoromethoxy)phenyl]triazol-4-yl]ethoxy]pyrimidine; 615-Chloro-2-[[1-[3-(difluoromethoxy)-4-fluoro- 0.003phenyl]triazol-4-yl]methoxy]pyrimidine; 622-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4- 0.007yl]methoxy]-5-(trifluoromethyl)pyrimidine; 632-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4- 0.003yl]methoxy]-5-methyl-pyrimidine; 642-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4- 0.007yl]methoxy]-4-methyl-pyrimidine; 652-[[1-[3-(Difluoromethyl)-4-fluoro-phenyl]triazol-4- 0.056yl]methoxy]-5-(trifluoromethyl)pyridine; 662-[[1-[4-Chloro-3-(difluoromethyl)phenyl]triazol-4- 0.052yl]methoxy]-5-fluoro-pyrimidine; 672-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4- 0.015yl]methoxy]-5-ethyl-pyrimidine; 682-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4- 0.007yl]methoxy]-5-methoxy-pyrimidine; 695-Chloro-2[[1-[3-(1,1-difluoroethyl)-4-fluoro- 0.009phenyl]triazol-4-yl]methoxy]pyrimidine; 702-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4- 0.044yl]methoxy]-5-isopropyl-pyrimidine; 712-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4- 0.040yl]methoxy]-5-(trifluoromethyl)pyrimidine; 72 5-Ethyl-2-[[1-[4-fluoro-3-0.010 (trifluoromethyl)phenyl]triazol-4-yl]methoxy]pyrimidine; 732-[[1-[4-Fluoro-3-(trifluoromethyl)phenyl]triazol-4- 0.008yl]methoxy]-5-methoxy-pyrimidine; 74 5-Chloro-2-[[1-[4-fluoro-3- 0.016(trifluoromethyl)phenyl]triazol-4-yl]methoxy]pyrimidine; 752-[[1-[4-Fluoro-3-(trifluoromethy)phenyl]triazol-4- 0.026yl]methoxy]-5-isopropyl-pyrimidine; 762-[[1-[4-Fluoro-3-(trifluoromethyl)phenyl]triazol-4- 0.035yl]methoxy]-5-(trifluoromethyl)pyrimidine; 772-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4- 0.004yl]methoxy]-5-methyl-pyrimidin; 782-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4- 0.060yl]methoxy]pyrimidine; 792-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4- 0.007yl]methoxy]-4-methyl-pyrimidine; 802-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4- 0.032yl]methoxy]-5-fluoro-pyrimidine; 812-[[1-[4-Fluoro-3-(trifluoromethyl)phenyl]triazol-4- 0.003yl]methoxy]-5-methyl-pyrimidine; 822-[[1-[4-Fluoro-3-(trifluoromethyl)phenyl]triazol-4- 0.126yl]methoxy]pyrimidine; 832-[[1-[4-Fluoro-3-(trifluoromethyl)phenyl]triazol-4- 0.020yl]methoxy]-4-methyl-pyrimidine; 84 5-Fuoro-2-[[1-[4-fluoro-3- 0.072(trifluoromethyl)phenyl]triazol-4-yl]methoxy]pyrimidine; 852-[[1-[3-Bromo-4-fluoro-phenyl)triazol-4-yl]methoxy]- 0.0034,5-dimethyl-pyrimidine; 862-[[1-[4-Chloro-3-(difluoromethyl)phenyl]triazol-4- 0.004yl]methoxy]-4,5-dimethyl-pyrimidine; 872-[[1-(4-Chloro-3-methoxy-phenyl)triazol-4- 0.012yl]methoxy]-5-methoxy-pyrimidine; 882-[[1-(4-Chloro-3-methoxy-phenyl)triazol-4- 0.019yl]methoxy]-5-methyl-pyrimidine; 892-[[1-[3-(Difluoromethyl)phenyl]triazol-4-yl]methoxy]- 0.0115-methyl-pyrimidine; 902-[[1-[3-(Difluoromethyl)phenyl]triazol-4-yl]methoxy]- 0.0125-methoxy-pyrimidine; 912-[[1-[3-(Difluoromethyl)phenyl]triazol-4-yl]methoxy]- 0.0045-ethyl-pyrimidine; 925-Chloro-2[[1-[3-(difluoromethyl)phenyl]triazol-4- 0.019yl]methoxy]pyrimidine; 93 2-[[1-[3-(Difluoromethyl)phenyl]triazol-4-0.493 yl]methoxy]pyrimidine; 942-[[1-(5-Bromo-6-methyl-2-pyridyl)triazol-4- 2.910yl]methoxy]-5-methyl-pyrimidine; 952-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4- 0.023yl]methoxy]-5-fluoro-pyrimidine; 962-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4- 0.008yl]methoxy]-5-(difluoromethyl)pyrimidine; 97N-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4- 0.106yl]methyl]oxazol-2-amine; 98N-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4- 0.331yl]methyl]pyrimidin-2-amine; 99N-[[1-[3-(Difluoromethyl)-4-fluoro-phenyl]triazol-4- 5.050yl]methyl]-1-methyl-pyrazol-4-amine; 100N-[[1-[3-(Difluoromethyl)-4-fluoro-phenyl]triazol-4- 0.894yl]methyl]-1-methyl-pyrazol-3-amine; 101N-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4- 0.374yl]methyl]-1-methyl-pyrazol-3-amine; 102N-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4- 3.250yl]methyl]-1-methyl-pyrazol-4-amine; 1033-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4- 0.064yl]methoxy]-2-methoxy-pyridine; 1045-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4- 0.729yl]methoxy]-2-methyl-pyridine; 105 3-Chloro-2-[[1-[4-chloro-3- 0.059(difluoromethoxy)phenyl]triazol-4-yl]methoxy]pyridine; 1065-Chloro-2-[[1-[4-chloro-3- 0.276(difluoromethoxy)phenyl]triazol-4-yl]methoxy]-3- methoxy-pyridine; 1072-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4- 0.119yl]methoxy]-3-fluoro-pyridine; 1082-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4- 0.114yl]methoxy]-3-methoxy-pyridine; 109N-[[1-[4-Chloro-3-(difluoromethyl)phenyl]triazol-4- 1.260yl]methyl]pyrimidin-2-amine; 110N-[[1-[4-Chloro-3-(difluoromethyl)phenyl]triazol-4- 7.570yl]methyl]pyrimidin-4-amine; 1112-[[1-[3-(Difluoromethyl)-4-fluoro-phenyl]triazol-4- 0.684yl]methoxy]pyridine; 112 5-Chloro-2-[[1-[3-(difluoromethyl)-4-fluoro-0.056 phenyl]triazol-4-yl]methoxy]pyridine; 1132-[[1-[3-(Difluoromethyl)-4-fluoro-phenyl]triazol-4- 0.038yl]methoxy]-6-methyl-pyridine; 1142-[[1-[3-(Difluoromethyl)-4-fluoro-phenyl]triazol-4- 0.021yl]methoxy]-5-methyl-pyridine; 1152-[[1-[3-(Difluoromethyl)-4-fluoro-phenyl]triazol-4- 0.170yl]methoxy]-4-methyl-pyridine; 1162-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4- 0.102yl]methoxy]-4-methyl-pyridine; 1175-Chloro-2-[[1-[3-(difluoromethoxy)-4-fluoro- 0.073phenyl]triazol-4-yl]methoxy]pyridine; 1182-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4- 0.026yl]methoxy]-5-methyl-pyridine; 1192-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4- 0.114yl]methoxy]-5-(trifluoromethyl)pyridine; 1205-Methyl-2-((1-(5-(trifluoromethyl)thiophen-2-yl)-1H- 0.0051,2,3-triazol-4-yl)methoxy)pyrimidine; 1215-Methyl-2-((1-(4-(trifluoromethyl)thiophen-2-yl)-1H- NT1,2,3-triazol-4-yl)methoxy)pyrimidine; 1222-((1-(3-(Difluoromethy)-2-fluorophenyl)-1H-1,2,3- NTtriazol-4-yl)methoxy)-5-methylpyrimidine; 1232-((1-(4-Chlorophenyl)-1H-1,2,3-triazol-4- NTyl)methoxy)-5-methylpyrimidine; 1242-((1-(4-Chloro-3-(oxetan-3-yl)phenyl)-1H-1,2,3- NTtriazol-4-yl)methoxy)-5-methylpyrimidine; 1252-((1-(4-Chloro-3-(difluoromethyl)phenyl)-5-fluoro-1H- NT1,2,3-triazol-4-yl)methoxy)-5-methylpyrimidine; 1262-((1-(4-Chloro-3-(difluoromethyl)phenyl)-5- NT(trifluoromethyl)-1H-1,2,3-triazol-4-yl)methoxy)-5- methylpyrimidine;127 2-((1-(4-Chloro-3-(difluoromethyl)phenyl)-5-methyl- NT1H-1,2,3-triazol-4-yl)methoxy)-5-methylpyrimidine; 1282-((1-(4-Chloro-3-(difluoromethyl)phenyl)-1H-1,2,3- NTtriazol-4-yl)methoxy)-5-methylthiazole; 1291-(4-Chloro-3-(difluoromethyl)phenyl)-4-(((5-methyl- NT1H-imidazol-2-yl)oxy)methyl)-1H-1,2,3-triazole; 1302-((1-(4-Chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3- NTtriazol-4-yl)methoxy)-5-methylpyridine; 1312-((1-(4-Chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3- NTtriazol-4-yl)methoxy)-6-methylpyridine; 1326-((1-(4-Chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3- NTtriazol-4-yl)methoxy)-2,3-dimethylpyridine; 1332-((1-(4-Chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3- NTtriazol-4-yl)methoxy)-6-methylpyrazine; 1345-((1-(4-Chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3- NTtriazol-4-yl)methoxy)-2,3-dimethylpyrazine; 1355-((1-(4-Chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3- NTtriazol-4-yl)methoxy)-2-methylpyrimidine; 1366-((1-(4-Chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3- NTtriazol-4-yl)methoxy)-3,4-dimethylpyridazine; 1373-((1-(4-Chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3- NTtriazol-4-yl)methoxy)-6-(trifluoromethyl)pyridazine; 1383-((1-(4-Chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3- NTtriazol-4-yl)methoxy)-6-methoxypyridazine; 1394-((1-(4-Chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3- NTtriazol-4-yl)methoxy)-2-methylpyrimidine; 1404-((1-(4-Chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3- NTtriazol-4-yl)methoxy)-2-(trifluoromethyl)pyrimidine; 1414-((1-(4-Chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3- NTtriazol-4-yl)methoxy)-2-methoxypyrimidine; 1422-((1-(5-Chloro-6-(trifluoromethyl)pyridin-2-yl)-1H- NT1,2,3-triazo1-4-yl)methoxy)-5-methylpyrimidine; 1432-((1-(2-(Difluoromethyl)pyridin-4-yl)-1H-1,2,3-triazol- NT4-yl)methoxy)-5-methylpyrimidine; 144N-((1-(4-Chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3- NTtriazol-4-yl)methyl)-5-methylpyrimidin-2-amine; 145N-((1-(4-Chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3- NTtriazol-4-yl)methyl)-4,5-dimethylpyrimidin-2-amine; 1463-((1-(4-Chloro-3-(yl)difluoromethoxy)phenyl)-1H-1,2,3- NTtriazol-4-yl)methoxy)-4-methoxypyridine; 1474-Chloro-3-((1-(4-chloro-3-(difluoromethoxy)phenyl)- NT1H-1,2,3-triazol-4-yl)methoxy)pyridine; 1484-((1-(3-(Difluoromethoxy)phenyl)-1H-1,2,3-triazol-4- NTyl)methoxy)-5-methoxypyrimidine; 1492-((1-(3-(Difluoromethyl)phenyl)-5-methyl-1H-1,2,3- 0.952triazol-4-yl)methoxy)-5-methylpyrimidine; 1505-Methyl-2-((1-(5-(trifluoromethyl)pyridin-2-yl)-1H- NT1,2,3-triazol-4-yl)methoxy)pyrimidine; 1512-((1-(5-Bromo-6-fluoropyridin-3-yl)-1H-1,2,3-triazol- NT4-yl)methoxy)-5-methylpyrimidine; 1525-Methyl-2-((1-(pyridin-4-yl)-1H-1,2,3-triazol-4- NTyl)methoxy)pyrimidine; 1535-Chloro-N-[[1-[3-(difluoromethyl)phenyl]triazol-4- 0.216yl]methyl]pyrimidin-2-amine; 154N-[[1-[4-Chloro-3-(difluoromethyl)phenyl]triazol-4- 0.030yl]methyl]-5-methyl-pyrimidin-2-amine; 1552-[[1-[3-(Difluoromethyl)phenyl]triazol-4-yl]methoxy]- 0.0064,5-dimethyl-pyrimidine; 1561-[2-[[1-[3-(Difluoromethyl)-4-fluoro-phenyl]triazol-4- 0.005yl]methoxy]pyrimidin-5-yl]ethanone; 157(R/S)-1-[2-[[1-[3-(Difluoromethyl)-4-fluoro- 0.018phenyl]triazol-4-yl]methoxy]pyrimidin-5-yl]ethanol; 1582-[[1-[4-Fluoro-3-(trifluoromethyl)phenyl]triazol-4- 3.040yl]methoxy]pyridine; 159 [2-[[1-[3-(Difluoromethyl)phenyl]triazol-4-0.408 yl]methoxy]pyrimidin-4-yl]methanol; 160[2-[[1-[3-(Difluoromethyl)phenyl]triazol-4- 0.173yl]methoxy]pyrimidin-5-yl]methanol; 1612-[[1-[3-(Difluoromethyl)phenyl]triazol-4-yl]methoxy]- 0.0555-methyl-pyrimidin-4-amine; 1622-[[1-[3-(Difluoromethyl)-4-fluoro-phenyl]triazol-4- >2.99yl]methoxy]-N-methyl-pyrimidine-4-carboxamide; 163 (R/S)1-[2-[[1-[3-(Difluoromethoxy)-4-fluoro- 1.400phenyl]triazol-4-yl]methoxy]pyrimidin-4-yl]ethanamine; 1645-Chloro-2-[[1-(4-fluorophenyl)triazol-4- 0.371 yl]methoxy]pyrimidine;165 5-(Azetidin-1-yl)-2-[[1-[3-(difluoromethoxy)-4-fluoro- 0.016phenyl]triazol-4-yl]methoxy]pyrimidine; 1662-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4- 0.144yl]methoxy]-4-(3,3-difluoropyrrolidin-1-yl)pyrimidine; 1672-((1-(3-(Difluoromethoxy)-4-fluorophenyl)-1H-1,2,3- 0.013triazol-4-yl)methoxy)-5-fluoropyrimidin-4-amine; 1682-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4- 0.008yl]methoxy]-4-pyrrolidin-1-yl-pyrimidine; 1692-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4- 0.031yl]methoxy]-4-(1-piperidyl)pyrimidine; 1704-[2-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol- 0.2604-yl]methoxy]pyrimidin-4-yl]morpholine; 1712-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4- 0.006yl]methoxy]-N-methyl-pyrimidin-4-amine; 1722-[[1-[3-(Difluoromethyl)phenyl]-5-methyl-triazol-4- 0.468yl]methoxy]-5-methoxy-pyrimidine; 1732[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]-5-methyl- 0.465triazol-4-yl]methoxy]-5-methyl-pyrimidine; 1745-Methyl-2[[1-(6-methyl-2-pyridyl)triazol-4- >2.99yl]methoxy]pyrimidine; 175 5-Methyl-2-[[1-(2-methyl-4-pyridyl)triazol-4-0.655 yl]methoxy]pyrimidine; 1765-Methyl-2-[[1-(5-methyl-3-pyridyl)triazol-4- 0.929yl]methoxy]pyrimidine; 1772-[[1-(2-Bromo-4-pyridyl)triazol-4-yl]methoxy]-5- 0.172methyl-pyrimidine; 178 2-[2-[[1-(3-Cyclobutyl-4-fluoro-phenyl)triazol-4-0.349 yl]methoxy]pyrimidin-5-yl]propan-2-ol; 1792-[2-[[1-(4-Fluoro-3-isopropyl-phenyl)triazol-4- 0.029yl]methoxy]pyrimidin-5-yl]propan-2-ol; 1802-[2-[[1-(3-Cyclopropyl-4-fluoro-phenyl)triazol-4- 0.133yl]methoxy]pyrimidin-5-yl]propan-2-ol; 1812-[2-[[1-(4-Fluoro-3-methyl-phenyl)triazol-4- 0.097yl]methoxy]pyrimidin-5-yl]propan-2-ol; 1822-[2-[[1-(3-Ethyl-4-fluoro-phenyl)triazol-4- 0.027yl]methoxy]pyrimidin-5-yl]propan-2-ol; 1835-Bromo-2-[[1-[3-(1,1-difluoroethyl)-4-fluoro- 0.009phenyl]triazol-4-yl]methoxy]pyrimidine; 1842-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4- 0.309yl]methoxy]-5-(1-methylpyrazol-3-yl)pyrimidine; 1852-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4- 0.166yl]methoxy]-5-(1H-pyrazol-4-yl)pyrimidine; 1862-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4- 1.360yl]methoxy]-4-(1H-pyrazol-4-yl)pyrimidine; 1874-(2-((1-(3-(1,1-Difluoroethyl)-4-fluorophenyl)-1H- 0.0881,2,3-triazol-4-yl)methoxy)pyrimidin-5-yl)morpholine; 1882-((1-(4-(Azetidin-1-yl)-3-(difluoromethyl)phenyl)-1H- 4.5801,2,3-triazol-4-yl)methoxy)pyrimidine; 1892-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4- 1.460yl]methoxy]-5-fluoro-pyrazine; 190 4-Chloro-2-[[1-[4-chloro-3- 0.026(difluoromethoxy)phenyl]triazol-4- yl]methoxy]pyrimidine; 1912-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4- 0.023yl]methoxy]-4-fluoro-pyrimidine; 1922-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4- 0.030yl]methoxy]-5-(2-fluoroethoxy)pyrimidine; 1932-[[1-[4-Chloro-3-(2-fluoroethoxy)phenyl]triazol-4- 0.089yl]methoxy]-5-methoxy-pyrimdine; 1942-[[1-[4-Fluoro-3-(3-fluoropropyl)phenyl]triazol-4- 0.061yl]methoxy]-5-methoxy-pyrimdine; 1952-[[1-[3-(3-Chloropropyl)-4-fluoro-phenyl]triazol-4- 0.136yl]methoxy]-5-methoxy-pyrimidine; 1962-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4- 0.024yl]methoxy]-5-(3-fluoropropyl)pyrimidine; 197N-[[1-[3-(Difluoromethyl)phenyl]triazol-4-yl]methyl]-5- 0.652fluoro-pyrimidin-2-amine; 198N-[[1-(4-Fluoro-3-methyl-phenyl)triazol-4-yl]methyl]-5- 0.147methyl-pyrimidin-2-amine; 1995-Chloro-N-[[1-(4-fluoro-3-methyl-phenyl)triazol-4- 0.051yl]methyl]-4-methyl-pyrimidin-2-amine; 200 5-Chloro-N-[[1-[4-chloro-3-0.131 (difluoromethyl)phenyl]triazol-4- yl]methyl]pyrimidin-2-amine; 201N-[[1-[4-Chloro-3-(difluoromethyl)phenyl]triazol-4- 0.100yl]methyl]-4-methyl-pyrimidin-2-amine; 202N-[[1-[4-Chloro-3-(difluoromethyl)phenyl]triazol-4- 0.044yl]methyl]-5-ethyl-pyrimidin-2-amine; 203N-[[1-[4-Chloro-3-(difluoromethyl)phenyl]triazol-4- 0.030yl]methyl]-5-methoxy-pyrimidin-2-amine; 204N-[[1-[4-Chloro-3-(difluoromethyl)phenyl]triazol-4- 0.240yl]methyl]-5-(difluoromethyl)pyrimidin-2-amine; 205N-[[1-[4-Chloro-3-(difluoromethyl)phenyl]triazol-4- 0.616yl]methyl]-5-(trifluoromethyl)pyrimidin-2-amine; 206N-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4- 0.219yl]methyl]-5-methyl-pyrimidin-2-amine; 207N-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4- 0.128yl]methyl]-5-ethyl-pyrimidin-2-amine; 208N-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4- 0.581yl]methyl]-5-isopropyl-pyrimidin-2-amine; 2095-Cyclopropyl-N-[[1-[3-(1,1-difluoroethyl)-4-fluoro- 0.104phenyl]triazol-4-yl]methyl]pyrimidin-2-amine; 210N-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4- 0.050yl]methyl]-4,5-dimethyl-pyrimidin-2-amine; 211N-[[1-[3-(Difluoromethyl)-4-fluoro-phenyl]triazol-4- 0.049yl]methyl]-5-methyl-pyrimidin-2-amine; 2125-Chloro-N-[[1-[3-(difluoromethyl)-4-fluoro- 0.074phenyl]triazol-4-yl]methyl]pyrimidin-2-amine; 213N-[[1-[3-(Difluoromethyl)-4-fluoro-phenyl]triazol-4- 0.108yl]methyl]-5-(trifluoromethyl)pyrimidin-2-amine; 2142-[2-[[1-[3-(Difluoromethyl)-4-fluoro-phenyl]triazol-4- 0.654yl]methylamino]pyrimidin-5-yl]propan-2-ol; 215N-((1-(3-(Difluoromethyl)-4-fluorophenyl)-1H-1,2,3- 0.986triazol-4-yl)methyl)pyridin-2-amine; 216N-((1-(3-(Difluoromethyl)-4-fluorophenyl)-1H-1,2,3- 0.026triazol-4-yl)methyl)-5-ethylpyrimidin-2-amine; 217N-((1-(3-(Difluoromethyl)-4-fluorophenyl)-1H-1,2,3- 0.012triazol-4-yl)methyl)-4,5-dimethylpyrimidin-2-amine; 2185-Chloro-N-((1-(3-(difluoromethyl)-4-fluorophenyl)- 0.0111H-1,2,3-triazol-4-yl)methyl)-4-methylpyrimidin-2- amine; 219N-((1-(3-(Difluoromethyl)-4-fluorophenyl)-1H-1,2,3- >10triazol-4-yl)methyl)-1-methyl-1H-pyrazol-5-amine; 220N-((1-(3-(Difluoromethyl)-4-fluorophenyl)-1H-1,2,3- 3.650triazol-4-yl)methyl)-1-methyl-1H-imidazol-2-amine; 221N-((1-(3-(Difluoromethoxy)-4-fluorophenyl)-1H-1,2,3- 0.724triazol-4-yl)methyl)pyridin-2-amine; 222N-((1-(3-(Difluoromethoxy)-4-fluorophenyl)-1H-1,2,3- 0.064triazol-4-yl)methyl)-5-methylpyrimidin-2-amine; 223N-((1-(3-(Difluoromethoxy)-4-fluorophenyl)-1H-1,2,3- 11.801triazol-4-yl)methyl)-1-methyl-1H-pyrazol-5-amine, and 224N-[(1R)-1-[1-[4-Chloro-3- 0.121(difluoromethoxy)phenyl]triazol-4-yl]ethyl]-5-methyl- pyrimidin-2-amine;225 5-Chloro-2[[1-(4-chlorophenyl)triazol-4- 0.070yl]methoxy]pyrimidine; 226 2-[[1-(4-Chlorophenyl)triazol-4-yl]methoxy-5-0.155 (trifluoromethyl)pyrimidine; 2272-[[1-(4-Chlorophenyl)triazol-4-yl]methoxy-5- 0.151(difluoromethoxy)pyrimidine; 2282-[[1-(3-Fluorophenyl)triazol-4-yl]methoxy]pyrimidine; 5.649 2295-Fluoro-2[[1-(3-fluorophenyl)triazol-4- 2.980 yl]methoxy]pyrimidine;230 2-[[1-(3-Fluorophenyl)triazol-4-yl]methoxy]-5- 0.275methoxy-pyrimidine; 231 5-Chloro-2-[[1-(3-fluorophenyl)triazol-4- 0.389yl]methoxy]pyrimidine; 2322-[[1-(3-Fluorophenyl)triazol-4-yl]methoxy]-5-methyl- 0.205 pyrimidine;233 5-Ethyl-2-[[1-(3-fluorophenyl)triazol-4- 0.075yl]methoxy]pyrimidine; 2342[[1-(3-Bromophenyl)triazo1-4-yl]methoxy]-5-methyl- 0.022 pyrimidine;235 2-[[1-(3-Bromophenyl)triazol-4-yl]methoxy]-4-methyl- NT pyrimidine;236 2-[[1-(o-Tolyl)triazol-4-yl]methoxy]pyrimidine; >10 2375-Fluoro-2[[1-(o-tolyl)triazol-4-yl]methoxy]pyrimidine; 16.600 2385-Methoxy-2[[1-(o-tolyl)triazol-4- 5.990 yl]methoxy]pyridine; 2395-Chloro-2[[1-(o-tolyl)triazol-4-yl]methoxy]pyrimidine; 4.800 2405-Methyl-2[[1-(o-tolyl)triazol-4-yl]methoxy]pyrimidine; 5.580 2415-Ethyl-2-[[1-(o-tolyl)triazo1-4-yl]methoxy]pyrimidine; 1.460 2422-[[1-(m-Tolyl)triazol-4-yl]methoxy]pyrimidine; 0.647 2435-Methyl-2-[[1-(m-tolyl)triazol-4- 0.014 yl]methoxy]pyrimidine; 2444-Methyl-2-[[1-(m-tolyl)triazol-4- 0.191 yl]methoxy]pyrimidine; 2455-Ethyl-2-[[1-(m-tolyl)triazol-4-yl]methoxy]pyrimidine; 0.010 2465-Chloro-2-[[1-(m-tolyl)triazol-4- 0.033 yl]methoxy]pyrimidine; 2475-Fluoro-24[1-(m-tolyl)triazol-4- 0.340 yl]methoxy]pyrimidine; 2485-Methoxy-2-[[1-(m-tolyl)triazol-4- 0.009 yl]methoxy]pyrimidine; 2492-[2-[[1-(m-Tolyl)triazol-4-yl]methoxy]pyrimidin-5- 0.289yl]propan-2-ol; 250 4-(Methoxymethyl)-2-[[1-(m-tolyl)triazol-4- 0.249yl]methoxy]pyrimidine; 251 4,5-Dimethyl-2-[[1-(m-tolyl)triazol-4- 0.002yl]methoxy]pyrimidine; 252 5-Fluoro-4-methyl-2-[[1-tolyl)triazol-4-0.065 yl]methoxy]pyrimidine; 2535-Chloro-4-methyl-2-[[1-(m-tolyl)triazol-4- 0.007 yl]methoxy]pyrimidine;254 5-Methyl-2-[[1-(m-tolyl)triazol-4-yl]methoxy]pyrimidin- 0.1514-amine; 255 1-[2-[[1-(m-Tolyl)triazol-4-yl]methoxy]pyrimidin-5- 0.224yl]ethanone; 256 2-[[1-(p-Tolyl)triazol-4-yl]methoxy]pyrimidine; 4.420257 5-Fluoro-2-[[1-(p-tolyl)triazol-4-yl]methoxy]pyrimidine; 2.690 2585-Methoxy-2-[[1-(p-tolyl)triazol-4- 0.225 yl]methoxy]pyridine; 2595-Chloro-2-[[1-(p-tolyl)triazol-4-yl]methoxy]pyrimidine; 0.711 2605-Methyl-2-[[1-(p-tolyl)triazol-4-yl]methoxy]pyrimidine; 0.271 2615-Ethyl-2-[[1-(p-tolyl)triazol-4-yl]methoxy]pyrimidine; 0.093 2622-[[1-(3-Isopropylphenyl)triazol-4- 0.358 yl]methoxy]pyrimidine; 2635-Fluoro-2[[1-(3-isopropylphenyl)triazol-4- 0.227 yl]methoxy]pyrimidine;264 2-[[1-(3-Isopropylphenyl)triazol-4-yl]methoxy]-5- 0.006methoxy-pyrimidine; 265 5-Chloro-2-[[1-(3-isopropylphenyl)triazol-4-0.016 yl]methoxy]pyrimidine; 2662-[[1-(3-Isopropylphenyl)triazol-4-yl]methoxy]-5- 0.010methyl-pyrimidine; 267 5-Ethyl-2-[[1-(3-isopropylphenyl)triazol-4- 0.012yl]methoxy]pyrimidine; 2682-[[1-[3-(Difluoromethyl)phenyl]triazol-4-yl]methoxy]- 0.1344-methyl-pyrimidine; 2692-[[1-[3-(Difluoromethyl)phenyl]triazol-4-yl]methoxy]- 0.3255-fluoro-pyrimidine; 2702-[[1-[3-(Difluoromethyl)phenyl]triazol-4-yl]methoxy]- 0.6174-isopropyl-pyrimidine; 2712[[1-[3-(Difluoromethyl)phenyl]triazol-4-yl]methoxy]- 0.3604-(methoxymethyl)pyrimidine; 2722-[2-[[1-[3-(Difluoromethyl)phenyl]triazol-4- 0.173yl]methoxy]pyrimidin-5-yl]propan-2-ol; 273 5-(Difluoromethyl)-2-[[1-[3-0.027 (difluoromethyl)phenyl]triazol-4- yl]methoxy]pyrimidine; 2744-(Difluoromethyl)-2-[[1-[3- 0.813 (difluoromethyl)phenyl]triazol-4-yl]methoxy]pyrimidine; 2752-[[1-[3-(Difluoromethyl)phenyl]triazol-4-yl]methoxy- 0.0255-(trifluoromethyl)pyrimidine; 276 5-(Difluoromethoxy)-2-[[1-[3- 0.031(difluoromethyl)phenyl]triazol-4- yl]methoxy]pyrimidine; 2772-[[1-[3-(Difluoromethyl)phenyl]triazol-4-yl]methoxy]- 0.041N,N-dimethyl-pyrimidin-4-amine; 2782-[[1-[3-(Difluoromethyl)phenyl]triazol-4-yl]methoxy]- 0.0425-fluoro-4-methyl-pyrimidine; 2795-Chloro-2-[[1-[3-(difluoromethyl)phenyl]triazol-4- 0.003yl]methoxy]-4-methyl-pyrimidine; 2802-Chloro-4-[[1-[3-(difluoromethyl)phenyl]triazol-4- 0.173yl]methoxy]-5-methyl-pyrimidine; 2812-[[1-[3-(Difluoromethyl)phenyl]triazol-4-yl]methoxy]- 0.130N,N,5-trimethyl-pyrimidin-4-amine; 2825-Cyclopropyl-2-[[1-[3-(difluoromethyl)phenyl]triazol- 0.0114-yl]methoxy]pyrimidine; 2834-Cyclopropyl-2-[[1[3-(difluoromethyl)phenyl]triazol- 0.1694-yl]methoxy]pyrimidine; 2842-[[1-[3-(Difluoromethyl)phenyl]triazol-4-yl]methoxy]- 0.0944-pyrrolidin-1-yl-pyrimidine; 2852-[[1-[3-(Difluoromethyl)phenyl]triazol-4-yl]methoxy]- 0.2994-(1-piperidyl)pyrimidine; 2865-Methyl-2-[[1-[3-(trifluoromethyl)phenyl]triazol-4- 0.012yl]methoxy]pyrimidine; 2875-Ethyl-2-[[1-[3-(trifluoromethyl)phenyl]triazol-4- 0.005yl]methoxy]pyrimidine; 2885-Isopropyl-2-[[1-[3-(trifluoromethyl)phenyl]triazol-4- 0.040yl]methoxy]pyrimidine; 289 5-(Difluoromethyl)-2-[[1-[3- 0.037(trifluoromethyl)phenyl]triazol-4- yl]methoxy]pyrimidine; 2904,5-Dimethyl-2-[[1-[3-(trifluoromethyl)phenyl]triazol-4- 0.007yl]methoxy]pyrimidine; 291 5-Chloro-4-methyl-2-[[1-[3- 0.009(trifluoromethyl)phenyl]triazol-4-yl]methoxy]pyridine; 2922-[[1-[3-(1,1-Difluoroethyl)phenyl]triazol-4- 0.105yl]methoxy]pyrimidine; 2935-Bromo-2-[[1-[3-(1,1-difluoroethyl)phenyl]triazol-4- 0.039yl]methoxy]pyrimidine; 2945-Chloro-2-[[1-[3-(1,1-difluoroethyl)phenyl]triazol-4- 0.003yl]methoxy]pyridine; 295 2-[[1-[3-(1,1-Difluoroethyl)phenyl]triazol-4-0.061 yl]methoxy]-5-fluoro-pyrimidine; 2962-[[1-[3-(1,1-Difluoroethyl)phenyl]triazol-4- 0.012yl]methoxy]-4-methyl-pyrimidine; 2972-[[1-[3-(1,1-Difluoroethyl)phenyl]triazol-4- 0.005yl]methoxy]-5-methyl-pyrimidine; 298[2-[[1-[3-(1,1-Difluoroethyl)phenyl]triazol-4- 0.034yl]methoxy]pyrimidin-5-yl]methanol; 299[2-[[1-[3-(1,1-Difluoroethyl)phenyl]triazol-4- 0.049yl]methoxy]pyrimidin-4-yl]methanol; 3002-[[1-[3-(1,1-Difluoroethyl)phenyl]triazol-4- 0.008yl]methoxy]-4-(methoxymethyl)pyrimidine; 3012-[2-[[1-[3-(1,1-Difluoroethyl)phenyl]triazol-4- 0.119yl]methoxy]pyrimidin-5-yl]propan-2-ol; 3022-[[1-[3-(1,1-Difluoroethyl)phenyl]triazol-4- 0.002yl]methoxy]-5-(difluoromethyl)pyrimidine; 3032-[[1-[3-(1,1-Difluoroethyl)phenyl]triazol-4- 0.085yl]methoxy]-4-(difluoromethyl)pyrimidine; 3042-[[1-[3-(1,1-Difluoroethyl)phenyl]triazol-4- 0.711yl]methoxy]-4-(trifluoromethyl)pyrimidine; 305(R/S)-2-[2-[[1-[3-(1,1-Difluoroethyl)phenyl]triazol-4- 0.496yl]methoxy]pyrimidin-5-yl]-1,1,1-trifluoro-propan-2-ol; 3062-[[1-[3-(1,1-Difluoroethyl)phenyl]triazol-4- 0.003yl]methoxy]-5-methoxy-pyrimidine; 3072-[[1-[3-(1,1-Difluoroethyl)phenyl]triazol-4- 0.033yl]methoxy]-4-methoxy-pyrimidine; 3082-[[1-[3-(1,1-Difluoroethyl)phenyl]triazol-4- 0.003yl]methoxy]-5-(difluoromethoxy)pyrimidine; 3091-[2-[[1-[3-(1,1-Difluoroethyl)phenyl]triazol-4- 0.010yl]methoxy]pyrimidin-5-yl]ethanone; 310(R/S)-1-[2-[[1-[3-(1,1-Difluoroethyl)phenyl]triazol-4- 0.037yl]methoxy]pyrimidin-5-yl]ethanol; 311(R/S)-2-[[1-[3-(1,1-Difluoroethyl)phenyl]triazol-4- 1.580yl]methoxy]-5-(1-methoxyethyl)pyrimidine; 3125-Chloro-2-[[1-[3-(1,1-difluoroethyl)phenyl]triazol-4- 0.004yl]methoxy]-4-methyl-pyrimidine; 3132-[[1-[3-(1,1-Difluoroethyl)phenyl]triazol-4- 0.005yl]methoxy]-5-fluoro-4-methyl-pyrimidine; 3142-[[1-[3-(1,1-Difluoroethyl)phenyl]triazol-4- 0.006yl]methoxy]-5-methyl-pyrimidin-4-amine; 3152-[[1-[3-(1,1-Difluoroethyl)phenyl]triazol-4- 0.158yl]methoxy]-5-fluoro-N-methyl-pyrimidin-4-amine; 3162-[[1-[3-(1,1-Difluoroethyl)phenyl]triazol-4- 0.183yl]methoxy]pyrimidin-4-amine; 3172-[[1-[3-(1,1-Difluoroethyl)phenyl]triazol-4- 0.026yl]methoxyl-N-methyl-pyrimidin-4-amine; 3182-[[1-[3-(1,1-Difluoroethyl)phenyl]triazol-4- 0.026yl]methoxy]-N,N-dimethyl-pyrimidin-4-amine; 3195-Cyclopropyl-2-[[1-[3-(1,1- 0.015difluoroethyl)phenyl]triazol-4-yl]methoxy]pyrimidine; 3205-(Azetidin-1-yl)-2-[[1-[3-(1,1- 0.061difluoroethyl)phenyl]triazol-4-yl]methoxy]pyrimidine; 3212-[[1-[3-(1,1-Difluoroethyl)phenyl]triazol-4- 0.104yl]methoxy]-5-(3-fluoroazetidin-1-yl)pyrimidine; 3222-[[1-[3-(1,1-Difluoroethyl)phenyl]triazol-4- 0.011yl]methoxy]-4-pyrrolidin-1-yl-pyrimidine; 3232-[[1-[3-(Difluoromethoxy)phenyl]triazol-4- 0.788 yl]methoxy]pyrimidine;324 2-[[1-[3-(Difluoromethoxy)phenyl]triazol-4- 0.494yl]methoxy]-5-fluoro-pyrimidine; 3252-[[1-[3-(Difluoromethoxy)phenyl]triazol-4- 0.027yl]methoxy]-5-methoxy-pyrimidine; 3265-Chloro-2-[[1-[3-(difluoromethoxy)phenyl]triazol-4- 0.069yl]methoxy]pyrimidine; 327 2-[[1-[3-(Difluoromethoxy)phenyl]triazol-4-0.015 yl]methoxy]-5-methyl-pyrimidine; 3282-[[1-[3-(Difluoromethoxy)phenyl]triazol-4- 0.029yl]methoxy]-5-ethyl-pyrimidine; 3292-[[1-[4-(Difluoromethoxy)phenyl]triazol-4- 0.854 yl]methoxy]pyridine;330 2-[[1-[4-(Difluoromethoxy)phenyl]triazol-4- 0.752yl]methoxy]-5-fluoro-pyrimidine; 3312-[[1-[4-(Difluoromethoxy)phenyl]triazol-4- 0.098yl]methoxy]-5-methoxy-pyrimidine; 3325-Chloro-2-[[1-[4-(difluoromethoxy)phenyl]triazol-4- 0.200yl]methoxy]pyrimidine; 333 2-[[1-[4-(Difluoromethoxy)phenyl]triazol-4-0.087 yl]methoxy]-5-methyl-pyrimidine; 3342-[[1-[4-(Difluoromethoxy)phenyl]triazol-4- 0.051yl]methoxy]-5-ethyl-pyrimidine; 3352-[[1-[4-(Trifluoromethoxy)phenyl]triazol-4- 3.120yl]methoxy]pyrimidine; 3365-Fluoro-2-[[1-[4-(trifluoromethoxy)phenyl]triazol-4- 11.301yl]methoxy]pyrimidine; 3375-Methoxy-2-[[1-[4-(trifluoromethoxy)phenyl]triazol-4- >10yl]methoxy]pyrimidine; 3385-Chloro-2-[[1-[4-(trifluoromethoxy)phenyl]triazol-4- 9.049yl]methoxy]pyrimidine; 3395-Methyl-2-[[1-[4-(trifluoromethoxy)phenyl]triazol-4- 1.130yl]methoxy]pyrimidine; 3405-Ethyl-2-[[1-[4-(trifluoromethoxy)phenyl]triazol-4- 0.794yl]methoxy]pyridine; 341 2-[[1-[3-(Trifluoromethoxy)phenyl]triazol-4-0.538 yl]methoxy]pyridine; 3425-Methyl-2-[[1-[3-(trifluoromethoxy)phenyl]triazol-4- 0.017yl]methoxy]pyrimidine; 3435-Methyl-2-[[1-[3-(trifluoromethoxy)phenyl]triazol-4- 0.040yl]methoxy]pyrimidin-4-amine; 3441-[2-[[1-[3-(Trifluoromethoxy)phenyl]triazol-4- 0.062yl]methoxy]pyrimidin-5-yl]ethanone; 3452-[2-[[1-[3-(Trifluoromethoxy)phenyl]triazol-4- 0.284yl]methoxy]pyrimidin-5-yl]propan-2-ol; 346 4-(Methoxymethyl)-2-[[1-[3-0.202 (trifluoromethoxy)phenyl]triazol-4- yl]methoxy]pyrimidine; 3474-Methyl-2-[[1-[3-(trifluoromethoxy)phenyl]triazol-4- 0.137yl]methoxy]pyrimidine; 3485-Fluoro-2-[[1-[3-(trifluoromethoxy)phenyl]triazol-4- 0.447yl]methoxy]pyrimidine; 3495-Methoxy-2-[[1-[3-(trifluoromethoxy)phenyl]triazol-4- 0.013yl]methoxy]pyrimidine; 3505-Chloro-2-[[1-[3-(trifluoromethoxy)phenyl]triazol-4- 0.050yl]methoxy]pyrimidine; 3515-Ethyl-2-[[1-[3-(trifluoromethoxy)phenyl]triazol-4- 0.015yl]methoxy]pyrimidine; 352N-Methyl-2-[[1-[3-(trifluoromethoxy)phenyl]triazol-4- 0.068yl]methoxy]pyrimidin-4-amine; 3532-[[1-[3-(Trifluoromethoxy)phenyl]triazol-4- 0.525yl]methoxy]pyrimidin-4-amine; 3542-[[1-(2,2-Difluoro-1,3-benzodioxol-5-yl)triazol-4- 0.073yl]methoxy]-5-methyl-pyrimidine; 3552-[[1-(2,2-Difluoro-1,3-benzodioxol-5-yl)triazol-4- 0.238yl]methoxy]pyrimidine; 3565-Chloro-2-[[1-(2,2-difluoro-1,3-benzodioxol-5- 0.185yl)triazol-4-yl]methoxy]pyrimidine; 3572-[[1-(2,2-Difluoro-1,3-benzodioxol-5-yl)triazol-4- 0.350yl]methoxy]-5-fluoro-4-methyl-pyrimidine; 3582-[[1-(2,2-Difluoro-1,3-benzodioxol-5-yl)triazol-4- 0.726yl]methoxy]-5-fluoro-pyrimidine; 3592-[[1-(2,2-Difluoro-1,3-benzodioxol-5-yl)triazol-4- 0.009yl]methoxy]-4,5-dimethyl-pyrimidine; 3602-[[1-(3,5-Dimethylphenyl)triazol-4- 0.791 yl]methoxy]pyrimidine; 3612-[[1-(3,5-Dimethylphenyl)triazol-4-yl]methoxy]-5- 0.587fluoro-pyrimidine; 3622-[[1-(3,5-Dimethylphenyl)triazol-4-yl]methoxy]-5- 0.032methoxy-pyrimidine; 363 5-Chloro-2-[[1-(3,5-dimethylphenyl)triazol-4-0.118 yl]methoxy]pyrimidine; 3642-[[1-(3,5-Dimethylphenyl)triazol-4-yl]methoxy]-5- 0.027methyl-pyrimidine; 3652-[[1-(3,5-Dimethylphenyl)triazol-4-yl]methoxy]-5- 0.022ethyl-pyrimidine; 366 2-[(1-Indan-5-yltriazol-4-yl)methoxy]-5-methyl-0.020 pyrimidine; 367 5-Chloro-2-[(1-indan-5-yltriazol-4- 0.053yl)methoxy]pyrimidine; 368 2-[(1-Indan-5-yltriazol-4-yl)methoxy]-4-0.114 (methoxymethyl)pyrimidine; 3692-[2-[(1-Indan-5-yltriazol-4-yl)methoxy]pyrimidin-5- 0.175yl]propan-2-ol; 370 4-(Difluoromethyl)-2-[(1-indan-5-yltriazol-4- 0.397yl)methoxy]pyrimidine; 3715-Chloro-2-[(1-indan-5-yltriazol-4-yl)methoxy]-4- 0.039methyl-pyrimidine; 3722-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4- 0.008yl]methoxy]-4,5-dimethyl-pyrimidine; 3732-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4- 0.010yl]methoxy]-5-isopropyl-pyrimidine; 374 2-[(1R)-1-[1-[4-Chloro-3- 0.011(difluoromethoxy)phenyl]triazol-4-yl]ethoxy]pyrimidine; 3755-Chloro-2-[(1R)-1-[1-[4-chloro-3- 0.010(difluoromethoxy)phenyl]triazol-4-yl]ethoxy]pyrimidine; 3762-[(1R)-1-[1-[4-Chloro-3- 0.011(difluoromethoxy)phenyl]triazol-4-yl]ethoxy]-5-methyl- pyrimidine; 3772-[(1R)-1-[1-[4-Chloro-3- 0.010(difluoromethoxy)phenyl]triazol-4-yl]ethoxy]-5- methoxy-pyrimidine; 3782-[(1S)-1-[1-[4-Chloro-3- 2.300(difluoromethoxy)phenyl]triazol-4-yl]ethoxy]pyrimidine; 3795-Chloro-2-[(1S)-1-[1-[4-chloro-3- 0.575(difluoromethoxy)phenyl]triazol-4-yl]ethoxy]pyrimidine; 3802-[(1S)-1-[1-[4-Chloro-3- 0.237(difluoromethoxy)phenyl]triazol-4-yl]ethoxy]-5-methyl- pyrimidine; 3812-[(1S)-1-[1-[4-Chloro-3- 0.196(difluoromethoxy)phenyl]triazol-4-yl]ethoxy]-5- methoxy-pyrimidine; 3822-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4- 0.021yl]methoxy]pyrimidin-4-amine; 383[2-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4- 0.008yl]methoxy]pyrimidin-4-yl]methanol; 3842-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4- 0.018yl]methoxy]-4-(methoxymethyl)pyrimidine; 3852-[2-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4- 0.028yl]methoxy]pyrimidin-5-yl]propan-2-ol; 3862-((1-(4-Chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3- 0.504triazol-4-yl)methoxy)-4-isopropoxypyrimidine; 387 Methyl2-((1-(4-chloro-3-(difluoromethoxy)phenyl)- 0.0681H-1,2,3-triazol-4-yl)methoxy)pyrimidine-4- carboxylate; 3882-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4- 0.842yl]methoxy]-N-(2,2-difluoroethyl)-5-fluoro-pyrimidin-4- amine; 3892-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4- 0.033yl]methoxy]-5-fluoro-N-methyl-pyrimidin-4-amine; 3902-((1-(4-Chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3- 0.006triazol-4-yl)methoxy)-5-fluoropyrimidin-4-amine; 3915-(Azetidin-1-yl)-2-((1-(4-chloro-3- 0.022(difluoromethoxy)phenyl)-1H-1,2,3-triazol-4- yl)methoxy)pyrimidine; 3922-((1-(4-Chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3- 0.017triazol-4-yl)methoxy)-5-(3-fluoroazetidin-1- yl)pyrimidine; 3932-((1-(4-Chloro-3-(difluoromethoxy)phenyl)-1H-1,2,3- 0.037triazol-4-yl)methoxy)-5-(3,3-difluoroazetidin-1- yl)pyrimidine; 3942-[[1-[4-Chloro-3-(difluoromethoxy)phenyl]triazol-4- 0.437yl]methoxy]-6-fluoro-pyridine; 3952-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4- 0.919yl]methoxy]-6-(trifluoromethyl)pyridine; 3962-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4- 0.647yl]methoxy]-5-methyl-pyrazine; 3972-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4- 10.700yl]methoxy]-5-(2-thienyl)pyrazine; 3985-Bromo-2-[[1-[3-(difluoromethyl)-4-fluoro- 0.003phenyl]triazol-4-yl]methoxy]pyrimidine; 3992-[[1-[3-(Difluoromethyl)-4-fluoro-phenyl]triazol-4- 0.023yl]methoxy]-4-(methoxymethyl)pyrimidine; 400[2-[[1-[3-(Difluoromethyl)-4-fluoro-phenyl]triazol-4- 0.036yl]methoxy]pyrimidin-4-yl]methanol; 4012-[2-[[1-[3-(Difluoromethyl)-4-fluoro-phenyl]triazol-4- 0.017yl]methoxy]pyrimidin-5-yl]propan-2-ol; 4024-(Difluoromethyl)-2[[1-[3-(difluoromethyl)-4-fluoro- 0.051phenyl]triazol-4-yl]methoxy]pyrimidine; 4032-[[1-[3-(Difluoromethyl)-4-fluoro-phenyl]triazol-4- 0.199yl]methoxy]-4-(trifluoromethyl)pyrimidine; 404(R/S)-2-[2-[[1-[3-(Difluoromethyl)-4-fluoro- 0.482phenyl]triazol-4-yl]methoxy]pyrimidin-5-yl]-1,1,1-trifluoro-propan-2-ol; 4055-(Difluoromethoxy)-2-[[1-[3-(difluoromethyl)-4-fluoro- 0.003phenyl]triazol-4-yl]methoxy]pyrimidine; 4065-Chloro-2-[[1-[3-(difluoromethyl)-4-fluoro- 0.001phenyl]triazol-4-yl]methoxy]-4-methyl-pyrimidine; 4072-[[1-[3-(Difluoromethyl)-4-fluoro-phenyl]triazol-4- 0.001yl]methoxy]-5-fluoro-4-methyl-pyrimidine; 4082-[[1-[3-(Difluoromethyl)-4-fluoro-phenyl]triazol-4- 0.002yl]methoxy]-4,5-dimethyl-pyrimidine; 4092-[[1-[3-(Difluoromethyl)-4-fluoro-phenyl]triazol-4- 0.149yl]methoxy]-N-methyl-pyrimidine-5-carboxamide; 4102-[[1-[3-(Difluoromethyl)-4-fluoro-phenyl]triazol-4- >2.99yl]methoxy]-N,N-dimethyl-pyrimidine-4-carboxamde; 4112-[[1-[3-(Difluoromethyl)-4-fluoro-phenyl]triazol-4- 0.021yl]methoxy]-4-methoxy-5-methyl-pyrimidine; 4122-[[1-[3-(Difluoromethyl)-4-fluoro-phenyl]triazol-4- 0.124yl]methoxy]pyrimidin-4-amine; 4132-[[1-[3-(Difluoromethyl)-4-fluoro-phenyl]triazol-4- 0.015yl]methoxy]-N-methyl-pyrimidin-4-amine; 4142-[[1-[3-(Difluoromethyl)-4-fluoro-phenyl]triazol-4- 0.122yl]methoxy]-5-fluoro-N-methyl-pyrimidin-4-amine; 4152-[[1-[3-(Difluoromethyl)-4-fluoro-phenyl]triazol-4- 0.008yl]methoxy]-N,N-dimethyl-pyrimidin-4-amine; 4162-((1-(3-(Difluoromethyl)-4-fluorophenyl)-1H-1,2,3- 0.010triazol-4-yl)methoxy)-5-(3-fluoroazetidin-1- yl)pyrimidine; 4175-(Azetidin-1-yl)-2-((1-(3-(difluoromethyl)-4- 0.006fluorophenyl)-1H-1,2,3-triazol-4- yl)methoxy)pyrimidine; 4182-((1-(3-(Difluoromethyl)-4-fluorophenyl)-1H-1,2,3- 0.271triazol-4-yl)methoxy)-5-(3-methoxyazetidin-1- yl)pyrimidine; 4195-(3,3-Difluoroazetidin-1-yl)-2-((1-(3-(difluoromethyl)- 0.0294-fluorophenyl)-1H-1,2,3-triazol-4- yl)methoxy)pyrimidine; 4202-((1-(3-(Difluoromethyl)-4-fluorophenyl)-1H-1,2,3- 0.260triazol-4-yl)methoxy)-5-(3-fluoro-3-methylazetidin-1- yl)pyrimidine; 4212-((1-(3-(Difluoromethyl)-4-fluorophenyl)-1H-1,2,3- 0.227triazol-4-yl)methoxy)-5-(3-(difluoromethyl)azetidin-1- yl)pyrimidine;422 2-((1-(3-(Difluoromethyl)-4-fluorophenyl)-1H-1,2,3- 0.068triazol-4-yl)methoxy)-5-(3,3-difluoropyrrolidin-1- yl)pyrimidine; 4235-Cyclopropyl-2-[[1[3-(difluoromethyl)-4-fluoro- 0.005phenyl]triazol-4-yl]methoxy]pyrimidine; 4242-[[1-[3-(Difluoromethyl)-4-fluoro-phenyl]triazol-4- 0.141yl]methoxy]-4-(2-furyl)pyrimidine; 4252-[[1-[3-(Difluoromethyl)-4-fluoro-phenyl]-5-iodo- 0.394triazol-4-yl]methoxy]-5-methyl-pyrimidine; 426[3H]-2-((1-(3-(Difluoromethyl)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl-5-t)methoxy)-5-methylpyrimidine; 4273-Fluoro-2-[[1-[4-fluoro-3- 0.897(trifluoromethyl)phenyl]triazol-4-yl]methoxy]pyridine; 4285-Chloro-2-[[1-[4-fluoro-3- 0.796(trifluoromethyl)phenyl]triazol-4-yl]methoxy]pyridine; 4292-[[1-[4-Fluoro-3-(trifluoromethyl)phenyl]triazol-4- 0.665yl]methoxy]-4-methyl-pyridine; 4302-[[1-[4-Fluoro-3-(trifluoromethyl)phenyl]triazol-4- 0.110yl]methoxy]-6-methyl-pyridine; 4312-[[1-[4-Fluoro-3-(trifluoromethyl)phenyl]triazol-4- 0.101yl]methoxy]-5-methyl-pyridine; 4322-[[1-[4-Fluoro-3-(trifluoromethyl)phenyl]triazol-4- 0.528yl]methoxy]-5-(trifluoromethyl)pyridine; 4332-[6-[[1[4-Fluoro-3-(trifluoromethyl)phenyl]triazol-4- 1.114yl]methoxy]-3-pyridyl]propan-2-ol; 4342-[[1-[4-Fluoro-3-(trifluoromethyl)phenyl]triazol-4- 6.390yl]methoxy]pyrazine; 4352-[2-[[1-[4-Fluoro-3-(trifluoromethyl)phenyl]triazol-4- 0.098yl]methoxy]pyrimidin-5-yl]propan-2-ol; 4362-[[1-[4-Fluoro-3-(trifluoromethyl)phenyl]triazol-4- 3.260yl]methoxy]-5-(1-methoxy-1-methyl-ethyl)pyrimidine; 4372-[[1-[4-Fluoro-3-(trifluoromethyl)phenyl]triazol-4- 0.071yl]methoxy]-5-(methoxymethyl)pyrimidine; 4382-[[1-[4-Fluoro-3-(trifluoromethyl)phenyl]triazol-4- 0.094yl]methoxy]-4-(methoxymethyl)pyrimidine; 4395-(Difluoromethyl)-2-[[1-[4-fluoro-3- 0.013(trifluoromethyl)phenyl]triazol-4-yl]methoxy]pyrimidine; 4404-(Difluoromethyl)-2-[[1-[4-fluoro-3- 0.098(trifluoromethyl)phenyl]triazol-4-yl]methoxy]pyrimidine; 441(R/S)-1,1,1-Trifluoro-2-[2-[[1-[4-fluoro-3- 0.412(trifluoromethyl)phenyl]triazol-4-yl]methoxy]pyrimidin-5-yl]propan-2-ol; 4422-[[1-[4-Fluoro-3-(trifluoromethyl)phenyl]triazol-4- 0.072yl]methoxy]-4-methoxy-pyrimidine; 443 5-Ethoxy-2-[[1-[4-fluoro-3- 0.004(trifluoromethyl)phenyl]triazol-4- yl]methoxy]pyrimidine; 4445-Chloro-2-[[1-[4-fluoro-3- 0.013(trifluoromethyl)phenyl]triazol-4-yl]methoxy]-4-methyl- pyrimidine; 4455-Fluoro-2-[[1-[4-fluoro-3- 0.006(trifluoromethyl)phenyl]triazol-4-yl]methoxy]-4-methyl- pyrimidine; 4462-[[1-[4-Fluoro-3-(trifluoromethyl)phenyl]triazol-4- 0.001yl]methoxy]-4,5-dimethyl-pyrimidine; 4471-[2-[[1-[4-Fluoro-3-(trifluoromethyl)phenyl]triazol-4- 0.014yl]methoxy]pyrimidin-5-yl]ethanone; 448 (R/S)-1-[2-[[1-[4-Fluoro-3-0.031 (trifluoromethyl)phenyl]triazol-4-yl]methoxy]pyrimidin-5-yl]ethanol; 449 2-[[1-[4-Fluoro-3-(trifluoromethyl)phenyl]triazol-4-0.034 yl]methoxy]-N-methyl-pyrimidin-4-amine; 4502-[[1-[4-Fluoro-3-(trifluoromethyl)phenyl]triazol-4- 0.030yl]methoxy]-N,N-dimethyl-pyrimidin-4-amine; 4515-Fluoro-2-[[1-[4-fluoro-3- 0.298(trifluoromethyl)phenyl]triazol-4-yl]methoxy]-N-methyl-pyrimidin-4-amine; 4522-[[1-[4-Fluoro-3-(trifluoromethyl)phenyl]triazol-4- 0.218yl]methoxy]-N-methyl-pyrimidine-5-carboxamide; 4535-Cyclopropyl-2-[[1-[4-fluoro-3- 0.022(trifluoromethyl)phenyl]triazol-4- yl]methoxy]pyrimidine; 4545-Bromo-2-((1-(4-fluoro-3-(trifluoromethyl)phenyl)- 0.0131H-1,2,3-triazol-4-yl)methoxy)pyrimidine; 4552-((1-(4-Fluoro-3-(trifluoromethyl)phenyl)-1H-1,2,3- 0.034triazol-4-yl)methoxy)-5-(3-fluoroazetidin-1- yl)pyrimidine; 4564-(2-((1-(4-Fluoro-3-(trifluoromethyl)phenyl)-1H-1,2,3- 0.500triazol-4-yl)methoxy)pyrimidin-5-yl)morpholine; 4575-(Azetidin-1-yl)-2-((1-(3-(trifluoromethyl)-4- 0.296fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-4- methylpyrimidine; 4582-((1-(3-(Trifluoromethyl)-4-fluorophenyl)-1H-1,2,3- 0.439triazol-4-yl)methoxy)-N-ethyl-4-methylpyrimidin-5- amine; 4592-((1-(3-(Trifluoromethyl)-4-fluorophenyl)-1H-1,2,3- 0.126triazol-4-yl)methoxy)-N-ethylpyrimidin-5-amine; 4602-((1-(3-(Trifluoromethyl)-4-fluorophenyl)-1H-1,2,3- 0.726triazol-4-yl)methoxy)-5-(3-methoxyazetidin-1- yl)pyrimidine; 4615-Chloro-2-[[1-[2-fluoro-3- 0.070(trifluoromethyl)phenyl]triazol-4-yl]methoxy]pyrimidine; 4624-[[1-(4-Fluoro-3-methyl-phenyl)triazol-4-yl]methoxy]- 3.0306-methyl-pyrimidine; 4635-Chloro-2-[[1-(3-fluoro-2-methyl-phenyl)triazol-4- 0.647yl]methoxy]pyrimidine; 4642-[[1-(3-Fluoro-2-methyl-phenyl)triazol-4-yl]methoxy]- 0.5155-methyl-pyrimidine; 4655-Fluoro-2-[[1-(3-fluoro-2-methyl-phenyl)triazol-4- 3.720yl]methoxy]-4-methyl-pyrimidine; 4662-[2-[[1-(3-Fluoro-2-methyl-phenyl)triazol-4- 7.010yl]methoxy]pyrimidin-5-yl]propan-2-ol; 4672-[[1-(2-Fluoro-3-methyl-phenyl)triazol-4-yl]methoxy]- 0.7115-methyl-pyrimidine; 4685-Chloro-2-[[1-(2-fluoro-3-methyl-phenyl)triazol-4- 1.250yl]methoxy]pyrimidine; 4692-[[1-(2-Fluoro-3-methyl-phenyl)triazol-4-yl]methoxy]- 1.0585-(trifluoromethyl)pyrimidine; 4705-Chloro-2-[[1-(2-fluoro-3-methyl-phenyl)triazol-4- 0.659yl]methoxy]-4-methyl-pyrimidine; 4715-(Difluoromethoxy)-2-[[1-(2-fluoro-3-methyl- 1.729phenyl)triazol-4-yl]methoxy]pyrimidine; 4722-[[1-(4-Fluoro-3-methyl-phenyptriazol-4- 0.149yl]methoxy]pyrimidin-4-amine; 4732-[[1-(4-Fluoro-3-methyl-phenyl)triazol-4- 0.072 yl]methoxy]pyrimidine;474 5-Fluoro-2-[[1-(4-fluoro-3-methyl-phenyl)triazol-4- 0.022yl]methoxy]pyrimidine; 4752-[[1-(4-Fluoro-3-methyl-phenyl)triazol-4-yl]methoxy]- 0.0015-methoxy-pyrimidine; 4765-Chloro-2-[[1-(4-fluoro-3-methyl-phenyl)triazol-4- 0.002yl]methoxy]pyrimidine; 4772-[[1-(4-Fluoro-3-methyl-phenyl)triazol-4-yl]methoxy]- 0.0015-methyl-pyrimidine; 4785-Ethyl-2-[[1-(4-fluoro-3-methyl-phenyl)triazol-4- 0.001yl]methoxy]pyrimidine; 4792-[[1-(4-Fluoro-3-methyl-phenyl)triazol-4-yl]methoxy]- 0.0364-(methoxymethyl)pyrimidine; 4802-[[1-(4-Fluoro-3-methyl-phenyl)triazol-4-yl]methoxy]- 0.0014,5-dimethyl-pyrimidine; 4815-Fluoro-2-[[1-(4-fluoro-3-methyl-phenyl)triazol-4- 0.002yl]methoxy]-4-methyl-pyrimidine; 4825-Chloro-2-[[1-(4-fluoro-3-methyl-phenyl)triazol-4- 0.001yl]methoxy]-4-methyl-pyrimidine; 4835-(2-Fluoroethoxy)-2-[[1-(4-fluoro-3-methyl- 0.007phenyl)triazol-4-yl]methoxy]pyrimidine; 4842-[[1-(2-Fluoro-5-methyl-phenyl)triazol-4-yl]methoxy]- 1.0005-methyl-pyrimidine; 4855-Chloro-2-[[1-(2-fluoro-5-methyl-phenyl)triazol-4- 1.010yl]methoxy]-4-methyl-pyrimidine; 4865-Fluoro-2-[[1-(2-fluoro-5-methyl-phenyl)triazol-4- >2.99yl]methoxy]-4-methyl-pyrimidine; 4875-Fluoro-2-[[1-(4-fluoro-2-methyl-phenyl)triazol-4- 16.199yl]methoxy]pyridine; 4882-[[1-(4-Fluoro-2-methyl-phenyl)triazol-4-yl]methoxy]- 2.6505-methoxy-pyrimidine; 4895-Chloro-2-[[1-(4-fluoro-2-methyl-phenyl)triazol-4- 4.420yl]methoxy]pyrimidine; 4902-[[1-(4-Fluoro-2-methyl-phenyl)triazol-4-yl]methoxy]- 2.4405-methyl-pyrimidine; 4915-Ethyl-2-[[1-(4-fluoro-2-methyl-phenyl)triazol-4- 1.170yl]methoxy]pyrimidine; 4922-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4- 0.026yl]methoxy]-5-fluoro-pyrimidine; 4932-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4- 0.004yl]methoxy]-5-fluoro-4-methyl-pyrimidine; 4945-Bromo-2-[[1-[3-(difluoromethoxy)-4-fluoro- 0.003phenyl]triazol-4-yl]methoxy]pyrimidine; 4952-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4- 0.010yl]methoxy]-4-ethyl-pyrimidine; 4962[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4- 0.114yl]methoxy]-4-isopropyl-pyrimidine; 4972-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4- 0.028yl]methoxy]-4-methoxy-pyrimidine; 498[2-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4- 0.019yl]methoxy]pyrimidin-4-yl]methanol; 4992-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4- 0.016yl]methoxy]-4-(methoxymethyl)pyrimidine; 5002-[2-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol- 0.0684-yl]methoxy]pyrimidin-5-yl]propan-2-ol; 5012-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4- 0.052yl]methoxy]pyrimidin-4-amine; 5022-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4- 0.136yl]methoxy]pyrimidin-5-amine; 5032-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4- 0.008yl]methoxyl-N-methyl-pyrimidin-4-amine; 5042-((1-(3-(Difluoromethoxy)-4-fluorophenyl)-1H-1,2,3- 0.007triazol-4-yl)methoxy)-N-ethylpyrimidin-4-amine; 5052-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4- 0.007yl]methoxy]-N,N-dimethyl-pyrimidin-4-amine; 5062-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4- 9.750yl]methoxy]-4-phenyl-pyrimidine; 5072-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4- 0.008yl]methoxy]-5-(3-fluoroazetidin-1-yl)pyrimidine; 5085-(3,3-Difluoroazetidin-1-yl)-2[[1-[3- 0.019(difluoromethoxy)-4-fluoro-phenyl]triazol-4- yl]methoxy]pyrimidine; 5094-(Azetidin-1-yl)-2-[[1-[3-(difluoromethoxy)-4-fluoro- 0.003phenyl]triazol-4-yl]methoxy]pyrimidine; 5102-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4- 0.025yl]methoxy]-4-(3-fluoroazetidin-1-yl)pyrimidine; 5114-(3,3-Difluoroazetidin-1-yl)-2-[[1-[3- 0.041(difluoromethoxy)-4-fluoro-phenyl]triazol-4- yl]methoxy]pyrimidine; 512(R)-2-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol- 0.3084-yl]methoxy]-4-[(3R)-3-fluoropyrrolidin-1- y]pyrimidine; 5135-Chloro-2-[[1-[3-(difluoromethoxy)-4-fluoro- 0.004phenyl]triazol-4-yl]methoxy]-4-methyl-pyrimidine; 5142-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4- 0.005yl]methoxy]-5-methyl-pyrimidin-4-amine; 5152-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4- 0.099yl]methoxy]-N,5-dimethyl-pyrimidin-4-amine; 5162-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4- 0.017yl]methoxy]-N,N,5-trimethyl-pyrimidin-4-amine; 517N-(2,2-Difluoroethyl)-2-[[1-[3-(difluoromethoxy)-4- 0.912fluoro-phenyl]triazol-4-yl]methoxy]-5-fluoro-pyrimidin- 4-amine; 5182-[[1-[3-(Difluoromethoxy)-4-fluoro-phenyl]triazol-4- 0.092yl]methoxy]-5-fluoro-N-methyl-pyrimidin-4-amine; 519N-Cyclopropyl-2-((1-(3-(difluoromethoxy)-4- 0.204fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-5- fluoropyrimidin-4-amine;520 1-(2-((1-(3-(Difluoromethoxy)-4-fluorophenyl)-1H- 0.6721,2,3-triazol-4-yl]methoxy)pyrimidin-4-yl)-N- methylmethanamine; 5212-[[1-[3-(Difluoromethoxy)-4-methyl-phenyl]triazol-4- 0.021yl]methoxy]-5-methyl-pyrimidin-4-amine; 5221-[2-[[1-[3-(Difluoromethoxy)-4-methyl-phenyl]triazol- 0.0934-yl]methoxy]pyrimidin-5-yl]ethanone; 5232-[[1-[3-(Difluoromethoxy)-4-methyl-phenyl]triazol-4- 0.114yl]methoxy]-4-methyl-pyrimidine; 5242-[[1-[3-(Difluoromethoxy)-4-methyl-phenyl]triazol-4- 0.028yl]methoxy]-5-methyl-pyrimidine; 5255-Bromo-2[[1-[3-(difluoromethoxy)-4-methyl- 0.040phenyl]triazol-4-yl]methoxy]pyrimidine; 5262-[2-[[1-[3-(Difluoromethoxy)-4-methyl-phenyl]triazol- 0.4254-yl]methoxy]pyrimidin-5-yl]propan-2-ol; 5272-[[1-[3-(Difluoromethoxy)-4-methyl-phenyl]triazol-4- 0.132yl]methoxy]-4-(methoxymethyl)pyrimidine; 5282-[[1-[3-(Difluoromethyl)phenyl]-5-methyl-triazol-4- 0.752yl]methoxy]-4,5-dimethyl-pyrimidine; 5295-Chloro-2-[[1-[3-(difluoromethyl)phenyl]-5-methyl- 1.320triazol-4-yl]methoxy]pyrimidine; 5302-[[1-[4-Chloro-3-(1,1-difluoroethyl)phenyl]triazol-4- 0.005yl]methoxy]-5-methyl-pyrimidine; 5312-[[1-[4-Chloro-3-(1,1-difluoroethyl)phenyl]triazol-4- 0.017yl]methoxy]-4-methyl-pyrimidine; 5322-[2-[[1-[4-Chloro-3-(1,1-difluoroethyl)phenyl]triazol- 0.0814-yl]methoxy]pyrimidin-5-yl]propan-2-ol; 533[2-[[1-[4-Chloro-3-(1,1-difluoroethyl)phenyl]triazol-4- 0.017yl]methoxy]pyrimidin-5-yl]methanol; 5342-[[1-[4-Chloro-3-(1,1-difluoroethyl)phenyl]triazol-4- 0.003yl]methoxy]-4-(methoxymethyl)pyrimidine; 5352-[[1-[4-Chloro-3-(1,1-difluoroethyl)phenyl]triazol-4- 0.009yl]methoxy]-5-(difluoromethyl)pyrimidine; 5362-[[1-[4-Chloro-3-(1,1-difluoroethyl)phenyl]triazol-4- 0.067yl]methoxy]-4-(difluoromethyl)pyrimidine; 5372-[[1-[4-Chloro-3-(1,1-difluoroethyl)phenyl]triazol-4- 0.016yl]methoxy]-5-(trifluoromethyl)pyrimidine; 5382-[[1-[4-Chloro-3-(1,1-difluoroethyl)phenyl]triazol-4- 0.318yl]methoxy]-4-(trifluoromethyl)pyrimidine; 539(R/S)-2-[2-[[1-[4-Chloro-3-(1,1- 0.450difluoroethyl)phenyl]triazol-4-yl]methoxy]pyrimidin-5-yl]-1,1,1-trifluoro-propan-2-ol; 540[2-[[1-[4-Chloro-3-(1,1-difluoroethyl)phenyl]triazol-4- 0.019yl]methoxy]pyrimidin-4-yl]methanol; 5412-[[1-[4-Chloro-3-(1,1-difluoroethyl)phenyl]triazol-4- 0.012yl]methoxy]-4-methoxy-pyrimidine; 5422-[[1-[4-Chloro-3-(1,1-difluoroethyl)phenyl]triazol-4- 0.012yl]methoxy]-5-(difluoromethoxy)pyrimidine; 5435-Chloro-2-[[1-[4-chloro-3-(1,1- 0.015difluoroethyl)phenyl]triazol-4-yl]methoxy]-4-methyl- pyrimidine; 5442-[[1-[4-Chloro-3-(1,1-difluoroethyl)phenyl]triazol-4- 0.015yl]methoxy]-5-fluoro-4-methyl-pyrimidine; 5452-[[1-[4-Chloro-3-(1,1-difluoroethyl)phenyl]triazol-4- 0.006yl]methoxy]-4,5-dimethyl-pyrimidine; 5462-[[1-[4-Chloro-3-(1,1-difluoroethyl)phenyl]triazol-4- 0.024yl]methoxy]-4,6-dimethyl-pyrimidine; 5472-[[1-[4-Chloro-3-(1,1-difluoroethyl)phenyl]triazol-4- 0.033yl]methoxy]pyrimidin-4-amine; 5482-[[1-[4-Chloro-3-(1,1-difluoroethyl)phenyl]triazol-4- 0.055yl]methoxy]-N-methyl-pyrimidin-4-amine; 5492-[[1-[4-Chloro-3-(1,1-difluoroethyl)phenyl]triazol-4- 0.094yl]methoxy]-5-fluoro-N-methyl-pyrimidin-4-amine; 5501-[2-[[1-[4-Chloro-3-(1,1-difluoroethyl)phenyl]triazol- 0.0164-yl]methoxy]pyrimidin-5-yl]ethanone; 551(R/S)-1-[2-[[1-[4-Chloro-3-(1,1- 0.014difluoroethyl)phenyl]triazol-4-yl]methoxy]pyrimidin-5- yl]ethanol; 5522-[[1-[4-Chloro-3-(1,1-difluoroethyl)phenyl]triazol-4- 0.086yl]methoxy]-5-cyclopropyl-pyrimidine; 5532-[[1-[4-Chloro-3-(1,1-difluoroethyl)phenyl]triazol-4- 0.043yl]methoxy]-4-pyrrolidin-1-yl-pyrimidine; 5542-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4- 1.640yl]methoxy]pyridine; 5552-[[1-[3-[1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4- 0.265yl]methoxy]-3-fluoro-pyridine; 5562-[[1-[3-[1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4- 0.098yl]methoxy]-6-methyl-pyridine; 5572-[[1-[3-[1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4- 0.246yl]methoxy]-4-methyl-pyridine; 5582-[[1-[3-[1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4- 0.125yl]methoxy]-5-methyl-pyridine; 5592-[[1-[3-[1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4- 0.812yl]methoxy]-5-(trifluoromethyl)pyridine; 5606-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4- 0.052yl]methoxy]-2,3-dimethyl-pyridine; 5613-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4- 0.476yl]methoxy]-2-methoxy-pyridine; 5622-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4- 0.014yl]methoxy]-5-(difluoromethyl)pyrimidine; 5632-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4- 0.048yl]methoxy]-4-(difluoromethyl)pyrimidine; 5642-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4- 0.272yl]methoxy]-4-(trifluoromethyl)pyrimidine; 565(R/S)-2-[2-[[1-[3-(1,1-Difluoroethyl)-4-fluoro- 0.308phenyl]triazol-4-yl]methoxy]pyrimidin-5-yl]-1,1,1-trifluoro-propan-2-ol; 5662-[2-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol- 0.0084-yl]methoxy]pyrimidin-5-yl]propan-2-ol; 5672-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4- 4.630yl]methoxy]-5-(1-methoxy-1-methyl-ethyl)pyrimidine; 568[2-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4- 0.025yl]methoxy]pyrimidin-4-yl]methanol; 5692-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4- 0.089yl]methoxy]-5-(methoxymethyl)pyrimidine; 5702-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4- 0.011yl]methoxy]-4-(methoxymethyl)pyrimidine; 571[2-[[1-[3-(1,1-difluoroethyl)-4-fluoro-phenyl]triazol-4- 0.021yl]methoxy]pyrimidin-5-yl]methanol; 5722-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4- 0.025yl]methoxy]-5-(difluoromethoxy)pyrimidine; 5732-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4- 0.019yl]methoxy]-4,5-dimethyl-pyrimidine; 5745-Chloro-2-[[1-[3-(1,1-difluoroethyl)-4-fluoro- 0.010phenyl]triazol-4-yl]methoxy]-4-methyl-pyrimidine; 5752-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4- 0.006yl]methoxy]-5-fluoro-4-methyl-pyrimidine; 5762-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4- 0.017yl]methoxy]-5-methyl-pyrimidin-4-amine; 5772-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4- 0.128yl]methoxy]-N,5-dimethyl-pyrimidin-4-amine; 5782-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4- 0.140yl]methoxy]-5-fluoro-N-methyl-pyrimidin-4-amine; 5792-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4- 0.087yl]methoxy]-N,N,5-trimethyl-pyrimidin-4-amine; 5802-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4- 0.088yl]methoxy]pyrimidin-4-amine; 5812-[[1-3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4- 0.033yl]methoxy]-N-methyl-pyrimidin-4-amine; 5822-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4- 0.028yl]methoxy]-N,N-dimethyl-pyrimidin-4-amine; 5832-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4- 0.067yl]methoxy]pyrimidine-5-carbonitrile; 5842-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4- 0.199yl]methoxy]-5-methylsulfonyl-pyrimidine; 5851-[2-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol- 0.0114-yl]methoxy]pyrimidin-5-yl]ethanone; 586(R/S)-1-[2-[[1-[3-(1,1-Difluoroethyl)-4-fluoro- 0.014phenyl]triazol-4-yl]methoxy]pyrimidin-5-yl]ethanol; 5875-Cyclopropyl-2-[[1-[3-(1,1-difluoroethyl)-4-fluoro- 0.041phenyl]triazol-4-yl]methoxy]pyrimidine; 5885-(Azetidin-1-yl)-2-[[1-[3-(1,1-difluoroethyl)-4-fluoro- 0.034phenyl]triazol-4-yl]methoxy]pyrimidine; 5892-((1-(3-(1,1-Difluoroethyl)-4-fluorophenyl)-1H-1,2,3- 0.013triazol-4-yl)methoxy)-5-(3-fluoroazetidin-1- yl)pyrimidine; 5902-((1-(3-(1,1-Difluoroethyl)-4-fluorophenyl)-1H-1,2,3- 0.039triazol-4-yl)methoxy)-N,N-dimethylpyrimidin-5-amine; 5912-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4- 0.016yl]methoxy]-4-pyrrolidin-1-yl-pyrimidine; 5922-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4- 0.271yl]methoxy]-4-(1-piperidyl)pyrimidine; 5932-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]-5-methyl- 0.486triazol-4-yl]methoxy]-5-ethyl-pyrimidine; 5945-Cyclopropyl-2-[[1-[3-(1,1-difluoroethyl)-4-fluoro- 0.171phenyl]-5-methyl-triazol-4-yl]methoxy]pyrimidine; 5952-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]-5-methyl- 0.706triazol-4-yl]methoxy]-4,5-dimethyl-pyrimidine; 5965-Chloro-2-[[1-[3-(1,1-difluoroethyl)-4-fluoro-phenyl]- 0.6015-methyl-triazol-4-yl]methoxy]-4-methyl-pyrimidine; 5972-[[1-(3,4-Difluorophenyl)triazol-4- 2.100 yl]methoxy]pyrimidine; 5982-[[1-(3,4-Difluorophenyl)triazol-4-yl]methoxy]-5- 1.450fluoro-pyrimidine; 5992-[[1-(3,4-Difluorophenyl)triazol-4-yl]methoxy]-5- 0.034methoxy-pyrimidine; 600 5-Chloro-2-[[1-(3,4-difluorophenyl)triazol-4-0.238 yl]methoxy]pyridine; 6012-[[1-(3,4-Difluorophenyl)triazol-4-yl]methoxy]-5- 0.048methyl-pyrimidine; 6022-[[1-(3,4-Difluorophenyl)triazol-4-yl]methoxy]-5- 0.023ethyl-pyrimidine; 603 2-[[1-(2,5-Difluorophenyl)triazol-4-yl]methoxy]-5-10.430 methyl-pyrimidine; 604 2-[2-[[1-(2,5-Difluoropheny)triazol-4-79.708 yl]methoxy]pyrimidin-5-yl]propan-2-ol; 6055-Chloro-2-[[1-(2,3-difluorophenyl)triazol-4- 4.360yl]methoxy]pyrimidine; 6062-[[1-(2,3-Difluorophenyl)triazol-4-yl]methoxy]-5- 17.499fluoro-pyrimidine; 607 2-[[1-(2,3-Difluorophenyl)triazol-4- 3.425yl]methoxy]pyrimidine; 608 2-[2-[[1-(2,3-Difluoropheny])triazol-4- >10yl]methoxy]pyrimidin-5-yl]propan-2-ol; 6092-[[1-(2,3-Difluorophenyl)triazol-4-yl]methoxy]-5- 15,900fluoro-4-methyl-pyrimidine; 6102-[[1-(3-Chloro-2-fluoro-phenyl)triazol-4-yl]methoxy]- 1.0345-methyl-pyrimidine; 611 2-[[1-(3-Chloro-2-fluoro-phenyl)triazol-4- >10yl]methoxy]pyrimidine; 6125-Chloro-2-[[1-(3-chloro-2-fluoro-phenyl)triazol-4- 1.737yl]methoxy]pyrimidine; 6132-[[1-(3-Chloro-2-fluoro-phenyl)triazol-4-yl]methoxy]- 1.4415-fluoro-4-methyl-pyrimidine; 6142-[[1-(3-Chloro-2-fluoro-phenyl)triazol-4-yl]methoxy]- 4.0325-fluoro-pyrimidine; 615 2-[2-[[1-(3-Chloro-2-fluoro-phenyl)triazol-4-4.658 yl]methoxy]pyrimidin-5-yl]propan-2-ol; 616[2-[[1-(3-Bromo-4-fluoro-phenyl)triazol-4- 0.030yl]methoxy]pyrimidin-5-yl]methanol; 617[2-[[1-(3-Bromo-4-fluoro-phenyl)triazol-4- 0.041yl]methoxy]pyrimidin-4-yl]methanol; 6182-[[1-(3-Bromo-4-fluoro-phenyl)triazol-4yl]methoxy]- 0.0065-(2-fluoroethoxy)pyrimidine; 6192-[[1-(3-Chloro-4-fluoro-phenyl)triazol-4- 0.217 yl]methoxy]pyrimidine;620 2-[[1-(3-Chloro-4-fluoro-phenyl)triazol-4-yl]methoxy]- 0.0085-methyl-pyrimidine; 6212-[[1-(3-Chloro-4-fluoro-phenyl)triazol-4-yl]methoxy]- 0.0035-ethyl-pyrimidine; 6222-[[1-(3-Chloro-4-fluoro-phenyl)triazol-4-yl]methoxy]- 0.0664-(methoxymethyl)pyrimidine; 6232-[[1-[4-Chloro-3-(difluoromethyl)phenyl]triazol-4- 0.129yl]methoxy]-4-isopropyl-pyrimidine; 624[2-[[1-[4-Chloro-3-(difluoromethyl)phenyl]triazol-4- 0.020yl]methoxy]pyrimidin-5-yl]methanol; 625[2-[[1-[4-Chloro-3-(difluoromethyl)phenyl]triazol-4- 0.017yl]methoxy]pyrimidin-4-yl]methanol; 6262-[2-[[1-[4-Chloro-3-(difluoromethyl)phenyl]triazol-4- 0.067yl]methoxy]pyrimidin-5-yl]propan-2-ol; 6272-[[1-[4-Chloro-3-(difluoromethyl)phenyl]triazol-4- 0.038yl]methoxy]-4-(methoxymethyl)pyrimidine; 6282-[[1-[4-Chloro-3-(difluoromethyl)phenyl]triazol-4- 0.042yl]methoxy]-4-(difluoromethyl)pyrimidine; 6292-[[1-[4-Chloro-3-(difluoromethyl)phenyl]triazol-4- 0.007yl]methoxy]-N,N-dimethyl-pyrimidin-4-amine; 6302-[[1-[4-Chloro-3-(difluoromethyl)phenyl]triazol-4- 0.013yl]methoxy]-5-cyclopropyl-pyrimidine; 6312-[[1-[4-Chloro-3-(difluoromethyl)phenyl]triazol-4- 0.042yl]methoxy]-4-cyclopropyl-pyrimidine; 6322-[[1-[4-chloro-3-(difluoromethyl)phenyl]triazol-4- 0.004yl]methoxy]-5-methyl-pyrimidin-4-amine; 6332-[[1-[4-Chloro-3-(duoromethyl)phenyl]triazol-4- 0.057yl]methoxy]-N,N,5-trimethyl-pyrimidin-4-amine; 6342-[[1-[4-Chloro-3-(difluoromethyl)phenyl]triazol-4- 0.012yl]methoxy]-4-pyrrolidin-1-yl-pyrimidine; 6352-[[1-[4-Chloro-3-(difluoromethyl)phenyl]triazol-4- 0.169yl]methoxy]-4-(1-piperidyl)pyrimidine; 6362-[[1-[4-Chloro-3-(difluoromethyl)phenyl]triazol-4- 0.010yl]methoxy]-5-(2-fluoroethoxy)pyrimidine; 6372-[[1-[4-Chloro-3-(difluoromethyl)phenyl]triazol-4- 0.011yl]methoxy]-5-(3-fluoropropyl)pyrimidine; 6382-((1-(4-(Azetidin-1-yl)-3-(difluoromethyl)phenyl)-1H- 0.5111,2,3-triazol-4-yl)methoxy)-5-methylpyrimidine; 6392-[[1-(2,4-Difluoro-3-methyl-phenyl)triazol-4- 0.052yl]methoxy]-5-isopropyl-pyrimidine; 6402-[[1-(2,4-Difluoro-3-methyl-phenyl)triazol-4- 1.980yl]methoxy]-4-isopropyl-pyrimidine; 6415-(Difluoromethyl)-2-[[1-(2,4-difluoro-3-methyl- 0.111phenyl)triazol-4-yl]methoxy]pyrimidine; 6424-(Difluoromethyl)-2-[[1-(2,4-difluoro-3-methyl- 2.210phenyl)triazol-4-yl]methoxy]pyrimidine; 6432-[[1-(2,4-Difluoro-3-methyl-phenyl)triazol-4- 0.200yl]methoxy]-5-(trifluoromethyl)pyrimidine; 6442-[2-[[1-(2,4-Difluoro-3-methyl-phenyl)triazol-4- 0.967yl]methoxy]pyrimidin-5-yl]propan-2-ol; 6452-[[1-(2,4-Difluoro-3-methyl-phenyl)triazol-4- 0.799yl]methoxy]-4-(methoxymethyl)pyrimidine; 6465-(Difluoromethoxy)-2-[[1-(2,4-difluoro-3-methyl- 0.099phenyl)triazol-4-yl]methoxy]pyrimidine; 6475-Cyclopropyl-2-[[1-(2,4-difluoro-3-methyl- 0.034phenyl)triazol-4-yl]methoxy]pyrimidine; 6484-Cyclopropyl-2-[[1-(2,4-difluoro-3-methyl- 0.592phenyl)triazol-4-yl]methoxy]pyrimidine; 6492-[[1-(2,4-Difluoro-3-methyl-phenyl)triazol-4- 0.152yl]methoxy]-5-fluoro-4-methyl-pyrimidine; 6505-Chloro-2-[[1-(2,4-difluoro-3-methyl-phenyl)triazol-4- 0.005yl]methoxy]-4-methyl-pyrimidine; 6512-[[1-(2,4-Difluoro-3-methyl-phenyl)triazol-4- 0.262yl]methoxy]-5-methyl-pyrimidin-4-amine; 6522-[[1-[3-(Difluoromethyl)-2,4-difluoro-phenyl]triazol-4- 0.112yl]methoxy]-5-(trifluoromethyl)pyrimidine; 6535-Chloro-2-[[1-(2,4-difluoro-5-methyl-phenyl)triazol-4- 1.490yl]methoxy]pyrimidine; 6542-[[1-(2,4-Difluoro-5-methyl-phenyl)triazol-4- 0.979yl]methoxy]-5-methyl-pyrimidine; 6552-[[1-(2,4-Difluoro-5-methyl-phenyl)triazol-4- 0.507yl]methoxy]-5-ethyl-pyrimidine; 6565-(Difluoromethyl)-2-[[1-(2,4-difluoro-5-methyl- 1.510phenyl)triazol-4-yl]methoxy]pyrimidine; 6575-Chloro-2[[1-(2,4-difluoro-5-methyl-phenyl)triazol-4- 0.781yl]methoxy]-4-methyl-pyrimidine; 6585-Cyclopropyl-2-[[1-(2,4-difluoro-5-methyl- 0.424phenyl)triazol-4-yl]methoxy]pyrimidine; 6595-Chloro-2[[1-(6-methyl-2-pyridyl)triazol-4- >2.99yl]methoxy]pyrimidine; 6605-Ethyl-2-[[1-(6-methyl-2-pyridyl)triazol-4- >2.99yl]methoxy]pyrimidine; 6615-Chloro-4-methyl-2-[[1-(6-methyl-2-pyridyl)triazol-4- >2.99yl]methoxy]pyrimidine; 6625-Methyl-2-[[1-(4-methyl-2-pyridyl)triazol-4- >2.99yl]methoxy]pyrimidine; 663 5-Ethyl-2-[[1-(4-methyl-2-pyridyl)triazol-4-2.450 yl]methoxy]pyrimidine; 6645-Ethyl-2-[[1-(2-methyl-4-pyridyl)triazol-4- 0.169yl]methoxy]pyrimidine; 6652-[[1-(2-Bromo-4-pyridyl)triazol-4-yl]methoxy]-5-ethyl- 0.261pyrimidine; 666 5-Methyl-2-[[1-[2-(trifluoromethyl)-4-pyridyl]triazol-4-0.668 yl]methoxy]pyrimidine; 6675-Ethyl-2-[[1-[2-(trifluoromethyl)-4-pyridyl]triazol-4- 0.184yl]methoxy]pyrimidine; 6685-Fluoro-4-methyl-2-((1-(5-(trifluoromethyl)thiophen- 0.0082-yl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidine; 6695-Methoxy-2-((1-(5-(trifluoromethyl)thiophen-2-yl)-1H- 0.0041,2,3-triazol-4-yl)methoxy)pyrimidine; 6705-(Trifluoromethyl)-2-((1-(5-(trifluoromethyl)thiophen- 0.0632-yl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidine; 6712-((1-(3-(Difluoromethoxy)-4-fluorophenyl)-1H-1,2,3- 0.126triazol-4-yl)methoxy)-N-(oxetan-3-yl)pyrimidin-4-amine; 6725-(Azetidin-1-yl)-2-((1-(3-(difluoromethoxy)-4- NTfluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyridine; 6732-((1-(3-(Difluoromethoxy)-4-fluorophenyl)-1H-1,2,3- NTtriazol-4-yl)methoxy)-5-(3-fluoroazetidin-1-yl)pyridine; 6745-(3,3-Difluoroazetidin-1-yl)-2-((1-(3- NT(difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyridine; 675 2-(Azetidin-1-yl)-6-((1-(3-(difluoromethoxy)-4-NT fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyridine; 6762-((1-(3-(Difluoromethoxy)-4-fluorophenyl)-1H-1,2,3- NTtriazol-4-yl)methoxy)-6-(3-fluoroazetidin-1-yl)pyridine; 6772-(3,3-Difluoroazetidin-1-yl)-6-((1-(3- NT(difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyridine; 678 4-(Azetidin-1-yl)-2-((1-(3-(difluoromethoxy)-4-NT fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyridine; 6792-((1-(3-(Difluoromethoxy)-4-fluorophenyl)-1H-1,2,3- NTtriazol-4-yl)methoxy)-4-(3-fluoroazetidin-1-yl)pyridine; 6804-(3,3-Difluoroazetidin-1-yl)-2-((1-(3- NT(difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyridine; 6812-((1-(3-(Difluoromethoxy)-4-fluorophenyl)-1H-1,2,3- 0.681triazol-4-yl)methoxy)-4-(1H-pyrrol-2-yl)pyrimidine; 6822-((1-(3-(Difluoromethoxy)-4-fluorophenyl)-1H-1,2,3- NTtriazol-4-yl)methoxy)-4-(1H-pyrazol-5-yl)pyrimidine; 6832-((1-(3-(Difluoromethoxy)-4-fluorophenyl)-1H-1,2,3- NTtriazol-4-yl)methoxy)-5-(1H-pyrrol-2-yl)pyrimidine; 6842-((1-(3-(Difluoromethoxy)-4-fluorophenyl)-1H-1,2,3- NTtriazol-4-yl)methoxy)-5-(1H-pyrazol-5-yl)pyrimidine; 6852-((1-(3-(Difluoromethoxy)-4-fluorophenyl)-1H-1,2,3- NTtriazol-4-yl)methoxy)-N-ethyl-5-fluoropyrimidin-4- amine; 6862-((1-(3-(Difluoromethoxy)-4-fluorophenyl)-1H-1,2,3- NTtriazol-4-yl)methoxy)-5-fluoro-N-(oxetan-3- yl)pyrimidin-4-amine; 687N-(3,3-Difluorocyclobutyl)-2-((1-(3-(difluoromethoxy)- NT4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-5-fluoropyrimidin-4-amine; 688 N-Cyclopropyl-2-((1-(3-(difluoromethoxy)-4-NT fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidin- 4-amine; 689N-(3,3-Difluorocyclobutyl)-2-((1-(3-(difluoromethoxy)- NT4-fluorophenyl)-1H-1,2,3-triazol-4- yl)methoxy)pyrimidin-4-amine; 690N-Cyclopropyl-2-((1-(3-(difluoromethyl)-4- 0.008fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidin- 4-amine; 691N-Ethyl-2-((1-(3-(difluoromethyl)-4-fluorophenyl)-1H- 0.0061,2,3-triazol-4-yl)methoxy)pyrimidin-4-amine; 6922-((1-(3-(Difluoromethyl)-4-fluorophenyl)-1H-1,2,3- 1.580triazol-4-yl)methoxy)-4-(2-methyl-1H-imidazol-1- yl)pyrimidine; 6932-((1-(3-(Difluoromethyl)-4-fluorophenyl)-1H-1,2,3- NTtriazol-4-yl)methoxy)-5-(2-methyl-1H-imidazol-1- yl)pyrimidine; 6942-((1-(3-(Difluoromethyl)-4-fluorophenyl)-1H-1,2,3- NTtriazol-4-yl)methoxy)-5(1H-pyrazol-5-yl)pyrimidine; 6952-((1-(3-(Difluoromethyl)-4-fluorophenyl)-1H-1,2,3- NTtriazol-4-yl)methoxy)-4-(1H-pyrazol-5-yl)pyrimidine; 6964-(1,1-Difluoroethyl)-2-((1-(3-(difluoromethyl)-4- 0.958fluorophenyl)-1H-1,2,3-triazol-4- yl)methoxy)pyrimidine; 6974-((Difluoromethoxy)methyl)-2-((1-(3-(difluoromethyl)- NT4-fluorophenyl)-1H-1,2,3-triazol-4- yl)methoxy)pyrimidine; 6982-((1-(3-(Difluoromethyl)-4-fluorophenyl)-1H-1,2,3- NTtriazol-4-yl)methoxy)-5-(1H-pyrazol-1-yl)pyrimidine; 6992-((1-(3-(Difluoromethyl)-4-fluorophenyl)-1H-1,2,3- 0.389triazol-4-yl)methoxy)-4-(1H-pyrazol-1-yl)pyrimidine; 700(E)-1-(2-((1-(3-(Difluoromethyl)-4-fluorophenyl)-1H- NT1,2,3-triazol-4-yl)methoxy)pyrimidin-5-yl)ethan-1-one oxime; 7015-(1,1-Difluoroethyl)-2-((1-(3-(difluoromethyl)-4- 0.958fluorophenyl)-1H-1,2,3-triazol-4- yl)methoxy)pyrimidine; 702(Z)-1-(2-((1-(3-(Difluoromethyl)-4-fluorophenyl)-1H- NT1,2,3-triazol-4-yl)methoxy)pyrimidin-4-yl)ethan-1-one oxime; 703(2-((1-(3-(Difluoromethoxy)-4-fluorophenyl)-1H-1,2,3- NTtriazol-4-yl)methoxy)-5-fluoropyrimidin-4-yl)methanol; 7042-((1-(3-(Difluoromethoxy)-4-fluorophenyl)-1H-1,2,3- NTtriazol-4-yl)methoxy)-4-((difluoromethoxy)methyl)-5- fluoropyrimidine;705 2-((1-(3-(Difluoromethoxy)-4-fluorophenyl)-1H-1,2,3- NTtriazol-4-yl)methoxy)-4- ((difluoromethoxy)methyl)pyrimidine; 7062-((1-(3-(Difluoromethoxy)-4-fluoropheny)-1H-1,2,3- NTtriazol-4-yl)methoxy)-5-fluoro-4- ((trifluoromethoxy)methyl)pyrimidine;707 2-((1-(3-(Difluoromethoxy)-4-fluorophenyl)-1H-1,2,3- NTtriazol-4-yl)methoxy)-4- ((trifluoromethoxy)methyl)pyrimidine; 7082-((1-(3-(Difluoromethoxy)-4-fluorophenyl)-1H-1,2,3- NTtriazol-4-y)methoxy)-4-(methoxymethyl- d2)pyrimidine; 7092-((1-(3-(Difluoromethoxy)-4-fluoropheny)-1H-1,2,3- NTtriazol-4-yl)methoxy)-4-((methoxy-d3)methyl- d2)pyrimidine; 7102-((1-(3-(Difluoromethoxy)-4-fluorophenyl)-1H-1,2,3- NTtriazol-4-yl)methoxy)-4-((methoxy- d3)methyl)pyrimidine; 7112-((1-(3-(Difluoromethoxy)-4-fluorophenyl)-1H-1,2,3- 0.043triazol-4-yl)methoxy)-4-(ethoxymethyl)pyrimidine; 7122-((1-(3-(Difluoromethoxy)-4-fluorophenyl)-1H-1,2,3- NTtriazol-4-yl)methoxy)-4-(1-methoxyethyl)pyrimidine; 7131-(2-((1-(3-(Difluoromethoxy)-4-fluorophenyl)-1H- NT1,2,3-triazol-4-yl)methoxy)pyrimidin-4-yl)ethan-1-ol; 7142-((1-(3-(Difluoromethoxy)-4-fluorophenyl)-1H-1,2,3- NTtriazol-4-yl)methoxy)-4-(2-methoxypropan-2- yl)pyrimidine; 7152-(2-((1-(3-(Difluoromethoxy)-4-fluorophenyl)-1H- NT1,2,3-triazol-4-yl)methoxy)pyrimidin-4-yl)propan-2-ol; and 7164-((2,2-Difluoroethoxy)methyl)-2-((1-(3- 0.049(difluoromethoxy)-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)pyrimidine. NT means not tested.

What is claimed:
 1. A method of treating a subject suffering from ordiagnosed with a disease, disorder, or medical condition mediated byNR2B receptor activity, comprising administering to a subject in need ofsuch treatment an effective amount of at least one compound selectedfrom compounds of Formula (I):

wherein: Ar¹ is selected from the group consisting of: (a) phenylsubstituted with one substituent selected from the group consisting of:halo, C₁₋₆alkyl, C₁₋₆perhaloalkyl, and OC₁₋₆perhaloalkyl; phenylsubstituted with two or three substituents each independently selectedfrom the group consisting of: halo, C₁₋₆alkyl, C₁₋₆perhaloalkyl,OC₁₋₆alkyl, OC₁₋₆perhaloalkyl, C₃₋₆-cycloalkyl, and azetidinyl; (b)pyridinyl; pyridinyl substituted with one or two members eachindependently selected from the group consisting of: halo, CH₃, CF₃, andCF₂H; and (c) thienyl substituted with CF₃;1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl; or 2,3-dihydro-1H-inden-5-yl;R¹ is H, halo, or CH₃; R² is H or CH₃; and Ar³ is selected from thegroup consisting of: (a) pyridinyl; pyridinyl substituted with one ortwo substituents each independently selected from the group consistingof: Cl, F, CH₃, OCH₃, CF₃, C(CH₃)₂OH; azetidin-1-yl;3-fluoroazetidin-1-yl; and 3,3-difluoroazetidin-1-yl; (b) pyridazinyl;pyridazinyl substituted with one or two substituents each independentlyselected from the group consisting of: CH₃, OCH₃, and CF₃; (c)pyrimidin-4-yl; pyrimidin-4-yl substituted with one or two substituentseach independently selected from the group consisting of: Cl, CH₃, CF₃,and OCH₃; pyrimidin-2-yl; pyrimidin-2-yl substituted one or two memberseach independently selected from the group consisting of: halo,C₁₋₆alkyl, C₁₋₆alkyl substituted with OH or OCH₃, C(OH)(CH₃)(CF₃),CH₂OCHF₂, CH₂OCF₃, CH₂OCH₂CH₃, CH(NH₂)CH₃, CH₂NH(CH₃), C₁₋₆perhaloalkyl,OC₁₋₆alkyl, OC₁₋₆perhaloalkyl, C(═N—OH)(CH₃), NH₂, NH(CH₃), N(CH₃)₂;NH(CH₂CH₃), NH(CH₂CHF₂), NH(cyclopropyl), NH(difluorocyclobutyl),NH-oxetanyl, CN, C(═O)CH₃, C(═O)NH(CH₃), C(═O)N(CH₃)₂, SO₂CH₃, CO₂CH₃,C(CH₃)(═N—OH), cyclopropyl, azetidin-1-yl, 3-fluoroazetidin-1-yl,3,3-difluoroazetidin-1-yl, 3-(difluoromethyl)azetidin-1-yl,3-methoxyazetidin-1-yl, 3-fluoro-3-methyl-azetidin-1-yl,pyrrolidin-1-yl, 3-fluoropyrrolidin-1-yl, 3,3-difluoropyrrolidin-1-yl,piperidin-1-yl, morpholinyl, 1H-pyrrol-2-yl, 2-furyl, 1H-pyrazol-4-yl,1H-pyrazol-5-yl, 1H-pyrazol-1-yl, 2-methyl-1H-imidazol-1-yl,1-methylpyrazol-3-yl, and phenyl; (d) 5-fluoro-pyrazin-2-yl;5-methylpyrazin-2-yl; 6-methylpyrazin-2-yl; pyrazin-4-yl;(2-thienyl)pyrazin-2-yl, and 2,3-dimethylpyrazin-5-yl; and (e)5-methyl-1H-imidazol-2-yl; 5-methylthiazol-2-yl; and pharmaceuticallyacceptable salts of compounds of Formula (I).
 2. A method of treating asubject suffering from or diagnosed with a disease, disorder, or medicalcondition mediated by NR2B receptor activity, comprising administeringto a subject in need of such treatment an effective amount of at leastone compound selected from compounds of Formula (II):

wherein: Ar^(1′) is phenyl substituted with C₁₋₆perhaloalkyl; or phenylsubstituted with two substituents each independently selected from thegroup consisting of: halo, C₁₋₃alkyl, C₁₋₆perhaloalkyl, andOC₁₋₆perhaloalkyl; R^(2′) is H or CH₃; and Ar² is selected from thegroup consisting of: (a) pyridin-2-yl; pyridazin-3-yl; pyrimidin-4-yl;pyrimidin-2-yl; or pyrimidin-2-yl substituted with one or twosubstituents each independently selected from the group consisting ofhalo, C₁₋₃alkyl, C(CH₃)₂OH, C₁₋₆perhaloalkyl, OCH₃, and cyclopropyl; and(b) 1-methyl-imidazol-2-yl; oxazol-2-yl; 1-methyl-pyrazol-4-yl;1-methyl-pyrazol-3-yl; or 1-methyl-1H-pyrazol-5-yl; and pharmaceuticallyacceptable salts of compounds of Formula (II).
 3. The method of claim 1,wherein the disorder, disease or medical condition mediated by NR2Breceptor activity is selected from the group consisting of: bipolardisorder, major depressive disorder, treatment-resistant depression,post-partum depression, seasonal affective disorder, Alzheimer'sdisease, Parkinson's disease, Huntington's chorea, multiple sclerosis,cognitive impairment, head injury, spinal cord injury, stroke, epilepsy,dyskinesias, amyotrophic lateral sclerosis, neurodegeneration associatedwith bacterial or chronic infections, pain, diabetic neuropathy,migraine, cerebral ischemia, schizophrenia, encephalitis, autism andautism spectrum disorders, memory and learning disorders, obsessivecompulsive disorder, attention deficit hyperactivity disorder (ADHD) andaddictive illnesses.
 4. The method of claim 1, wherein the disorder,disease or medical condition mediated by NR2B receptor activity isselected from the group consisting of treatment resistant depression andmajor depressive disorder.
 5. The method of claim 1, wherein thedisorder, disease or medical condition mediated by NR2B receptoractivity is a neurologic or psychiatric disorder.
 6. The method of claim5, wherein the neurologic disorder is epilepsy.
 7. The method of claim5, wherein the psychiatric disorder is a mood disorder,treatment-resistant depression or major depressive disorder.
 8. Themethod of claim 1, wherein: Ar¹ is phenyl substituted with twosubstituents each independently selected from the group consisting of:halo, C₁₋₆alkyl, C₁₋₆perhaloalkyl, OC₁₋₆alkyl, OC₁₋₆perhaloalkyl,C₃₋₆cycloalkyl, and azetidinyl; R¹ is H, halo, or CH₃; R² is H or CH₃;and and Ar³ is pyrimidin-4-yl; pyrimidin-4-yl substituted with one ortwo substituents each independently selected from the group consistingof: Cl, CH₃, CF₃, and OCH₃; pyrimidin-2-yl; pyrimidin-2-yl substitutedone of two members each independently selected from the group consistingof: halo, C₁₋₆alkyl, C₁₋₆alkyl substituted with OH or OCH₃,C(OH)(CH₃)(CF₃), CH₂OCHF₂, CH₂OCF₃, CH₂OCH₂CH₃, CH(NH₂)CH₃, CH₂NH(CH₃),C₁₋₆perhaloalkyl, OC₁₋₆alkyl, OC₁₋₆perhaloalkyl, C(=N−OH)(CH₃), NH₂,NH(CH₃), N(CH₃)₂; NH(CH₂CH₃), NH(CH₂CHF₂), NH(cyclopropyl),NH(difluorocyclobutyl), NH-oxetanyl, CN, C(=O)CH₃, C(=O)NH(CH₃),C(=O)N(CH₃)₂, C(CH₃)(=N−OH), cyclopropyl, azetidin-1-yl,3-fluoroazetidin-1-yl, 3,3-difluoroazetidin-1-yl, b3-(difluoromethyl)azetidin-1-yl, 3-methoxyazetidin-1-yl,3-fluoro-30methyl-azetidin-yl, pyrrolidin-1-yl, 3-fluoropyrrolidin-1-yl,3,3-difluoropyrrolidin-1-yl, piperidin-1-yl, morpholinyl,1H-pyrrol-2-yl, 2-furyl, 1H-pyrazol-4-yl, 1H-pyrazol-5-yl,1H-pyrazol-1-yl, 2-methyl-1H-imidazol-1-yl, 1-methylpyrazol-3-yl, andphenyl.
 9. The method of claim 8, wherein R¹ is H, F, I or CH_(3.) 10.The method of claim 8, wherein R¹ is H.
 11. The method of claim 8,wherein R² is H.
 12. The method of claim 8, wherein Ar¹ is phenylsubstituted with two substituents each independently selected from thegroup consisting of: Br, Cl, F, CH₃, CH₂CH₃, CH(CH₃)₂, CF₃, CF₂H,CF₂CH₃, CH₂CH₂CH₂Cl, CH₂CH₂CH₂F, OCH₃,OCF₂H, OCH₂CH₂F, cyclopropyl, andazetidin-1-yl.
 13. The method of claim 8, wherein Ar¹ is4-chloro-3-(difluoromethoxy)phenyl, 3-(difluoromethyl)-4-fluoro-phenyl,4-chloro-3-(1,1-difluoroethyl)phenyl,3-(1,1-difluoroethyl)-4-fluoro-phenyl,3-(difluoromethoxy)-4-fluoro-phenyl, 4-chloro-3-(difluoromethyl)phenyl,4-chloro-3-(2-fluoroethoxy)phenyl, 3-(3-chloropropyl)-4-fluoro-phenyl,or 5-(trifluoromethyl)thiophen-2-yl.
 14. The method of claim 8, whereinAr³ is pyrimidin-2-yl; pyrimidin-2-yl substituted one or two member eachindependently selected from the group consisting of: halo, C₁₋₃alkyl,C₁₋₃alkyl substituted with OH or OCH₃, C(OH)(CH₃)(CF₃), CH(NH₂)CH₃,CH₂NH(CH₃), C₁₋₃perhaloalkyl, OC₁₋₃alkyl, OC₁₋₃perhaloalkyl, NH₂;NH(CH₃), N(CH₃)₂, NH(CH₂CH₃), NH(CH₂CHF₂), CN, C(=O)CH₃, C(=O)NH(CH₃),C(=O)N(CH₃)₂, SO₂CH₃,CO₂CH₃, cyclopropyl, azetidin-1-yl,3-fluoroazetidin-1-yl, 3,3-difluoroazetidin-1-yl,3-(difluoromethyl)azetidin-1-yl, 3-methoxyazetidin-1-yl,3-fluoro-3-methyl-azetidin-1-yl, pyrrolidin-1-yl,3-fluoropyrrolidin-1-yl, 3,3-difluoropyrrolidin-1-yl, piperidin-1-yl,morpholinyl, 2-furyl, 1H-pyrazol-4-yl, and 1-methylpyrazol-3-yl.
 15. Themethod of claim 8, wherin Ar³ is pyrimidin-2-yl substituted one or twomembers each independently selected from the group consisting of: halo,C₁₋₆-alkyl, C₁₋₆alkyl substituted with OH or CH₃, C₁₋₆perhaloalkyl,OC₁₋₆alkyl, OC₁₋₆perhaloalkyl, and azetidine-1-yl.
 16. The method ofclaim 8, wherin the compound has or pharmaceutically acceptable saltthereof has the structure of Formula (IB):

wherein Ar¹is phenyl substituted with two substituents eachindependently selected from the group consisting of: halo, C₁₋₃alkyl,C₁₋₃perhaloalkyl, OCH₃, and OC_(1-3perhaloalkyl;) R¹ is selected fromthe group consisting of: H, F, I, and CH_(3;) R²is H or CH₃; n is 0, 1,or 2; and each R⁴ is independently selected from the group consistingof: halo, C₁₋₆alkyl, C₁₋₆alkyl substituted with OH or OCH₃,C(OH)(CH₃)(CF₃), CH(NH₂)CH₃, CH₂NH(CH₃), C₁₋₆perhaloalkyl, OC₁₋₆alkyl,OC₁₋₆perhaloalkyl, NH₂, NH(CH₃), N(CH₃)₂, NH(CH₂CH₃), NH(CH₂CHF₂), CN,C(=O)CH₃, C(=O)NH(CH₃), C(=O)N(CH₃)₂, SO₂CH₃, CO₂CH₃, cyclopropyl,azetidin-1-yl, 3-fluoroazetidin-1-yl, 3-fluoro-3methyl-azetidin-1-yl,pyrrolidin-1-yl, 3-fluoropyrrolidin-1-yl, 3,3-difluoropyrrolidin-1-yl,piperidin-1-yl, morpholine, 2-furyl, 1H-pyrazol-4-yl, and1-methylpyrazol-3-yl.
 17. The method of claim 16, wherein Ar¹ isselected from the group consisting of:4-chloro-3-(difluoromethoxy)phenyl, 3-(difluoromethoxy)-4-fluoro-phenyl,3-(difluoromethoxy)-4-methyl-phenyl,4-chloro-3-(1,1-difluoroethyl)phenyl,3-(1,1-difluoroethyl-4-fluoro-phenyl, 4-chloro-3-(2-fluoroethoxy)phenyl,3-(6-chloropropyl)-4-fluoro-phenyl, 4-fluoro-3-(3-floropropyl)phenyl,3-bromo-4-fluoro-phenyl, 2-fluoro-3-(trifluoromethyl)phenyl,3-(difluoromethyl)-4-fluoro-phenyl, 4-chloro-3-(difluoromethyl)phenyl,4-chloro-3-methoxy-phenyl), 4-fluoro-3-isopropyl-phenyl,3-chloro-4-fluoro-phenyl, 3-ehtyl-4-fluoro-phenyl, 3,4-difluorophenyl,4-difluorophenyl, 4-fluoro-3-methyl-phenyl, and 3,5-dimethylphenyl; R¹is H; R² is H; n is 1 or 2; and each R⁴ is independently selected fromthe group consistion of: CI, F, C₁₋₃alkyl, C₁₋₃perhaloalkyl, CH₂OH,CH₂OCH₃, C(CH₃)₂(OH), OCH₃, OC₁₋₃perhaloalkyl, C(=O)CH₃, andazetidine-1-yl.
 18. The method of claim 2, wherein the compound ofpharmaceutically acceptable salt thereof has the structure of Formula(IIA):

wherein: Ar¹ is selected from the group consisting of:4-chloro-3-(difluoromethoxy)phenyl, 3-(difluoromethoxy)-4-fluoro-phenyl,4-fluoro-3-(trifluoromethyl)phenyl, 3-(difluoromethyl)-4-fluoro-phenyl,and 4-chloro-3-(difluoromethyl)phenyl; and Ar² is selected from thegroup consisting of: oxazol-2-yl, pyrimidin-4-yl, 1-methyl-pyrazol-3-yl,1-methyl-imidazol-2-yl, and 1-methyl-pyrazol-4-yl.
 19. The method ofclaim 2, wherein the compound or pharmaceutically acceptable saltthereof has the structure of Formula (IIB):

wherein: Ar¹ is selected from the group consisting of:3-(difluoromethyl)phenyl, 4-fluoro-3-methyl-phenyl,4-chloro-3-(difluoromethoxy)phenyl, 3-(difluoromethoxy)-4-fluoro-phenyl,4-fluoro-3-(trifluoromethyl)phenyl, 3-(difluoromethyl)-4-fluoro-phenyl,4-chloro-3-(difluoromethyl)phenyl, and3-(1,1-difluoroethyl)-4-fluoro-phenyl; n is 1 or 2; and each R⁴ isindependently selected from the group consisting of halo, C₁₋₃alkyl,C(CH₃)₂OH, C₁₋₃perhaloalkyl, OCH₃, and cyclopropyl.
 20. The method ofclaim 8, wherein the compound is2-[[1-[1-(difluoromethoxy)-4-fluoro-phenyl]triazol-4-yl]methoxy]-4-(methoxymethyl)pyrimidineor a pharmaceutically acceptable salt thereof.